PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Majeed, A; Lehmann, P; Kirby, L; Coleman, MP				Majeed, A; Lehmann, P; Kirby, L; Coleman, MP			Mortality from dementias and neurodegenerative disorders in people aged 15-64 in England and Wales in 1979-96	BRITISH MEDICAL JOURNAL			English	Article									Off Natl Stat, London SW1V 2QQ, England		Majeed, A (corresponding author), Off Natl Stat, London SW1V 2QQ, England.		Coleman, Michel/AAA-9543-2020	Coleman, Michel/0000-0001-8940-3807; Majeed, Azeem/0000-0002-2357-9858				Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HOMER AC, 1988, BMJ-BRIT MED J, V297, P894, DOI 10.1136/bmj.297.6653.894; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					320	321		10.1136/bmj.317.7154.320	http://dx.doi.org/10.1136/bmj.317.7154.320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685278	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000075409500022
J	Pollock, AM; Vickers, N				Pollock, AM; Vickers, N			Deprivation and emergency admissions for cancers of colorectum, lung, and breast in south east England: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RATES; CONSULTATION; SURVIVAL; SURGERY; IMPACT	Objectives: To examine the relation between deprivation and acute emergency admissions for cancers of the colon, rectum, lung, and breast in south east England. Design: Ecological analysis with data from hospital episode statistics and 1991 census. Setting: North and South Thames Regional Health Authorities (population about 14 million), divided into 10 aggregations of 31 470 census enumeration districts (median population 462). Subjects: 146 639 admissions relating to 76 552 patients aged < 100 years on admission, resident in the Thames regions, admitted between 1 April 1992 and 31 March 1995. Results: Residents living in deprived areas were more likely to be admitted as emergencies and has ordinary inpatient admissions and less likely to be admitted as day cases. Adjusted odds of ordinary admissions from the most deprived tenth occurring as emergencies (relative to admissions from the most affluent tenth) were 2.29 (95% confidence interval 2.09 to 2.52) for colorectal cancer, 2.20 (1.99 to 2.43) for lung cancer, and 2.41 (2.17 to 2.67) for female breast cancer; adjusted odds of admissions as day cases were 0.70 (0.64 to 0.76), 0.50 (0.44 to 0.56), and 0.56 (0.50 to 0.62), respectively. Patients from deprived areas with lung or breast cancers were less likely to be recorded as having surgical interventions. Adjusted odds of patients fi-om the most deprived tenth receiving surgery were 0.88 (0.78 to 1.00), 0.58 (0.48 to 0.70), and 0.63 (0.56 to 0.71), respectively. Admissions for colorectal cancer from the most deprived areas were less likely to be to hospitals admitting 100 or more new patients a year; the opposite held true for breast cancer admissions. No association was found for lung cancer admissions. Conclusions: Earlier diagnostic and referral procedures in primary care in deprived areas are required if there are to be significant reductions in mortality from these cancers. A national information strategy is required to ensure the continued availability of population based data on NHS patients and to mandate standardised datasets from the private sector. Rationalisation of acute services, hospital mergers, and plans for bed closures must take into account the increased healthcare needs and inequities in access to treatment and care of residents in areas with high levels of deprivation Health authorities and primary care groups should re-examine their purchasing intentions, service reviews, and monitoring arrangements in the light of these findings.	St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London	Pollock, AM (corresponding author), UCL, Sch Publ Hlth, London WC1E 7HN, England.			pollock, allyson/0000-0002-7388-3110				BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; CHATURVEDI N, 1995, BRIT J GEN PRACT, V45, P127; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; *EXP ADV GROUP CAN, 1994, POL FRAM COMM CANC S; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GILL L, 1993, J EPIDEMIOL COMMUN H, V47, P316, DOI 10.1136/jech.47.4.316; *GOV STAT SERV, 1993, HOSP EP STAT 1989 19; LAMDEN KH, 1995, J PUBLIC HEALTH MED, V17, P63; *LIANG BUISS, 1996, LIANGS REV PRIV HLTH; MAJEED F, 1995, BRIT MED J, V310, P1674, DOI 10.1136/bmj.310.6995.1674a; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MCCORMICK A, 1994, MORBIDITY STAT GEN P; SCHRIJVERS CTM, 1995, CANCER-AM CANCER SOC, V75, P2946, DOI 10.1002/1097-0142(19950615)75:12<2946::AID-CNCR2820751223>3.0.CO;2-6; SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403; SCHRIJVERS CTM, 1995, EUR J CANCER, V31A, P1660, DOI 10.1016/0959-8049(95)00272-K; SCHRIJVERS CTM, 1995, INT J CANCER, V63, P324, DOI 10.1002/ijc.2910630303; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; Townsend P, 1988, HLTH DEPRIVATION INQ	24	67	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					245	252		10.1136/bmj.317.7153.245	http://dx.doi.org/10.1136/bmj.317.7153.245			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677214	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000075081900021
J	Sakai, DH				Sakai, DH			A visit from my daughter	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					321	321		10.1001/jama.280.4.321	http://dx.doi.org/10.1001/jama.280.4.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686541				2022-12-01	WOS:000074804200018
J	Carpenter, EP; Hawkins, AR; Frost, JW; Brown, KA				Carpenter, EP; Hawkins, AR; Frost, JW; Brown, KA			Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis	NATURE			English	Article							PENTAFUNCTIONAL AROM PROTEIN; ASPERGILLUS-NIDULANS; 3-DEHYDROQUINATE; SHIKIMATE	Dehydroquinate synthase (DHQS) has long been regarded as a catalytic marvel because of its ability to perform several consecutive chemical reactions in one active site(1-7). There has been considerable debate as to whether DHQS is actively involved in all these steps(1,2), or whether several steps occur spontaneously, making DHQS a spectator in its own mechanism(3-5). DHQS performs the second step in the shikimate pathway, which is required for the synthesis of aromatic compounds in bacteria, microbial eukaryotes and plants(8). This enzyme is a potential target for new antifungal and antibacterial drugs(9,10) as the shikimate pathway is absent from mammals and DHQS is required for pathogen virulence(11). Here we report the crystal structure of DHQS, which has several unexpected features, including a previously unobserved mode for NAD(+)-binding and an active-site organization that is surprisingly similar to that of alcohol dehydrogenase, in a new protein fold, The structure reveals interactions between the active site and a substrate-analogue inhibitor, which indicate how DHQS can perform multistep catalysis without the formation of unwanted by-products.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Med Sch Newcastle Upon Tyne, New Med Sch, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Imperial College London; MRC National Institute for Medical Research; Newcastle University - UK; Michigan State University	Brown, KA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Exhibit Rd, London SW7 2AY, England.	k.brown@ic.ac.uk		Carpenter, Liz/0000-0001-9138-2937				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTLETT PA, 1988, J AM CHEM SOC, V110, P1628, DOI 10.1021/ja00213a049; BARTLETT PA, 1994, J ORG CHEM, V59, P2082, DOI 10.1021/jo00087a024; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CASE ME, 1971, P NATL ACAD SCI USA, V68, P58, DOI 10.1073/pnas.68.1.58; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gunel- Ozcan A., 1997, MICROBIAL PATHOGEN, V17, P169; HAWKINS AR, 1993, J GEN MICROBIOL, V139, P2891, DOI 10.1099/00221287-139-12-2891; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P27; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; LAMBERT JM, 1985, BIOCHEM J, V226, P817, DOI 10.1042/bj2260817; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Montchamp JL, 1997, J AM CHEM SOC, V119, P7645, DOI 10.1021/ja961771z; MOORE JD, 1994, BIOCHEM J, V301, P297, DOI 10.1042/bj3010297; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pittard AJ, 1987, ESCHERICHIA COLI SAL, P368; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SRINIVASAN PR, 1963, J BIOL CHEM, V238, P3176; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; TRONRUD DE, 1993, TNT REFINEMENT PACKA, P1; VANDENHOMBERGH JPTW, 1992, BIOCHEM J, V284, P861, DOI 10.1042/bj2840861; WIDLANSKI T, 1989, J AM CHEM SOC, V111, P2299, DOI 10.1021/ja00188a052; [No title captured]	29	113	138	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					299	302		10.1038/28431	http://dx.doi.org/10.1038/28431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685163				2022-12-01	WOS:000074851900054
J	Glover, JR; Lindquist, S				Glover, JR; Lindquist, S			Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins	CELL			English	Article							HEAT-SHOCK PROTEINS; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; RNA-POLYMERASE; YEAST; DNAJ; THERMOTOLERANCE; HOMOLOG	Hsp104 is a stress tolerance factor that promotes the reactivation of heat-damaged proteins in yeast by an unknown mechanism. Herein, we demonstrate that Hsp104 functions in this process directly. Unlike other chaperones, Hsp104 does not prevent the aggregation of denatured proteins. However, in concert with Hsp40 and Hsp70, Hsp104 can reactivate proteins that have been denatured and allowed to aggregate, substrates refractory to the action of other chaperones. Hsp104 cooperates with the chaperones present in reticulocyte lysates but not with DnaK of E. coli. We conclude that Hsp104 has a protein remodeling activity that acts on trapped, aggregated proteins and requires specific interactions with conventional chaperones to promote refolding of the intermediates it produces.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker J, 1996, MOL CELL BIOL, V16, P4378; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Bush GL, 1996, J CELL BIOL, V135, P1229, DOI 10.1083/jcb.135.5.1229; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; LEE YRJ, 1994, PLANT CELL, V6, P1889, DOI 10.1105/tpc.6.12.1889; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Schirmer EC, 1997, P NATL ACAD SCI USA, V94, P13932, DOI 10.1073/pnas.94.25.13932; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609; Xie YS, 1996, PROTEIN SCI, V5, P517; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	49	1064	1101	3	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					73	82		10.1016/S0092-8674(00)81223-4	http://dx.doi.org/10.1016/S0092-8674(00)81223-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674429	Bronze			2022-12-01	WOS:000074790800011
J	Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P				Takei, K; Haucke, V; Slepnev, V; Farsad, K; Salazar, M; Chen, H; De Camilli, P			Generation of coated intermediates of clathrin-mediated endocytosis on protein-free liposomes	CELL			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; HIGH-AFFINITY BINDING; NERVE-TERMINALS; ALPHA-ADAPTIN; GOLGI STACK; IN-VITRO; DYNAMIN; MEMBRANE; DOMAIN; TRANSPORT	Clathrin-coated buds and dynamin-coated tubules morphologically similar to corresponding structures observed in synaptic membranes can be generated on protein-free liposomes by incubation with cytosol, or with clathrin coat proteins and purified dynamin, respectively. Dynamin- and clathrin-coated intermediates may form independently of each other, despite the coupling between the two processes typically observed in synaptic membranes. Formation of both structures on liposomes can occur in the absence of nucleotides. These findings indicate that interfaces between lipids and cytosolic proteins are fully sufficient to deform lipids bilayers into buds and tubules. They suggest that a main function of membrane proteins is to act as positive and negative regulators of coat assembly, therefore controlling these processes in time and space.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993; Takei, Kohji/0000-0002-6555-9425	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHEN H, 1998, IN PRESS NATURE; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HAMA K, 1977, J NEUROCYTOL, V6, P361, DOI 10.1007/BF01178223; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HEUSER J, 1971, PROC R SOC SER B-BIO, V179, P247, DOI 10.1098/rspb.1971.0096; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LOVAS B, 1971, Z ZELLFORSCH MIK ANA, V121, P341, DOI 10.1007/BF00337638; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; MORRIS MB, 1992, J CELL BIOCHEM, V48, P356, DOI 10.1002/jcb.240480404; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RAPAPORT I, 1997, EMBO J, V16, P2240; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617; YE W, 1991, J BIOL CHEM, V266, P4442; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	60	279	283	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					131	141		10.1016/S0092-8674(00)81228-3	http://dx.doi.org/10.1016/S0092-8674(00)81228-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674434	hybrid			2022-12-01	WOS:000074790800016
J	Becker, S; Groner, B; Muller, CW				Becker, S; Groner, B; Muller, CW			Three-dimensional structure of the Stat3 beta homodimer bound to DNA	NATURE			English	Article							B P50 HOMODIMER; ELECTRON-DENSITY MAPS; TRANSCRIPTIONAL ACTIVITY; SIGNAL TRANSDUCERS; TROPONIN-C; BINDING; STAT; DOMAIN; RECOGNITION; ACTIVATION	STAT proteins are a family of eukaryotic transcription factors that mediate the response to a large number of cytokines and growth factors. Upon activation by cell-surface receptors or their associated kinases, STAT proteins dimerize, translocate to the nucleus and bind to specific promoter sequences on their target genes. Here we report the first crystal structure of a STAT protein bound to its DNA recognition site at 2.25 Angstrom resolution. The structure provides insight into the various steps by which STAT proteins deliver a response signal directly from the cell membrane to their target genes in the nucleus.	European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Inst Expt Canc Res, Tumor Biol Ctr, D-79106 Freiburg, Germany	European Molecular Biology Laboratory (EMBL)	Muller, CW (corresponding author), European Mol Biol Lab, Grenoble Outstn, ILL BP 156, F-38042 Grenoble 9, France.	mueller@embl-grenoble.fr	Müller, Christoph W/I-7420-2012	Müller, Christoph W/0000-0003-2176-8337				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FOTELLE EDL, 1997, METHOD ENZYMOL, V276, P472; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HELM MH, 1995, SCIENCE, V267, P1347; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Muller CW, 1996, NAT STRUCT BIOL, V3, P224, DOI 10.1038/nsb0396-224; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P189; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	46	648	688	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					145	151		10.1038/28101	http://dx.doi.org/10.1038/28101			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671298				2022-12-01	WOS:000074705900043
J	Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH				Shekelle, PG; Courter, I; Hurwitz, EL; Genovese, B; Adams, AH; Mior, SA; Brook, RH			Congruence between decisions to initiate chiropractic spinal manipulation for low back pain and appropriateness criteria in North America	ANNALS OF INTERNAL MEDICINE			English	Article						low back pain; spine; chiropractic; manipulation, orthopedic; quality of health care	RANDOMIZED CLINICAL-TRIAL; NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CORONARY-ANGIOGRAPHY; NECK COMPLAINTS; MANUAL THERAPY; CAROTID ENDARTERECTOMY; OUTCOME MEASURES; PERSISTENT BACK; FOLLOW-UP	Background: Recent U.S. practice guidelines recommend spinal manipulation for some patients with low back pain. If followed, these guidelines are likely to increase the number of persons referred for chiropractic care. Concerns have been raised about the appropriate use of chiropractic care, but systematic data are lacking. Objective: To determine the appropriateness of chiropractors' decisions to use spinal manipulation for patients with low back pain. Design: Retrospective review of chiropractic office records against preset criteria for appropriateness that were developed from a systematic review of the literature and a nine-member panel of chiropractic and medical specialists. Appropriateness criteria reflect the expected balance between risk and benefit. Setting: 131 of 185 (71%) chiropractic offices randomly sampled from sites in the United States and Canada. Patients: 10 randomly selected records of patients presenting with low back pain from each office (1310 patients total). Measurements: Sociodemographic data on patients and chiropractors; use of health care services by patients; assessment of the decision to initiate spinal manipulation as appropriate, uncertain, or inappropriate. Results: Of the 1310 patients who sought chiropractic care for low back pain, 1088 (83%) had spinal manipulation. For 859 of these patients (79%), records contained data sufficient to determine whether care was congruent with appropriateness criteria. Care was classified as appropriate in 46% of cases, uncertain in 25% of cases, and inappropriate in 29% of cases. Patients who did not undergo spinal manipulation were less likely to have a presentation judged appropriate and were more likely to have a presentation judged inappropriate than were patients who did undergo spinal manipulation (P = 0.01). Conclusions: The proportion of chiropractic spinal manipulation judged to be congruent with appropriateness criteria is similar to proportions previously described for medical procedures; thus, the findings provide some reassurance about the appropriate application of chiropractic care. However, more than one quarter of patients were treated for indications that were judged inappropriate. The number of inappropriate decisions to use chiropractic spinal manipulation should be decreased.	Rand Corp, Santa Monica, CA 90401 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Los Angeles Coll Chiropract, Whittier, CA 90609 USA; Canadian Mem Chiropract Coll, Toronto, ON M4G 3E6, Canada	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shekelle, PG (corresponding author), Rand Corp, 1700 Main St,POB 2138, Santa Monica, CA 90401 USA.		Mior, Silvano A/L-4786-2015	Mior, Silvano A/0000-0001-6575-2797				BALLANTINE HT, 1972, NEW ENGL J MED, V286, P237, DOI 10.1056/NEJM197202032860504; BENGTSON A, 1994, JAMA-J AM MED ASSOC, V271, P1260, DOI 10.1001/jama.271.16.1260; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BIGOS SJ, 1992, AHCPR PUBLICATION; BLOMBERG S, 1994, SPINE, V19, P569, DOI 10.1097/00007632-199403000-00013; BROOK RH, 1993, SCHWEIZ MED WSCHR, V123, P249; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1989, APPROPRIATENESS USE; CURTIS P, 1992, J FAM PRACTICE, V35, P551; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; ERHARD RE, 1994, PHYS THER, V74, P1093, DOI 10.1093/ptj/74.12.1093; FELLEGI IP, 1980, J AM STAT ASSOC, V75, P261, DOI 10.2307/2287444; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HERZOG W, 1991, J MANIP PHYSIOL THER, V14, P104; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HSIEH CYJ, 1992, J MANIP PHYSIOL THER, V15, P4; Hurwitz EL, 1998, AM J PUBLIC HEALTH, V88, P771, DOI 10.2105/AJPH.88.5.771; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KAHN KL, 1988, J CLIN EPIDEMIOL, V41, P115, DOI 10.1016/0895-4356(88)90085-6; Kahn KL., 1992, EFFECTS DRG BASED PR, pxxiv 343; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; KOSECOFF J, 1987, MED CARE, V25, P196, DOI 10.1097/00005650-198703000-00003; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; Leape LL, 1996, ANN INTERN MED, V125, P8, DOI 10.7326/0003-4819-125-1-199607010-00003; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; POPE MH, 1994, SPINE, V19, P2571, DOI 10.1097/00007632-199411001-00013; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SHEKELLE PG, 1995, J MANIP PHYSIOL THER, V18, P265; SHEKELLE PG, 1991, APPROPRIATE USE SPIN; SHEKELLE PG, 1994, USE COSTS CHIROPRACT; SHEKELLE PG, IN PRESS INT J TECH; THOMAS DR, 1987, J AM STAT ASSOC, V82, P630, DOI 10.2307/2289475; TRIANO JJ, 1995, SPINE, V20, P948, DOI 10.1097/00007632-199504150-00013; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V258, P2568, DOI 10.1001/jama.258.18.2568; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; Wreje Ullacarin, 1992, Scandinavian Journal of Primary Health Care, V10, P310, DOI 10.3109/02813439209014080	50	37	37	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					9	+		10.7326/0003-4819-129-1-199807010-00003	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9653012				2022-12-01	WOS:000074513300002
J	Tagliaro, F; De Battisti, Z; Smith, FP; Marigo, M				Tagliaro, F; De Battisti, Z; Smith, FP; Marigo, M			Death from heroin overdose: findings from hair analysis	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MORPHINE; BLOOD; COCAINE	Background Morphine analysis of hair is used in forensic toxicology to study the addiction history of heroin addicts. To clarify the features underlying fatal heroin intake, we measured hair morphine content in a group of deceased heroin addicts, to verify a possible correlation between fatal heroin overdoses and the addiction behaviour of these individuals before death. Methods 91 deaths were attributed to heroin overdose in Verona, Italy, in 1993-96. We analysed the hair of 37 of these individuals, and of 37 active heroin addicts, 37 former heroin users abstinent from the drug for several months, and 20 individuals with no evidence of exposure to opioids. From each individual, a hair sample of about 150 mg was analysed by RIA and high-performance liquid chromatography, to measure the morphine content. Findings The mean morphine content in the hair of the addicts who had died was 1.15 ng/mg (SD 2.35 ng/mg; range 0-12.25 ng/mg) compared with 6.07 ng/mg (4.29; 1.15-17.0) in the active heroin addicts, 0.74 ng/mg (0.93; 0.10-3.32) in the abstinent former addicts, and values below the detection limit in the non-exposed group. Hair morphine content among those who had died was significantly lower than that in active heroin consumers (p<0.0001), but not significantly different from that in the former addicts (p=0.978). Interpretation Although our findings may be subject to selection bias, since suitable hair samples were available for only 37 of the 91 addicts who had died, these findings support the theory of high susceptibility to opioid overdose after periods of intentional or unintentional abstinence, due to loss of tolerance. Medical staff running detoxification programmes should be aware of the risk inherent in relapse to heroin after a period of abstinence. Moreover, occasional heroin use without a build-up of tolerance could also give a high risk of overdose.	Univ Verona Policlin, Inst Forens Med, I-37134 Verona, Italy; Univ Alabama, Dept Justice Sci, Birmingham, AL USA	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Alabama System; University of Alabama Birmingham	Tagliaro, F (corresponding author), Univ Verona Policlin, Inst Forens Med, I-37134 Verona, Italy.		Tagliaro, Franco/AAB-8631-2022	Tagliaro, Franco/0000-0002-2187-9128				ADDINGTON WW, 1972, CHEST, V62, P199, DOI 10.1378/chest.62.2.199; Baselt R., 1995, DISPOSITION TOXIC DR; BRASHEAR RE, 1974, J LAB CLIN MED, V83, P451; CONE EJ, 1991, J ANAL TOXICOL, V15, P250, DOI 10.1093/jat/15.5.250; HARDINGPINK D, 1988, BRIT MED J, V297, P596, DOI 10.1136/bmj.297.6648.596; HENDERSON GL, 1993, FORENSIC SCI INT, V63, P19, DOI 10.1016/0379-0738(93)90256-A; *IT MIN INT AFF, 1996, DIR CENTR SERV ANT; KINTZ P, 1992, EUR J CLIN PHARMACOL, V42, P351; LEVINE B, 1995, J FORENSIC SCI, V40, P808; LORATAMAYO C, 1987, J CHROMATOGR-BIOMED, V422, P267, DOI 10.1016/0378-4347(87)80462-0; MARIGO M, 1986, J ANAL TOXICOL, V10, P158, DOI 10.1093/jat/10.4.158; MIYAZAWA N, 1991, FORENSIC SCI INT, V51, P65, DOI 10.1016/0379-0738(91)90206-X; PUSCHEL K, 1983, FORENSIC SCI INT, V21, P181, DOI 10.1016/0379-0738(83)90108-1; PUSCHEL K, 1993, FORENSIC SCI INT, V62, P129, DOI 10.1016/0379-0738(93)90057-H; QUESTEL F, 1996, ANN INTERN MED, V15, P616; Richards R G, 1976, J Forensic Sci, V21, P467; SACHS H, 1995, FORENSIC SCI INT, V70, P53, DOI 10.1016/0379-0738(94)01611-8; Skopp G, 1997, FORENSIC SCI INT, V84, P43, DOI 10.1016/S0379-0738(96)02047-6; Smith FP, 1996, FORENSIC SCI INT, V83, P179, DOI 10.1016/S0379-0738(96)02035-X; SPIEHLER V, 1987, J FORENSIC SCI, V32, P906; STAUB C, 1990, INT J LEGAL MED, V104, P39, DOI 10.1007/BF01816482; TAGLIARO D, 1997, FORENSIC SCI INT, V84, P129; TAGLIARO F, 1994, J CHROMATOGR A, V674, P207, DOI 10.1016/0021-9673(94)85225-1; TAGLIARO F, 1988, CHROMATOGRAPHIA, V26, P163, DOI 10.1007/BF02268144; UEMATSU T, 1989, EUR J CLIN PHARMACOL, V37, P239, DOI 10.1007/BF00679777; UGES DRA, 1996, TIAFT B, V26, P5; *US GEN ASS OFF, 1993, DRUG US MEAS STRENGT	27	89	91	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1923	1925		10.1016/S0140-6736(97)10101-5	http://dx.doi.org/10.1016/S0140-6736(97)10101-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654260				2022-12-01	WOS:000074464700010
J	Fleming, A; Copp, AJ				Fleming, A; Copp, AJ			Embryonic folate metabolism and mouse neural tube defects	SCIENCE			English	Article							MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE; FOLIC-ACID; SPINA-BIFIDA; RAT EMBRYOS; MUTANT; PAX-3; PREVENTION; GENE; VITAMIN-B12; METHIONINE	Folic acid prevents 70 percent of human neural tube defects (NTDs) but its mode of action is unclear. The deoxyuridine suppression test detects disturbance of folate metabolism in homozygous splotch (Pax3) mouse embryos that are developing NTDs in vitro. Excessive incorporation of [(3)H]thymidine in splotch embryos indicates a metabolic deficiency in the supply of folate for the biosynthesis of pyrimidine. Exogenous folic acid and thymidine both correct the biosynthetic defect and prevent some NTDs in splotch homozygotes, whereas methionine has an exacerbating effect. These data support a direct normalization of neurulation by folic acid in humans and suggest a metabolic basis for folate action.	UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England	University of London; University College London	Copp, AJ (corresponding author), UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England.	a.copp@ich.ucl.ac.uk	Copp, Andrew/C-4174-2008	Copp, Andrew/0000-0002-2544-9117; Fleming, Angeleen/0000-0003-3721-7126	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028882] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 28882] Funding Source: Medline; Wellcome Trust Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		BADEN JM, 1991, BRIT J ANAESTH, V66, P500, DOI 10.1093/bja/66.4.500; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; CHATKUPT S, 1995, J MED GENET, V32, P200, DOI 10.1136/jmg.32.3.200; COCKROFT DL, 1991, HUM REPROD, V6, P148, DOI 10.1093/oxfordjournals.humrep.a137250; COPP AJ, 1985, J EMBRYOL EXP MORPH, V88, P39; COPP AJ, 1994, DEV BIOL, V165, P20, DOI 10.1006/dbio.1994.1230; Daston G, 1996, DEVELOPMENT, V122, P1017; deFranchis R, 1995, LANCET, V346, P1703, DOI 10.1016/S0140-6736(95)92865-0; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Greene NDE, 1997, NAT MED, V3, P60, DOI 10.1038/nm0197-60; HELD MK, 1992, J NUTR, V122, P888; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1; KIRKE PN, 1993, Q J MED, V86, P703; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Morrison K, 1997, J MED GENET, V34, P958, DOI 10.1136/jmg.34.11.958; Papapetrou C, 1996, LANCET, V348, P58, DOI 10.1016/S0140-6736(05)64382-6; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; SCOTT JM, 1994, CIBA F SYMP, V181, P180; SELLER MJ, 1994, CIBA F SYMP, V181, P161; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; VANAERTS LAGJM, 1994, TERATOLOGY, V50, P348, DOI 10.1002/tera.1420500506; VANALLEN MI, 1993, AM J MED GENET, V47, P723, DOI 10.1002/ajmg.1320470528; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; WHITEHEAD AS, 1995, J MED, V88, P763; Wilcken DEL, 1996, LANCET, V347, P340, DOI 10.1016/S0140-6736(96)90526-7; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	34	195	205	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2107	2109		10.1126/science.280.5372.2107	http://dx.doi.org/10.1126/science.280.5372.2107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641914				2022-12-01	WOS:000074435900042
J	Rizzuto, CD; Wyatt, R; Hernandez-Ramos, N; Sun, Y; Kwong, PD; Hendrickson, WA; Sodroski, J				Rizzuto, CD; Wyatt, R; Hernandez-Ramos, N; Sun, Y; Kwong, PD; Hendrickson, WA; Sodroski, J			A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-ACID CHANGES; ENVELOPE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VARIABLE LOOP; FUSION; INFECTION; PEPTIDE	The entry of primate immunodeficiency viruses into target cells depends on a sequential interaction of the gp120 envelope glycoprotein with the cellular receptors, CD4 and members of the chemokine receptor family. The gp120 third variable (V3) loop has been implicated in chemokine receptor binding, but the use of the CCR5 chemokine receptor by diverse primate immunodeficiency viruses suggests the involvement of an additional, conserved gp120 element. Through the use of gp120 mutants, a highly conserved gp120 structure was shown to be critical for CCR5 binding. This structure is located adjacent to the V3 loop and contains neutralization epitopes induced by CD4 binding. This conserved element may be a useful target for pharmacologic or prophylactic intervention in human immunodeficiency virus (HIV) infections.	Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University; Howard Hughes Medical Institute; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Boston, MA 02115 USA.				NIAID NIH HHS [AI 41851, AI 40895] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040895, R01AI041851] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARILLO A, 1996, J VIROL, V70, P1301; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOLLY ML, 1987, J MOL GRAPHICS, V5, P103; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUJITA K, 1992, J VIROL, V66, P4445, DOI 10.1128/JVI.66.7.4445-4451.1992; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; KELLER R, 1993, J VIROL, V67, P6253, DOI 10.1128/JVI.67.10.6253-6258.1993; KIRCHHOFF F, 1995, VIROLOGY, V213, P179, DOI 10.1006/viro.1995.1558; KWONG P, IN PRESS NATURE; KWONG P, UNPUB; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MORRISON HG, 1993, VIROLOGY, V195, P167, DOI 10.1006/viro.1993.1357; MYERS G, 1996, HUMAN RETROVIRUSES A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POSNER MR, 1991, J IMMUNOL, V146, P4325; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RIZZUTO C, UNPUB; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; WYATT R, 1992, J VIROL, V66, P6997, DOI 10.1128/JVI.66.12.6997-7004.1992; WYATT R, IN PRESS NATURE	49	737	776	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1949	1953		10.1126/science.280.5371.1949	http://dx.doi.org/10.1126/science.280.5371.1949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632396				2022-12-01	WOS:000074323800068
J	Pablos-Mendez, A; Raviglione, MC; Laszlo, A; Binkin, N; Rieder, HL; Bustreo, F; Cohn, DL; Lambregts-van Weezenbeek, CSB; Kim, SJ; Chaulet, P; Nunn, P				Pablos-Mendez, A; Raviglione, MC; Laszlo, A; Binkin, N; Rieder, HL; Bustreo, F; Cohn, DL; Lambregts-van Weezenbeek, CSB; Kim, SJ; Chaulet, P; Nunn, P		World Hlth Org Int Union TB Lung Dis Working G	Global surveillance for antituberculosis-drug resistance, 1994-1997	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; DIRECTLY OBSERVED THERAPY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; HIV-INFECTION; OUTBREAK; TRANSMISSION; EPIDEMIOLOGY; EMERGENCE; MORTALITY	Background Drug-resistant tuberculosis threatens efforts to control the disease. This report describes the prevalence of resistance to four first-line drugs in 35 countries participating in the World Health Organization-lnternational Union against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance between 1994 and 1997. Methods The data are from cross-sectional surveys and surveillance reports. Participating countries followed guidelines to ensure the use of representative samples, accurate histories of treatment, standardized laboratory methods, and common definitions. A network of reference laboratories provided quality assurance. The median number of patients studied in each country or region was 555 (range, 59 to 14,344). Results Among patients with no prior treatment, a median of 9.9 percent of Mycobacterium tuberculosis strains were resistant to at least one drug (range, 2 to 41 percent); resistance to isoniazid (7.3 percent) or streptomycin (6.5 percent) was more common than resistance to rifampin (1.8 percent) or ethambutol (1.0 percent). The prevalence of primary multidrug resistance was 1.4 percent (range, 0 to 14.4 percent). Among patients with histories of treatment for one month or less, the prevalence of resistance to any of the four drugs was 36.0 percent (range, 5.3 to 100 percent), and the prevalence of multidrug resistance was 13 percent (range, 0 to 54 percent). The overall prevalences were 12.6 percent for single-drug resistance (range, 2.3 to 42.4 percent) and 2.2 percent for multidrug resistance (range, 0 to 22.1 percent). Particularly high prevalences of multidrug resistance were found in the former Soviet Union, Asia, the Dominican Republic, and Argentina. Conclusions Resistance to antituberculosis drugs was found in all 35 countries and regions surveyed, suggesting that it is a global problem. (C) 1998, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, Div Gen Med, New York, NY 10032 USA; Columbia Univ, Div Epidemiol, New York, NY 10032 USA; WHO, Global TB Program, CH-1211 Geneva, Switzerland; Lab Ctr Dis Control, Ottawa, ON K1A 0L2, Canada; Int Union TB & Lung Dis, Paris, France; Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA; Denver Publ Hlth Dept, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Royal Netherlands TB Assoc, The Hague, Netherlands; Korean Inst TB, Seoul, South Korea	Columbia University; Columbia University; World Health Organization; Centers for Disease Control & Prevention - USA; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Pablos-Mendez, A (corresponding author), Columbia Univ Coll Phys & Surg, Div Gen Med, 622 W 168th St,PH-9E-105, New York, NY 10032 USA.			RAVIGLIONE, Mario/0000-0002-9331-2067				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; CHAULET P, 1993, ANN I PASTEUR, V4, P181; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; COHN ML, 1959, J CLIN INVEST, V38, P1349, DOI 10.1172/JCI103910; CONINX R, 1997, INT J TUBERC LUNG S1, V1, pS43; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CROFTON J, 1948, BMJ-BRIT MED J, V2, P1009, DOI 10.1136/bmj.2.4588.1009; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; *HONG KONG GOV TUB, 1964, TUBERCLE, V45, P77; KENNEDY N, 1993, BRIT MED J, V306, P514, DOI 10.1136/bmj.306.6876.514; KIM SJ, 1992, TUBERCLE LUNG DIS, V73, P219, DOI 10.1016/0962-8479(92)90090-7; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; LAMBREGTSVANWEC.CS, 1997, EUR RESP MONOGR, V2, P298; Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; Morcillo N, 1996, MEDICINA-BUENOS AIRE, V56, P45; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223; PABLOSMENDEZ A, 1997, PUBLICATION WHO GTB; *PHS COOP INV, 1964, AM RESP DIS, V89, P327; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SIDDIQI SH, 1989, BACTECT TB SYSTEM PR; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STYBLO K, 1967, B WORLD HEALTH ORGAN, V37, P819; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; *WHO, 1961, WHO TECH REP SER, V210, P3; *WHO, 1994, WHO PUBL; WHO, 1997, OBESITY PREVENTING M; *WHO, 1983, MAN BACT TUB; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; 1991, MMWR MORB MORTAL WKL, V40, P585; 1996, MMWR MORB MORTAL WKL, V45, P330	56	684	719	0	55	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1641	1649		10.1056/NEJM199806043382301	http://dx.doi.org/10.1056/NEJM199806043382301			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614254	Bronze			2022-12-01	WOS:000073978000001
J	Minkoff, H; O'Sullivan, MJ				Minkoff, H; O'Sullivan, MJ			The case for rapid HIV testing during labor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; MOTHER-TO-INFANT; COCAINE USE; ZIDOVUDINE TREATMENT; TRANSMISSION; TYPE-1; INFECTION; CITY; WOMEN; ASSOCIATION		Maimonides Hosp, Dept Obstet & Gynecol, Brooklyn, NY 11219 USA; SUNY, Hlth Sci Ctr, Brooklyn, NY USA; Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA	Maimonides Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; SUNY Maritime College; University of Miami	Minkoff, H (corresponding author), Maimonides Hosp, Dept Obstet & Gynecol, 4800 10th Ave, Brooklyn, NY 11219 USA.	hminkoff@maimonidesmed.org						BIRKHEAD GS, 1998, 5 C RETR FEBR 1 5 19; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Centers for Disease Control, 1994, MMWR, V43, P1; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; *CTR DIS CONTR, 1991, MMWR-MORBID MORTAL W, V40, P1; *CTR DIS CONTR PRE, 1996, MMWR-MORBID MORTAL W, V46, P468; DEROSSI A, 1993, AIDS, V7, P1528, DOI 10.1097/00002030-199311000-00020; DULIEGE AM, 1995, J PEDIATR-US, V126, P625, DOI 10.1016/S0022-3476(95)70365-9; DUNN DT, 1995, AIDS, V9, pF9; Fiscus Susan A., 1996, JAMA (Journal of the American Medical Association), V275, P1483, DOI 10.1001/jama.275.19.1483; GOEDERT JJ, 1989, LANCET, V2, P1351; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; Mayaux MJ, 1996, JAMA-J AM MED ASSOC, V275, P606, DOI 10.1001/jama.275.8.606; MAYERS MM, 1991, PEDIATRICS, V88, P1248; McCalla S, 1995, AM J PUBLIC HEALTH, V85, P1695, DOI 10.2105/AJPH.85.12.1695; MINKOFF HL, 1990, AM J OBSTET GYNECOL, V163, P521, DOI 10.1016/0002-9378(90)91188-I; NANDA D, 1990, NEW YORK STATE J MED, V90, P488; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SIMMONDS RJ, 1996, P 11 INT C AIDS JUL; SPEILBERG F, 1996, ANN INTERN MED, V125, P509; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stetler HC, 1997, AIDS, V11, P369, DOI 10.1097/00002030-199703110-00015	25	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1743	1744		10.1001/jama.279.21.1743	http://dx.doi.org/10.1001/jama.279.21.1743			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624029				2022-12-01	WOS:000073878700037
J	Takahashi, N; Nishida, H; Kato, H; Imanishi, K; Sakata, Y; Uchiyama, T				Takahashi, N; Nishida, H; Kato, H; Imanishi, K; Sakata, Y; Uchiyama, T			Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period	LANCET			English	Article							HUMAN T-CELLS; STAPHYLOCOCCAL ENTEROTOXIN-B; CLASS-II MOLECULES; YERSINIA-PSEUDOTUBERCULOSIS; BACTERIAL SUPERANTIGEN; PATHOLOGIC FINDINGS; ACCESSORY CELLS; MICE; STIMULATION; ACTIVATION	Background We have seen a number of patients who developed systemic exanthema and thrombocytopenia in the first week of life. Although nearly 100% of the patients were cariers of meticillin-resistant Staphylococcus aureus (MRSA), no clear link between MRSA and this exanthematous disease has yet been made. Methods 20 neonates with exanthema and thrombocytopenia were selected for study. To see whether superantigenic exotoxins from MRSA are involved in the pathogensis of the exanthematous disease, we studied the production of these exotoxins by MRSA isolates from the neonates. We studied the expression of T-cell-receptor VP and CD45R0 in T cells taken from four of the neonates. We also analysed the DNA sequences of 16 cloned V beta 2-positive T-cell-receptor-chain genes taken from two of the neonates. Findings Although most of the patients recovered within 5 days of onset of the exanthematous disease without any active treatment, two preterm infants died in the recovery phase. All patients showed colonisation by MRSA. The MRSA produced toxic shock syndrome toxin-1 (TSST-1). The number of T cells positive for T-cell-receptor V beta 2, reactive to TSST-1, was increased in the four patients studied (p<0.0001), and these T cells expressed CD45R0 (p=0.0185). None of the V beta 2 clones had the same junctional sequences. Interpretation The polyclonal expansion of V beta 2-positive T cells in patients colonised by TSST-1-producing MRSA suggests that the pathogenic micro-organism of this neonatal exanthematous disease is S aureus, mainly MRSA, and that in its pathogenesis it activates T cells by TSST-1. Although the pathogenesis of both this exanthematous disease and toxic shock syndrome are fundamentally the same, a diagnosis of toxic shock syndrome cannot be made in this case, based on the clinical criteria for toxic shock syndrome. We propose neonatal toxic-shock-syndrome-like exanthematous disease (NTED) as the name for this disease.	Tokyo Womens Univ, Sch Med, Maternal & Perinatal Ctr, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1628666, Japan		Takahashi, N (corresponding author), Tokyo Womens Univ, Sch Med, Maternal & Perinatal Ctr, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.							Abe J, 1997, J CLIN INVEST, V99, P1823, DOI 10.1172/JCI119349; ABE J, 1993, J IMMUNOL, V151, P4183; AKATSUKA H, 1994, CLIN EXP IMMUNOL, V96, P422; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWAMURA M, 1995, ACTA PAEDIATR, V84, P10, DOI 10.1111/j.1651-2227.1995.tb13475.x; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kuroda K, 1996, J IMMUNOL, V157, P1422; LARKIN SM, 1982, ANN INTERN MED, V96, P858, DOI 10.7326/0003-4819-96-6-858; LOTZE MT, 1985, J IMMUNOL, V135, P2865; MAKIMOTO A, 1996, J JPN PEDIAT SOC, V100, P609; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATSUO Y, 1997, J JPN SOC PREMATURE, V9, P86; MIYOSHIAKIYAMA T, 1995, J IMMUNOL, V154, P5228; OKADA T, 1997, J JPN PEDIAT SOC, V101, P631; PARIS AL, 1982, ANN INTERN MED, V96, P852, DOI 10.7326/0003-4819-96-6-852; PARSONNET J, 1987, INFECT IMMUN, V55, P1070, DOI 10.1128/IAI.55.5.1070-1076.1987; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SAKATA Y, 1997, JPN J OBSTET GYNECOL, V7, pS107; SCHATTNER A, 1981, LANCET, V2, P497; TAKAHASHI N, 1995, J IMMUNOL, V155, P5213; Takahashi N, 1997, ARCH DIS CHILD-FETAL, V77, pF79; Takahashi N., 1995, ACTA NEONAT JPN, V31, P371; TAUCHI M, 1993, J JPN PEDIAT SOC, V97, P1184; TODD J K, 1988, Clinical Microbiology Reviews, V1, P432; UCHIYAMA T, 1993, J IMMUNOL, V151, P4407; UCHIYAMA T, 1994, MICROBIOL IMMUNOL, V38, P245, DOI 10.1111/j.1348-0421.1994.tb01772.x; UCHIYAMA T, 1989, J IMMUNOL, V143, P3175; UCHIYAMA T, 1989, EUR J IMMUNOL, V19, P1803, DOI 10.1002/eji.1830191007; UCHIYAMA T, 1987, CLIN EXP IMMUNOL, V68, P638; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAMANISHI K, 1988, LANCET, V1, P1065	35	80	82	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1614	1619		10.1016/S0140-6736(97)11125-4	http://dx.doi.org/10.1016/S0140-6736(97)11125-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620715				2022-12-01	WOS:000074026600008
J	Guttman, DS; Charlesworth, D				Guttman, DS; Charlesworth, D			An X-linked gene with a degenerate Y-linked homologue in a dioecious plant	NATURE			English	Article							DOSAGE COMPENSATION; SEX DETERMINATION; MELANDRIUM-ALBUM; FLOWERING PLANTS; EVOLUTION; CHROMOSOMES; EXPRESSION; OVERLAP; SILENE; MODEL	Most flowering plants are hermaphroditic, having flowers with both male and female parts. Less than 4% of plant species are dioecious (with individuals of separate sexes), and many of these species have chromosome-mediated sex determination. The taxonomic distribution of separate sexes and chromosomal sex-determination systems in the flowering planes indicates that plant sex chromosomes have evolved recently through replicated, independent events(1-4), contrasting with the ancient origins of mammalian and insect sex chromosomes. Plant sex chromosomes, therefore, offer opportunities to study the most interesting early stages of the evolution of sex chromosomes. Here we show that a gene encoding a male-specific protein is linked to the X chromosome in the dioecious plant Silene latifolia, and that it has a degenerate homologue in the non-pairing region of the Y chromosome. The Y-linked locus has degenerated as a result of nucleotide deletion and the accumulation of repetitive sequences. We have identified both the first X-linked gene and the first pair of homologous sex-linked loci to be found in plants. The homology between the active X-linked locus and the degenerate Y-linked locus supports a common ancestry for these two loci.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Guttman, DS (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 1103 E 57th St, Chicago, IL 60637 USA.		Guttman, David S/A-7839-2011; Charlesworth, Deborah/F-3071-2011	Guttman, David S/0000-0001-8479-3869; 				CHARLESWORTH B, 1978, AM NAT, V112, P975, DOI 10.1086/283342; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Charlesworth D., 1985, EVOLUTION ESSAYS HON, P237; Darwin C.R., 1876, EFFECTS CROSS SELF F; Desfeux C, 1996, P ROY SOC B-BIOL SCI, V263, P409, DOI 10.1098/rspb.1996.0062; Donnison IS, 1996, GENETICS, V144, P1893; GRANT S, 1994, DEV GENET, V15, P214, DOI 10.1002/dvg.1020150304; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Guttman DS, 1996, J CLIN MICROBIOL, V34, P652, DOI 10.1128/JCM.34.3.652-656.1996; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; JUKES T H, 1969, P21; Matsunaga S, 1996, PLANT J, V10, P679, DOI 10.1046/j.1365-313X.1996.10040679.x; MAYER SS, 1992, EVOLUTION, V46, P207, DOI 10.1111/j.1558-5646.1992.tb01995.x; Nei M., 1987, MOL EVOLUTIONARY GEN, P1, DOI DOI 10.7312/NEI-92038; PEDERSEN S, 1987, THEOR APPL GENET, V75, P200, DOI 10.1007/BF00249164; REJON CR, 1994, HEREDITY, V72, P209, DOI 10.1038/hdy.1994.28; STINSON JR, 1987, PLANT PHYSIOL, V83, P442, DOI 10.1104/pp.83.2.442; TANKSLEY SD, 1981, SCIENCE, V213, P453, DOI 10.1126/science.213.4506.453; VANNIGTE.G, 1966, GENETICA, V37, P281, DOI 10.1007/BF01547140; VANNIGTEVECHT G, 1966, GENETICA, V37, P307, DOI 10.1007/BF01547141; VYSKOT B, 1993, MOL GEN GENET, V239, P219, DOI 10.1007/BF00281621; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; ZUK J, 1969, CHROMOSOMES TODAY, V2, P183	25	110	118	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					263	266		10.1038/30492	http://dx.doi.org/10.1038/30492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607762				2022-12-01	WOS:000073761000052
J	Newburg, DS; Peterson, JA; Ruiz-Palacios, GM; Matson, DO; Morrow, AL; Shults, J; Guerrero, MD; Chaturvedi, P; Newburg, SO; Scallan, CD; Taylor, MR; Ceriani, RL; Pickering, LK				Newburg, DS; Peterson, JA; Ruiz-Palacios, GM; Matson, DO; Morrow, AL; Shults, J; Guerrero, MD; Chaturvedi, P; Newburg, SO; Scallan, CD; Taylor, MR; Ceriani, RL; Pickering, LK			Role of human-milk lactadherin in protection against symptomatic rotavirus infection	LANCET			English	Article							FAT-GLOBULE-MEMBRANE; ESCHERICHIA-COLI; MEXICAN CHILDREN; OLIGOSACCHARIDES; DIARRHEA; RECEPTOR; GASTROENTERITIS; INHIBITION; COHORT; MUCIN	Background Human milk contains a 46 kDa mucin-associated glycoprotein, lactadherin, which binds specifically to rotavirus and inhibits its replication. This study tested the hypothesis that lactadherin protects against symptoms of rotavirus infection. Methods 200 infants in Mexico City were recruited at birth and monitored by regular stool EIA for rotavirus, serology, and recording of feeding and stool patterns. Milk samples were obtained from the mothers weekly until 4 weeks post partum then monthly. The sample taken immediately before an infant's episode of rotavirus infection was assayed for lactadherin, butyrophilin, mucin, and secretory IgA. An infection was defined as symptomatic if diarrhoea occurred in the 5 days before or after detection of the virus. Findings 31 infants developed rotavirus infection; 15 were symptomatic and 16 had no symptoms. The median concentration of lactadherin in the milk samples (obtained 4-41 days [median 13] before the infection) was 484 (range 5.6-180) mu g/mL in the asymptomatic group and 29.2 (6.2-103.4) mu g/mL in the symptomatic group. Although these medians did not differ significantly, in logistic regression analysis adjusted for age at infection and secretory IgA concentration there was a significant difference between the groups (p=0.01). No association between symptom status and concentrations of butyrophilin, mucin, or secretory IgA was found. Interpretation Protection against rotavirus by human milk is associated with the glycoprotein lactadherin. This association is independent of products of the secretory immune system.	Shriver Ctr Mental Retardat, Waltham, MA 02254 USA; Harvard Univ, Sch Med, Boston, MA USA; Canc Res Inst Contra Costa, Walnut Creek, CA USA; Inst Nacl Nutr Salvador Zubiran, Mexico City 14000, DF, Mexico; Childrens Hosp Kings Daughters, Ctr Pediat Res, Norfolk, VA USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA	Harvard University; Harvard Medical School; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Eastern Virginia Medical School	Newburg, DS (corresponding author), Shriver Ctr Mental Retardat, 200 Trapelo Rd, Waltham, MA 02254 USA.		Morrow, Ardythe/GQO-8482-2022; Ruiz-Palacios, Guillermo/GYQ-5462-2022; Newburg, david/ABE-8139-2020; Taylor, Michael/K-1379-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD013021] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030444] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA039932] Funding Source: NIH RePORTER; NCI NIH HHS [CA39932] Funding Source: Medline; NICHD NIH HHS [HD30444, HD13021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; Ashkenazi S, 1991, Adv Exp Med Biol, V310, P173; Buchheim W., 1988, Nestle Nutrition Workshop Series, V15, P27; CALVA JJ, 1988, LANCET, V1, P503; CERIANI RL, 1992, ANAL BIOCHEM, V201, P178, DOI 10.1016/0003-2697(92)90192-A; CERIANI RL, 1992, MONOCLONAL ANTIBODIE, P398; DUWE AK, 1989, BIOCHEM BIOPH RES CO, V165, P1305, DOI 10.1016/0006-291X(89)92745-9; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; LOPEZVIDA Y, 1990, J INFECT DIS, V162, P442, DOI 10.1093/infdis/162.2.442; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Newburg DS, 1996, J MAMMARY GLAND BIOL, V1, P271, DOI 10.1007/BF02018080; NEWBURG DS, 1992, J INFECT DIS, V166, P832, DOI 10.1093/infdis/166.4.832; NEWBURG DS, 1992, PEDIATR RES, V31, P22, DOI 10.1203/00006450-199201000-00004; NEWBURG DS, 1990, J INFECT DIS, V162, P1075, DOI 10.1093/infdis/162.5.1075; NEWBURG DS, 1996, PEDIATR RES, V39, P229; NEWBURG DS, 1996, PEDIATR RES, V39, pA229; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; OTNAESS AB, 1980, ACTA PATH MICRO IM C, V88, P247; Peterson J. A., 1996, Pediatric Research, V39, p126A; PICKERING LK, 1988, J PEDIATR-US, V112, P361, DOI 10.1016/S0022-3476(88)80313-5; RUIZPALACIOS GM, 1992, CAMPLYLOBACTER JEJUNI, P176; SCHROTEN H, 1992, INFECT IMMUN, V60, P2893, DOI 10.1128/IAI.60.7.2893-2899.1992; SHIMIZU M, 1986, BIOCHEM J, V233, P725, DOI 10.1042/bj2330725; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; VELAZQUEZ FR, 1993, PEDIATR INFECT DIS J, V12, P54, DOI 10.1097/00006454-199301000-00013; VIVERGE D, 1985, ANN NUTR METAB, V29, P1, DOI 10.1159/000176947; WARREN C, 1997, GLYCOBIOLOGY, V6, P730; WEINBERG RJ, 1984, PEDIATRICS, V74, P250; YOLKEN RH, 1992, J CLIN INVEST, V90, P1984, DOI 10.1172/JCI116078; [No title captured]	30	225	252	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1160	1164		10.1016/S0140-6736(97)10322-1	http://dx.doi.org/10.1016/S0140-6736(97)10322-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643686				2022-12-01	WOS:000073220200008
J	Werther, G				Werther, G			Measuring height: to stretch or not to stretch?	LANCET			English	Editorial Material							GROWTH		Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Werther, G (corresponding author), Royal Childrens Hosp, Ctr Hormone Res, Melbourne, Vic 3052, Australia.		Werther, George/B-3784-2012					AHMED ML, 1990, ARCH DIS CHILD, V65, P1345, DOI 10.1136/adc.65.12.1345; BUCKLER JMH, 1978, ARCH DIS CHILD, V53, P762, DOI 10.1136/adc.53.9.762; STRICKLAND AL, 1972, J PEDIATR-US, V80, P1023, DOI 10.1016/S0022-3476(72)80018-0; Voss LD, 1997, ARCH DIS CHILD, V77, P319, DOI 10.1136/adc.77.4.319; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340; WASSE J, 1726, PHILOS T ROY SOC LON, V33, P87; Werther GA, 1996, J PEDIATR-US, V128, pS47, DOI 10.1016/S0022-3476(96)70011-2; WHITEHOUSE RH, 1974, ANN HUM BIOL, V1, P103, DOI 10.1080/03014467400000101	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					309	310		10.1016/S0140-6736(05)78342-2	http://dx.doi.org/10.1016/S0140-6736(05)78342-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652608				2022-12-01	WOS:000071864000006
J	Walter, DH; Schachinger, V; Elsner, M; Dimmeler, S; Zeiher, AM				Walter, DH; Schachinger, V; Elsner, M; Dimmeler, S; Zeiher, AM			Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis	LANCET			English	Article							BALLOON ANGIOPLASTY; ARTERY DISEASE; PLACEMENT	Background Coronary stents are an effective treatment for selected coronary stenoses. However, thrombosis of the stented segment is a major adverse complication. Platelet aggregation has a key role in stent thrombosis. We investigated whether a polymorphism of platelet glycoprotein IIIa gene (PIA2) Is associated with an increased risk of coronary stent thrombosis. Methods 318 consecutive patients were followed up for 30 days after coronary stent insertion. The primary endpoints were death, myocardial infarction, stent-vessel occlusion, and coronary artery bypass surgery. Gel electrophoresis of PCR products was used to identify the PIA1 and PIA2 alleles. The relative risk of stent occlusion was calculated from the odds ratio on logistic regression analysis. Findings 63 (19.8%) of patients had the P1(A2) allele and 255 (80.2%) were homozygous for PIA1. Baseline clinical, angiographic, and procedural features did not differ between the groups with and without the PIA2 allele. Occlusion of the stent vessel occurred in five (1.9%) patients homozygous for PIA1 and six (9.5%) patients with PIA2 allele (odds ratio 5.26 [95% CI 1.55-17.85]). On multivariate regression analysis PIA1/A2 genotype was the only significant independent predictor of stent thrombosis. Interpretation Patients with the PIA2 allele have an increased risk of coronary stent thrombosis, which may warrant antiplatelet therapy with glycoprotein-IIb/IIIa inhibitors, although bleeding complications may also increase.	UNIV FRANKFURT, DEPT INTERNAL MED 4, DIV CARDIOL, D-60590 FRANKFURT, GERMANY	Goethe University Frankfurt				Dimmeler, Stefanie/0000-0002-1045-2436				Albiero R, 1997, CIRCULATION, V95, P1145; Baim DS, 1997, CIRCULATION, V95, P1098; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Carter AM, 1996, LANCET, V348, P485, DOI 10.1016/S0140-6736(05)64592-8; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Neumann FJ, 1996, J AM COLL CARDIOL, V27, P15, DOI 10.1016/0735-1097(95)00433-5; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; REIBER JHC, 1994, PROGR QUANTITATIVE C; Ridker PM, 1997, LANCET, V349, P385, DOI 10.1016/S0140-6736(97)80010-4; Samani NJ, 1997, CARDIOVASC RES, V33, P693, DOI 10.1016/S0008-6363(96)00222-2; SCHACHINGER V, 1994, CIRCULATION, V90, P2258, DOI 10.1161/01.CIR.90.5.2258; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schuhlen H, 1997, CIRCULATION, V95, P2015, DOI 10.1161/01.CIR.95.8.2015; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	23	159	164	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 25	1997	350	9086					1217	1219		10.1016/S0140-6736(97)05399-3	http://dx.doi.org/10.1016/S0140-6736(97)05399-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652563				2022-12-01	WOS:A1997YD23800012
J	Petka, WA; Harden, JL; McGrath, KP; Wirtz, D; Tirrell, DA				Petka, WA; Harden, JL; McGrath, KP; Wirtz, D; Tirrell, DA			Reversible hydrogels from self-assembling artificial proteins	SCIENCE			English	Article							GCN4 LEUCINE-ZIPPER; COILED-COILS; SEQUENCES; MODEL	Recombinant DNA methods were used to create artificial proteins that undergo reversible gelation in response to changes in pH or temperature. The proteins consist of terminal Leucine zipper domains flanking a central, flexible, water-soluble polyelectrolyte segment. Formation of coiled-coil aggregates of the terminal domains in near-neutral aqueous solutions triggers formation of a three-dimensional polymer network, with the polyelectrolyte segment retaining solvent and preventing precipitation of the chain. Dissociation of the coiled-coil aggregates through elevation of pH or temperature causes dissolution of the gel and a return to the viscous behavior that is characteristic of polymer solutions. The mild conditions under which gel formation can be controlled (near-neutral pH and near-ambient temperature) suggest that these materials have potential in bioengineering applications requiring encapsulation or controlled release of molecular and cellular species.	Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; USA, Sci & Technol Directorate, Natick Res Dev & Engn Ctr, Natick, MA 01760 USA	University of Massachusetts System; University of Massachusetts Amherst; Johns Hopkins University	Tirrell, DA (corresponding author), Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA.		Wirtz, Denis/A-3257-2010					CLARK AH, 1987, ADV POLYM SCI, V83, P57; Guenet J.M., 1992, THERMOREVERSIBLE GEL; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mason TG, 1996, J MOL STRUCT, V383, P81, DOI 10.1016/S0022-2860(96)09272-1; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; McGrath K., 1997, PROTEIN BASED MAT; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MORRIS ER, 1980, J MOL BIOL, V138, P349, DOI 10.1016/0022-2836(80)90291-0; Nijenhuis K., 1997, THERMOREVERSIBLE NET; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0; Yu SJM, 1997, NATURE, V389, P167, DOI 10.1038/38254; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	27	887	942	10	386	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					389	392		10.1126/science.281.5375.389	http://dx.doi.org/10.1126/science.281.5375.389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665877				2022-12-01	WOS:000074918800040
J	Poinar, HN; Hofreiter, M; Spaulding, WG; Martin, PS; Stankiewicz, BA; Bland, H; Evershed, RP; Possnert, G; Paabo, S				Poinar, HN; Hofreiter, M; Spaulding, WG; Martin, PS; Stankiewicz, BA; Bland, H; Evershed, RP; Possnert, G; Paabo, S			Molecular coproscopy: Dung and diet of the extinct ground sloth Nothrotheriops shastensis	SCIENCE			English	Article							ANCIENT DNA; ENZYMATIC AMPLIFICATION; EXTRACTION; MECHANISM; RETRIEVAL; SEQUENCES; DAMAGE; PLANTS; FOOD; PCR	DNA from excrements can be amplified by means of the polymerase chain reaction. However, this has not been possible with ancient feces. Cross-Links between reducing sugars and amino groups were shown to exist in a Pleistocene coprolite from Gypsum Cave, Nevada. A chemical agent, N-phenacylthiazolium bromide,,that cleaves such cross-links made it possible to amplify DNA sequences. Analyses of these DNA sequences showed that the coprolite is derived from an extinct sloth, presumably the Shasta ground sloth Nothrotheriops shastensis. Plant DNA sequences from seven groups of plants were identified in the coprolite. The plant assemblage that formed part of the sloth's diet exists today at elevations about 800 meters higher than the cave.	Univ Munich, Max Planck Inst Evolutionary Anthropol, D-80333 Munich, Germany; Univ Munich, Inst Zool, D-80333 Munich, Germany; Dames & Moore, Las Vegas, NV 89119 USA; Univ Arizona, Dept Geosci, Desert Lab, Tucson, AZ 85721 USA; Univ Bristol, Dept Geol, Biogeochem Res Ctr, Bristol BS8 1RJ, Avon, England; Div Ion Phys, Angstrom Lab, S-75121 Uppsala, Sweden	Max Planck Society; University of Munich; University of Munich; University of Arizona; University of Bristol	Poinar, HN (corresponding author), Univ Munich, Max Planck Inst Evolutionary Anthropol, Luisenstr 14, D-80333 Munich, Germany.		Hofreiter, Michael/A-3996-2017	Hofreiter, Michael/0000-0003-0441-4705				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; Evershed RP, 1997, SCIENCE, V278, P432, DOI 10.1126/science.278.5337.432; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; Handt O, 1996, AM J HUM GENET, V59, P368; HANDT O, 1994, SCIENCE, V264, P1775, DOI 10.1126/science.8209259; HANSEN RM, 1978, PALEOBIOLOGY, V4, P302, DOI 10.1017/S0094837300006011; HARRINGTON MR, 1933, GYPSUM CAVE, V8; Hickman J.C., 1993, JEPSON MANUAL; HOSS M, 1993, NUCLEIC ACIDS RES, V21, P3913, DOI 10.1093/nar/21.16.3913; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; HOSS M, 1992, NATURE, V359, P199, DOI 10.1038/359199a0; HOSS M, 1995, THESIS LUDWIGMAXIMIL; KOHN M, 1995, MOL ECOL, V4, P95, DOI 10.1111/j.1365-294X.1995.tb00196.x; Kohn MH, 1997, TRENDS ECOL EVOL, V12, P223, DOI 10.1016/S0169-5347(97)01050-1; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; KRINGS M, 1997, CELL, V90; Laudermilk J.D., 1934, CARNEGIE I WASHINGTO, V453, P31; LEE AT, 1987, MUTAT RES, V179, P151, DOI 10.1016/0027-5107(87)90305-8; LONG A, 1974, SCIENCE, V186, P638, DOI 10.1126/science.186.4164.638; MARTIN PS, 1961, AM J SCI, V259, P102, DOI 10.2475/ajs.259.2.102; MAURON J, 1981, PROG FOOD NUTR SCI, V5, P5; MULDER MM, 1991, J ANAL APPL PYROL, V19, P175, DOI 10.1016/0165-2370(91)80042-7; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1993, SCI AM, V269, P86; Paabo S., 1990, PCR PROTOCOLS GUIDE, P159; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; POINAR HN, UNPUB; SAIZJIMENEZ C, 1984, ORG GEOCHEM, V6, P417, DOI DOI 10.1016/0146-6380(84)90064-0; SPAULDING WG, 1990, PACKRAT MIDDENS LAST, pCH9; Stankiewicz BA, 1997, NEW PHYTOL, V135, P375, DOI 10.1046/j.1469-8137.1997.00638.x; Stankiewicz BA, 1997, SCIENCE, V276, P1541, DOI 10.1126/science.276.5318.1541; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAYLOR P, 1996, MOL BIOL EVOL, V13, P2839; THORNE RF, 1992, BOT REV, V58, P225, DOI 10.1007/BF02858611; VANBERGEN PF, 1994, GEOCHIM COSMOCHIM AC, V58, P3823, DOI 10.1016/0016-7037(94)90366-2; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; WEENEN H, 1994, ACS SYM SER, V543, P142	41	351	373	4	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					402	406		10.1126/science.281.5375.402	http://dx.doi.org/10.1126/science.281.5375.402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665881				2022-12-01	WOS:000074918800044
J	Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK				Shin, DM; Walsh, GL; Komaki, R; Putnam, JB; Nesbitt, J; Ro, JY; Shin, HJC; Ki, KH; Wimberley, A; Pisters, KMW; Schrump, D; Gregurich, MA; Cox, JD; Roth, JA; Hong, WK			A multidisciplinary approach to therapy for unresectable malignant thymoma	ANNALS OF INTERNAL MEDICINE			English	Article							INVASIVE THYMOMA; NEOADJUVANT CHEMOTHERAPY; CLINICAL STAGES; CISPLATIN; SURVIVAL; CYCLOPHOSPHAMIDE; INTERGROUP; RESECTION; PHASE	Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma has been poor. Objective: To improve tumor resectability and patient survival rates by studying a multimodal approach to therapy for unresectable malignant thymoma. Design: Prospective cohort study. Setting: Tertiary care cancer center. Participants: All eligible patients had newly diagnosed, histologically proven, unresectable malignant thymoma. Intervention: The treatment regimen consisted of induction chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone), surgical resection, postoperative radiation therapy, and consolidation chemotherapy (three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone). Tissue samples were taken at the time of surgical resection for assessment of tumor necrosis and Ki-67 expression. Measurements: Tumor response and resectability (both overall and after induction chemotherapy) and disease-free survival rate in patients who received multimodal therapy. Results: 13 patients were consecutively enrolled from February 1990 to December 1996, and 12 evaluable patients were assessed for response. Disease responded to induction chemotherapy completely in 3 patients (25%) and partially in 8 patients (67%); 1 patient had a minor response (8%). Eleven patients had surgical resection; 1 refused surgery. Tumors were removed completely in 9 (82%) and incompletely in 2 (18%) of 11 patients who had been receiving radiation therapy and consolidation chemotherapy. All 12 patients are alive (100% at 7 years), with a median follow-up of 43 months, and 10 patients are disease free (73 % disease-free survival at 7 years). A high correlation was seen between tumor necrosis after induction chemotherapy and Ki-67 expression (r = -0.88). Conclusions: Aggressive multimodal treatment is highly effective and may cure locally advanced, unresectable malignant thymoma.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Shin, DM (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Ray, Dana M/C-3470-2013; Shin, Dong Moon/G-9649-2013	Shin, Dong Moon/0000-0002-8245-4174; Putnam, Joe/0000-0002-7504-2104				BERRUTI A, 1993, ANN ONCOL, V4, P429, DOI 10.1093/oxfordjournals.annonc.a058527; BLUMBERG D, 1995, ANN THORAC SURG, V60, P908, DOI 10.1016/0003-4975(95)00669-C; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COWEN D, 1995, RADIOTHER ONCOL, V34, P9, DOI 10.1016/0167-8140(94)01493-M; Giaccone G, 1996, J CLIN ONCOL, V14, P814, DOI 10.1200/JCO.1996.14.3.814; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOMAKI R, 1994, MOSS RAD ONCOLOGY RA, P320; LOEHRER PJ, 1990, ANN INTERN MED, V113, P520, DOI 10.7326/0003-4819-113-7-520; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164, DOI 10.1200/JCO.1994.12.6.1164; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093, DOI 10.1200/JCO.1997.15.9.3093; MACCHIARINI P, 1991, CANCER, V68, P706, DOI 10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H; MAGGI G, 1986, CANCER-AM CANCER SOC, V58, P765, DOI 10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO;2-S; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; MCCART JA, 1993, J SURG ONCOL, V54, P233, DOI 10.1002/jso.2930540409; PARK HS, 1994, CANCER-AM CANCER SOC, V73, P2491, DOI 10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6; REA F, 1993, J THORAC CARDIOV SUR, V106, P543; THOMAS C R JR, 1990, Current Opinion in Oncology, V2, P359; Uematsu M, 1996, INT J RADIAT ONCOL, V35, P357, DOI 10.1016/0360-3016(96)00086-7; VERLEY JM, 1985, CANCER, V55, P1074, DOI 10.1002/1097-0142(19850301)55:5<1074::AID-CNCR2820550524>3.0.CO;2-T; Yang WI, 1996, HUM PATHOL, V27, P70, DOI 10.1016/S0046-8177(96)90140-9	20	92	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					100	104		10.7326/0003-4819-129-2-199807150-00006	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669967				2022-12-01	WOS:000074852000004
J	Fioretto, P; Steffes, MW; Sutherland, DER; Goetz, FC; Mauer, M				Fioretto, P; Steffes, MW; Sutherland, DER; Goetz, FC; Mauer, M			Reversal of lesions of diabetic nephropathy after pancreas transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR STRUCTURE; NORMAL KIDNEYS; IDDM PATIENTS; LONG-TERM; PROGRESSION; RECIPIENTS; MESANGIUM; MELLITUS; MEMBRANE; GLUCOSE	Background In patients with type 1 diabetes mellitus who do not have uremia and have not received a kidney transplant, pancreas transplantation does not ameliorate established lesions of diabetic nephropathy within five years after transplantation, but the effects of longer periods of normoglycemia are un known. Methods We studied kidney function and performed renal biopsies before pancreas transplantation and 5 and 10 years thereafter in eight patients with type 1 diabetes but without uremia who had mild to advanced lesions of diabetic nephropathy at the time of transplantation. The biopsy samples were analyzed morphometrically. Results All patients had persistently normal glycosylated hemoglobin values after transplantation. The median urinary albumin excretion rate was 103 mg per day before transplantation, 30 mg per day 5 years after transplantation, and 20 mg per day 10 years after transplantation (P=0.07 for the comparison of values at base line and at 5 years; P=0.11 for the comparison between base line and 10 years). The mean (+/-SD) creatinine clearance rate declined from 108+/-20 ml per minute per 1.73 m(2) of body-surface area at base line to 74+/-16 ml per minute per 1.73 m(2) at 5 years (P<0.001) and 74+/-14 ml per minute per 1.73 m(2) at 10 years (P<0.001). The thickness of the glomerular and tubular basement membranes was similar at 5 years (570+/-64 and 928+/-173 nm, respectively) and at base line (594+/-81 and 911+/-133 nm, respectively) but had decreased by 10 years (to 404+/-38 and 690+/-111 nm, respectively; P<0.001 and P=0.004 for the comparisons with the base-line values). The mesangial fractional volume (the proportion of the glomerulus occupied by the mesangium) increased from base line (0.33+/-0.07) to 5 years (0.39+/-0.10, P=0.02) but had decreased at 10 years (0,27+/-0.02, P=0.05 for the comparison with the baseline value and P=0.006 for the comparison with the value at 5 years), mostly because of a reduction in mesangial matrix. Conclusions Pancreas transplantation can reverse the lesions of diabetic nephropathy, but reversal requires more than five years of normoglycemia, (N Engl J Med 1998;339:69-75.) (C)1998, Massachusetts Medical Society.	Univ Minnesota, Sch Med, Dept Pediat, UMHC, Minneapolis, MN 55455 USA; Univ Padua, Sch Med, Dept Internal Med, Padua, Italy; Univ Padua, Sch Med, Natl Res Council, Ctr Study Aging, Padua, Italy; Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Padua; University of Padua; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Mauer, M (corresponding author), Univ Minnesota, Sch Med, Dept Pediat, UMHC, Box 491,420 Delaware St SE, Minneapolis, MN 55455 USA.		Mauer, Michael/ABD-5415-2020; fioretto, paola/AHD-4415-2022	FIORETTO, PAOLA/0000-0003-3445-0387	NIDDK NIH HHS [DK43605, DK13083] Funding Source: Medline; PHS HHS [MO1-KK00400] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043605, P01DK013083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGSTAD HJ, 1994, DIABETOLOGIA, V37, P483, DOI 10.1007/s001250050136; BARBOSA J, 1994, JAMA-J AM MED ASSOC, V272, P600, DOI 10.1001/jama.272.8.600; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; Brito PL, 1998, KIDNEY INT, V53, P754, DOI 10.1046/j.1523-1755.1998.00809.x; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; FEUTREN G, 1992, NEW ENGL J MED, V326, P1654, DOI 10.1056/NEJM199206183262502; FIORETTO P, 1993, LANCET, V342, P1193, DOI 10.1016/0140-6736(93)92183-T; FIORETTO P, 1995, KIDNEY INT, V48, P1929, DOI 10.1038/ki.1995.493; FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358; FIORETTO P, 1995, KIDNEY INT, V48, P489, DOI 10.1038/ki.1995.318; FIORETTO P, 1992, AM J KIDNEY DIS, V20, P549, DOI 10.1016/S0272-6386(12)70217-2; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LUBEC G, 1980, Renal Physiology, V3, P4; MAUER SM, 1989, DIABETES, V38, P516, DOI 10.2337/diabetes.38.4.516; MAUER SM, 1983, DIABETES, V32, P948, DOI 10.2337/diabetes.32.10.948; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; Moriya Rika, 1996, Journal of the American Society of Nephrology, V7, P1362; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; OSTERBY R, 1991, DIABETOLOGIA, V34, P668, DOI 10.1007/BF00400997; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI DOI 10.2337/DIACARE.1.3.168; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; STEFFES MW, 1985, NEW ENGL J MED, V312, P1282, DOI 10.1056/NEJM198505163122003; SUTHERLAND DER, 1993, AM J SURG, V166, P456, DOI 10.1016/S0002-9610(05)81142-0; SUTHERLAND DER, 1994, TRANSPL P, V26, P379; WEIBEL ER, 1962, J APPL PHYSIOL, V17, P343, DOI 10.1152/jappl.1962.17.2.343; 1994, AM J KIDNEY DIS S2, V24, pS48	33	823	849	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1998	339	2					69	75		10.1056/NEJM199807093390202	http://dx.doi.org/10.1056/NEJM199807093390202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY828	9654536	Bronze			2022-12-01	WOS:000074665300002
J	Cowie, LL; Songaila, A				Cowie, LL; Songaila, A			Heavy-element enrichment in low-density regions of the intergalactic medium	NATURE			English	Article							LYMAN-ALPHA FOREST; GRAVITATIONAL COLLAPSE; CLOUDS; MODEL; ABUNDANCE	Models for the composition of the diffuse intergalactic medium(1,2) predict that low-density intergalactic gas at high redshift should be very poor in heavy elements. This is because locations of early star formation land thus of heavy-element synthesis) and of gas delivery from such stars are located preferentially within higher-density regions of the intergalactic gas. Here we present a method for analysing carbon and oxygen absorption lines in quasar spectra that allows us to probe the heavy-element abundances at a redshift of three within low-density regions of intergalactic gas. We find that the ratio of triply ionized carbon to neutral hydrogen is roughly constant over a wide range of densities, and that, even as the density approaches zero, the ratio remains high. This unexpected enrichment of low-density gas in heavy elements suggests that early generations of small galaxies might be much more efficient at ejecting heavy elements into the intergalactic medium than has previously been thought.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	University of Hawaii System	Cowie, LL (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.			Cowie, Lennox/0000-0002-6319-1575; Cowie Songaila, Antoinette/0000-0001-9028-6978				Bi HG, 1997, ASTROPHYS J, V479, P523, DOI 10.1086/303908; CEN RY, 1994, ASTROPHYS J, V437, pL9, DOI 10.1086/187670; COWIE LL, 1995, ASTRON J, V109, P1522, DOI 10.1086/117381; Croft RAC, 1997, ASTROPHYS J, V488, P532, DOI 10.1086/304723; Dave R, 1997, ASTROPHYS J, V477, P21, DOI 10.1086/303712; Giroux ML, 1997, ASTRON J, V113, P1505, DOI 10.1086/118367; Gnedin NY, 1998, MON NOT R ASTRON SOC, V294, P407, DOI 10.1046/j.1365-8711.1998.01156.x; Gnedin NY, 1997, ASTROPHYS J, V486, P581, DOI 10.1086/304548; Haardt F, 1996, ASTROPHYS J, V461, P20, DOI 10.1086/177035; Haiman Z, 1997, ASTROPHYS J, V483, P21, DOI 10.1086/304238; Hellsten U, 1997, ASTROPHYS J, V487, P482, DOI 10.1086/304641; Hernquist L, 1996, ASTROPHYS J, V457, pL51, DOI 10.1086/309899; HU EM, 1995, ASTRON J, V110, P1526, DOI 10.1086/117625; Hui L, 1997, MON NOT R ASTRON SOC, V292, P27, DOI 10.1093/mnras/292.1.27; LU LM, 1991, ASTROPHYS J, V379, P99, DOI 10.1086/170487; MEYER D, 1987, ASTROPHYS J, V315, pL8; MiraldaEscude J, 1996, ASTROPHYS J, V471, P582, DOI 10.1086/177992; MiraldaEscude J, 1997, ASTROPHYS J, V478, pL57, DOI 10.1086/310550; NORRIS J, 1983, ASTROPHYS J, V273, P450, DOI 10.1086/161383; PETITJEAN P, 1995, ASTRON ASTROPHYS, V295, pL9; Petitjean P., 1995, Science with VLT. Proceedings of the ESO Workshop, P339; Rauch M, 1997, ASTROPHYS J, V481, P601, DOI 10.1086/304085; SARGENT LL, ASTROPH9802189; Songaila A, 1997, ASTROPHYS J, V490, pL1, DOI 10.1086/311006; Songaila A, 1996, ASTRON J, V112, P335, DOI 10.1086/118018; SONGALILA A, IN PRESS ASTRON J; TYTLER D, 1994, ASTROPHYS J, V424, pL87, DOI 10.1086/187281; ZHANG Y, 1995, ASTROPHYS J, V453, pL57	28	131	132	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					44	46		10.1038/27845	http://dx.doi.org/10.1038/27845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665126				2022-12-01	WOS:000074579600041
J	Pastuszak, AL; Schuler, L; Speck-Martins, CE; Coelho, KEFA; Cordello, SM; Vargas, F; Brunoni, D; Schwarz, IVD; Larrandaburu, M; Safattle, H; Meloni, VFA; Koren, G				Pastuszak, AL; Schuler, L; Speck-Martins, CE; Coelho, KEFA; Cordello, SM; Vargas, F; Brunoni, D; Schwarz, IVD; Larrandaburu, M; Safattle, H; Meloni, VFA; Koren, G			Use of misoprostol during pregnancy and Mobius syndrome in infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOEBIUS SYNDROME; VASCULAR ETIOLOGY; ILLEGAL ABORTION; BRAZIL; TERATOGENICITY; MIFEPRISTONE; TRIMESTER	Background Patients with upper gastrointestinal ulceration may be treated with misoprostol, but it is not recommended for pregnant women because it may stimulate uterine contractions and cause vaginal bleeding and miscarriage. Recent data from Bra zil, where misoprostol is used orally and vaginally as an abortifacient, have suggested a relation between the use of misoprostol by women in an unsuccessful attempt to terminate pregnancy and Mobius' syndrome (congenital facial paralysis) in their infants. Methods We compared the frequency of misoprostol use during the first trimester by mothers of infants in whom Mobius' syndrome was diagnosed and mothers of infants with neural-tube defects in Brazil. All diagnoses in infants were made between January 16, 1990, and May 31, 1996, by clinical geneticists at seven hospitals who also interviewed the mothers and recorded information about the administration of misoprostol, among other data. Results We identified 96 infants with Mobius' syndrome and matched them with 96 infants with neural-tube defects. The mean age at the time of the diagnosis of Mobius' syndrome was 16 months (range, 0.5 to 78), and the diagnosis of neural-tube defects was made within 1 week of birth in most cases. Among the mothers of the 96 infants with Mobius' syndrome, 47 (49 percent) had used misoprostol in the first trimester of pregnancy, as compared with 3 (3 percent) of the mothers of the 96 infants with neural-tube defects (odds ratio, 29.7; 95 percent confidence interval, 11.6 to 76.0). Twenty of the mothers of the infants with Mobius' syndrome had taken misoprostol only orally (odds ratio, 38.8; 95 percent confidence interval, 9.5 to 159.4), 20 had taken misoprostol both orally and vaginally, 3 had taken the drug vaginally, and 4 did not report how they took the drug. Conclusions Attempted abortion with misoprostol is associated with an increased risk of Mobius' syndrome in infants. (N Engl J Med 1998;338:1881-5.) (C) 1998, Massachusetts Medical Society.	Univ Toronto, Hosp Sick Children, Fetal Diag & Treatment Ctr, Motherisk Program, Toronto, ON M5G 1X8, Canada; Univ Fed Rio Grande Sul, Dept Genet, Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Unidade Genet, Porto Alegre, RS, Brazil; Rede Hosp Sarah, Setor Genet, Brasilia, DF, Brazil; Rede Hosp Sarah, Setor Genet, Salvador, BA, Brazil; Hosp Univ Graffre Guinle, Setor Genet, Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Genet, Sao Paulo, Brazil; Hosp Serv Publ Estado Sao Paulo, Unidade Citogenet, Sao Paulo, Brazil	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Universidade Federal do Rio Grande do Sul; Universidade Federal de Sao Paulo (UNIFESP); Instituto de Assistencia Medica ao Servidor Publico Estadual (IAMSPE)	Pastuszak, AL (corresponding author), Univ Toronto, Hosp Sick Children, Fetal Diag & Treatment Ctr, Motherisk Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Meloni, Vera/O-8378-2015; SCHULER-FACCINI, LAVINIA/C-8309-2013; Schwartz, Ida/M-1422-2015; Brunoni, Decio/K-3155-2012; Vargas, Fernando/V-1934-2019; SCHULER-FACCINI, LAVINIA/K-2927-2016; Koren, Gideon/AAG-7726-2019	Meloni, Vera/0000-0003-4954-8766; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Schwartz, Ida/0000-0002-7933-6687; SCHULER-FACCINI, LAVINIA/0000-0002-2428-0460; Koren, Gideon/0000-0002-9234-0875				BAIRD DT, 1992, LANCET, V339, P313, DOI 10.1016/0140-6736(92)91392-L; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; CASTILLA EE, 1994, AM J MED GENET, V51, P161, DOI 10.1002/ajmg.1320510217; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; COSTA SH, 1993, LANCET, V341, P1486; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P189; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P213; ESAKI K, 1985, JITCHUKEN ZENRINSHO, V11, P167; Fonseca W, 1996, REV SAUDE PUBL, V30, P13, DOI 10.1590/S0034-89101996000100003; Genest D. R., 1994, Teratology, V49, P418; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; HOLMES LB, 1995, J PEDIATR-US, V126, P131, DOI 10.1016/S0022-3476(95)70516-3; KUMAR D, 1990, J MED GENET, V27, P122, DOI 10.1136/jmg.27.2.122; LIPSON AH, 1989, TERATOLOGY, V40, P339, DOI 10.1002/tera.1420400406; Lipson AH, 1996, EUR J PEDIATR, V155, P800, DOI 10.1007/BF02002911; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PAUMGARTTEN FJR, 1995, BRAZ J MED BIOL RES, V28, P355; SCHULER L, 1992, LANCET, V339, P437, DOI 10.1016/0140-6736(92)90131-L; Schuler L., 1997, Teratology, V55, P36; SHEPARD TH, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91540-0; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	24	149	160	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1881	1885		10.1056/NEJM199806253382604	http://dx.doi.org/10.1056/NEJM199806253382604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637807				2022-12-01	WOS:000074352800004
J	Chen, CY; Del Gatto-Konczak, F; Wu, ZG; Karin, M				Chen, CY; Del Gatto-Konczak, F; Wu, ZG; Karin, M			Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway	SCIENCE			English	Article							MESSENGER-RNA DEGRADATION; TUMOR-NECROSIS-FACTOR; AU-RICH ELEMENTS; PROTEIN-KINASE; 3'-UNTRANSLATED REGION; MAP KINASE; GENE-EXPRESSION; ACTIVATION; CELLS; IDENTIFICATION	Signaling pathways that stabilize interleukin-2 (IL-2) messenger RNA (mRNA) in activated T cells were examined. IL-2 mRNA contains at least two cis elements that mediated its stabilization in response to different signals, including activation of c-Jun amino-terminal kinase (JNK). This response was mediated through a cis element encompassing the 5' untranslated region (UTR) and the beginning of the coding region. IL-2 transcripts lacking this 5' element no longer responded to JNK activation but were still responsive to other signals generated during T cell activation, which were probably sensed through the 3' UTR. Thus, multiple elements within IL-2 mRNA modulate its stability in a combinatorial manner, and the JNK pathway controls turnover as well as synthesis of IL-2 mRNA.	Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA.		Del Gatto-Konczak, Fabienne/L-1506-2015					AKAHANE K, 1991, J IMMUNOL, V146, P4190; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen C.L., UNPUB; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1028; ELIAS JA, 1990, J IMMUNOL, V145, P161; GUBA SC, 1989, J CLIN INVEST, V84, P1701, DOI 10.1172/JCI114352; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IWAI Y, 1993, J IMMUNOL, V150, P4386; IWAI Y, 1991, J BIOL CHEM, V266, P17959; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KRAMNIK I, 1993, J IMMUNOL METHODS, V162, P143, DOI 10.1016/0022-1759(93)90379-L; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	41	318	325	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1945	1949		10.1126/science.280.5371.1945	http://dx.doi.org/10.1126/science.280.5371.1945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632395				2022-12-01	WOS:000074323800067
J	Ho, DD				Ho, DD			Toward HIV eradication or remission: The tasks ahead	SCIENCE			English	Editorial Material							LIFE-SPAN; IN-VIVO; T-CELLS; LYMPHOCYTES; TURNOVER; NAIVE		Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Rockefeller University	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org						Cao Y., UNPUB; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; HAVLIR DV, 1998, 5 C RETR OPP INF CHI, pLB16; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; MORRIS L, IN PRESS J EXP MED; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PERELSON AS, UNPUB; RAFFI F, 1998, 5 C RETR OPP INF CHI, pLB15; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; VESANEN M, 1997, INT WORKSH HIV DRUG; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	23	148	158	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1866	1867		10.1126/science.280.5371.1866	http://dx.doi.org/10.1126/science.280.5371.1866			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669944				2022-12-01	WOS:000074323800040
J	Link, MS; Wang, PJ; Pandian, NG; Bharati, S; Udelson, JE; Lee, MY; Vecchiotti, MA; VanderBrink, BA; Mirra, G; Maron, BJ; Estes, NAM				Link, MS; Wang, PJ; Pandian, NG; Bharati, S; Udelson, JE; Lee, MY; Vecchiotti, MA; VanderBrink, BA; Mirra, G; Maron, BJ; Estes, NAM			An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BASEBALL; HEART	Background The syndrome of sudden death due to low-energy trauma to the chest wall (commotio cordis) has been described in young sports participants, but the mechanism is unknown. Methods We developed a swine model of commotio cordis in which a low-energy impact to the chest wall was produced by a wooden object the size and weight of a regulation baseball. This projectile was thrust at a velocity of 30 miles (48 km) per hour and was timed to the cardiac cycle. Results We first studied 18 young pigs, 6 subjected to multiple chest impacts and 12 to single impacts. Of the 10 impacts occurring within the window from 30 to 15 msec before the peak of the T wave on the electrocardiogram, 9 produced ventricular fibrillation. Ventricular fibrillation was not produced by impacts at any other time during the cardiac cycle. Of the 10 impacts sustained during the QRS complex, 4 resulted in transient complete heart block. We also studied whether the use of safety baseballs, which are softer than standard ones, would reduce the risk of arrhythmia. A total of 48 additional animals sustained up to three impacts during the T-wave window of vulnerability to ventricular fibrillation with a regulation baseball and safety baseballs of three degrees of hardness. We found that the likelihood of ventricular fibrillation was proportional to the hardness of the ball, with the softest balls associated with the lowest risk (two instances of ventricular fibrillation after 26 impacts, as compared with eight instances after 23 impacts with regulation baseballs). Conclusions This experimental model of commotio cordis closely resembles the clinical profile of this catastrophic event. Whether ventricular fibrillation occurred depended on the precise timing of the impact. Safety baseballs, as compared with regulation balls, may reduce the risk of commotio cordis. (C) 1998, Massachusetts Medical Society.	Tufts Univ, New England Med Ctr, Cardiac Arrhythmia Serv, Boston, MA 02111 USA; EHS Christ Hosp & Med Ctr, Heart Inst Children, Maurice Lev Congenital Heart & Conduct Ctr, Oak Lawn, IL 60453 USA; Minneapolis Heart Inst Fdn, Cardiovasc Res Div, Minneapolis, MN USA	Tufts Medical Center; Tufts University; Minneapolis Heart Institute Foundation	Link, MS (corresponding author), Tufts Univ, New England Med Ctr, Cardiac Arrhythmia Serv, Box 197,750 Washington St, Boston, MA 02111 USA.							ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; Adler P, 1996, YOUTH BASEBALL PROTE, P1; BHARATI S, 1991, CHEST, V100, P207, DOI 10.1378/chest.100.1.207; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; HOWE BB, 1968, ACTA ANAT, V71, P13, DOI 10.1159/000143165; Janda DH., 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KLEBER AG, 1978, CIRC RES, V42, P603, DOI 10.1161/01.RES.42.5.603; KYLE SB, 1996, YOUTH BASEBALL PROTE; LIEDTKE AJ, 1974, AM J PHYSIOL, V226, P377, DOI 10.1152/ajplegacy.1974.226.2.377; LINK MS, IN PRESS CHEST; Maron BJ, 1997, AM J CARDIOL, V79, P840, DOI 10.1016/S0002-9149(96)00887-9; MARON BJ, 1995, NEW ENGL J MED, V333, P337, DOI 10.1056/NEJM199508103330602; MARON BJ, 1997, CIRCULATION S1, V96, P755; Morikawa M, 1996, CLIN CARDIOL, V19, P831; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Viano DC, 1992, CLIN J SPORT MED, V2, P166	19	235	242	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1805	1811		10.1056/NEJM199806183382504	http://dx.doi.org/10.1056/NEJM199806183382504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632447				2022-12-01	WOS:000074197500004
J	Poulson, J				Poulson, J			Bitter pills to swallow	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada	University of Toronto	Poulson, J (corresponding author), Univ Toronto, Fac Med, Toronto, ON M5S 1A1, Canada.								0	11	12	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1998	338	25					1844	1846		10.1056/NEJM199806183382512	http://dx.doi.org/10.1056/NEJM199806183382512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU443	9632455				2022-12-01	WOS:000074197500012
J	Rosenberg, PS; Biggar, RJ				Rosenberg, PS; Biggar, RJ			Trends in HIV incidence among young adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJECTING DRUG-USERS; INCUBATION PERIOD; HOMOSEXUAL MEN; AIDS EPIDEMIC; INFECTION; MORTALITY; AGE	Context.-Behaviors that result in potential exposure to human immunodeficiency virus (HIV) usually begin in adolescence or young adulthood, but trends in HIV incidence in young people remain unclear. Objective.-To estimate trends in HIV incidence in teenagers and young adults. Design and Setting.-Back-calculation of past HIV incidence in persons born between 1960 and 1974 using US national acquired immunodeficiency syndrome (AIDS) incidence data and estimates of the distribution of times between HIV infection and AIDS. Main Outcome Measures.-Incidence and prevalence of HIV in 1988 and 1993 in persons aged 20 and 25 years, respectively, in each of those years. Results.-As of January 1993, about 22 000 men and 11 000 women aged 18 to 22 years were living with HIV infection in the United States. Homosexual contact was the leading route of infection among young men. Heterosexual contact was the leading route of infection among young women. The HIV incidence attributed to homosexual contact or injection drug use decreased among persons aged 20 and 25 years between 1988 and 1993, but HIV incidence attributed to heterosexual contact was stable or increasing. Notably, in men aged 20 and 25 years, HIV prevalence declined by about 50% in white men but was relatively stable in black and Hispanic men. In contrast, HIV prevalence in women aged 20 and 25 years rose by 36% and 45%, respectively, because of increasing heterosexual transmission. Overall, HIV prevalence in persons aged 20 and 25 years declined by only 14% between 1988 and 1993. Conclusions.-In young persons, HIV incidence in homosexual men and injection drug users was slowing by 1993; this favorable trend was offset by increasing heterosexual transmission, especially in minorities.	NCI, Biostat Branch, Bethesda, MD 20892 USA; NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, PS (corresponding author), NCI, Biostat Branch, 6130 Execut Blvd,EPN-403, Bethesda, MD 20892 USA.			Rosenberg, Philip/0000-0001-6349-9126	NIAID NIH HHS [U01-AI-35041, U01-AI-35040, U01-AI-35039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041, U01AI035039, U01AI035040] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1996, HIV AIDS SURV REP, P1; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P889; CELUM C, 1997, 4 C RETR OPP INF JAN; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V18, P1; Cohen J, 1997, SCIENCE, V275, P615, DOI 10.1126/science.275.5300.615; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HOOVER DR, 1996, 11 INT C AIDS JUL 7; *I MED, 1997, HIDD EP CONFR SEX TR; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Karon JM, 1997, J ACQ IMMUN DEF SYND, V16, P116, DOI 10.1097/00042560-199710010-00007; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; McQuillan GM, 1997, J ACQ IMMUN DEF SYND, V14, P355, DOI 10.1097/00042560-199704010-00008; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Rosenberg PS, 1998, STAT MED, V17, P155, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;155::AID-SIM758&gt;3.0.CO;2-O; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; *US CENS BUR, 1997, OFF STAT; VANHAASTRECHT HJA, 1994, AIDS, V8, P363, DOI 10.1097/00002030-199403000-00011; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911; ZACCARELLI M, 1994, AIDS, V8, P345, DOI 10.1097/00002030-199403000-00008	25	99	100	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1894	1899		10.1001/jama.279.23.1894	http://dx.doi.org/10.1001/jama.279.23.1894			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT653	9634261	Bronze			2022-12-01	WOS:000074109700037
J	Blanch, G; Quenby, S; Ballantyne, ES; Gosden, CM; Neilson, JP; Holland, K				Blanch, G; Quenby, S; Ballantyne, ES; Gosden, CM; Neilson, JP; Holland, K			Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study	BRITISH MEDICAL JOURNAL			English	Article									Univ Liverpool, Dept Obstet & Gynaecol, Liverpool L69 3BX, Merseyside, England; Liverpool Womens Hosp, Day Care Abort Unit, Liverpool, Merseyside, England	University of Liverpool; University of Liverpool	Blanch, G (corresponding author), Univ Liverpool, Dept Obstet & Gynaecol, Liverpool L69 3BX, Merseyside, England.			Quenby, Siobhan/0000-0003-3221-5471				Everett C, 1997, BRIT MED J, V315, P32, DOI 10.1136/bmj.315.7099.32; HUME RF, 1994, FETAL DIAGN THER, V9, P239; KLINE J, 1990, EARLY PREGNANCY FAIL, P240; LELAIDIER C, 1993, HUM REPROD, V8, P492, DOI 10.1093/oxfordjournals.humrep.a138078; WALD NJ, 1994, CIBA F SYMP, V181, P192	5	15	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1712	1713		10.1136/bmj.316.7146.1712	http://dx.doi.org/10.1136/bmj.316.7146.1712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614021	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000074129500023
J	Atkins, C				Atkins, C			God save the child	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1677	1677		10.1001/jama.279.21.1677	http://dx.doi.org/10.1001/jama.279.21.1677			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624008				2022-12-01	WOS:000073878700001
J	Lee, D; Lis, JT				Lee, D; Lis, JT			Transcriptional activation independent of TFIIH kinase and the RNA polymerase II mediator in vivo	NATURE			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; HSP70 GENE; PHOSPHORYLATION; CTD; HOLOENZYME; YEAST; REQUIREMENT; PROMOTER; ENHANCER	The carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II becomes multiply phosphorylated by protein kinases during early steps in the gene transcription cycle both in vivo(1) and in vitro(2). In yeast, the major CTD kinase is a subunit of the general transcription factor TFIIH, and is encoded by an essential gene, KIN28 (ref. 3). Although the CTD and its phosphorylation are important for transcription(4-6), in vitro studies(7,8) have challenged whether CTD phosphorylation is an absolutely required step. The general importance of CTD phosphorylation by Kin28 for transcription in yeast has been suggested because, for all genes tested, transcription is inhibited at the non-permissive temperature in temperature-sensitive kin28 mutants(9,10). However, using such a mutant and a copper-inducible targeted destruction method, we show here that transcription of certain genes can be highly induced even when cells lack Kin28. We also show that transcription of these Kin28-independent genes is independent of Srb4 and Srb6, critical components of the CTD-associated transcriptional mediator complex(11). These results indicate that there are at least two distinct pathways for transcriptional activation: one is dependent on Kin28 and the mediator complex, and the other is not.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Lis, JT (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA.							AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GERBER HP, 1995, NATURE, V374, P60; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316	30	88	88	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					389	392		10.1038/30770	http://dx.doi.org/10.1038/30770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620805				2022-12-01	WOS:000073883600060
J	Schroeter, EH; Kisslinger, JA; Kopan, R				Schroeter, EH; Kisslinger, JA; Kopan, R			Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain	NATURE			English	Article							GOLGI-COMPLEX; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR; PROTEINS; CELLS; VIRUS; RBP-J-KAPPA/SU(H); TRANSDUCTION; SUPPRESSOR; EXPRESSION	Notch proteins are ligand-activated transmembrane receptors involved in cell-fate selection throughout development(1-3). No known enzymatic activity is contained within Notch and the molecular mechanism by which it transduces signals across the cell membrane is poorly understood. In many instances, Notch activation results in transcriptional changes in the nucleus through an association with members of the CSL family of DNA-binding proteins (where CSL stands for CBF1, Su(H), Lag-1)(1-4). As Notch is located in the plasma membrane and CSL is a nuclear protein, two models have been proposed to explain how they interact (Fig. I). The first suggests that the two interact transiently at the membrane(1,5-7). The second postulates that Notch is cleaved by a protease, enabling the cleaved fragment to enter the GRAPHICS nucleus(6,8-14). Here we show that signalling by a constitutively active membrane-bound Notch-1 protein requires the proteolytic release of the Notch inh acellular domain (NICD), which interacts preferentially with CSL, Very small amounts of NICD are active, explaining why it is hard to detect in the nucleus in vivo, We also show that it is ligand binding that induces release of NICD.	Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Kopan, R (corresponding author), Washington Univ, Div Dermatol, Box 8123,4940 Parkview Pl, St Louis, MO 63110 USA.	kopan@pharmdec.wustl.edu	Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022	Kopan, Raphael/0000-0002-0350-2730				ArtavanisTsakonas S, 1997, NAT GENET, V16, P212, DOI 10.1038/ng0797-212; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 1997, J BIOL CHEM, V272, P11336; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gho M, 1996, DEVELOPMENT, V122, P1673; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; QUINN P, 1983, J CELL BIOL, V96, P851, DOI 10.1083/jcb.96.3.851; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wettstein DA, 1997, DEVELOPMENT, V124, P693	30	1339	1396	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					382	386		10.1038/30756	http://dx.doi.org/10.1038/30756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620803				2022-12-01	WOS:000073883600058
J	Springer, S; Schekman, R				Springer, S; Schekman, R			Nucleation of COPII vesicular coat complex by endoplasmic reticulum to Golgi vesicle SNAREs	SCIENCE			English	Article							TRANSPORT VESICLES; SORTING SIGNALS; PROTEINS; RECEPTORS; GLYCOPROTEIN; FUSION; YEAST	Protein trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus involves specific uptake into coat protein complex II (COPII)-coated vesicles of secretory and of vesicle targeting (V-SNARE) proteins. Here, two ER to Golgi v-SNAREs, Bet1p and Bos1p, were shown to interact specifically with Sar1p, Sec23p, and Sec24p, components of the COPII coat, in a guanine nucleotide-dependent fashion. Other v-SNAREs, Sec22p and Ykt6p, might interact more weakly with the COPII coat or interact indirectly by binding to Bet1p or Bos1p. The data suggest that transmembrane proteins can be taken up into COPII vesicles by direct interactions with the coat proteins and may play a structural role in the assembly of the COPII coat complex.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.	schekman@uclink4.berkeley.edu	Springer, Sebastian/AAJ-7036-2021	Springer, Sebastian/0000-0002-5527-6149				Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cellbio.11.1.677; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SPRINGER S, UNPUB; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	32	172	178	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					698	700		10.1126/science.281.5377.698	http://dx.doi.org/10.1126/science.281.5377.698			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685263				2022-12-01	WOS:000075107900042
J	Conti, E; Uy, M; Leighton, L; Blobel, G; Kuriyan, J				Conti, E; Uy, M; Leighton, L; Blobel, G; Kuriyan, J			Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha	CELL			English	Article							AMINO-ACID MOTIF; LARGE-T-ANTIGEN; LOCATION SEQUENCE; PORE COMPLEXES; PROTEIN IMPORT; IDENTIFICATION; BINDING; TRANSPORT; BETA; SUBSTRATE	Selective nuclear import is mediated by nuclear localization signals (NLSs) and cognate transport factors known as karyopherins or importins. Karyopherin alpha recognizes "classical" monopartite and bipartite NLSs. We report the crystal structure of a 50 kDa fragment of the 60 kDa yeast karyopherin alpha, in the absence and presence of a monopartite NLS peptide at 2.2 Angstrom and 2.8 Angstrom resolution, respectively. The structure shows a tandem array of ten armadillo repeats, organized in a right-handed superhelix of helices. Binding of the NLS peptide occurs at two sites within a helical surface groove that is lined by conserved residues. The structure reveals the determinants of NLS specificity and suggests a model for the recognition of bipartite NLSs.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Conti, Elena/0000-0003-1254-5588				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNGER AT, 1998, CRYSTALLOGRAPHIC NMR; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WOZNIAK RW, 1998, IN PRESS TRENDS CELL; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	50	650	668	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					193	204		10.1016/S0092-8674(00)81419-1	http://dx.doi.org/10.1016/S0092-8674(00)81419-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695948	Bronze			2022-12-01	WOS:000075020100008
J	Rees, K; Wright, A; Keeling, JW; Douglas, NJ				Rees, K; Wright, A; Keeling, JW; Douglas, NJ			Facial structure in the sudden infant death syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article							SLEEP-APNEA		Univ Edinburgh, Royal Infirm, Dept Med, Resp Med Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Dept Med, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Paediat Pathol, Edinburgh EH8 9YL, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh	Douglas, NJ (corresponding author), Univ Edinburgh, Royal Infirm, Dept Med, Resp Med Unit, Edinburgh EH3 9YW, Midlothian, Scotland.	n.j.douglas@ed.ac.uk	Douglas, Neil/B-1491-2013	Rees, Karen/0000-0003-1832-3679				KAHN A, 1992, SLEEP, V15, P287, DOI 10.1093/sleep/15.4.287; MATHUR R, 1995, ANN INTERN MED, V122, P174, DOI 10.7326/0003-4819-122-3-199502010-00003; MATHUR R, 1994, LANCET, V344, P819, DOI 10.1016/S0140-6736(94)92375-2; SKATVEDT O, 1994, ARCH DIS CHILD, V71, P133; Tishler PV, 1996, AM J RESP CRIT CARE, V153, P1857, DOI 10.1164/ajrccm.153.6.8665046	5	20	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					179	180		10.1136/bmj.317.7152.179	http://dx.doi.org/10.1136/bmj.317.7152.179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665897	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000075047800024
J	Lutz, C; Ledermann, B; Kosco-Vilbois, MH; Ochsenbein, AF; Zinkernagel, RM; Kohler, G; Brombacher, F				Lutz, C; Ledermann, B; Kosco-Vilbois, MH; Ochsenbein, AF; Zinkernagel, RM; Kohler, G; Brombacher, F			IgD can largely substitute for loss of IgM function in B cells	NATURE			English	Article							IMMUNOGLOBULIN MU-CHAIN; DEFICIENT MICE; GENE; ANTIGEN; TERMINATION; LYMPHOCYTES; EXPRESSION; DISRUPTION; DIFFERENTIATION; RECOMBINATION	The mu and delta heavy chains of IgM and IgD, the first antibody isotypes expressed during bone-marrow B-cell development, are encoded by a common transcription unit. Expression of the mu chain on the surface of late pre-B cells allows their further development to immature B cells. Coexpression of the delta chain and emigration of the immature B cells to the periphery eventually leads to the development of naive mature IgM/IgD double-positive cells. Although IgM is important in driving B-cell development(1), the contribution of IgD is not clear. Here we investigate the function of IgD. We generated mice deficient in IgM (IgM(-/-) mice) by deleting the mu. region in embryonic stem cells. IgM-/- mice showed normal B-cell development and maturation, with IgD replacing membrane-bound and secretory IgM. Moreover, specific B-cell responses and isotype class switches occurred during immunization or infection. In contrast to mice deficient in B cells, IgM(-/-) mice survived infection with vesicular stomatitis virus by developing neutralizing immunoglobulins, but they were more susceptible than wild-type controls with delayed specific immunoglobulin responses. These data lead us to conclude that IgD is largely able to substitute for IgM functions.	Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Novartis Pharma Inc Res, Basel, Switzerland; Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, Plan Les Ouates, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa	Max Planck Society; Novartis; GlaxoSmithKline; University of Zurich; University of Cape Town	Brombacher, F (corresponding author), Max Planck Inst Immunobiol, Stubeweg 51, D-7800 Freiburg, Germany.	fbrombac@uctgshl.uct.ac.za		Ochsenbein, Adrian/0000-0003-1773-5436				Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; Brundler MA, 1996, EUR J IMMUNOL, V26, P2257, DOI 10.1002/eji.1830260943; COICO RF, 1983, J IMMUNOL, V131, P2254; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FREER G, 1994, J VIROL, V68, P3650, DOI 10.1128/JVI.68.6.3650-3655.1994; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; IGLESIAS A, 1987, NATURE, V330, P482, DOI 10.1038/330482a0; Kalinke U, 1996, EUR J IMMUNOL, V26, P2801, DOI 10.1002/eji.1830261202; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LEIST TP, 1987, J IMMUNOL, V138, P2278; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MUMMERY CL, 1990, CELL DIFFER DEV, V30, P195, DOI 10.1016/0922-3371(90)90139-N; NITSCHKE L, 1993, P NATL ACAD SCI USA, V90, P1887, DOI 10.1073/pnas.90.5.1887; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; WEISS EA, 1991, MOL IMMUNOL, V28, P687, DOI 10.1016/0161-5890(91)90110-6; Yuan D, 1996, J IMMUNOL, V157, P2073	30	113	120	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					797	801		10.1038/31716	http://dx.doi.org/10.1038/31716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655395				2022-12-01	WOS:000074433100052
J	Nuorti, JP; Butler, JC; Crutcher, JM; Guevara, R; Welch, D; Holder, P; Elliott, JA				Nuorti, JP; Butler, JC; Crutcher, JM; Guevara, R; Welch, D; Holder, P; Elliott, JA			An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LOUISIANA				TERM-CARE FACILITIES; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; UNITED-STATES; RISK-FACTORS; POLYSACCHARIDE VACCINE; ANTIBIOTIC-THERAPY; HOSPITAL OUTBREAK; CHILDREN; INFECTIONS	Background Outbreaks of pneumococcal disease are uncommon and have occurred mainly in institutional settings. Epidemic, invasive, drug-resistant pneumococcal disease has not been seen among adults in the United States. In February 1996, there was an outbreak of multidrug-resistant pneumococcal pneumonia among the residents of a nursing home in rural Oklahoma. Methods We obtained nasopharyngeai swabs for culture from residents and employees. Streptococcus pneumoniae isolates were serotyped and compared by pulsed-field gel electrophoresis. A retrospective cohort study was conducted to identify factors associated with colonization and disease. Results Pneumonia developed in 11 of 84 residents (13 percent), 3 of whom died. Multidrug-resistant S. pneumoniae, serotype 23F, was isolated from blood and sputum from 7 of the 11 residents with pneumonia (64 percent) and from nasopharyngeal specimens from 17 of the 74 residents tested (23 percent) and 2 of the 69 employees tested (3 percent). All the serotype 23F isolates were identical according to pulsed-field gel electrophoresis. Recent use of antibiotics was associated with both colonization (relative risk, 2.3; 95 percent confidence interval, 1.3 to 4.2) and disease (relative risk, 3.6; 95 percent confidence interval, 1.2 to 10.8). Only three residents (4 percent) had undergone pneumococcal vaccination. After residents received pneumococcal vaccine and prophylactic antibiotics, there were no additional cases of pneumonia, and the rates of carriage decreased substantially. Conclusions In this outbreak a single pneumococcal strain was disseminated among the residents and employees of a nursing home. The high prevalence of colonization with a virulent organism in an unvaccinated population contributed to the high attack rate. Clusters of pneumococcal disease may be underrecognized in nursing homes, and wider use of pneumococcal vaccine is important to prevent institutional outbreaks of drug-resistant S. pneumoniae infection. (N Engl J Med 1998;338:1861-8.) (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; Oklahoma State Dept Hlth, Oklahoma City, OK USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Oklahoma System; University of Oklahoma Health Sciences Center	Butler, JC (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, MS C-23,1600 Clifton Rd, Atlanta, GA 30333 USA.							[Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; BECKSAGUE C, 1994, INFECT CONT HOSP EP, V15, P494; BERK SL, 1985, SOUTHERN MED J, V78, P159, DOI 10.1097/00007611-198502000-00010; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; CARTER R, 1997, 37 INT C ANT AG CHEM, P55; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; CRAIG AS, 1997, 35 ANNM SAN FRANC SE, P77; Dean A.G., 1994, EPI INFO VERSION 6 W; DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FENOLL A, 1991, REV INFECT DIS, V13, P56; Finland M, 1942, MEDICINE, V21, P307, DOI 10.1097/00005792-194209010-00003; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; GESLIN P, 1992, CLIN INFECT DIS, V15, P95, DOI 10.1093/clinids/15.1.95; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; GRAY GC, 1994, AM J EPIDEMIOL, V139, P793, DOI 10.1093/oxfordjournals.aje.a117076; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAGLUND LA, 1993, J INFECT DIS, V168, P1532, DOI 10.1093/infdis/168.6.1532; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; Herrmann KL, 1995, DIAGNOSTIC PROCEDURE, V7th, P121; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JONES SR, 1987, AM J MED, V83, P499, DOI 10.1016/0002-9343(87)90761-3; KATZ PR, 1990, ARCH INTERN MED, V150, P1465, DOI 10.1001/archinte.150.7.1465; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P320; KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84, DOI 10.1093/clinids/15.1.84; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MANDIGERS CMPW, 1994, EUR RESPIR J, V7, P1635, DOI 10.1183/09031936.94.07091635; Mannheimer SB, 1996, J INFECT DIS, V174, P513, DOI 10.1093/infdis/174.3.513; Marrie TJ, 1996, DRUG AGING, V8, P338, DOI 10.2165/00002512-199608050-00003; MCDOUGAL LK, 1995, ANTIMICROB AGENTS CH, V39, P2282, DOI 10.1128/AAC.39.10.2282; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MILLAR MR, 1994, J HOSP INFECT, V27, P99, DOI 10.1016/0195-6701(94)90002-7; MOORE EP, 1988, J INFECTION, V16, P199, DOI 10.1016/S0163-4453(88)94147-3; MUSHER DM, 1993, CLIN INFECT DIS, V17, P66, DOI 10.1093/clinids/17.1.66; Musher DM, 1997, CLIN INFECT DIS, V24, P441, DOI 10.1093/clinids/24.3.441; *NCCLS, 1993, M7A3 NCCLS; Nicolle LE, 1996, INFECT CONT HOSP EP, V17, P119; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RADETSKY MS, 1981, LANCET, V2, P771; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; Reichler MR, 1996, J INFECT DIS, V173, P374, DOI 10.1093/infdis/173.2.374; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHARTZ JS, 1988, ANN INTERN MED, V109, P762; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Snow R, 1995, PUBLIC HEALTH REP, V110, P720; STRAHAN GW, 1997, ADV DATA VITAL HLTH, V280; Strausbaugh LJ, 1996, INFECT CONT HOSP EP, V17, P129; TAN TQ, 1993, PEDIATRICS, V92, P761; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; ZIMMER JG, 1986, J AM GERIATR SOC, V34, P703, DOI 10.1111/j.1532-5415.1986.tb04301.x; 1996, MMWR MORB MORTAL WKL, V45, P853; 1997, MMWR MORB MORTAL WKL, V46, P60; 1995, MMWR MORB MORTAL WKL, V43, P949; 1996, MMWR MORTAL WKLY REP, V45, P1; 1994, MMWR MORB MORTAL WKL, V43, P23; 1995, MMWR MORB MORTAL WKL, V44, P97	78	190	193	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1861	1868		10.1056/NEJM199806253382601	http://dx.doi.org/10.1056/NEJM199806253382601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637804	Bronze			2022-12-01	WOS:000074352800001
J	Gekakis, N; Staknis, D; Nguyen, HB; Davis, FC; Wilsbacher, LD; King, DP; Takahashi, JS; Weitz, CJ				Gekakis, N; Staknis, D; Nguyen, HB; Davis, FC; Wilsbacher, LD; King, DP; Takahashi, JS; Weitz, CJ			Role of the CLOCK protein in the mammalian circadian mechanism	SCIENCE			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; EXPRESSION; CLONING; RETINA; SYSTEM	The mouse Clock gene encodes a bHLH-PAS protein that regulates circadian rhythms and is related to transcription factors that act as heterodimers. Potential partners of CLOCK were isolated in a two-hybrid screen, and one, BMAL1, was coexpressed with CLOCK and PER1 at known circadian clock sites in brain and retina. CLOCK-BMAL1 heterodimers activated transcription from E-box elements, a type of transcription factor-binding site, found adjacent to the mouse per1 gene and from an identical E-box known to be important for per gene expression in Drosophila. Mutant CLOCK from the dominant-negative Clock allele and BMAL1 formed heterodimers that bound DNA but failed to activate transcription, Thus, CLOCK-BMAL1 heterodimers appear to drive the positive component of per transcriptional oscillations, which are thought to underlie circadian rhythmicity.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Natl Sci Fdn, Ctr Biol Timing, Evanston, IL 60208 USA	Harvard University; Harvard Medical School; Northeastern University; Howard Hughes Medical Institute; Northwestern University; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Takahashi, Joseph S./Y-2781-2019; Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S/0000-0003-0384-8878				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BESHARSE JC, 1983, NATURE, V305, P133, DOI 10.1038/305133a0; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1117; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Edmunds L.N., 1988, CELLULAR MOL BASES B; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GEKAKIS N, UNPUB; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Inouye S, 1997, BIOCHEM BIOPH RES CO, V233, P349, DOI 10.1006/bbrc.1997.6452; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOVYEV V, 1997, ISMB, V5, P294; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VITATERNA MH, UNPUB; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; ZELAER E, 1997, GENE DEV, V11, P2079; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZYLKA MJ, IN PRESS NEURON	43	1486	1545	8	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1564	1569		10.1126/science.280.5369.1564	http://dx.doi.org/10.1126/science.280.5369.1564			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616112				2022-12-01	WOS:000074061200030
J	Teglund, S; McKay, C; Schuetz, E; van Deursen, JM; Stravopodis, D; Wang, DM; Brown, M; Bodner, S; Grosveld, G; Ihle, JN				Teglund, S; McKay, C; Schuetz, E; van Deursen, JM; Stravopodis, D; Wang, DM; Brown, M; Bodner, S; Grosveld, G; Ihle, JN			Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses	CELL			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; GROWTH FACTOR-I; MICE LACKING; ERYTHROPOIETIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION	A variety of cytokines mediate the activation of Janus protein tyrosine kinases (Jaks). The Jaks then phosphorylate cellular substrates, including members of the signal transducers and activators of transcription (Stat) family of transcription factors. Among the Stats, the two highly related proteins, Stat5a and Stat5b, are activated by a variety of cytokines. To assess the role of the Stat5 proteins, mutant mice were derived that have the genes deleted individually or together. The phenotypes of the mice demonstrate an essential, and often redundant, role for the two Stat5 proteins in a spectrum of physiological responses associated with growth hormone and prolactin. Conversely, the responses to a variety of cytokines that activate the Stat5 proteins, including erythropoietin, are largely unaffected.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA.		Wang, Demin/AAX-4449-2020; Schuetz, Erin/N-8087-2018; Brown, Michael/C-2081-2014	Wang, Demin/0000-0001-5549-3795; Stravopodis, Dimitrios/0000-0002-9535-2134; Brown, Michael/0000-0002-5796-1932	NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DONAHUE LR, 1993, J ENDOCRINOL, V136, P91, DOI 10.1677/joe.0.1360091; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hogan B., 2014, MANIPULATING MOUSE E; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; Ogawa S, 1996, ONCOGENE, V13, P183; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PARMER TG, 1991, ENDOCRINOLOGY, V129, P2924, DOI 10.1210/endo-129-6-2924; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shuai K, 1996, ONCOGENE, V13, P247; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; TIAN SS, 1994, BLOOD, V84, P1760; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Woldman I, 1997, J IMMUNOL, V159, P877; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833; ZHOU Y, 1994, P NATL ACAD SCI USA, V94, P13215	62	1041	1061	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1998	93	5					841	850		10.1016/S0092-8674(00)81444-0	http://dx.doi.org/10.1016/S0092-8674(00)81444-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630227	Bronze			2022-12-01	WOS:000073956700019
J	Borgstein, J				Borgstein, J			The poetry of genetics: or reading a genetic sequence - a literary model for cellular mechanisms	LANCET			English	Article											Borgstein, J (corresponding author), Hercules 9,Col Credito Constructor, Mexico City 03940, DF, Mexico.							Blake William, 1968, AUGURIES INNOCENCE; KIPLING R, 1987, JUST SO STORIES ELEP	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1353	1354		10.1016/S0140-6736(97)12036-0	http://dx.doi.org/10.1016/S0140-6736(97)12036-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643814				2022-12-01	WOS:000073439400043
J	Liu, B; Anderson, G; Mittmann, N; To, T; Axcell, T; Shear, N				Liu, B; Anderson, G; Mittmann, N; To, T; Axcell, T; Shear, N			Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people	LANCET			English	Article							MEDICATION USE; NURSING-HOME; FALLS; WOMEN; EPIDEMIOLOGY; OSTEOPOROSIS; METAANALYSIS; DEPRESSION; THERAPY	Background Tricyclic antidepressants (TCAs) are associated with an increased risk of falls and hip fractures in elderly people. Selective serotonin-reuptake inhibitors (SSRIs) are reported to be better tolerated than TCAs. We investigated the risk of hip fractures associated with SSRIs and TCAs. Methods This case-control study used administrative healthcare data from the province of Ontario, Canada. 8239 cases-patients aged 66 years or older, treated in hospital between April, 1994, and March, 1995, for hip fracture-were each matched for age and sex to five controls. Logistic regression was used to calculate the odds ratio for hip fracture with adjustment for potential confounding effects produced by concomitant drug use and comorbidity. Findings With participants who had no exposure to antidepressants as the reference category, the adjusted odds ratio for hip fracture was 2.4 (95% CI 2.0-2.7) for exposure to SSRIs, 2.2 (1.8-2.8) for exposure to secondary-amine TCAs, and 1.5 (1.3-1.7) for exposure to tertiary-amine TCAs, For all types of antidepressants, current use was associated with a higher risk of hip fracture than former use, The odds ratios for hip fracture were higher for new current users than for continuous current users in all three drug classes. The proportion of current use in the low-dose range was 22% for SSRIs, 50% for secondary-amine TCAs, and 58% for tertiary-amine TCAs. Interpretation Exposure to any of the three classes of antidepressants is associated with a significant increase in the risk of hip fracture. Despite differences in dose distribution, this analysis suggests that SSRIs do not offer an advantage over TCAs in terms of risk of hip fracture.	Sunnybrook Hlth Sci Ctr, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Clin Res Unit, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Div Geriatr Med, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Dept Med, Div Clin Pharmacol, Toronto, ON, Canada; Univ Toronto, Fac Med, Inst Clin & Evaluat Sci Ontario, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Hlth Adm, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Pharmacol & Drug Safety Res, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Baycrest; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Liu, B (corresponding author), 2075 Bayview Ave,Room E240, Toronto, ON M4N 3M5, Canada.							ANDERSON G, 1996, PATTERNS HLTH CARE O, P323; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; CAMPBELL A J, 1991, Drugs and Aging, V1, P289, DOI 10.2165/00002512-199101040-00005; CLAYER MT, 1989, J TRAUMA, V29, P1673, DOI 10.1097/00005373-198912000-00016; *COMM PROF HOSP AC, 1978, INT CLASS DIS; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; de Jonghe F, 1992, Drugs, V43 Suppl 2, P40; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; GREENDALE GA, 1995, J AM GERIATR SOC, V43, P955, DOI 10.1111/j.1532-5415.1995.tb05557.x; HERINGS RMC, 1995, ARCH INTERN MED, V155, P1801, DOI 10.1001/archinte.155.16.1801; LEONARD BE, 1993, J CLIN PSYCHIAT, V54, P3; LEVINSON ML, 1991, DICP ANN PHARMAC, V25, P657; LIU BA, 1995, J AM GERIATR SOC, V43, P1141, DOI 10.1111/j.1532-5415.1995.tb07016.x; LORD SR, 1995, BRIT J CLIN PHARMACO, V39, P227, DOI 10.1111/j.1365-2125.1995.tb04441.x; Macdonald J B, 1985, Clin Geriatr Med, V1, P621; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; Mittmann N, 1997, J AFFECT DISORDERS, V46, P191, DOI 10.1016/S0165-0327(97)00107-9; NEVITT MC, 1994, RHEUM DIS CLIN N AM, V20, P535; PRESKORN SH, 1993, AM J MED, V94, pS2; PRESKORN SH, 1995, INT CLIN PSYCHOPHARM, V10, P129, DOI 10.1097/00004850-199510030-00001; RAY WA, 1990, AM J EPIDEMIOL, V131, P502, DOI 10.1093/oxfordjournals.aje.a115524; RAY WA, 1991, ARCH INTERN MED, V151, P754, DOI 10.1001/archinte.151.4.754; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; RUTHAZER R, 1993, AM J PUBLIC HEALTH, V83, P746, DOI 10.2105/AJPH.83.5.746; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; SULSER F, 1983, J CLIN PSYCHIAT, V44, P14; THRONGREN KG, 1993, CLIN ORTHOP RELAT R, V287, P76; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; *WHO COLL CTR DRUG, 1991, ATC IND; Williams J. I., 1996, PATTERNS HLTH CARE O, P339	34	286	291	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1303	1307		10.1016/S0140-6736(97)09528-7	http://dx.doi.org/10.1016/S0140-6736(97)09528-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643791				2022-12-01	WOS:000073439400006
J	Stern, S; Altkorn, D; Levinson, W				Stern, S; Altkorn, D; Levinson, W			Detection of prostate and colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN; SERUM		Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Dept Med, Gen Internal Med Sect, 5841 S Maryland,MC 6098, Chicago, IL 60637 USA.	wendy@medicine.bsd.uchicago.edu						Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Coley CM, 1997, ANN INTERN MED, V126, P394, DOI 10.7326/0003-4819-126-5-199703010-00010; Coley CM, 1997, ANN INTERN MED, V126, P480; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Helfand M, 1997, JAMA-J AM MED ASSOC, V277, P44, DOI 10.1001/jama.277.1.44; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; Smart CR, 1997, CANCER, V80, P1835, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1835::AID-CNCR23>3.0.CO;2-5; US Preventive Services Task Force, 1998, GUID CLIN PREV SERV; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46; vonEschenbach A, 1997, CANCER, V80, P1805, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1805::AID-CNCR17>3.3.CO;2-8; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					117	118		10.1001/jama.280.2.117	http://dx.doi.org/10.1001/jama.280.2.117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669770				2022-12-01	WOS:000074608400001
J	Kahn, J				Kahn, J			Success and sadness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					89	89		10.1001/jama.280.1.89	http://dx.doi.org/10.1001/jama.280.1.89			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660370				2022-12-01	WOS:000074379400030
J	Siriwasin, W; Shaffer, N; Roongpisuthipong, A; Bhiraleus, P; Chinayon, P; Wasi, C; Singhanati, S; Chotpitayasunondh, T; Chearskul, S; Pokapanichwong, W; Mock, P; Weniger, BG; Mastro, TD				Siriwasin, W; Shaffer, N; Roongpisuthipong, A; Bhiraleus, P; Chinayon, P; Wasi, C; Singhanati, S; Chotpitayasunondh, T; Chearskul, S; Pokapanichwong, W; Mock, P; Weniger, BG; Mastro, TD		Bangkok Collaborative Perinatal HIV Transmissi	HIV prevalence, risk, and partner serodiscordance among pregnant women in Bangkok	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	10th International Conference on AIDS	AUG 07-12, 1994	YOKOHAMA, JAPAN				HUMAN-IMMUNODEFICIENCY-VIRUS; TO-MALE TRANSMISSION; YOUNG MEN; NORTHERN THAILAND; INFECTION; FEMALE	Context.-Most prior studies of the human immunodeficiency virus (H[V) epidemic in Thailand have focused on commercial sex encounters; however, because the epidemic increasingly concerns stable heterosexual relationships, determining risk factors for this form of transmission is warranted. Objectives.-To determine temporal trends in HIV prevalence, risk factors for H[V seropositivity, and rates of partner serodiscordance for pregnant women in Bangkok, Thailand. Design.-Retrospective review of hospital antenatal clinic HIV test results from 1991 through 1996. Baseline demographic and behavioral risk factors for HIV were assessed for subjects enrolled from November 1992 through March 1994. Setting.-Two Bangkok hospitals with routine antenatal clinic HIV counseling and testing. Participants.-The HIV-positive pregnant women enrolled in a perinatal HIV transmission study and their partners and HIV-negative pregnant controls. Results.-From 1991 through 1996, antenatal clinic HIV seroprevalence increased from 1.0% to 2.3%. On multivariate analysis of data from 342 HIV-positive and 344 HIV-negative pregnant women, more than 1 lifetime sex partner, history of a sexually transmitted disease, and a high-risk sex partner were the most important factors for seropositivity tall P<.001). Twenty-six percent of partners of HIV-positive women were HIV negative. Women reporting more than 1 lifetime sex partner were more likely to have an HIV-negative partner than women reporting only 1 (45% vs 8%; relative risk, 5.5; 95% confidence interval, 3.2-9.5; P<.001); women reporting no high-risk behaviors were less likely to have an H[V-negative partner (10% vs 44%; relative risk, 0.2; 95% confidence interval, 0.1-0.4; P<.001). Conclusions.-Prevalence of HIV in pregnant women has increased steadily in Bangkok from 1991 through 1996, Sex with current partners was the only identified risk exposure for about half (52%) of the HIV-positive women. Although few HIV-positive pregnant women reported high-risk behaviors, more than 1 lifetime partner and a partner with high-risk behavior were strong risk factors for seropositivity. Together with the unexpected finding that one fourth of partners of seropositive pregnant women were seronegative, these data emphasize that women in the general population are at risk for HIV because of the risk behavior of both current and previous partners.	Minist Publ Hlth, HIV AIDS Collaborat, Nonthaburi 11000, Thailand; Minist Publ Hlth, Rajavithi Hosp, Bangkok, Thailand; Ctr Dis Control & Prevent, Atlanta, GA USA; Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, Thailand; Minist Publ Hlth, Childrens Hosp, Dept Med Serv, Bangkok, Thailand	Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Rajavithi Hospital; Centers for Disease Control & Prevention - USA; Mahidol University; Ministry of Public Health - Thailand	Shaffer, N (corresponding author), Minist Publ Hlth, HIV AIDS Collaborat, DMS 6 Bldg,Tivanon Rd, Nonthaburi 11000, Thailand.	nas4@cdc.gov		Weniger, Bruce/0000-0002-5450-5464				ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; DEVINCENZI I, 1992, BRIT MED J, V304, P809; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; Manopaiboon C, 1998, J ACQ IMMUN DEF SYND, V18, P54, DOI 10.1097/00042560-199805010-00009; MASON CJ, 1995, AIDS, V9, P1061, DOI 10.1097/00002030-199509000-00012; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MASTRO TD, 1995, AIDS, V9, P523; Mertens T E, 1995, AIDS, V9 Suppl A, pS259; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NICOLOSI A, 1994, EPIDEMIOLOGY, V5, P570, DOI 10.1097/00001648-199411000-00003; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; SHAFFER N, 1996, 11 INT C AIDS JUL 7; Sirisopana N, 1996, J ACQ IMMUN DEF SYND, V11, P492, DOI 10.1097/00042560-199604150-00010; SITTITRAI W, 1994, AIDS, V8, pS143; SITTITRAI W, 1992, REPORT 1990 SURVEY P, P33; *THAIL MIN PUBL HL, 1996, RESULTS 14 ROUND HIV; UNGCHUSAK K, 1997, WKLY EPIDEMIOL SURVE, V28, P225; UNGCHUSAK K, 1997, WKLY EPIDEMIOL SURVE, V28, P237; UNGEHUSAK K, 1995, THAI AIDS J, V7, P177; UNGEHUSAK K, 1996, J ACQ IMMUN DEF SYND, V12, P500; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	29	58	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					49	54		10.1001/jama.280.1.49	http://dx.doi.org/10.1001/jama.280.1.49			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZW145	9660363	Bronze			2022-12-01	WOS:000074379400023
J	Walker, BD; Basgoz, N				Walker, BD; Basgoz, N			Treat HIV-1 infection like other infections - Treat it	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-LYMPHOCYTES; IN-VIVO		Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Div Infect Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	bwalker@helix.mgh.harvard.edu						Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CURRIER JS, 1998, 5 C RETR OPP INF FEB; DEEKS S, 1998, JAMA-J AM MED ASSOC, V27, P1343; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Harrer T, 1996, J IMMUNOL, V156, P2616; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; MILLER K, IN PRESS CLIN INFECT; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Pantaleo G, 1996, ANNU REV MICROBIOL, V50, P825, DOI 10.1146/annurev.micro.50.1.825; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Spruance SL, 1997, ANN INTERN MED, V126, P355, DOI 10.7326/0003-4819-126-5-199703010-00003; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	21	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					91	93		10.1001/jama.280.1.91	http://dx.doi.org/10.1001/jama.280.1.91			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660371				2022-12-01	WOS:000074379400031
J	Ban, N; Freeborn, B; Nissen, P; Penczek, P; Grassucci, RA; Sweet, R; Frank, J; Moore, PB; Steitz, TA				Ban, N; Freeborn, B; Nissen, P; Penczek, P; Grassucci, RA; Sweet, R; Frank, J; Moore, PB; Steitz, TA			A 9 angstrom resolution x-ray crystallographic map of the large ribosomal subunit	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; 3-DIMENSIONAL RECONSTRUCTION; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; PROTEIN; CRYSTALLIZATION; REFINEMENT; EXTENSION; PARTICLES; SYMMETRY	The 50S subunit of the ribosome catalyzes the peptidyl-transferase reaction of protein synthesis. We have generated X-ray crystallographic electron density maps of the large ribosomal subunit from Haloarcula marismortui at various resolutions up to 9 Angstrom using data from crystals that diffract to 3 Angstrom. Positioning a 20 Angstrom resolution EM image of these particles in the crystal lattice produced phases accurate enough to locate the bound heavy atoms in three derivatives using difference Fourier maps, thus demonstrating the correctness of the EM model and its placement in the unit cell. At 20 Angstrom resolution, the X-ray map is similar to the EM map; however, at 9 Angstrom it reveals long, continuous, but branched features whose shape, diameter, and right-handed twist are consistent with segments of double-helical RNA that crisscross the subunit.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; United States Department of Energy (DOE); Brookhaven National Laboratory	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Nissen, Poul/D-5774-2014; Steitz, Thomas A./C-6559-2009	Nissen, Poul/0000-0003-0948-6628	NIGMS NIH HHS [GM-54216, GM-29169, GM-22778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169, R37GM029169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BECKMANN R, 1997, BOTT, V278, P2123; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1997, METHOD ENZYMOL, V276, P558, DOI 10.1016/S0076-6879(97)76078-6; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CARSON M, 1991, J APPL CRYSTALLOGR, V13, P458; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Dube P, 1998, STRUCTURE, V6, P389, DOI 10.1016/S0969-2126(98)00040-9; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EISENSTEIN M, 1994, BIOPHYSICAL METHODS, P213; FRANCESCHI F, 1993, TRANSLATIONAL APPARATUS, P397; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HUBER R, 1985, MOL REPLACEMENT, P58; JACK A, 1975, J MOL BIOL, V97, P163, DOI 10.1016/S0022-2836(75)80032-5; KNALEIN J, 1997, J MOL BIOL, V270, P1; LADENSTEIN R, 1987, J MOL BIOL, V195, P751, DOI 10.1016/0022-2836(87)90196-3; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LEONARD KR, 1979, J MOL BIOL, V128, P155; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MALHOTRA A, 1998, IN PRESS J MOL BIOL; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Neuefeind T, 1997, BIOL CHEM, V378, P219; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Podjarny AD, 1997, METHOD ENZYMOL, V276, P641, DOI 10.1016/S0076-6879(97)76084-1; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; ROSSMANN MG, 1995, CURR OPIN STRUC BIOL, V5, P650, DOI 10.1016/0959-440X(95)80058-1; Schlunzen F, 1995, BIOCHEM CELL BIOL, V73, P739, DOI 10.1139/o95-082; SHEVACK A, 1985, FEBS LETT, V184, P68, DOI 10.1016/0014-5793(85)80655-4; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOEFFLER G, 1986, STRUCTURE FUNCTION G, P28; Thygesen J, 1996, STRUCTURE, V4, P513, DOI 10.1016/S0969-2126(96)00057-3; VANBOHLEN K, 1991, J MOL BIOL, V222, P11; Verschoor A, 1998, NUCLEIC ACIDS RES, V26, P655, DOI 10.1093/nar/26.2.655; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOESE CR, 1996, RIBOSOMAL RNA STRUCT, P23; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; YONATH AE, 1980, BIOCHEM INT, V1, P428; Zhu J, 1997, J STRUCT BIOL, V118, P197, DOI 10.1006/jsbi.1997.3845	56	211	222	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1105	1115		10.1016/S0092-8674(00)81455-5	http://dx.doi.org/10.1016/S0092-8674(00)81455-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657144	hybrid			2022-12-01	WOS:000074491100006
J	Liu, JP; Zhu, JK				Liu, JP; Zhu, JK			A calcium sensor homolog required for plant salt tolerance	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; CALCINEURIN; YEAST; ARABIDOPSIS; ACTIVATION; ADAPTATION; RECOVERIN; CELLS	Excessive sodium (Na+) in salinized soils inhibits plant growth and development. A mutation in the SOS3 gene renders Arabidopsis thaliana plants hypersensitive to Na+-induced growth inhibition. SOS3 encodes a protein that shares significant sequence similarity with the calcineurin B subunit from yeast and neuronal calcium sensors from animals. The results suggest that intracellular calcium signaling through a calcineurin-like pathway mediates the beneficial effect of calcium on plant salt tolerance.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University of Arizona	Zhu, JK (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; LIU, JIPING/0000-0002-7558-0025				[Anonymous], 1972, MINERAL NUTR PLANTS; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; CHOI S, 1995, WEEDS WORLD, V2, P17; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; LAHAYE PA, 1969, SCIENCE, V166, P395, DOI 10.1126/science.166.3903.395; Lauchli A, 1990, AM SOC PLANT PHYSL S; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Liu JP, 1997, P NATL ACAD SCI USA, V94, P14960, DOI 10.1073/pnas.94.26.14960; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MURGUIA JR, 1995, SCIENCE, V267, P232; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617	29	593	706	15	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1943	1945		10.1126/science.280.5371.1943	http://dx.doi.org/10.1126/science.280.5371.1943			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632394				2022-12-01	WOS:000074323800066
J	Feng, WJ; Ribeiro, RCJ; Wagner, RL; Nguyen, H; Apriletti, JW; Fletterick, RJ; Baxter, JD; Kushner, PJ; West, BL				Feng, WJ; Ribeiro, RCJ; Wagner, RL; Nguyen, H; Apriletti, JW; Fletterick, RJ; Baxter, JD; Kushner, PJ; West, BL			Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; CONSERVED REGION; DOMAIN; PROTEIN; COMPLEX	The ligand-binding domain of nuclear receptors contains a transcriptional activation function (AF-2) that mediates hormone-dependent binding of coactivator proteins. Scanning surface mutagenesis on the human thyroid hormone receptor was performed to define the site that binds the coactivators, glucocorticoid receptor-interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1), The residues involved encircle a small surface that contains a hydrophobic cleft. Ligand activation of transcription involves formation of this surface by folding the carboxyl-terminal cr helix against a scaffold of three other helices. These features may represent general ones for nuclear receptors.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Universidade de Brasilia; University of California System; University of California San Francisco	West, BL (corresponding author), Univ Calif San Francisco, Metab Res Unit, Box 0540, San Francisco, CA 94143 USA.	kushner@itsa.ucsf.edu; west@socrates.ucsf.edu		West, Brian/0000-0002-5320-3691	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051281, F32DK009516] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR01081] Funding Source: Medline; NIDDK NIH HHS [DK09516, DK51281] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; ONATE SA, 1995, SCIENCE, V270, P1354; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	36	476	495	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1747	1749		10.1126/science.280.5370.1747	http://dx.doi.org/10.1126/science.280.5370.1747			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624051				2022-12-01	WOS:000074197800040
J	Warrick, JM; Paulson, HL; Gray-Board, GL; Bui, QT; Fischbeck, KH; Pittman, RN; Bonini, NM				Warrick, JM; Paulson, HL; Gray-Board, GL; Bui, QT; Fischbeck, KH; Pittman, RN; Bonini, NM			Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila	CELL			English	Article							MACHADO-JOSEPH DISEASE; PROGRAMMED CELL-DEATH; SPINOCEREBELLAR ATAXIA; CAG EXPANSIONS; GENE; EXPRESSION; RETINA; EYE; DIFFERENTIATION; MELANOGASTER	Spinocerebellar ataxia type 3 (SCA3/MJD) is one of at least eight human neurodegenerative diseases caused by glutamine-repeat expansion. We have recreated glutamine-repeat disease in Drosophila using a segment of the SCA3/MJD protein. Targeted expression of the protein with an expanded polyglutamine repeat led to nuclear inclusion (NI) formation and late-onset cell degeneration. Differential sensitivity to the mutant transgene was observed among different cell types, with neurons being particularly susceptible; NI formation alone was not sufficient for degeneration. The viral antiapoptotic gene P35 mitigated polyglutamine-induced degeneration in vivo. Our results demonstrate that cellular mechanisms of human glutamine-repeat disease are conserved in invertebrates. This fly model will aid in identifying additional factors that modulate neurodegeneration.	Univ Penn, Dept Biol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Iowa	Bonini, NM (corresponding author), Univ Penn, Dept Biol, Sch Med, Philadelphia, PA 19104 USA.			Bonini, Nancy/0000-0003-0226-5291				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRAND AH, 1993, DEVELOPMENT, V118, P401; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; RANUM LPW, 1995, AM J HUM GENET, V57, P603; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wolff Tanya, 1993, P1277; Yin JCP, 1996, CURR OPIN NEUROBIOL, V6, P264, DOI 10.1016/S0959-4388(96)80082-1; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	40	505	522	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					939	949		10.1016/S0092-8674(00)81200-3	http://dx.doi.org/10.1016/S0092-8674(00)81200-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635424	hybrid			2022-12-01	WOS:000074205700006
J	Poloniecki, J; Valencia, O; Littlejohns, P				Poloniecki, J; Valencia, O; Littlejohns, P			Cumulative risk adjusted mortality chart for detecting changes in death rate: observational study of heart surgery	BRITISH MEDICAL JOURNAL			English	Article							STRATIFICATION; OUTCOMES	Objective: To detect changes in mortality after surgery with allowance being made for variations in case mix. Design: Observational study of postoperative mortality from January 1992 to August 1995. Setting: Regional cardiothoracic unit. Subjects: 3983 patients aged 16 and over who had open heart operations. Main outcome measures: Preoperative risk factors and postoperative mortality in hospital within 30 days were recorded for all surgical heart operations. Mortality was adjusted for case mix using a preoperative estimate of risk based on additive Parsonnet factors. The number of operations required for statistical power to detect a doubling of mortality was examined, and control limits at a nominal significance level of P = 0.01 for detection of an adverse trend were determined. Results: Total mortality of 7.0% was 26% below the Parsonnet predictor (P < 0.0001). There was a highly significant variation in annual case mix (Parsonnet scores 8.7-10.6, P < 0.0001). There was no significant variation in mortality after adjustment for case mix (odds ratio 1-1.5, P = 0.18) with monitoring by calendar year. With continuous monitoring, however, nominal 99% control limits based on 16 expected deaths were crossed on two occasions. Conclusions: Hospital league tables for mortality from heart surgery will be of limited value because year to year differences in death rate can be large (odds ratio 1.5) even when the underlying risk or case mix does not change. Statistical quality control of a single series with adjustment for case mix is the only way to take into account recent performance when informing a patient of the risk of surgery at a particular hospital. If there is an increase in the number of deaths the chances of the next patient surviving surgery can be calculated from the last 16 deaths.	St George Hosp, Sch Med, London SW17 0RE, England; St George Hosp, Reg Cardiothorac Unit, London SW17 0RE, England	St Georges University London; St Georges University London	Poloniecki, J (corresponding author), St George Hosp, Sch Med, Cranmer Terrace, London SW17 0RE, England.							Capewell S, 1996, HEART, V76, P70, DOI 10.1136/hrt.76.1.70; COPELAND GP, 1995, BRIT J SURG, V82, P408, DOI 10.1002/bjs.1800820344; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; deLeval MR, 1997, LANCET, V349, P723, DOI 10.1016/S0140-6736(96)11327-1; DYER C, 1997, GUARDIAN        0502, P10; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; ELLIS SG, 1997, CIRCULATION, V96, P2479; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; LOVEGOVE J, 1997, HEART, V77, P18; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; NASHEF SAM, 1992, BRIT MED J, V305, P1066, DOI 10.1136/bmj.305.6861.1066; PARSONNET V, 1989, CIRCULATION, V79, P3; REESMOGG W, 1996, TIMES           0401, P16; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; TAYLOR K, 1991, BRIT J HEALTHCA 0530, P30; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	16	136	136	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1697	1700		10.1136/bmj.316.7146.1697	http://dx.doi.org/10.1136/bmj.316.7146.1697			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614015	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000074129500014
J	Geraghty, RJ; Krummenacher, C; Cohen, GH; Eisenberg, RJ; Spear, PG				Geraghty, RJ; Krummenacher, C; Cohen, GH; Eisenberg, RJ; Spear, PG			Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; CELL-SURFACE RECEPTORS; PSEUDORABIES VIRUS; GLYCOPROTEIN-D; HEPARAN-SULFATE; PENETRATION; EXPRESSION; MEMBER; FORMS; BIND	A human member of the immunoglobulin superfamily was shown to mediate entry of several alphaherpesviruses, including herpes simplex viruses (HSV) 1 and 2, porcine pseudorabies virus (PRV), and bovine Herpesvirus 1 (BHV-1). This membrane glycoprotein is poliovirus receptor-related protein 1 (Prr1), designated here as HveC, Incubation of HSV-1 with a secreted form of HveC inhibited subsequent infection of a variety of cell lines, suggesting that HveC interacts directly with the virus. Poliovirus receptor (Pvr) itself mediated entry of PRV and BHV-1 but not of the HSV strains tested. HveC was expressed in human cells of epithelial and neuronal origin; it is the prime candidate for the coreceptor that allows both HSV-1 and HSV-2 to infect epithelial cells on mucosal surfaces and spread to cells of the nervous system.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	Northwestern University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	p-spear@nwu.edu		Geraghty, Robert/0000-0002-0560-6509; Krummenacher, Claude/0000-0002-3492-4987	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036731, P01NS030606] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 36293] Funding Source: Medline; NINDS NIH HHS [NS-36731, NS-30606] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babic N, 1996, J GEN VIROL, V77, P2277, DOI 10.1099/0022-1317-77-9-2277; CAMPADELLIFIUME G, 1988, J VIROL, V62, P159, DOI 10.1128/JVI.62.1.159-167.1988; CHASE CCL, 1993, VIROLOGY, V194, P365, DOI 10.1006/viro.1993.1269; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; FRANCKE U, 1981, SOMAT CELL GENET, V7, P171; GERAGHTY RJ, UNPUB; HOGGAN MD, 1959, AM J HYG, V70, P208, DOI 10.1093/oxfordjournals.aje.a120071; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; JOHNSON DC, 1988, J VIROL, V62, P4605, DOI 10.1128/JVI.62.12.4605-4612.1988; JOHNSON DC, 1990, J VIROL, V64, P2569, DOI 10.1128/JVI.64.6.2569-2576.1990; KARGER A, 1993, VIROLOGY, V194, P654, DOI 10.1006/viro.1993.1305; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; KRUMMENACHER C, UNPUB; KRUMMENACHER C, IN PRESS J VIROL; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; LEE WC, 1993, J VIROL, V67, P5088, DOI 10.1128/JVI.67.9.5088-5097.1993; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mettenleiter Thomas C., 1995, P367, DOI 10.1016/B978-012397570-6/50022-8; MILLER JM, 1995, AM J VET RES, V56, P870; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nicola AV, 1998, J VIROL, V72, P3595, DOI 10.1128/JVI.72.5.3595-3601.1998; PETROVSKIS EA, 1988, J VIROL, V62, P2196, DOI 10.1128/JVI.62.6.2196-2199.1988; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; TERRYALLISON T, IN PRESS J VIROL; Thomas JT, 1998, J VIROL, V72, P1131, DOI 10.1128/JVI.72.2.1131-1137.1998; WARNER MW, IN PRESS VIROLOGY; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willey JC, 1996, AM J RESP CELL MOL, V14, P262, DOI 10.1165/ajrcmb.14.3.8845177	33	742	765	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1618	1620		10.1126/science.280.5369.1618	http://dx.doi.org/10.1126/science.280.5369.1618			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616127				2022-12-01	WOS:000074061200045
J	Brunet, LJ; McMahon, JA; McMahon, AP; Harland, RM				Brunet, LJ; McMahon, JA; McMahon, AP; Harland, RM			Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton	SCIENCE			English	Article							CHICK LIMB; BONE; EXPRESSION; MOUSE; GENES; REGULATORS; BMP-4; MICE	Noggin is a bone morphogenetic protein (BMP) antagonist expressed in Spemann's organizer. Murine Noggin is expressed in condensing cartilage and immature chondrocytes, as are many BMPs. In mice lacking Noggin, cartilage condensations initiated normally but developed hyperplasia, and initiation of joint development failed as measured by the expression of growth and differentiation factor-5. The maturation of cartilage and Herd expression were unaffected. Excess BMP activity in the absence of Noggin antagonism may enhance the recruitment of cells into cartilage, resulting in oversized growth plates; chondrocytes are also refractory to joint-inducing positional cues.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University of California System; University of California Berkeley; Harvard University	Harland, RM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	harland@socrates.berkeley.edu	McMahon, Andrew P/ABE-7520-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Davis AP, 1996, DEVELOPMENT, V122, P1175; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GROFF DJ, 1997, DEVELOPMENT, V124, P627; Hofmann C, 1996, DEV GENET, V19, P43, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;43::AID-DVG5&gt;3.0.CO;2-0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; Macias D, 1997, DEVELOPMENT, V124, P1109; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Storm EE, 1996, DEVELOPMENT, V122, P3969; Thorogood P.V., 1983, CARTILAGE DEV DIFFER, VVol. 2, P223; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	24	645	674	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1455	1457		10.1126/science.280.5368.1455	http://dx.doi.org/10.1126/science.280.5368.1455			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603738				2022-12-01	WOS:000073883400061
J	Willinger, M; Hoffman, HJ; Wu, KT; Hou, JR; Kessler, RC; Ward, SL; Keens, TG; Corwin, MJ				Willinger, M; Hoffman, HJ; Wu, KT; Hou, JR; Kessler, RC; Ward, SL; Keens, TG; Corwin, MJ			Factors associated with the transition to nonprone sleep positions of infants in the United States - The National Infant Sleep Position Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; RISK-FACTORS; NEW-ZEALAND; SIDS; EPIDEMIOLOGY; MORTALITY; TASMANIA; COHORT	Context.-Studies have demonstrated strong associations between the prone sleep position (on the stomach) and sudden infant death syndrome (SIDS), In 1992, the American Academy of Pediatrics recommended that infants be placed to sleep laterally (on their side) or supine (on their back) to reduce SIDS risk, and in 1994, the national public education campaign "Back to Sleep" was launched. Objective.-To determine the typical sleep position of infants younger than 8 months in the United States, the changes that occurred after these recommendations, and the factors associated with the placement of infants prone or supine. Design.-Annual nationally representative telephone surveys. Setting.-The 48 contiguous states of the United States. Participants.-Nighttime caregivers of infants born within the last 7 months between 1992 and 1996, Approximately 1000 interviews were conducted per year. Main Outcome Measures.-The position the infant was usually placed in for sleep, and the position the infant was most commonly found in when checked during the night's sleep. Results.-Ninety-seven percent of respondents in each wave of the survey usually placed their infant to sleep in a specific position. Infants were placed in the prone position by 70% of caregivers in 1992, prior to the campaign, but only 24% in 1996, Supine and lateral placements increased during this time period, from 13% in 1992 to 35% in 1996 and from 15% in 1992 to 39% in 1996, respectively. Significant predictors of prone placement included maternal race reported as black (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.68-3.26), mother's age 20 to 29 years (OR, 1.28; 95% CI, 1.09-1.50), region reported as the mid-Atlantic (OR, 1.41; 95% CI, 1.12-1.78) or southern states (OR, 1.47; 95% CI, 1.22-1.70), mothers with a previous child (OR, 1.68; 95% CI, 1.43-1.97), and infants younger than 8 weeks (OR, 0.63; 95% CI, 0.46-0.85), Infants aged 8 to 15 weeks were significantly more likely to be placed nonprone over time compared with the other age groups. Most of the risk factors for prone were significantly related in the opposite direction to supine placement. Conclusions.-The prevalence of infants placed in the prone sleep position declined by 66% between 1992 and 1996, Although causality cannot be proved, SIDS rates declined approximately 38% during this period. To achieve further reduction in prone sleeping, efforts to promote the supine sleep position should be aimed at groups at high risk for prone placement.	NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, Epidemiol Stat & Data Syst Branch, NIH, Bethesda, MD USA; Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Neonatol & Pediat Pulmonol, Los Angeles, CA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Boston Univ, Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Children's Hospital Los Angeles; University of Southern California; Harvard University; Harvard Medical School; Boston University	Willinger, M (corresponding author), NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, NIH, Execut Bldg,Room 4B03,6100 Execut Blvd,MSC 7510, Bethesda, MD 20892 USA.	mw75q@nih.gov		Corwin, Michael/0000-0002-6591-209X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022996, U10HD029067] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-2-9067, HD-2-2996] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON RN, 1997, MON VITAL STAT RE S2, V45, P66; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P859; CHESSARE JB, 1995, PEDIATRICS, V96, P893; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; DAVIES DP, 1989, BMJ-BRIT MED J, V298, P1518; DEJONGE GA, 1993, ARCH DIS CHILD, V69, P660, DOI 10.1136/adc.69.6.660; DOLLFUS C, 1990, PEDIATRICS, V86, P176; DWYER T, 1991, J PAEDIATR CHILD H, V27, P340, DOI 10.1111/j.1440-1754.1991.tb00415.x; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; GIBSON E, 1995, PEDIATRICS, V96, P69; GILBERT R, 1994, ARCH DIS CHILD, V70, P445, DOI 10.1136/adc.70.5.445; Guyer B, 1996, PEDIATRICS, V98, P1007; Hiley CMH, 1996, BRIT MED J, V312, P1397, DOI 10.1136/bmj.312.7043.1397a; HOFFMAN HJ, 1992, CLIN PERINATOL, V19, P717, DOI 10.1016/S0095-5108(18)30427-5; HOFFMAN HJ, 1996, 4 SIDS INT C JUN 23; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HUNT CE, 1992, PEDIATRICS, V90, P115; IRGENS LM, 1995, ARCH DIS CHILD, V72, P478, DOI 10.1136/adc.72.6.478; KATTWINKEL J, 1994, PEDIATRICS, V93, P820; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KOCHANEK KD, 1995, MON VITAL STAT REP S, V43, P62; LEVIN ML, 1978, AM J EPIDEMIOL, V108, P78; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; ORENSTEIN SR, 1993, PEDIATRICS, V91, P497; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; Platt MJ, 1996, ARCH DIS CHILD, V75, P527, DOI 10.1136/adc.75.6.527; PONSONBY AL, 1995, PAEDIATR PERINAT EP, V9, P256, DOI 10.1111/j.1365-3016.1995.tb00141.x; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; Ray BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e12; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; Ventura S. J., 1994, MONTHLY VITAL STAT R, V43, P1; VENTURA SJ, 1997, MON VITAL STAT REP S, V45, P38; VENTURA SJ, 1997, MON VITAL STAT RE S2, V46, P28; VENTURA SJ, 1997, MON VITAL STAT REP S, V45, P49; WILLINGER M, 1994, PEDIATRICS, V93, P814; WILLINGER M, 1991, Pediatric Pathology, V11, P677	43	183	186	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					329	335		10.1001/jama.280.4.329	http://dx.doi.org/10.1001/jama.280.4.329			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686549	Bronze			2022-12-01	WOS:000074804200032
J	Olson, MF; Paterson, HF; Marshall, CJ				Olson, MF; Paterson, HF; Marshall, CJ			Signals from Ras and Rho GTPases interact to regulate expression of p21(Waf1/Cip1)	NATURE			English	Article							CELL-TRANSFORMATION; KINASE; ACTIVATION; GROWTH; NIH-3T3-CELLS; REQUIREMENT; ONCOGENES	Small GTPases act as molecular switches in intracellular signal-transduction pathways(1). In the case of the Ras family of GTPases, one of their most important roles is as regulators of cell proliferation, and the mitogenic response to a variety of growth factors and oncogenes can be blocked by inhibiting Ras function(23). But in certain situations, activation of Ras signalling pathways arrests the cell cycle rather than causing cell proliferation(4-6). Extracellular signals may trigger different cellular responses by activating Ras-dependent signalling pathways to varying degrees(7-9). Other signalling pathways could also influence the consequences of Ras signalling. Here we show that when signalling through the Ras-related GTPase Rho is inhibited, constitutively active Ras induces the cyclin-dependent-kinase inhibitor p2I(Waf1/Cip1) and entry into the DNA-synthesis phase of the cell cycle is blocked. When Rho is active, induction of p21(Waf1/Cip1) by Ras is suppressed and Ras induces DNA synthesis. Cells that lack p21(Watl/Cip1) do not require Rho signalling for the induction of DNA synthesis by activated Ras, indicating that, once Ras has become activated, the primary requirement for Rho signalling is the suppression of p21(Waf1/Cip1) induction.	Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1987, ONCOGENE, V2, P41; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zeng YX, 1996, ONCOGENE, V12, P1557	29	389	401	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					295	299		10.1038/28425	http://dx.doi.org/10.1038/28425			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685162				2022-12-01	WOS:000074851900053
J	Clarke, PBS				Clarke, PBS			Tobacco smoking, genes, and dopamine	LANCET			English	Editorial Material							NICOTINE; SYSTEM; REWARD		McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YC, Canada	McGill University	Clarke, PBS (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1YC, Canada.							CLARKE PBS, 1985, BRAIN RES, V348, P355, DOI 10.1016/0006-8993(85)90456-1; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LAWFORD BR, 1995, NAT MED, V1, P337, DOI 10.1038/nm0495-337; Noble EP, 1998, JNCI-J NATL CANCER I, V90, P343, DOI 10.1093/jnci/90.5.343; Rose JE, 1997, PSYCHOPHARMACOLOGY, V130, P28, DOI 10.1007/s002130050209; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; True WR, 1997, ADDICTION, V92, P1277, DOI 10.1111/j.1360-0443.1997.tb02847.x; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203	12	18	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					84	85		10.1016/S0140-6736(98)85006-X	http://dx.doi.org/10.1016/S0140-6736(98)85006-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672270				2022-12-01	WOS:000074775100006
J	Warren, WS; Ahn, S; Mescher, M; Garwood, M; Ugurbil, K; Richter, W; Rizi, RR; Hopkins, J; Leigh, JS				Warren, WS; Ahn, S; Mescher, M; Garwood, M; Ugurbil, K; Richter, W; Rizi, RR; Hopkins, J; Leigh, JS			MR imaging contrast enhancement based on intermolecular zero quantum coherences	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MULTIPLE SPIN ECHOES; SOLUTION NMR; DIPOLAR-FIELD; LIQUIDS	A new method for magnetic resonance imaging (MRI) based on the detection of relatively strong signal from intermolecular zero-quantum coherences (iZQCs) is reported. Such a signal would not be observable in the conventional framework of magnetic resonance; it originates in Long-range dipolar couplings (10 micrometers to 1 millimeter) that are traditionally ignored. Unlike conventional MRI, where image contrast is based on variations in spin density and relaxation times (often with injected contrast agents), contrast with iZQC images comes from variations in the susceptibility over a distance dictated by gradient strength. phantom and in vivo (rat brain) data confirm that iZQC images give contrast enhancement. This contrast might be useful in the detection of small tumors, in that susceptibility correlates with oxygen concentration and in functional MRI.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA; Natl Res Council Canada, Inst Biodiagnost, Winnipeg, MB R3B 1Y6, Canada; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA	Princeton University; University of Minnesota System; University of Minnesota Twin Cities; National Research Council Canada; University of Pennsylvania	Warren, WS (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	wwarren@princeton.edu	Ahn, Sangdoo/A-4615-2009; Ugurbil, Kamil/AAD-6058-2022	Garwood, Michael/0000-0003-1578-9166	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02305, RR08079] Funding Source: Medline; NIGMS NIH HHS [GM35253] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BHUJWALLA ZM, 1994, NMR PHYSL BIOMEDICIN, P311; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; Broekaert P, 1996, J MAGN RESON SER A, V120, P97, DOI 10.1006/jmra.1996.0103; Cremillieux Y, 1998, MAGN RESON MED, V39, P285, DOI 10.1002/mrm.1910390216; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; DURNEY CH, 1989, J MAGN RESON, V85, P554, DOI 10.1016/0022-2364(89)90245-X; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; JEENER J, 1995, J CHEM PHYS, V103, P1309, DOI 10.1063/1.469808; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; Lee S, 1996, J CHEM PHYS, V105, P874, DOI 10.1063/1.471968; Levitt MH, 1996, CONCEPT MAGNETIC RES, V8, P77, DOI 10.1002/(SICI)1099-0534(1996)8:2<77::AID-CMR1>3.0.CO;2-L; McKinstry RC, 1998, SCIENCE, V279, P1965, DOI 10.1126/science.279.5358.1965; Mori S, 1997, MAGNET RESON MED, V37, P336, DOI 10.1002/mrm.1910370305; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Robyr P, 1996, J MAGN RESON SER A, V121, P206, DOI 10.1006/jmra.1996.0162; SCHUPP DG, 1993, MAGNET RESON MED, V30, P18, DOI 10.1002/mrm.1910300105; Springer C. S., 1994, NMR PHYSL BIOMEDICIN, P75; Vathyam S, 1996, SCIENCE, V272, P92, DOI 10.1126/science.272.5258.92; Warren WS, 1995, CHEM PHYS LETT, V247, P207, DOI 10.1016/0009-2614(95)01184-5; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; ZHOU X, 1991, P SOC MAGN RESON MED, P345	25	167	178	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					247	251		10.1126/science.281.5374.247	http://dx.doi.org/10.1126/science.281.5374.247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657717				2022-12-01	WOS:000074714200046
J	Chistoserdova, L; Vorholt, JA; Thauer, RK; Lidstrom, ME				Chistoserdova, L; Vorholt, JA; Thauer, RK; Lidstrom, ME			C-1 transfer enzymes and coenzymes linking methylotrophic bacteria and methanogenic Archaea	SCIENCE			English	Article							METHYLOBACTERIUM-EXTORQUENS AM1; TETRAHYDROMETHANOPTERIN FORMYLTRANSFERASE; FORMYLMETHANOFURAN; METHANOBACTERIUM; CYCLOHYDROLASE; DEHYDROGENASE; MECHANISM; SEQUENCE; GENE	Methanogenic and sulfate-reducing Archaea are considered to have an energy metabolism involving C-1 transfer coenzymes and enzymes unique for this group of strictly anaerobic microorganisms. An aerobic methylotrophic bacterium, Methylobacterium extorquens AM1, was found to contain a cluster of genes that are predicted to encode some of these enzymes and was shown to contain two of the enzyme activities and one of the methanogenic coenzymes. Insertion mutants were all unable to grow on C-1 compounds, suggesting that the archaeal enzymes function in aerobic C-1 metabolism. Thus, methylotrophy and methanogenesis involve common genes that cross the bacterial/archaeal boundaries.	Univ Washington, Dept Microbiol, Dept Chem Engn, Seattle, WA 98195 USA; Max Planck Inst Terr Microbiol, Dept Biochem, D-35043 Marburg, Germany	University of Washington; University of Washington Seattle; Max Planck Society	Lidstrom, ME (corresponding author), Univ Washington, Dept Microbiol, Dept Chem Engn, Seattle, WA 98195 USA.		Vorholt, Julia/K-3514-2016; Chistoserdova, Ludmila/K-2364-2017	Vorholt, Julia/0000-0002-6011-4910; Chistoserdova, Ludmila/0000-0002-5777-0263	NIGMS NIH HHS [GM36296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREITUNG J, 1992, EUR J BIOCHEM, V210, P971, DOI 10.1111/j.1432-1033.1992.tb17502.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHISTOSERDOV AY, 1994, J BACTERIOL, V176, P4052, DOI 10.1128/JB.176.13.4052-4065.1994; Chistoserdova L, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P16; CHISTOSERDOVA L, UNPUB; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P1957, DOI 10.1128/jb.176.7.1957-1968.1994; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; DONNELLY MI, 1985, ARCH BIOCHEM BIOPHYS, V242, P430, DOI 10.1016/0003-9861(85)90227-9; GORRIS LGM, 1994, BIOFACTORS, V4, P139; KLENK HP, 1997, ATURE, V390, P364; Lidstrom ME, 1991, PROKARYOTES, P431; MARISON IW, 1982, J GEN MICROBIOL, V128, P1441; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; POMPER B, UNPUB; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWORER B, 1993, ARCH MICROBIOL, V159, P225, DOI 10.1007/BF00248476; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; Vaupel M, 1996, EUR J BIOCHEM, V236, P294, DOI 10.1111/j.1432-1033.1996.00294.x; VORHOLT J, 1995, ARCH MICROBIOL, V163, P112, DOI 10.1007/s002030050179; Vorholt JA, 1997, MOL MICROBIOL, V23, P1033, DOI 10.1046/j.1365-2958.1997.2931653.x; Vorholt JA, 1997, ARCH MICROBIOL, V167, P19, DOI 10.1007/s002030050411; White RH, 1998, BBA-GEN SUBJECTS, V1380, P257, DOI 10.1016/S0304-4165(97)00148-7; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245	24	218	231	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					99	102		10.1126/science.281.5373.99	http://dx.doi.org/10.1126/science.281.5373.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651254				2022-12-01	WOS:000074685800046
J	Janssen, RS; Satten, GA; Stramer, SL; Rawal, BD; O'Brien, TR; Weiblen, BJ; Hecht, FM; Jack, N; Cleghorn, FR; Kahn, JO; Chesney, MA; Busch, MP				Janssen, RS; Satten, GA; Stramer, SL; Rawal, BD; O'Brien, TR; Weiblen, BJ; Hecht, FM; Jack, N; Cleghorn, FR; Kahn, JO; Chesney, MA; Busch, MP			New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FRANCISCO MENS HEALTH; HOMOSEXUAL BISEXUAL MEN; EARLY DIAGNOSTIC-TESTS; AIDS EPIDEMIC; TYPE-1 SEROCONVERSION; ANTIBODY-RESPONSE; INCIDENCE RATES; UNITED-STATES; PLASMA	Context.-Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but important for estimating HIV incidence and for purposes of clinical care and prevention. Objective.-To develop and validate a serologic testing algorithm in which HIV-1-positive persons with reactive test results on a sensitive HIV-1 enzyme immunoassay (EIA) but nonreactive results on a less sensitive (LS) EIA are identified as having early infection. Design.-Diagnostic test and testing strategy development, validation, and application. Specimens were tested with both a sensitive HIV-1 EIA (3A11 assay) and a less sensitive modification of the same EIA (3A11-LS assay). Settings and Participants.-For assay development: 104 persons seroconverting to HIV-1 comprising 38 plasma donors, 18 patients of a sexually transmitted disease clinic in Trinidad, and 48 participants in the San Francisco Men's Health Study (SFMHS); 268 men without the acquired immunodeficiency syndrome (AIDS) in the SFMHS who had been infected for at least 2.5 years; and 207 persons with clinical AIDS; for testing strategy validation: 488 men in the SFMHS from 1985 through 1990 and 1 275 449 repeat blood donors at 3 American Red Cross blood centers from 1993 through 1995; and for HIV-1 incidence estimates: 2 717 910 first-time blood donors. We retrospectively identified persons eligible for a study of early infection. Main Outcome Measure.-Ability to identify early HIV infection. Results.-Estimated mean time to being 3A11 reactive/3A11-LS nonreactive was 129 days (95% confidence interval [CI], 109-149 days). Our testing strategy accurately diagnosed 95% of persons with early infection; however, 0.4% (1/268) of men with established infection and 2% (5/207) of persons with late-stage AIDS were misdiagnosed as having early HIV-1 infection. Average yearly incidence estimates in SFMHS subjects were 1.5% per year vs observed average incidence of 1.4 per 100 person-years. Incidence in repeat blood donors using the sensitive/less sensitive assay testing strategy was 2.95 per 100 000 per year (95% CI, 1.14-6.53/ 100 000) vs observed incidence of 2.60 per 100 000 person-years (95% CI, 1.49-4.21/100 000). Overall incidence in first-time blood donors was 7.18 per 100 000 per year (95% CI, 4.51-11.20/100 000) and did not change statistically significantly between 1993 and 1996. Use of the sensitive/less sensitive testing strategy alone would have identified all 17 persons with antibodies to HIV-1 eligible for a study of early HIV-1 infection and would have increased enrollment. Conclusions.-The sensitive/less sensitive testing strategy provides accurate diagnosis of early HIV-1 infection, provides accurate estimates of HIV-1 incidence, can facilitate clinical studies of early HIV-1 infection, and provides information on HIV-1 infection duration for care planning.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Atlanta, GA 30333 USA; Amer Red Cross, Natl Reference Lab Infect Dis, Rockville, MD USA; Blood Ctr Pacific, Irwin Ctr, San Francisco, CA USA; NCI, Viral Epidemiol Branch, Rockville, MD USA; Boston Biomed Inc, W Bridgewater, MA USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Aids Prevent Studies, San Francisco, CA 94143 USA; Med Res Ctr, Port Spain, Trinidad Tobago; Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	Centers for Disease Control & Prevention - USA; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System of Maryland; University of Maryland Baltimore	Janssen, RS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Mailstop E-06,1600 Clifton Rd, Atlanta, GA 30333 USA.	RXJ1@cdc.gov		Hecht, Frederick/0000-0002-5782-1171; Satten, Glen/0000-0001-7275-5371				*ABB LAB, 1994, ENZ IMM DET ANT HUM; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BACCHETTI P, 1993, STAT SCI, V8, P82, DOI 10.1214/ss/1177010994; Beyrer C, 1996, J ACQ IMMUN DEF SYND, V12, P495, DOI 10.1097/00042560-199608150-00009; BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1995, AM J EPIDEMIOL, V142, P709, DOI 10.1093/oxfordjournals.aje.a117700; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1994, NAT HIV SER SUMM RES, V3, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chambers JM., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cleghorn Farley R., 1996, P147; CLEGHORN FR, 1995, 2 NAT C HUM RETR REL, P57; CONWAY B, 1998, 5 C RETR OPP INF CHI, P189; COOPER DA, 1987, J INFECT DIS, V155, P1113, DOI 10.1093/infdis/155.6.1113; *DCDP, 1997, HIV AIDS SURV REP, V9, P5; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; KAHN JO, IN PRESS N ENGL J ME; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LANGE JMA, 1988, AIDS, V2, P31, DOI 10.1097/00002030-198802000-00005; Lilienfeld AM, 1976, FDN EPIDEMIOLOGY; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; MCDOUGAL JS, 1987, J CLIN INVEST, V80, P316, DOI 10.1172/JCI113075; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; OBRIEN TR, 1994, J ACQ IMMUN DEF SYND, V7, P705; Pantaleo G, 1998, NAT MED, V4, P341, DOI 10.1038/nm0398-341; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Rothenberg ML, 1996, SEMIN ONCOL, V23, P21; SAGET B, 1998, 5 C RETR OPP INF CHI, P189; Satten GA, 1997, MATH BIOSCI, V141, P101, DOI 10.1016/S0025-5564(96)00185-X; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SILVERMAN BW, 1990, J ROY STAT SOC B MET, V52, P271; Snedecor GW, 1967, STAT METHODS; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TORIAN LV, 1997, 4 C RETR OPP INF WAS, P97; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; *UN AIDS WHO WORK, 1997, REP GLOB HIV AIDS EP, P1; Weinstock Hillard S., 1996, P336; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; [No title captured]	56	552	572	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					42	48		10.1001/jama.280.1.42	http://dx.doi.org/10.1001/jama.280.1.42			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660362				2022-12-01	WOS:000074379400022
J	Crawford, SE; Stellmach, V; Murphy-Ullrich, JE; Ribeiro, SMF; Lawler, J; Hynes, RO; Boivin, GP; Bouck, N				Crawford, SE; Stellmach, V; Murphy-Ullrich, JE; Ribeiro, SMF; Lawler, J; Hynes, RO; Boivin, GP; Bouck, N			Thrombospondin-1 is a major activator of TGF-beta 1 in vivo	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; HAMSTER OVARY CELLS; FACTOR-BETA; TGF-BETA; ENDOTHELIAL-CELLS; FACTOR-BETA-1-DEFICIENT MICE; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; TRANSGENIC MICE; LATENT FORMS	The activity of TGF-beta 1 is regulated primarily extracellularly where the secreted latent form must be modified to expose the active molecule. Here we show that thrombospondin-1 is responsible for a significant proportion of the activation of TGF-beta 1 in vivo. Histological abnormalities in young TGF-beta 1 null and thrombospondin-1 null mice were strikingly similar in nine organ systems. Lung and pancreas pathologies similar to those observed in TGF-beta 1 null animals could be induced in wild-type pups by systemic treatment with a peptide that blocked the activation of TGF-beta 1 by thrombospondin-1. Although these organs produced little active TGF-beta 1 in thrombospondin null mice, when pups were treated with a peptide derived from thrombospondin-l that could activate TGF-beta 1, active cytokine was detected in situ, and the lung and pancreatic abnormalities reverted toward wild type.	Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Chicago, IL 60614 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Beth Israel Deaconness Med Ctr, Dept Pathol, Boston, MA 02215 USA; MIT, Dept Biol, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Cincinnati, Dept Pathol, Cincinnati, OH 45267 USA	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Alabama System; University of Alabama Birmingham; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati	Crawford, SE (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA.		Lawler, Jack/AAJ-1379-2020		NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061, R01HL028749] Funding Source: NIH RePORTER; NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NHLBI NIH HHS [R01 HL050061, HL28749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; BOIVIN GP, 1995, AM J PATHOL, V146, P276; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Caver TE, 1996, J CLIN INVEST, V98, P2496, DOI 10.1172/JCI119068; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DAWSON DW, 1998, ANGIOGENIC AGENTS; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; JIRTLE RL, 1991, J BIOL CHEM, V266, P22444; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIOUBIN MN, 1991, J CELL BIOCHEM, V45, P112, DOI 10.1002/jcb.240450118; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIYAZONO K, 1991, CIBA F SYMP, V157, P81; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1981, CANCER RES, V41, P2842; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAYCHAUDHURY A, 1994, J CELL SCI, V107, P39; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SANVITO F, 1994, DEVELOPMENT, V120, P3451; SAPERSTEIN LA, 1994, HEPATOLOGY, V19, P412; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHULZ E, 1994, ACROS CHIMICA ACTA, V1, P1; Serra R, 1996, NAT MED, V2, P390, DOI 10.1038/nm0496-390; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SJOHOLM A, 1991, AM J PHYSIOL, V260, pC1046, DOI 10.1152/ajpcell.1991.260.5.C1046; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; YAMANAKA Y, 1993, DIABETES, V42, P746, DOI 10.2337/diabetes.42.5.746; Yang YB, 1997, BIOCHEMISTRY-US, V36, P11923, DOI 10.1021/bi9710479; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	72	921	975	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1159	1170		10.1016/S0092-8674(00)81460-9	http://dx.doi.org/10.1016/S0092-8674(00)81460-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657149	Bronze			2022-12-01	WOS:000074491100011
J	Benigni, A; Remuzzi, G				Benigni, A; Remuzzi, G			Transplant tolerance: will genes protect the graft?	LANCET			English	Editorial Material									Osped Riuniti Bergamo, Ist Ric Farmacol Mario Negri, Dept Transplant Immunol & Innovat Antireject The, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Benigni, A (corresponding author), Osped Riuniti Bergamo, Ist Ric Farmacol Mario Negri, Dept Transplant Immunol & Innovat Antireject The, I-24100 Bergamo, Italy.		Ariela, Benigni/ABH-3492-2020; Remuzzi, Giuseppe/V-9766-2017	Ariela, Benigni/0000-0002-4721-5485; Remuzzi, Giuseppe/0000-0002-6194-3446				CHAHINE AA, 1995, TRANSPLANTATION, V59, P1313, DOI 10.1097/00007890-199505150-00016; Deng S, 1997, TRANSPL P, V29, P770, DOI 10.1016/S0041-1345(96)00477-0; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Knechtle SJ, 1997, J IMMUNOL, V159, P152; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; LUTZ J, 1997, J AM SOC NEPHROL S, V8, pA502; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; Olthoff KM, 1998, NAT MED, V4, P194, DOI 10.1038/nm0298-194; Perico N, 1997, DRUGS, V54, P533, DOI 10.2165/00003495-199754040-00003; Perico N, 1997, INT J CLIN LAB RES, V27, P165, DOI 10.1007/BF02912453; QIN LH, 1995, TRANSPLANTATION, V59, P809, DOI 10.1097/00007890-199503270-00002; SAYEGH MH, 1997, KIDNEY INT S58, V51, pS11; Swenson KM, 1998, TRANSPLANTATION, V65, P155	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1749	1751		10.1016/S0140-6736(05)78739-0	http://dx.doi.org/10.1016/S0140-6736(05)78739-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635942				2022-12-01	WOS:000074197600003
J	Boshuizen, HC; Izaks, GJ; van Buuren, S; Ligthart, GJ				Boshuizen, HC; Izaks, GJ; van Buuren, S; Ligthart, GJ			Blood pressure and mortality in elderly people aged 85 and older: community based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; SEX	Objective: To determine whether the inverse relation between blood pressure and all cause mortality in elderly people over 85 years of age can be explained by adjusting for health status, and to determine whether high blood pressure is a risk factor for mortality when the effects of poor health are accounted for. Design: 5 to 7 year follow up of community residents aged 85 years and older. Setting: Leiden, the Netherlands. Subjects: 835 subjects whose blood pressure was recorded between 1987 and 1989. Main outcome measure: All cause mortality. Results: An inverse relation between blood pressure and all cause mortality was observed. For diastolic blood pressure crude year all cause mortality decreased from 88% (52/59) (95% confidence interval 79% to 95%) in those with diastolic blood pressures < 65 mm Hg to 59% (27/46) (44% to 72%) in those with diastolic pressures > 100 mm Hg. For systolic blood pressure crude 5 year all cause mortality decreased from 85% (95/112) (78% to 91%) in those with systolic pressures < 125 mm Hg to 59% (13/22) (38% to 78%) in those with systolic pressures > 200 min Hg. This decrease was no longer significant after adjustment for indicators of poor health. No relation existed between blood pressure and mortality from cardiovascular causes or stroke after adjustment for age and sex, but after adjustment for age, sex, and indicators of poor health there was a positive relation between diastolic blood pressure and mortality from both cardiovascular causes and stroke. Conclusion: The inverse relation between blood pressure and all cause mortality in elderly people over 85 is associated with health status.	TNO Prevent & Hlth, Div Publ Hlth & Prevent, Leiden, Netherlands; Leiden Univ, Dept Gen Internal Med, Sect Gerontol & Geriatr, Med Ctr, Leiden, Netherlands	Netherlands Organization Applied Science Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Boshuizen, HC (corresponding author), TNO Prevent & Hlth, Div Publ Hlth & Prevent, Leiden, Netherlands.	HC.Boshuizen@PG.TNO.NL	Izaks, Gerbrand/F-5089-2014; Boshuizen, Hendriek/M-3415-2014; Boshuizen, Hendriek C/B-3718-2014	Izaks, Gerbrand/0000-0003-3213-7637; Boshuizen, Hendriek/0000-0002-3916-9095; van Buuren, Stef/0000-0003-1098-2119	NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06354] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMERY A, 1986, LANCET, V2, P589; [Anonymous], 1991, JAMA, V265, P3255; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GLYNN RJ, 1995, LANCET, V345, P825, DOI 10.1016/S0140-6736(95)92964-9; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; HEIKINHEIMO RJ, 1990, J HYPERTENS, V8, P361, DOI 10.1097/00004872-199004000-00010; HOLME I, 1976, ACTA MED SCAND, V200, P229; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LANGER RD, 1991, AM J EPIDEMIOL, V134, P29, DOI 10.1093/oxfordjournals.aje.a115990; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; RAJALA S, 1983, LANCET, V2, P520; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9	16	152	158	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1780	+		10.1136/bmj.316.7147.1780	http://dx.doi.org/10.1136/bmj.316.7147.1780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624064	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000074286300024
J	Balsalobre, A; Damiola, F; Schibler, U				Balsalobre, A; Damiola, F; Schibler, U			A serum shock induces circadian gene expression in mammalian tissue culture cells	CELL			English	Article							LEUCINE-ZIPPER PROTEINS; C-FOS; RHYTHMS; CLOCK; TRANSCRIPTION; ENTRAINMENT; LIGHT; TEF; DBP	The treatment of cultured rat-1 fibroblasts or H35 hepatoma cells with high concentrations of serum induces the circadian expression of various genes whose transcription also oscillates in living animals. Oscillating genes include rper1 and rper2 (rat homologs of the Drosophila clock gene period), and the genes encoding the transcription factors Rev-Erb alpha, DBP, and TEF. In rat-1 fibroblasts, up to three consecutive daily oscillations with an average period length of 22.5 hr could be recorded. The temporal sequence of the various mRNA accumulation cycles is the same in cultured cells and in vivo. The serum shock of rat-1 fibroblasts also results in a transient stimulation of c-fos and rper expression and thus mimics light-induced immediate-early gene expression in the suprachiasmatic nucleus.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Schibler, U (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Damiola, Francesca/0000-0002-0238-1252				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chrousos GP, 1998, ENDOCRINOLOGY, V139, P437, DOI 10.1210/endo.139.2.5857; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; EWER J, 1992, J NEUROSCI, V12, P3321; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; Gwinner E, 1997, BRAIN RES BULL, V44, P439, DOI 10.1016/S0361-9230(97)00224-4; HASTINGS HM, 1997, CURR BIOL, V7, P670; Honrado GI, 1996, J COMP PHYSIOL A, V178, P563; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Kornhauser JM, 1996, BEHAV GENET, V26, P221, DOI 10.1007/BF02359382; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; MOORE RY, 1992, CIRCADIAN RHYTHMS, P26; Morris ME, 1998, SCIENCE, V279, P1544, DOI 10.1126/science.279.5356.1544; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Okano T, 1997, J PINEAL RES, V22, P145, DOI 10.1111/j.1600-079X.1997.tb00316.x; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Portaluppi F, 1996, ANN NY ACAD SCI, V783, P113, DOI 10.1111/j.1749-6632.1996.tb26711.x; Rabinowitz L, 1996, KIDNEY INT, V49, P1738, DOI 10.1038/ki.1996.258; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Tosini G, 1998, J NEUROSCI, V18, P1105; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	49	1460	1493	5	111	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					929	937		10.1016/S0092-8674(00)81199-X	http://dx.doi.org/10.1016/S0092-8674(00)81199-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635423	Bronze			2022-12-01	WOS:000074205700005
J	Rizzuto, R; Pinton, P; Carrington, W; Fay, FS; Fogarty, KE; Lifshitz, LM; Tuft, RA; Pozzan, T				Rizzuto, R; Pinton, P; Carrington, W; Fay, FS; Fogarty, KE; Lifshitz, LM; Tuft, RA; Pozzan, T			Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses	SCIENCE			English	Article							CALCIUM LOADS; INTACT-CELLS; LIVING CELLS; HOMEOSTASIS; AEQUORIN; NEURONS	The spatial relation between mitochondria and endoplasmic reticulum (ER) in living HeLa cells was analyzed at high resolution in three dimensions with two differently colored, specifically targeted green fluorescent proteins. Numerous close contacts were observed between these organelles, and mitochondria in situ formed a largely interconnected, dynamic network. A Ca2+-sensitive photoprotein targeted to the outer face of the inner mitochondrial membrane showed that, upon opening of the inositol 1,4,5-triphosphate (IP3)-gated channels of the ER, the mitochondrial surface was exposed to a higher concentration of Ca2+ than was the bulk cytosol. These results emphasize the importance of cell architecture and the distribution of organelles in regulation of Ca2+ signaling.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Natl Res Council, Ctr Study Biomembranes, I-35121 Padua, Italy; Univ Massachusetts, Med Ctr, Biomed Imaging Grp, Worcester, MA 01605 USA	University of Padua; University of Padua; University of Massachusetts System; University of Massachusetts Worcester	Rizzuto, R (corresponding author), Univ Padua, Dept Biomed Sci, Via Colombo 3, I-35121 Padua, Italy.	rizzuto@civ.bio.unipd.it	Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008	Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097	NCRR NIH HHS [RR09799] Funding Source: Medline; NHLBI NIH HHS [HL14523] Funding Source: Medline; Telethon [845, 850] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014523, R01HL014523] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKEEVA LE, 1978, BIOCHIM BIOPHYS ACTA, V501, P349, DOI 10.1016/0005-2728(78)90104-4; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CAMPBELL CL, 1994, MOL BIOL CELL, V5, P899, DOI 10.1091/mbc.5.8.899; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; DAVISON MT, 1977, J GEN MICROBIOL, V98, P147, DOI 10.1099/00221287-98-1-147; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KIEDROWSKI L, 1995, MOL PHARMACOL, V47, P140; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; MacDonald MJ, 1996, ARCH BIOCHEM BIOPHYS, V326, P79, DOI 10.1006/abbi.1996.0049; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, IN PRESS TRENDS CELL; ROBBGASPERS LD, UNPUB; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; WERTH JL, 1994, J NEUROSCI, V14, P348; WHITE RJ, 1995, J NEUROSCI, V15, P1318	35	1722	1765	5	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1763	1766		10.1126/science.280.5370.1763	http://dx.doi.org/10.1126/science.280.5370.1763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624056				2022-12-01	WOS:000074197800045
J	Serpell, MG; Haldane, GJ; Jamieson, DRS; Carson, D				Serpell, MG; Haldane, GJ; Jamieson, DRS; Carson, D			Prevention of headache after lumbar puncture: questionnaire survey of neurologists and neurosurgeons in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							NEEDLE		Univ Glasgow, Western Infirm, Dept Anaesthesia, Glasgow G11 6NT, Lanark, Scotland; So Gen Hosp NHS Trust, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; Ulster Hosp, Dept Anaesthesia, Belfast BT16 0RH, Antrim, North Ireland	University of Glasgow; University of Glasgow	Serpell, MG (corresponding author), Univ Glasgow, Western Infirm, Dept Anaesthesia, Glasgow G11 6NT, Lanark, Scotland.							CARBAAT PAT, 1981, LANCET, V2, P1133; Carson D, 1996, NEUROLOGY, V47, P33, DOI 10.1212/WNL.47.1.33; KUNTZ KM, 1992, NEUROLOGY, V42, P1884, DOI 10.1212/WNL.42.10.1884; MIHIC D N, 1986, Regional-Anaesthesie, V9, P54; TOURTELLOTTE WW, 1972, HEADACHE, V12, P73, DOI 10.1111/j.1526-4610.1972.hed1202073.x	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1998	316	7146					1709	1710		10.1136/bmj.316.7146.1709	http://dx.doi.org/10.1136/bmj.316.7146.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT806	9614018	Green Accepted, Green Submitted, Bronze, Green Published			2022-12-01	WOS:000074129500020
J	Cooper, MK; Porter, JA; Young, KE; Beachy, PA				Cooper, MK; Porter, JA; Young, KE; Beachy, PA			Teratogen-mediated inhibition of target tissue response to Shh signaling	SCIENCE			English	Article							MOTOR-NEURON INDUCTION; A REDUCTASE-ACTIVITY; SONIC-HEDGEHOG; CHOLESTEROL-BIOSYNTHESIS; FLOOR PLATE; GENE; CELLS; PROGESTERONE; HOMEOSTASIS; AUTOPROTEOLYSIS	Veratrum alkaloids and distal inhibitors of cholesterol biosynthesis have been studied for more than 30 years as potent teratogens capable of inducing cyclopia and other birth defects. Here, it is shown that these compounds specifically block the Sonic hedgehog (Shh) signaling pathway. These teratogens did not prevent the sterol modification of Shh during autoprocessing but rather inhibited the response of target tissues to Shh, possibly acting through the sterol sensing domain within the Patched protein regulator of Shh response.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.							ALTABA AR, 1995, DEV BIOL, V170, P299; AUFENANGER J, 1986, BIOCHEM PHARMACOL, V35, P911, DOI 10.1016/0006-2952(86)90076-6; Beachy PA, 1997, COLD SPRING HARB SYM, V62, P191; BELL JJ, 1976, J BIOL CHEM, V251, P1745; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BINNS W, 1963, AM J VET RES, V24, P1164; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN MM, 1992, J CRAN GENET DEV BIO, V12, P196; COOPER MD, UNPUB; Dehart DB, 1997, AM J MED GENET, V68, P328, DOI 10.1002/(SICI)1096-8628(19970131)68:3<328::AID-AJMG15>3.0.CO;2-V; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Gaffield W, 1996, J NAT TOXINS, V5, P25; GIBSON KM, 1990, J LIPID RES, V31, P515; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KRAML M, 1964, BIOCHEM BIOPH RES CO, V15, P455, DOI 10.1016/0006-291X(64)90485-1; Lange Y, 1996, J LIPID RES, V37, P534; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MARTI E, 1995, DEVELOPMENT, V121, P2537; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; MILLER SC, 1984, J LIPID RES, V25, P991; POPJAK G, 1989, J BIOL CHEM, V264, P6230; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; ROUX C, 1966, CR SOC BIOL, V160, P1353; ROUX CHARLES, 1964, ARCH FRANC PEDIAT, V21, P451; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Wang B., UNPUB; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOSHIKAWA H, 1991, BRAIN DEV-JPN, V13, P115, DOI 10.1016/S0387-7604(12)80118-5	47	728	770	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1603	1607		10.1126/science.280.5369.1603	http://dx.doi.org/10.1126/science.280.5369.1603			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616123				2022-12-01	WOS:000074061200041
J	Schreiber-Agus, N; Meng, Y; Hoang, T; Hou, H; Chen, K; Greenberg, R; Cordon-Cardo, C; Lee, HW; DePinho, RA				Schreiber-Agus, N; Meng, Y; Hoang, T; Hou, H; Chen, K; Greenberg, R; Cordon-Cardo, C; Lee, HW; DePinho, RA			Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth	NATURE			English	Article							TRANSGENIC MICE; PROSTATE-CANCER; C-MYC; REPRESSOR SIN3; MAX; MODELS; MOUSE; GENE; DIFFERENTIATION; TRANSFORMATION	Mxi1 belongs to the Mad (Mxi1) family of proteins, which function as potent antagonists of Myc oncoproteins(1-4). This antagonism relates partly to their ability to compete with Myc for the protein Max and for consensus DNA binding sites and to recruit transcriptional co-repressors(4-6). Mad(Mxi1) proteins have been suggested to be essential in cellular growth control and/or in the induction and maintenance of the differentiated state(6-7) Consistent with these roles, mxi1 may be the tumour-suppressor gene that resides at region 24-26 of the long arm of chromosome 10. This region is a cancer hotspot, and mutations here may be involved in several cancers, including prostate adenocarcinoma(8-10). Here we show that mice lacking Mxi1 exhibit progressive, multisystem abnormalities. These mice also show increased susceptibility to tumorigenesis either following carcinogen treatment or when also deficient in Ink4a. This cancer-prone phenotype may correlate with the enhanced ability of several mxi1-deficient cell types, including prostatic epithelium, to proliferate. Our results show that Mxi1 is involved in the homeostasis of differentiated organ systems, acts as a tumour suppressor in vivo and engages the Myc network in functionally relevant manner.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	DePinho, RA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	depinho@aecom.yu.edu		DePinho, Ronald/0000-0002-5625-577X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; Dedeoglu IO, 1996, PEDIATR PATHOL LAB M, V16, P941, DOI 10.1080/15513819609168717; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gerlach C, 1997, LAB INVEST, V77, P697; GRAY IC, 1995, CANCER RES, V55, P4800; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HECKER E, 1992, J CANCER RES CLIN, V118, P321, DOI 10.1007/BF01208624; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Jenkins RB, 1997, CANCER RES, V57, P524; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROCHOWNIK EV, IN PRESS GENES CHROM; RAIMONDI SC, 1988, BLOOD, V72, P1560; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, IN PRESS BIOESSAYS; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; THOMPSON TC, 1993, CANCER, V71, P1165, DOI 10.1002/1097-0142(19930201)71:3+<1165::AID-CNCR2820711440>3.0.CO;2-U; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	164	170	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					483	487		10.1038/31008	http://dx.doi.org/10.1038/31008			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624006				2022-12-01	WOS:000074020000049
J	Mohri, M; Koyanagi, M; Egashira, K; Tagawa, H; Ichiki, T; Shimokawa, H; Takeshita, A				Mohri, M; Koyanagi, M; Egashira, K; Tagawa, H; Ichiki, T; Shimokawa, H; Takeshita, A			Angina pectoris caused by coronary microvascular spasm	LANCET			English	Article							INDUCED MYOCARDIAL-ISCHEMIA; ARTERY SPASM; SYNDROME-X; VARIANT ANGINA; NITRIC-OXIDE; ACETYLCHOLINE; ARTERIOGRAMS; VASODILATION; SITE; RESISTANCE	Background Microvascular angina can occur during exercise and at rest. Reduced vasodilator capacity of the coronary microvessels is implicated as a cause of angina during exercise, but the mechanism of angina at rest is not known. Our aim was to test the hypothesis that primary hyperconstriction (spasm) of microvessels causes myocardial ischaemia at rest. Methods Acetylcholine induces coronary artery spasm in patients with variant angina. We tested the effects of intracoronary acetylcholine at graded doses in 117 consecutive patients with chest pain (at rest, during exertion, or both) and no flow-limiting (>50%) organic stenosis in the large epicardial coronary arteries. We also assessed the metabolism of myocardial lactate during acetylcholine administration in 36 of the patients by measurement of lactate in paired blood samples from the coronary artery and coronary sinus vein. Findings Of the 117 patients, 63 (54%) had large-artery spasm, 29 (25%) had microvascular spasm, and 25 (21%) had atypical chest pain. The 29 patients with microvascular spasm developed angina-like chest pain, ischaemic electrocardiogram (ECG) changes, or both spontaneously (two patients) or after administration of acetylcholine (27 patients) without spasm of the large epicardial coronary arteries. Testing of paired samples of arterial and coronary sinus venous blood showed that lactate was produced during angina attack in nine of 11 patients with microvascular spasm. There was more women (p<0.01) and fewer coronary risk factors (p<0.01) in patients with microvascular spasm than in those with large-artery spasm. Interpretation Coronary microvascular spasm and resultant myocardial ischaemia may be the cause of chest pain in a subgroup of patients with microvascular angina.	Kyushu Univ, Fac Med, Angiocardiol Res Inst, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Cardiovasc Clin, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Mohri, M (corresponding author), Kyushu Univ, Fac Med, Angiocardiol Res Inst, Higashi Ku, 3-1-1 maidashi, Fukuoka 8128582, Japan.	mmohri@med.kyushu-u.ac.jp						BORTONE AS, 1989, CIRCULATION, V79, P516, DOI 10.1161/01.CIR.79.3.516; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1983, J AM COLL CARDIOL, V1, P359; Egashira K, 1996, J AM COLL CARDIOL, V27, P1444, DOI 10.1016/0735-1097(96)00021-6; Egashira K, 1996, CIRCULATION, V94, P130, DOI 10.1161/01.CIR.94.2.130; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; EPSTEIN SE, 1986, J AM COLL CARDIOL, V8, P459, DOI 10.1016/S0735-1097(86)80067-5; EPSTEIN SE, 1991, CIRCULATION, V83, P73; ITO A, 1995, CIRCULATION, V92, P2636, DOI 10.1161/01.CIR.92.9.2636; KASKI JC, 1995, J AM COLL CARDIOL, V25, P807, DOI 10.1016/0735-1097(94)00507-M; Kemp H G, 1967, Trans Assoc Am Physicians, V80, P59; KEMP HG, 1991, J AM COLL CARDIOL, V17, P507, DOI 10.1016/S0735-1097(10)80123-8; KUGA T, 1995, CIRCULATION, V92, P183, DOI 10.1161/01.CIR.92.2.183; LIKOFF W, 1967, NEW ENGL J MED, V276, P1063, DOI 10.1056/NEJM196705112761904; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; MOSSERI M, 1986, CIRCULATION, V74, P964, DOI 10.1161/01.CIR.74.5.964; MOTZ W, 1991, AM J CARDIOL, V68, P996, DOI 10.1016/0002-9149(91)90485-4; NAGAI H, 1994, ANGIOLOGY, V45, P391, DOI 10.1177/000331979404500509; OKUMURA K, 1988, J AM COLL CARDIOL, V12, P883, DOI 10.1016/0735-1097(88)90449-4; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; QUYYUMI AA, 1992, CIRCULATION, V86, P1864, DOI 10.1161/01.CIR.86.6.1864; SEKIYA M, 1993, ANGIOLOGY, V44, P811, DOI 10.1177/000331979304401008; SEROTA H, 1991, AM HEART J, V121, P1807, DOI 10.1016/0002-8703(91)90031-C; SUGIISHI M, 1993, CIRCULATION, V87, P76, DOI 10.1161/01.CIR.87.1.76; SUZUKI H, 1994, INT J CARDIOL, V43, P139, DOI 10.1016/0167-5273(94)90003-5; VRINTS CJM, 1992, J AM COLL CARDIOL, V19, P21, DOI 10.1016/0735-1097(92)90046-P; Yamagishi H, 1997, JPN CIRC J, V61, P87, DOI 10.1253/jcj.61.87; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	28	219	224	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1165	1169		10.1016/S0140-6736(97)07329-7	http://dx.doi.org/10.1016/S0140-6736(97)07329-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643687				2022-12-01	WOS:000073220200009
J	Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Balkau, B; Nordisk, N				Borch-Johnsen, K; Eriksson, J; Qiao, Q; Tuomilehto, J; Balkau, B; Nordisk, N		DECODE Study Grp	Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; RISK-FACTORS; FOLLOW-UP; MEN; PREVALENCE; POPULATION; FINLAND; NIDDM	Objective: To evaluate the impact of the revised diagnostic criteria far diabetes mellitus adopted by the American Diabetes Association on prevalence of diabetes and on classification of patients. For epidemiological purposes the American criteria use a fasting plasma glucose concentration greater than or equal to 7.0 mmol/l in contrast with the current World Health Organisation criteria of 2 hour glucose concentration greater than or equal to 11.1 mmol/l. Design: Data were collected from 13 populations and three occupational based studies from eight European countries. Ail studies used a 75 g oral glucose tolerance test to measure fasting and 2 hour glucose concentrations. Subjects: 17 881 men; 8309 women; age range 17-92 years. Main outcome measures: Classification of diabetes according to both sets of criteria. Results: The application of the American criteria on European populations induced changes in prevalence of diabetes ranging from a reduction of 4.0% to an increase of 13.2%. A total of 1517 previously undiagnosed individuals had diabetes according to either the WHO or the American criteria. Among 1044 with diabetes according to American criteria, only 45% had 2 hour values fulfilling the WHO criteria. The risk of disagreement of classification decreased with increasing body mass index (P < 0.00001) and increasing age (P < 0.0001); the impact of sex was not significant (P = 0.08). Conclusions: This shift in strategy from using 2 hour to fasting plasma glucose will cause an increase in the prevalence of diabetes in some European populations. A high degree of disagreement in the classification was observed between the two recommendations. Prospective data are needed to evaluate whether the WHO or the American criteria best identify individuals at risk of developing microvascular complications and cardiovascular disease. Wider implementation of revised diagnostic criteria should await prospective data.	Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Steno Diabetes Center	Borch-Johnsen, K (corresponding author), Steno Diabet Ctr, Steensens Vej 2, DK-2820 Gentofte, Denmark.	kbjo@novo.dk		Eriksson, Johan/0000-0002-2516-2060				[Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; FESKENS EJM, 1994, ARTERIOSCLER THROMB, V14, P1641, DOI 10.1161/01.ATV.14.10.1641; FONTBONNE A, 1992, DIABETES, V41, P1385, DOI 10.2337/diabetes.41.11.1385; GARANCINI MP, 1995, DIABETOLOGIA, V38, P306, DOI 10.1007/BF00400635; Gavin JR, 1997, DIABETES CARE, V20, P1183; HAGERUP L, 1987, SYGDOM SUNDHED BEFOL; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HITUNEN L, 1994, DIABETIC MED, V11, P241; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; Kangas T, 1996, DIABETES CARE, V19, P494, DOI 10.2337/diacare.19.5.494; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; KLEINMAN JC, 1981, AM J PUBLIC HEALTH, V71, P73, DOI 10.2105/AJPH.71.1.73; Lindberg O, 1997, J AM GERIATR SOC, V45, P407, DOI 10.1111/j.1532-5415.1997.tb05163.x; McCance DR, 1997, DIABETOLOGIA, V40, P247, DOI 10.1007/s001250050671; MOOY JM, 1995, DIABETES CARE, V18, P1270, DOI 10.2337/diacare.18.9.1270; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Pajak Andrzej, 1995, European Heart Journal, V16, P143; PYRALA K, 1979, J CHRON DIS, V32, P45; RAJALA U, 1995, SCAND J PRIM HEALTH, V13, P222, DOI 10.3109/02813439508996765; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; STENGARD JH, 1993, DIABETES METAB, V19, P121; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160; Vanhala M J, 1997, J Cardiovasc Risk, V4, P291, DOI 10.1097/00043798-199708000-00010; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; *WHO EXP COMM DIAB, 1980, WHO TECH REP SER, V646, P1; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	31	346	351	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 8	1998	317	7155					371	375						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694750				2022-12-01	WOS:000075409600021
J	Miskin, JE; Abrams, CC; Goatley, LC; Dixon, LK				Miskin, JE; Abrams, CC; Goatley, LC; Dixon, LK			A viral mechanism for inhibition of the cellular phosphatase calcineurin	SCIENCE			English	Article							SWINE FEVER VIRUS; TRANSCRIPTION FACTOR NFAT1; NF-KAPPA-B; CONSTRUCTION	The transcription factor NFAT (nuclear factor of activated T cells) controls the expression of many immunomodulatory proteins. African swine Fever virus inhibits proinflammatory cytokine expression in infected macrophages, and a viral protein A238L was found to display the activity of the immunosuppressive drug cyclosporin A by inhibiting NFAT-regulated gene transcription in vivo. This it does by binding the catalytic subunit of calcineurin and inhibiting calcineurin phosphatase activity.	AFRC, Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Dixon, LK (corresponding author), AFRC, Inst Anim Hlth, Pirbright Lab, Pirbright GU24 0NF, Surrey, England.		Goatley, Lynnette/ABI-1426-2020; Dixon, Linda K/B-9063-2019	Goatley, Lynnette/0000-0001-6792-2235; Dixon, Linda/0000-0003-3845-3016				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; DavisPoynter NJ, 1996, IMMUNOL CELL BIOL, V74, P513, DOI 10.1038/icb.1996.84; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HARPER JW, 1993, CELL, V75, P805; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MISKIN JE, UNPUB; Neilan JG, 1997, VIROLOGY, V235, P377, DOI 10.1006/viro.1997.8693; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RODRIGUEZ JM, 1992, VIROLOGY, V188, P67, DOI 10.1016/0042-6822(92)90735-8; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	17	112	118	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					562	565		10.1126/science.281.5376.562	http://dx.doi.org/10.1126/science.281.5376.562			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677199				2022-12-01	WOS:000075012300041
J	Gordon, LK; Levin, LA				Gordon, LK; Levin, LA			Visual loss in giant cell arteritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; BIOPSY FINDINGS; PROGNOSIS; DIAGNOSIS		Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Levin, LA (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 600 Highland Ave, Madison, WI 53792 USA.							ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ALBERT DM, 1976, ARCH OPHTHALMOL-CHIC, V94, P2072; Boehme MWJ, 1996, AM J MED, V101, P387, DOI 10.1016/S0002-9343(96)00230-6; Cornblath WT, 1997, OPHTHALMOLOGY, V104, P854, DOI 10.1016/S0161-6420(97)30222-X; FAUCHALD P, 1972, ANN INTERN MED, V77, P845, DOI 10.7326/0003-4819-77-6-845; Fineman MS, 1996, AM J OPHTHALMOL, V122, P428, DOI 10.1016/S0002-9394(14)72073-2; Font C, 1997, BRIT J RHEUMATOL, V36, P251; Ghanchi FD, 1997, SURV OPHTHALMOL, V42, P99, DOI 10.1016/S0039-6257(97)00052-0; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; Hayreh SS, 1997, AM J OPHTHALMOL, V123, P285, DOI 10.1016/S0002-9394(14)70123-0; JONASSON F, 1979, SCOT MED J, V24, P111, DOI 10.1177/003693307902400203; Lauwerys BR, 1997, J RHEUMATOL, V24, P1570; Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744; LIU GT, 1994, OPHTHALMOLOGY, V101, P1779; MELBERG NS, 1995, OPHTHALMOLOGY, V102, P1611; Myklebust G, 1996, BRIT J RHEUMATOL, V35, P1161; RodriguezValverde V, 1997, AM J MED, V102, P331, DOI 10.1016/S0002-9343(97)00117-4; SALVARANI C, 1995, ANN INTERN MED, V123, P192, DOI 10.7326/0003-4819-123-3-199508010-00006; Schmidt WA, 1997, NEW ENGL J MED, V337, P1336, DOI 10.1056/NEJM199711063371902; SLAVIN ML, 1994, AM J OPHTHALMOL, V117, P81, DOI 10.1016/S0002-9394(14)73018-1; Sorbi D, 1996, ARTHRITIS RHEUM-US, V39, P1747, DOI 10.1002/art.1780391019; Sudlow C, 1997, BRIT MED J, V315, P549, DOI 10.1136/bmj.315.7107.549; Wagner AD, 1996, AM J PATHOL, V148, P1925; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105	25	35	36	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					385	386		10.1001/jama.280.4.385	http://dx.doi.org/10.1001/jama.280.4.385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686559				2022-12-01	WOS:000074804200044
J	Andersson, OK; Almgren, T; Persson, B; Samuelsson, O; Hedner, T; Wilhelmsen, L				Andersson, OK; Almgren, T; Persson, B; Samuelsson, O; Hedner, T; Wilhelmsen, L			Survival in treated hypertension: follow up study after two decades	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PREVENTION; GOTEBORG; SWEDEN; LIPIDS; DEATH; TRIAL; MEN	Objective: To compare survival and cause specific mortality in hypertensive men with non-hypertensive men derived from the same random population, and to study mortality aid morbidity from cardiovascular diseases in the hypertensive men in relation to effects on cardiovascular risk factors during 22-23 years of follow up. Design: Prospective, population based observational study. Subjects and methods: 686 hypertensive men aged 47-55 at screening compared with 6810 non-hypertensive men. The hypertensive men were having stepped care treatment with either beta adrenergic blocking drugs, thiazide diuretics, or combination treatment. Mortality, morbidity and adverse effects were registered at yearly examinations and from death certificates. Main outcome measures: All cause mortality and cause specific mortality. Results: Treated hypertensive men had significantly impaired probability of total survival as well as survival from coronary heart disease and stroke. All cause mortality as well as coronary heart disease and stroke mortality were very similar in hypertensive men and normotensive men during the first decade, but increased steadily thereafter despite continuous good blood pressure control. Smoking, signs of target organ damage, and high serum cholesterol levels, but not blood pressure at screening, were significantly related to the incidence of coronary heart disease during follow up. In time dependent Cox's regression analysis, the incidence of coronary heart disease was significantly related only to serum cholesterol concentrations in the study. Cancer mortality was almost similar in treated hypertensive men (61/686, 8.9%) and non-hypertensive men (732/6810, 10.8%). Conclusion: Treated hypertensive men had impaired survival and increased mortality from cardiovascular disease compared with non-hypertensive men of similar age. These differences were observed during the second decade of follow up. During an observation period of 22-23 years-about 15 000 patient years-hypertensive men receiving diuretics and beta blockers had no increased risk of cancer or non-cardiovascular disease.	Sahlgrens Univ Hosp, Dept Med, Nephrol Sect, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Heart & Lung Dis, Sect Prevent Cardiol, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital	Andersson, OK (corresponding author), Sahlgrens Univ Hosp, Dept Med, Nephrol Sect, S-41345 Gothenburg, Sweden.							ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; ANDERSSON O, 1978, ACTA MED SCAND, V203, P391; BERGLUND G, 1976, ACTA MED SCAND, V200, P163; BULPITT CJ, 1986, J HYPERTENS, V4, P93, DOI 10.1097/00004872-198602000-00015; BULPITT CJ, 1979, LANCET, V2, P134; Chobanian AV, 1996, CIRCULATION, V93, P638, DOI 10.1161/01.CIR.93.4.638; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; DAY JL, 1982, BRIT MED J, V284, P1145, DOI 10.1136/bmj.284.6323.1145; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; ELMFELDT D, 1975, J CHRON DIS, V28, P173, DOI 10.1016/0021-9681(75)90005-3; ERIKSSON H, 1992, J INTERN MED, V232, P389, DOI 10.1111/j.1365-2796.1992.tb00604.x; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; HARMSEN P, 1972, ACTA MED SCAND, V191, P463; LEREN P, 1980, LANCET, V2, P4; PEDERSEN TR, 1994, LANCET, V344, P1383; RAY AA, 1982, SAS USERS GUIDE BASI; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rose GA, 1968, WHO MONOGRAPHY SERIE, V56, P98; Samuelsson O, 1996, BMJ-BRIT MED J, V313, P660; *SAS I, 1991, SAS STAT SOFTWARE PH; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMIRK FH, 1972, AM HEART J, V83, P825, DOI 10.1016/0002-8703(72)90216-5; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065	26	163	167	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1998	317	7152					167	171		10.1136/bmj.317.7152.167	http://dx.doi.org/10.1136/bmj.317.7152.167			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665894	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000075047800018
J	Kros, CJ; Ruppersberg, JP; Rusch, A				Kros, CJ; Ruppersberg, JP; Rusch, A			Expression of a potassium current in inner hair cells during development of hearing in mice	NATURE			English	Article							GUINEA-PIG; COCHLEA; CALCIUM; SODIUM; CHICK; NERVE	Excitable cells use ion channels to tailor their biophysical properties to the functional demands made upon them(1). During development, these demands may alter considerably, often associated with a change in the cells' complement of ion channels(2-4). Here we present evidence for such a change in inner hair cells, the primary sensory receptors in the mammalian cochlea. In mice, responses to sound can first be recorded from the auditory nerve and observed behaviourally from 10-12 days after birth; these responses mature rapidly over the next 4 days(5-8). Before this time, mouse inner hair cells have slow voltage responses and fire spontaneous and evoked action potentials. During development of auditory responsiveness a large, fast potassium conductance is expressed, greatly speeding up the membrane time constant and preventing action potentials. This change in potassium channel expression turns the inner hair cell from a regenerative, spiking pacemaker into a high-frequency signal transducer.	Univ Bristol, Sch Med Sci, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, ENT Hosp, Div Sensory Biophys, D-72076 Tubingen, Germany	University of Bristol; University of Sussex; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Kros, CJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.		Huisman, Jeroen/B-7859-2009					Appenrodt P, 1997, J PHYSIOL-LONDON, V501P, pP147; ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; Ehret G., 1983, DEV AUDITORY VESTIBU, P211; EVANS MG, 1987, BIOPHYS J, V52, P649, DOI 10.1016/S0006-3495(87)83256-3; FUCHS PA, 1990, P ROY SOC B-BIOL SCI, V241, P122, DOI 10.1098/rspb.1990.0075; FUCHS PA, 1988, J NEUROSCI, V8, P2460; Geleoc GSG, 1997, P ROY SOC B-BIOL SCI, V264, P611, DOI 10.1098/rspb.1997.0087; GUMMER AW, 1994, NEUROREPORT, V5, P685, DOI 10.1097/00001756-199402000-00006; Hille B., 1992, IONIC CHANNELS EXCIT; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KETTNER RE, 1985, J NEUROSCI, V5, P275; Kirkwood NK, 1997, J PHYSIOL-LONDON, V504P, pP127; KROS CJ, 1990, J PHYSIOL-LONDON, V421, P263, DOI 10.1113/jphysiol.1990.sp017944; KROS CJ, 1993, J PHYSIOL-LONDON, V473, pP231; KROS CJ, 1996, COCHLEA, P318; LIPPE WR, 1994, J NEUROSCI, V14, P1486, DOI 10.1523/JNEUROSCI.14-03-01486.1994; Mikaelian D, 1965, ACTA OTO-LARYNGOL, V59, P451, DOI [DOI 10.3109/00016486509124579, 10.3109/00016486509124579]; Mu MY, 1997, DEV BRAIN RES, V99, P29, DOI 10.1016/S0165-3806(96)00194-0; ODOWD DK, 1988, J NEUROSCI, V8, P792; PALMER AR, 1986, HEARING RES, V24, P1, DOI 10.1016/0378-5955(86)90002-X; PUJOL R, 1998, DEV AUDITORY SYSTEM, P146; Romand R., 1983, DEV AUDITORY VESTIBU, P47; RUBSAMEN R, 1998, DEV AUDITORY SYSTEM, P193; RUSSELL IJ, 1987, HEARING RES, V31, P9, DOI 10.1016/0378-5955(87)90210-3; SHNERSON A, 1982, DEV BRAIN RES, V2, P65; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; SUGIHARA I, 1989, J NEUROPHYSIOL, V62, P1330, DOI 10.1152/jn.1989.62.6.1330; Walsh Edward J., 1992, P161	29	301	306	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					281	284		10.1038/28401	http://dx.doi.org/10.1038/28401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685158				2022-12-01	WOS:000074851900049
J	Meerding, WJ; Bonneux, L; Polder, JJ; Koopmanschap, MA; van der Maas, PJ				Meerding, WJ; Bonneux, L; Polder, JJ; Koopmanschap, MA; van der Maas, PJ			Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study	BRITISH MEDICAL JOURNAL			English	Article								Objectives:To determine the demands on healthcare resources caused by different types of illnesses and variation with age and sex. Design: Information on healthcare use was obtained from all 22 healthcare sectors in the Netherlands. Most important sectors (hospitals, nursing homes, inpatient psychiatric care, institutions for mentally disabled people) have national registries. Total expenditures for each sector were subdivided into 21 age groups, sex, and 34 diagnostic groups. Setting: Netherlands, 1994. Main outcome measures: Proportion of healthcare budget spent on each category of disease and cost of health care per person at various ages. Results: After the first year of life, costs per person for children were lowest Costs rose slowly throughout adult life and increased exponentially from age 50 onwards till the oldest age group (greater than or equal to 95). The top five areas of healthcare costs were mental retardation, musculoskeletal disease (predominantly joint disease and dorsopathy), dementia, a heterogeneous group of other mental disorders, and ill defined conditions. Stroke, all cancers combined, and coronary heart disease ranked 7, 8, and 10, respectively Conclusions: The main determinants of healthcare use in the Netherlands are old age and disabling conditions, particularly mental disability. A large share of the healthcare budget is spent on long term nursing care, and this cost will inevitably increase further in an ageing population, Non-specific cost containment measures may endanger the quality of care for old and mentally disabled people.	Erasmus Univ, Fac Med & Hlth Sci, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Dept Hlth Policy & Management, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	Meerding, WJ (corresponding author), Erasmus Univ, Fac Med & Hlth Sci, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands.	meerding@mgz.fgg.eur.nl						AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; *AUSTR I HLTH WELF, 1996, AUSTR HLTH 1996; *EX NHS, 1996, BURD DIS DISC DOC; GROENENBOOPM GKC, 1995, ELDERLY CARE EC PERS; Koopmanschap M, 1994, EUR J PUBLIC HEALTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KOOPMANSCHAP MA, 1991, COSTS DIS NETHERLAND; LINDGREN B, 1990, KLIN PHARM, V4, P12; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; *MIN HLTH, 1996, ANN OV HLTH CAR 1997; MOORE R, 1997, EC BURDEN ILLNESS CA; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL., 1996, GLOBAL BURDEN DIS, P201; Polder JJ, 1997, COSTS DIS NETHERLAND; World Health Organization, 1977, INT CLASS DIS	14	212	217	0	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					111	+		10.1136/bmj.317.7151.111	http://dx.doi.org/10.1136/bmj.317.7151.111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657785	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000075081700020
J	Price, JL; Blau, J; Rothenfluh, A; Abodeely, M; Kloss, B; Young, MW				Price, JL; Blau, J; Rothenfluh, A; Abodeely, M; Kloss, B; Young, MW			Double-time is a novel Drosophila clock gene that regulates PERIOD protein accumulation	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; BIOLOGICAL CLOCK; NERVOUS-SYSTEM; NUCLEAR ENTRY; MUTANTS; MELANOGASTER; EXPRESSION; MUTATION; REVEALS; BRAIN	We have isolated three alleles of a novel Drosophila clock gene, double-time (dbt). Short- (dbts) and long-period (dbt(L)) mutants after both behavioral rhythmicity and molecular oscillations from previously identified clock genes, period and timeless. A third allele, dbf(P), causes pupal lethality and eliminates circadian cycling of per and tim gene products in larvae. In dbt(P) mutants, PER proteins constitutively accumulate, remain hypophosphorylated, and no longer depend on TIM proteins for their accumulation. We propose that the normal function of DOUBLETIME protein is to reduce the stability and thus the level of accumulation of monomeric PER proteins. This would promote a delay between per/tim transcription and PER/TIM complex function, which is essential for molecular rhythmicity.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Natl Sci Fdn, Sci & Technol Ctr Biol Timing, New York, NY 10021 USA	Rockefeller University; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University	Blau, J (corresponding author), Rockefeller Univ, Genet Lab, 1230 York Ave, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Kloss, Brian/0000-0003-0130-8739; Rothenfluh, Adrian/0000-0002-3813-5723	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054339] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54339] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BRUCE VG, 1972, GENETICS, V70, P537; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1994, J BIOL RHYTHM, V9, P189, DOI 10.1177/074873049400900303; KUNES S, 1993, J NEUROSCI, V13, P752; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Leloup JC, 1998, J BIOL RHYTHM, V13, P70, DOI 10.1177/074873098128999934; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Myers MP, 1997, NUCLEIC ACIDS RES, V25, P4710, DOI 10.1093/nar/25.23.4710; PITTENDRIGH CS, 1967, P NATL ACAD SCI USA, V58, P1762, DOI 10.1073/pnas.58.4.1762; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Stanewsky R, 1997, J NEUROSCI, V17, P676; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	57	650	669	1	90	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					83	95		10.1016/S0092-8674(00)81224-6	http://dx.doi.org/10.1016/S0092-8674(00)81224-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674430	Bronze			2022-12-01	WOS:000074790800012
J	Zhang, GY; Darst, SA				Zhang, GY; Darst, SA			Structure of the Escherichia coli RNA polymerase alpha subunit amino-terminal domain	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; FUNCTIONAL MAP; ASSEMBLY DOMAIN; TRANSCRIPTION ACTIVATION; ASSOCIATION; PREDICTION; PROMOTERS; ERRORS; GENE	The 2.5 angstrom resolution x-ray crystal structure of the Escherichia coli RNA polymerase (RNAP) alpha subunit amino-terminal domain (alpha NTD), which is necessary and sufficient to dimerize and assemble the other RNAP subunits into a transcriptionally active enzyme and contains all of the sequence elements conserved among eukaryotic alpha homologs, has been determined. The alpha NTD monomer comprises two distinct, flexibly linked domains, only one of which participates in the dimer interface. In the alpha NTD dimer, a pair of helices from one monomer interact with the cognate helices of the other to form an extensive hydrophobic core. ALL of the determinants for interactions with the other RNAP subunits lie on one face of the aNTD dimer. Sequence alignments, combined with secondary-structure predictions, support proposals that a heterodimer of the eukaryotic RNAP subunits related to Saccharomyces cerevisiae Rpb3 and Rpb11 plays the role of the alpha NTD dimer in prokaryotic RNAP.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53759, GM19441-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Ishihama A, 1981, Adv Biophys, V14, P1; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; KIMURA M, 1995, J MOL BIOL, V254, P342, DOI 10.1006/jmbi.1995.0621; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; Svetlov V, 1998, J BIOL CHEM, V273, P10827, DOI 10.1074/jbc.273.18.10827; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; ZILLIG W, 1976, RNA POLYMERASE, P101	34	91	95	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					262	266		10.1126/science.281.5374.262	http://dx.doi.org/10.1126/science.281.5374.262			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657722				2022-12-01	WOS:000074714200051
J	Garside, P; Ingulli, E; Merica, RR; Johnson, JG; Noelle, RJ; Jenkins, MK				Garside, P; Ingulli, E; Merica, RR; Johnson, JG; Noelle, RJ; Jenkins, MK			Visualization of specific B and T lymphocyte interactions in the lymph node	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; GERMINAL-CENTERS; CELLS; ANTIGEN; (4-HYDROXY-3-NITROPHENYL)ACETYL; IMMUNOGLOBULIN; TOLERANCE; INDUCTION; FOLLICLES; INSITU	Early events in the humoral immune response were visualized in Lymph nodes by simultaneous tracking of antigen-specific CD4 T and B cells after immunization. The T cells were initially activated in the T cell areas when the B cells were still randomly dispersed in the B cell-rich follicles. Both populations then migrated to the edges of the follicles and interacted there, resulting in CD154-dependent B cell proliferation and germinal center formation. These results provide visual documentation of cognate T-B cell interactions and Localize them to the follicular border.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Glasgow, Western Infirm, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Ctr Immunol, Minneapolis, MN 55455 USA; Dartmouth Med Coll, Dept Microbiol, Lebanon, NH USA	University of Minnesota System; University of Minnesota Twin Cities; University of Glasgow; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Dartmouth College	Jenkins, MK (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.		Garside, Paul/A-4227-2009; Jenkins, Marc K/G-1063-2012	Jenkins, Marc K/0000-0001-8009-7655	NIAID NIH HHS [AI27998, AI35296, AI39614] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039614, P01AI035296, R01AI027998, R37AI027998] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAUN J, 1982, J IMMUNOL, V128, P1198; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Cyster JG, 1995, IMMUNITY, V3, P691, DOI 10.1016/1074-7613(95)90059-4; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; FULLER KA, 1993, J IMMUNOL, V151, P4505; GARSIDE P, UNPUB; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GulbransonJudge A, 1996, EUR J IMMUNOL, V26, P1830, DOI 10.1002/eji.1830260825; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Liu CP, 1996, J EXP MED, V184, P1619, DOI 10.1084/jem.184.5.1619; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; Luther SA, 1997, J EXP MED, V185, P551, DOI 10.1084/jem.185.3.551; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Raff M C, 1970, Nature, V226, P1257, DOI 10.1038/2261257a0; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; Vora KA, 1998, J IMMUNOL, V160, P728; ZHDNG B, 1996, J EXP MED, V1874, P1083	29	591	610	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					96	99		10.1126/science.281.5373.96	http://dx.doi.org/10.1126/science.281.5373.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651253				2022-12-01	WOS:000074685800045
J	Seto, TB; Mittleman, MA; Davis, RB; Taira, DA; Kawachi, I				Seto, TB; Mittleman, MA; Davis, RB; Taira, DA; Kawachi, I			Seasonal variation in coronary artery disease mortality in Hawaii: observational study	BRITISH MEDICAL JOURNAL			English	Article									Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, New England Med Ctr, Hlth Inst, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Seto, TB (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA.	tseto@bidmc.harvard.edu		Mittleman, Murray/0000-0001-9788-7274				DEPASQUALE N, 1961, AM J MED SCI, V242, P468, DOI 10.1097/00000441-196110000-00012; DOUGLAS AS, 1990, AUST NZ J MED, V20, P669, DOI 10.1111/j.1445-5994.1990.tb00397.x; DOUGLAS AS, 1991, SCOT MED J, V36, P76, DOI 10.1177/003693309103600304; FAMIGHETTI R, 1993, WORLD ALMANAC BOOK F, P407; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2	5	33	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1946	1947		10.1136/bmj.316.7149.1946	http://dx.doi.org/10.1136/bmj.316.7149.1946			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641932	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000074636700027
J	Schaffer, R; Ramsay, N; Samach, A; Corden, S; Putterill, J; Carre, IA; Coupland, G				Schaffer, R; Ramsay, N; Samach, A; Corden, S; Putterill, J; Carre, IA; Coupland, G			The late elongated hypocotyl mutation of Arabidopsis disrupts circadian rhythms and the photoperiodic control of flowering	CELL			English	Article							DNA-BINDING DOMAIN; PROTEIN; PERIOD; CLOCK; EXPRESSION; TIMELESS; MYB; AUTOREGULATION; INSERTION; MUTANT	The dominant late elongated hypocotyl (lhy) mutation of Arabidopsis disrupted circadian clock regulation of gene expression and leaf movements and caused flowering to occur independently of photoperiod. LHY was shown to encode a MYB DNA-binding protein. In wild-type plants, the LHY mRNA showed a circadian pattern of expression with a peak around dawn but in the mutant was expressed constantly at high levels. Increased LHY expression from a transgene caused the endogenous gene to be expressed at a constant level, suggesting that LHY was part of a feedback circuit that regulated its own expression. Thus, constant expression of LHY disrupts several distinct circadian rhythms in Arabidopsis, and LHY may be closely associated with the central oscillator of the circadian clock.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Warwick	Coupland, G (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.		CARRE, Isabelle A/D-8802-2011; Coupland, George/AAP-8609-2020; Schaffer, Robert J/D-1018-2011	CARRE, Isabelle A/0000-0002-0548-7378; Coupland, George/0000-0001-6988-4172; Schaffer, Robert/0000-0003-1272-667X				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Edmunds L.N., 1988, CELLULAR MOL BASES B; ENGELMANN W, 1992, Z NATURFORSCH C, V47, P925; Feldbrugge M, 1997, PLANT J, V11, P1079, DOI 10.1046/j.1365-313X.1997.11051079.x; Finlayson SA, 1998, PLANT PHYSIOL, V116, P17, DOI 10.1104/pp.116.1.17; FOLLET BK, 1985, REPROD MAMMALS; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; HALL JC, 1995, TRENDS NEUROSCI, V18, P218; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Kreps JA, 1997, PLANT CELL, V9, P297, DOI 10.1105/tpc.9.3.297; LOGEMANN J, 1987, ANAL BIOCHEM, V141, P329; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; RIKIN A, 1984, PLANT PHYSIOL, V75, P493, DOI 10.1104/pp.75.2.493; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SCHAFFER R, 1997, THESIS U E ANGLIA NO; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Thomas B., 1996, PHOTOPERIODISM PLANT; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Wilson K, 1996, PLANT CELL, V8, P659, DOI 10.1105/tpc.8.4.659	39	675	737	9	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1219	1229		10.1016/S0092-8674(00)81465-8	http://dx.doi.org/10.1016/S0092-8674(00)81465-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657154	Bronze			2022-12-01	WOS:000074491100016
J	Yang, N; Higuchi, O; Ohashi, K; Nagata, K; Wada, A; Kangawa, K; Nishida, E; Mizuno, K				Yang, N; Higuchi, O; Ohashi, K; Nagata, K; Wada, A; Kangawa, K; Nishida, E; Mizuno, K			Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization	NATURE			English	Article							PROTEIN-KINASE; STRESS FIBERS; ZINC-FINGER; IDENTIFICATION; RHO; GTPASES; FAMILY; CDC42; MOTIF	Rac is a small GTPase of the Rho family that mediates stimulus-induced actin cytoskeletal reorganization to generate lamellipodia(1-5). Little is known about the signalling pathways that link pac activation to changes in actin filament dynamics. Cofilin is known to be a potent regulator of actin filament dynamics(6-10), and its ability to bind and depolymerize actin is abolished by phosphorylation of serine residue at 3 (refs 11, 12); however, the kinases responsible for this phosphorylation have not been identified. Here we show that LIM-kinase 1 (LIMK-1), a serine/threonine kinase containing LIM and PDZ domains(13-16), phosphorylates cofilin at Ser3, both in vitro and in vivo. When expressed in cultured cells, LIMK-1 induces actin reorganization and reverses cofilin-induced actin depolymerization. Expression of an inactive form of LIMK-1 suppresses lamellipodium formation induced by pac or insulin. Furthermore, insulin and an active form of Rac increase the activity of LIMK-1. Taken together, our results indicate that LIMK-1 participates in,Rac-mediated actin cytoskeletal reorganization, probably by phosphorylating cofilin.	Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Japan Sci & Technol Corp, PRESTO, Kyoto 6190237, Japan	Kyushu University; Kyoto University; National Cerebral & Cardiovascular Center - Japan; Japan Science & Technology Agency (JST)	Mizuno, K (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan.		Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUNOUE K, 1995, ONCOGENE, V11, P701; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roof DJ, 1997, J CELL BIOL, V138, P575, DOI 10.1083/jcb.138.3.575; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4	21	1023	1047	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					809	812		10.1038/31735	http://dx.doi.org/10.1038/31735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655398				2022-12-01	WOS:000074433100055
J	Patton, BL; Chiu, AY; Sanes, JR				Patton, BL; Chiu, AY; Sanes, JR			Synaptic laminin prevents glial entry into the synaptic cleft	NATURE			English	Article							PROTEIN S-LAMININ; NEUROMUSCULAR-JUNCTIONS; SKELETAL-MUSCLE; NEURONS; REGENERATION; AXOTOMY	Presynaptic and postsynaptic membranes directly oppose each other at chemical synapses, minimizing the delay in transmitting information across the synaptic cleft. Extrasynaptic neuronal surfaces, in contrast, are almost entirely covered by processes from glial cells(1). The exclusion of glial cells from the synaptic deft, and the long-term stability of synapses, presumably result in large part from the tight adhesion between presynaptic and postsynaptic elements(2,3). Here we show that there is another requirement for synaptic maintenance: glial cells of the skeletal neuromuscular synapse, Schwann cells, are actively inhibited from entering the synaptic deft between the motor nerve terminal and the muscle fibre. One inhibitory component is laminin 11, a heterotrimeric glycoprotein that is concentrated in the synaptic cleft(4). Regulation of an inhibitory interaction between glial cells and synaptic deft components may contribute to synaptic rearrangements, and loss of this inhibition may underlie the loss of synapses that results from injury to the postsynaptic cell(5-12).	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA	Washington University (WUSTL); City of Hope; Beckman Research Institute of City of Hope	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108, St Louis, MO 63110 USA.							ANTON ES, 1994, DEV BIOL, V164, P133, DOI 10.1006/dbio.1994.1186; Bargmann C, 1998, NATURE, V391, P435, DOI 10.1038/35020; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; COVAULT J, 1987, J CELL BIOL, V105, P2479, DOI 10.1083/jcb.105.6.2479; DUCHEN LW, 1974, J NEUROL SCI, V21, P391, DOI 10.1016/0022-510X(74)90041-0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JIRMANOVA I, 1975, J NEUROCYTOL, V4, P141, DOI 10.1007/BF01098779; Kreutzberg Georg W., 1995, P355; MATTHEWS MR, 1975, J PHYSIOL-LONDON, V245, P91, DOI 10.1113/jphysiol.1975.sp010837; MILEDI R, 1968, PROC R SOC SER B-BIO, V169, P289, DOI 10.1098/rspb.1968.0012; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; Son YJ, 1996, TRENDS NEUROSCI, V19, P280, DOI 10.1016/S0166-2236(96)10032-1; SVENSSON M, 1993, EXP NEUROL, V120, P123, DOI 10.1006/exnr.1993.1046; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; WINLOW W, 1975, J NEUROCYTOL, V4, P377, DOI 10.1007/BF01261371	29	114	116	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					698	701		10.1038/31502	http://dx.doi.org/10.1038/31502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641682				2022-12-01	WOS:000074289600057
J	Karjalainen, J; Kujala, UM; Kaprio, J; Sarna, S; Viitasalo, M				Karjalainen, J; Kujala, UM; Kaprio, J; Sarna, S; Viitasalo, M			Lone atrial fibrillation in vigorously exercising middle aged men: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; PREVALENCE		Cent Mil Hosp, Helsinki 00301, Finland; Univ Helsinki, Inst Biomed, Unit Sports & Exercise Med, Helsinki 00250, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00290 Helsinki, Finland; Helsinki Univ Hosp, Dept Med 1, Helsinki 00290, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Karjalainen, J (corresponding author), Cent Mil Hosp, Box 50, Helsinki 00301, Finland.	jouko.kajalainen@pp.inet.fi	Kaprio, Jaakko/A-1820-2008; Kujala, Urho/AAP-2547-2020	Kaprio, Jaakko/0000-0002-3716-2455; Kujala, Urho/0000-0002-9262-1992; Sarna, Seppo/0000-0003-3458-1627				COUMEL P, 1994, EUR HEART J, V15, P9, DOI 10.1093/eurheartj/15.suppl_A.9; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; MORRIS JN, 1980, LANCET, V2, P1207	5	221	225	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1998	316	7147					1784	+		10.1136/bmj.316.7147.1784	http://dx.doi.org/10.1136/bmj.316.7147.1784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624065	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000074286300025
J	Cachero, TG; Morielli, AD; Peralta, EG				Cachero, TG; Morielli, AD; Peralta, EG			The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C3 ADP-RIBOSYLTRANSFERASE; SERINE-THREONINE KINASE; TYROSINE KINASE; ACETYLCHOLINE-RECEPTOR; PUTATIVE TARGET; FOCAL ADHESIONS; FAMILY GTPASES; K+ CHANNELS; CELLS	Tyrosine kinases activated by G protein-coupled receptors can phosphorylate and thereby suppress the activity of the delayed rectifier potassium channel Kv1.2. Using a yeast two-hybrid screen, we identified the small GTP-binding protein RhoA as a necessary component in this process. Coimmunoprecipitation experiments confirmed that RhoA associates with Kv1.2. Electrophysiological analyses revealed that overexpression of RhoA markedly reduced the basal current generated by Kv1.2 expressed in Xenopus oocytes. Furthermore, in 293 cells expressing Kv1.2 and m1 muscarinic acetylcholine receptors, inactivating RhoA using C3 exoenzyme blocked the ability of mi receptors to suppress Kv1.2 current. Therefore, these results demonstrate that RhoA regulates Kv1.2 activity and is a central component in the mechanism of receptor-mediated tyrosine kinase-dependent suppression of Kv1.2.	Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA	Harvard University	Peralta, EG (corresponding author), Harvard Univ, Dept Cellular & Mol Biol, Cambridge, MA 02138 USA.							AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BARRY ST, 1994, J CELL SCI, V107, P2033; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; CARROLL RC, 1995, CURR BIOL, V5, P536, DOI 10.1016/S0960-9822(95)00106-0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITZGERALD EM, 1995, BIOCHEM SOC T, V23, pS193, DOI 10.1042/bst023193s; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hille B., 1992, IONIC CHANNELS EXCIT; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Keller J, 1997, FEBS LETT, V403, P299, DOI 10.1016/S0014-5793(97)00067-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SUGAI M, 1992, J BIOL CHEM, V267, P2600; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; YAMAGISHI T, 1995, EUR J PHARMACOL, V281, P151, DOI 10.1016/0014-2999(95)00240-L; YATANI A, 1991, J BIOL CHEM, V266, P22222; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	57	82	90	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1077	1085		10.1016/S0092-8674(00)81212-X	http://dx.doi.org/10.1016/S0092-8674(00)81212-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635436	Bronze			2022-12-01	WOS:000074205700018
J	Yost, C; Farr, GH; Pierce, SB; Ferkey, DM; Chen, MM; Kimelman, D				Yost, C; Farr, GH; Pierce, SB; Ferkey, DM; Chen, MM; Kimelman, D			GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; DORSOVENTRAL AXIS; SPEMANN ORGANIZER; WINGLESS SIGNAL; LAEVIS EMBRYOS; PROTEIN; LITHIUM; TAU	Dorsal accumulation of beta-catenin in early Xenopus embryos is required for body axis formation. Recent evidence indicates that beta-catenin is dorsally stabilized by the localized inhibition of the kinase Xgsk-3, utilizing a novel Wnt ligand-independent mechanism. Using a two-hybrid screen, we identified GBP, a maternal Xgsk-3-binding protein that is homologous to a T cell protooncogene in three well-conserved domains. GBP inhibits in vivo phosphorylation by Xgsk-3, and ectopic GBP expression induces an axis by stabilizing beta-catenin within Xenopus embryos. Importantly, antisense oligonucleotide depletion of the maternal GBP mRNA demonstrates that GBP is required for the establishment of the dorsal-ventral axis in Xenopus embryos. Our results define a family of GSK-3-binding proteins with roles in development and cell proliferation.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.			Pierce, Sarah/0000-0001-6739-7135	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27262, T32-HDO7183] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BYSTROFF C, 1998, IN PRESS J MOL BIOL; Carnac G, 1996, DEVELOPMENT, V122, P3055; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fagotto F, 1997, DEVELOPMENT, V124, P453; Fan MJ, 1997, DEVELOPMENT, V124, P2581; GERHART J, 1991, BOD MAR LAB, P57; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KUCHARZ EJ, 1988, INT J IMMUNOPHARMACO, V10, P253, DOI 10.1016/0192-0561(88)90056-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1998, IN PRESS BIOESSAYS; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PIERCE SB, 1995, DEVELOPMENT, V121, P755; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sorensen AB, 1996, J VIROL, V70, P4063; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WU YY, 1991, P SOC EXP BIOL MED, V198, P620; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; [No title captured]	66	283	292	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1031	1041		10.1016/S0092-8674(00)81208-8	http://dx.doi.org/10.1016/S0092-8674(00)81208-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635432	Bronze			2022-12-01	WOS:000074205700014
J	Costanzi, C; Pehrson, JR				Costanzi, C; Pehrson, JR			Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals	NATURE			English	Article							DOSAGE COMPENSATION; XIST GENE; MOUSE; MAINTENANCE; EXPRESSION; NUCLEUS; REGION; RNA	In female mammals one of the X chromosomes is rendered almost completely transcriptionally inactive(1,2) to equalize expression of X-linked genes in males and females. The inactive X chromosome is distinguished from its active counterpart by its condensed appearance in interphase nuclei(3), late replication(4), altered DNA methylation(2), hypoacetylation of histone H4 (ref. 5), and by transcription of a large cis-acting nuclear RNA called Xist(6-10). Although it is believed that the inactivation process involves the association of specific protein(s) with the chromatin of the inactive X, no such proteins have been identified(11). We discovered a new gene family encoding a core histone which we called macroH2A (mH2A)(12,13). The amino-terminal third of mH2A proteins is similar to a full-length histone H2A, but the remaining two-thirds is unrelated to any known histones. Here we show that an mH2A1 subtype is preferentially concentrated in the inactive X chromosome of female mammals. Our results link X inactivation with a major alteration of the nucleosome, the primary structural unit of chromatin.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pehrson, JR (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.							BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRENEMAN JW, 1993, CHROMOSOMA, V102, P591, DOI 10.1007/BF00352306; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; EVANS EP, 1982, NATURE, V300, P433; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; HWA TC, 1965, HEREDITAS, V52, P320; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KASLOW DC, 1987, P NATL ACAD SCI USA, V84, P6210, DOI 10.1073/pnas.84.17.6210; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MIGEON BR, 1985, P NATL ACAD SCI USA, V82, P3390, DOI 10.1073/pnas.82.10.3390; MONESTIER M, 1994, J IMMUNOL, V152, P667; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; Willard H, 1997, NATURE, V386, P228, DOI 10.1038/386228a0	25	463	476	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					599	601		10.1038/31275	http://dx.doi.org/10.1038/31275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634239				2022-12-01	WOS:000074150100058
J	Abbate, E; Albianelli, A; Azzaroli, A; Benvenuti, M; Tesfamariam, B; Bruni, P; Cipriani, N; Clarke, RJ; Ficcarelli, G; Macchiarelli, R; Napoleone, G; Papini, M; Rook, L; Sagri, M; Tecle, TM; Torre, D; Villa, I				Abbate, E; Albianelli, A; Azzaroli, A; Benvenuti, M; Tesfamariam, B; Bruni, P; Cipriani, N; Clarke, RJ; Ficcarelli, G; Macchiarelli, R; Napoleone, G; Papini, M; Rook, L; Sagri, M; Tecle, TM; Torre, D; Villa, I			A one-million-year-old Homo cranium from the Danakil (Afar) Depression of Eritrea	NATURE			English	Article							MIDDLE-AWASH VALLEY; ETHIOPIA	One of the most contentious topics in the study of human evolution is that of the time, place and mode of origin of Homo sapiens(1-3). The discovery in the Northern Danakil (Afar) Depression, Eritrea, of a well-preserved Homo cranium with a mixture of characters typical of H. erectus and H. sapiens contributes significantly to this debate. The cranium was found in a succession of fluvio-deltaic and lacustrine deposits and is associated with a rich mammalian fauna of early to early-middle Pleistocene age. A magnetostratigraphic survey indicates two reversed and two normal magnetozones. The layer in which the cranium was found is near the top of the lower normal magnetozone, which is identified as the Jaramillo subchron. Consequently, the human remains can be dated at similar to 1 million years before present.	Univ Florence, Dipartimento Sci Terra, I-50121 Florence, Italy; Univ Florence, Sez Geol & Paleontol, Museo Storia Nat, I-50121 Florence, Italy; Eritrea Natl Museum, Asmara, Eritrea; Univ Witwatersrand, Sch Med, Dept Anat Sci, Palaeoanthropol Res Unit, ZA-2193 Johannesburg, South Africa; Museo Nazl Preistor Etnog L Pigorini, Sez Antropol, I-00144 Rome, Italy; Minist Energy Water & Mineral Resources, Dept Mines, Asmara, Eritrea; Univ Bern, Inst Mineral, Abt Isotopengeol, CH-3012 Bern, Switzerland	University of Florence; University of Florence; University of Witwatersrand; University of Bern	Abbate, E (corresponding author), Univ Florence, Dipartimento Sci Terra, I-50121 Florence, Italy.	abbate@cesitl.unifi.it	Benvenuti, Marco/G-9229-2011; Rook, Lorenzo/AAA-5014-2019; Rook, Lorenzo/D-9675-2011	Rook, Lorenzo/0000-0001-8923-5428; Rook, Lorenzo/0000-0001-8923-5428; Tecle, Tesfaldet/0000-0002-3558-5673				BANNERT D, 1970, GEOL RUNDSCH, V59, P409; BARBERI F, 1977, GEOL SOC AM BULL, V88, P1251, DOI 10.1130/0016-7606(1977)88<1251:VOASPT>2.0.CO;2; BERGGREN WA, 1995, SEPM SPECIAL PUBLICA, V54; Brauer G, 1997, NATURE, V386, P337, DOI 10.1038/386337a0; Brinckmann J., 1970, GEOLOGICAL SKETCHMAP; CLARK JD, 1994, SCIENCE, V264, P1907, DOI 10.1126/science.8009220; deCastro JMB, 1997, SCIENCE, V276, P1392; GARLAND CR, 1980, GEOLOGICAL SURVEY ET, V1; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; Merla G., 1979, GEOLOGICAL MAP ETHIO; TOBIAS PVOLDUVATI, 1991, WOLP, V4, pCH5; Ward R, 1997, NATURE, V388, P225, DOI 10.1038/40746; WOLPOFF MH, HUMAN EVOLUTION, P97; Wood B., 1991, HOMINID CRANIAL REMA, V4	14	107	109	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					458	460		10.1038/30954	http://dx.doi.org/10.1038/30954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623999				2022-12-01	WOS:000074020000041
J	de Jong, R; Altare, F; Haagen, IA; Elferink, DG; de Boer, T; Vriesman, PJCV; Kabel, PJ; Draaisma, JMT; van Dissel, JT; Kroon, FP; Casanova, JL; Ottenhoff, THM				de Jong, R; Altare, F; Haagen, IA; Elferink, DG; de Boer, T; Vriesman, PJCV; Kabel, PJ; Draaisma, JMT; van Dissel, JT; Kroon, FP; Casanova, JL; Ottenhoff, THM			Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients	SCIENCE			English	Article							IFN-GAMMA PRODUCTION; INTERFERON-GAMMA; CYTOKINE; RESISTANCE; COMPLEX; CELLS	Interleukin-12 (IL-12) is a cytokine that promotes cell-mediated immunity to intracellular pathogens by inducing type 1 helper T cell (T(H)1) responses and interferon-gamma (IFN-gamma) production. IL-12 binds to high-affinity beta 1/beta 2 heterodimeric IL-12 receptor (IL-12R) complexes on T cell and natural killer cells. Three unrelated individuals with severe, idiopathic mycobacterial and Salmonella infections were found to lack IL-12R beta 1 chain expression. Their cells were deficient in IL-12R signaling and IFN-gamma production, and their remaining T cell responses were independent of endogenous IL-12. IL-12R beta 1 sequence analysis revealed genetic mutations that resulted in premature stop codons in the extracellular domain. The lack of IL-12R beta 1 expression results in a human immunodeficiency and shows the essential role of IL-12 in resistance to infections due to intracellular bacteria.	Leiden Univ, Med Ctr, Dept Immunohematol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Blood Bank, NL-2300 RC Leiden, Netherlands; Hop Necker Enfants Malad, INSERM, U429, F-75743 Paris, France; Univ Hosp Maastricht, Dept Immunol, NL-6202 AZ Maastricht, Netherlands; St Elizabeth Hosp, Dept Med Microbiol & Immunol, NL-5000 AS Tilburg, Netherlands; St Elizabeth Hosp, Dept Pediat, NL-5000 AS Tilburg, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Maastricht University; Maastricht University Medical Centre (MUMC); Elisabeth-TweeSteden Ziekenhuis (ETZ); Elisabeth-TweeSteden Ziekenhuis (ETZ); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Ottenhoff, THM (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol, POB 9600, NL-2300 RC Leiden, Netherlands.	ihbsecr@euronet.nl	altare, frederic/K-8664-2015; Draaisma, J.M.T./L-4283-2015; Casanova, Jean-Laurent/I-3418-2017	altare, frederic/0000-0002-5077-4616; Casanova, Jean-Laurent/0000-0002-7782-4169				Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Casanova JL, 1996, PEDIATRICS, V98, P774; CHIZZONITE R, 1992, J IMMUNOL, V148, P3117; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; deJong R, 1997, J IMMUNOL, V159, P786; DEJONG R, UNPUB; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Frucht DM, 1996, J IMMUNOL, V157, P411; Gollob JA, 1996, J IMMUNOL, V157, P1886; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Hilkens CMU, 1996, J IMMUNOL, V157, P4316; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Kohno K, 1997, J IMMUNOL, V158, P1541; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Modlin RL, 1995, RES IMMUNOL, V146, P526, DOI 10.1016/0923-2494(96)83027-6; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Presky DH, 1995, RES IMMUNOL, V146, P439, DOI 10.1016/0923-2494(96)83013-6; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; Wu CY, 1997, J IMMUNOL, V159, P1658	30	667	679	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1435	1438						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603733				2022-12-01	WOS:000073883400056
J	Cavalli, G; Paro, R				Cavalli, G; Paro, R			The Drosophila Fab-7 chromosomal element conveys epigenetic inheritance during mitosis and meiosis	CELL			English	Article							POSITION-EFFECT VARIEGATION; BITHORAX COMPLEX; REGULATORY SEQUENCES; RESPONSE ELEMENT; GENE ENCODES; GAGA FACTOR; WHITE GENE; POLYCOMB; MELANOGASTER; CHROMATIN	Polycomb group (PcG) and trithorax group (trxG) gene products are responsible for the maintenance of repressed and active expression patterns of many developmentally important regulatory genes including the homeotic genes. In Drosophila embryos, Polycomb protein and the trxG protein GAGA factor colocalize at the Fab-7 DNA element of the bithorax complex. In transgenic lines, the Fab-7 element induces extensive silencing on a flanking GAL4-driven lacZ reporter and mini-white genes. However, a short single pulse of GAL4 during embryogenesis is sufficient to release PcG-dependent silencing from the transgene. Such an activated state of Fab-7 is mitotically inheritable through development and can be transmitted in a GAL4-independent manner to the subsequent generations through female meiosis. Thus, Fab-7 is a switchable chromosomal element, which can convey memory of epigenetically determined active and repressed chromatin states.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Paro, R (corresponding author), Univ Heidelberg, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		Cavalli, Giacomo/A-7958-2008; cavalli, giacomo/Z-2754-2019	Cavalli, Giacomo/0000-0003-3709-3469; cavalli, giacomo/0000-0003-3709-3469				Ahmad K, 1996, GENETICS, V144, P657; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BAKER WK, 1963, AM ZOOL, V3, P57; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CAMPBELL SD, 1991, GENETICS, V127, P367; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; DORN R, 1993, GENETICS, V133, P279; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GINDHART JG, 1995, GENETICS, V139, P797; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; Hollick JB, 1997, TRENDS GENET, V13, P302, DOI 10.1016/S0168-9525(97)01184-0; KARCH F, 1994, NUCLEIC ACIDS RES, V22, P3138, DOI 10.1093/nar/22.15.3138; KASSIS JA, 1994, GENETICS, V136, P1025; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LEVIS R, 1985, EMBO J, V4, P3489, DOI 10.1002/j.1460-2075.1985.tb04108.x; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; Mihaly J, 1997, DEVELOPMENT, V124, P1809; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Paro R., 1996, EPIGENETIC MECH GENE, P507; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; PIRROTTA V, 1995, GENETICS, V141, P1429; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; REUTER G, 1981, MOL GEN GENET, V182, P516, DOI 10.1007/BF00293947; REUTER G, 1985, CHROMOSOMA, V93, P132, DOI 10.1007/BF00293160; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; STELLER H, 1985, EMBO J, V4, P3765, DOI 10.1002/j.1460-2075.1985.tb04146.x; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x; ZINK D, 1994, THESIS U HEIDELBERG	51	299	311	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					505	518		10.1016/S0092-8674(00)81181-2	http://dx.doi.org/10.1016/S0092-8674(00)81181-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604927	Bronze			2022-12-01	WOS:000073722200005
J	Roberts, DL; Weix, DJ; Dahms, NM; Kim, JJP				Roberts, DL; Weix, DJ; Dahms, NM; Kim, JJP			Molecular basis of lysosomal enzyme recognition: Three-dimensional structure of the cation-dependent mannose 6-phosphate receptor	CELL			English	Article							GROWTH FACTOR-II; HUMAN BETA-GLUCURONIDASE; LIGAND-BINDING; ARGININE RESIDUES; BOVINE LIVER; CLONING; EXPRESSION; SITES; GLYCOSYLATION; PURIFICATION	Targeting of newly synthesized lysosomal hydrolases to the lysosome is mediated by the cation-dependent mannose 6-phosphate receptor (CD-MPR) and the insulin-like growth factor II/cation-independent mannose 6-phosphate receptor (IGF-II/CI-MPR). The two receptors, which share sequence similarities, constitute the P-type family of animal lectins. We now report the three-dimensional structure of a glycosylation-deficient, yet fully functional form of the extracytoplasmic domain of the bovine CD-MPR (residues 3-154) complexed with mannose 6-phosphate at 1.8 Angstrom resolution. The extracytoplasmic domain of the CD-MPR crystallizes as a dimer, and each monomer folds into a nine-stranded flattened beta barrel, which bears a striking resemblance to avidin. The distance of 40 Angstrom between the two ligand-binding sites of the dimer provides a structural basis for the observed differences in binding affinity exhibited by the CD-MPR toward various lysosomal enzymes.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dahms, NM (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.			Weix, Daniel/0000-0002-9552-3378	NIDDK NIH HHS [DK-42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042667, R56DK042667, R01DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARTER C, 1979, J BIOL CHEM, V246, P12219; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1995, ARCH BIOCHEM BIOPHYS, V317, P497, DOI 10.1006/abbi.1995.1193; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; DRICKAMER K, 1995, NAT STRUCT BIOL, V2, P437, DOI 10.1038/nsb0695-437; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FUREY W, 1997, MACROMOLECULAR CRYST; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1991, BIOL CHEM H-S, V372, P297, DOI 10.1515/bchm3.1991.372.1.297; LI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P150, DOI 10.1016/0003-9861(90)90625-9; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MA ZM, 1992, J BIOL CHEM, V267, P19017; MA ZM, 1991, J BIOL CHEM, V266, P10589; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McPherson A, 1982, PREPARATION ANAL PRO; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; OTOWINSKI Z, 1996, METHOD ENZYMOL, V276, P307; Punnonen EL, 1996, EUR J BIOCHEM, V237, P809, DOI 10.1111/j.1432-1033.1996.0809p.x; READ RA, 1986, ACTA CRYSTALLOGR D, V5, P760; ROUSSEL A, 1994, TURBOFRODO MANUAL VE; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; Sleat DE, 1997, J BIOL CHEM, V272, P731, DOI 10.1074/jbc.272.2.731; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TERWILLIGER T, 1994, HEAVY VERSION 3 0 MA; TONG PY, 1988, J BIOL CHEM, V263, P2585; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENDLAND M, 1991, J BIOL CHEM, V266, P7132; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; ZHANG Y, 1993, BIOCHEM J, V295, P841, DOI 10.1042/bj2950841	50	91	96	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					639	648		10.1016/S0092-8674(00)81192-7	http://dx.doi.org/10.1016/S0092-8674(00)81192-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604938	Bronze			2022-12-01	WOS:000073722200016
J	Calarota, S; Bratt, G; Nordlund, S; Hinkula, J; Leandersson, AC; Sandstrom, E; Wahren, B				Calarota, S; Bratt, G; Nordlund, S; Hinkula, J; Leandersson, AC; Sandstrom, E; Wahren, B			Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPSTEIN-BARR-VIRUS; QUANTITATIVE-ANALYSIS; IMMUNE-RESPONSES; HIGH-FREQUENCY; LYMPHOCYTES-T; HIV-1; INDIVIDUALS; INFECTION; EXPANSION	Background DNA vaccination is known to generate immune responses against HIV-1 in animal models. We aimed to assess the efficacy of DNA vaccination in induction of immune responses in HIV-1-infected human beings. Methods Nine symptom-free HIV-1-infected patients were immunised with DNA constructs encoding the nef, rev, or tat regulatory genes of HIV-1. The patients were selected for having no or low antibody reactivities to these antigens. HIV-1-specific cytotoxic T-lymphocytes (CTLs), precursor frequencies, and antigen-specific proliferative responses were measured before, during, and after three immunisations over 6 months. Findings Cellular immune reactivities against the HIV-1 regulatory proteins were absent or low before DNA immunisation. DNA vaccination induced detectable memory cells in all patients and specific cytotoxicity in eight patients. CTLs were MHC-class-I restricted and mainly of CD8+ origin. In three patients the cellular activity was transient, decreasing after an initial response. Interpretation DNA immunisation with HIV-1 genes can induce specific cellular responses in human beings with no apparent side-effects. It is theoretically possible that HIV-1-specific cytotoxic responses to regulatory proteins could lead to infected cells being eliminated before they have released new viral particles. However, it is possible that the patients we selected responded less than would nonselected or non-infected individuals. The small number of patients presented here does not allow generalisation of our findings.	Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, S-10521 Stockholm, Sweden; South Hosp, Dept Dermatovenereol, Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control	Wahren, B (corresponding author), Karolinska Inst, Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, S-10521 Stockholm, Sweden.		Hinkula, Jorma/P-6849-2018	Hinkula, Jorma/0000-0003-1908-5609				Asakura Y, 1996, AM J HEMATOL, V53, P116, DOI 10.1002/(SICI)1096-8652(199610)53:2&lt;116::AID-AJH9&gt;3.0.CO;2-2; BOYER JD, 1997, NAT MED, V3, P525; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Geretti AM, 1996, J INFECT DIS, V174, P34, DOI 10.1093/infdis/174.1.34; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Hinkula J, 1997, VACCINE, V15, P874, DOI 10.1016/S0264-410X(96)00257-5; Hinkula J, 1997, J VIROL, V71, P5528, DOI 10.1128/JVI.71.7.5528-5539.1997; HYDENBURGFULLER D, 1994, AIDS RES HUM RETROV, V10, P1433; Johnson R P, 1994, Curr Top Microbiol Immunol, V189, P35; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAMHAMEDICHERRADI S, 1995, AIDS, V9, P421, DOI 10.1097/00002030-199509050-00002; LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002; LEANDERSSON AC, IN PRESS AIDS; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LUBAKI MN, 1994, AIDS RES HUM RETROV, V10, P1427, DOI 10.1089/aid.1994.10.1427; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Ratto S, 1996, J ACQ IMMUN DEF SYND, V11, P128, DOI 10.1097/00042560-199602010-00003; Riviere Y, 1994, Curr Top Microbiol Immunol, V189, P65; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; Rowland-Jones S, 1997, ADV IMMUNOL, V65, P277, DOI 10.1016/S0065-2776(08)60745-2; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; STRIJBOSCH LWG, 1988, INT J BIOMED COMPUT, V23, P279, DOI 10.1016/0020-7101(88)90020-7; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004; WAHREN B, 1994, J ACQ IMMUN DEF SYND, V7, P220; Wahren B, 1995, ANN NY ACAD SCI, V772, P278, DOI 10.1111/j.1749-6632.1995.tb44759.x; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996; Zhong Q, 1997, VACCINE, V15, P497, DOI 10.1016/S0264-410X(97)00223-5	35	335	357	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1320	1325		10.1016/S0140-6736(97)09440-3	http://dx.doi.org/10.1016/S0140-6736(97)09440-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643795				2022-12-01	WOS:000073439400010
J	Wakayama, T; Perry, ACF; Zuccotti, M; Johnson, KR; Yanagimachi, R				Wakayama, T; Perry, ACF; Zuccotti, M; Johnson, KR; Yanagimachi, R			Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei	NATURE			English	Article							MOUSE OOCYTES; TRANSPLANTATION; FERTILIZATION; EMBRYOS; MICROINJECTION; INVITRO; GENE	Until recently, fertilization was the only way to produce viable mammalian offspring, a process implicitly involving male and female gametes, However, techniques involving fusion of embryonic or fetal somatic cells with enucleated oocytes have become steadily more successful in generating cloned young(1-3). Dolly the sheep(4) was produced by electrofusion of sheep mammary-derived cells with enucleated sheep oocytes. Here we investigate the factors governing embryonic development by introducing nuclei from somatic cells (Sertoli, neuronal and cumulus cells) taken from adult mice into enucleated mouse oocytes. We found that some enucleated oocytes receiving Sertoli or neuronal nuclei developed in vitro and implanted following transfer, but none developed beyond 8.5 days post coitum; however, a high percentage of enucleated oocytes receiving cumulus nuclei developed in vitro. Once transferred, many of these embryos implanted and, although most were subsequently resorbed, a significant proportion (2 to 2.8%) developed to term. These experiments show that for mammals, nuclei from terminally differentiated, adult somatic cells of known phenotype introduced into enucleated oocytes are capable of supporting full development.	Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA; Univ Tokyo, Fac Agr, Dept Vet Anat, Bunkyo Ku, Tokyo 113, Japan; Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England; Univ Pavia, Dipartimento Biol Anim, Lab Biol Sviluppo, I-27100 Pavia, Italy; Jackson Lab, Bar Harbor, ME 04609 USA	University of Hawaii System; University of Tokyo; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Pavia; Jackson Laboratory	Yanagimachi, R (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA.			Perry, Tony/0000-0003-3136-5355				BosMikich A, 1997, DEV BIOL, V182, P172, DOI 10.1006/dbio.1996.8468; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; COLLAS P, 1994, MOL REPROD DEV, V38, P264, DOI 10.1002/mrd.1080380306; CZOLOWSKA R, 1984, J CELL SCI, V69, P19; DIETRICH W, 1992, GENETICS, V131, P423; Eppig JJ, 1997, BIOL REPROD, V56, P976, DOI 10.1095/biolreprod56.4.976; Epstein C.J, 1986, CONSEQUENCES CHROMOS; ERICKSON RP, 1993, MOL REPROD DEV, V35, P114, DOI 10.1002/mrd.1080350203; JOHNSON KR, 1992, GENOMICS, V12, P503, DOI 10.1016/0888-7543(92)90441-T; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; KONO T, 1993, MOL REPROD DEV, V34, P43, DOI 10.1002/mrd.1080340107; Kono T, 1997, Rev Reprod, V2, P74; Kono Tomohiro, 1993, Journal of Reproduction and Development, V39, P301, DOI 10.1262/jrd.39.301; Kuretake S, 1996, BIOL REPROD, V55, P789, DOI 10.1095/biolreprod55.4.789; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; Schuetz AW, 1996, REPROD FERT DEVELOP, V8, P935, DOI 10.1071/RD9960935; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; TSUNODA Y, 1993, J REPROD FERTIL, V98, P537, DOI 10.1530/jrf.0.0980537; TSUNODA Y, 1989, DEVELOPMENT, V107, P407; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YANAGIDA K, 1991, BIOL REPROD, V44, P440, DOI 10.1095/biolreprod44.3.440	26	1730	2043	0	156	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					369	374		10.1038/28615	http://dx.doi.org/10.1038/28615			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690471				2022-12-01	WOS:000074968800051
J	Lever, AF; Hole, DJ; Gillis, CR; McCallum, IR; McInnes, GT; MacKinnon, PL; Meredith, PA; Murray, LS; Reid, JL; Robertson, JWK				Lever, AF; Hole, DJ; Gillis, CR; McCallum, IR; McInnes, GT; MacKinnon, PL; Meredith, PA; Murray, LS; Reid, JL; Robertson, JWK			Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?	LANCET			English	Article							GENE-EXPRESSION; BLOOD-PRESSURE; HYPERTENSION; PROLIFERATION; ANGIOGENESIS; INDUCTION; MORTALITY; MYOCYTES; GROWTH; TUMORS	Background Previous studies have reported an increased risk of cancer with calcium-channel blockers in man. Other work in animals suggests that inhibitors of angiotensin-1-converting enzyme (ACE) protect against cancer. We aimed to assess the risk of cancer in hypertensive patients receiving ACE inhibitors or other antihypertensive drugs. Methods Our retrospective cohort study was based on the records of 5207 patients who attended the Glasgow Blood Pressure Clinic between Jan 1, 1980, and Dec 31, 1995. The patients' records are linked with the Registrar General Scotland and the West of Scotland Cancer Registry. Findings Compared with the West of Scotland controls, the relative risks of incident and fatal cancer among the 1559 patients receiving ACE inhibitors were 0.72 (95% CI 0.55-0.92) and 0.65 (0.44-0.93). Among the 3648 patients receiving antihypertensive drugs other than ACE inhibitors (calcium-channel blockers 1416, diuretics 2099, beta-blockers 2681), the corresponding relative risks were 1.10 (0.97-1.22) and 1.03 (0.87-1.20). The relative risk of cancer was lowest in women on ACE inhibitors: 0.63 (0.41-0.93) for incident cancer; 0.48 (0.23-0.88) for fatal cancer; and 0.37 (0.12-0.87) for female-specific cancers. The reduced relative risk of cancer in patients on ACE inhibitors was greatest with follow-up of longer than 3 years. Calcium-channel blockers, diuretics, and beta-blockers had no apparent effect on risk of cancer. Interpretation Long-term use of ACE inhibitors may protect against cancer. The status of this finding is more that of hypothesis generation than of hypothesis testing; randomised controlled trials are needed.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Ruchill Hosp, W Scotland Canc Surveillance Unit, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	Lever, AF (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.							Alderman M, 1997, J HYPERTENS, V15, P105; BOEHM T, 1997, NATURE, V390, P335; BROWN JJ, 1979, HYPERTENSION, V1, P159, DOI 10.1161/01.HYP.1.3.159; CHEN L, 1991, P SOC EXP BIOL MED, V196, P280; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DATTA M, 1993, LANCET, V342, P345, DOI 10.1016/0140-6736(93)91478-5; Elliott WJ, 1996, AM J HYPERTENS, V9, P409; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GILLIS CR, 1987, CANC INCIDENCE 5 CON, V5, P704; Hamet P, 1996, HYPERTENSION, V28, P321, DOI 10.1161/01.HYP.28.3.321; HANSSON L, 1994, AM J HYPERTENS, V7, pS82; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P287; Hii SI, 1998, BRIT J CANCER, V77, P880, DOI 10.1038/bjc.1998.145; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; HOLE DJ, 1993, BRIT MED J, V306, P609, DOI 10.1136/bmj.306.6878.609; INWANG ER, 1997, BRIT J CANCER, V75, P79; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; leNoble FAC, 1996, J VASC RES, V33, P480, DOI 10.1159/000159187; LEON DA, 1993, LANCET, V342, P479, DOI 10.1016/0140-6736(93)91599-H; Lindop GBM, 1993, RENIN ANGIOTENSIN SY, P54; LYALL F, 1992, J HYPERTENS, V10, P1463, DOI 10.1097/00004872-199210120-00005; Marsigliante S, 1996, CANCER LETT, V110, P19, DOI 10.1016/S0304-3835(96)04449-7; MCINNES GT, 1995, J HUM HYPERTENS, V9, P429; *MEMB CLIN GLASG B, 1972, J R COLL PHYSICIANS, V7, P87; NEYSES L, 1993, J HYPERTENS, V11, P927, DOI 10.1097/00004872-199309000-00006; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; Reddy MK, 1995, P SOC EXP BIOL MED, V210, P221; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TAYLOR GM, 1988, AM J PATHOL, V130, P543; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; *WHO INT AG RES CA, 1991, IARC SCI PUBL, V95; Wing LMH, 1997, CLIN EXP PHARMACOL P, V24, P188; YEO WW, 1991, Q J MED, V293, P763	41	477	496	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					179	184		10.1016/S0140-6736(98)03228-0	http://dx.doi.org/10.1016/S0140-6736(98)03228-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683206				2022-12-01	WOS:000074859800010
J	Gutman, S; Richter, K; Alpert, S				Gutman, S; Richter, K; Alpert, S			Update on FDA regulation of in vitro diagnostic devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Device Evaluat, Ctr Devices & Radiol Hlth, Rockville, MD 20850 USA	US Food & Drug Administration (FDA)	Gutman, S (corresponding author), US FDA, Off Device Evaluat, Ctr Devices & Radiol Hlth, 2098 Gaither Rd, Rockville, MD 20850 USA.							*FDA, 1988, ASS SAF EFF HOM US I; *INT STAND O, 1994, QUAL SYST MOD QUAL A; 1995, FED REG, V60, P237; 1996, FED REG, V61, P195	4	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					190	192		10.1001/jama.280.2.190	http://dx.doi.org/10.1001/jama.280.2.190			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669798				2022-12-01	WOS:000074608400039
J	Bellaiche, Y; The, I; Perrimon, N				Bellaiche, Y; The, I; Perrimon, N			Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion	NATURE			English	Article							HEREDITARY MULTIPLE EXOSTOSES; INDIAN HEDGEHOG; PROTEIN; GENE; FAMILY	Hedgehog (Hh) proteins act through both short-range and long-range signalling to pattern tissues during invertebrate and vertebrate development(1). The mechanisms allowing Hedgehog to diffuse over a long distance and to exert its long-range effects are not understood. Here we identify a new Drosophila gene, named tout-velu, that is required for diffusion of Hedgehog. Characterization of tout-velu shows that it encodes an integral membrane protein that belongs to the EXT gene family. Members of this family are involved in the human multiple exostoses syndrome, which affects bone morphogenesis(2-4). Our results, together with the previous characterization of the role of Indian Hedgehog in bone morphogenesis(5-7), lead us to propose that the multiple exostoses syndrome is associated with abnormal diffusion of Hedgehog proteins. These results show the existence of a new conserved mechanism required for diffusion of Hedgehog.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	perrimon@rascal.med.harvard.edu	The, Inge/B-8884-2011	Perrimon, Norbert/0000-0001-7542-472X				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; Chen CH, 1996, LAB ROBOTICS AUTOMAT, V8, P87; Clines GA, 1997, GENOME RES, V7, P359, DOI 10.1101/gr.7.4.359; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Mullor JL, 1997, DEVELOPMENT, V124, P1227; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Perrimon N, 1996, GENETICS, V144, P1681; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIEMER D, 1995, J CELL SCI, V108, P3189; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; STICKENS D, BIOCH MOL MED, V16, P97; Strigini M, 1997, DEVELOPMENT, V124, P4697; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WICKLUND CL, 1995, AM J MED GENET, V55, P43, DOI 10.1002/ajmg.1320550113; XU T, 1993, DEVELOPMENT, V117, P1223	28	416	426	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					85	88		10.1038/27932	http://dx.doi.org/10.1038/27932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665133				2022-12-01	WOS:000074579600054
J	Johnston, LA; Edgar, BA				Johnston, LA; Edgar, BA			Wingless and Notch regulate cell-cycle arrest in the developing Drosophila wing	NATURE			English	Article							GENE-EXPRESSION; LINEAGE RESTRICTION; S-PHASE; ACHAETE; EMBRYOGENESIS; MELANOGASTER; RECEPTION; BOUNDARY; TISSUES; SIGNAL	In developing organs, the regulation of cell proliferation and patterning of cell fates is coordinated. How this coordination is achieved, however, is unknown. In the developing Drosophila wing, both cell proliferation and patterning require the secreted morphogen Wingless (Wg) at the dorsoventral compartment boundary (reviewed in ref. 1). Late in wing development, Wg also induces a zone of non-proliferating cells at the dorsoventral boundary. This zone gives rise to sensory bristles of the adult wing margin(2,3). Here we investigate how Wg coordinates the cell cycle with patterning by studying the regulation of this growth arrest. We show that Wg, in conjunction with Notch, induces arrest in both the G1 and G2 phases of the cell cycle in separate subdomains of the zone of non-proliferating cells. Wg induces G2 arrest in two subdomains by inducing the proneural genes achaete and scute, which downregulate the mitosis-inducing phosphatase String (Cdc25)(4), Notch activity creates a third domain by preventing arrest at G2 in wg-expressing cells, resulting in their arrest in G1.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Johnston, LA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373, R01GM051186] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017373, F32 GM017373-03, F32 GM017373-04, R01 GM051186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; deCelis JF, 1996, DEVELOPMENT, V122, P359; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; Johnston LA, 1996, DEVELOPMENT, V122, P3519; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SERRANO N, 1997, CURR BIOL, V7, P186; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; USUI K, 1992, DEVELOPMENT, V116, P601; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; XU T, 1993, DEVELOPMENT, V117, P1223; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	30	222	227	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					82	84		10.1038/27925	http://dx.doi.org/10.1038/27925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665132				2022-12-01	WOS:000074579600053
J	Nightingale, SL				Nightingale, SL			Video program on guidelines for the use of antiretroviral agents in pediatric HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-01	WOS:000074379400007
J	Pierre, P; Mellman, I				Pierre, P; Mellman, I			Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells	CELL			English	Article							HUMAN CYSTATIN-C; CYSTEINE PROTEINASE-INHIBITORS; COLONY-STIMULATING FACTOR; CATHEPSIN-S; LANGERHANS CELLS; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; CYTOPLASMIC TAIL; DOWN-REGULATION; HLA-DM	Dendritic cells (DCs) developmentally regulate their capacity for antigen presentation by controlling the transport and surface expression of MHC class II molecules. These events reflect a developmental regulation of invariant (li) chain cleavage, most likely by the cysteine protease cathepsin S. In immature DCs, inefficient Il chain cleavage due to low cathepsin S activity leads to the transport of class II-ii chain complexes to lysosomes, while in mature DCs, elevated cathepsin S activity results in efficient delivery of class II alpha beta dimers to.the plasma membrane. Cathepsin S is not controlled transcriptionally but by a novel mechanism involving alterations in the expression and localization of an endogenous cathepsin S inhibitor cystatin C. Thus, the ratio of cystatin C to cathepsin S in developing DCs helps to determine the fate of newly synthesized MHC class II molecules.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Yale University; Yale University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Mellman, Ira/ABG-5896-2020	pierre, philippe/0000-0003-0863-8255	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034098, R01AI034098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033904] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34098] Funding Source: Medline; NIGMS NIH HHS [GM-33904] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ABRAHAMSON M, 1991, BIOMED BIOCHIM ACTA, V50, P587; AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chapman HA, 1998, CURR OPIN IMMUNOL, V10, P93, DOI 10.1016/S0952-7915(98)80038-1; Cresswell P, 1998, SCIENCE, V280, P394, DOI 10.1126/science.280.5362.394; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Drake JR, 1997, J EXP MED, V186, P1299, DOI 10.1084/jem.186.8.1299; Ekiel I, 1996, J BIOL CHEM, V271, P1314, DOI 10.1074/jbc.271.3.1314; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KNOCH H, 1994, INT J ONCOL, V5, P77; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LENARCIC B, 1991, FEBS LETT, V280, P211, DOI 10.1016/0014-5793(91)80295-E; Leonardi A, 1996, BIOL CHEM H-S, V377, P319; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mellman I, 1998, TRENDS CELL BIOL, V8, P231, DOI 10.1016/S0962-8924(98)01276-8; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Miyake T, 1996, MOL BRAIN RES, V37, P273; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; Pierre P, 1998, CURR OPIN IMMUNOL, V10, P145, DOI 10.1016/S0952-7915(98)80242-2; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; PIETERS J, 1993, J CELL SCI, V106, P831; Rider BJ, 1996, MOL IMMUNOL, V33, P625, DOI 10.1016/0161-5890(96)00022-3; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; SHI GP, 1994, J BIOL CHEM, V269, P11530; SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	62	318	326	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1135	1145		10.1016/S0092-8674(00)81458-0	http://dx.doi.org/10.1016/S0092-8674(00)81458-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657147	hybrid			2022-12-01	WOS:000074491100009
J	DiGabriele, AD; Lax, I; Chen, DI; Svahn, CM; Jaye, M; Schlessinger, J; Hendrickson, WA				DiGabriele, AD; Lax, I; Chen, DI; Svahn, CM; Jaye, M; Schlessinger, J; Hendrickson, WA			Structure of a heparin-linked biologically active dimer of fibroblast growth factor	NATURE			English	Article							SIGNAL TRANSDUCTION; BINDING DOMAIN; RECEPTOR; OLIGOMERIZATION; IDENTIFICATION; MITOGENESIS; ACTIVATION	The fibroblast growth factors (FGFs) form a large family of structurally related, multifunctional proteins that regulate various biological responses(1.) They mediate cellular functions by binding to transmembrane FGF receptors(2), which are protein tyrosine kinases. FGF receptors are activated by oligomerization(3), and both this activation and FGF-stimulated biological responses require heparin-like molecules as well as FGF(4), Heparins are linear anionic polysaccharide chains; they are typically heterogeneously sulphated on alternating L-iduronic and D-glucosamino sugars, and are nearly ubiquitous in animal tissues as heparan sulphate proteoglycans on cell surfaces and in the extracellular matrix. Although several crystal structures have been described for FGF molecules in complexes with heparin-like sugars(5-7), the nature of a biologically active complex has been unknown until now. Here we describe the X-ray crystal structure, at 2.9 Angstrom resolution, of a biologically active dimer of human acidic FGF in a complex with a fully sulphated, homogeneous heparin decassacharide. The dimerization of heparin-linked acidic FGF observed here is an elegant mechanism for the modulation of signalling through combinatorial homodimerization and heterodimerization of the 12 known members of the FGF family.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA; Pharmacia & Upjohn Inc, S-11287 Stockholm, Sweden; Rhone Poulenc Rorer, Collegeville, PA 19426 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; New York University; Pfizer; Pharmacia Corporation	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	hendw@convex.hhmi.columbia.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; HENDERSON IC, 1990, ANN ONCOL, V1, P9, DOI 10.1093/oxfordjournals.annonc.a057685; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OTWINOWSKI Z, 1993, 15662 DENZO SERC DAR; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	29	318	332	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					812	817		10.1038/31741	http://dx.doi.org/10.1038/31741			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655399				2022-12-01	WOS:000074433100056
J	Lannin, DR; Mathews, HF; Mitchell, J; Swanson, MS; Swanson, FH; Edwards, MS				Lannin, DR; Mathews, HF; Mitchell, J; Swanson, MS; Swanson, FH; Edwards, MS			Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN WOMEN; CARE-SEEKING BEHAVIOR; CERVICAL-CANCER; UNITED-STATES; MAMMOGRAPHY UTILIZATION; WHITE WOMEN; SURVIVAL; RACE; BLACK; DIAGNOSIS	Context.-Breast cancer mortality is higher among African American women than among white women in the United States, but the reasons for the racial difference are not known. Objective.-To evaluate the influence of socioeconomic and cultural factors on the racial difference in breast cancer stage at diagnosis. Design.-Case-control study of patients diagnosed as having breast cancer at the University Medical Center of Eastern Carolina from 1985 through 1992. Setting.-The major health care facility for 2 rural counties in eastern North Carolina. Subjects.-Five hundred forty of 743 patients with newly diagnosed breast cancer and 414 control women from the community matched by age, race, and area of residence. Main Outcome Measures.-Breast cancer stage at diagnosis. Results.-Of the 540 patients, 94 (17.4%) presented with TNM stage III or IV disease. The following demographic and socioeconomic factors were significant predictors of advanced stage: being African American (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.9-4.7); having low income (OR, 3.7; 95% CI, 2.1-6.5); never having been married (OR, 2.9; 95% CI, 1.4-5.9); having no private health insurance (OR, 2.5; 95% CI, 1.6-4.0);delaying seeing a physician because of money (OR, 1.6, 95% CI, 1.1-2.5); or lacking transportation (OR, 2.0; 95% CI, 1.2-3.6). Univariate analysis also revealed a large number of cultural beliefs to be significant predictors. Examples include the following beliefs: air causes a cancer to spread (OR, 2.8; 95% CI, 1.8-4.3); the devil can cause a person to get cancer (OR, 2.1, 95% CI, 1.2-3.5);women who have breast surgery are no longer attractive to men (OR, 1.9, 95% CI, 1.1-3.5); and chiropractic is an effective treatment for breast cancer (OR, 2.4; 95% CI, 1.4-4.4). When the demographic and socioeconomic variables were included in a multivariate logistic regression model, the OR for late stage among Af rican Americans decreased to 1.8 (95% CI, 1.1-3.2) compared with 3.0 (95% CI, 1.9-4.7) for race alone. However, when the belief measures were included with the demographic and socioeconomic variables, the OR for late stage among African Americans decreased further to 1.2 (95% CI, 0.6-2.5). Conclusions.-Socioeconomic factors alone were not sufficient to explain the dramatic effect of race on breast cancer stage; however, socioeconomic variables in conjunction with cultural beliefs and attitudes could largely account for the observed effect.	E Carolina Univ, Sch Med, Dept Surg, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Family Med, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Sociol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Dept Anthropol, Greenville, NC 27858 USA; E Carolina Univ, Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Lannin, DR (corresponding author), E Carolina Univ, Sch Med, Dept Surg, PCMH 304, Greenville, NC 27858 USA.							AZTELL LM, 1978, J NATL CANCER I, V60, P1209; BAILEY EJ, 1987, J NATL MED ASSOC, V79, P389; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BAQUET CR, 1986, PUBL NIH; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BUESCHER PA, 1994, CHES STUDIES SPECIAL, V82, P1; CAPLAN LS, 1992, J GERONTOL, V47, P101; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; CHAVEZ LR, 1995, MED ANTHROPOL Q, V9, P40, DOI 10.1525/maq.1995.9.1.02a00030; CHEN VW, 1994, CANCER EPIDEM BIOMAR, V3, P127; Chevarley F, 1997, AM J PUBLIC HEALTH, V87, P775, DOI 10.2105/AJPH.87.5.775; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DRESSLER WW, 1993, MED ANTHROPOL Q, V7, P325, DOI 10.1525/maq.1993.7.4.02a00030; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; FLETCHER SW, 1993, JNCI-J NATL CANCER I, V85, P112, DOI 10.1093/jnci/85.2.112; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; FREEMAN HP, 1989, CA, V39, P267; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; GREGG J, 1994, SOC SCI MED, V39, P519, DOI 10.1016/0277-9536(94)90094-9; Hsu JL, 1997, J NATL CANCER I, V89, P1311, DOI 10.1093/jnci/89.17.1311; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; JONES BA, 1995, CANCER, V75, P2103, DOI 10.1002/1097-0142(19950415)75:8<2103::AID-CNCR2820750813>3.0.CO;2-2; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Kleinbaum DG, 1994, LOGISTIC REGRESSION; LAUVER D, 1992, NURS RES, V41, P236; LAUVER D, 1994, RES NURS HEALTH, V17, P421, DOI 10.1002/nur.4770170605; LOEHRER PJ, 1991, CANCER, V68, P1665, DOI 10.1002/1097-0142(19911001)68:7<1665::AID-CNCR2820680734>3.0.CO;2-3; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MATHEWS HF, 1994, SOC SCI MED, V38, P789, DOI 10.1016/0277-9536(94)90151-1; MICHIELUTTE R, 1982, SOC SCI MED, V16, P245, DOI 10.1016/0277-9536(82)90335-5; Mitchell J, 1997, RES AGING, V19, P199, DOI 10.1177/0164027597192003; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; OMalley MS, 1997, AM J PUBLIC HEALTH, V87, P782, DOI 10.2105/AJPH.87.5.782; OVERBY MM, 1997, ANTHR NEWSLETT, V38, P1; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; REYNOLDS P, 1994, CANCER EPIDEM BIOMAR, V3, P253; RICHARDSON JL, 1992, BRIT J CANCER, V65, P922, DOI 10.1038/bjc.1992.193; ROACH M, 1995, J NATL MED ASSOC, V87, P214; SWANSON GM, 1990, CANCER-AM CANCER SOC, V66, P1297, DOI 10.1002/1097-0142(19900915)66:6<1297::AID-CNCR2820660633>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; TROCK B, 1993, CANCER EPIDEM BIOMAR, V2, P151; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; Wilson-Ford V, 1992, Health Soc Work, V17, P28; YOUNG JL, 1984, J NATL CANCER I, V73, P341, DOI 10.1093/jnci/73.2.341; [No title captured]	51	469	474	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1801	1807		10.1001/jama.279.22.1801	http://dx.doi.org/10.1001/jama.279.22.1801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR635	9628711	Bronze			2022-12-01	WOS:000073998500032
J	Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL				Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL			Distribution of rock, metals, and ices in Callisto	SCIENCE			English	Article							GALILEAN SATELLITES; TIDAL DISSIPATION; ICY SATELLITES; INTERNAL STRUCTURES; GANYMEDE; MODELS; IO; EVOLUTION; MIXTURES	Radio Doppler data from a single encounter (C3) of the Galileo spacecraft with Callisto, the outermost Galilean moon of Jupiter, indicated that Callisto was probably undifferentiated. Now, similar data from a second encounter (C9) corroborate this conclusion, but more accurate data from a third encounter (C10) indicate that the rock and ice within Callisto have partially, but not completely, separated. Callisto may be differentiated into a rock-metal core less than 25 percent of Callisto's radius, an outer layer of clean ice less than 350 km thick, and a middle layer of mixed rock and ice. Models in which ice and rock are mixed all the way to the center of Callisto are also consistent with the data.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1997, NATURE, V387, P264, DOI 10.1038/387264a0; ANDERSON JD, 1974, EXPT GRAVITATION, P163; COHEN ER, 1996, PHYS TODAY, V49, pBG9; Collins GC, 1998, GEOPHYS RES LETT, V25, P233, DOI 10.1029/97GL03772; Davies ME, 1992, CELEST MECH DYN ASTR, V53, P377, DOI 10.1007/BF00051818; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; FRIEDSON AJ, 1983, ICARUS, V56, P1, DOI 10.1016/0019-1035(83)90124-0; HOBBS PV, 1974, ICE PHYSICS; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; Kaula W. M., 1966, THEORY SATELLITE GEO; KESZTHELYI L, IN PRESS ICARUS; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; KLEMASZEWSKI J, COMMUNICATION; LELIWAKOPYSTYNSKI J, 1994, PLANET SPACE SCI, V42, P545, DOI 10.1016/0032-0633(94)90076-0; LIESKE JH, 1980, ASTRON ASTROPHYS, V82, P340; LUPO MJ, 1982, ICARUS, V52, P40, DOI 10.1016/0019-1035(82)90167-1; MALHOTRA R, 1991, ICARUS, V94, P399, DOI 10.1016/0019-1035(91)90237-N; MCEWEN AB, UNPUB; McKinnon WB, 1997, ICARUS, V130, P540, DOI 10.1006/icar.1997.5826; Moyer T., 1971, JPLTR321527 CALTECH; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; PAPPALARDO RR, UNPUB; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PROCKTER LM, UNPUB; ROSS MN, 1985, ICARUS, V64, P391, DOI 10.1016/0019-1035(85)90063-6; SCHENK PM, 1995, J GEOPHYS RES-PLANET, V100, P19023, DOI 10.1029/95JE01855; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1981, ICARUS, V47, P46, DOI 10.1016/0019-1035(81)90090-7; SCHUBERT G, 1986, SATELLITES, P629; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; Showman AP, 1997, ICARUS, V127, P93, DOI 10.1006/icar.1996.5669; SHOWMAN DJ, 1997, ICARUS, V129, P367; Squyres S. W., 1986, SATELLITES, P293; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; WOO R, 1979, J GEOPHYS RES-SPACE, V84, P7288, DOI 10.1029/JA084iA12p07288; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5; [No title captured]	39	67	71	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1573	1576		10.1126/science.280.5369.1573	http://dx.doi.org/10.1126/science.280.5369.1573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616114				2022-12-01	WOS:000074061200032
J	Griffiths, I; Klugmann, M; Anderson, T; Yool, D; Thomson, C; Schwab, MH; Schneider, A; Zimmermann, F; McCulloch, M; Nadon, N; Nave, KA				Griffiths, I; Klugmann, M; Anderson, T; Yool, D; Thomson, C; Schwab, MH; Schneider, A; Zimmermann, F; McCulloch, M; Nadon, N; Nave, KA			Axonal swellings and degeneration in mice lacking the major proteolipid of myelin	SCIENCE			English	Article							PELIZAEUS-MERZBACHER DISEASE; PROTEIN GENE; TRANSPORTED ORGANELLES; JIMPY MOUSE; EXPRESSION; MUTATION; FAMILY; HYPOMYELINATION; ACCUMULATION; DISRUPTION	Glial cells produce myelin and contribute to axonal morphology in the nervous system. Two myelin membrane proteolipids, PLP and DM20, were shown to be essential for the integrity of myelinated axons. In the absence of PLP-DM20, mice assembled compact myelin sheaths but subsequently developed widespread axonal swellings and degeneration, associated predominantly with small-caliber nerve fibers. Similar swellings were absent in dysmyelinated shiverer mice, which lack myelin basic protein (MBP), but recurred in (MBPPLP)-P-star double mutants. Thus, fiber degeneration, which was probably secondary to impaired axonal transport, could indicate that myelinated axons require local oligodendroglial support.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Glasgow, Dept Vet Clin Sci, Appl Neurobiol Grp, Glasgow G61 1QH, Lanark, Scotland	Ruprecht Karls University Heidelberg; Oklahoma Medical Research Foundation; University of Glasgow	Nave, KA (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	nave@sun0.urz.uni-heldelberg.de	Nave, Klaus-Armin/C-8883-2011	Yool, Donald/0000-0002-3562-9111	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anzini P, 1997, J NEUROSCI, V17, P4545; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BOISON D, 1994, P NATL ACAD SCI USA, V91, P11709, DOI 10.1073/pnas.91.24.11709; BUCHHEIT TE, 1992, J NEUROBIOL, V23, P217, DOI 10.1002/neu.480230303; DENTINGER P, 1982, J NEUROCYTOL, V11, P671; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Duncan A, 1996, GLIA, V17, P349, DOI 10.1002/(SICI)1098-1136(199608)17:4<349::AID-GLIA10>3.3.CO;2-V; DUNCAN ID, 1987, P NATL ACAD SCI USA, V84, P6287, DOI 10.1073/pnas.84.17.6287; DUNCAN ID, 1989, GLIA, V2, P148, DOI 10.1002/glia.440020303; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; FRIEDE RL, 1972, ANAT RECORD, V172, P1, DOI 10.1002/ar.1091720101; Garbern JY, 1997, NEURON, V19, P205, DOI 10.1016/S0896-6273(00)80360-8; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; Gow A, 1996, NAT GENET, V13, P422, DOI 10.1038/ng0896-422; Griffiths I. M., UNPUB; GRIFFITHS IR, 1981, J NEUROL SCI, V50, P423, DOI 10.1016/0022-510X(81)90154-4; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; HELYNCK G, 1983, EUR J BIOCHEM, V133, P689, DOI 10.1111/j.1432-1033.1983.tb07518.x; Jung M, 1996, J NEUROSCI, V16, P7920; KITAGAWA K, 1993, NEURON, V11, P433, DOI 10.1016/0896-6273(93)90148-K; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; MCDONALD WI, 1994, J NEUROPATH EXP NEUR, V53, P338, DOI 10.1097/00005072-199407000-00003; NADON NL, 1994, J NEUROCHEM, V63, P822; OLDFIELD BJ, 1982, J NEUROCYTOL, V11, P627, DOI 10.1007/BF01262428; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; READHEAD C, 1994, NEURON, V12, P583, DOI 10.1016/0896-6273(94)90214-3; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; Sanchez I, 1996, J NEUROSCI, V16, P5095; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHNEIDER A, 1995, P NATL ACAD SCI USA, V92, P4447, DOI 10.1073/pnas.92.10.4447; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; Seitelberger F, 1996, NEURODYSTROPHIES NEU, P559; Sistermans EA, 1996, HUM GENET, V97, P337, DOI 10.1007/s004390050046; SKOFF R, 1981, BRAIN RES, V212, P175, DOI 10.1016/0006-8993(81)90047-0; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; SNIPES GJ, 1995, BRAIN PATHOL, V5, P233, DOI 10.1111/j.1750-3639.1995.tb00600.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSUKITA S, 1980, J CELL BIOL, V84, P513, DOI 10.1083/jcb.84.3.513; TYTELL M, 1986, BRAIN RES, V363, P161, DOI 10.1016/0006-8993(86)90671-2; WILLIAMS MA, 1977, PRACTICAL METHODS EL, V6, P5	40	638	642	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1610	1613		10.1126/science.280.5369.1610	http://dx.doi.org/10.1126/science.280.5369.1610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616125				2022-12-01	WOS:000074061200043
J	Lan, N; Howrey, RP; Lee, SW; Smith, CA; Sullenger, BA				Lan, N; Howrey, RP; Lee, SW; Smith, CA; Sullenger, BA			Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors	SCIENCE			English	Article							MESSENGER-RNA; TETRAHYMENA; HEMOGLOBIN; SEQUENCE; GENE; MORBIDITY; GELATION	Sickle cell anemia is the most common heritable hematological disease, yet no curative treatment exists for this disorder. Moreover, the intricacies of globin gene expression have made the development of treatments for hemoglobinopathies based on gene therapy difficult. An alternative genetic approach to sickle cell therapy is based on RNA repair. A trans-splicing group I ribozyme was used to alter mutant beta-globin transcripts in erythrocyte precursors derived from peripheral blood from individuals with sickle cell disease. Sickle beta-globin transcripts were converted into messenger RNAs encoding the anti-sickling protein gamma-globin. These results suggest that RNA repair may become a useful approach in the treatment of genetic disorders.	Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Genet, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Surg, Durham, NC 27710 USA.	sulle001@mc.duke.edu		Lee, Seong-Wook/0000-0003-1718-7601	NHLBI NIH HHS [HL57606] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIN C, 1994, BIOCHEM CELL BIOL, V72, P377, DOI 10.1139/o94-050; ASHCROFT MT, 1976, LANCET, V2, P784; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEHE MJ, 1979, J MOL BIOL, V133, P137, DOI 10.1016/0022-2836(79)90254-7; Bertrand E, 1997, RNA, V3, P75; CAMPBELL TB, 1995, RNA, V1, P598; CAVALLESCO C, 1980, GENE, V12, P215, DOI 10.1016/0378-1119(80)90103-1; CECH T, 1995, BIO-TECHNOL, V13, P323, DOI 10.1038/nbt0495-323; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; GRASSO JA, 1977, J CELL BIOL, V73, P206, DOI 10.1083/jcb.73.1.206; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; Jones JT, 1997, NAT BIOTECHNOL, V15, P902, DOI 10.1038/nbt0997-902; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; KRAMER MS, 1978, NEW ENGL J MED, V299, P686, DOI 10.1056/NEJM197809282991303; LAN N, UNPUB; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PLATT OS, 1993, HEMATOLOGY INFANCY C, P732; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; RAMIREZ F, 1975, J BIOL CHEM, V250, P6054; RUCKNAGEL DL, 1987, DEV CONTROL GLOBIN G, P487; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; SEARS DA, 1978, AM J MED, V64, P1021, DOI 10.1016/0002-9343(78)90458-8; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SUNSHINE HR, 1978, NATURE, V275, P238, DOI 10.1038/275238a0; TELEN MJ, 1987, VOX SANG, V52, P236, DOI 10.1111/j.1423-0410.1987.tb03035.x; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	29	179	192	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1593	1596		10.1126/science.280.5369.1593	http://dx.doi.org/10.1126/science.280.5369.1593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616120				2022-12-01	WOS:000074061200038
J	Yin, MJ; Christerson, LB; Yamamoto, Y; Kwak, YT; Xu, SC; Mercurio, F; Barbosa, M; Cobb, MH; Gaynor, RB				Yin, MJ; Christerson, LB; Yamamoto, Y; Kwak, YT; Xu, SC; Mercurio, F; Barbosa, M; Cobb, MH; Gaynor, RB			HTLV-I tax protein binds to MEKK1 to stimulate I kappa B kinase activity and NF-kappa B activation	CELL			English	Article							CELL LEUKEMIA-VIRUS; SITE-SPECIFIC PHOSPHORYLATION; ALPHA; GENE; IDENTIFICATION; TRANSFORMATION; PATHWAYS; CASCADE; REGION; CREB	NF-kappa B, a key regulator of the cellular inflammatory and immune response, is activated by the HTLV-I transforming and transactivating protein Tax. We show that Tax binds to the amino terminus of the protein kinase MEKK1, a component of an I kappa B kinase complex, and stimulates MEKK1 kinase activity. Tax expression increases the activity of I kappa B kinase 8 (IKK beta) to enhance phosphorylation of serine residues in I kappa B alpha that lead to its degradation. Dominant negative mutants of both IKK beta and MEKK1 prevent Tax activation of the NF-kappa B pathway. Furthermore, recombinant MEKK1 stimulates IKK beta phosphorylation of I kappa B alpha. Thus, Tax-mediated increases in NF-kappa B nuclear translocation result from direct interactions of Tax and MEKK1 leading to enhanced IKK beta phosphorylation of I kappa B alpha.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Harold Simmons Canc Ctr,Div Hematol Oncol, Dallas, TX 75235 USA; Signal Pharmaceut Inc, San Diego, CA 92121 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOI KY, 1994, CELL, V78, P499; DEAK JC, 1997, J BIOCH, V322, P185; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FELBER BK, 1985, SCIENCE, V229, P54; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KOEFFLER HP, 1984, BLOOD, V64, P482; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POLESZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAN MH, 1994, NATURE, V372, P798; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	229	234	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					875	884		10.1016/S0092-8674(00)81447-6	http://dx.doi.org/10.1016/S0092-8674(00)81447-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630230	Bronze			2022-12-01	WOS:000073956700022
J	King, M				King, M			Misled by moonshine	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1218	1218		10.1016/S0140-6736(05)79179-0	http://dx.doi.org/10.1016/S0140-6736(05)79179-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643734				2022-12-01	WOS:000073220200076
J	Gangarosa, EJ; Galazka, AM; Wolfe, CR; Phillips, LM; Gangarosa, RE; Miller, E; Chen, RT				Gangarosa, EJ; Galazka, AM; Wolfe, CR; Phillips, LM; Gangarosa, RE; Miller, E; Chen, RT			Impact of anti-vaccine movements on pertussis control: the untold story	LANCET			English	Review							UNITED-STATES; CHILDREN; IMMUNIZATION; EPIDEMIOLOGY; EXPERIENCE; EFFICACY; SAFETY	To assess the impact of anti-vaccine movements that targeted pertussis whole-cell vaccines, we compared pertussis incidence in countries where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the former East Germany, Poland, and the USA) with countries where immunisation was disrupted by anti-vaccine movements (Sweden, Japan, Uh, The Russian Federation, Ireland, Italy, the former West Germany, and Australia). Pertussis incidence was 10 to 100 times lower in countries where high vaccine coverage was maintained than in countries where immunisation programs were compromised by anti-vaccine movements. Comparisons of neighbouring countries with high and low vaccine coverage further underscore the efficacy of these vaccines. Given the safety and cost-effectiveness of whole-cell pertussis vaccines, our study shows that, far from being obsolete, these vaccines continue to have an important role in global immunisation.	Emory Univ, Gangarosa Int Hlth Fdn, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; WHO, CH-1211 Geneva, Switzerland; Ctr Dis Control & Prevent, Georgia, GA 30333 USA; Publ Hlth Lab Serv, London, England	Emory University; Emory University; Rollins School Public Health; World Health Organization; Centers for Disease Control & Prevention - USA; Public Health England	Gangarosa, EJ (corresponding author), 5305 Greencastle Way, Stone Mt, GA 30087 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367				[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1982, BRIT MED J, V285, P357; BINKIN NJ, 1992, PEDIATR INFECT DIS J, V11, P653; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P22; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; COULTER HL, 1991, DTP SHOT DARK WHY P; Evans G, 1996, PEDIATR INFECT DIS J, V15, P477, DOI 10.1097/00006454-199606000-00002; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; FINGER H, 1991, DEV BIOLOGICALS, V73, P343; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Galazka Artur, 1992, World Health Statistics Quarterly, V45, P238; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; Halsey NA, 1996, PEDIATRICS, V97, P279; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Howell F, 1992, Commun Dis Rep CDR Rev, V2, pR31; JOO I, 1991, DEV BIOLOGICALS, V73, P357; KANAI K, 1980, JPN J MED SCI BIOL, V33, P107, DOI 10.7883/yoken1952.33.107; KIMURA M, 1990, LANCET, V336, P30, DOI 10.1016/0140-6736(90)91530-N; KIMURA M, 1988, Acta Paediatrica Japonica, V30, P109; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; LESTER R, 1993, MED J AUSTRALIA, V159, P631, DOI 10.5694/j.1326-5377.1993.tb138057.x; Lindgren C, 1997, EUR J PEDIATR, V156, P405, DOI 10.1007/s004310050626; MACINTYRE CR, 1994, MED J AUSTRALIA, V161, P295; MALLESON PN, 1977, LANCET, V1, P237; MENDELSOHN R, 1988, IMMUNICATIONS TERRIB; MILLER E, 1996, DEV BIOL STAND, V89, P301; NICOLL A, 1988, ARCH DIS CHILD, V63, P41, DOI 10.1136/adc.63.1.41; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Plotkin SA, 1997, PEDIATR INFECT DIS J, V16, P508, DOI 10.1097/00006454-199705000-00011; ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005; SALISBURY D, 1992, 25 NAT IMM C P 1991, P49; SCHEIBNER V, 1996, VACCINATION 100 YEAR; STEWART GT, 1977, LANCET, V1, P234; STROFFOLINI T, 1989, INFECTION, V17, P280, DOI 10.1007/BF01650708; STROM J, 1960, BRIT MED J, V2, P1184, DOI 10.1136/bmj.2.5207.1184; SUTTER RW, 1992, JAMA-J AM MED ASSOC, V267, P386, DOI 10.1001/jama.267.3.386; Taylor CE, 1997, AM J PUBLIC HEALTH, V87, P922, DOI 10.2105/AJPH.87.6.922; VELIMIROVIC B, 1991, WHO M NAT PROGR MAN	42	426	446	2	83	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					356	361		10.1016/S0140-6736(97)04334-1	http://dx.doi.org/10.1016/S0140-6736(97)04334-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652634				2022-12-01	WOS:000071864000044
J	Boer, R; de Koning, H; Threlfall, A; Warmerdam, P; Street, A; Friedman, E; Woodman, C				Boer, R; de Koning, H; Threlfall, A; Warmerdam, P; Street, A; Friedman, E; Woodman, C			Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To compare the cost effectiveness of two possible modifications to the current UK screening programme: shortening the screening interval from three to true years and extending the age of invitation to a final screen from 64 to 69. Design: Computer simulation model which first simulates life histories for women in the absence of a screening programme for breast cancer and then assesses haw these life histories would be changed by introducing different screening policies. The model was informed by screening and cost data from the NHS breast screening programme. Setting: North West region of England. Main outcome measures: Numbers of deaths prevented, life years gained, and costs. Results: Compared with the current breast screening programme both modifications would increase the number of deaths prevented and the number of life years saved. The current screening policy costs pound 2522 per life year gained; extending the age range of the programme would cost pound 2612 and shortening the interval pound 2709 per life year gained: The marginal cost per life year gained of extending the age range of the screening programme is pound 2990 and of shortening the screening interval is pound 3545. Conclusions: If the budget for the NHS breast screening-programme were to allow for two more invitations per woman, substantial mortality reductions would follow from extending the age range screened or reducing the screening interval. The difference between the two policies is so small that either could be chosen.	Erasmus Univ, Dept Publ Hlth, Inst Maatschappelijke Gezondheidszorg, NL-3000 DR Rotterdam, Netherlands; Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England; Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England; W Pennine Hlth Author, Dept Publ Hlth Med, Oldham OL1 2PN, England	Erasmus University Rotterdam; University of Manchester; University of York - UK	Boer, R (corresponding author), Erasmus Univ, Dept Publ Hlth, Inst Maatschappelijke Gezondheidszorg, POB 1738, NL-3000 DR Rotterdam, Netherlands.	boer@mgz.fgg.eur.nl	Boer, Robert/AFM-0525-2022; Boer, Robert/AAH-2901-2022; Boer, Rob/E-6473-2015; de+Koning, Harry/AAF-9062-2019	Boer, Robert/0000-0003-0680-001X; Boer, Robert/0000-0003-0680-001X; Boer, Rob/0000-0003-0680-001X; de+Koning, Harry/0000-0003-4682-3646				BEEMSTERBOER PMM, 1994, INT J CANCER, V58, P623, DOI 10.1002/ijc.2910580502; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHAMBERLAIN J, 1993, BRIT MED J, V307, P543; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; FORREST APM, 1987, REPORT HLTH MINISTER; PACI E, 1995, J CANC, V3, P348; *SCOTT CANC THER N, 1996, SCOTT BREAST CANC AU; Street AD, 1996, P2003 U YORK YORK HL; VANINEVELD BM, 1993, EUR J CANCER, V29A, P1663, DOI 10.1016/0959-8049(93)90100-T; VANOORTMARSSEN GJ, 1990, CANCER-AM CANCER SOC, V66, P1601, DOI 10.1002/1097-0142(19901001)66:7<1601::AID-CNCR2820660727>3.0.CO;2-O	12	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					376	379						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694752				2022-12-01	WOS:000075409600023
J	Vanhala, M; Vanhala, P; Kumpusalo, E; Halonen, P; Takala, J				Vanhala, M; Vanhala, P; Kumpusalo, E; Halonen, P; Takala, J			Relation between obesity from childhood to adulthood and the metabolic syndrome: population based study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Pieksamaki Dist Hlth Ctr, Pieksamaki 76101, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland	University of Eastern Finland	Vanhala, M (corresponding author), Community Hlth Ctr City Imatra, Virastokatu 2, Imatra 55100, Finland.	Mauno.Vanhala@pp.inet.fi						BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; LAAKSO M, 1993, CARDIOVASC RISK FACT, V1, P55; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Vanhala M J, 1997, J Cardiovasc Risk, V4, P291, DOI 10.1097/00043798-199708000-00010	5	161	170	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					319	319		10.1136/bmj.317.7154.319	http://dx.doi.org/10.1136/bmj.317.7154.319			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685277	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000075409500021
J	Swanson, WJ; Vacquier, VD				Swanson, WJ; Vacquier, VD			Concerted evolution in an egg receptor for a rapidly evolving abalone sperm protein	SCIENCE			English	Article							SPECIES-SPECIFICITY; POSITIVE SELECTION; TRANSCRIPTION; FERTILIZATION; DIVERGENCE; MODULES; BINDING; LYSIN	Gamete interactions during fertilization exhibit species specificity. In abalone, the sperm protein Lysin species-specifically creates a hole in the egg envelope. Lysin evolves rapidly by positive Darwinian selection. Evolution of the egg receptor for Lysin provides the selective pressure for Lysin's divergence. The egg receptor for lysin is a tandemly repeated sequence that evolves by concerted evolution. Concerted evolution in the egg receptor could explain the rapid, adaptive evolution in sperm Lysin and may provide an underlying molecular mechanism that gives rise to species-specific fertilization.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Swanson, WJ (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA.			Swanson, Willie/0000-0002-6553-0921	NICHD NIH HHS [HD12986] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DOVER GA, 1993, CURR OPIN GENET DEV, V3, P902, DOI 10.1016/0959-437X(93)90012-E; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; Giudice G, 1973, DEV BIOL SEA URCHIN, P162; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; LEE YH, 1995, MOL BIOL EVOL, V12, P231; METZ EC, 1994, BIOL BULL-US, V187, P23, DOI 10.2307/1542162; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; MIESFELD R, 1984, MOL CELL BIOL, V4, P221, DOI 10.1128/MCB.4.2.221; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; Muse SV, 1996, MOL BIOL EVOL, V13, P105, DOI 10.1093/oxfordjournals.molbev.a025549; NEI M, 1986, MOL BIOL EVOL, V3, P418; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; OHTA T, 1984, GENETICS, V108, P501; OSANAI K, 1982, GAMETE RES, V5, P49, DOI 10.1002/mrd.1120050106; Owen B, 1971, Bull Los Ang City Mus Sci, VNo. 9, P1; PALUMBI SR, 1994, ANNU REV ECOL SYST, V25, P547, DOI 10.1146/annurev.ecolsys.25.1.547; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; ROLDAN ERS, 1989, J EXP ZOOL, V250, P321, DOI 10.1002/jez.1402500312; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SHAW A, 1993, SCIENCE, V262, P1864, DOI 10.1126/science.8266073; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SUMMERS RG, 1975, EXP CELL RES, V96, P63, DOI 10.1016/S0014-4827(75)80037-1; Swanson WJ, 1997, P NATL ACAD SCI USA, V94, P6724, DOI 10.1073/pnas.94.13.6724; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Vacquier VD, 1997, J MOL EVOL, V44, pS15, DOI 10.1007/PL00000049; Vacquier VD, 1993, ZYGOTE, V1, P181, DOI 10.1017/S0967199400001465; Yanagimachi R., 1988, P135	31	173	183	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					710	712		10.1126/science.281.5377.710	http://dx.doi.org/10.1126/science.281.5377.710			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685267				2022-12-01	WOS:000075107900046
J	England, LJ; Imperial, J; Jacobsen, R; Craig, AG; Gulyas, J; Akhtar, M; Rivier, J; Julius, D; Olivera, BM				England, LJ; Imperial, J; Jacobsen, R; Craig, AG; Gulyas, J; Akhtar, M; Rivier, J; Julius, D; Olivera, BM			Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; FUNCTIONAL EXPRESSION; FAMILY; DIVERSITY; DISTINCT; PEPTIDE	The venom of predatory marine snails is a rich source of natural products that act on specific receptors and ion channels within the mammalian nervous system. A 41-amino acid peptide, sigma-conotoxin GVIIIA, was purified on the basis of its ability to inactivate the 5-HT3 receptor, an excitatory serotonin-gated ion channel. sigma-Conotoxin contains a brominated tryptophan residue, which may be important for peptide activity because the endogenous Ligand for the 5-HT3 receptor is a hydroxylated derivative of tryptophan. sigma-Conotoxin inactivates the 5-HT3 receptor through competitive antagonism and is a highly selective inhibitor of this receptor. Serotonin receptors can now be included among the molecular targets of natural polypeptide neurotoxins.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah; Salk Institute	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@socrates.ucsf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044298, P01GM048677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48677, GM44298] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Green T, 1998, NEURON, V20, P427, DOI 10.1016/S0896-6273(00)80986-1; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LUCAS JJ, 1995, TRENDS PHARMACOL SCI, V16, P246, DOI 10.1016/S0165-6147(00)89034-3; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; PATRICK J, 1987, ANN NY ACAD SCI, V505, P194; SAXENA PR, 1995, PHARMACOL THERAPEUT, V66, P339, DOI 10.1016/0163-7258(94)00005-N; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; ZIFA E, 1992, PHARMACOL REV, V44, P401	26	112	118	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					575	578		10.1126/science.281.5376.575	http://dx.doi.org/10.1126/science.281.5376.575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677203				2022-12-01	WOS:000075012300045
J	Nudler, E; Gusarov, I; Avetissova, E; Kozlov, M; Goldfarb, A				Nudler, E; Gusarov, I; Avetissova, E; Kozlov, M; Goldfarb, A			Spatial organization of transcription elongation complex in Escherichia coli	SCIENCE			English	Article							RNA-POLYMERASE; TERMINATION	During RNA synthesis in the ternary elongation complex, RNA polymerase enzyme holds nucleic acids in three contiguous sites: the double-stranded DNA-binding site (DBS) ahead of the transcription bubble, the RNA-DNA heteroduplex-binding site (HBS), and the RNA-binding site (RBS) upstream of HBS. Photochemical cross-linking allowed mapping of the DNA and RNA contacts to specific positions on the amino acid sequence. Unexpectedly, the same protein regions were found to participate in both DBS and RES. Thus, DNA entry and RNA exit occur close together in the RNA polymerase molecule, suggesting that the three sites constitute I single unit. The results explain how RNA in the integrated unit RBS-HBS-DBS may stabilize the ternary complex, whereas a hairpin in RNA result in its dissociation.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; Publ Hlth Res Inst City New York Inc, New York, NY 10016 USA	New York University	Nudler, E (corresponding author), NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA.		Kozlov, Maxim/GLN-3047-2022; Gusarov, Ivan/AAJ-6282-2020	Kozlov, Maxim/0000-0002-5994-9099; Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; KUMAR S A, 1975, Journal of Biological Chemistry, V250, P2878; KURIYAN J, 1994, J MOL BIOL, V234, P915; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; NUDLER E, UNPUB; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793	16	71	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					424	428		10.1126/science.281.5375.424	http://dx.doi.org/10.1126/science.281.5375.424			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665887				2022-12-01	WOS:000074918800050
J	Schroder, FC; Farmer, JJ; Attygalle, AB; Smedley, SR; Eisner, T; Meinwald, J				Schroder, FC; Farmer, JJ; Attygalle, AB; Smedley, SR; Eisner, T; Meinwald, J			Combinatorial chemistry in insects: A library of defensive macrocyclic polyamines	SCIENCE			English	Article							EPILACHNA-BOREALIS; SQUASH-BEETLE; SECRETION	The pupal defensive secretion of the coccinellid beetle Epilachna borealis is composed principally of a combinatorial Library of macrocyclic polyamines. These compounds constitute a previously unrecognized family of natural products, characterized by extremely Large-ring lactonic structures derived from a small set of (2-hydroxyethylamino)alkanoic acids. The combinatorial assembly of these simple building blocks generates a high degree of structural diversity, which is further increased by slow. spontaneous intramolecular rearrangement of the macrocycles.	Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA; Trinity Coll, Dept Biol, Hartford, CT 06106 USA; Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA	Cornell University; Trinity College; Cornell University	Schroder, FC (corresponding author), Cornell Univ, Baker Lab, Dept Chem, Ithaca, NY 14853 USA.		Schroeder, Frank/H-5026-2012	Attygalle, Athula/0000-0002-5847-2794; Schroeder, Frank/0000-0002-4420-0237	NIAID NIH HHS [AI2908] Funding Source: Medline; NIGMS NIH HHS [GM53830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI002908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attygalle AB, 1996, EXPERIENTIA, V52, P616, DOI 10.1007/BF01969741; Attygalle AB, 1996, NATURWISSENSCHAFTEN, V83, P277; ATTYGALLE AB, 1993, P NATL ACAD SCI USA, V90, P5204, DOI 10.1073/pnas.90.11.5204; Daloze Desire, 1995, Chemoecology, V5-6, P173, DOI 10.1007/BF01240602; Eisner Thomas, 1992, Psyche (Cambridge), V99, P265, DOI 10.1155/1992/54859; GIANNIS A, 1989, ANGEW CHEM INT EDIT, V28, P218, DOI 10.1002/anie.198902181; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; HINTON H. E., 1955, TRANS SOC BRIT ENT, V12, P49; King AG, 1996, CHEM REV, V96, P1105; MUKAIYAMA T, 1977, CHEM LETT, P441, DOI 10.1246/cl.1977.441; OLIYAI R, 1995, BIOORG MED CHEM LETT, V5, P2735, DOI 10.1016/0960-894X(95)00454-2; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; SCHRODER FR, UNPUB	13	57	61	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					428	431		10.1126/science.281.5375.428	http://dx.doi.org/10.1126/science.281.5375.428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665888				2022-12-01	WOS:000074918800051
J	Calignano, A; La Rana, G; Giuffrida, A; Piomelli, D				Calignano, A; La Rana, G; Giuffrida, A; Piomelli, D			Control of pain initiation by endogenous cannabinoids	NATURE			English	Article							MOLECULAR CHARACTERIZATION; FORMALIN TEST; RECEPTOR; BRAIN; RATS; ANANDAMIDE; NEURONS; TISSUE	The potent analgesic effects of cannabis-like drugs(1-4) and the presence of CB1-type cannabinoid receptors in pain-processing areas of the brain and spinal cord(5,6) indicate that endogenous cannabinoids such as anandamide(7) may contribute to the control of pain transmission within the central nervous system (CNS)(8). Here we show that anandamide attenuates the pain behaviour produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor(9), exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR141716A and the CB2 antagonist SR144528 prolong and enhance the pain behaviour produced by tissue damage. These results indicate that peripheral CB1-like and CBZ-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PEA may mediate this effect.	Univ Naples, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Inst Neurosci, San Diego, CA 92121 USA	University of Naples Federico II	Piomelli, D (corresponding author), Univ Naples, Dipartimento Farmacol Sperimentale, 49 Via D Montesano, I-80131 Naples, Italy.	piomelli@nsi.edu	Giuffrida, Andrea/H-3770-2013	Giuffrida, Andrea/0000-0002-3773-0694; CALIGNANO, Antonio/0000-0002-1742-3179				ALOE L, 1993, AGENTS ACTIONS, V39, pC145, DOI 10.1007/BF01972748; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Cadas H, 1997, J NEUROSCI, V17, P1226; CODERRE TJ, 1992, J NEUROSCI, V12, P3665; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DICKENSON AH, 1987, PAIN, V30, P349, DOI 10.1016/0304-3959(87)90023-6; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Fields H. L., 1987, PAIN; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; JAGGAR SI, IN PRESS PAIN; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585; MARTIN BR, 1981, LIFE SCI, V29, P565, DOI 10.1016/0024-3205(81)90434-3; MARTIN WJ, 1993, BRAIN RES, V629, P300, DOI 10.1016/0006-8993(93)91334-O; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Richardson JD, 1998, J NEUROSCI, V18, P451; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Tsou K, 1996, NEUROSCIENCE, V70, P791, DOI 10.1016/S0306-4522(96)83015-6	29	869	905	1	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					277	281		10.1038/28393	http://dx.doi.org/10.1038/28393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685157	Green Submitted			2022-12-01	WOS:000074851900048
J	Margaglione, M; Brancaccio, V; Giuliani, N; D'Andrea, G; Cappucci, G; Iannaccone, L; Vecchione, G; Grandone, E; Di Minno, G				Margaglione, M; Brancaccio, V; Giuliani, N; D'Andrea, G; Cappucci, G; Iannaccone, L; Vecchione, G; Grandone, E; Di Minno, G			Increased risk for venous thrombosis in carriers of the prothrombin G -> A(20210) gene variant	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	ACTIVATED PROTEIN-C; FACTOR-V LEIDEN; COAGULATION-FACTOR-V; ANTIPHOSPHOLIPID ANTIBODIES; DEFICIENT FAMILIES; RESISTANCE; THROMBOEMBOLISM; THROMBOPHILIA; MUTATION	Background: A mutation in the prothrombin gene (G-->A(20210)) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis. Objective: To determine whether the prothrombin A(20210) allele is independently associated with the occurrence of venous thrombosis. Design: Case-control study. Setting: Two thrombosis centers in southern Italy. Patients: 281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls. Measurements: Medical history was collected on standardized questionnaires. The presence of prothrombin G-->A(20210) and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function. Results: In 150 controls, increased prothrombin activity (P < 0.001) was associated with the prothrombin A(20210) allele. This allele was more frequent in patients than in controls (8.01% compared with 2.29%; P < 0.001) and was associated with an increased risk for thrombosis (odds ratio, 3.88 [95% CI, 2.23 to 6.74]). The increased prevalence of this allele was independent of the presence of the factor V Leiden mutation. After adjustment for sex, age, arterial thrombosis, and factor V Leiden mutation, the risk was still significantly elevated (odds ratio, 3.13 [CI, 1.89 to 5.21]). Moreover, the overall prevalence of inherited coagulation abnormalities was significantly higher in patients with thrombosis of the lower extremities than in patients with thrombosis of the upper extremities (odds ratio, 3.77 [CI, 1.10 to 12.93]). Fourteen patients carried both the prothrombin G-->A(20210) and factor V Leiden mutations. Conclusions: The prothrombin A(20210) allele is independently associated with the occurrence of venous thrombosis, particularly in patients with a history of thrombosis of the lower extremities.	IRCCS, Unita Aterosclerosi & Trombosi, I-71013 San Giovanni Rotondo, Italy; Osped Antonio Cardarelli, Naples, Italy; Univ Palermo, Palermo, Italy	IRCCS Casa Sollievo Della Sofferenza; Antonio Cardarelli Hospital; University of Palermo	Margaglione, M (corresponding author), IRCCS, Unita Aterosclerosi & Trombosi, Casa Sollievo Sofferenza,Viale Cappuccini, I-71013 San Giovanni Rotondo, Italy.		Grandone, Elvira/M-1127-2019	Grandone, Elvira/0000-0002-8980-9783; MARGAGLIONE, MAURIZIO/0000-0001-5627-9221; Di Minno, Giovanni/0000-0003-4235-7166				AMES PRJ, 1995, THROMB HAEMOSTASIS, V73, P768; Ames PRJ, 1996, THROMB HAEMOSTASIS, V76, P190; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Margaglione M, 1996, THROMB HAEMOSTASIS, V76, P814; MARGAGLIONE M, 1995, THROMB HAEMOSTASIS, V73, P579; Martinelli I, 1997, ANN INTERN MED, V126, P707, DOI 10.7326/0003-4819-126-9-199705010-00006; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417	19	198	204	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					89	93		10.7326/0003-4819-129-2-199807150-00003	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669991				2022-12-01	WOS:000074852000002
J	Tian, SS; Lamb, P; King, AG; Miller, SG; Kessler, L; Luengo, JI; Averill, L; Johnson, RK; Gleason, JG; Pelus, LM; Dillon, SB; Rosen, J				Tian, SS; Lamb, P; King, AG; Miller, SG; Kessler, L; Luengo, JI; Averill, L; Johnson, RK; Gleason, JG; Pelus, LM; Dillon, SB; Rosen, J			A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor	SCIENCE			English	Article							FACTOR-RECEPTOR; TYROSINE PHOSPHORYLATION; CELL-LINE; STAT3; ERYTHROPOIETIN; INTERLEUKIN-6; DIMERIZATION; BINDING; CSF	A nonpeptidyl small molecule SB 247464, capable of activating granulocyte-colony-stimulating factor (G-CSF) signal transduction pathways, was identified in a high-throughput assay in cultured cells. Like G-CSF, SE 247464 induced tyrosine phosphorylation of multiple signaling proteins and stimulated primary murine bone marrow cells to form granulocytic colonies in vitro. It also elevated peripheral blood neutrophil counts in mice. The extracellular domain of the murine G-CSF receptor was required for the activity of SE 247464, suggesting that the compound acts by oligomerizing receptor chains. The results indicate that a small molecule can activate a receptor that normally binds a relatively Large protein Ligand.	Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA; SmithKline Beecham Pharmaceut, Dept Mol Virol & Host Def US, Collegeville, PA 19426 USA; Ligand Pharmaceut Inc, Dept New Leads Discovery, San Diego, CA 92121 USA; SmithKline Beecham Pharmaceut, Dept Med Chem US, Collegeville, PA 19426 USA; SmithKline Beecham Pharmaceut, Dept Oncol, King Of Prussia, PA 19406 USA	Ligand Pharmaceuticals; GlaxoSmithKline; Ligand Pharmaceuticals; GlaxoSmithKline; GlaxoSmithKline	Lamb, P (corresponding author), Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA.							ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; DEMETRI GD, 1991, BLOOD, V78, P2791; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KOMATSU N, 1993, BLOOD, V82, P456; METCALF D, 1983, J CELL PHYSIOL, V116, P198, DOI 10.1002/jcp.1041160211; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	19	149	165	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					257	259		10.1126/science.281.5374.257	http://dx.doi.org/10.1126/science.281.5374.257			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657720				2022-12-01	WOS:000074714200049
J	Dahl, M; Tybjaerg-Hansen, A; Lange, P; Nordestgaard, BG				Dahl, M; Tybjaerg-Hansen, A; Lange, P; Nordestgaard, BG			Delta F508 heterozygosity in cystic fibrosis and susceptibility to asthma	LANCET			English	Article							OBLIGATE HETEROZYGOTES; BRONCHIAL-ASTHMA; REACTIVITY; AIRWAY	Background Cystic fibrosis is a recessive disorder mainly characterised by lung disease. We tested the hypothesis that individuals heterozygous for the common cystic fibrosis Delta F508 mutation are at risk of obstructive pulmonary disease. Methods We studied a cross-sectional sample from the general population of Copenhagen, Denmark, aged 20 years and older, We did spirometry to measure forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), and did genotyping on blood samples of 9141 individuals. We asked all participants whether they had asthma, and asked for information on smoking and other factors that could have contributed to obstructive pulmonary disease. Findings We identified 250 carriers of the Delta F508 mutation (2.7% [95% CI 2.5-3.1]). 9% of carriers reported having asthma compared with 6% of non-carriers (p=0.04). The odds ratio for asthma in participants heterozygous for Delta F508 mutation was 2.0 (1.2-3.5, p=0.02). Furthermore, among individuals with airway obstruction, the percentage predicted FEV1 and FVC were significantly lower in participants heterozygous for Delta F508 than in non-carriers (49 vs 58%, p=0.004; and 70 vs 82%, p<0.001, respectively), mainly due to an effect in those with self-reported asthma. Interpretation Cystic fibrosis Delta F508 heterozygosity may be over-represented among people with asthma and seems to be associated with decreased pulmonary function in people with airway obstruction who also have asthma.	Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Bispebjerg Univ Hosp, Copenhagen City Heart Study, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital	Nordestgaard, BG (corresponding author), Glostrup Univ Hosp, Dept Clin Biochem, Nordre Ringvej, DK-2600 Glostrup, Denmark.		Nordestgaard, Borge Gronne/ABF-1310-2020; Dahl, Morten/F-4219-2014	Dahl, Morten/0000-0002-6686-312X				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BATTEN J, 1963, LANCET, V1, P1348; BYARD PJ, 1988, AM REV RESPIR DIS, V138, P312, DOI 10.1164/ajrccm/138.2.312; COUNAHAN R, 1975, ARCH DIS CHILD, V50, P477, DOI 10.1136/adc.50.6.477; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVIS PB, 1989, J APPL PHYSIOL, V66, P2124, DOI 10.1152/jappl.1989.66.5.2124; DAVIS PB, 1984, AM REV RESPIR DIS, V129, P911; DAVIS PB, 1987, THORAX, V42, P120, DOI 10.1136/thx.42.2.120; GOLD WM, 1994, TXB RESP MED, P870; HALLETT WY, 1965, AM REV RESPIR DIS, V90, P714; KHOURY MJ, 1993, FUNDAMENTALS GENETIC, P77; LANGE P, 1991, EUR RESPIR J, V4, P1080; Leupold W, 1979, Monogr Paediatr, V10, P119; MENNIE M, 1995, NAT MED, V1, P978, DOI 10.1038/nm1095-978b; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; ORZALESI MM, 1963, ACTA PAEDIATR, V52, P267, DOI 10.1111/j.1651-2227.1963.tb03779.x; Sandford AJ, 1997, EUR RESPIR J, V10, P1380, DOI 10.1183/09031936.97.10061380; SCHROEDER SA, 1995, NAT MED, V1, P703, DOI 10.1038/nm0795-703; SCHWARTZ M, 1992, ACTA PAEDIATR, V81, P522, DOI 10.1111/j.1651-2227.1992.tb12287.x; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323; WOOD JA, 1959, NEW ENGL J MED, V260, P951, DOI 10.1056/NEJM195905072601901; WOOLCOCK AJ, 1994, TXB RESP MED, P1288	25	88	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1911	1913		10.1016/S0140-6736(97)11419-2	http://dx.doi.org/10.1016/S0140-6736(97)11419-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654257				2022-12-01	WOS:000074464700007
J	Blitzer, RD; Conner, JH; Brown, GP; Wong, T; Shenolikar, S; Iyengar, R; Landau, EM				Blitzer, RD; Conner, JH; Brown, GP; Wong, T; Shenolikar, S; Iyengar, R; Landau, EM			Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT KINASE-II; PHOSPHORYLATION; INHIBITOR-1; MEMORY; TRANSMISSION; LOCALIZATION; HIPPOCAMPUS; ACTIVATION; NEURONS	Long-term potentiation (LTP) at the Schaffer collateral-CA1 synapse involves interacting signaling components, including calcium (Ca2+)/calmodulin-dependent protein kinase II (CaMKII) and cyclic adenosine monophosphate (cAMP) pathways. Postsynaptic injection of thiophosphorylated inhibitor-1 protein, a specific inhibitor of protein phosphatase-1 (PP1), substituted for cAMP pathway activation in LTP. Stimulation that induced LTP triggered cAMP-dependent phosphorylation of endogenous inhibitor-1 and a decrease in PP1 activity. This stimulation also increased phosphorylation of CaMKII at Thr(286) and Ca2+-independent CaMKII activity in a cAMP-dependent man ner. The blockade of LTP by a CaMKII inhibitor was not overcome by thiophosphorylated inhibitor-1. Thus, the cAMP pathway uses PP1 to gate CaMKII signaling in LTP.	Bronx VA Med Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27712 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Duke University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Blitzer, RD (corresponding author), Bronx VA Med Ctr, New York, NY 10029 USA.			Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [DK52054] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline; NINDS NIH HHS [NS33646] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033646] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLITCH JG, 1995, AI EXCHANGE, V9, P15; BRAUN AP, 1995, J PHYSIOL-LONDON, V488, P37, DOI 10.1113/jphysiol.1995.sp020944; CAHILL L, 1994, NATURE, V371, P702, DOI 10.1038/371702a0; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Huang Y Y, 1994, Learn Mem, V1, P74; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SHARP GWG, 1973, ANNU REV MED, V24, P19, DOI 10.1146/annurev.me.24.020173.000315; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	27	336	343	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1940	1943		10.1126/science.280.5371.1940	http://dx.doi.org/10.1126/science.280.5371.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632393				2022-12-01	WOS:000074323800065
J	Luecke, H; Richter, HT; Lanyi, JK				Luecke, H; Richter, HT; Lanyi, JK			Proton transfer pathways in bacteriorhodopsin at 2.3 Angstrom resolution	SCIENCE			English	Article							RELEASE; RESIDUES; CYCLE; PUMP	Photoisomerization of the retinal of bacteriorhodopsin initiates a cyclic reaction in which a proton is translocated across the membrane. Studies of this protein promise a better understanding of how ion pumps function. Together with a large amount of spectroscopic and mutational data, the atomic structure of bacteriorhodopsin, determined in the last decade at increasing resolutions, has suggested plausible but often contradictory mechanisms. X-ray diffraction of bacteriorhodopsin crystals grown in cubic lipid phase revealed unexpected two-fold symmetries that indicate merohedral twinning along the crystallographic c axis. The structure, refined to 2.3 angstroms taking this twinning into account, is different from earlier models, including that most recently reported. One of the carboxyl oxygen atoms of the proton acceptor Asp(85) is connected to the proton donor, the retinal Schiff base, through a hydrogen-bonded water and forms a second hydrogen bond with another water. The other carboxyl oxygen atom of Asp(85) accepts a hydrogen bond from Thr(89). This structure forms the active site. The nearby Arg(82) is the center of a network of numerous hydrogen-bonded residues and an ordered water molecule. This network defines the pathway of the proton from the buried Schiff base to the extracellular surface.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Luecke, Hartmut/F-4712-2012; Lanyi, Janos/C-3808-2011	Luecke, Hartmut/0000-0002-4938-0775; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029498, R01GM056445] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM29498, R01-GM56445] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; BALASHOV SP, 1993, BIOCHEMISTRY-US, V32, P10331, DOI 10.1021/bi00090a008; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; BROWN LO, UNPUB; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; Kimura Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P764, DOI 10.1111/j.1751-1097.1997.tb03221.x; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; MARTI T, 1991, J BIOL CHEM, V266, P6919; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; YAMAZAKI Y, 1995, BIOCHEMISTRY-US, V34, P577; ZHOU F, 1993, BIOCHEMISTRY-US, V32, P2291, DOI 10.1021/bi00060a022	25	529	537	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1934	1937		10.1126/science.280.5371.1934	http://dx.doi.org/10.1126/science.280.5371.1934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632391				2022-12-01	WOS:000074323800063
J	Tsien, RY; Miyawaki, A				Tsien, RY; Miyawaki, A			Seeing the machinery of live cells	SCIENCE			English	Article							EXCITATION; MICROSCOPY; PROTEINS		Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	rtsien@ucsd.edu	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Farinas J, 1998, BIOPHYS J, V74, pA184; GRIFFIN BA, IN PRESS SCIENCE; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIYAWAKI A, UNPUB; Murphy JT, 1997, CURR BIOL, V7, P870, DOI 10.1016/S0960-9822(06)00375-7; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; Tsien Roger Y., 1993, Trends in Cell Biology, V3, P242, DOI 10.1016/0962-8924(93)90124-J; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	28	141	146	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1954	1955		10.1126/science.280.5371.1954	http://dx.doi.org/10.1126/science.280.5371.1954			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669950				2022-12-01	WOS:000074323800069
J	Shingyoji, C; Higuchi, H; Yoshimura, M; Katayama, E; Yanagida, T				Shingyoji, C; Higuchi, H; Yoshimura, M; Katayama, E; Yanagida, T			Dynein arms are oscillating force generators	NATURE			English	Article							SEA-URCHIN SPERM; IONTOPHORETIC APPLICATION; MICROTUBULES INVITRO; FLAGELLAR AXONEMES; TETRAHYMENA CILIA; SUBUNIT; ACTOMYOSIN; DIRECTION; ATP	Eukaryotic flagella beat rhythmically(1). Dynein is a protein that powers flagellar motion, and oscillation may be inherent to this protein(2-5). Here we determine whether oscillation is a property of dynein arms themselves or whether oscillation requires an intact axoneme(6), which is the central core of the flagellum and consists of a regular array of microtubules. Using optical trapping nanometry(7,8), we measured the force generated by a few dynein arms on an isolated doublet microtubule, When the dynein arms on the doublet microtubule contact a singlet microtubule and are activated by photolysis of caged ATP(8), they generate a peak force of similar to 6 pN and move the singlet microtubule over the doublet microtubule in a processive manner. The force and displacement oscillate with a peak-to-peak force and amplitude of similar to 2 pN and similar to 30 nm, respectively. The geometry of the interaction indicates that very few (possibly one) dynein arms are needed to generate the oscillation. The maximum frequency of the oscillation at 0.75 mM ATP is similar to 70 Hz; this frequency decreases as the ATP concentration decreases. A similar oscillatory force is also generated by inner dynein arms alone on doublet microtubules that are depleted of outer dynein arms. The oscillation of the dynein arm may be a basic mechanism underlying flagellar beating.	Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Tokyo 1130033, Japan; JRDC, ERATO, Yanagida Biotron Project, Osaka 5620035, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1080071, Japan; Osaka Univ, Sch Med, Dept Physiol, Osaka 5650871, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; Osaka University	Shingyoji, C (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Tokyo 1130033, Japan.	chikako@biol.s.u-tokyo.ac.jp	Yanagida, Toshio/D-1919-2009					Brokaw C.J., 1989, CELL MOVEMENT, V1, P267; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FOX LA, 1987, J CELL BIOL, V105, P1781, DOI 10.1083/jcb.105.4.1781; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS BH, 1973, J CELL SCI, V13, P337; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; MOSS AG, 1992, J CELL BIOL, V118, P1177, DOI 10.1083/jcb.118.5.1177; OMOTO CK, 1989, J THEOR BIOL, V137, P163, DOI 10.1016/S0022-5193(89)80203-6; SALE WS, 1977, P NATL ACAD SCI USA, V74, P2045, DOI 10.1073/pnas.74.5.2045; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7016, DOI 10.1021/bi00443a035; SHINGYOJI C, 1995, J CELL SCI, V108, P1359; SHINGYOJI C, 1977, NATURE, V265, P269, DOI 10.1038/265269a0; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TAKAHASHI K, 1982, SYM SOC EXP BIOL, P159; Thomas N, 1998, J PHYS D APPL PHYS, V31, P253, DOI 10.1088/0022-3727/31/3/002; Thomas N, 1996, J PHYSIOL-LONDON, V491P, pP124; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; YOKOTA E, 1994, J CELL SCI, V107, P353	30	197	202	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					711	714		10.1038/31520	http://dx.doi.org/10.1038/31520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641685				2022-12-01	WOS:000074289600060
J	Hippisley-Cox, J; Fielding, K; Pringle, M				Hippisley-Cox, J; Fielding, K; Pringle, M			Depression as a risk factor for ischaemic heart disease in men: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL CONCENTRATION; ACUTE MYOCARDIAL-INFARCTION; GENERAL-PRACTICE; MORTALITY; SYMPTOMS; EVENTS; TRIALS	Objective: To determine the relation between depression, anxiety, and use of antidepressants and the onset of ischaemic heart disease. Design: Population based case-control study. Setting: All 5623 patients registered with one general practice. Subjects: 188 male cases with ischaemic heart disease matched by age to 485 male controls without ischaemic heart disease; 139 female cases with ischaemic heart disease matched by age to 412 female controls. Main outcome measure: Adjusted odds ratios calculated by conditional logistic regression. Results: The risk of ischaemic heart disease was three times higher among men with a recorded diagnosis of depression than among controls of the sane age (odds ratio 3.09; 95% confidence interval 1.33 to 7.21; P = 0.009). This association persisted when smoking status, diabetes, hypertension, and underprivileged area (UPA(8)) score were included in a multivariate model (adjusted 2.75; 1.13 to 6.69; P = 0.03). Men with depression within the preceding 10 years were three times more likely to develop ischaemic heart disease than were the controls (3.13; 1.27 to 7.70; P = 0.01). Men with ischaemic heart disease had a higher risk of subsequent ischaemic heart disease than men without ischaemic heart disease (adjusted 2.34; 1.34 to 4.10; P = 0.003). Depression was not a risk factor for ischaemic heart disease in women on multivariate analysis (adjusted 1.34; 0.70 to 2.56; P = 0.38). Anxiety and subsequent ischaemic heart disease were not significantly associated in men or women. Conclusion: Depression may be an independent risk factor for ischaemic heart disease in men, but not in women.	Queens Med Ctr, Sch Med, Dept Gen Practice, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Med, Trent Inst Hlth Serv Res, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Hippisley-Cox, J (corresponding author), Queens Med Ctr, Sch Med, Dept Gen Practice, Nottingham NG7 2UH, England.	julia.h-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283				APPELS A, 1990, BRIT J PSYCHIAT, V156, P465, DOI 10.1192/bjp.156.4.465; BROWN SL, 1994, BRIT MED J, V308, P1328, DOI 10.1136/bmj.308.6940.1328; CARNEY RM, 1990, PSYCHOSOM MED, V52, P603, DOI 10.1097/00006842-199011000-00001; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; FIELDING R, 1991, SOC SCI MED, V32, P1017, DOI 10.1016/0277-9536(91)90159-A; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; KEECH A, 1994, EUR HEART J, V15, P255, DOI 10.1093/oxfordjournals.eurheartj.a060485; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Lesperance F, 1996, PSYCHOSOM MED, V58, P99, DOI 10.1097/00006842-199603000-00001; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OCONNOR NJ, 1995, CIRCULATION, V92, P1458, DOI 10.1161/01.CIR.92.6.1458; PRINGLE M, 1995, BRIT J GEN PRACT, V45, P537; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SIEGLER IC, 1992, AM J EPIDEMIOL, V136, P146, DOI 10.1093/oxfordjournals.aje.a116481; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P113, DOI 10.1192/bjp.147.2.113; SIRELING LI, 1985, BRIT J PSYCHIAT, V147, P119, DOI 10.1192/bjp.147.2.119; THOMAS C, 1992, J GERONTOL, V47, pS80, DOI 10.1093/geronj/47.2.S80; TILYARD MW, 1995, NEW ZEAL MED J, V108, P118; Wardle J, 1996, BRIT MED J, V313, P75, DOI 10.1136/bmj.313.7049.75; WassertheilSmoller S, 1996, ARCH INTERN MED, V156, P553, DOI 10.1001/archinte.156.5.553; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; Zureik M, 1996, BMJ-BRIT MED J, V313, P649, DOI 10.1136/bmj.313.7058.649	26	136	140	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	1998	316	7146					1714	1719		10.1136/bmj.316.7146.1714	http://dx.doi.org/10.1136/bmj.316.7146.1714			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT806	9614024	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000074129500024
J	Farquhar, J; Thiemens, MH; Jackson, T				Farquhar, J; Thiemens, MH; Jackson, T			Atmosphere-surface interactions on Mars: Delta O-17 measurements of carbonate from ALH 84001	SCIENCE			English	Article							SNC METEORITES; MARTIAN ATMOSPHERE; ISOTOPIC COMPOSITION; OXYGEN-ISOTOPE; VOLATILE EVOLUTION; CHAOTIC OBLIQUITY; STRATOSPHERIC CO2; WATER; ORIGIN; FRACTIONATION	Oxygen isotope measurements of carbonate from martian meteorite ALH 84001 (delta(18)O = 18.3 +/- 0.4 per mil, delta(17)O = 10.3 +/- 0.2 per mil, and Delta(17)O = 0.8 +/- 0.05 per mil) are fractionated with respect to those of silicate minerals. These measurements support the existence of two oxygen isotope reservoirs (the atmosphere and the silicate planet) on Mars at the time of carbonate growth. The cause of the atmospheric oxygen isotope anomaly may be exchange between CO2 and O(D-1) produced by the photodecomposition of ozone. Atmospheric oxygen isotope compositions may be transferred to carbonate minerals by CO2-H2O exchange and mineral growth. A sink of O-17-depleted oxygen, as required by mass balance, may exist in the planetary regolith.	Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Farquhar, J (corresponding author), Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA.	jfarquha@ucsd.edu; mht@ucsd.edu; tjackson@ucsd.edu						BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BARTH CA, 1986, PHOTOCHEMISTRY ATMOS, P337; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BHATTACHARYA SK, 1989, Z NATURFORSCH A, V44, P435; BJORAAKER GL, 1989, B AM ASTRON SOC, V29, P991; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; CARR MH, 1986, ICARUS, V68, P187, DOI 10.1016/0019-1035(86)90019-9; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1963, GEOCHIM COSMOCHIM AC, V27, P43, DOI 10.1016/0016-7037(63)90071-1; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P1, DOI 10.1016/0012-821X(83)90066-3; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; COPLEN TB, 1983, NATURE, V302, P236, DOI 10.1038/302236a0; CRISS RE, 1986, REV MINERAL, V16, P373; DONAHUE TM, 1995, NATURE, V374, P432, DOI 10.1038/374432a0; FANALE FP, 1971, NATURE, V230, P502, DOI 10.1038/230502a0; FANALE FP, 1974, J GEOPHYS RES, V79, P3397, DOI 10.1029/JC079i024p03397; Farmer C. B., 1977, Journal of Geophysical Research, V82, P4225, DOI 10.1029/JS082i028p04225; Forget F, 1997, SCIENCE, V278, P1273, DOI 10.1126/science.278.5341.1273; FORSYTHE RD, 1998, LUNAR PLANET SCI C, V29, P1410; GEISSLER PE, 1993, ICARUS, V106, P380, DOI 10.1006/icar.1993.1179; Gregory R. T., 1991, GEOCHEM SOC SPEC PUB, V3, P65; Gulick VC, 1997, ICARUS, V130, P68, DOI 10.1006/icar.1997.5802; GULICK VC, 1990, J GEOPHYS RES-SOLID, V95, P14325, DOI 10.1029/JB095iB09p14325; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; Holland H. D., 1984, CHEM EVOLUTION ATMOS; Hutchins KS, 1996, J GEOPHYS RES-PLANET, V101, P14933, DOI 10.1029/96JE00860; JAKOSKY BM, 1993, ICARUS, V102, P286, DOI 10.1006/icar.1993.1049; Jakosky BM, 1997, REV GEOPHYS, V35, P1, DOI 10.1029/96RG02903; Jakosky BM, 1997, ICARUS, V130, P87, DOI 10.1006/icar.1997.5799; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JAKOSKY BM, 1994, NATURE, V370, P328, DOI 10.1038/370328a0; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; Johnston JC, 1997, J GEOPHYS RES-ATMOS, V102, P25395, DOI 10.1029/97JD02075; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; KARRISON HR, 1992, SCIENCE, V255, P1409; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KERRIDGE JF, 1988, LUNAR PLANET SCI, V19, P599; KRASNOPOLSKY VA, 1996, ICARUS, V553, P124; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; LESHIN LA, 1997, LUNAR PLANET SCI, V28, P805; LESHIN LA, 1998, LUNAR PLANET SCI C, V29, P1468; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MAUERSBERGER K, 1987, GEOPHYS RES LETT, V14, P80, DOI 10.1029/GL014i001p00080; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MCELROY MB, 1976, SCIENCE, V194, P70, DOI 10.1126/science.194.4260.70; MCSWEEN HY, 1984, GEOLOGY, V12, P3, DOI 10.1130/0091-7613(1984)12<3:SMATMR>2.0.CO;2; MELLON MT, 1995, J GEOPHYS RES-PLANET, V100, P11781, DOI 10.1029/95JE01027; MUEHLENBACHS K, 1976, J GEOPHYS RES, V81, P4365, DOI 10.1029/JB081i023p04365; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; NIER AO, 1976, SCIENCE, V194, P68, DOI 10.1126/science.194.4260.68; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; PEPIN RO, 1994, ICARUS, V111, P289, DOI 10.1006/icar.1994.1146; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; ROSENBAUM J, 1986, GEOCHIM COSMOCHIM AC, V50, P1147, DOI 10.1016/0016-7037(86)90396-0; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SCAMBOS TA, 1990, J GEOPHYS RES-SOLID, V95, P14779, DOI 10.1029/JB095iB09p14779; THIEMENS MH, 1991, GEOPHYS RES LETT, V18, P669, DOI 10.1029/91GL00121; THIEMENS MH, 1995, SCIENCE, V270, P969, DOI 10.1126/science.270.5238.969; THIEMENS MH, 1995, GEOPHYS RES LETT, V22, P255, DOI 10.1029/94GL02996; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WALLIS MK, 1978, PLANET SPACE SCI, V26, P949, DOI 10.1016/0032-0633(78)90077-6; WALLIS MK, 1989, EARTH PLANET SC LETT, V93, P321, DOI 10.1016/0012-821X(89)90031-9; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; Wood C.A., 1981, P LUNAR PLANET SCI C, V12B, P1359; WRIGHT IP, 1990, J GEOPHYS RES-SOLID, V95, P14789, DOI 10.1029/JB095iB09p14789; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; [No title captured]	79	108	113	5	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1580	1582		10.1126/science.280.5369.1580	http://dx.doi.org/10.1126/science.280.5369.1580			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616116				2022-12-01	WOS:000074061200034
J	Smith, L				Smith, L			Death in springtime	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Smith, L (corresponding author), Mt Sinai Hosp, 1 Gustave L Levy Pl,Box 118, New York, NY 10029 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					955	955		10.7326/0003-4819-128-11-199806010-00019	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634438				2022-12-01	WOS:000073808600014
J	Wannamethee, SG; Shaper, AG; Walker, M				Wannamethee, SG; Shaper, AG; Walker, M			Changes in physical activity, mortality, and incidence of coronary heart disease in older men	LANCET			English	Article							AGED BRITISH MEN; LEISURE-TIME; RISK-FACTORS; ACTIVITY LEVEL; FOLLOW-UP; DEATH; EXERCISE; ATTACK; RATES	Background We studied the relations between physical activity and changes in physical activity, all-cause mortality, and incidence of major coronary-heart-disease events in older men. Methods In 1978-80 (Q1), 7735 men aged 40-59 were selected from general practices in 24 British towns, and enrolled in a prospective study of cardiovascular disease, which included physical activity data. In 1992 (Q92), 12-14 years later, 5934 of the men (91% of available survivors, mean age 63 years) gave further information on physical activity and,were then followed up for a further 4 years. The main endpoints were all-cause mortality during 4 years of follow-up from Q92, and major fatal and non-fatal coronary-heart-disease events during 3 years of follow-up from Q92. Findings Among 4311 men with no history of coronary heart disease, stroke, or "other heart trouble" by Q92 and who did not report "poor health", there were 219 deaths. In the inactive/occasionally active, light, moderate, and moderately vigorous/vigorous activity groups there were 101 (18.5/1000 person-years) 48 (11.4), 23 (7.3), and 47 (9.1) deaths, respectively (adjusted risk ratios 1.00, 0.61 [95% CI 0.48-0.86], 0.50 [0.31-0.79], 0.65 [0.45-0.94]). Men who were sedentary at Q1 and who began at least light activity by Q92 had significantly lower all-cause mortality than those who remained sedentary, even after adjustment for potential confounders (risk ratio=0.55 [0.36-0.84]). Physical activity improved both cardiovascular mortality (0.66 [0.35-1.23]) and noncardiovascular mortality (0.48 [0.27-0.85]). The relation between physical activity at Q92, changes in physical activity, and mortality were similar for men with pre-existing cardiovascular disease. Interpretation Maintaining or taking up light or moderate physical activity reduces mortality and heart attacks in older men with and without diagnosed cardiovascular disease. Our results support public-health recommendations for older sedentary people to increase physical activity, and for active middle-aged people to continue their activity into old age.	Royal Free Hosp, Sch Med, Dept Publ Hlth & Primary Care, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Wannamethee, SG (corresponding author), Royal Free Hosp, Sch Med, Dept Publ Hlth & Primary Care, London NW3 2PF, England.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351				[Anonymous], 1996, JAMA, V276, P241; ASTRAND PO, 1986, ACTA MED SCAND, P241; Bennett N, 1995, HLTH SURVEY ENGLAND; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; CHAVE SPW, 1978, J EPIDEMIOL COMMUN H, V32, P239, DOI 10.1136/jech.32.4.239; *DEP HLTH PHYS ACT, 1995, MOR PEOPL MOR ACT MO; EDWARDS KE, 1992, CLIN GERIATR MED, V1, P35; HAGBERG JM, 1994, PHYSICAL ACTIVITY FI, P993; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Hein H. O., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P57; *HLTH ED AUTH, 1995, HLTH UPD PHYS ACT; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; MORRIS JN, 1990, BRIT HEART J, V63, P325; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1994, J HUM HYPERTENS, V8, P3; SHERMAN SE, 1994, AM HEART J, V128, P965, DOI 10.1016/0002-8703(94)90596-7; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; WANNAMETHEE G, 1993, AM J EPIDEMIOL, V137, P735, DOI 10.1093/oxfordjournals.aje.a116734; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0	30	349	357	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1603	1608		10.1016/S0140-6736(97)12355-8	http://dx.doi.org/10.1016/S0140-6736(97)12355-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620713				2022-12-01	WOS:000074026600006
J	Hardt, WD; Chen, LM; Schuebel, KE; Bustelo, XR; Galan, JE				Hardt, WD; Chen, LM; Schuebel, KE; Bustelo, XR; Galan, JE			S-typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells	CELL			English	Article							CULTURED EPITHELIAL-CELLS; SALMONELLA-TYPHIMURIUM; PROTEIN SECRETION; INVASION GENES; FAMILY; ENTRY; IDENTIFICATION; GROWTH; RAS; CYTOSKELETAL	S. typhimurium stimulates signaling pathways leading to membrane ruffling, actin cytoskeleton rearrangements, and nuclear responses. The stimulation requires a protein secretion system (type III) that translocates bacterial proteins into the host cell. We show that SopE, a substrate of this secretion system, stimulates cytoskeletal reorganization and JNK activation in a CDC42- and Rac-1-dependent manner. A lambda gt11 cDNA library screen for proteins that interact with SopE identified Rac-1 and CDC42. Furthermore, purified SopE was shown to stimulate GDP/GTP nucleotide exchange in several Rho GTPases in vitro, including Rac-1 and CDC42. These findings establish a paradigm for microbial stimulation of cellular responses in which the pathogen induces signaling events by directly engaging the signaling machinery within the host cell.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Galan, JE (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.		Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Hardt, Wolf-Dietrich/0000-0002-9892-6420	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030492, R01AI030492, R29AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NCI NIH HHS [CA7373501] Funding Source: Medline; NIAID NIH HHS [AI30492] Funding Source: Medline; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD JW, 1993, MICROB PATHOGENESIS, V14, P217, DOI 10.1006/mpat.1993.1021; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1996, ANNU REV CELL DEV BI, V12, P219; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; Hobbie S, 1997, J IMMUNOL, V159, P5550; Hotchin NA, 1996, CANCER SURV, V27, P311; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; LI J, 1995, P NATL ACAD SCI USA, V92, P7252, DOI 10.1073/pnas.92.16.7252; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEGUES DA, 1995, MOL MICROBIOL, V17, P169, DOI 10.1111/j.1365-2958.1995.mmi_17010169.x; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; XU X, 1997, BIOCHEMISTRY-US, V36, P826	40	640	657	1	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					815	826		10.1016/S0092-8674(00)81442-7	http://dx.doi.org/10.1016/S0092-8674(00)81442-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630225	Bronze			2022-12-01	WOS:000073956700017
J	Kaufer, D; Friedman, A; Seidman, S; Soreq, H				Kaufer, D; Friedman, A; Seidman, S; Soreq, H			Acute stress facilitates long-lasting changes in cholinergic gene expression	NATURE			English	Article							HUMAN ACETYLCHOLINESTERASE; ALZHEIMERS-DISEASE; GULF-WAR; PROMOTER; BRAIN; PYRIDOSTIGMINE; NEURONS; CALCIUM; TACRINE; CELLS	Acute traumatic stress may lead to post-traumatic stress disorder (PTSD)(1), which is characterized by delayed neuropsychiatric symptoms including depression, irritability, and impaired cognitive performance(2). Curiously, inhibitors of the acetylcholine-hydrolysing enzyme acetylcholinesterase may induce psychopathologies that are reminiscent of PTSD3,4. It is unknown how a single stressful event mediates long-term neuronal plasticity. Moreover, no mechanism has been proposed to explain the convergent neuropsychological outcomes of stress and of acetylcholinesterase inhibition. However, acute stress elicits a transient increase in the amounts released of the neurotransmitter acetylcholine and a phase of enhanced neuronal excitability(5). Inhibitors of acetylcholinesterase also promote enhanced electrical brain activity(6), presumably by increasing the survival of acetylcholine at the synapse. Here we report that there is similar bidirectional modulation of genes that regulate acetylcholine availability after stress and blockade of acetylcholinesterase. These calcium-dependent changes in gene expression coincide with phases of rapid enhancement and delayed depression of neuronal excitability, Both of these phases are mediated by muscarinic acetylcholine receptors, Our results suggest a model in which robust cholinergic stimulation triggers rapid induction of the gene encoding the transcription factor c-Fos. This protein then mediates selective regulatory effects on the long-lasting activities of genes involved in acetylcholine metabolism.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Neurosurg, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University; Ben Gurion University	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@shum.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X				Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; BAUSERO P, 1993, NEUROREPORT, V4, P287, DOI 10.1097/00001756-199303000-00015; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; ENNIS M, 1992, EXP NEUROL, V118, P164, DOI 10.1016/0014-4886(92)90033-M; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; FRIEDMAN A, 1989, EUR J NEUROSCI, V1, P374, DOI 10.1111/j.1460-9568.1989.tb00802.x; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; IMPERATO A, 1991, BRAIN RES, V538, P111, DOI 10.1016/0006-8993(91)90384-8; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; LI Y, 1993, J BIOL CHEM, V268, P3563; MILNER IB, 1994, JAMA-J AM MED ASSOC, V271, P661, DOI 10.1001/jama.1994.03510330039024; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Wickelgren I, 1997, SCIENCE, V278, P1404; WINKER MA, 1994, JAMA-J AM MED ASSOC, V271, P1023, DOI 10.1001/jama.271.13.1023	27	509	527	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					373	377		10.1038/30741	http://dx.doi.org/10.1038/30741			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620801				2022-12-01	WOS:000073883600056
J	Williams, SP; Sigler, PB				Williams, SP; Sigler, PB			Atomic structure of progesterone complexed with its receptor	NATURE			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; RETINOIC ACID; C-TERMINUS; ACTIVATION; DIMERIZATION; RU486; MECHANISM; DNA	The physiological effects of progestins are mediated by the progesterone receptor, a member of the steroid/nuclear receptor superfamily(1). As progesterone is required for maintenance of pregnancy, its receptor has been a target for pharmaceuticals(2). Here we report the 1.8 Angstrom crystal structure of a progesterone-bound ligand-binding domain of the human progesterone receptor. The nature of this structure explains the receptor's selective affinity for progestins and establishes a common mode of recognition of 3-oxy steroids by the cognate receptors. Although the overall fold of the progesterone receptor is similar to that found in related receptors(3-6), the progesterone receptor has a quite different mode of dimerization(3,6). A hormone-induced stabilization of the carboxy-terminal secondary structure of the ligand-binding domain of the progesterone receptor accounts for the stereo-chemistry of this distinctive dimer, explains the receptor's characteristic pattern of ligand-dependent protease resistance and its loss of repression(7,8), and indicates how the anti-progestin RU486 might work in birth control. The structure also indicates that the analogous 3-keto-steroid receptors may have a similar mechanism of action.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	Sigler, PB (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 160 Whitney Ave, New Haven, CT 06510 USA.			Williams, Shawn/0000-0001-8311-2638				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DEMARZO AM, 1992, BIOCHEMISTRY-US, V31, P10491, DOI 10.1021/bi00158a012; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EDWARDS DP, 1995, J STEROID BIOCHEM, V53, P449, DOI 10.1016/0960-0760(95)00091-D; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jeyakumar M, 1997, MOL ENDOCRINOL, V11, P755, DOI 10.1210/me.11.6.755; Klotzbucher M, 1997, MOL ENDOCRINOL, V11, P768, DOI 10.1210/me.11.6.768; LANZ R, 1996, ENDOCRINOLOGY, V135, P2183; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SKAFAR DF, 1993, J STEROID BIOCHEM, V44, P39, DOI 10.1016/0960-0760(93)90149-Q; SKAFAR DF, 1991, BIOCHEMISTRY-US, V30, P6148, DOI 10.1021/bi00239a010; TETAL MJ, 1997, MOL ENDOCRINOL, V11, P1114; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P687; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	28	541	563	3	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					392	396		10.1038/30775	http://dx.doi.org/10.1038/30775			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620806				2022-12-01	WOS:000073883600061
J	Rocha, BA; Scearce-Levie, K; Lucas, JJ; Hiroi, N; Castanon, N; Crabbe, JC; Nestler, EJ; Hen, R				Rocha, BA; Scearce-Levie, K; Lucas, JJ; Hiroi, N; Castanon, N; Crabbe, JC; Nestler, EJ; Hen, R			Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor	NATURE			English	Article							PROGRESSIVE-RATIO SCHEDULE; 5-HT1B; ADDICTION; DOPAMINE; PROTEINS; ALCOHOL; ABUSE; BRAIN	There is increasing evidence that genetic factors can influence individual differences in vulnerability to drugs of abuse(1,2). Serotonin (5-hydroxytryptamine, 5-HT), acting through many receptors can modulate the activity of neural reward pathways and thus the effects of various drugs of abuse(3-8). Here we examine the effects of cocaine in mice lacking one of the serotonin-receptor subtypes, the 5-HT1B receptor(9). We show that mice lacking 5-HT1B display increased locomotor responses to cocaine and that they are more motivated to self-administer cocaine. We propose that even drug-naive 5-HT1B-knockout mice are in a behavioural and biochemical state that resembles that of wild-type mice sensitized to cocaine by repeated exposure to the drug. This altered state might be responsible for their increased vulnerability to cocaine.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Univ N Texas, Hlth Sci Ctr, Dept Pharmacol, Ft Worth, TX 76107 USA; Yale Univ, Sch Med, Mol Psychiat Lab, New Haven, CT 06508 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Dept Vet Affairs Med Ctr, Portland, OR 97201 USA	Columbia University; University of North Texas System; University of North Texas Health Science Center; Yale University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	Hen, R (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, 722 W 168th St,PI Annes 731, New York, NY 10032 USA.	rh95@columbia.edu	Hiroi, Noboru/E-2215-2013; Lucas, Jose J./U-6543-2019	Hiroi, Noboru/0000-0002-6846-5969; Castanon, Nathalie/0000-0002-0079-0562; Lucas, Jose J./0000-0003-1597-3916	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOSCHERT U, 1994, NEUROSCIENCE, V58, P167, DOI 10.1016/0306-4522(94)90164-3; BROWNE SP, 1991, J FORENSIC SCI, V36, P1662; Brunner D, 1997, ANN NY ACAD SCI, V836, P81, DOI 10.1111/j.1749-6632.1997.tb52356.x; CALLAHAN PM, 1995, J PHARMACOL EXP THER, V274, P1414; CAMERON DL, 1994, J NEUROSCI, V14, P6763; CARROLL ME, 1990, PHARMACOL BIOCHEM BE, V35, P237, DOI 10.1016/0091-3057(90)90232-7; CASTANON N, 1996, SOC NEUR 26 ANN M WA; Chen JS, 1997, J NEUROSCI, V17, P4933; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; DEPOORTERE RY, 1993, PHARMACOL BIOCHEM BE, V45, P539, DOI 10.1016/0091-3057(93)90503-L; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; HORGER BA, 1990, PHARMACOL BIOCHEM BE, V37, P707, DOI 10.1016/0091-3057(90)90552-S; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; Lucas JJ, 1997, MOL PHARMACOL, V51, P755, DOI 10.1124/mol.51.5.755; Mandelzys A, 1997, J NEUROSCI, V17, P5407; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Parsons LH, 1996, PSYCHOPHARMACOLOGY, V128, P150, DOI 10.1007/s002130050120; PARSONS LH, 1993, BRAIN RES, V606, P195, DOI 10.1016/0006-8993(93)90984-U; PARSONS LH, 1996, SOC NEUR 26 ANN M WA; PELTIER R, 1993, PSYCHOPHARMACOLOGY, V110, P390, DOI 10.1007/BF02244643; Rocha BA, 1997, PHARMACOL BIOCHEM BE, V57, P407, DOI 10.1016/S0091-3057(96)00444-3; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	29	266	270	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1998	393	6681					175	178		10.1038/30259	http://dx.doi.org/10.1038/30259			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603521				2022-12-01	WOS:000073619900050
J	Fulop, V; Bocskei, Z; Polgar, L				Fulop, V; Bocskei, Z; Polgar, L			Prolyl oligopeptidase: An unusual beta-propeller domain regulates proteolysis	CELL			English	Article							PROLINE-SPECIFIC ENDOPEPTIDASE; ALPHA/BETA-HYDROLASE FOLD; FLAVOBACTERIUM-MENINGOSEPTICUM; CRYSTAL-STRUCTURE; G-PROTEIN; SECONDARY-STRUCTURE; ENZYME; SEQUENCE; CLONING; PURIFICATION	Prolyl oligopeptidase is a large cytosolic enzyme that belongs to a new class of serine peptidases. The enzyme is involved in the maturation and degradation of peptide hormones and neuropeptides, which relate to the induction of amnesia. The 1.4 Angstrom resolution crystal structure is presented here. The enzyme contains a peptidase domain with an alpha/beta hydrolase fold, and its catalytic triad (Ser554, His680, Asp641) is covered by. the central tunnel of an unusual beta propeller. This domain makes prolyl oligopeptidase an oligopeptidase by excluding large structured peptides from the active. site. In this way, the propeller protects larger peptides and proteins from proteolysis in the cytosol. The structure is also obtained with a transition state inhibitor, which may facilitate drug design to treat memory disorders.	Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Eotvos Lorand Univ, Dept Theoret Chem, H-117 Budapest, Hungary; Chinoin Chem & Pharmaceut Works Ltd, H-1325 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	University of Oxford; University of Warwick; Eotvos Lorand University; Sanofi-Aventis; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Fulop, V (corresponding author), Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.		Fulop, Vilmos/AAZ-7720-2021		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOCSKEI Z, 1998, IN PRESS ACTA CRYS D; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAMARGO ACM, 1979, J BIOL CHEM, V254, P5304; CHEVALLIER S, 1992, J BIOL CHEM, V267, P8192; CONNOLLY ML, 1985, J APPL CRYSTALLOGR, V18, P499, DOI 10.1107/S0021889885010779; CYGLER M, 1993, PROTEIN SCI, V2, P366; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEFENTHAL T, 1993, APPL MICROBIOL BIOT, V40, P90, DOI 10.1007/BF00170434; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FABER HR, 1995, STRUCTURE, V3, P551, DOI 10.1016/S0969-2126(01)00189-7; FUKUNARI A, 1994, NEUROSCI LETT, V176, P201, DOI 10.1016/0304-3940(94)90082-5; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; ISHIURA S, 1990, FEBS LETT, V260, P131, DOI 10.1016/0014-5793(90)80084-V; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; MORIYAMA A, 1988, J BIOCHEM, V104, P112, DOI 10.1093/oxfordjournals.jbchem.a122404; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; Polg?r L., 1987, NEW COMPREHENSIVE BI, V16, P159; POLGAR L, 1993, FEBS LETT, V322, P227, DOI 10.1016/0014-5793(93)81575-K; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; POLGAR L, 1989, MECHANISMS PROTEASE, P87; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SCALONI A, 1994, J BIOL CHEM, V269, P15076; Shinoda M, 1997, BIOCHEM BIOPH RES CO, V235, P641, DOI 10.1006/bbrc.1997.6730; Smith L. C., 1992, CURR OPIN STRUC BIOL, V2, P490, DOI DOI 10.1016/0959-440X(92)90076-J; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; VANHOOF G, 1994, GENE, V149, P363, DOI 10.1016/0378-1119(94)90177-5; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730; YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786	60	443	454	2	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					161	170		10.1016/S0092-8674(00)81416-6	http://dx.doi.org/10.1016/S0092-8674(00)81416-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695945	Bronze			2022-12-01	WOS:000075020100005
J	Draguhn, A; Traub, RD; Schmitz, D; Jefferys, JGR				Draguhn, A; Traub, RD; Schmitz, D; Jefferys, JGR			Electrical coupling underlies high-frequency oscillations in the hippocampus in vitro	NATURE			English	Article							FIELD BURST ACTIVITY; RAT HIPPOCAMPAL; PYRAMIDAL NEURONS; SLICES; CELLS; MECHANISMS; POTENTIALS; NETWORKS; MODEL; PH	Coherent oscillations, in which ensembles of neurons fire in a repeated and synchronous manner, are thought to be important in higher brain functions. In the hippocampus, these discharges are categorized according to their frequency as theta (4-10 Hz)(1), gamma (20-80 Hz)(2) and high-frequency (similar to 200 Hz)(3-5) discharges, and they occur in relation to different behavioural states. The synaptic bases of theta and gamma rhythms have been extensively studied(6,7) but the cellular bases for high-frequency oscillations are not understood. Here we report that high-frequency network oscillations are present in rat brain slices in vitro, occurring as a brief series of repetitive population spikes at 150-200 Hz in all hippocampal principal cell layers. Moreover, this synchronous activity is not mediated through the more commonly studied modes of chemical synaptic transmission, but is in fact a result of direct electrotonic coupling of neurons, most Likely through gap-junctional connections. Thus high-frequency oscillations synchronize the activity of electrically coupled subsets of principal neurons within the well-documented synaptic network of the hippocampus.	Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England; Humboldt Univ, Inst Physiol Charite, D-10117 Berlin, Germany	University of Birmingham; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Draguhn, A (corresponding author), Univ Birmingham, Sch Med, Dept Physiol, Birmingham B15 2TT, W Midlands, England.		Jefferys, John G R/AAF-1164-2021; Jefferys, John/E-6132-2012	Jefferys, John G R/0000-0003-0106-4412; Jefferys, John/0000-0003-0106-4412; Schmitz, Dietmar/0000-0003-2741-5241	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Chrobak JJ, 1996, J NEUROSCI, V16, P3056; CHURCH J, 1991, J NEUROSCI, V11, P3289; COBB SR, 1995, NATURE, V378, P612; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; JEFFERYS JGR, 1981, J PHYSIOL-LONDON, V319, P143, DOI 10.1113/jphysiol.1981.sp013897; JEFFERYS JGR, 1982, NATURE, V300, P448, DOI 10.1038/300448a0; LESLIE J, 1998, J PHYSIOL-LONDON, V146, pP506; LLINAS R, 1974, J NEUROPHYSIOL, V37, P560, DOI 10.1152/jn.1974.37.3.560; Logan SD, 1996, J PHYSIOL-LONDON, V495, P491, DOI 10.1113/jphysiol.1996.sp021609; MACVICAR BA, 1985, BRAIN RES, V330, P141, DOI 10.1016/0006-8993(85)90015-0; MACVICAR BA, 1981, SCIENCE, V213, P782, DOI 10.1126/science.6266013; Patrylo PR, 1996, NEUROSCIENCE, V74, P107, DOI 10.1016/0306-4522(96)00111-X; PEREZVELAZQUEZ JL, 1994, J NEUROSCI, V14, P4308; PINAULT D, 1995, BRAIN RES REV, V21, P42, DOI 10.1016/0165-0173(95)00004-M; Rash JE, 1997, J COMP NEUROL, V388, P265, DOI 10.1002/(SICI)1096-9861(19971117)388:2<265::AID-CNE6>3.0.CO;2-#; Simburger E, 1997, HISTOCHEM CELL BIOL, V107, P127, DOI 10.1007/s004180050097; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Strata F, 1997, J NEUROSCI, V17, P1435; STUMPF C, 1965, ELECTROEN CLIN NEURO, V18, P477, DOI 10.1016/0013-4694(65)90128-8; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, P3; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Traub RD, 1995, J COMPUT NEUROSCI, V2, P283, DOI 10.1007/BF00961440; VALIANTE TA, 1995, J NEUROSCI, V15, P6946; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; VANEY DI, 1993, P ROY SOC B-BIOL SCI, V252, P93, DOI 10.1098/rspb.1993.0051; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; YLINEN A, 1995, J NEUROSCI, V15, P30	30	526	535	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					189	192		10.1038/28184	http://dx.doi.org/10.1038/28184			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671303				2022-12-01	WOS:000074705900056
J	Mandelbrot, L; Le Chenadec, J; Berrebi, A; Bongain, M; Benifla, JL; Delfraissy, JF; Blanche, S; Mayaux, MJ				Mandelbrot, L; Le Chenadec, J; Berrebi, A; Bongain, M; Benifla, JL; Delfraissy, JF; Blanche, S; Mayaux, MJ		French Perinatal Cohort	Perinatal HIV-1 transmission - Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOTHER-TO-CHILD; CESAREAN-SECTION; INFECTED WOMEN; INFANT; COMPLICATIONS; PREGNANCY; RISK	Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.	Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France; INSERM, U149, Paris, France; INSERM, U292, Le Kremlin Bicetre, France; Hop La Grave, Serv Gynecol Obstet, Toulouse, France; Hop Archet 2, Serv Gynecol Obstet, Nice, France; Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France; Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; Hop Necker Enfants Malad, Serv Pediat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mandelbrot, L (corresponding author), Hop Cochin Port Royal, Serv Gynecol Obstet 1, 123 Blvd Port Royal, F-75014 Paris, France.	laurent.mandelbrot@cch.ap-hop-paris.fr	Mandelbrot, Laurent/AAD-3554-2019	Mandelbrot, Laurent/0000-0002-5883-7597				[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Bulterys M, 1996, AIDS, V10, P923, DOI 10.1097/00002030-199607000-00019; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; HOGBERG U, 1994, OBSTET GYNECOL, V84, P240; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Kuhn L, 1997, AIDS, V11, P429, DOI 10.1097/00002030-199704000-00005; KUHN L, 1994, AM J PUBLIC HEALTH, V84, P1110, DOI 10.2105/AJPH.84.7.1110; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Lin HH, 1996, OBSTET GYNECOL, V87, P244, DOI 10.1016/0029-7844(95)00385-1; LoussertAjaka I, 1997, AIDS, V11, P1575, DOI 10.1097/00002030-199713000-00005; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 1997, AIDS PATIENT CARE ST, V11, P139, DOI 10.1089/apc.1997.11.139; MANDELBROT L, 1997, 1 SEM ANN RECH CLIN, pA42; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; NEWELL ML, 1994, LANCET, V343, P1464; Newell ML, 1996, AIDS, V10, P1675; Newell ML, 1998, BRIT J OBSTET GYNAEC, V105, P281, DOI 10.1111/j.1471-0528.1998.tb10087.x; ROMERO R, 1988, CLIN OBSTET GYNECOL, V31, P553, DOI 10.1097/00003081-198809000-00006; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; SCARAVELLI G, 1995, EUR J OBSTET GYN R B, V62, P7, DOI 10.1016/0301-2115(95)02143-U; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; THOMAS PA, 1994, PEDIATR INFECT DIS J, V13, P489, DOI 10.1097/00006454-199406000-00005; VANDEPERRE P, 1995, AM J OBSTET GYNECOL, V173, P483, DOI 10.1016/0002-9378(95)90270-8	40	202	208	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					55	60		10.1001/jama.280.1.55	http://dx.doi.org/10.1001/jama.280.1.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660364	Bronze			2022-12-01	WOS:000074379400024
J	Ayanian, JZ; Landrum, MB; Normand, SLT; Guadagnoli, E; McNeil, BJ				Ayanian, JZ; Landrum, MB; Normand, SLT; Guadagnoli, E; McNeil, BJ			Rating the appropriateness of coronary angiography - Do practicing physicians agree with an expert panel and with each other?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; NEW-YORK-STATE; PRACTICE GUIDELINES; PRIMARY ANGIOPLASTY; CARDIAC PROCEDURES; CLINICAL-PRACTICE; UNITED-STATES; MEDICAL-CARE; SPECIALTY; CARDIOLOGISTS	Background Evaluations of the appropriateness of medical care are important to monitor the quality of care and to contain costs and enhance safety by reducing inappropriate care. Experts' views are usually incorporated into evaluations of appropriateness. However, practicing physicians may not concur with these views, and physicians' clinical backgrounds may influence their beliefs. Methods We asked 1058 internists, family practitioners, and cardiologists in California, Florida, New York, Pennsylvania, and Texas to rate the appropriateness of coronary angiography after acute myocardial infarction for 20 common indications. Nine clinical experts also rated these indications using an established consensus method. Results For 17 of the 20 indications, median ratings of surveyed physicians and the expert panel agreed within 1 unit on a 9-unit scale. Patients' older age had a negative effect on ratings by the expert panel but not on ratings by surveyed physicians. In multivariable analyses of surveyed physicians, cardiologists rated angiography as significantly more appropriate than did primary care physicians for complicated indications, and for uncomplicated indications cardiologists who performed invasive procedures gave higher appropriateness ratings for angiography than did cardiologists who did not perform such procedures and primary care physicians. For uncomplicated indications, physicians from hospitals providing coronary angioplasty and bypass surgery rated angiography as more appropriate than physicians from other hospitals. Physicians from New York and those employed by health maintenance organizations rated angiography as less appropriate than other physicians. Conclusions Surveyed physicians agreed with clinical experts about the appropriateness of coronary angiography after myocardial infarction for most indications, indicating that well-designed expert panels can closely reflect the views of practicing physicians. Variations in beliefs among practicing physicians suggest that evaluations of medical practice should incorporate the views of a range of relevant types of physicians. (N Engl J Med 1998;338:1896-904.) (C) 1998, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.			Normand, Sharon-Lise/0000-0001-7027-4769	AHRQ HHS [HS07081] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY L, 1989, DESIGNING CONDUCTING; [Anonymous], CORONARY ANGIOGRAPHY; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; BATTISTA RN, 1995, J CLIN EPIDEMIOL, V48, P875, DOI 10.1016/0895-4356(94)00199-Z; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; BOROWSKY SJ, 1995, J AM COLL CARDIOL, V26, P1484, DOI 10.1016/0735-1097(95)00337-1; BROOK RH, 1988, LANCET, V1, P750; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; DiSalvo TG, 1996, J AM COLL CARDIOL, V27, P262, DOI 10.1016/0735-1097(95)00488-2; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; GILKS WR, 1994, STATISTICIAN, V43, P169, DOI 10.2307/2348941; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.268.11.1417; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Kahan JP, 1996, MED CARE, V34, P512, DOI 10.1097/00005650-199606000-00002; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LANDRUM MB, IN PRESS STAT MED; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Layde PM, 1996, J CLIN EPIDEMIOL, V49, P835, DOI 10.1016/0895-4356(96)00006-6; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Peterson ED, 1997, ANN INTERN MED, V126, P561, DOI 10.7326/0003-4819-126-7-199704010-00012; Peterson ED, 1997, ANN INTERN MED, V126, P556, DOI 10.7326/0003-4819-126-7-199704010-00012; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; PILOTE L, 1995, MED CARE, V33, P598, DOI 10.1097/00005650-199506000-00003; Poses RM, 1997, MED CARE, V35, P603, DOI 10.1097/00005650-199706000-00006; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Wennberg DE, 1997, J GEN INTERN MED, V12, P172	41	134	134	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1998	338	26					1896	1904		10.1056/NEJM199806253382608	http://dx.doi.org/10.1056/NEJM199806253382608			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV898	9637811				2022-12-01	WOS:000074352800008
J	Rainer, G; Asaad, WF; Miller, EK				Rainer, G; Asaad, WF; Miller, EK			Selective representation of relevant information by neurons in the primate prefrontal cortex	NATURE			English	Article							NEURAL MECHANISMS; VISUAL-ATTENTION; MEMORY	The severe limitation of the capacity of working memory, the ability to store temporarily and manipulate information(1), necessitates mechanisms that restrict access to it. Here we report tests to discover whether the activity of neurons in the prefrontal (PF) cortex, the putative neural correlate of working memory(2-8), might reflect these mechanisms and preferentially represent behaviourally relevant information. Monkeys performed a 'delayed-matching-to-sample' task with an array of three objects. Only one of the objects in the array was relevant for task performance and the monkeys needed to find that object (the target) and remember its location. For many PF neurons, activity to physically identical arrays varied with the target location; the location of the non-target objects had little or no influence on activity. Information about the target location was present in activity as early as 140 ms after array onset. Also, information about which object was the target was reflected in the sustained activity of many PF neurons. These results suggest that the prefrontal cortex is involved in selecting and maintaining behaviourally relevant information.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Miller, EK (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.	ekm@ai.mit.edu	Miller, Earl K./AAE-8187-2019; Asaad, Wael/I-8485-2012; Rainer, Gregor/B-5876-2012	Miller, Earl K./0000-0002-0582-6958; Asaad, Wael/0000-0003-4406-9096; Rainer, Gregor/0000-0002-5805-2220				Baddeley A.D., 1986, WORKING MEMORY; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DIPELLEGRINO G, 1991, BRAIN, V114, P951; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; Hasegawa R, 1998, J NEUROPHYSIOL, V79, P322, DOI 10.1152/jn.1998.79.1.322; HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794; Kahneman D., 1973, ATTENTION EFFORT; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Miller EK, 1996, J NEUROSCI, V16, P5154; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; Moody SL, 1998, J NEUROSCI, V18, P399; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; SHEPARD M, 1997, Q J EXP PSYCHOL-A, V38, P475	19	428	436	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					577	579		10.1038/31235	http://dx.doi.org/10.1038/31235			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634233				2022-12-01	WOS:000074150100052
J	Sillanpaa, M; Jalava, M; Kaleva, O; Shinnar, S				Sillanpaa, M; Jalava, M; Kaleva, O; Shinnar, S			Long-term prognosis of seizures with onset in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN UNEXPLAINED DEATH; ANTIEPILEPTIC DRUGS; EPILEPSY; PREDICTORS; ADJUSTMENT; REMISSION; CHILDREN; THERAPY; COHORT	Background The long-term prognosis of seizures that begin in childhood is uncertain. Methods We prospectively studied 245 children from the catchment area of Turku University Hospital in Turku, Finland, who had active epilepsy diagnosed between 1961 and 1964. Sixty-eight patients (28 percent) had idiopathic seizures (presumed to have a genetic origin), 54 (22 percent) had cryptogenic seizures (occurring in otherwise normal persons with no clear cause), and 123 (50 percent) had remote symptomatic seizures (with no immediate cause but occurring in persons with a prior brain injury or a static encephalopathy). Results At the final follow-up in 1992, we had sufficient data on 220 patients (90 percent), 176 of whom were alive and 44 of whom had died; the remaining 25 had emigrated, could not be traced, or declined to participate. Thirty-nine patients who died were not free of seizures at the time of death, and 33 had remote symptomatic seizures. Among the surviving patients, 112 (64 percent) had been seizure-free for at least five years, including 83 (47 percent) who were not taking antiepileptic medications. The most important predictors of being seizure-free for at least five years were a rapid response to therapy (defined as a reduction in the frequency of seizures of 75 to 100 percent within three months of beginning treatment) and a diagnosis of idiopathic seizures. As compared with a matched control group, 99 patients with epilepsy but no other initial neurologic impairment were of similar socioeconomic status and had similar rates of passing an examination given after 12 years of school. Significantly more patients, however, had completed only six years of school (relative risk, 2.13), were unemployed (relative risk, 3.76), were not married (relative risk, 3.50), and did not have children (relative risk, 3.00). Conclusions Although the majority of patients with epilepsy in childhood are free of seizures by the time they become adults, they are at increased risk for social and educational problems. Patients whose epilepsy does not remit also have an increased risk of death. (C) 1998, Massachusetts Medical Society.	Univ Turku, Dept Pediat Neurol, Turku, Finland; Univ Turku, Dept Biostat, Turku, Finland; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Comprehens Epilepsy Management Ctr, Bronx, NY 10467 USA	University of Turku; University of Turku; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Sillanpaa, M (corresponding author), Turku Univ Hosp TYKS, Dept Child Neurol, FIN-20520 Turku, Finland.		Sillanpaa, Matti L/G-4708-2015	Sillanpaa, Matti L/0000-0003-4190-3698	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26151] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1979, EPILEPSIA, V20, P729, DOI 10.1111/j.1528-1157.1979.tb04857.x; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BEGHI E, 1988, EPILEPSIA, V29, P236, DOI 10.1111/j.1528-1157.1988.tb03712.x; Berg A T, 1995, CHILDHOOD SEIZURES, P1; Berg AT, 1996, EPILEPSIA, V37, P24, DOI 10.1111/j.1528-1157.1996.tb00507.x; BERG AT, 1995, EPILEPSIA, V36, P3; BERG AT, 1995, CHILDHOOD SEIZURES, P93; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; CALLAGHAN N, 1992, IRISH MED J, V85, P17; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; CAMFIELD C, 1993, J PEDIATR-US, V122, P869, DOI 10.1016/S0022-3476(09)90009-9; Camfield CS, 1996, EPILEPSIA, V37, P19, DOI 10.1111/j.1528-1157.1996.tb00506.x; CARLTONFORD S, 1995, J HEALTH SOC BEHAV, V36, P285, DOI 10.2307/2137344; *CENTR STAT OFF, 1989, CLASS SOC GROUPS; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COX DR, 1972, J R STAT SOC B, V34, P187; Derby LE, 1996, EPILEPSIA, V37, P931, DOI 10.1111/j.1528-1157.1996.tb00529.x; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Dixon W.J, 1990, BMDP STAT SOFTWARE; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HUTTENLOCHER PR, 1990, ANN NEUROL, V28, P699, DOI 10.1002/ana.410280516; Jacoby A, 1996, EPILEPSIA, V37, P148, DOI 10.1111/j.1528-1157.1996.tb00006.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, METHODS OBSERVATIONA; LATHERS CM, 1990, EPILEPSY SUDDEN DEAT; LEESTMA JE, 1989, ANN NEUROL, V26, P195, DOI 10.1002/ana.410260203; MITCHELL WG, 1991, J CHILD NEUROL, V6, P65, DOI 10.1177/088307389100600114; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; OLSSON I, 1993, EPILEPSIA, V34, P846, DOI 10.1111/j.1528-1157.1993.tb02101.x; OUNSTED C, 1987, 103 CLIN DEV MED; SCHUPF N, 1994, EPILEPSIA, V35, P750, DOI 10.1111/j.1528-1157.1994.tb02506.x; Shinnar S, 1996, EPILEPSIA, V37, P701, DOI 10.1111/j.1528-1157.1996.tb00639.x; Sillanpaa M., 1973, ACTA PAEDIATR SC   S, V237, P1; SOFIJANOV NG, 1982, EPILEPSIA, V23, P61, DOI 10.1111/j.1528-1157.1982.tb05053.x; TENNIS P, 1995, EPILEPSIA, V36, P29, DOI 10.1111/j.1528-1157.1995.tb01661.x; WESTBROOK LE, 1991, J EPILEPSY, V4, P87, DOI 10.1016/S0896-6974(05)80066-0; World Health Organization, 1980, INT CLASS IMP DIS HA	45	496	502	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1998	338	24					1715	1722		10.1056/NEJM199806113382402	http://dx.doi.org/10.1056/NEJM199806113382402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT654	9624191				2022-12-01	WOS:000074109800002
J	Agmon-Snir, H; Carr, CE; Rinzel, J				Agmon-Snir, H; Carr, CE; Rinzel, J			The role of dendrites in auditory coincidence detection	NATURE			English	Article							INTERAURAL TIME DIFFERENCES; MEDIAL SUPERIOR OLIVE; COCHLEAR NUCLEUS; BRAIN-STEM; NEURONS; CELLS; INFORMATION; MODEL; INTERNEURONS; INTEGRATION	Coincidence-detector neurons in the auditory brainstem of mammals and birds use interaural time differences to localize sounds(1,2). Each neuron receives many narrow-band inputs from both ears and compares the time of arrival of the inputs with an accuracy of 10-100 mu s (refs 3-6). Neurons that receive low-frequency auditory inputs (up to about 2 kHz) have bipolar dendrites, and each dendrite receives inputs from only one ear(7,8). Using a simple model that mimics the essence of the known electrophysiology and geometry of these cells, we show here that dendrites improve the coincidence-detection properties of the cells. The biophysical mechanism for this improvement is based on the nonlinear summation of excitatory inputs in each of the dendrites and the use of each dendrite as a current sink for inputs to the other dendrite. This is a rare casein which the contribution of dendrites to the known computation of a neuron may be understood. Our results show that, in these neurons, the cell morphology and the spatial distribution of the inputs enrich the computational power of these neurons beyond that expected from 'point neurons' (model neurons lacking dendrites).	Univ Maryland, Dept Zool, College Pk, MD 20742 USA; NIDDK, Math Res Branch, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Carr, CE (corresponding author), Univ Maryland, Dept Zool, College Pk, MD 20742 USA.	carr@zool.umd.edu						Agmon-Snir H., 1996, Society for Neuroscience Abstracts, V22, P402; BORST A, 1994, TRENDS NEUROSCI, V17, P257, DOI 10.1016/0166-2236(94)90009-4; Borst A, 1996, ACTA PHYSIOL SCAND, V157, P403, DOI 10.1046/j.1365-201X.1996.30250000.x; Brughera AR, 1996, AUDIT NEUROSCI, V2, P219; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CARR CE, 1990, J NEUROSCI, V10, P3227; COLBURN HS, 1990, HEARING RES, V49, P335, DOI 10.1016/0378-5955(90)90112-3; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; Haag J, 1996, NATURE, V379, P639, DOI 10.1038/379639a0; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; MANIS PB, 1991, J NEUROSCI, V11, P2865; MEL BW, 1994, NEURAL COMPUT, V6, P1031, DOI 10.1162/neco.1994.6.6.1031; MORRIS C, 1981, BIOPHYS J, V35, P193, DOI 10.1016/S0006-3495(81)84782-0; OVERHOLT EM, 1992, J NEUROSCI, V12, P1698; PARKS TN, 1978, J COMP NEUROL, V180, P439, DOI 10.1002/cne.901800303; Pinsky P F, 1994, J Comput Neurosci, V1, P39, DOI 10.1007/BF00962717; REYES AD, 1994, J NEUROSCI, V14, P5352; Reyes AD, 1996, J NEUROSCI, V16, P993; Rinzel J., 1989, METHODS NEURONAL MOD, P135; SEGEV I, 1995, HDB BRAIN THEORY NEU, P282; Shepherd G.M., 1995, THEORETICAL FDN DEND; SMITH DJ, 1979, J COMP NEUROL, V186, P213, DOI 10.1002/cne.901860207; SMITH PH, 1995, J NEUROPHYSIOL, V73, P1653, DOI 10.1152/jn.1995.73.4.1653; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STOTLER WA, 1953, J COMP NEUROL, V98, P401, DOI 10.1002/cne.900980303; WARCHOL ME, 1990, J COMP PHYSIOL A, V166, P721; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; ZHANG S, 1994, J NEUROPHYSIOL, V72, P705, DOI 10.1152/jn.1994.72.2.705	30	268	271	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					268	272		10.1038/30505	http://dx.doi.org/10.1038/30505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607764				2022-12-01	WOS:000073761000054
J	Pellegrino, ED				Pellegrino, ED			Emerging ethical issues in palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Georgetown Univ, Med Ctr, Ctr Clin Bioeth, Washington, DC 20007 USA	Georgetown University	Pellegrino, ED (corresponding author), Georgetown Univ, Med Ctr, Ctr Clin Bioeth, 4000 Reservior Rd NW,Room D-238, Washington, DC 20007 USA.							ASHLEY BM, 1989, HLTH CARE ETHICS, P184; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Canadian Palliative Care Association, 1995, PALL CAR CONS STAND; CLARK D, 1993, FUTURE PALLIATIVE CA; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FOLEY KM, 1993, OPIOIDS, V2, P697; Glick SM, 1997, NEW ENGL J MED, V336, P954, DOI 10.1056/NEJM199703273361312; GREGORY J, 1772, DUTIES OFFICES PHYSI; HIGGINSON I, 1993, J PUBLIC HEALTH MED, V15, P3, DOI 10.1093/oxfordjournals.pubmed.a042817; HIPPOCRATES, 1972, JOINTS 8, V2, P299; Hippocrates, 1923, ART HIPPOCRATES, V2, P193; Kaldjian LC, 1998, AIDS, V12, P103, DOI 10.1097/00002030-199801000-00012; Limbird, 1996, GOODMAN GILMANS PHAR, P557; Lynn J, 1997, New Horiz, V5, P56; Nash A, 1989, Prof Nurse, V4, P443; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; PELLEGRINO ED, 1981, PHILOS BASIS MED PRA, P223; PIUS XII, 1957, ALLOCUTIO ACTA APOST, V49, P129; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; RANDALL F, 1996, PALLIATIVE CARE ETHI; Sulmasy DP, 1996, CLIN PULM MED, V3, P86; SURBONE A, 1997, COMMUNICATION CANC P; WOODRUFF R, 1993, PALLIATIVE MED SYMPT	23	34	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1521	1522		10.1001/jama.279.19.1521	http://dx.doi.org/10.1001/jama.279.19.1521			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605885				2022-12-01	WOS:000073608100013
J	Dodwell, DJ				Dodwell, DJ			Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions	LANCET			English	Editorial Material							BENEFIT		Cookridge Hosp, York Ctr Clin Oncol, Leeds LS16 6QB, W Yorkshire, England; Leeds Gen Infirm, Breast Unit, Leeds, W Yorkshire, England	Cookridge Hospital; Leeds General Infirmary; University of Leeds	Dodwell, DJ (corresponding author), Cookridge Hosp, York Ctr Clin Oncol, Leeds LS16 6QB, W Yorkshire, England.							ABE O, 1992, LANCET, V339, P71; COATES AS, 1992, INTRO NEW TREATMENTS, P448; *EARL BREAST CANC, 1992, LANCET, V339, P1; FETTING JH, 1990, J CLIN ONCOL, V8, P1476, DOI 10.1200/JCO.1990.8.9.1476; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; Gelber RD, 1996, LANCET, V347, P1066, DOI 10.1016/S0140-6736(96)90277-9; Hurny C, 1996, LANCET, V347, P1279; LINDLEY CM, 1995, P AN M AM SOC CLIN, V14, P149; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; McNeil C, 1997, J NATL CANCER I, V89, P838; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; RICHARDS MA, 1995, EUR J CANCER, V31A, P112, DOI 10.1016/0959-8049(94)00478-N; SAINSBURY R, 1995, BRIT J CANCER, V71, P1275, DOI 10.1038/bjc.1995.246; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458	14	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1506	1507		10.1016/S0140-6736(97)11247-8	http://dx.doi.org/10.1016/S0140-6736(97)11247-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605820				2022-12-01	WOS:000073707300043
J	Sinei, SK; Morrison, CS; Sekadde-Kigondu, C; Allen, M; Kokonya, D				Sinei, SK; Morrison, CS; Sekadde-Kigondu, C; Allen, M; Kokonya, D			Complications of use of intrauterine devices among HIV-1-infected women	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; INFECTION; TRANSMISSION; KENYA; RISK; CRITERIA; NAIROBI	Background A WHO expert group and the International Planned Parenthood Federation recommend against use of intrauterine devices (IUDs) in HIV-1-infected women based on theoretical concerns about pelvic infection and increased blood loss, We investigated whether the risk of complications after IUD insertion is higher in HIV-1-infected women than in non-infected women. Methods 649 (156 HIV-1 infected 493 non-infected) women in Nairobi, Kenya, who requested and met local eligibility criteria for insertion of an IUD were enrolled, We gathered information on IUD-related complications, including pelvic inflammatory disease, removals due to infection, pain, or bleeding, expulsions, and pregnancies at 1 and 4 months after insertion. Patients' HIV-1 status was masked from physicians. Findings Complications were identified in 48 of 615 women (11 [7.6%] HIV-1-infected women, 37 [7.9%] non-infected), Incident pelvic inflammatory disease (two [1.4%] HIV-1 infected, one [0.2%] non-infected) and infection-related complications (any tenderness, removal of IUD for infection or pain; ten [6.9%] HIV-1 infected, 27 [5.7%] non-infected) were also rare and similar in the two groups. Complication rates were similar by CD4 (immune) status. Multivariate analyses suggested no association between HIV-1 infection and increased risks for overall complications (odds ratio 0.8 [95% CI 0.4-1.7]) or infection-related complications (1.0 [0.5-2.3]), adjusted for marital status, study site, previous IUD use, ethnic origin, and frequency of sexual intercourse, but a slight increase cannot be ruled out. Interpretation Our data suggest that IUDs may be a safe contraceptive method for appropriately selected HIV-1-infected women with continuing access to medical services.	Family Hlth Int, Res Triangle Pk, NC 27709 USA; Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya	University of Nairobi	Morrison, CS (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	cmorrison@fhi.org	Kokonya, Donald/GLR-2492-2022	Kokonya, Donald/0000-0002-4206-9933				BRBOSA C, 1997, OBSTET GYNECOL, V89, P65; BUKUSI E, 1996, 11 INT C AIDS JUL; CARAEL M, 1988, AIDS, V2, P201; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; COHEN C, 1996, 11 INT C AIDS JUL; DEVINCENZI I, 1992, BRIT MED J, V304, P809; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; HAGER WD, 1983, OBSTET GYNECOL, V61, P113; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; *IPPF INT MED ADV, 1991, IPPF MED B, V25, P1; Kapiga SH, 1998, AIDS, V12, P75, DOI 10.1097/00002030-199801000-00009; KELSEY JL, 1986, METHODS OBSERVATIONA; KORN AP, 1993, OBSTET GYNECOL, V82, P765; LADIPO O A, 1991, Advances in Contraception, V7, P43, DOI 10.1007/BF01850718; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; MATI JKG, 1995, INT J GYNECOL OBSTET, V48, P61; MAULDIN WP, 1994, P 4 INT C IUDS, P1; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUSICCO M, 1994, P 4 INT C IUDS, P179; PLOURDE PJ, 1992, J INFECT DIS, V166, P86, DOI 10.1093/infdis/166.1.86; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; Sweet RL, 1997, LANCET, V349, P1265, DOI 10.1016/S0140-6736(05)62501-9; *UNAIDS WHO, 1997, REP GLOB HIV AIDS EP; *WHO, 1992, WKLY EPIDEMIOL REC, V67, P145; *WHO SCI WORK GROU, 1996, MED EL CRIT IN CONT	29	73	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1238	1241		10.1016/S0140-6736(97)10319-1	http://dx.doi.org/10.1016/S0140-6736(97)10319-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643743				2022-12-01	WOS:000073283600009
J	Godward, S; Dezateux, C				Godward, S; Dezateux, C		MRC Working Paryt Congenital Dislocation Hip	Surgery for congenital dislocation of the hip in the UK as a measure of outcome of screening	LANCET			English	Article							LATE DIAGNOSIS; MANAGEMENT; INFANTS	Background Universal clinical screening for congenital dislocation of the hip to detect hip instability in neonates was introduced in the UK as a national policy in 1969, but its effectiveness is not known. We aimed to assess the extent to which surgery for congenital dislocation of the hip is the result of a failure of detection through screening or follows non-surgical treatment after detection by screening. Methods We established a national orthopaedic surveillance scheme and used routine hospital data for inpatients for 20% of births in the UK (Scotland and the Northern and Wessex regions) to ascertain the number of children aged under 5 years per 1000 livebirths who had received at lease one operative procedure for congenital dislocation of the hip from April, 1993, to April, 1994. Estimates of the incidence of operative procedures were adjusted for under-ascertainment by capture-recapture techniques. Findings The ascertainment-adjusted incidence of a first operative procedure for congenital dislocation of the hip in the UK was 0.78 per 1000 livebirths (95% CI 0.72-0.84). Congenital dislocation of the hip had not been detected by routine screening in 222 (70%) of 318 children reported to the national orthopaedic surveillance scheme. In 112 (35%) children the diagnosis was made primarily as a result of parental concern. 67 (21%) children had previously received non-surgical treatment. In Scotland and the Northern and Wessex regions, 81 cases were notified to the national orthopaedic surveillance scheme, 62 cases were identified only through routine hospital data on inpatients, and an estimated 20 cases were not identified by either source, making a total of 163 cases. Thus, 81 (50%) of these 163 cases were identified by surveillance, 125 (77%) by routine data, and 143 (88%) by both sources. Interpretation The incidence of a first operative procedure for congenital dislocation of the hip in the UK was similar to that reported before screening was introduced. In most children who received surgery, congenital dislocation of the hip was not detected by screening, Formal evaluation of current and alternative screening policies, including universal primary ultrasound imaging, is needed.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Dezateux, C (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.	c.dezateux@ich.ucl.ac.uk	Dezateux, Carol/A-3416-2009	Dezateux, Carol/0000-0001-9787-6276				BENNET GC, 1992, J BONE JOINT SURG BR, V74, P643, DOI 10.1302/0301-620X.74B5.1527106; CATFORD JC, 1982, BMJ-BRIT MED J, V285, P1527, DOI 10.1136/bmj.285.6354.1527; CATTERALL A, 1994, J BONE JOINT SURG BR, V76B, P515, DOI 10.1302/0301-620X.76B4.8027129; DAVID TJ, 1983, LANCET, V2, P147; Dezateux C, 1996, ARCH DIS CHILD, V74, P445, DOI 10.1136/adc.74.5.445; Dezateux C, 1995, J Med Screen, V2, P200; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; GODWARD S, 1996, ARCH DIS CHILD, V75, P1; Hall S M, 1988, Arch Dis Child, V63, P344; HEY K, 1994, ARCH DIS CHILD-FETAL, V71, pF198, DOI 10.1136/fn.71.3.F198; Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192; KNOX EG, 1987, J EPIDEMIOL COMMUN H, V41, P283, DOI 10.1136/jech.41.4.283; LECK I, 1986, J ROY COLL PHYS LOND, V20, P56; LECK I, 1968, TERATOLOGY, V1, P263, DOI 10.1002/tera.1420010305; LENNOX IAC, 1993, J BONE JOINT SURG BR, V75, P72, DOI 10.1302/0301-620X.75B1.8421040; MacFarlane A, 1980, J MATERN CHILD HLTH, V5, P13; MACKENZIE IG, 1981, J BONE JOINT SURG BR, V63, P38, DOI 10.1302/0301-620X.63B1.7204472; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; *OFF NAT STAT, 1996, POP TRENDS, P84; *OFF POP CENS SURV, 1993, CLASS SURG OP PROC; PATTERSON CC, 1995, PAEDIATR PERINAT EP, V9, P90, DOI 10.1111/j.1365-3016.1995.tb00121.x; PLACE MJ, 1978, LANCET, V2, P249; RAO S, 1986, NEW ZEAL MED J, V99, P752; RECORD R G, 1958, Br J Prev Soc Med, V12, P8; RICHARDS ID, 1971, BRIT J PREV SOC MED, V25, P59; SANFRIDSON J, 1991, ACTA ORTHOP SCAND, V62, P87, DOI 10.3109/17453679108999228; SMITHELLS RW, 1968, BRIT J PREV SOC MED, V22, P36; *STAND MED ADV COM, 1969, SCREEN DET CONG DISL; Standing Medical Advisory Committee and the Standing Nursing and Midwifery Advisory Committee, 1986, SCREEN DET CONG DISL; STONE DH, 1992, AM J EPIDEMIOL, V136, P498, DOI 10.1093/oxfordjournals.aje.a116523; TREDWELL SJ, 1992, CLIN ORTHOP RELAT R, P63; *WHO, 1977, MAN INT STAT CLASS D; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1047; YNGVE D, 1990, J PEDIATR ORTHOPED, V10, P777, DOI 10.1097/01241398-199011000-00013; 1991, LANCET, V337, P947	35	92	93	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1149	1152		10.1016/S0140-6736(97)10466-4	http://dx.doi.org/10.1016/S0140-6736(97)10466-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643684				2022-12-01	WOS:000073220200006
J	Colavita, A; Krishna, S; Zheng, H; Padgett, RW; Culotti, JG				Colavita, A; Krishna, S; Zheng, H; Padgett, RW; Culotti, JG			Pioneer axon guidance by UNC-129, a C-elegans TGF-beta	SCIENCE			English	Article							GROWTH-FACTOR-BETA; DAUER LARVA DEVELOPMENT; CAENORHABDITIS-ELEGANS; TRANSFORMING GROWTH-FACTOR-BETA-2; 3-DIMENSIONAL STRUCTURE; COLORECTAL-CANCER; NETRIN CUES; GENE; RECEPTOR; ENCODES	The unc-129 gene, Like the unc-6 netrin gene, is required.to guide pioneer motoraxons along the dorsoventral axis of Caenorhabditis elegans. unc-129 encodes a member of the transforming growth factor-beta (TGF-beta) superfamily of secreted signaling molecules and is expressed in dorsal, but not ventral, rows of body wall muscles. Ectopic expression of UNC-129 from ventral body wall muscle disrupts growth cone and cell migrations that normally occur along the dorsoventral axis. Thus, UNC-129 mediates expression of dorsoventral polarity information required for axon guidance and guided cell migrations in C. elegans.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Rutgers State Univ, Waksman Inst, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Culotti, JG (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	culotti@mshri.on.ca	Culotti, Joseph/G-6467-2013	Culotti, Joseph/0000-0001-6325-4612; Colavita, Antonio/0000-0001-9391-5282				[Anonymous], [No title captured]; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; COLAVITA A, UNPUB; DURBIN RM, 1987, THESIS KINGS COLL CA; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NASH B, UNPUB; OKKEMA PG, 1993, GENETICS, V135, P385; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Su M.-D., UNPUB; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	27	185	199	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					706	709		10.1126/science.281.5377.706	http://dx.doi.org/10.1126/science.281.5377.706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685266				2022-12-01	WOS:000075107900045
J	Leon, DA; Lithell, HO; Vagero, D; Koupilova, I; Mohsen, R; Berglund, L; Lithell, UB; McKeigue, PM				Leon, DA; Lithell, HO; Vagero, D; Koupilova, I; Mohsen, R; Berglund, L; Lithell, UB; McKeigue, PM			Reduced fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 Swedish men and women born 1915-29	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; ADULT LIFE; INFANCY	Objective: To establish whether fetal growth rate (as distinct from size at birth) is associated with mortality from ischaemic heart disease. Design: Cohort study based on uniquely detailed obstetric records with 97% follow up over the entire life course and linkage to census data in adult life. Subjects: All 14 611 babies delivered at the Uppsala Academic Hospital, Sweden, during 1915-29 followed up to end of 1995. Main outcome measures: Mortality from ischaemic heart disease and other causes. Results: Cardiovascular disease showed an inverse association with birth weight for both men and women, although this was significant only for men. In men a 1000 g increase in birth weight was associated with a proportional reduction in the rate of ischaemic heart disease of 0.77 (95% confidence interval 0.67 to 0.90). Adjustment for socioeconomic circumstances at birth and in adult life led to slight attenuation of this effect Relative to the lowest fourth of birth weight for gestational age, mortality from ischaemic heart disease in men in the second, third, and fourth fourths was 0.81 (0.66 to 0.98), 0.63 (0.50 to 0.78), and 0.67 (0.54 to 0.82), respectively The inclusion of birth weight per se and birth weight for gestational age in the same model strengthened the association with birth weight for gestational age but removed the association with birth weight Conclusion: This study provides by far the most persuasive evidence of a real association between size at birth and mortality from ischaemic heart disease in men, which cannot be explained by methodological artefact or socioeconomic confounding. It strongly suggests that it is variation in fetal growth rate rather than size at birth that is aetiologically important.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Uppsala Univ, Inst Geriatr, S-75125 Uppsala, Sweden; Univ Stockholm, Dept Sociol, S-10691 Stockholm, Sweden	University of London; London School of Hygiene & Tropical Medicine; Uppsala University; Stockholm University	Leon, DA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, Keppel St, London WC1E 7HT, England.	dleon@lshtm.ac.uk	Leon, David A/G-2195-2010; Berglund, Lars/AAD-3856-2019; Berglund, Lars/AAA-3188-2019; Koupil, Ilona/AAC-9067-2020	Leon, David A/0000-0001-9747-1762; Berglund, Lars/0000-0002-7437-9047; Koupil, Ilona/0000-0002-7034-1922; Vagero, Denny/0000-0002-1854-2292				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Erikson Robert, 1992, CONSTANT FLUX STUDY; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; Joseph KS, 1996, EPIDEMIOL REV, V18, P158, DOI 10.1093/oxfordjournals.epirev.a017923; KOUPILOVA I, 1996, J EPIDEMIOL COMMUNIT, V50, P592; KOUPILOVA I, 1997, J HYPERTENS       S4, V15, P46; KOUPILOVA I, 1997, ACTA U UPSAL, V698, P7; KRAMER MS, 1990, PEDIATRICS, V86, P707; KRAMER MS, 1987, PEDIATRICS, V80, P502; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LEON DA, 1997, LIFE COURSE INFLUENC; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROTHWELL PM, 1994, LANCET, V343, P731, DOI 10.1016/S0140-6736(94)91610-1; *STAT CORP, 1997, STAT REF MAN REL 5; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Vik T, 1997, EARLY HUM DEV, V48, P167, DOI 10.1016/S0378-3782(96)01852-X	24	574	584	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 25	1998	317	7153					241	245		10.1136/bmj.317.7153.241	http://dx.doi.org/10.1136/bmj.317.7153.241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677213	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000075081900020
J	Ron, E; Doddy, MM; Becker, DV; Brill, AB; Curtis, RE; Goldman, MB; Harris, BSH; Hoffman, DA; McConahey, WM; Maxon, HR; Preston-Martin, S; Warshauer, ME; Wong, FL; Boice, JD				Ron, E; Doddy, MM; Becker, DV; Brill, AB; Curtis, RE; Goldman, MB; Harris, BSH; Hoffman, DA; McConahey, WM; Maxon, HR; Preston-Martin, S; Warshauer, ME; Wong, FL; Boice, JD		Cooperative Thyrotoxicosis Therapy Follow Stud	Cancer mortality following treatment for adult hyperthyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THYROID-CANCER; I-131 THERAPY; GRAVES-DISEASE; THYROTOXICOSIS; CARCINOMA; WOMEN; RISK	Context.-High-dose iodine 131 is the treatment of choice in the United States for most adults with hyperthyroid disease. Although there is little evidence to link therapeutic I-131 to the development of cancer, its extensive medical use indicates the need for additional evaluation. Objective.-To evaluate cancer mortality among hyperthyroid patients, particularly after I-131 treatment. Design.-A retrospective cohort study. Setting.-Twenty-five clinics in the United States and 1 clinic in England. Patients.-A total of 35 593 hyperthyroid patients treated between 1946 and 1964 in the original Cooperative Thyrotoxicosis Therapy Follow-up Study; 91% had Graves disease, 79% were female, and 65% were treated with I-131. Main Outcome Measure.-Standardized cancer mortality ratios (SMRs) after 3 treatment modalities for hyperthyroidism. Results.-Of the study cohort, 50.5% had died by the end of follow-up in December 1990. The total number of cancer deaths was close to that expected based on mortality rates in the general population (2950 vs 2857.6), but there was a small excess of mortality from cancers of the lung, breast, kidney, and thyroid, and a deficit of deaths from cancers of the uterus and the prostate gland. Patients with toxic nodular goiter had an SMR of 1.16 (95% confidence interval [CI], 1.03-1.30). More than 1 year after treatment, an increased risk of cancer mortality was seen among patients treated exclusively with antithyroid drugs (SMR, 1.31; 95% CI, 1.06-1.60). Radioactive iodine was not linked to total cancer deaths (SMR, 1.02; 95% CI, 0.98-1.07) or to any specific cancer with the exception of thyroid cancer (SMR, 3.94; 95% CI, 2.52-5.86). Conclusions.-Neither hyperthyroidism nor I-131 treatment resulted in a significantly increased risk of total cancer mortality. While there was an elevated risk of thyroid cancer mortality following I-131 treatment, in absolute terms the excess number of deaths was small, and the underlying thyroid disease appeared to play a role. Overall, I-131 appears to be a safe therapy for hyperthyroidism.	NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA; Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA; Vanderbilt Univ, Nashville, TN USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; George Washington Univ, Washington, DC 20052 USA; Mayo Clin, Rochester, MN USA; Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; Univ So Calif, Los Angeles, CA 90089 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; NewYork-Presbyterian Hospital; Vanderbilt University; Harvard University; Harvard T.H. Chan School of Public Health; Research Triangle Institute; George Washington University; Mayo Clinic; University System of Ohio; University of Cincinnati; University of Southern California	Ron, E (corresponding author), NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA.		Brill, Aaron/H-3732-2014	Brill, Aaron/0000-0001-7538-086X	NCI NIH HHS [N01-CP-41060] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP041060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Becker David V., 1996, P943; BECKER DV, 1989, RAD THYROID, P57; BECKER DV, 1971, FURTHER ADV THYROID, P603; Cox DR, 1979, THEORETICAL STAT; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; DOBYNS BM, 1977, RAD ASS THYROID CARC, P459; FRANCESCHI S, 1989, INT J EPIDEMIOL, V18, P578, DOI 10.1093/ije/18.3.578; FURSZYFE.J, 1972, METABOLISM, V21, P197, DOI 10.1016/0026-0495(72)90041-8; GLOBEL B, 1989, RAD RISK PROTECTOIN, P565; GOLDMAN MB, 1990, CANCER RES, V50, P2283; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; GRAHAM GD, 1986, ANN INTERN MED, V105, P900, DOI 10.7326/0003-4819-105-6-900; GREEN M, 1961, BRIT MED J, V1, P210; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HALL P, 1992, INT J CANCER, V50, P886, DOI 10.1002/ijc.2910500611; Hall P, 1996, RADIAT RES, V145, P86, DOI 10.2307/3579200; HALNAN KE, 1983, BMJ-BRIT MED J, V287, P8121; HANCOCK BW, 1977, CANCER, V39, P298, DOI 10.1002/1097-0142(197701)39:1<298::AID-CNCR2820390146>3.0.CO;2-C; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOFFMAN DA, 1982, INT J EPIDEMIOL, V11, P218, DOI 10.1093/ije/11.3.218; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1988, JNCI-J NATL CANCER I, V80, P1132, DOI 10.1093/jnci/80.14.1132; *INT COMM RAD PROT, 1988, ANN ICRP, V18, P275; KLEIN I, 1994, ANN INTERN MED, V121, P281, DOI 10.7326/0003-4819-121-4-199408150-00010; LOEVINGER R, 1956, RAD DOSIMETRY, P870; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; Preston DL, 1993, EPICURE USERS GUIDE; RON E, 1987, JNCI-J NATL CANCER I, V79, P1; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SAENGER EL, 1968, J AMER MED ASSOC, V205, P855, DOI 10.1001/jama.205.12.855; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Tompkins E, 1970, MED RADIONUCLIDES RA, P431; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; *US DHEW, 1967, PHS PUBL, V1693; Volpe R, 1989, THYROID FUNCTION DIS, P214; WILLIAMS ED, 1986, LANCET, V2, P456; World Health Organization, 1957, MAN INT STAT CLASS D; ZANZONICO P B, 1989, Journal of Nuclear Medicine, V30, P833	39	247	268	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					347	355		10.1001/jama.280.4.347	http://dx.doi.org/10.1001/jama.280.4.347			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686552	Bronze			2022-12-01	WOS:000074804200035
J	Martyn, CN; Gale, CR; Jespersen, S; Sherriff, SB				Martyn, CN; Gale, CR; Jespersen, S; Sherriff, SB			Impaired fetal growth and atherosclerosis of carotid and peripheral arteries	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; ADULT LIFE; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; IN-UTERO; DEATH; MEN; BIRTH; WEIGHT; SIZE	Background Although epidemiological studies suggest that people with low birthweight are at higher risk of coronary heart disease and stroke in adult life than those of higher birthweight, the mechanisms underlying this relation are unclear. We investigated whether impaired fetal growth leads to an increased risk of atherosclerosis by assessment of the carotid and lower-limb arteries in a group of people aged around 70 years for whom birthweight data were available. Methods 2232 singleton babies were born to married mothers at a maternity hospital in Sheffield, UK, between 1922 and 1926, and had complete birth records. We traced 829 survivors and invited 395 who still lived in Sheffield to take part in this study. 322 agreed; they were interviewed at home and 181 underwent duplex ultrasonographic examination of the extracranial parts of the carotid arteries. Atherosclerosis in the arteries of the lower limb was assessed in 186 people by the ankle brachial-pressure index (ABPI). Findings The prevalence and severity of carotid atherosclerosis was greatest in those with the lowest recorded birthweight. The risk of carotid stenosis was greater for people who had weighed 6.5 lb or less at birth than for those who weighed over 7.5 lb (odds ratio 5.3 [95% CI 2.0-14.0]), after adjustment for cardiovascular risk factors and gestational age at birth. The odds ratio for atherosclerotic disease in the lower limbs (low ABPI) was highest in people with the lowest recorded birthweight, but this relation was not significant (odds ratio 2.3 [1.0-5.6]). Interpretation Increased atherogenesis may be one mechanism mediating the observed epidemiological link between impaired fetal growth and cardiovascular disease. Adaptations made by the fetus in response to influences that retard its growth may have long-term consequences for the structure and metabolism of the vascular system.	Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; No Gen Hosp, Dept Med Phys, Sheffield S5 7AU, S Yorkshire, England	University of Southampton; Northern General Hospital	Martyn, CN (corresponding author), Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.	c.martyn@mrc.soton.ac.uk	Gale, Catharine R/B-1653-2012					ALLAN PLP, 1991, EPIDEMIOLOGY PERIPHE, P41; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; GIRAL P, 1991, ARCH INTERN MED, V151, P950, DOI 10.1001/archinte.151.5.950; JOENSUU T, 1994, J INTERN MED, V236, P79; KOUPILOVA I, 1996, J EPIDEMIOL COMMUNIT, V50, P592; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; Martyn CN, 1996, BRIT MED J, V312, P1393; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Pasterkamp G, 1998, ATHEROSCLEROSIS, V137, P205, DOI 10.1016/S0021-9150(97)00255-4; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; RIZZO G, 1991, AM J OBSTET GYNECOL, V165, P876, DOI 10.1016/0002-9378(91)90431-P; SALONEN JT, 1993, CIRCULATION, V87, P56; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; SUTTON KC, 1987, STROKE, V18, P817, DOI 10.1161/01.STR.18.5.817	23	125	128	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					173	178		10.1016/S0140-6736(97)10404-4	http://dx.doi.org/10.1016/S0140-6736(97)10404-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683205				2022-12-01	WOS:000074859800009
J	Buchel, C; Price, C; Friston, K				Buchel, C; Price, C; Friston, K			A multimodal language region in the ventral visual pathway	NATURE			English	Article							TEMPORAL-LOBE; CORTEX; EXTRASTRIATE; WORDS; ACTIVATION; IMPAIRMENT; ALEXIA; OBJECT; FACES; AREA	Reading words and naming pictures involves the association of visual stimuli with phonological and semantic knowledge. Damage to a region of the brain in the left basal posterior temporal lobe (BA37), which is strategically situated between the visual cortex and the more anterior temporal cortex, leads to reading and naming deficits(1,2). Additional evidence implicating this region in linguistic processing comes from functional neuroimaging studies of reading in normal subjects(3-7) and subjects with developmental dyslexia(8,9). Here we test whether the visual component of reading is essential for activation of BA37 by comparing cortical activations elicited by word processing in congenitally blind, late-blind and sighted subjects using functional neuroimaging. Despite the different modalities used (visual and tactile), all groups of subjects showed a common activation of BA37 by words relative to non-word letter-strings. These findings agree with the proposal that BA37 is an association area that integrates converging inputs from many regions(10). Our study confirms a prediction of theories of brain function that depend on convergence zones; the absence of one input (that is, visual) does not alter the response properties of such a convergence region.	Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London	Buchel, C (corresponding author), Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.		Friston, Karl/D-9230-2011	Friston, Karl/0000-0001-7984-8909; Price, Catherine/0000-0001-7448-4835	Wellcome Trust [051067] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLISON T, 1994, CEREB CORTEX, V4, P544, DOI 10.1093/cercor/4.5.544; Bookheimer SY, 1995, HUM BRAIN MAPP, V3, P93, DOI 10.1002/hbm.460030206; BRUNSWICK N, UNPUB BRAIN; Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; BURNSTINE TH, 1990, NEUROLOGY, V40, P966, DOI 10.1212/WNL.40.6.966; Damasio A., 1994, LARGE SCALE NEURONAL, P61; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; DEsposito M, 1997, NEUROPSYCHOLOGIA, V35, P725, DOI 10.1016/S0028-3932(96)00121-2; FARAH MJ, 1990, VISUAL AGNOSIA; FIEZ JA, 1995, J COGNITIVE NEUROSCI, V7, P357, DOI 10.1162/jocn.1995.7.3.357; Foundas AL, 1998, NEUROCASE, V4, P35, DOI 10.1093/neucas/4.1.35; Friedman RF, 1993, CLIN NEUROPSYCHOLOGY, P37; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Kanwisher N, 1997, J NEUROSCI, V17, P4302; LUDERS H, 1986, NEUROLOGY, V36, P505, DOI 10.1212/WNL.36.4.505; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1997, NEUROIMAGE, V5, P261, DOI 10.1006/nimg.1997.0269; Puce A, 1996, J NEUROSCI, V16, P5205; RAPCSAK SZ, 1987, BRAIN LANG, V31, P109, DOI 10.1016/0093-934X(87)90063-0; Rumsey JM, 1997, ARCH NEUROL-CHICAGO, V54, P562, DOI 10.1001/archneur.1997.00550170042013; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; SUZUKI WA, 1993, J NEUROSCI, V13, P2430, DOI 10.1523/JNEUROSCI.13-06-02430.1993; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3	28	298	304	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					274	277		10.1038/28389	http://dx.doi.org/10.1038/28389			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685156				2022-12-01	WOS:000074851900047
J	Grant, PA; Schieltz, D; Pray-Grant, MG; Steger, DJ; Reese, JC; Yates, JR; Workman, JL				Grant, PA; Schieltz, D; Pray-Grant, MG; Steger, DJ; Reese, JC; Yates, JR; Workman, JL			A subset of TAF(II)s are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation	CELL			English	Article							TATA-BINDING PROTEIN; YEAST SWI/SNF COMPLEX; HISTONE ACETYLATION; X-CHROMOSOME; ACTIVATION; CHROMATIN; H4; ENHANCEMENT; REPRESSION; CELLS	A number of transcriptional coactivator proteins have been identified as histone acetyltransferase (HAT) proteins, providing a direct molecular basis for the coupling of histone acetylation and transcriptional activation. The yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex requires the coactivator protein Gcn5 for HAT activity. Identification of protein subunits by mass spectrometry and immunoblotting revealed that the TATA binding protein-associated factors (TAF(II)s) TAF(II)90, -68/61, -60, -25/23, and -20/17 are integral components of this complex. in addition, TAF(II)68 was required for both SAGA-dependent nucleosomal HAT activity and transcriptional activation from chromatin templates in vitro. These results illustrate a role for certain TAF(II) proteins in the regulation of gene expression at the level of chromatin modification that is distinct from the TFIID complex and TAF(II)145.	Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Washington, Hlth Sci Ctr, Dept Mol Biotechnol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Washington; University of Washington Seattle	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, University Pk, PA 16802 USA.				PHS HHS [11823-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GAITLIN CL, 1998, IN PRESS J ANAL BIOC; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Johnson CA, 1998, NUCLEIC ACIDS RES, V26, P994, DOI 10.1093/nar/26.4.994; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakatani Y, 1996, J BIOL CHEM, V271, P6575, DOI 10.1074/jbc.271.12.6575; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; UTLEY RT, 1998, IN PRESS NATURE; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Welihinda AA, 1997, P NATL ACAD SCI USA, V94, P4289, DOI 10.1073/pnas.94.9.4289; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YATES JR, 1994, CELL BIOL LABORATORY, P380	59	376	395	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					45	53		10.1016/S0092-8674(00)81220-9	http://dx.doi.org/10.1016/S0092-8674(00)81220-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674426	Bronze			2022-12-01	WOS:000074790800008
J	Schnitzler, G; Sif, S; Kingston, RE				Schnitzler, G; Sif, S; Kingston, RE			Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state	CELL			English	Article							TRANSCRIPTIONAL ACTIVATORS; RETINOBLASTOMA PROTEIN; CHROMATIN STRUCTURE; COMPLEX; DNA; BINDING; DISRUPTION; SEQUENCES; RECEPTOR; FAMILY	The human SWI/SNF complex remodels nucleosome structure in an ATP-dependent manner, although the nature of this change has not been determined. Here we show that hSWI/SNF and ATP generate an altered nucleosomal structure that is stable in the absence of SWI/SNF. This product has an altered sensitivity to digestion by DNAse, restriction enzymes, and micrococcal nuclease, and an increased affinity for GAL4. It has the same protein composition but is approximately twice the size of a normal nucleosome. Incubation of the altered nucleosome with hSWI/SNF converts this structure back to a standard nucleosome in an ATP-dependent process. These results suggest that hSWI/SNF acts by facilitating an exchange between normal and altered, more accessible, nucleosome conformations.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA.		Sif, Said/AAE-5554-2019	Sif, Said/0000-0001-6268-1145				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; NOLL H, 1989, METHOD ENZYMOL, V170, P55; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Strober BE, 1996, MOL CELL BIOL, V16, P1576; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Utley RT, 1996, METHOD ENZYMOL, V274, P276; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU HM, 1979, BIOCHEMISTRY-US, V18, P3960, DOI 10.1021/bi00585a018	36	246	249	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					17	27		10.1016/S0092-8674(00)81217-9	http://dx.doi.org/10.1016/S0092-8674(00)81217-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674423	Bronze			2022-12-01	WOS:000074790800005
J	Nightingale, SL				Nightingale, SL			Advisory on need for caution with use of vacuum-assisted delivery devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-01	WOS:000074379400006
J	McWhinney, IR				McWhinney, IR			Primary care: core values - Core values in a changing world	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; GENERAL-PRACTITIONERS; COMMUNITY		Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	McWhinney, IR (corresponding author), Univ Western Ontario, Ctr Studies Family Med, Dept Family Med, London, ON N6A 5C1, Canada.							Brown JB, 1997, CAN FAM PHYSICIAN, V43, P901; Carmichael LP, 1997, AM FAM PHYSICIAN, V56, P713; Dostoevsky Fyodor, 1958, BROTHERS KARAMAZOV; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; HART JT, 1970, LANCET, V2, P223; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; *I MED, 1978, IOM PUBL, V7302; MacIntyre A., 1984, VIRTUE STUDY MORAL T; MAY WF, 1983, PHYSICIANS COVENANT; MCCORMICK J, 1994, LANCET, V344, P390; Nutting P A, 1986, Am J Prev Med, V2, P140; NUTTING PA, 1986, AM J PUBLIC HEALTH, V76, P279, DOI 10.2105/AJPH.76.3.279; SALTMAN DC, 1995, MED J AUSTRALIA, V162, P3, DOI 10.5694/j.1326-5377.1995.tb138397.x; SMITH LFP, 1994, J MED ETHICS, V20, P175, DOI 10.1136/jme.20.3.175; Stewart M., 1995, PATIENT CTR MED PATIENT CTR MED; VEALE BM, 1996, THESIS AUSTR NATL U; WHITE KL, 1987, INT CLASSIFICATION P; Wilber K., 1995, SEX ECOLOGY SPIRITUA; World Health Organisation, 1978, ALM 1978 PRIM HLTH C; WRIGHT RA, 1993, JAMA-J AM MED ASSOC, V269, P2544, DOI 10.1001/jama.269.19.2544	21	89	89	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1807	1809		10.1136/bmj.316.7147.1807	http://dx.doi.org/10.1136/bmj.316.7147.1807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624075	Green Published			2022-12-01	WOS:000074286300032
J	Zou, YR; Kottmann, AH; Kuroda, M; Taniuchi, I; Littman, DR				Zou, YR; Kottmann, AH; Kuroda, M; Taniuchi, I; Littman, DR			Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development	NATURE			English	Article							NERVOUS-SYSTEM; BONE-MARROW; LYMPHOCYTE CHEMOATTRACTANT; HIV-1 ENTRY; CELL-LINE; SDF-1; LESTR/FUSIN; EXPRESSION; MIGRATION; LIGAND	Chemokines and their receptors are important in cell migration during inflammation(1), in the establishment of functional lymphoid microenvironments(2), and in organogenesis(3). The chemokine receptor CXCR4 is broadly expressed in cells of both the immune and the central nervous systems(4,5) and can mediate migration of resting leukocytes and haematopoietic progenitors in response to its ligand, SDF-1 (refs 6-9). CXCR4 is also a major receptor for strains of human immunodeficiency virus-1 (HIV-1) that arise during progression to immunodeficiency and AIDS dementia(10). Here we show that mice lacking CXCR4 exhibit haematopoietic and cardiac defects identical to those of SDF-1-deficient mice(3), indicating that CXCR4 may be the only receptor for SDF-1. Furthermore, fetal cerebellar development in mutant animals is markedly different from that in wild-type animals, with many proliferating granule cells invading the cerebellar anlage. This is, to our knowledge, the first demonstration df the involvement of a G-protein-coupled chemokine receptor in neuronal cell migration and patterning in the central nervous system. These results may be important for designing strategies to block HIV entry into cells and for understanding mechanisms of pathogenesis in AIDS dementia.	NYU, Med Ctr, Div Mol Pathogenesis, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	New York University; Howard Hughes Medical Institute; New York University; Columbia University	Zou, YR (corresponding author), NYU, Med Ctr, Div Mol Pathogenesis, New York, NY 10016 USA.	zou@saturn.med.nyu.edu	Taniuchi, Ichiro/N-6399-2015; Kottmann, Andreas/Y-1180-2019	Taniuchi, Ichiro/0000-0002-9853-9068; Kottmann, Andreas/0000-0002-5435-7502				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; Jazin EE, 1997, J NEUROIMMUNOL, V79, P148, DOI 10.1016/S0165-5728(97)00117-3; LANDRETH KS, 1988, J IMMUNOL, V140, P845; Moepps B, 1997, EUR J IMMUNOL, V27, P2102, DOI 10.1002/eji.1830270839; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0	29	2008	2114	1	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					595	599		10.1038/31269	http://dx.doi.org/10.1038/31269			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634238				2022-12-01	WOS:000074150100057
J	Boardman, LA; Thibodeau, SN; Schaid, DJ; Lindor, NM; McDonnell, SK; Burgart, LJ; Ahlquist, DA; Podratz, KC; Pittelkow, M; Hartmann, LC				Boardman, LA; Thibodeau, SN; Schaid, DJ; Lindor, NM; McDonnell, SK; Burgart, LJ; Ahlquist, DA; Podratz, KC; Pittelkow, M; Hartmann, LC			Increased risk for cancer in patients with the Peutz-Jeghers syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						Peutz-Jeghers syndrome; genital neoplasms, female; breast neoplasms; gastrointestinal neoplasms; risk	SEX CORD TUMOR; ANNULAR TUBULES; POLYPOSIS SYNDROMES; ADENOMA-MALIGNUM	Background: Some reports describe an increased risk for cancer in patients with the Peutz-Jeghers syndrome. Objective: To characterize occurrences of cancer in a large cohort of patients with the Peutz-Jeghers syndrome. Design: Retrospective cohort study. Setting: Tertiary care center. Patients: 34 patients with the Peutz-Jeghers syndrome identified from Mayo Clinic records from 1945 to 1996. Measurements: Cases of cancer documented by chart review and telephone follow-up. Results: 26 cases of noncutaneous cancer developed in 18 of the 34 patients: 10 cases of gastrointestinal cancer and 16 cases of extraintestinal cancer. With the use of SEER (Surveillance, Epidemiology, and End Results) data for comparison, the relative risk for cancer was 18.5 (95% CI, 8.5 to 35.2) in women with the Peutz-Jeghers syndrome and 6.2 (CI, 2.5 to 12.8) in men with the syndrome (P = 0.001). In women, the relative risk for breast and gynecologic cancer was 20.3 (CI, 7.4 to 44.2). Conclusions: The Peutz-Jeghers syndrome is associated with an increased risk for cancer. The relative risk for breast and gynecologic cancers is particularly high.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Hartmann, LC (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.			McDonnell, Shannon/0000-0001-6201-369X				Amos CI, 1997, CANCER RES, V57, P3653; CANTU JM, 1980, CANCER, V46, P223, DOI 10.1002/1097-0142(19800701)46:1<223::AID-CNCR2820460137>3.0.CO;2-8; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; COHEN PR, 1991, AM J MED, V90, P606; DOZOIS RR, 1969, ARCH SURG-CHICAGO, V98, P509; DUBOIS RS, 1982, J PEDIATR-US, V101, P568, DOI 10.1016/S0022-3476(82)80705-1; FINAN MC, 1989, DERMATOL CLIN, V7, P419, DOI 10.1016/S0733-8635(18)30575-8; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gilchrist DM, 1997, CAN J GASTROENTEROL, V11, P421, DOI 10.1155/1997/859106; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kleinbaum D.G., 1982, EPIDEMIOLOGIC RES PR, P1; LINOS DA, 1981, ARCH SURG-CHICAGO, V116, P1182; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5; NUSS DD, 1978, ARCH DERMATOL, V114, P743, DOI 10.1001/archderm.114.5.743; *SEER PROGR, 1993, NIH PUB; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; SRIVATSA PJ, 1994, GYNECOL ONCOL, V53, P256, DOI 10.1006/gyno.1994.1127; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5	20	284	302	3	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					896	+		10.7326/0003-4819-128-11-199806010-00004	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634427				2022-12-01	WOS:000073808600003
J	Mindel, A				Mindel, A			Genital herpes - how much of a public-health problem?	LANCET			English	Article							SIMPLEX VIRUS TYPE-2; RISK-FACTORS; INFECTION; PREVALENCE; TRANSMISSION; VALACICLOVIR; EPIDEMIOLOGY; FAMCICLOVIR; FREQUENCY; ANTIBODY		Sydney Hosp, Acad Unit Sexual Hlth Med, Sydney, NSW 2001, Australia		Mindel, A (corresponding author), Sydney Hosp, Acad Unit Sexual Hlth Med, GPO Box 1614, Sydney, NSW 2001, Australia.	amindel@mail.usyd.edu.au		Mindel, Adrian/0000-0002-8780-9982				Ashley RL, 1997, GENITOURIN MED, V73, P235; BASSETT I, 1994, MED J AUSTRALIA, V160, P697, DOI 10.5694/j.1326-5377.1994.tb125907.x; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; CAMERON DW, 1989, LANCET, V2, P403; CARNEY O, 1993, GENITOURIN MED, V69, P457; *CDCP, 1982, MMWR-MORBID MORTAL W, V31, P137; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1997, 37 INT C ANT AG CHEM; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; Fairley I, 1997, GENITOURIN MED, V73, P259; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; *GOV STAT SERV, 1996, SEX TRANSM DIS ENGL, P1; Huerta K, 1996, J ADOLESCENT HEALTH, V18, P384, DOI 10.1016/1054-139X(96)00019-5; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; Langeland N, 1998, INT J STD AIDS, V9, P104, DOI 10.1258/0956462981921765; MEHEUS A, 1983, SEX TRANSM DIS, V10, P33, DOI 10.1097/00007435-198301000-00007; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MINDEL A, 1995, ANTIVIRAL CHEMOTHERA; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PERSSON K, 1995, SCAND J INFECT DIS, V27, P195, DOI 10.3109/00365549509019008; Rosenthal SL, 1997, CLIN INFECT DIS, V24, P135, DOI 10.1093/clinids/24.2.135; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SMITH J, 1997, HERPES, V4, P55; Spruance SL, 1996, ARCH INTERN MED, V156, P1729, DOI 10.1001/archinte.156.15.1729; TAYAL SC, 1994, INT J STD AIDS, V5, P359, DOI 10.1177/095646249400500514; Thackray AM, 1996, ANTIMICROB AGENTS CH, V40, P846, DOI 10.1128/AAC.40.4.846; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WHITLEY RJ, 1993, J MED VIROL, P13	34	39	39	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN	1998	351			3			16	18						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV844	9652715				2022-12-01	WOS:000074347300006
J	Anderson, GB; Seidel, GE				Anderson, GB; Seidel, GE			Developmental biology - Cloning for profit	SCIENCE			English	Article							SHEEP EMBRYOS; NUCLEAR TRANSPLANTATION; INVIVO		Univ Calif Davis, Dept Anim Sci, Livermore, CA 95616 USA; Colorado State Univ, Anim Reprod & Biotechnol Lab, Ft Collins, CO 80523 USA	University of California System; University of California Davis; Colorado State University	Anderson, GB (corresponding author), Univ Calif Davis, Dept Anim Sci, Livermore, CA 95616 USA.		Seidel, George/AAE-2371-2019					Butler D, 1998, NATURE, V392, P113, DOI 10.1038/32238; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Seidel G. E. Jr., 1997, Theriogenology, V47, P236, DOI 10.1016/S0093-691X(97)82363-1; SMITH LC, 1989, BIOL REPROD, V40, P1027, DOI 10.1095/biolreprod40.5.1027; SZELL A, 1991, THERIOGENOLOGY, V36, P379, DOI 10.1016/0093-691X(91)90466-Q; Vignon X, 1998, THERIOGENOLOGY, V49, P392, DOI 10.1016/S0093-691X(98)90745-2; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	11	13	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1400	1401		10.1126/science.280.5368.1400	http://dx.doi.org/10.1126/science.280.5368.1400			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9634416				2022-12-01	WOS:000073883400044
J	Chalmers, R; Guhathakurta, A; Benjamin, H; Kleckner, N				Chalmers, R; Guhathakurta, A; Benjamin, H; Kleckner, N			IHF modulation of Tn10 transposition: Sensory transduction of supercoiling status via a proposed protein/DNA molecular spring	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; DNA; INVIVO; FAVOR	Architectural protein IHF modulates Tn10 transposition in vitro. IHF stimulates transposon excision. Also, separately, IHF forces transposon end/target DNA interactions into a constrained pathway, "channeling," that yields only unknotted intratransposon inversion circles. Negative supercoiling influences both effects, differently. We infer that IHF is an architectural catalyst: it promotes initial transpososome assembly and is then ejected from the transpososome. IHF then rebinds, altering transpososome conformation to promote channeling. We also infer that the developing transpososome is a molecular spring: DNA provides basic elasticity; a conformational change in transposase provides force; and IHF and/or supercoiling provide conformational inputs. In vivo, IHF is a sensory transducer of chromosomal supercoiling status: with supercoiling absent, IHF is "supercoiling relief factor"; with supercoiling present, stimulation and channeling comprise a homeostatic pair such that modest changes in chromosome condition strongly influence transpositional outcome.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Chalmers, R (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			chalmers, ronald/0000-0002-1395-7173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Carmona M, 1997, P NATL ACAD SCI USA, V94, P9568, DOI 10.1073/pnas.94.18.9568; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Chalmers RM, 1996, EMBO J, V15, P5112, DOI 10.1002/j.1460-2075.1996.tb00892.x; HUISMAN O, 1989, EMBO J, V8, P211; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KLECKNER N, 1990, GENETICS, V124, P449; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LEE MS, 1997, P ANTL ACAD SCI US, V91, P9823; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; Nash Howard A., 1996, P149; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; SAKAI J, 1996, THESIS HARVARD U CAM; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SIGNON L, 1995, GENE DEV, V9, P1123, DOI 10.1101/gad.9.9.1123; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	28	94	94	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					897	908		10.1016/S0092-8674(00)81449-X	http://dx.doi.org/10.1016/S0092-8674(00)81449-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630232	Bronze			2022-12-01	WOS:000073956700024
J	Grindstaff, KK; Yeaman, C; Anandasabapathy, N; Hsu, SC; Rodriguez-Boulan, E; Scheller, RH; Nelson, WJ				Grindstaff, KK; Yeaman, C; Anandasabapathy, N; Hsu, SC; Rodriguez-Boulan, E; Scheller, RH; Nelson, WJ			Sec6/8 complex is recruited to cell-cell contacts and specifies transport vesicle delivery to the basal-lateral membrane in epithelial cells	CELL			English	Article							CANINE KIDNEY-CELLS; GTP-BINDING-PROTEIN; PLASMA-MEMBRANE; NONPOLARIZED CELLS; TIGHT JUNCTION; SEC15 PROTEIN; MDCK CELLS; POLARITY; YEAST; SURFACE	In budding yeast, the Sec6/8p complex is essential for generating cell polarity by specifying vesicle delivery to the bud tip. We show that Sec6/8 homologs are components of a cytosolic, similar to 17S complex in nonpolarized MDCK epithelial cells. Upon initiation of calcium-dependent cell-cell adhesion, similar to 70% of Sec6/8 is rapidly (t(1/2) = 3-6 hr) recruited to sites of cell-cell contact. In streptolysin-O-permeabilized MDCK cells, Sec8 antibodies inhibit delivery of LDL receptor to the basal-lateral membrane, but not p75(NTR) to the apical membrane. These results indicate that lateral membrane recruitment of the Sec6/8 complex is a consequence of cell-cell adhesion and is essential for the biogenesis of epithelial cell surface polarity.	Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Cornell Univ, Coll Med, Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Cornell University; Dyson; Cornell University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.		Yeaman, Charles A/A-1624-2009	Yeaman, Charles/0000-0001-6149-628X; Anandasabapathy, Niroshana/0000-0002-0473-8358	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035527, R37GM035527, R01GM034107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09368] Funding Source: Medline; NIGMS NIH HHS [GM35527, GM34107, R01 GM034107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; Herskowitz I, 1995, COLD SPRING HARB SYM, V60, P717, DOI 10.1101/SQB.1995.060.01.078; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHELLER RH, 1995, NEURON, V14, P893; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; WANG AZ, 1990, J CELL SCI, V95, P137; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101	39	424	430	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					731	740		10.1016/S0092-8674(00)81435-X	http://dx.doi.org/10.1016/S0092-8674(00)81435-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630218	hybrid			2022-12-01	WOS:000073956700010
J	Anthony, RG; Waldin, TR; Ray, JA; Bright, SWJ; Hussey, PJ				Anthony, RG; Waldin, TR; Ray, JA; Bright, SWJ; Hussey, PJ			Herbicide resistance caused by spontaneous mutation of the cytoskeletal protein tubulin	NATURE			English	Article							DINITROANILINE HERBICIDES; ELEUSINE-INDICA; GENE FAMILY; ZEA-MAYS; PLANTS; INVITRO; CELLS	The dinitroaniline herbicides (such as trifluralin and oryzalin) have been developed for the selective control of weeds in arable crops. However, prolonged use of these chemicals has resulted in the selection of resistant biotypes of goosegrass, a major weed. These herbicides bind to the plant tubulin protein but not to mammalian tubulin(1). Here we show that the major alpha-tubulin gene of the resistant biotype has three base changes within the coding sequence. These base changes swap cytosine and thymine, most likely as the result of the spontaneous deamination of methylated cytosine. One of these base changes causes an amino-acid change in the protein: normal threonine at position 239 is changed to isoleucine. This position is dose to the site of interaction between tubulin dimers in the microtubule protofilament. We show that the mutated gene is the cause of the herbicide resistance by using it to transform maize and confer resistance to dinitroaniline herbicides. Our results provide a molecular explanation for the resistance of goosegrass to dinitroanaline herbicides, a phenomenon that has arisen, and been selected for, as a result of repeated exposure to this class of herbicide.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Zeneca Agrochem, Jeolotts Hill Res Stn, Bracknell RG42 6ET, Berks, England	University of London; Royal Holloway University London	Hussey, PJ (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham Hill, Egham TW20 0EX, Surrey, England.			Hussey, Patrick/0000-0002-7349-8722				AKASHI T, 1988, PLANT CELL PHYSIOL, V29, P1053; APPLEBY AP, 1989, WEED TECHNOL, V3, P198, DOI 10.1017/S0890037X00031626; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Burns Roy G., 1994, V13, P3; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRAME BR, 1994, PLANT J, V6, P941, DOI 10.1046/j.1365-313X.1994.6060941.x; HUSSEY PJ, 1990, PLANT MOL BIOL, V15, P957, DOI 10.1007/BF00039438; JIANG CJ, 1993, J CELL SCI, V105, P891; LAST DI, 1991, THEOR APPL GENET, V81, P581, DOI 10.1007/BF00226722; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; MOREJOHN LC, 1987, PLANTA, V172, P252, DOI 10.1007/BF00394595; MOREJOHN LC, 1991, PHARMACOL THERAPEUT, V51, P217, DOI 10.1016/0163-7258(91)90078-Z; MUDGE LC, 1984, WEED SCI, V32, P591, DOI 10.1017/S0043174500059610; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PARKA SJ, 1977, WEED SCI, V25, P79, DOI 10.1017/S0043174500032975; THOMPSON C, 1995, EUPHYTICA, V85, P169, DOI 10.1007/BF00023945; VAUGHN KC, 1987, PLANT PHYSIOL, V83, P956, DOI 10.1104/pp.83.4.956; VILLEMUR R, 1992, J MOL BIOL, V227, P81, DOI 10.1016/0022-2836(92)90683-B; WALDIN TR, 1992, PLANTA, V188, P258, DOI 10.1007/BF00216822	19	113	117	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					260	263		10.1038/30484	http://dx.doi.org/10.1038/30484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607761				2022-12-01	WOS:000073761000051
J	Kawasaki, H; Eckner, R; Yao, TP; Taira, K; Chiu, R; Livingston, DM; Yokoyama, KK				Kawasaki, H; Eckner, R; Yao, TP; Taira, K; Chiu, R; Livingston, DM; Yokoyama, KK			Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation	NATURE			English	Article							300 KDA PROTEIN; TRANSCRIPTIONAL ADAPTER; COACTIVATOR; CELLS; APOPTOSIS; ANTIGEN; TARGET; E1A	The related proteins p300 and CBP (cAMP-response-element-binding protein (CREB)-binding protein)) are transcriptional co-activators that act with other factors to regulate gene expression(1-5) and play roles in many cell-differentiation add signal transduction pathways(6-10). Both proteins have intrinsic histone-acetyltransferase activity(11,12) and may act directly on chromatin, of which histone is a component, to facilitate transcription. They are also involved in growth control pathways, as shown by their interaction with the tumour-suppressor p53 (refs 13-15) and the viral oncogenes E1A (refs 1, 2, 16) and SV40 T antigen(5). Here we report functional differences of p300 and CBP in vivo. We examined their roles during retinoic-acid-induced differentiation, cell-cycle exit and programmed cell death (apoptosis) of embryonal carcinoma F9 cells(17,20), using hammerhead ribozymes capable of cleaving either p300 or CBP messenger RNAs. F9 cells expressing a p300-specific ribozyme became resistant to retinoic-acid-induced differentiation, whereas cells expressing a CBP-specific ribozyme were unaffected. Similarly, retinoic-acid-induced transcriptional upregulation of the cell-cycle inhibitor p21(Cip1) required normal levels of p300, but not CBP, whereas the reverse was true for p27(Kip1). In contrast, both ribozymes blocked retinoic-acid-induced apoptosis, indicating that both co-activators are required for this process. Thus, despite their similarities, p300 and CBP have distinct functions during retinoic-acid-induced differentiation of F9 cells.	Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba Sci City 3050074, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba Sci City 3050006, Japan; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Dept Surg Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA	RIKEN; University of Tsukuba; University of Zurich; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Yokoyama, KK (corresponding author), Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba Sci City 3050074, Japan.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAMBON P, 1996, FASEB J, V10, P1187; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1996, NUCLEIC ACIDS RES, V24, P3010, DOI 10.1093/nar/24.15.3010; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUND J, 1995, MG PESH INST LEIDEN, V8, P85; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TANAKA Y, 1995, P NATL ACAD SCI USA, V94, P10125; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	28	292	302	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					284	289		10.1038/30538	http://dx.doi.org/10.1038/30538			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607768				2022-12-01	WOS:000073761000058
J	Koepp, MJ; Gunn, RN; Lawrence, AD; Cunningham, VJ; Dagher, A; Jones, T; Brooks, DJ; Bench, CJ; Grasby, PM				Koepp, MJ; Gunn, RN; Lawrence, AD; Cunningham, VJ; Dagher, A; Jones, T; Brooks, DJ; Bench, CJ; Grasby, PM			Evidence for striatal dopamine release during a video game	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; C-11 RACLOPRIDE; BASAL GANGLIA; MOTOR CONTROL; HUMAN BRAIN; PET; ACTIVATION; RESPONSES; NEURONS; BINDING	Dopaminergic neurotransmission may be involved in learning, reinforcement of behaviour, attention, and sensorimotor integration(1,2). Binding of the radioligand C-11-labelled raclopride to dopamine D-2 receptors is sensitive to levels of endogenous dopamine, which can be released by pharmacological challenge(3-8). Here we use C-11-labelled raclopride and positron emission tomography scans to provide evidence that endogenous dopamine is released in the human striatum during a goal-directed motor task, namely a video game. Binding of raclopride to dopamine receptors in the striatum was significantly reduced during the video game compared with baseline levels of binding, consistent with increased release and binding of dopamine to its receptors. The reduction in binding of raclopride in the striatum positively correlated with the performance level during the task and was greatest in the ventral striatum. These results show, to our knowledge for the first time, behavioural conditions under which dopamine is released in humans, and illustrate the ability of positron emission tomography to detect neurotransmitter fluxes in vivo during manipulations of behaviour.	Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Neurosci & Psychol Med, London W6 8RP, England	Imperial College London; Imperial College London	Grasby, PM (corresponding author), Hammersmith Hosp, MRC, Cyclotron Unit, DuCane Rd, London W12 0NN, England.	grasby@cu.rpms.ac.uk	Lawrence, Andrew/A-1673-2010; Gunn, Roger/H-1666-2012	Gunn, Roger/0000-0003-1181-5769; Law, Ian/0000-0001-9644-7496				ASHBURNER J, 1996, QUANTIFICATION BRAIN, P301; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; BROOKS DJ, 1995, J NEUROL SCI, V128, P1, DOI 10.1016/0022-510X(94)00206-4; DEWEY SL, 1993, P NATL ACAD SCI USA, V90, P11816, DOI 10.1073/pnas.90.24.11816; Endres CJ, 1997, J CEREBR BLOOD F MET, V17, P932, DOI 10.1097/00004647-199709000-00002; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; Fisher RE, 1995, HUM BRAIN MAPP, V3, P24, DOI 10.1002/hbm.460030104; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; HUME SP, 1992, SYNAPSE, V12, P47, DOI 10.1002/syn.890120106; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Laruelle M, 1997, SYNAPSE, V25, P1, DOI 10.1002/(SICI)1098-2396(199701)25:1<1::AID-SYN1>3.0.CO;2-H; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LOGAN J, 1994, J CEREBR BLOOD F MET, V14, P995, DOI 10.1038/jcbfm.1994.132; Morris ED, 1995, HUM BRAIN MAPP, V3, P35, DOI 10.1002/hbm.460030105; Richardson NR, 1996, J NEUROSCI, V16, P8160; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; SALAMONE JD, 1994, PHARM BIOCH BEHAV, V49, P651; Schultz W, 1997, CURR OPIN NEUROBIOL, V7, P191, DOI 10.1016/S0959-4388(97)80007-4; SCHULTZ W, 1993, J NEUROSCI, V13, P900; THIERRY AM, 1976, NATURE, V263, P242, DOI 10.1038/263242a0; VOLKOW ND, 1993, J NUCL MED, V34, P609; VOLKOW ND, 1994, SYNAPSE, V16, P255, DOI 10.1002/syn.890160402; WISE R, 1980, TRENDS NEUROSCI, V3, P91, DOI 10.1016/0166-2236(80)90035-1; YAMAMURO Y, 1994, NEUROSCI LETT, V177, P83, DOI 10.1016/0304-3940(94)90050-7	26	794	814	4	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					266	268		10.1038/30498	http://dx.doi.org/10.1038/30498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607763				2022-12-01	WOS:000073761000053
J	Paul, AV; van Boom, JH; Filippov, D; Wimmer, E				Paul, AV; van Boom, JH; Filippov, D; Wimmer, E			Protein-primed RNA synthesis by purified poliovirus RNA polymerase	NATURE			English	Article							GENOME-LINKED PROTEIN; DNA-REPLICATION; INITIATION; 3AB; TRANSLATION; SEQUENCE; VIRUSES; LINKAGE; POLY(A); ENTRY	A small protein, VPg, is covalently linked to the 5' end of the plus-stranded poliovirus genomic RNA(1-3). Poliovirus messenger RNA, identical in nucleotide sequence to genomic RNA,is not capped at its 5' end by the methylated structure that is common to most eukaryotic mRNAs, These discoveries presented two problems. First, as cap structures are usually required for transition of mRNA into protein, how does this uncapped viral RNA act as a template for translation? Second, what is the function of VPg? The identification of the internal ribosomal-entry site, which allows the entry of ribosomes into viral mRNA independently of the 5' mRNA end, has solved the first conundrum(4-6). Here we describe the resolution of the second problem. VPg is linked to the genomic RNA through the 5'-terminal uridylic acid of the RNA. We show that VPg can be uridylylated by the poliovirus RNA polymerase 3D(pol). Uridylylated VPg can then prime the transcription of polyadenylate RNA by 3D(pol) to produce VPg-linked poly(U). Initiation of transcription of the poliovirus genome from the polyadenylated 3' end therefore depends on VPg.	SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Leiden Univ, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Leiden University; Leiden University - Excl LUMC	Paul, AV (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	apaul@asterix.bio.sunysb.edu	Filippov, Dmitri/J-7612-2017	Filippov, Dmitri/0000-0002-6978-7425				AMBROS V, 1978, J BIOL CHEM, V253, P5263; Barton DJ, 1996, VIROLOGY, V217, P459, DOI 10.1006/viro.1996.0140; CAO XM, 1995, VIROLOGY, V209, P315, DOI 10.1006/viro.1995.1263; DORSCHHASLER K, 1975, J VIROL, V16, P1512; DREEFTROMP CM, 1992, NUCLEIC ACIDS RES, V20, P2435, DOI 10.1093/nar/20.10.2435; ESTEBAN JA, 1992, BIOCHEMISTRY-US, V31, P350, DOI 10.1021/bi00117a006; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P961, DOI 10.1073/pnas.74.3.961; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; HSIEH JC, 1990, P NATL ACAD SCI USA, V87, P8665, DOI 10.1073/pnas.87.21.8665; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KUHN RJ, 1988, P NATL ACAD SCI USA, V85, P519, DOI 10.1073/pnas.85.2.519; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; LEE YF, 1976, PROGR NUCL ACID RES, P89; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0; PATA JD, 1995, RNA, V1, P466; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RODRIGUEZ PL, 1992, J VIROL, V66, P1971, DOI 10.1128/JVI.66.4.1971-1976.1992; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; Xiang WK, 1995, RNA, V1, P892; YOGO Y, 1972, P NATL ACAD SCI USA, V69, P1877, DOI 10.1073/pnas.69.7.1877; YOGO Y, 1975, J MOL BIOL, V92, P467, DOI 10.1016/0022-2836(75)90292-2	30	286	296	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1998	393	6682					280	284		10.1038/30529	http://dx.doi.org/10.1038/30529			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607767				2022-12-01	WOS:000073761000057
J	Winberg, ML; Mitchell, KJ; Goodman, GS				Winberg, ML; Mitchell, KJ; Goodman, GS			Genetic analysis of the mechanisms controlling target selection: Complementary and combinatorial functions of netrins, semaphorins, and IgCAMs	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; MOTOR AXON; NEUROMUSCULAR SPECIFICITY; COLORECTAL-CANCER; COMMISSURAL AXONS; SYNAPSE FORMATION; DROSOPHILA; UNC-6; MOTONEURON	The molecular mechanisms controlling the ability of motor axons to recognize their appropriate muscle targets were dissected using Drosophila genetics to add or subtract Netrin A, Netrin B, Semaphorin II, and Fasciclin II alone or in combination, Fas II and Sema II are expressed by all muscles where they promote (Fas II) or inhibit (Sema II) promiscuous synaptogenesis, NetB is expressed by a subset of muscles where it attracts some axons and repels others, However, growth cones in this system apparently do not rely solely on single molecular labels on individual targets, Rather, these growth cones assess the relative balance of attractive and repulsive forces and select their targets based on the combinatorial and simultaneous input of multiple cues.	Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, 229 Stanley Hall, Berkeley, CA 94720 USA.			Mitchell, Kevin/0000-0002-3433-4530	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021294, R37HD021294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21294] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALL EE, 1985, J NEUROSCI, V5, P1808; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BRAND AH, 1993, DEVELOPMENT, V118, P401; CASH S, 1992, J NEUROSCI, V12, P2051; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHIANG C, 1994, DEVELOPMENT, V120, P3581; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CHIBA A, 1993, J NEUROSCI, V13, P714; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; HALFON MS, 1995, DEV BIOL, V169, P151, DOI 10.1006/dbio.1995.1134; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Kose H, 1997, DEVELOPMENT, V124, P4143; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Sink H., 1994, Society for Neuroscience Abstracts, V20, P1283; SINK H, 1991, DEVELOPMENT, V113, P701; Stewart B., 1973, DROS INFORM SERV, V50, P167; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	37	212	215	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					581	591		10.1016/S0092-8674(00)81187-3	http://dx.doi.org/10.1016/S0092-8674(00)81187-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604933	Bronze, Green Published			2022-12-01	WOS:000073722200011
J	Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, JS				Gaston, B; Sears, S; Woods, J; Hunt, J; Ponaman, M; McMahon, T; Stamler, JS			Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure	LANCET			English	Article							NITRIC-OXIDE; NITROSOGLUTATHIONE	Background Nitric oxide (NO) gas concentrations are high in the expired air of individuals with asthma, but not consistently so in the expired air of people with pneumonia. S-nitrosothiols are naturally occurring bronchodilators, the concentrations of which are raised in the airways of patients with pneumonia. Airway S-nitrosothiols have not been studied in asthma. Methods Tracheal S-nitrosothiol concentrations from eight asthmatic children in respiratory failure were compared with those of 21 children undergoing elective surgery. Results Mean S-nitrosothiol concentrations in asthmatic children were lower than in normal children (65 [SD 45] nmol/L vs 502 [SD 429] nmol/L) and did not vary with inspired oxygen concentration or airway thiol concentration. Interpretation Severe asthma is associated with low concentrations of airway S-nitrosothiols. This is the first reported deficiency of an endogenous bronchodilator in the human asthmatic airway lining fluid, We suggest that S-nitrosothiol metabolism may be a target for the development of new asthma therapies.	Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA; USN, Med Ctr, Dept Pediat, Div Pulm, San Diego, CA 92152 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA	University of Virginia; United States Department of Defense; United States Navy; Duke University; Howard Hughes Medical Institute; Duke University	Gaston, B (corresponding author), Univ Virginia Hlth Syst, Box 386, Charlottesville, VA 22908 USA.	bmg3g@virginia.edu	McMahon, Tim/K-3986-2012	McMahon, Tim/0000-0002-3404-3223; Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582, R01HL052529] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52529, HLO2582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; BANNENBERG G, 1995, J PHARMACOL EXP THER, V272, P1238; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; FANG K, 1998, IN PRESS AM J RESP C; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; JIA L, 1996, NATURE, V380, P21; Lewis SJ, 1996, EUR J PHARMACOL, V312, pR3, DOI 10.1016/0014-2999(96)00607-3; LEWIS SJ, 1993, AM REV RESPIR DIS, V147, P1461; MASSARO AF, 1995, AM J RESP CRIT CARE, V151, P832; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEHTA S, 1997, AM J PHYSIOL, V272, P124; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Raghavender B, 1997, J PEDIATR-US, V130, P944, DOI 10.1016/S0022-3476(97)70281-6; RICCIARDOLO F, 1998, IN PRESS LANCET; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RUTGERS S, 1992, AM J RESP CRIT CARE, V155; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; VANIN AF, 1997, BIOL CHEM, V1, P191; ZEHR BB, 1989, CHEST, V95, P1059, DOI 10.1378/chest.95.5.1059	27	181	187	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1998	351	9112					1317	1319		10.1016/S0140-6736(97)07485-0	http://dx.doi.org/10.1016/S0140-6736(97)07485-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643794				2022-12-01	WOS:000073439400009
J	Parkin, DE				Parkin, DE			Prognostic factors for success of endometrial ablation and resection	LANCET			English	Editorial Material							HYSTERECTOMY; MENORRHAGIA; TRIAL; WOMEN		Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland	University of Aberdeen	Parkin, DE (corresponding author), Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB25 2ZN, Scotland.							ABRAMOVICH DR, 1995, BRIT J OBSTET GYNAEC, V102, P249; Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Chullapram T, 1996, OBSTET GYNECOL, V88, P71, DOI 10.1016/0029-7844(96)00085-3; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1360, DOI 10.1111/j.1471-0528.1997.tb11004.x; Davis JR, 1998, AM J CLIN PATHOL, V109, P96; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; Gannon MJ, 1996, BRIT J OBSTET GYNAEC, V103, P1029, DOI 10.1111/j.1471-0528.1996.tb09556.x; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979	8	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1147	1148		10.1016/S0140-6736(05)79116-9	http://dx.doi.org/10.1016/S0140-6736(05)79116-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643682				2022-12-01	WOS:000073220200004
J	Suhara, T; Sudo, Y; Yoshida, K; Okubo, Y; Fukuda, H; Obata, T; Yoshikawa, K; Suzuki, K; Sasaki, Y				Suhara, T; Sudo, Y; Yoshida, K; Okubo, Y; Fukuda, H; Obata, T; Yoshikawa, K; Suzuki, K; Sasaki, Y			Lung as reservoir for antidepressants in pharmacokinetic drug interactions	LANCET			English	Article							BINDING-SITES; TRICYCLIC ANTIDEPRESSANTS; SEROTONIN TRANSPORTER; H-3 IMIPRAMINE; AMINES; BRAIN; ACCUMULATION; FLUOXETINE; INHIBITION; COCAINE	Background Although high-affinity imipramine binding sites have been reported in both rat and human lung, the role of the lungs in the pharmacokinetics of antidepressants has not received much attention. Substantial accumulation of selective serotonin-reuptake inhibitors (SSRIs) in the lungs has been reported. We have investigated the role of the lungs in pharmacokinetic drug interactions between tricyclic antidepressants and SSRIs. Methods We used a carbon-11-labelled form of the imipramine derivative cyanoimipramine to measure uptake in the lungs and brain of healthy volunteers by positron emission tomography. Clomipramine (50 mg) was administered to measure the effect of antidepressants with high affinity for the serotonin transporter on lung and brain uptake. Findings A large proportion of the injected C-11-cyanoimipramine (68-86% in the four volunteers) was extracted by the lungs. Clomipramine decreased the lung uptake from 68% to 35% and from 81% to 54% in the two volunteers studied. By contrast, whole-brain uptake was low in control studies (1.7-2.0% in three volunteers) and increased after clomipramine administration (to 4.5-4.9%). Plasma radioactivity was also higher after clomipramine than in control studies. Interpretation The lungs may function as a reservoir for antidepressants with high affinity to the serotonin transporter. The accumulated antidepressants may be displaced by other antidepressants, and this displacement would substantially increase plasma concentrations and thus cause toxic effects.	Natl Inst Radiol Sci, Div Adv Technol Med Imaging, Inage Ku, Chiba 263, Japan; Japan Sci & Technol Corp, CREST, Chiba, Japan	National Institutes for Quantum Science & Technology; Japan Science & Technology Agency (JST)	Suhara, T (corresponding author), Natl Inst Radiol Sci, Div Adv Technol Med Imaging, Inage Ku, 9-1 Anagawa 4 Chome, Chiba 263, Japan.	suhara@nirs.go.jp	Obata, Takayuki/AAR-9820-2020	Obata, Takayuki/0000-0001-7678-5033				ANDERSON MW, 1974, J PHARMACOL EXP THER, V189, P456; CATRAVAS JD, 1980, J PHARMACOL EXP THER, V213, P120; DOWNS JM, 1989, AM J PSYCHIAT, V146, P814; HASHIMOTO K, 1987, NUCL MED BIOL, V14, P587; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IWASAWA Y, 1973, J PHARMACOL EXP THER, V186, P498; JUNOD AF, 1972, J PHARMACOL EXP THER, V183, P182; JUNOD AF, 1975, LUNG METABOLISM, P219; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; MORIN D, 1984, BIOCHEM BIOPH RES CO, V120, P926, DOI 10.1016/S0006-291X(84)80195-3; PAUL SM, 1980, LIFE SCI, V26, P953, DOI 10.1016/0024-3205(80)90116-2; PISTOLESI M, 1988, AM REV RESPIR DIS, V138, P1429, DOI 10.1164/ajrccm/138.6.1429; RAISMAN R, 1983, EUR J PHARMACOL, V94, P345, DOI 10.1016/0014-2999(83)90426-0; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SCHLYER DJ, 1992, SYNAPSE, V11, P10, DOI 10.1002/syn.890110103; SHIUE CY, 1995, NUCL MED BIOL, V22, P613, DOI 10.1016/0969-8051(94)00146-B; Suhara T, 1996, Ann Nucl Med, V10, P85; TAYLOR D, 1995, BRIT J PSYCHIAT, V167, P575, DOI 10.1192/bjp.167.5.575; VESTAL RE, 1980, J PHARMACOL EXP THER, V214, P106; WILSON AGE, 1982, DRUG METAB DISPOS, V10, P281; WOLFE J, 1987, J PHARMACOL EXP THER, V241, P196	21	74	76	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					332	335		10.1016/S0140-6736(97)07336-4	http://dx.doi.org/10.1016/S0140-6736(97)07336-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652614				2022-12-01	WOS:000071864000014
J	Hasegawa, I; Fukushima, T; Ihara, T; Miyashita, Y				Hasegawa, I; Fukushima, T; Ihara, T; Miyashita, Y			Callosal window between prefrontal cortices: Cognitive interaction to retrieve long-term memory	SCIENCE			English	Article							CORPUS-CALLOSUM; MONKEYS; CORTEX; COMMISSUROTOMY; ASSOCIATION; ACTIVATION; NEURONS; RETINA	A perceptual image can be recalled from memory without sensory stimulation. However, the neural origin of memory retrieval remains unsettled. To examine whether memory retrieval can be regulated by top-down processes originating from the prefrontal cortex, a visual associative memory task was introduced into the partial split-brain paradigm in monkeys. Long-term memory acquired through stimulus-stimulus association did not transfer via the anterior corpus callosum, a key part interconnecting prefrontal cortices. Nonetheless, when a visual cue was presented to one hemisphere, the anterior callosum could instruct the other hemisphere to retrieve the correct stimulus specified by the cue. Thus, although visual Long-term memory is stored in the temporal cortex, memory retrieval is under the executive control of the prefrontal cortex.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 444, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Hasegawa, I (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Hasegawa, Isao/AAW-5682-2021; Miyashita, Yasushi/B-7171-2019	Hasegawa, Isao/0000-0002-8633-2502; Miyashita, Yasushi/0000-0003-3496-8637				BLACK P, 1964, SCIENCE, V146, P799, DOI 10.1126/science.146.3645.799; Buckner RL, 1996, J NEUROSCI, V16, P6219; DOTY RW, 1988, BEHAV BRAIN RES, V29, P267, DOI 10.1016/0166-4328(88)90031-9; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EACOTT MJ, 1990, BEHAV BRAIN RES, V38, P109, DOI 10.1016/0166-4328(90)90009-4; FENDRICH R, 1989, NEUROPSYCHOLOGIA, V27, P273, DOI 10.1016/0028-3932(89)90018-3; Fuster J.M., 1995, MEMORY CEREBRAL CORT; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; GAZZANIGA MS, 1969, EXP NEUROL, V23, P11, DOI 10.1016/0014-4886(69)90029-6; GAZZANIGA MS, 1966, NEUROPSYCHOLOGIA, V4, P183, DOI 10.1016/0028-3932(66)90047-9; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; HALSBAND U, 1985, BEHAV BRAIN RES, V18, P269, DOI 10.1016/0166-4328(85)90035-X; HAMILTON CR, 1986, 2 HEMISPHERES ONE BR, P315; Higuchi S, 1996, P NATL ACAD SCI USA, V93, P739, DOI 10.1073/pnas.93.2.739; HOLTZMAN JD, 1984, VISION RES, V24, P801, DOI 10.1016/0042-6989(84)90151-2; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MATSUDA K, 1996, NEUROSCI RES       S, V20, pS270; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; NOBLE J, 1973, BRAIN RES, V50, P147, DOI 10.1016/0006-8993(73)90601-X; Pandya DN., 1986, 2 HEMISPHERES ONE BR, P47; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PETRIDES M, 1987, FRONTAL LOBES REVISI, P91; SAKAI K, 1995, MAGNET RESON MED, V33, P736, DOI 10.1002/mrm.1910330521; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673; STONE J, 1973, J COMP NEUROL, V150, P333, DOI 10.1002/cne.901500306; STUSS DT, 1989, FRONTAL LOBES; SUGISHITA M, 1978, NEUROPSYCHOLOGIA, V16, P417, DOI 10.1016/0028-3932(78)90065-9; SUGISHITA M, 1994, NEUROPSYCHOLOGIA, V32, P399, DOI 10.1016/0028-3932(94)90086-8; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; ZEKI SM, 1973, J COMP NEUROL, V148, P167, DOI 10.1002/cne.901480204	34	114	117	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					814	818		10.1126/science.281.5378.814	http://dx.doi.org/10.1126/science.281.5378.814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694651				2022-12-01	WOS:000075295600047
J	Wan, L; Molloy, SS; Thomas, L; Liu, GP; Xiang, Y; Rybak, SL; Thomas, G				Wan, L; Molloy, SS; Thomas, L; Liu, GP; Xiang, Y; Rybak, SL; Thomas, G			PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization	CELL			English	Article							CASEIN KINASE-II; MANNOSE 6-PHOSPHATE RECEPTOR; CYTOPLASMIC DOMAIN; INTRACELLULAR TRAFFICKING; PHOSPHORYLATION SITE; PROPROTEIN CONVERTASE; MESSENGER-RNAS; CELL-SURFACE; FURIN; IDENTIFICATION	We report the role of one member of a novel gene family, PACS-1, in the localization of trans-Golgi network (TGN) membrane proteins. PACS-1 directs the TGN localization of furin by binding to the protease's phosphorylated cytosolic domain. Antisense studies show TGN localization of furin and mannose-6-phosphate receptor, but not TGN46, is strictly dependent on PACS-1.Analyses in vitro and in vivo show PACS-1 has properties of a coat protein and connects furin to components of the clathrin-sorting machinery. Cell-free assays indicate TGN localization of furin is directed by a PACS-1-mediated retrieval step. Together, these findings explain a mechanism by which membrane proteins in mammalian cells are localized to the TGN.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Thomas, G (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.				NIDDK NIH HHS [DK37274, DK09394, R01 DK037274, DK44629] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009394, R01DK044629, R01DK037274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hartmann C, 1997, DEV GENES EVOL, V207, P186, DOI 10.1007/s004270050106; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Ikonen E, 1997, J CELL SCI, V110, P2155; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KORNER C, 1994, J BIOL CHEM, V269, P16529; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mallet WG, 1996, J CELL SCI, V109, P3059; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; Norais N, 1996, J VIROL, V70, P5716, DOI 10.1128/JVI.70.8.5716-5719.1996; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Sambrook J., 1989, MOL CLONING, V1; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seaman MNJ, 1996, J BIOL CHEM, V271, P25446, DOI 10.1074/jbc.271.41.25446; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WONG SH, 1993, J BIOL CHEM, V268, P22853; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAO ZB, 1993, J VIROL, V67, P4464, DOI 10.1128/JVI.67.8.4464-4473.1993	47	306	316	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					205	216		10.1016/S0092-8674(00)81420-8	http://dx.doi.org/10.1016/S0092-8674(00)81420-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695949	Bronze			2022-12-01	WOS:000075020100009
J	Ding, JM; Buchanan, GF; Tischkau, SA; Chen, D; Kuriashkina, L; Faiman, LE; Alster, JM; McPherson, PS; Campbell, KP; Gillette, MU				Ding, JM; Buchanan, GF; Tischkau, SA; Chen, D; Kuriashkina, L; Faiman, LE; Alster, JM; McPherson, PS; Campbell, KP; Gillette, MU			A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock	NATURE			English	Article							CALCIUM-RELEASE CHANNEL; CA2+ RELEASE; CAFFEINE; PROTEIN; SHIFTS; THAPSIGARGIN; RAPAMYCIN; RETICULUM; MUSCLE; RIBOSE	Circadian clocks are complex biochemical systems that cycle with a period of approximately 24 hours. They integrate temporal information regarding phasing of the solar cycle, and adjust their phase so as to synchronize an organism's internal state to the local environmental day and night(1,2). Nocturnal light is the dominant regulator of this entrainment. In mammals, information about nocturnal light is transmitted by glutamate released om retinal projections to the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Clock resetting requires the activation of ionotropic glutamate receptors, which mediate Ca2+ influx(3). The response induced by such activation depends on the clock's temporal state: during early night it delays the clock phase, whereas in late night the clock phase is advanced. To investigate this differential response, we sought signalling elements that contribute solely to phase delay. We analysed intracellular calcium-channel ryanodine receptors, which mediate coupled Ca2+ signalling, Depletion of intracellular Ca2+ stores during early night blocked the effects of glutamate. Activators of ryanodine receptors induced phase resetting only in early night; inhibitors selectively blocked delays induced by light and glutamate. These findings implicate the release of intracellular Ca2+ through ryanodine receptors in the light-induced phase delay of the circadian clock restricted to the early night.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Neurosci Program, Urbana, IL 61801 USA; Univ Illinois, Comp & Commun Serv Off, Urbana, IL 61801 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol, Iowa City, IA 52242 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; McGill University; Howard Hughes Medical Institute; University of Iowa; University of Iowa	Gillette, MU (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Buchanan, Gordon/0000-0003-2371-4455; Campbell, Kevin/0000-0003-2066-5889				BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33; DENT M, 1996, NEUR ABSTR, V22; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; Liu C, 1997, J NEUROSCI, V17, P659; Mathur A, 1996, AM J PHYSIOL-REG I, V270, pR1031, DOI 10.1152/ajpregu.1996.270.5.R1031; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; OMARA SM, 1995, NEUROSCIENCE, V68, P621, DOI 10.1016/0306-4522(95)00233-9; PARNESS J, 1995, J BIOL CHEM, V270, P18465, DOI 10.1074/jbc.270.31.18465; Pawlikowska L, 1996, J NEUROSCI, V16, P5372; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6812, DOI 10.1073/pnas.86.17.6812; PROSSER RA, 1989, J NEUROSCI, V9, P1073; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER ET, 1995, BRAIN RES, V692, P137; WEBER ET, 1995, NEUROSCI LETT, V197, P227, DOI 10.1016/0304-3940(95)11961-U; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; ZATZ M, 1995, J NEUROCHEM, V65, P1332	27	182	184	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					381	384		10.1038/28639	http://dx.doi.org/10.1038/28639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690474				2022-12-01	WOS:000074968800054
J	Zhang, NA; Gridley, T				Zhang, NA; Gridley, T			Defects in somite formation in lunatic fringe deficient mice	NATURE			English	Article							EXPRESSION; DORSAL; BOUNDARY; DELTA; NOTCH	Segmentation in vertebrates first arises when the unsegmented paraxial mesoderm subdivides to form paired epithelial spheres called somites(1,2). The Notch signalling pathway is important in regulating the formation and anterior-posterior patterning of the vertebrate somite(3-7). One component of the Notch signalling pathway in Drosophila is the fringe gene, which encodes a secreted signalling molecule required for activation of Notch during specification of the wing margins-(8-11). Here we show that mice homozygous for a targeted mutation of the lunatic fringe (Lfng) gene, one of the mouse homologues(12,13) of fringe, have defects in somite formation and anterior-posterior patterning of the somites. Somites in the mutant embryos are irregular in size and shape, and their anterior-posterior patterning is disturbed. Marker analysis revealed that in the presomitic mesoderm of the mutant embryos, sharply demarcated domains of expression of several components of the Notch signalling pathway are replaced by even gradients of gene expression. These results indicate that Lfng encodes an essential component of the Notch signalling pathway during somitogenesis in mice.	Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Gridley, T (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	gridley@jax.org						BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BLAIR SS, 1997, CURR BIOL, V7, pR636; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; deCelis JF, 1996, DEVELOPMENT, V122, P359; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; GOSSLER A, 1997, CURR TOP DEV BIOL, V33, P225; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; MONTARRAS D, 1991, NEW BIOL, V3, P592; Neidhardt LM, 1997, DEV GENES EVOL, V207, P330, DOI 10.1007/s004270050120; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SWIATEK P, 1993, GENE DEV, P2071; Tannahill D, 1997, CELL TISSUE RES, V290, P275, DOI 10.1007/s004410050932; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WONG C, 1997, NATURE, V387, P288	27	343	351	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					374	377		10.1038/28625	http://dx.doi.org/10.1038/28625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690472				2022-12-01	WOS:000074968800052
J	Imai, Y; Kawata, S; Tamura, S; Yabuuchi, I; Noda, S; Inada, M; Maeda, Y; Shirai, Y; Fukuzaki, T; Kaji, I; Ishikawa, H; Matsuda, Y; Nishikawa, M; Seki, K; Matsuzawa, Y				Imai, Y; Kawata, S; Tamura, S; Yabuuchi, I; Noda, S; Inada, M; Maeda, Y; Shirai, Y; Fukuzaki, T; Kaji, I; Ishikawa, H; Matsuda, Y; Nishikawa, M; Seki, K; Matsuzawa, Y		Osaka Hepatocellular Carcinoma Prevention Stud	Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER-DISEASE; B VIRAL-HEPATITIS; CHRONIC NON-A; ALPHA-INTERFERON; CONTROLLED TRIAL; RISK-FACTORS; RANDOMIZED TRIAL; ALFA THERAPY; VIRUS	Background: The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined. Objective: To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Design: Retrospective cohort study. Setting: One university hospital and seven university-affiliated hospitals. Patients: 419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls). Intervention: Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-alpha 2a, or recombinant interferon-alpha 2b for 6 months. Measurements: The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography. Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up. Relapse was defined as a normal serum ALT revel at the end of treatment with an increase to an abnormal level after cessation of treatment. Nonresponse included all other ALT patterns. Results: Median follow-up in the interferon and control groups was 47.6 and 46.8 months, respectively. During follow-up, hepatocellular carcinoma was found in 28 interferon-treated patients and 19 controls. Cox proportional hazards regression analysis that included all patients revealed that interferon therapy (P = 0.041), older age (P = 0.003), greater histologic activity (P = 0.029), and higher histologic stage (P = 0.049) were independent factors associated with the development of hepatocellular carcinoma. The risk ratios for development of hepatocellular carcinoma in patients with sustained response, relapse, and nonresponse were 0.06 (95% CI, 0.01 to 0.46), 0.51 (CI, 0.20 to 1.27), and 0.95 (CI, 0.48 to 1.84), respectively, compared with controls. Conclusions: The incidence of hepatocellular carcinoma was lower in patients with sustained response to interferon therapy than historical controls and nonresponders. Interferon therapy may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis C.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan	Osaka University	Kawata, S (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							BRUIX J, 1989, LANCET, V2, P1004; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1002/hep.1840220303; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVID E, 1992, AM J CLIN PATHOL, V98, P397, DOI 10.1093/ajcp/98.4.397; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DIBISCEGLIE AM, 1995, SEMIN LIVER DIS, V15, P64, DOI 10.1055/s-2007-1007263; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIODATI G, 1991, J MED VIROL, V35, P151, DOI 10.1002/jmv.1890350302; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1002/hep.1840180109; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MANABE N, 1993, HEPATOLOGY, V18, P1344, DOI 10.1002/hep.1840180610; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; MURAKAMI R, 1990, INT J CANCER, V46, P159, DOI 10.1002/ijc.2910460203; MURAKAMI R, 1990, CANCER, V65, P1255, DOI 10.1002/1097-0142(19900301)65:5<1255::AID-CNCR2820650536>3.0.CO;2-P; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OKUDA K, 1987, CANCER RES, V47, P4967; Poynard T, 1996, HEPATOLOGY, V24, P778; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502	31	296	304	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					94	99		10.7326/0003-4819-129-2-199807150-00005	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669992				2022-12-01	WOS:000074852000003
J	Pittet, D; Harbarth, S				Pittet, D; Harbarth, S			What techniques for diagnosis of ventilator-associated pneumonia?	LANCET			English	Editorial Material									Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Geneva; Harvard University; Harvard T.H. Chan School of Public Health	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, Geneva 14, Switzerland.							Campbell GD, 1996, AM J RESP CRIT CARE, V153, P1711; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Flaherty JP, 1996, INFECT CONT HOSP EP, V17, P236; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; Pittet D, 1998, HOSP INFECT, P381; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					83	84		10.1016/S0140-6736(98)85005-8	http://dx.doi.org/10.1016/S0140-6736(98)85005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672269				2022-12-01	WOS:000074775100005
J	Fisahn, A; Pike, FG; Buhl, EH; Paulsen, O				Fisahn, A; Pike, FG; Buhl, EH; Paulsen, O			Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro	NATURE			English	Article							GABAERGIC INTERNEURONS; PYRAMIDAL CELLS; NEURONS; RAT; CORTEX; SLICE; SYNCHRONIZATION; EXCITATION; RHYTHMS; MODEL	Acetylcholine is vital for cognitive functions of the brain. Although its actions in the individual cell are known in some detail(1), its effects at the network level are poorly understood(2). The hippocampus, which receives a major cholinergic input from the medial septum/diagonal band(3), is important in memory(4,5) and exhibits network activity at 40 Hz during relevant behaviours(6). Here we show that cholinergic activation is sufficient to induce 40-Hz network oscillations(7) in the hippocampus in vitro. Oscillatory activity is generated spontaneously in the CA3 subfield and can persist for hours. During the oscillatory state, principal neurons fire action potentials that are phase-related to the extracellular oscillation, but each neuron fires in only a small proportion of the cycles. Both excitatory and inhibitory synaptic events participate during the network oscillation in a precise temporal pattern. These results indicate that subcortical cholinergic input can control hippocampal memory processing by inducing fast network oscillations.	Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England	University of Oxford	Fisahn, A (corresponding author), Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Mansfield Rd, Oxford OX1 3TH, England.		Paulsen, Ole/ABB-4843-2020	Paulsen, Ole/0000-0002-2258-5455	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENARDO LS, 1982, BRAIN RES, V249, P315, DOI 10.1016/0006-8993(82)90066-X; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAGIN A, 1995, J NEUROSCI, V15, P47; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Cobb SR, 1997, NEUROSCIENCE, V79, P629, DOI 10.1016/S0306-4522(97)00055-9; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; COLE AE, 1983, SCIENCE, V221, P1299, DOI 10.1126/science.6612345; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; FELLOUS JM, IN PRESS P COMP NEUR; FREEMAN WJ, 1968, J NEUROPHYSIOL, V31, P337, DOI 10.1152/jn.1968.31.3.337; Gray CM, 1996, SCIENCE, V274, P109, DOI 10.1126/science.274.5284.109; HASSELMO ME, 1994, J NEUROSCI, V14, P3898; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KONOPACKI J, 1987, BRAIN RES, V405, P196, DOI 10.1016/0006-8993(87)91009-2; LILJENSTROM H, 1995, J NEUROPHYSIOL, V74, P288, DOI 10.1152/jn.1995.74.1.288; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILLES R, 1990, J PHYSL, V428, P61; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; SHUTE CCD, 1963, NATURE, V199, P1160, DOI 10.1038/1991160a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Whittington MA, 1997, P NATL ACAD SCI USA, V94, P12198, DOI 10.1073/pnas.94.22.12198; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Williams JH, 1997, J NEUROPHYSIOL, V78, P2631, DOI 10.1152/jn.1997.78.5.2631; WILSON M, 1992, J NEUROPHYSIOL, V67, P981, DOI 10.1152/jn.1992.67.4.981	30	655	665	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					186	189		10.1038/28179	http://dx.doi.org/10.1038/28179			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671302				2022-12-01	WOS:000074705900055
J	Kemp, M				Kemp, M			Lane's landscapes	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					135	135		10.1038/28072	http://dx.doi.org/10.1038/28072			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671295	Bronze			2022-12-01	WOS:000074705900035
J	Lamarche, B; Tchernof, A; Mauriege, P; Cantin, B; Dagenais, GR; Lupien, PJ; Despres, JP				Lamarche, B; Tchernof, A; Mauriege, P; Cantin, B; Dagenais, GR; Lupien, PJ; Despres, JP			Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; PLASMA TRIGLYCERIDE CONCENTRATION; MYOCARDIAL-INFARCTION; LDL CHOLESTEROL; HDL-CHOLESTEROL; A-I; MEN; ASSOCIATION; HYPERINSULINEMIA; SUBFRACTION	Context.-Epidemiological studies have established a relationship between cholesterol and low-density lipoprotein cholesterol (LDL-C) concentrations and the risk of ischemic heart disease (IHD), but up to half of patients with IHD may have cholesterol levels in the normal range. Objective.-To assess the ability to predict the risk of IHD using a cluster of nontraditional metabolic risk factors that includes elevated fasting insulin and apolipoprotein B levels as well as small, dense LDL particles. Design.-Nested case-control study. Setting.-Cases and controls were identified from the population-based cohort of the Quebec Cardiovascular Study, a prospective study conducted in men free of IHD in 1985 and followed up for 5 years. Participants.-Incident IHD cases were matched with controls selected from among the sample of men who remained IHD free during follow-up. Matching variables were age, smoking habits, body mass index, and alcohol consumption. The sample included 85 complete pairs of nondiabetic IHD cases and controls, Main Outcome Measures.-Ability of fasting insulin level, apolipoprotein B level, and LDL particle diameter to predict IHD events, defined as angina, coronary insufficiency, nonfatal myocardial infarction, anti coronary death. Results.-The risk of IHD was significantly increased in men who had elevated fasting plasma insulin and apolipoprotein B levels and small, dense LDL particles, compared with men who had normal levels for 2 of these 3 risk factors (odds ratio [OR], 5.9; 95% confidence interval [CI], 2.3-15.4). Multivariate adjustment for LDL-C, triglycerides, and high-density lipoprotein cholesterol (HDL-C) did not attenuate the relationship between the cluster of nontraditional risk factors and IHD (OR, 5.2; 95% CI, 1.7-15.7). On the other hand, the risk of IHD in men having a combination of elevated LDL-C and triglyceride levels and reduced HDL-C levels was no longer significant (OR, 1.4, 95% CI, 0.5-3.5) after multivariate adjustment for fasting plasma insulin level, apolipoprotein B level, and LDL particle size. Conclusion.-Results from this prospective study suggest that the measurement of fasting plasma insulin level, apolipoprotein B level, and LDL particle size may provide further information on the risk of IHD compared with the information provided by conventional lipid variables.	Laval Univ Hosp, Res Ctr, Lipid Res Ctr, St Foy, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Despres, JP (corresponding author), CHUL, Res Ctr, Lipid Res Ctr, 2705 Laurier Blvd,TR-93, St Foy, PQ G1V 4G2, Canada.		应, 宁宁/G-9472-2011; Lamarche, Benoit/ABA-4785-2021	Lamarche, Benoit/0000-0002-4443-5378; Tchernof, Andre/0000-0002-2587-1000				ALBERS JJ, 1978, CLIN CHEM, V24, P323; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; ASSMANN G, 1994, ATHEROSCLEROSIS, V110, pS11, DOI 10.1016/0021-9150(94)05386-W; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CORESH J, 1993, J LIPID RES, V34, P1687; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; Davignon J, 1996, ATHEROSCLEROSIS, V124, pS57, DOI 10.1016/0021-9150(96)05858-3; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; Despres Jean-Pierre, 1993, Nutrition Research Reviews, V6, P137, DOI 10.1079/NRR19930010; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FRIEDEWALD WT, 1972, SCAND J CLIN LAB INV, V124, P23; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GINSBURG GS, 1991, AM J CARDIOL, V68, P187, DOI 10.1016/0002-9149(91)90742-4; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; HAFFNER SM, 1993, DIABETES, V42, P1297, DOI 10.2337/diabetes.42.9.1297; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KRAUSS RM, 1982, J LIPID RES, V23, P97; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lamarche B, 1996, CIRCULATION, V94, P273, DOI 10.1161/01.CIR.94.3.273; LAMARCHE B, 1995, AM J CARDIOL, V75, P1189, DOI 10.1016/S0002-9149(99)80760-7; Lamarche B, 1996, ATHEROSCLEROSIS, V119, P235, DOI 10.1016/0021-9150(95)05653-X; Lamarche B, 1997, ARTERIOSCL THROM VAS, V17, P1098, DOI 10.1161/01.ATV.17.6.1098; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MCNAMARA JR, 1992, ARTERIOSCLER THROMB, V12, P1284, DOI 10.1161/01.ATV.12.11.1284; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MOORJANI S, 1987, METABOLISM, V36, P244, DOI 10.1016/0026-0495(87)90183-1; NIGON F, 1991, J LIPID RES, V32, P1741; Perry IJ, 1996, AM J EPIDEMIOL, V144, P224, DOI 10.1093/oxfordjournals.aje.a008917; Pyorala K, 1979, Diabetes Care, V2, P131, DOI 10.2337/diacare.2.2.131; REAVEN GM, 1988, DIABETES, V37, P1495; Sniderman AD, 1996, CLIN CHEM, V42, P489; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Superko HR, 1996, CIRCULATION, V94, P2351, DOI 10.1161/01.CIR.94.10.2351; Tchernof A, 1996, DIABETES CARE, V19, P629, DOI 10.2337/diacare.19.6.629; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293; YARNELL JWG, 1994, BRIT HEART J, V71, P293; YUAN JN, 1994, ATHEROSCLEROSIS, V110, P1, DOI 10.1016/0021-9150(94)90062-0	44	303	325	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1955	1961		10.1001/jama.279.24.1955	http://dx.doi.org/10.1001/jama.279.24.1955			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643858	Bronze			2022-12-01	WOS:000074252100031
J	Piot, P				Piot, P			The science of AIDS: A tale of two worlds	SCIENCE			English	Editorial Material									UNAIDS, CH-1211 Geneva 27, Switzerland	UNAIDS	Piot, P (corresponding author), UNAIDS, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.								0	29	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1844	1845		10.1126/science.280.5371.1844	http://dx.doi.org/10.1126/science.280.5371.1844			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669936				2022-12-01	WOS:000074323800028
J	Gauss, R; Seifert, R; Kaupp, UB				Gauss, R; Seifert, R; Kaupp, UB			Molecular identification of a hyperpolarization-activated channel in sea urchin sperm	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; GATED CHANNEL; CAMP; DROSOPHILA; FAMILY; ROD; SEQUENCE; GENES	Sea urchin eggs attract sperm through chemotactic peptides, which evoke complex changes in membrane voltage and in the concentrations of cyclic AMP, cyclic GMP and Ca2+ ions (see ref. 1 for a review). The intracellular signalling pathways and their cellular targets are largely unknown. We have now cloned, from sea urchin testis, the complementary DNA encoding a channel polypeptide, SPIH, Functional expression of SPIH gives rise to weakly K+-selective hyperpolarization-activated channels, whose activity is enhanced by the direct action of cAMP. Thus, SPIH is under the dual control of voltage and cAMP. The SPIH channel, which is confined to the sperm flagellum, may be involved in the control of flagellar beating. SPM currents exhibit all the hallmarks of hyperpolarization-activated currents (I-h)(2,3), which participate in the rhythmic firing of central neurons, control pacemaking in the heart, and curtail saturation by bright light in retinal photoreceptors(2,3). Because of their sequence(4) and functional properties, I-h channels form a class of their own within the superfamily of voltage-gated and cyclic-nucleotide-gated channels.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	a.eckert@fz-juelich.de						AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BABCOCK DE, 1992, P NATL ACAD SCI USA, V86, P6001; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; Darszon A., 1994, Methods (Orlando), V6, P37, DOI 10.1006/meth.1994.1006; DIFRANCESCO D, 1984, J PHYSIOL-LONDON, V348, P341, DOI 10.1113/jphysiol.1984.sp015114; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.ph.55.030193.002323; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FINN JT, ANN REV PHYSL, V58, P395; Hagen V, 1996, BIOCHEMISTRY-US, V35, P7762, DOI 10.1021/bi952895b; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Labarca P, 1996, DEV BIOL, V174, P271, DOI 10.1006/dbio.1996.0072; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.physiol.58.1.299; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WOLLMUTH LP, 1992, J GEN PHYSIOL, V100, P749, DOI 10.1085/jgp.100.5.749	30	363	373	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					583	587		10.1038/31248	http://dx.doi.org/10.1038/31248			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634235				2022-12-01	WOS:000074150100054
J	Tamura, M; Gu, JG; Matsumoto, K; Aota, S; Parsons, R; Yamada, KM				Tamura, M; Gu, JG; Matsumoto, K; Aota, S; Parsons, R; Yamada, KM			Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN	SCIENCE			English	Article							INTEGRINS; KINASE	The tumor suppressor PTEN is a phosphatase with sequence similarity to the cytoskeletal protein tensin. Here the cellular roles of PTEN were investigated. Overexpression of PTEN inhibited cell migration, whereas antisense PTEN enhanced migration. Integrin-mediated cell spreading and the formation of focal adhesions were down-regulated by wild-type PTEN but not by PTEN with an inactive phosphatase domain. PTEN interacted with the focal adhesion kinase FAK and reduced its tyrosine phosphorylation. Overexpression of FAK partially antagonized the effects of PTEN. Thus, PTEN phosphatase may function as a tumor suppressor by negatively regulating cell interactions with the extracellular matrix.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University; Columbia University	Tamura, M (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Room 421,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	mtamura@yoda.nidr.nih.gov; kyamada@yoda.nidr.nih.gov	Gu, Jianguo/ABC-9257-2020	Parsons, Ramon/0000-0002-6656-3514; Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Arregui Carlos O., 1997, Molecular Biology of the Cell, V8, p290A; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lin Shin, 1993, P240; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Okami K, 1998, CANCER RES, V58, P509; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAMURA M, UNPUB; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	25	1017	1140	6	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1998	280	5369					1614	1617		10.1126/science.280.5369.1614	http://dx.doi.org/10.1126/science.280.5369.1614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616126				2022-12-01	WOS:000074061200044
J	Gonzalez, CH; Marques-Dias, MJ; Kim, CA; Sugayama, SMM; Da Paz, JA; Huson, SM; Holmes, LB				Gonzalez, CH; Marques-Dias, MJ; Kim, CA; Sugayama, SMM; Da Paz, JA; Huson, SM; Holmes, LB			Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy	LANCET			English	Article							PARAPLEGIA; ABORTION; SEQUENCE	Background Misoprostol is commonly used to induce abortion in Brazil, and in other countries in South and Central America where abortions are illegal. However, misoprostol is not very effective in inducing abortions, and exposure to the drug in utero can cause abnormalities in the fetus. We aimed to define the common phenotypical effects of exposure to the drug. Methods We studied 42 infants from Sao Paulo, Brazil, who were exposed to misoprostol during the first 3 months of gestation, and then born with congenital abnormalities. We interviewed each of the infants' mothers to find out about misoprostol exposure and dosage. Each infant was physically examined by a geneticist or a neuropaediatrician. Findings 17 of the infants had equinovarus with cranial-nerve defects. Ten children had equinovarus as part of more extensive arthrogryposis. The most distinctive phenotypes were arthrogryposis confined to the legs (five cases) and terminal transverse-limb defects (nine cases) with or without Mobius sequence. The most common dose of misoprostol taken was 800 mu g (range 200-16 000 mu g). Interpretation Deformities attributed to vascular disruption were found in these children. We suggest that the uterine contractions induced by misoprostol cause vascular disruption in the fetus, including brain-stem ischaemia. Information on the effects of taking misoprostol during pregnancy should be made more widely available, to dissuade women from misusing the drug.	Massachusetts Gen Hosp, Genet & Teratol Univ, Boston, MA 02115 USA; Univ Sao Paulo, Fac Med, Inst Crianca, Sao Paulo, Brazil; Oxford Radcliffe Hosp, Dept Clin Genet, Oxford, England	Harvard University; Massachusetts General Hospital; Universidade de Sao Paulo; University of Oxford	Holmes, LB (corresponding author), Massachusetts Gen Hosp, Genet & Teratol Univ, Warren 801,55 Fruit St, Boston, MA 02115 USA.			Kim, Chong/0000-0002-1754-1300	NICHD NIH HHS [R0I HD 33222] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033222] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOUWESBAVINCK JN, 1986, AM J MED GENET, V23, P903, DOI 10.1002/ajmg.1320230405; Bugalho A, 1996, CONTRACEPTION, V53, P243, DOI 10.1016/0010-7824(96)00044-3; CLEMENS GR, 1997, TOXICOLOGIST, V36, P260; COELHO HLL, 1991, LANCET, V338, P247, DOI 10.1016/0140-6736(91)90379-4; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; DOWNIE WW, 1991, LANCET, V338, P247; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; GOVAERT P, 1989, PEDIATRICS, V84, P570; Hall JG, 1996, AM J MED GENET, V63, P293, DOI 10.1002/(SICI)1096-8628(19960503)63:1<293::AID-AJMG48>3.0.CO;2-G; HOLMES LB, 1995, J PEDIATR-US, V126, P131, DOI 10.1016/S0022-3476(95)70516-3; KOTSONIS FN, 1985, DIGEST DIS SCI, V30, pS142, DOI 10.1007/BF01309401; LIPSON AH, 1989, TERATOLOGY, V40, P339, DOI 10.1002/tera.1420400406; ORNOY A, 1982, ISRAEL J MED SCI, V18, P235; Pastuszak A. L., 1997, Teratology, V55, P36; PERSAUD TVN, 1979, ADV STUDY BIRTH DEFE, P161; RINGEL RE, 1983, J PEDIATR-US, V103, P251, DOI 10.1016/S0022-3476(83)80358-8; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; Schuler L., 1997, Teratology, V55, P36; SHEPARD TH, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91540-0; SODRE H, 1990, J PEDIATR ORTHOPED, V10, P101; VERLOES A, 1990, J MED GENET, V27, P213, DOI 10.1136/jmg.27.3.213-b; WEYERTS LK, 1992, AM J MED GENET, V43, P751, DOI 10.1002/ajmg.1320430420	24	161	173	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1624	1627		10.1016/S0140-6736(97)12363-7	http://dx.doi.org/10.1016/S0140-6736(97)12363-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620717				2022-12-01	WOS:000074026600010
J	deCharms, RC; Blake, DT; Merzenich, MM				deCharms, RC; Blake, DT; Merzenich, MM			Optimizing sound features for cortical neurons	SCIENCE			English	Article							PRIMARY AUDITORY-CORTEX; CAT STRIATE CORTEX; SPECTRO-TEMPORAL CHARACTERISTICS; SPECIES-SPECIFIC VOCALIZATIONS; COMBINATION-SENSITIVE NEURONS; SIMPLE RECEPTIVE-FIELDS; SPATIOTEMPORAL ORGANIZATION; FUNCTIONAL-ORGANIZATION; MULTIFREQUENCY SOUNDS; POPULATION RESPONSES	The brain's cerebral cortex decomposes visual images into information about oriented edges, direction and velocity information, and color. How does the cortex decompose perceived sounds? A reverse correlation technique demonstrates that neurons in the primary auditory cortex of the awake primate have complex patterns of sound-feature selectivity that indicate sensitivity to stimulus edges in frequency or in time, stimulus transitions in frequency or intensity, and feature conjunctions. This allows the creation of classes of stimuli matched to the processing characteristics of auditory cortical neurons. Stimuli designed for a particular neuron's preferred feature pattern can drive that neuron with higher sustained firing rates than have typically been recorded with simple stimuli. These data suggest that the cortex decomposes an auditory scene into component parts using a feature-processing system reminiscent of that used for the cortical decomposition of visual images.	Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Merzenich, MM (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA.	merz@keck.ucsf.edu						ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; BAKER CL, 1990, VISUAL NEUROSCI, V4, P101, DOI 10.1017/S0952523800002273; Bieser A, 1996, EXP BRAIN RES, V108, P273; Brosch M, 1997, J NEUROPHYSIOL, V77, P923, DOI 10.1152/jn.1997.77.2.923; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; BRUGGE JF, 1969, J NEUROPHYSIOL, V32, P1005, DOI 10.1152/jn.1969.32.6.1005; CALFORD MB, 1995, J NEUROPHYSIOL, V73, P1876, DOI 10.1152/jn.1995.73.5.1876; Chew SJ, 1996, SCIENCE, V274, P1909, DOI 10.1126/science.274.5294.1909; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1118, DOI 10.1152/jn.1993.69.4.1118; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1091, DOI 10.1152/jn.1993.69.4.1091; DEANGELIS GC, 1995, TRENDS NEUROSCI, V18, P451, DOI 10.1016/0166-2236(95)94496-R; DEAR SP, 1993, J NEUROPHYSIOL, V70, P1988, DOI 10.1152/jn.1993.70.5.1988; DEBOER E, 1968, IEEE T BIO-MED ENG, VBM15, P169, DOI 10.1109/TBME.1968.4502561; DEBOER E, 1978, J ACOUST SOC AM, V63, P115, DOI 10.1121/1.381704; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; Doupe AJ, 1997, J NEUROSCI, V17, P1147; EGGERMONT JJ, 1991, HEARING RES, V56, P153, DOI 10.1016/0378-5955(91)90165-6; EGGERMONT JJ, 1983, HEARING RES, V10, P167, DOI 10.1016/0378-5955(83)90052-7; EGGERMONT JJ, 1983, Q REV BIOPHYS, V16, P341, DOI 10.1017/S0033583500005126; EGGERMONT JJ, 1994, HEARING RES, V74, P51, DOI 10.1016/0378-5955(94)90175-9; FITZPATRICK DC, 1993, J NEUROSCI, V13, P931; GLASS I, 1979, EXP BRAIN RES, V34, P489; Heil P, 1997, J NEUROPHYSIOL, V77, P2616, DOI 10.1152/jn.1997.77.5.2616; Heil P, 1997, J NEUROPHYSIOL, V77, P2642, DOI 10.1152/jn.1997.77.5.2642; HERMES DJ, 1981, HEARING RES, V5, P147, DOI 10.1016/0378-5955(81)90043-5; HERMES DJ, 1982, HEARING RES, V6, P103, DOI 10.1016/0378-5955(82)90009-0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; Kao MC, 1997, BIOSYSTEMS, V40, P103, DOI 10.1016/0303-2647(96)01635-8; KAWASAKI M, 1988, J NEUROPHYSIOL, V59, P623, DOI 10.1152/jn.1988.59.2.623; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; KNUDSEN EI, 1995, ANNU REV NEUROSCI, V18, P19, DOI 10.1146/annurev.ne.18.030195.000315; KONISHI M, 1994, BRAIN BEHAV EVOLUT, V44, P279, DOI 10.1159/000113582; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3524, DOI 10.1152/jn.1996.76.5.3524; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3503, DOI 10.1152/jn.1996.76.5.3503; LEWICKI MS, 1995, P NATL ACAD SCI USA, V92, P5582, DOI 10.1073/pnas.92.12.5582; MARGOLIASH D, 1983, J NEUROSCI, V3, P1039; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; MENDELSON JR, 1993, EXP BRAIN RES, V94, P65; MERZENICH MM, 1973, BRAIN RES, V63, P343, DOI 10.1016/0006-8993(73)90101-7; MERZENICH MM, 1985, DYNAMIC ASPECTS NEOC, P397; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MILLER JM, 1974, BRAIN RES, V69, P101, DOI 10.1016/0006-8993(74)90374-6; Nelken I, 1997, J NEUROPHYSIOL, V78, P800, DOI 10.1152/jn.1997.78.2.800; NELKEN I, 1994, HEARING RES, V72, P237, DOI 10.1016/0378-5955(94)90222-4; NELKEN I, 1994, HEARING RES, V72, P223, DOI 10.1016/0378-5955(94)90221-6; NELKEN I, 1994, HEARING RES, V72, P206, DOI 10.1016/0378-5955(94)90220-8; PHILLIPS DP, 1985, HEARING RES, V18, P87, DOI 10.1016/0378-5955(85)90112-1; PHILLIPS DP, 1987, EXP BRAIN RES, V67, P479; PHILLIPS DP, 1994, EXP BRAIN RES, V102, P210; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; REID RC, 1991, J NEUROPHYSIOL, V66, P505, DOI 10.1152/jn.1991.66.2.505; Rieke F., 1997, SPIKES EXPLORING NEU; Ringach DL, 1997, NATURE, V387, P281, DOI 10.1038/387281a0; RIQUIMAROUX H, 1991, SCIENCE, V251, P565, DOI 10.1126/science.1990432; Schreiner C E, 1992, Curr Opin Neurobiol, V2, P516, DOI 10.1016/0959-4388(92)90190-V; SCHREINER CE, 1988, HEARING RES, V32, P49, DOI 10.1016/0378-5955(88)90146-3; SCHREINER CE, 1990, J NEUROPHYSIOL, V64, P1442, DOI 10.1152/jn.1990.64.5.1442; SCHREINER CE, 1988, CODING TEMPORAL PATT; SCHREINER CE, COMMUNICATION; SEMPLE MN, 1993, J NEUROPHYSIOL, V69, P462, DOI 10.1152/jn.1993.69.2.462; SEMPLE MN, 1993, J NEUROPHYSIOL, V69, P449, DOI 10.1152/jn.1993.69.2.449; SHAMMA SA, 1985, HEARING RES, V19, P1, DOI 10.1016/0378-5955(85)90094-2; SHAMMA SA, 1997, SOC NEUR ABSTR, V23, P805; SIMMONS JA, 1993, J COMP PHYSIOL A, V172, P533, DOI 10.1007/BF00213677; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; SUGA N, 1989, J EXP BIOL, V146, P277; SUGA N, 1965, J PHYSIOL-LONDON, V179, P26, DOI 10.1113/jphysiol.1965.sp007648; SUTTER ML, 1995, J NEUROPHYSIOL, V73, P190, DOI 10.1152/jn.1995.73.1.190; Wang XQ, 1995, J NEUROPHYSIOL, V74, P2685, DOI 10.1152/jn.1995.74.6.2685; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; WOLLBERG Z, 1972, SCIENCE, V175, P212, DOI 10.1126/science.175.4018.212	75	335	337	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1439	1443		10.1126/science.280.5368.1439	http://dx.doi.org/10.1126/science.280.5368.1439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603734				2022-12-01	WOS:000073883400057
J	Storey, A; Thomas, M; Kalita, A; Harwood, C; Gardiol, D; Mantovani, F; Breuer, J; Leigh, IM; Matlashewski, G; Banks, L				Storey, A; Thomas, M; Kalita, A; Harwood, C; Gardiol, D; Mantovani, F; Breuer, J; Leigh, IM; Matlashewski, G; Banks, L			Role of a p53 polymorphism in the development of human papillomavirus-associated cancer	NATURE			English	Article							CARCINOMA CELL-LINES; RENAL-TRANSPLANT RECIPIENTS; LUNG-CANCER; BROAD-SPECTRUM; GENE-PRODUCT; E6; DEGRADATION; PROTEIN; TYPE-16; BINDING	The E6 oncoprotein derived from tumour-associated human papillomaviruses (HPVs) binds to and induces the degradation of the cellular tumour-suppressor protein p53. A common polymorphism that occurs in the p53 amino-acid sequence results In the presence of either a proline or an arginine at position 72, The effect of this polymorphism on the susceptibility of p53 to EG-mediated degradation has been Investigated and the arginine form of p53 was found to be significantly more susceptible than the proline form. Moreover, allelic analysis of patients with HPV-associated tumours revealed a striking overrepresentation of homozygous arginine-72 p53 compared with the normal population, which indicated that individuals homozygous for arginine 72 are about seven times more susceptible to HPV-associated tumorigenesis than heterozygotes. The arginine-encoding allele therefore represents a significant risk factor in the development of HPV-associated cancers.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Imperial Canc Res Fund, Skin Tumour Lab, London E1 2AT, England; McGill Univ, Inst Parasitol, St Anne De Bellevue, PQ H9X 3V9, Canada; McGill Univ, McGill Canc Ctr, St Anne De Bellevue, PQ H9X 3V9, Canada; St Bartholomews & Royal London Hosp, Sch Med & Dent, Queen Mary & Westfield Coll, Dept Med Microbiol, London E1 1BB, England	International Center for Genetic Engineering & Biotechnology (ICGEB); Cancer Research UK; McGill University; McGill University; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Storey, Alan/0000-0003-2001-9772; Breuer, Judith/0000-0001-8246-0534; Harwood, Catherine/0000-0002-1375-0965				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; BENTON EC, 1989, IMMUNODEFICIENCY SKI, P168; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; BIRGANDER R, 1995, CARCINOGENESIS, V16, P2233, DOI 10.1093/carcin/16.9.2233; BLESSING K, 1989, HISTOPATHOLOGY, V14, P129, DOI 10.1111/j.1365-2559.1989.tb02123.x; BOYLE J, 1993, CANCER RES, V53, P5328; BUTZ K, 1995, ONCOGENE, V10, P927; CHAN SY, 1995, J VIROL, V69, P3074, DOI 10.1128/JVI.69.5.3074-3083.1995; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; CROOK T, 1991, ONCOGENE, V6, P873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Glover Mary T., 1993, Cancer Bulletin (Houston), V45, P220; GOLDBERG A, 1992, EUR J BIOCHEM, V203, P285; HERSHKO D, 1992, ANNU REV BIOCHEM, V61, P761; JIN XM, 1995, CARCINOGENESIS, V16, P2205, DOI 10.1093/carcin/16.9.2205; KAWAJIRI K, 1993, CARCINOGENESIS, V14, P1085, DOI 10.1093/carcin/14.6.1085; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; MANOS MM, 1989, CANCER CEL, V7, P209; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOREAU F, 1992, BIOCHEM CELL BIOL, V70, P1014, DOI 10.1139/o92-145; Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261; PURDIE KJ, 1993, CANCER RES, V53, P5328; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; SHAMANIN V, 1994, J GEN VIROL, V75, P1149, DOI 10.1099/0022-1317-75-5-1149; SHAMANIN V, 1994, CANCER RES, V54, P4610; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; Sun XF, 1996, ONCOGENE, V13, P407; THOMAS M, 1995, ONCOGENE, V10, P261; VOGAN K, 1993, CANCER RES, V53, P5269; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	48	810	854	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					229	234		10.1038/30400	http://dx.doi.org/10.1038/30400			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607760				2022-12-01	WOS:000073761000041
J	Hawkey, PM				Hawkey, PM			Action against antibiotic resistance: no time to lose	LANCET			English	Editorial Material									Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Hawkey, PM (corresponding author), Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England.							Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; Chiew YF, 1998, J ANTIMICROB CHEMOTH, V41, P247, DOI 10.1093/jac/41.2.247; HALL A, 1976, NATURE, V264, P803, DOI 10.1038/264803a0; *HOUS LORDS SEL CO, 1998, 7 HOUS LORDS SEL CO, P1; *JOINT COMM US ANT, 1969, REP JOINT COMM US AN; LACEY RW, 1984, LANCET, V2, P1022; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; Munro S, 1998, AM J CLIN PATHOL, V109, P144; Piddock LJV, 1997, J ANTIMICROB CHEMOTH, V39, P177, DOI 10.1093/jac/39.2.177; Piddock LJV, 1996, J ANTIMICROB CHEMOTH, V38, P1, DOI 10.1093/jac/38.1.1; Woodford N, 1998, ANTIMICROB AGENTS CH, V42, P502, DOI 10.1128/AAC.42.3.502	11	41	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1298	1299		10.1016/S0140-6736(98)22018-6	http://dx.doi.org/10.1016/S0140-6736(98)22018-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643787				2022-12-01	WOS:000073439400002
J	Sone, S; Takashima, S; Li, F; Yang, ZG; Honda, T; Maruyama, Y; Hasegawa, M; Yamanda, T; Kubo, K; Hanamura, K; Asakura, K				Sone, S; Takashima, S; Li, F; Yang, ZG; Honda, T; Maruyama, Y; Hasegawa, M; Yamanda, T; Kubo, K; Hanamura, K; Asakura, K			Mass screening for lung cancer with mobile spiral computed tomography scanner	LANCET			English	Article							DETECTION PROGRAM; NEW-YORK; PREVALENCE; SURVIVAL	Background The incidence of and mortality from lung cancer have increased steadily. Most lung cancers are not localised when first detected, but early detection is mandatory to improve prognosis. Since curable early cases are hard to visualise with conventional chest radiography, a new diagnostic means must be found. We assessed whether population-based mass screening with a spiral computed tomography scanner could contribute substantially to detection of smaller cancers, and decrease mortality. Methods In 1996, we screened in a mobile unit 5483 individuals from the general population of Matsumoto, Japan, aged between 40 years and 74 years who had undergone annual chest radiography (miniature fluorophotography) and cytological assessment of sputum. All participants had a low-dose X-ray spiral computed tomography (CT) scan of the thorax; 3967 also underwent miniature fluorophotography. We compared smokers and non-smokers. Further assessments were done for probably benign but suspicious lesions; suspicion of cancer; and indeterminate small nodules by chest radiography and conventional CT, with additional transbronchial biopsy when possible. Thoracotomy was recommended when it was strongly suspected that the patients had lung cancer. Findings 19 patients were diagnosed as having lung cancer--14 with suspicion of lung cancer, three with benign but suspicious lesions, and two with indeterminate small nodules. 18 cases were surgically confirmed, and one was clinically diagnosed. The mean size of lesions was 17 mm (range 6-47). In four of 19 patients, lung abnormality was seen on CT and miniature fluorophotography, The lung-cancer detection rate with CT was 0 4846, significantly higher than the 0 03-0 05% for standard mass assessments done previously in the same area. CT missed one case that was found solely on a sputum cytology examination. Interpretation Our results show that miniature fluorophotography or conventional chest radiography, which have been the main diagnostic techniques for lung cancer, showed few small cancers. CT was more accurate in mass screening for lung cancer and led to early detection and an accurate diagnosis of lung cancer, and should be considered in future health plans.	Shinshu Univ, Sch Med, Dept Radiol, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 390862, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 390862, Japan; Japan Matsumoto Res Ctr, Telecommun Advancement Org, Matsumoto, Nagano, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University; National Institute of Information & Communications Technology (NICT) - Japan	Sone, S (corresponding author), Shinshu Univ, Sch Med, Dept Radiol, 3-1-1 Asahi, Matsumoto, Nagano 390862, Japan.							BERLIN NI, 1984, AM REV RESPIR DIS, V130, P545; EBELING K, 1987, INT J CANCER, V40, P141, DOI 10.1002/ijc.2910400202; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Hillerdal G, 1996, LUNG CANCER-J IASLC, V15, P21, DOI 10.1016/0169-5002(96)00567-3; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; MELAMED M, 1977, CANCER, V39, P369, DOI 10.1002/1097-0142(197702)39:2<369::AID-CNCR2820390202>3.0.CO;2-I; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; SOBUE T, 1992, INT J CANCER, V50, P230, DOI 10.1002/ijc.2910500212	12	688	726	0	65	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1242	1245		10.1016/S0140-6736(97)08229-9	http://dx.doi.org/10.1016/S0140-6736(97)08229-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643744				2022-12-01	WOS:000073283600010
J	Wennerholm, UB; Albertsson-Wikland, K; Bergh, C; Hamberger, L; Niklasson, A; Nilsson, L; Thiringer, K; Wennergren, M; Wikland, M; Borres, MP				Wennerholm, UB; Albertsson-Wikland, K; Bergh, C; Hamberger, L; Niklasson, A; Nilsson, L; Thiringer, K; Wennergren, M; Wikland, M; Borres, MP			Postnatal growth and health in children born after cryopreservation as embryos	LANCET			English	Article							IN-VITRO FERTILIZATION; CONGENITAL-MALFORMATIONS; ASSISTED REPRODUCTION; INVITRO FERTILIZATION; CHRONIC ILLNESS; BIRTH; PREGNANCIES; PREVALENCE; WEIGHT	Background There is uncertainty about the health of children born from in-vitro fertilisation (IVF) with cryopreserved embryos. We investigated the postnatal growth and health (up to 18 months) of these children compared with those born after standard IVF with fresh embryos and those from spontaneous pregnancies. Methods 255 children from cryopreserved embryos were matched by maternal age, parity, single or twin pregnancy, and date of delivery with 255 children born after IVF with fresh embryos, and 252 children from spontaneous pregnancies. The main endpoint was growth; secondary endpoints were the prevalence of chronic illness, major malformations, cumulative incidence of common diseases, and development during the first 18 months. Growth was assessed by comparison with standard Swedish growth charts and by standard deviation scores. Findings Growth features were similar for both singletons and twins in the three groups, There were 6 (2.4%) of 255, 9 (3.5%) of 255, and 8 (3.2%) of 252 major malformations in the cryopreserved group, standard IVF, and spontaneous groups, respectively (p=0.6 between the cryopreserved and standard IVF group). The prevalence of chronic diseases did not differ between the three groups, with 18.0%, 15.3%, and 16.7% of children with a chronic illness in the cryopreserved group, standard IVF, and spontaneous groups, respectively. Interpretation The cryopreservation process does not adversely affect the growth and health of children during infancy and early childhood. Minor handicaps, behavioural disturbances, learning difficulties, and dysfunction of attention and perception cannot be ruled out at this age.	Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Paediat, S-41345 Gothenburg, Sweden; Univ Goteborg, Carlanderska Hosp, Fertil Ctr Scandinavla, Gothenburg, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg	Wennerholm, UB (corresponding author), Sahlgrens Univ Hosp, Dept Obstet & Gynaecol, S-41345 Gothenburg, Sweden.		Albertsson-Wikland, Kerstin/D-3843-2012					BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BRANDES JM, 1992, PEDIATRICS, V90, P424; BYLUND B, IN PRESS ACTA SCAND; CADMAN D, 1987, PEDIATRICS, V79, P805; Cederblad M, 1996, HUM REPROD, V11, P2052; DARIN N, IN PRESS DEV MED CHI; DEMOUZON J, 1997, J ASSIST REPROD GEN, V14, pS251; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; FOYLE LW, 1995, ARCH DIS CHILD, V73, pF143; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; Golombok S, 1996, HUM REPROD, V11, P2324; Hagberg B, 1996, ACTA PAEDIATR, V85, P954, DOI 10.1111/j.1651-2227.1996.tb14193.x; HAGELIN E, 1991, J ADV NURS, V16, P15, DOI 10.1111/j.1365-2648.1991.tb01492.x; KARLBERG J, 1987, ACTA PAEDIATR SCAND, V76, P478, DOI 10.1111/j.1651-2227.1987.tb10503.x; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KARLBERG P, 1976, ACTA PAEDIATR SC   S, V258, P1; Kohler L, 1991, CHILDRENS HLTH SWEDE; KOHLER L, 1987, CLIN DEV MED, V98, P36; LASSALLE B, 1985, FERTIL STERIL, V44, P645; MORIN NC, 1989, J PEDIATR-US, V115, P222, DOI 10.1016/S0022-3476(89)80069-1; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Olivennes F, 1996, HUM REPROD, V11, P1565; RAOULDUVAL A, 1994, HUM REPROD, V9, P1097, DOI 10.1093/oxfordjournals.humrep.a138639; Saunders K, 1996, PEDIATRICS, V97, P688; SCHEFFZEK A, 1989, MONATSSCHR KINDERH, V137, P42; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; SUTCLIFFE AG, 1995, ARCH DIS CHILD, V72, P290, DOI 10.1136/adc.72.4.290; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; Wennerholm UB, 1997, HUM REPROD, V12, P1819, DOI 10.1093/humrep/12.8.1819; WESTBOM L, 1987, SCAND J SOC MED, V15, P87, DOI 10.1177/140349488701500206; WIDLUND G, 1986, SCAND J SOC MED, V14, P97, DOI 10.1177/140349488601400210; WIKLAND M, 1994, HUM REPROD, V9, P1430, DOI 10.1093/oxfordjournals.humrep.a138724	33	88	95	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1085	1090		10.1016/S0140-6736(97)08247-0	http://dx.doi.org/10.1016/S0140-6736(97)08247-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660577				2022-12-01	WOS:000073090200009
J	Backstrom, BT; Muller, U; Hausmann, B; Palmer, E				Backstrom, BT; Muller, U; Hausmann, B; Palmer, E			Positive selection through a motif in the alpha beta T cell receptor	SCIENCE			English	Article							NEGATIVE SELECTION; CD4+8+ THYMOCYTES; TRANSGENIC MICE; ANTIGEN; CHAIN; THYMUS; TOLERANCE; MOLECULES; DELETION; IMMATURE	The two Lineages of T cells, alpha beta and gamma delta, differ in their developmental requirements: only alpha beta cells require major histocompatibility complex recognition, a process known as positive selection, The alpha beta T cell receptor (TCR), but not its gamma delta counterpart, contains a motif within the alpha-chain connecting peptide domain (alpha-CPM) that has been conserved over the Last 500 million years. In transgenic mice expressing an alpha beta TCR Lacking the alpha-CPM, thymocytes were blocked in positive selection but could undergo negative selection. Thus, the alpha-CPM seems to participate in the generation of signals required for positive selection.	Basel Inst Immunol, CH-4005 Basel, Switzerland		Palmer, E (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.							AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Backstrom BT, 1997, EUR J IMMUNOL, V27, P1433; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BACKSTROM BT, UNPUB; BIGBY M, 1993, J IMMUNOL, V151, P4465; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; COHN M, 1982, BEHRING I MITT, V70, P219; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; CURNOW SJ, 1994, CYTOMETRY, V16, P41, DOI 10.1002/cyto.990160107; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DIGIUSTO DL, 1994, MOL IMMUNOL, V31, P693, DOI 10.1016/0161-5890(94)90179-1; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; PAGE DM, 1993, J IMMUNOL, V151, P1868; Partula S, 1996, J IMMUNOL, V157, P207; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; Schweighoer E, 1996, J EXP MED, V183, P2033, DOI 10.1084/jem.183.5.2033; SHIOHARA T, 1987, J IMMUNOL, V138, P1979; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	30	97	98	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					835	838		10.1126/science.281.5378.835	http://dx.doi.org/10.1126/science.281.5378.835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694657				2022-12-01	WOS:000075295600053
J	Gross, DM; Forsthuber, T; Tary-Lehmann, M; Etling, C; Ito, K; Nagy, ZA; Field, JA; Steere, AC; Huber, BT				Gross, DM; Forsthuber, T; Tary-Lehmann, M; Etling, C; Ito, K; Nagy, ZA; Field, JA; Steere, AC; Huber, BT			Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis	SCIENCE			English	Article							SURFACE PROTEIN-A; BORRELIA-BURGDORFERI; RHEUMATOID-ARTHRITIS; ANTIGEN EXPRESSION; ASSOCIATION; DISEASE; PEPTIDE; RECOGNITION; PREDICTION; DISTINCT	Treatment-resistant Lyme arthritis is associated with immune reactivity to outer surface protein A (OspA) of Borrelia burgdorferi, the agent of Lyme disease, and the major histocompatibility complex class II allele DRB1*0401. The immunodominant epitope of OspA for T helper cells was identified. A homology search revealed a peptide from human leukocyte function-associated antigen-1 (hLFA-1) as a candidate autoantigen. Individuals with treatment-resistant Lyme arthritis, but not other forms of arthritis, generated responses to OspA, hLFA-1, and their highly related peptide epitopes. Identification of the initiating bacterial antigen and a cross-reactive autoantigen may provide a model for development of autoimmune disease.	Tufts Univ, Dept Pathol, Boston, MA 02111 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Hoffmann La Roche Inc, Dept Immunol, Nutley, NJ 07110 USA; New England Med Ctr, Dept Rheumatol, Boston, MA 02111 USA	Tufts University; Case Western Reserve University; Roche Holding; Tufts Medical Center	Gross, DM (corresponding author), Tufts Univ, Dept Pathol, Boston, MA 02111 USA.		Forsthuber, Thomas/AID-8080-2022	Steere, Allen/0000-0002-5268-9853; /0000-0003-0692-7125	NIAMS NIH HHS [R01 AR20358] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BRADLEY JF, 1994, ANN INTERN MED, V120, P487, DOI 10.7326/0003-4819-120-6-199403150-00007; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; FENG SL, 1995, J INFECT DIS, V172, P286, DOI 10.1093/infdis/172.1.286; Golde WT, 1998, INFECT MED, V15, P38; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Gross D., UNPUB; Gross DM, 1998, J IMMUNOL, V160, P1022; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; Kamradt T, 1996, INFECT IMMUN, V64, P1284, DOI 10.1128/IAI.64.4.1284-1289.1996; LAHESMAA R, 1993, J IMMUNOL, V150, P4125; LANCHBURY JSS, 1991, HUM IMMUNOL, V32, P56, DOI 10.1016/0198-8859(91)90117-R; LENGLJANSSEN B, 1994, J EXP MED, V180, P2069, DOI 10.1084/jem.180.6.2069; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARSHALL KW, 1995, J IMMUNOL, V154, P5927; MORENO J, 1991, J IMMUNOL, V147, P3306; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, UNPUB; SZTEIN MB, 1984, J CLIN INVEST, V73, P556, DOI 10.1172/JCI111243; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6	28	371	408	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					703	706		10.1126/science.281.5377.703	http://dx.doi.org/10.1126/science.281.5377.703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685265				2022-12-01	WOS:000075107900044
J	Chou, JJ; Matsuo, H; Duan, H; Wagner, G				Chou, JJ; Matsuo, H; Duan, H; Wagner, G			Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment	CELL			English	Article							DEATH DOMAIN; PROTEINS; NMR; RESONANCE; FADD; C-13; FAS	Apoptosis requires recruitment of caspases by receptor-associated adaptors through homophilic interactions between the CARDs (caspase recruitment domains) of adaptor proteins and prodomains of caspases. We have solved the CARD structure of the RAIDD adaptor protein that recruits ICH-1/caspase-2. It consists of six tightly packed helices arranged in a topology homologous to the Fas death domain. The surface contains a basic and an acidic patch on opposite sides. This polarity is conserved in the ICH-1 CARD as indicated by homology modeling. Mutagenesis data suggest that these patches mediate CARD/CARD interaction between RAIDD and ICH-1. Subsequent modeling of the CARDs of Apaf-1 and caspase-9, as well as Ced-4 and Ced-3, showed that the basic/acidic surface polarity is highly conserved, suggesting a general mode for CARD/CARD interaction.	Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA	Harvard University; Harvard University; Harvard Medical School; Pfizer	Wagner, G (corresponding author), Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA.		Chou, James/AAD-6230-2022; Chou, James J/N-9840-2013	Chou, James/0000-0002-4442-0344; Chou, James J/0000-0002-4442-0344	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467, R01GM038608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47467, GM 38608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker SJ, 1996, ONCOGENE, V12, P1; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUNGER AT, 1994, XPLOR 3851 SYSTEM XR; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou KC, 1997, FEBS LETT, V419, P49, DOI 10.1016/S0014-5793(97)01246-5; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DELRIOPORTILLA F, 1994, J MAGN RESON SER A, V111, P132, DOI 10.1006/jmra.1994.1238; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LEVITT M, 1995, LOOK VERSION 2 0 MOL; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Matsuo H, 1996, J MAGN RESON SER B, V110, P112, DOI 10.1006/jmrb.1996.0018; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	36	275	281	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					171	180		10.1016/S0092-8674(00)81417-8	http://dx.doi.org/10.1016/S0092-8674(00)81417-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695946	Bronze			2022-12-01	WOS:000075020100006
J	Kobayashi, K; Nakahori, Y; Miyake, M; Matsumura, K; Kondo-Iida, E; Nomura, Y; Segawa, M; Yoshioka, M; Saito, K; Osawa, K; Hamano, K; Sakakihara, Y; Nonaka, I; Nakagome, Y; Kanazawa, I; Nakamura, Y; Tokunaga, K; Toda, T				Kobayashi, K; Nakahori, Y; Miyake, M; Matsumura, K; Kondo-Iida, E; Nomura, Y; Segawa, M; Yoshioka, M; Saito, K; Osawa, K; Hamano, K; Sakakihara, Y; Nonaka, I; Nakagome, Y; Kanazawa, I; Nakamura, Y; Tokunaga, K; Toda, T			An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy	NATURE			English	Article							LINKAGE-DISEQUILIBRIUM; GLYCOPROTEIN COMPLEX; LOCALIZATION; GENE; PROTEINS; FCMD	Fukuyama-type congenital muscular dystrophy (FCMD), one of the most common autosomal recessive disorders in Japan (incidence is 0.7-1.2 per 10,000 births), is characterized by congenital muscular dystrophy associated with brain malformation (micropolygria) due to a defect in the migration of neurons(1). We previously mapped the FCMD gene to a region of less than 100 kilobases which included the marker locus D9S2107 on chromosome 9q31 (refs 2-4). We have also described a haplotype that is shared by more than 80% of FCMD chromosomes, indicating that most chromosomes bearing the FCMD mutation could be derived hom a single ancestor(5). Here we report that there is a retrotransposal insertion of tandemly repeated sequences within this candidate-gene interval in all FCMD chromosomes carrying the founder haplotype (87%). The inserted sequence is about 3 kilobases long and is located in the 3' untranslated region of a gene encoding a new 461-amino-acid protein. This gene is expressed in various tissues in normal individuals, but not in FCMD patients who carry the insertion. Two independent point mutations confirm that mutation of this gene is responsible for FCMD. The predicted protein, which we term fukutin, contains an amino-terminal signal sequence, which together with results from transfection experiments suggests that fukutin is a secreted protein. To our knowledge, FCMD is the first human disease to be caused by an ancient retrotransposal integration.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Neurol, Tokyo 1130033, Japan; Univ Tokushima, Sch Med, Dept Publ Hlth, Tokushima 7708503, Japan; Teikyo Univ, Sch Med, Dept Neurol, Tokyo 1738605, Japan; Tokyo Womens Med Coll, Dept Pediat, Tokyo 1628666, Japan; Segawa Neurol Clin Children, Tokyo 1010062, Japan; Kobe Gen Hosp, Dept Pediat, Kobe, Hyogo 6500046, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 3058576, Japan; Natl Inst Neurosci, NCNP, Dept Ultrastruct Res, Tokyo 1878502, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Tokushima University; Teikyo University; Tokyo Women's Medical University; Kobe City Medical Center General Hospital; University of Tsukuba; National Center for Neurology & Psychiatry - Japan	Toda, T (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	toda@ims.u-tokyo.ac.jp	Kobayashi, Kazuhiro/AAH-8638-2021	Kobayashi, Kazuhiro/0000-0001-7801-147X; Saito, Kayoko/0000-0003-2632-0873; Toda, Tatsushi/0000-0002-0717-1123				BANNAI M, 1994, EUR J IMMUNOGENET, V21, P1, DOI 10.1111/j.1744-313X.1994.tb00170.x; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; des Portes V, 1998, CELL, V92, P51; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FUKUYAMA Y, 1981, BRAIN DEV-JPN, V3, P1; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HAYASHI YK, 1993, J NEUROL SCI, V119, P53, DOI 10.1016/0022-510X(93)90191-Z; Ishii H, 1997, NEUROMUSCULAR DISORD, V7, P191, DOI 10.1016/S0960-8966(97)00462-8; KOBAYASHI K, IN PRESS HUM GENET; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakano I, 1996, ACTA NEUROPATHOL, V91, P313, DOI 10.1007/s004010050431; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TODA T, 1993, NAT GENET, V5, P283, DOI 10.1038/ng1193-283; Toda T, 1996, AM J HUM GENET, V59, P1313; TODA T, 1994, AM J HUM GENET, V55, P946; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; [No title captured]	22	621	636	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					388	392		10.1038/28653	http://dx.doi.org/10.1038/28653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690476				2022-12-01	WOS:000074968800056
J	Griffin, BA; Adams, SR; Tsien, RY				Griffin, BA; Adams, SR; Tsien, RY			Specific covalent labeling of recombinant protein molecules inside live cells	SCIENCE			English	Article								Recombinant proteins containing four cysteines at the i, i + 1, i + 4, and i + 5 positions of an alpha helix were fluorescently labeled in Living cells by extracellular administration of 4',5'-bis(1,3,2-dithioarsolan-2-yl)fluor This designed small Ligand is membrane-permeant and nonfluorescent until it binds with high affinity and specificity to the tetracysteine domain, Such in situ Labeling adds much Less mass than does green fluorescent protein and offers greater versatility in attachment sites as well as potential spectroscopic and chemical properties. This system provides a recipe for slightly modifying a target protein so that it can be singled out from the many other proteins inside Live cells and fluorescently stained by small nonfluorescent dye molecules added from outside the cells.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NCI NIH HHS [T32 CA09523] Funding Source: Medline; NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHALFIE M, 1998, GFP GREEN FLUORESCEN; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Ford C F, 1991, Protein Expr Purif, V2, P95, DOI 10.1016/1046-5928(91)90057-P; GRIFFIN BA, 1998, THESIS U CALIFORNIA; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hermanson G. T., 2010, BIOCONJUGATE TECHNIQ; KALEF E, 1994, METHOD ENZYMOL, V233, P395; Lowe WG, 1935, J AM CHEM SOC, V57, P1081, DOI 10.1021/ja01309a035; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P4245, DOI 10.1021/bi00231a020; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; SPANG C, 1989, CHEM BER, V122, P1247, DOI 10.1002/cber.19891220706; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WEBB EC, 1947, BIOCHEM J, V41, P74, DOI 10.1042/bj0410074; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WHITTAKER VP, 1947, BIOCHEM J, V41, P56, DOI 10.1042/bj0410056; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	18	1198	1328	9	247	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					269	272		10.1126/science.281.5374.269	http://dx.doi.org/10.1126/science.281.5374.269			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657724				2022-12-01	WOS:000074714200053
J	Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA				Goldberg, RM; Fleming, TR; Tangen, CM; Moertel, CG; Macdonald, JS; Haller, DG; Laurie, JA		Eastern Cooperative Oncology Grp; N Cent Canc Treatment Grp; SW Oncology Grp	Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection	ANNALS OF INTERNAL MEDICINE			English	Article						surgical procedures, operative; colonic neoplasms; salvage therapy; outcome and process assessment (health care); disease-free survival	COLORECTAL-CARCINOMA; SURGICAL-TREATMENT; ADJUVANT THERAPY; POLYPS; FLUOROURACIL; LEVAMISOLE; METASTASES; LIVER	Background: Follow-up testing after surgery for colon cancer is recommended principally to identify resectable recurrences, but data on the efficacy of, outcomes of, and optimal strategies for this testing are limited. Objectives: To determine the relation between followup tests and salvage surgery, assess outcomes, and document surgical mortality. Design: Retrospective cohort study. Setting: A North American multi-institutional trial comparing postoperative chemotherapy plus follow-up with follow-up alone. Patients: 1247 patients with resected stage II and stage III colon cancer. Intervention: The protocol mandated follow-up testing that could be supplemented at the discretion of treating physicians. Indications of recurrent disease were documented. Measurements: Recurrence, resectable recurrence, surgical mortality, and survival were studied. Results: 548 patients had recurrence of colon cancer. Salvage surgery was attempted in 222 patients (41%). In 109 patients (20%), curative-intent surgery was done for hepatic recurrence (28 patients), pulmonary metastasis (20 patients), local recurrence (24 patients), or recurrence at other sites (37 patients). Most curative-intent surgical procedures were motivated by follow-up testing (36 patients), elevated carcinoembryonic antigen level (41 patients), or symptoms (27 patients). The median follow-up time after curative-intent surgery exceeded 5 years; the estimated 5-year disease-free survival rate was 23%. A solitary lesion was a favorable prognostic factor. The surgical mortality rate was 2%. Curative-intent resections were done in 15 patients with second primary colorectal cancer; 12 of these patients have survived disease-free. Conclusions: Second operations for colon cancer that are triggered by follow-up testing or symptoms are common and can result in long-term disease-free survival.	Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Temple Univ, Sch Med, Philadelphia, PA 19122 USA; Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA; Grand Forks Clin Ltd, Grand Forks, ND 58201 USA	Mayo Clinic; Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Goldberg, RM (corresponding author), Mayo Clin, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.	goldberg.richard@mayo.edu	Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013	Goldberg, Richard/0000-0003-3713-6895; 	NATIONAL CANCER INSTITUTE [U10CA025224, U10CA037404, P01CA031224] Funding Source: NIH RePORTER; NCI NIH HHS [CA-25224, CA-37404, CA-31224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BALLANTYNE GH, 1993, CANCER, V71, P4252, DOI 10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO;2-6; ECKARDT VF, 1988, CANCER, V61, P2552, DOI 10.1002/1097-0142(19880615)61:12<2552::AID-CNCR2820611227>3.0.CO;2-6; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; HUGHES KS, 1986, SURGERY, V100, P278; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCAFEE MK, 1992, ANN THORAC SURG, V53, P780, DOI 10.1016/0003-4975(92)91435-C; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; NELSON RL, 1993, CANCER-AM CANCER SOC, V71, P4298, DOI 10.1002/1097-0142(19930615)71:12+<4298::AID-CNCR2820711819>3.0.CO;2-9; NORFLEET RG, 1991, GASTROINTEST ENDOSC, V37, P531, DOI 10.1016/S0016-5107(91)70822-5; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; *SAS I INC, 1990, SAS STAT US GUID VER, P1027; STEELE G, 1993, CANCER, V71, P4225, DOI 10.1002/1097-0142(19930615)71:12+<4225::AID-CNCR2820711811>3.0.CO;2-C; TURK PS, 1993, CANCER-AM CANCER SOC, V71, P4267, DOI 10.1002/1097-0142(19930615)71:12+<4267::AID-CNCR2820711816>3.0.CO;2-O; WERNECKE K, 1991, AM J ROENTGENOL, V157, P731, DOI 10.2214/ajr.157.4.1892027; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301	19	226	229	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1998	129	1					27	+		10.7326/0003-4819-129-1-199807010-00007	http://dx.doi.org/10.7326/0003-4819-129-1-199807010-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX413	9652996				2022-12-01	WOS:000074513300004
J	Lotan, T; Ohto, M; Yee, KM; West, MAL; Lo, R; Kwong, RW; Yamagishi, K; Fischer, RL; Goldberg, RB; Harada, JJ				Lotan, T; Ohto, M; Yee, KM; West, MAL; Lo, R; Kwong, RW; Yamagishi, K; Fischer, RL; Goldberg, RB; Harada, JJ			Arabidopsis LEAFY COTYLEDON1 is sufficient to induce embryo development in vegetative cells	CELL			English	Article							CCAAT-BINDING-FACTOR; MOSAIC VIRUS-35S PROMOTER; HAP3 TRANSCRIPTION FACTOR; GENE-EXPRESSION; NF-Y; LATE EMBRYOGENESIS; SEED DEVELOPMENT; ABSCISIC-ACID; DNA-BINDING; PROTEIN	The Arabidopsis LEAN COTYLEDON1 (LEC1) gene is required for the specification of cotyledon identity and the completion of embryo maturation. We isolated the LEC1 gene and showed that it functions at an early developmental stage to maintain embryonic cell fate. The LEC1 gene encodes a transcription factor homolog, the CCAAT box-binding factor HAP3 subunit. LEC1 RNA accumulates only during seed development in embryo cell types and in endosperm tissue. Ectopic postembryonic expression of the LEC I gene in vegetative cells induces the expression of embryo-specific genes and initiates formation of embryo-like structures. Our results suggest that LEC1 is an important regulator of embryo development that activates the transcription of genes required for both embryo morphogenesis and cellular differentiation.	Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA	University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Los Angeles	Harada, JJ (corresponding author), Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA.			Lotan, Tamar/0000-0002-1679-4904				Albani D, 1995, GENE, V167, P209, DOI 10.1016/0378-1119(95)00680-X; BAUMLEIN H, 1994, PLANT J, V6, P379, DOI 10.1046/j.1365-313X.1994.06030379.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; Devic M, 1996, PLANT J, V9, P205, DOI 10.1046/j.1365-313X.1996.09020205.x; DIETRICH RA, 1989, PLANT CELL, V1, P73, DOI 10.1105/tpc.1.1.73; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; GUARENTE L, 1984, CELL, V32, P317; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; Harada JJ, 1997, ADV CELL MOL BIOL PL, V4, P545; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEITH K, 1994, PLANT CELL, V6, P589, DOI 10.1105/tpc.6.5.589; KENG T, 1987, P NATL ACAD SCI USA, V84, P9113, DOI 10.1073/pnas.84.24.9113; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEINKE DW, 1992, SCIENCE, V258, P1647, DOI 10.1126/science.258.5088.1647; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; MULDER W, 1994, MOL GEN GENET, V245, P96, DOI 10.1007/BF00279755; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAMBARA E, 1992, PLANT J, V2, P435, DOI 10.1111/j.1365-313X.1992.00435.x; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; Ogas J, 1997, SCIENCE, V277, P91, DOI 10.1126/science.277.5322.91; OLSEN LJ, 1993, PLANT CELL, V5, P941, DOI 10.1105/tpc.5.8.941; Papagiannopoulos P, 1996, MOL GEN GENET, V251, P412, DOI 10.1007/s004380050184; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Parcy F, 1997, PLANT CELL, V9, P1265, DOI 10.1105/tpc.9.8.1265; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SCHWARTZ BW, 1994, DEVELOPMENT, V120, P3235; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; STEEVES TA, 1983, CAN J BOT, V61, P3550, DOI 10.1139/b83-404; Steeves TA, 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; Tsugeki R, 1996, PLANT J, V10, P479, DOI 10.1046/j.1365-313X.1996.10030479.x; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WALBOT V, 1978, DORMANCY DEV ARREST, P113; WEST MAL, 1994, PLANT CELL, V6, P1731, DOI 10.1105/tpc.6.12.1731; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; YADEGARI R, 1994, PLANT CELL, V6, P1713, DOI 10.1105/tpc.6.12.1713	56	699	824	9	117	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1195	1205		10.1016/S0092-8674(00)81463-4	http://dx.doi.org/10.1016/S0092-8674(00)81463-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657152	Bronze			2022-12-01	WOS:000074491100014
J	Roberts, F; Roberts, CW; Johnson, JJ; Kyle, DE; Krell, T; Coggins, JR; Coombs, GH; Milhous, WK; Tzipori, S; Ferguson, DJP; Chakrabarti, D; McLeod, R				Roberts, F; Roberts, CW; Johnson, JJ; Kyle, DE; Krell, T; Coggins, JR; Coombs, GH; Milhous, WK; Tzipori, S; Ferguson, DJP; Chakrabarti, D; McLeod, R			Evidence for the shikimate pathway in apicomplexan parasites	NATURE			English	Article							CHORISMATE SYNTHASE; PLASMODIUM-FALCIPARUM; NEUROSPORA-CRASSA; CLONING; GENES; ACID; 3-PHOSPHATE; SULFADOXINE; GLYPHOSATE; MECHANISMS	Parasites of the phylum Apicomplexa cause substantial morbidity, mortality and economic losses, and new medicines to treat them are needed urgently(1,2). The shikimate pathway is an attractive target for herbicides and antimicrobial agents because it is essential in algae, higher plants, bacteria and fungi, but absent from mammals(3,4). Here we present biochemical, genetic and chemotherapeutic evidence for the presence of enzymes of the shikimate pathway in apicomplexan parasites. In vitro growth of Toxoplasma gondii, Plasmodium falciparum (malaria) and Cryptosporidium parvum was inhibited by the herbicide glyphosate, a well-characterized inhibitor(3) of the shikimate pathway enzyme 5-enolpyruvyl shikimate 3-phosphate synthase. This effect on T. gondii and P. falciparum was reversed by treatment with p-aminobenzoate, which suggests that the shikimate pathway supplies folate precursors for their growth. Glyphosate in combination with pyrimethamine limited T. gondii infection in mice. Four shikimate pathway enzymes were detected in extracts of I: gondii and glyphosate inhibited 5-enolpyruvyl shikimate 3-phosphate synthase activity. Genes encoding chorismate synthase, the final shikimate pathway enzyme, were cloned from T. gondii and P.falciparum This discovery of a functional shikimate pathway in apicomplexan parasites provides several targets for the development of new antiparasite agents.	Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA; Univ Chicago, Chicago, IL 60616 USA; Univ Strathclyde, Dept Immunol, Glasgow G4 0NR, Lanark, Scotland; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; Univ Cent Florida, Orlando, FL 32816 USA	Michael Reese Hospital & Medical Center; University of Chicago; University of Strathclyde; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; University of Glasgow; Tufts University; University of Oxford; State University System of Florida; University of Central Florida	McLeod, R (corresponding author), Michael Reese Hosp & Med Ctr, Chicago, IL 60616 USA.	rmcleod@midway.uchicago.edu	Roberts, Craig William/B-8016-2008; Krell, Tino/G-7296-2015	Roberts, Craig William/0000-0002-0653-835X; Krell, Tino/0000-0002-9040-3166; Kyle, Dennis/0000-0002-0238-965X; Ferguson, David/0000-0001-5045-819X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANERJI S, 1995, J EUKARYOT MICROBIOL, V42, P675, DOI 10.1111/j.1550-7408.1995.tb01614.x; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; COGGINS JR, 1987, METHOD ENZYMOL, V142, P325; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DIECKMANN A, 1986, MOL BIOCHEM PARASIT, V19, P143, DOI 10.1016/0166-6851(86)90119-2; DUGGAN PJ, 1995, BIOORG MED CHEM LETT, V5, P2347, DOI 10.1016/0960-894X(95)00405-I; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GORLACH J, 1993, PLANT MOL BIOL, V23, P707, DOI 10.1007/BF00021526; HACKSTEIN JHP, 1995, PARASITOL RES, V81, P207; Haslam E, 1993, SHIKIMIC ACID METABO; HAUCKE V, 1997, CELL BIOL, V7, P103; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; JONES DGL, 1991, MOL MICROBIOL, V5, P2143, DOI 10.1111/j.1365-2958.1991.tb02144.x; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; MACK DG, 1984, ANTIMICROB AGENTS CH, V26, P26, DOI 10.1128/AAC.26.1.26; Marzabadi MR, 1996, BIOCHEMISTRY-US, V35, P4199, DOI 10.1021/bi9521349; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MILHOUS WK, 1985, ANTIMICROB AGENTS CH, V27, P525, DOI 10.1128/AAC.27.4.525; MOUSDALE DM, 1985, J CHROMATOGR, V329, P268, DOI 10.1016/S0021-9673(01)81929-4; ODUOLA AMJ, 1988, EXP PARASITOL, V66, P86, DOI 10.1016/0014-4894(88)90053-7; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; SCHMIDT J, 1993, J BIOL CHEM, V268, P27447; STEINRUCKEN HC, 1980, BIOCHEM BIOPH RES CO, V94, P1207, DOI 10.1016/0006-291X(80)90547-1; Tzipori S, 1998, ADV PARASIT, V40, P187, DOI 10.1016/S0065-308X(08)60121-9; WHITFIELD W, 1988, J ROYAL SOC HLTH, V1, P1; WILLIAMSON DH, 1994, MOL GEN GENET, V243, P249, DOI 10.1007/BF00280323	30	412	440	3	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					801	805		10.1038/31723	http://dx.doi.org/10.1038/31723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655396				2022-12-01	WOS:000074433100053
J	Staels, B; Koenig, W; Habib, A; Merval, R; Lebret, M; Torra, IP; Delerive, P; Fadel, A; Chinetti, G; Fruchart, JC; Najib, J; Maclouf, J; Tedgui, A				Staels, B; Koenig, W; Habib, A; Merval, R; Lebret, M; Torra, IP; Delerive, P; Fadel, A; Chinetti, G; Fruchart, JC; Najib, J; Maclouf, J; Tedgui, A			Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators	NATURE			English	Article							FACTOR-KAPPA-B; PHARMACOKINETIC PROPERTIES; THERAPEUTIC USE; EXPRESSION; CYCLOOXYGENASE-2; DYSLIPIDEMIA; SYNTHASE-2; RECEPTOR; ANGINA; SERUM	Peroxisome proliferator-activated receptors (PPARs) are key players in lipid and glucose metabolism and are implicated in metabolic disorders predisposing to atherosclerosis, such as dyslipidaemia and diabetes(1). Whereas PPAR gamma promotes Lipid storage by regulating adipocyte differentiation, PPAR alpha stimulates the beta-oxidative degradation of fatty acids. PPAR alpha-deficient mice show a prolonged response to inflammatory stimuli, suggesting that PPAR alpha is also a modulator of inflammation(2). Hypolipidaemic fibrate drugs are PPAR alpha ligands that inhibit the progressive formation of atherosclerotic lesions, which involves chronic inflammatory processes: even in the absence of their atherogenic lipoprotein-lowering effect(4,5). Here we show that PPAR alpha is expressed in human aortic smooth-muscle cells, which participate in plaque formation and post-angioplasty re-stenosis(3). In these smooth-muscle cells, we find that PPAR alpha ligands, and not PPAR gamma ligands, inhibit interleukin-1-induced production of interleukin-6 and prostaglandin and expression of cyclooxygenase-2. This inhibition of cyclooxygenase-2 induction occurs transcriptionally as a result of PPAR alpha repression of NF-kappa B signalling, In hyperlipidaemic patients, fenofibrate treatment decreases the plasma concentrations of interleukin-6, fibrinogen and C-reactive protein. We conclude that activators of PPAR alpha inhibit the inflammatory response of aortic smooth-muscle cells and decrease the concentration of plasma acute-phase proteins, indicating that PPAR alpha in the vascular wall may influence the process of atherosclerosis and re-stenosis.	Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany; INSERM, U348, F-75745 Paris 10, France; INSERM, U141, F-75745 Paris 10, France; IFR Circulat Lariboisiere, F-75745 Paris 10, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Ulm University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	Bart.Staels@pasteur-lille.fr	chinetti, giulia/Q-6901-2016; Habib, Aida/H-8647-2019; Staels, Bart/N-9497-2016	chinetti, giulia/0000-0001-8048-8138; Habib, Aida/0000-0001-6027-0043; Staels, Bart/0000-0002-3784-1503				Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; HABIB A, 1993, J BIOL CHEM, V268, P23448; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TODD PA, 1988, DRUGS, V36, P314, DOI 10.2165/00003495-198836030-00004; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	30	972	1008	3	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 25	1998	393	6687					790	793		10.1038/31701	http://dx.doi.org/10.1038/31701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655393				2022-12-01	WOS:000074433100050
J	Perrin, L; Telenti, A				Perrin, L; Telenti, A			HIV treatment failure: Testing for HIV resistance in clinical practice	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PREVALENCE; ZIDOVUDINE		CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	Perrin, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland.		Telenti, Amalio/AAY-1674-2021					Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1133, DOI 10.1126/science.279.5354.1133; DEEKS S, 1998, 5 C RETR OPP INF CHI; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; GERVAIX A, COMMUNICATION; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; HAVLIR DV, 1998, 5 C RETR OPP INF CHI; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jellinger RM, 1997, J INFECT DIS, V175, P561, DOI 10.1093/infdis/175.3.561; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lorenzi P, 1997, AIDS, V11, pF95, DOI 10.1097/00002030-199712000-00002; MAYERS D, 1997, INT WORKSH HIV DRUG; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Nijhuis M, 1997, J INFECT DIS, V176, P398, DOI 10.1086/514056; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PERRIN L, UNPUB; Quigg M, 1997, AIDS, V11, P835; RAFFI R, 1998, 5 C RETR OPP INF CHI; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Roederer M, 1998, NAT MED, V4, P145, DOI 10.1038/nm0298-145; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; Schinazi R. F., 1997, International Antiviral News, V5, P129; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; Stuyver L, 1997, ANTIMICROB AGENTS CH, V41, P284, DOI 10.1128/AAC.41.2.284; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; YERLY S, COMMUNICATION; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	38	172	179	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1871	1873		10.1126/science.280.5371.1871	http://dx.doi.org/10.1126/science.280.5371.1871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669946				2022-12-01	WOS:000074323800042
J	Hewson, MG				Hewson, MG			Traditional healers in southern Africa	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	One task of medical anthropologists is to search for similarities and differences among cultural conceptions of illness and healing. This search may identify common, if not universal, characteristics of healing and effective patient care. This paper describes traditional healing practices in southern Africa as related by six traditional healers. Despite the seemingly exotic nature of their practice, the traditional healers' underlying strategies (probing deeply into the psychological, spiritual, and social contexts of illness and using healing ceremonies and natural medicinal preparations) seem to be effective in certain circumstances. Perhaps more important, these strategies can leave both patient and practitioner with a sense of connection and satisfaction. A study of these strategies reveals some general qualities of the healing process that are more apparent in the absence of sophisticated technology.	Cleveland Clin Fdn, Div Educ, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hewson, MG (corresponding author), Cleveland Clin Fdn, Div Educ, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Cassel, 1991, NATURE SUFFERING GOA; Damasio AR., 2006, DESCARTES ERROR EMOT; Fadiman J. A., 1977, AFR STUD REV, V20, P87, DOI [10.2307/523864, DOI 10.2307/523864]; Frank J. D., 1973, PERSUASION HEALING C; Hewson MG, 1996, J GEN INTERN MED, V11, P481, DOI 10.1007/BF02599044; HEWSON MGA, 1985, ANTHROPOL EDUC QUART, V16, P31, DOI 10.1525/aeq.1985.16.1.05x0849q; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kuhn TS., 1970, STRUCTURE SCI REVOLU, P174; Levenstein J, 1989, COMMUNICATING MED PA; Levin J S, 1997, JAMA, V278, P792, DOI 10.1001/jama.278.9.792; Lincoln Y.S., 1986, NATURALISTIC INQUIRY, V1986, P73, DOI 10.1002/ev.1427; LIPKING M, 1995, MED INTERVIEW CLIN; MBITI JS, 1969, AFRICAN REL PHILOS; MCCALLUM TG, 1992, WHITE WOMAN WITCHDOC; Micozzi Marc S, 1996, FUNDAMENTALS COMPLEM; NGUBANE H, 1992, SOCIAL BASIS HLTH HE; NOVACK DH, 1995, MED INTERVIEW CLIN C; OSLER W, 1910, BMJ-BRIT MED J, V2, P1470; RANTALA E, 1992, BASELINE STUDY HLTH; Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; Smith RC, 1996, PATIENTS STORY INTEG; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125	23	55	57	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1029	1034		10.7326/0003-4819-128-12_Part_1-199806150-00014	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625666				2022-12-01	WOS:000074201300010
J	Moser, M				Moser, M			Why are physicians not prescribing diuretics more frequently in the management of hypertension?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ANTIHYPERTENSIVE DRUG-THERAPY; LEFT-VENTRICULAR HYPERTROPHY; FACTOR INTERVENTION TRIAL; DIABETIC-PATIENTS; CARDIAC-ARREST; BETA-BLOCKERS; RISK; LIPOPROTEINS; LIPIDS	Diuretics have again been recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) as one of the first-choice medications in the management of hypertension. This recommendation is based on the results of numerous randomized, diuretic-based, long-term controlled clinical trials that have demonstrated a reduction in both cerebrovascular and cardiovascular morbidity. Despite this and other national recommendations, the use of diuretics has steadily decreased over the past 15 years. Reasons include heavy promotion of other medications and the perception that diuretics produce adverse metabolic effects and do not reduce coronary heart disease events. Data, however, indicate that (1) changes in glucose and cholesterol metabolism are minor, especially with the smaller doses now being used; (2) cardiovascular morbidity and mortality have been reduced in hypertensive patients, even in those with hyperlipidemia or diabetes, when diuretics are used; and (3) concerns about hypokalemia-induced arrhythmias have been overstated. While special indications exist for other medications in the treatment of hypertension, for example, use of an angiotensin-converting enzyme inhibitor (usually in addition to a diuretic) for a patient with heart failure or diabetic nephropathy, most patients, including those with hyperlipidemia or glucose intolerance, can be effectively treated with a diuretic as initial therapy or as part of a combination regimen, Diuretics should be used more not less frequently; use of diuretics would reduce the number of resistant hypertensive patients.	Yale Univ, Sch Med, New Haven, CT USA	Yale University	Moser, M (corresponding author), 13 Murray Hill Rd, Scarsdale, NY 10583 USA.							AMES RP, 1986, DRUGS, V32, P260, DOI 10.2165/00003495-198632030-00003; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413; BLACK HR, 1993, HYPERTENSION, V21, P335; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; GREENBERG G, 1984, AM J MED, V76, P45, DOI 10.1016/0002-9343(84)90956-2; Grimm RH, 1997, ARCH INTERN MED, V157, P638, DOI 10.1001/archinte.157.6.638; GURWITZ JH, 1993, ANN INTERN MED, V118, P273, DOI 10.7326/0003-4819-118-4-199302150-00005; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HOES AW, 1995, ANN INTERN MED, V123, P481, DOI 10.7326/0003-4819-123-7-199510010-00001; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; HOLLIFIELD JW, 1981, ACTA MED SCAND, P67; HOUSTON MC, 1989, AM HEART J, V117, P911, DOI 10.1016/0002-8703(89)90631-5; *HYP DET FOLL UP P, 1988, JAMA-J AM MED ASSOC, V259, P2118; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LANGFORD HG, 1986, PROG CARDIOVASC DIS, V29, P29, DOI 10.1016/0033-0620(86)90033-2; LASSER NL, 1984, AM J MED, V76, P52, DOI 10.1016/0002-9343(84)90957-4; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCINNES GT, 1992, J HYPERTENS, V10, P317; MESSERLI FH, 1989, ARCH INTERN MED, V149, P1263, DOI 10.1001/archinte.149.6.1263; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; MIDDEKE M, 1987, CLIN CARDIOL, V10, P94, DOI 10.1002/clc.4960100204; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; Moser M, 1996, J AM COLL CARDIOL, V27, P1214, DOI 10.1016/0735-1097(95)00606-0; MOSER M, 1993, CLEV CLIN J MED, V60, P27; MOSER M, 1984, AM HEART J, V107, P616, DOI 10.1016/0002-8703(84)90121-2; MOSER M, 1994, NEW ENGL J MED, V331, P1235; MOSER M, 1991, EUR HEART J, V12, P1034, DOI 10.1093/eurheartj/12.9.1034; MOSER M, 1989, AM HEART J, V118, P1362, DOI 10.1016/0002-8703(89)90059-8; MOSER M, 1992, EUR HEART J, V13, P72, DOI 10.1093/eurheartj/13.suppl_G.72; MOSER M, 1993, DIABETES CARE, V16, P542, DOI 10.2337/diacare.16.2.542; MOSER M, 1979, CHLORTHALIDONE 25 MG, P13; *MRFIT RES GROUP, 1990, JAMA-J AM MED ASSOC, V263, P1765; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; *ROYAL AUSTR COLL, 1991, HYP DIAGN TREATM MAI; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; Siegel D, 1997, JAMA-J AM MED ASSOC, V278, P1745, DOI 10.1001/jama.278.21.1745; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541; ZUSMAN RM, 1986, HYPERTENSION, V8, P837, DOI 10.1161/01.HYP.8.10.837	55	74	75	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1813	1816		10.1001/jama.279.22.1813	http://dx.doi.org/10.1001/jama.279.22.1813			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628713				2022-12-01	WOS:000073998500034
J	Nightingale, SL				Nightingale, SL			Hypersensitivity to chlorhexidine-impregnated medical devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-01	WOS:000073878700005
J	Leeman, E				Leeman, E			Misuse of psychiatric epidemiology	LANCET			English	Editorial Material							NATIONAL-COMORBIDITY-SURVEY; UNITED-STATES; PREVALENCE; DISORDERS		Columbia Univ, Dept Psychiat, New York, NY 10032 USA	Columbia University	Leeman, E (corresponding author), Columbia Univ, Dept Psychiat, New York, NY 10032 USA.							BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; EATON WW, 1984, ARCH GEN PSYCHIAT, V41, P942; FREEDMAN DX, 1984, ARCH GEN PSYCHIAT, V41, P931; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; *PC MENT HLTH, 1978, REP PRES PRES COMM M, V1; Regier DA, 1998, ARCH GEN PSYCHIAT, V55, P109, DOI 10.1001/archpsyc.55.2.109; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; ROBINS LN, 1982, PSYCHOL MED, V12, P855, DOI 10.1017/S0033291700049151; Spitzer RL, 1998, ARCH GEN PSYCHIAT, V55, P120, DOI 10.1001/archpsyc.55.2.120	10	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1601	1602		10.1016/S0140-6736(05)77684-4	http://dx.doi.org/10.1016/S0140-6736(05)77684-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR900	9620712				2022-12-01	WOS:000074026600005
J	Reidy, A; Minassian, DC; Vafidis, G; Joseph, J; Farrow, S; Wu, J; Desai, P; Connolly, A				Reidy, A; Minassian, DC; Vafidis, G; Joseph, J; Farrow, S; Wu, J; Desai, P; Connolly, A			Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							URBAN-POPULATION	Objective: To estimate the magnitude of serious eye disorders and of visual impairment in a defined elderly population of a typical metropolitan area in England, and to assess the frequency they were in touch with, Or known to, the eye care services. Design: Cross sectional survey using two stage cluster random sampling. Setting: General practices in north London. Subjects: Random sample of people aged 65 and older, drawn from a defined population of elderly people registered with 17 general practice groups. Main outcome measures: Proportions and population prevalence estimates were determined for visual acuity, assessed with the person's own spectacles (if any), classified into four categories: prevalence of cataract, age related macular degeneration, and refractive error causing visual impairment and of definite primary open angle glaucoma; and status of contact with eye services. Results: 1547 of 1840 (84%) eligible people were examined. The population prevalence of bilateral Sampling visual impairment (visual acuity < 6/12) was 30%, of which 72% was potentially remediable. 92 of these 448 cases (21%) had visual acuity < 6/60 ("blindness") in one or both eyes. Prevalence of cataract causing visual impairment was 30%; 88% of these people were not in touch with the eye services. The prevalence of vision impairing, age related macular degeneration was 8% and of glaucoma (definite cases) was 3%. Three quarters of the people with definite glaucoma were not known to the eye services. Conclusions: Untreated visual impairment and eye disorders affect a substantial proportion of people aged 65 years and older. These findings should contribute to the setting up of future strategies for preservation of sight and eye health services in general.	UCL, Inst Ophthalmol, London EC1V 9EJ, England; Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; Cent Middlesex Hosp, London NW10 7NS, England; Middlesex Univ, London N11 2NQ, England; Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England	University of London; University College London; University of Southampton; Imperial College London; Middlesex University; University of Southampton	Minassian, DC (corresponding author), UCL, Inst Ophthalmol, London EC1V 9EJ, England.							Attebo K, 1996, OPHTHALMOLOGY, V103, P357; CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330; Cochran W.G., 1963, SAMPLING TECHNIQUES; COFFEY M, 1993, BRIT J OPHTHALMOL, V77, P17, DOI 10.1136/bjo.77.1.17; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; Livingston P M, 1995, Ophthalmic Epidemiol, V2, P151, DOI 10.3109/09286589509057097; Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1; Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226	12	165	168	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1643	1646		10.1136/bmj.316.7145.1643	http://dx.doi.org/10.1136/bmj.316.7145.1643			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603746	Bronze, Green Published			2022-12-01	WOS:000074022700023
J	Khokhlatchev, AV; Canagarajah, B; Wilsbacher, J; Robinson, M; Atkinson, M; Goldsmith, E; Cobb, MH				Khokhlatchev, AV; Canagarajah, B; Wilsbacher, J; Robinson, M; Atkinson, M; Goldsmith, E; Cobb, MH			Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation	CELL			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; C-JUN; CRYSTAL-STRUCTURE; PC12 CELLS; MITOGEN; TRANSCRIPTION; RECEPTOR; SIGNAL; JNK	The MAP kinase ERK2 is widely involved in eukaryotic signal transduction. Upon activation it translocates to the nucleus of the stimulated cell, where it phosphorylates nuclear targets. We find that nuclear accumulation of microinjected ERK2 depends on its phosphorylation state rather than on its activity or on upstream components of its signaling pathway. Phosphorylated ERK2 forms dimers with phosphorylated and unphosphorylated ERK2 partners. Disruption of dimerization by mutagenesis of ERK2 reduces its ability to accumulate in the nucleus, suggesting that dimerization is essential for its normal ligand-dependent relocalization. The crystal structure of phosphorylated ERK2 reveals the basis for dimerization. Other MAP kinase family members also form dimers. The generality of this behavior suggests that dimerization is part of the mechanism of action of the MAP kinase family.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75710 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046993, R01DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46993, DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CASSEL D, 1982, P NATL ACAD SCI-BIOL, V79, P2231, DOI 10.1073/pnas.79.7.2231; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; CHIYING FH, 1996, P NATL ACAD SCI USA, V93, P10078; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4185; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; NGAI PK, 1991, BIOCHEM J, V280, P805, DOI 10.1042/bj2800805; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; SETH A, 1992, J BIOL CHEM, V267, P24796; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	64	565	603	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					605	615		10.1016/S0092-8674(00)81189-7	http://dx.doi.org/10.1016/S0092-8674(00)81189-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604935	Bronze			2022-12-01	WOS:000073722200013
J	Britton, TC				Britton, TC			Torticollis - what is straight ahead?	LANCET			English	Editorial Material							SPASMODIC TORTICOLLIS		Univ London Kings Coll Hosp, Dept Neurol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Britton, TC (corresponding author), Univ London Kings Coll Hosp, Dept Neurol, Denmark Hill, London SE5 9RS, England.							Anastasopoulos D, 1997, MOVEMENT DISORD, V12, P561, DOI 10.1002/mds.870120413; Anastasopoulos D, 1997, MOVEMENT DISORD, V12, P709, DOI 10.1002/mds.870120514; Anastasopoulos D, 1998, BRAIN, V121, P91, DOI 10.1093/brain/121.1.91; Couch J R, 1976, Adv Neurol, V14, P245; Lekhel H, 1997, BRAIN, V120, P583, DOI 10.1093/brain/120.4.583; LEPLOW B, 1994, PERCEPT MOTOR SKILL, V78, P1363, DOI 10.2466/pms.1994.78.3c.1363; STELL R, 1989, J NEUROL NEUROSUR PS, V52, P57, DOI 10.1136/jnnp.52.1.57	7	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1223	1224		10.1016/S0140-6736(05)79313-2	http://dx.doi.org/10.1016/S0140-6736(05)79313-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643739				2022-12-01	WOS:000073283600005
J	van Duijn, CM; Delasnerie-Laupretre, N; Masullo, C; Zerr, I; de Silva, R; Wientjens, DPWM; Brandel, JP; Weber, T; Bonavita, V; Zeidler, M; Alperovitch, A; Poser, S; Granieri, E; Hofman, A; Will, RG				van Duijn, CM; Delasnerie-Laupretre, N; Masullo, C; Zerr, I; de Silva, R; Wientjens, DPWM; Brandel, JP; Weber, T; Bonavita, V; Zeidler, M; Alperovitch, A; Poser, S; Granieri, E; Hofman, A; Will, RG		Eur Union Collaborat Study Grp CJD	Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95	LANCET			English	Article							HUMAN GROWTH-HORMONE; PERSON TRANSMISSION; PRION DISEASES; HUMAN-BLOOD; EPIDEMIOLOGY; RECIPIENT; FRANCE; GENE	Background Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy. Genetic and iatrogenic forms have been recognised but most are sporadic and of unknown cause. We have studied risk factors for CJD as part of the 1993-95 European Union collaborative studies of CJD in Europe. Methods The 405 patients with definite or probable CJD who took part in our study had taken part in population-based studies done between 1993 and 1995 in Belgium, France, Germany, Italy, the Netherlands, and the UK. Data on putative risk factors from these patients were compared with data from 405 controls. Findings We found evidence for familiar aggregation of CJD with dementia due to causes other than CJD (relative risk [RR] 2.26, 95% CI 1.31-3.90). No significant increased risk of CJD in relation to a history of surgery and blood tranfusion was shown. There was no evidence for an association between the risk of CJD and the consumption of beef, veal, lamb, cheese, or milk. No association was found with occupational exposure to animals or leather. The few positive findings of the study include increased risk in relation to consumption of raw meat (RR 1.63 [95% CI 1.18-2.23]) and brain (1.68 [1.18-2.39]), frequent exposure to leather products (1.94 [1.13-3.33]), and exposure to fertiliser consisting of hoofs and horns (2.32 [138-2.91]). Additional analyses, for example stratification by country and of exposures pre-1985 and post-1985, suggest that these results should be interpreted with great caution. Interpretation Within the limits of the retrospective design of the study, our findings suggest that genetic factors other than the known CJD mutations may play an important part in CJD. latrogenic transmission of disease seems rare in this large population-based sample of patients with CJD. There is little evidence for an association between the risk of CJD and either animal exposure, or consumption of processed bovine meat or milk products for the period studied.	Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, NL-3000 DR Rotterdam, Netherlands; Hop La Pitie Salpetriere, INSERM, U360, Paris, France; Univ Cattolica Sacro Cuore, Dept Neurol, I-00168 Rome, Italy; Univ Gottingen, Neurol Klin, D-3400 Gottingen, Germany; Western Gen Hosp, CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Marien Hosp, Hamburg, Germany; Univ Naples Federico II, Dept Neurol, Naples, Italy; Univ Ferrara, Dept Neurol, I-44100 Ferrara, Italy	Erasmus University Rotterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Gottingen; University of Edinburgh; St. Marien Hospital; University of Naples Federico II; University of Ferrara	van Duijn, CM (corresponding author), Erasmus Univ, Dept Epidemiol & Biostat, Sch Med, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Giese, Armin/F-3271-2010	Giese, Armin/0000-0002-8238-4102; Granieri, Enrico/0000-0003-4038-3192; Weber, Thomas/0000-0002-3833-6197				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BERNOULLI C, 1977, LANCET, V1, P478; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; *DEP EP POP SCI NA, 1995, 4 DEP EP POP SCI NAT; DUFFY P, 1974, NEW ENGL J MED, V290, P692; GIBBS CJ, 1985, NEW ENGL J MED, V313, P734, DOI 10.1056/NEJM198509193131207; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; MANUELIDIS EE, 1985, LANCET, V2, P896; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; POWELLJACKSON J, 1985, LANCET, V2, P244; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; SALVATORE M, 1994, HUM GENET, V94, P375, DOI 10.1007/BF00201596; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; TATEISHI J, 1985, LANCET, V2, P1074; THADANI V, 1988, J NEUROSURG, V69, P766, DOI 10.3171/jns.1988.69.5.0766; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; Wientjens DPWM, 1996, NEUROLOGY, V46, P1287, DOI 10.1212/WNL.46.5.1287; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1982, J NEUROL NEUROSUR PS, V45, P235, DOI 10.1136/jnnp.45.3.235; WILL RG, IN PRESS ANN NEUROL; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204	27	151	151	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	1998	351	9109					1081	1085		10.1016/S0140-6736(97)09468-3	http://dx.doi.org/10.1016/S0140-6736(97)09468-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660576				2022-12-01	WOS:000073090200008
J	Verhoog, LC; Brekelmans, CTM; Seynaeve, C; van den Bosch, LMC; Dahmen, G; van Geel, AN; Tilanus-Linthorst, MMA; Bartels, CCM; Wagner, A; van den Ouweland, A; Devilee, P; Meijers-Heijboer, EJ; Klijn, JGM				Verhoog, LC; Brekelmans, CTM; Seynaeve, C; van den Bosch, LMC; Dahmen, G; van Geel, AN; Tilanus-Linthorst, MMA; Bartels, CCM; Wagner, A; van den Ouweland, A; Devilee, P; Meijers-Heijboer, EJ; Klijn, JGM			Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1	LANCET			English	Article							HISTOPROGNOSTIC GRADE; CARCINOMA; CARRIERS; LINKAGE; AGE	Background Hereditary breast cancer has been associated with mutations in the BRCA1 and BRCA2 genes and has a natural history different from sporadic breast cancer. We investigated disease-free and overall survival for patients with a proven BRCA1 alteration. Methods We estimated disease-free adn overall survival for 49 Dutch patients from 19 consecutive families with a proven specific BRCA1 mutation and one family with strong evidence for linkage to the BRCA1 gene. We compared clinical outcome and data on tumour size, histology, axillary nodal status, contralateral breast cancer, and oestrogen-receptor and progesterone-receptor status with those of 196 patients with sporadic breast cancer, matched for age and year of diagnosis. Findings Disease-free survival for BRCA1 and sporadic patients at 5 years was 49% (95% CI 33-64) and 51% (43-59), respectively (p=0.98). Overall survival at 5 years was 63% (47-76) and 69% (62-76), respectively (p=0.88). Recurrence and death rates did not differ significantly between groups. Hazard ratios for recurrence and death among BRCA1 patients were 1.00 (0.65-1.55) and 1.04 (0.63-1.71) relative to sporadic patients (p=0.88), and these did not differ significantly after adjustment for prognostic factors. Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001). Interpretation We showed that disease-free and overall survival were similar for sporadic and hereditary breast cancer in the presence of different tumour characteristics, which has implications for screening prophylactic therapy, and different treatments of hereditary breast cancer.	Dr Daniel Denhoed Clin, Dept Med Oncol, Family Canc Clin, NL-3075 EA Rotterdam, Netherlands; Rotterdam Canc Inst, Dept Patient Registrat, Rotterdam, Netherlands; Acad Hosp Rotterdam Dijkzigt, Rotterdam, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Dept Human Genet, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Leiden University; Leiden University - Excl LUMC	Klijn, JGM (corresponding author), Dr Daniel Denhoed Clin, Dept Med Oncol, Family Canc Clin, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.		DEVILEE, PETER/ABR-2140-2022					Coebergh JWW, 1995, CANC INCIDENCE SURVI; CORNELIS RS, 1995, HUM GENET, V95, P539, DOI 10.1007/BF00223866; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eisinger F, 1996, CANCER RES, V56, P471; FOEKENS JA, 1989, CANCER RES, V49, P5823; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Henderson IC, 1997, LANCET, V349, P1488, DOI 10.1016/S0140-6736(97)22021-0; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Jacquemier J, 1996, LANCET, V348, P1098, DOI 10.1016/S0140-6736(05)64441-8; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(97)89007-7; Kalbfleisch JD., 2002, STAT ANAL FAILURE TI, V2, DOI [10.1002/9781118032985, DOI 10.1016/0197-2456(81)90009-X]; KLIJN JGM, 1993, CANCER SURV, V18, P165; Klijn JGM, 1997, EUR J CANCER, V33, P2149, DOI 10.1016/S0959-8049(97)00360-2; Lakhani SR, 1997, LANCET, V349, P1505; LEES AW, 1989, BREAST CANCER RES TR, V13, P143, DOI 10.1007/BF01806526; LYNCH HT, 1981, JAMA-J AM MED ASSOC, V246, P1197, DOI 10.1001/jama.246.11.1197; LYNCH HT, 1993, P ASCO, V12, P82; LYNCH HT, 1994, P ASCO, V13, P56; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Sobol A, 1996, CANCER RES, V56, P3216; SOLIN LJ, 1996, J LIBBEY EUROTEXT, P351; WOBBES T, 1987, EUR J SURG ONCOL, V13, P119	30	367	374	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 31	1998	351	9099					316	321		10.1016/S0140-6736(97)07065-7	http://dx.doi.org/10.1016/S0140-6736(97)07065-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652611				2022-12-01	WOS:000071864000009
J	McKinney, FK; Lidgard, S; Sepkoski, JJ; Taylor, PD				McKinney, FK; Lidgard, S; Sepkoski, JJ; Taylor, PD			Decoupled temporal patterns of evolution and ecology in two post-Paleozoic clades	SCIENCE			English	Article							DIVERSITY; DIVERSIFICATION; HISTORY; DOMINANCE; CRINOIDS; BIOMASS; TIME	Counts of taxonomic diversity are the prevailing standards for documenting Large-scall patterns of evolution in the fossil record, However, the secular pattern of relative ecological importance between the bryozoan clades Cyclostomata and Cheilostomata is not reflected fully in compilations of generic diversity or within-fauna species richness, and the delayed ecological recovery of the Cheilostomata after the mass extinction at the Cretaceous-Tertiary boundary is missed entirely. These observations demonstrate that evolutionary success and ecological dominance can be decoupled and profoundly different, even over tons of millions of years.	Appalachian State Univ, Dept Geol, Boone, NC 28608 USA; Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England	University of North Carolina; Appalachian State University; Field Museum of Natural History (Chicago); University of Chicago; Natural History Museum London	McKinney, FK (corresponding author), Appalachian State Univ, Dept Geol, Boone, NC 28608 USA.	mckinneyfk@appstate.edu		Taylor, Paul/0000-0002-3127-080X	NIDCR NIH HHS [DEB 9306729] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], 1975, COMMUNITIES ECOSYSTE; AUSICH WI, 1981, OHIO J SCI, V81, P268; AUSICH WI, 1982, SCIENCE, V216, P173, DOI 10.1126/science.216.4542.173; BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BERGLUND BE, 1996, PALEOECOLOGICAL EVEN; BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; Cheetham A. H., 1971, Smithsonian Contributions to Paleobiology, V6, P1; FOOTE M, 1991, PALAEONTOLOGY, V34, P461; FOOTE M, 1991, Contributions from the Museum of Paleontology University of Michigan, V28, P101; Foote M, 1996, SCIENCE, V274, P1492, DOI 10.1126/science.274.5292.1492; FOOTE M, 1992, P NATL ACAD SCI USA, V89, P7325, DOI 10.1073/pnas.89.16.7325; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; FOOTE M, 1995, PALEOBIOLOGY, V21, P273, DOI 10.1017/S0094837300013300; FOWELL SJ, 1993, TECTONOPHYSICS, V222, P361, DOI 10.1016/0040-1951(93)90359-R; Gaston K.J, 1996, BIODIVERSITY BIOL NU; GORDON DP, 1996, BRYOZOANS SPACE TIME, P213; HAKANSSON E, 1962, DANMARKS GEOL UNDERS, V83, P1; Jackson J.B.C., 1988, PALEOBIOLOGY, V14, P307; Krause D. W., 1986, CONTRIBUTIONS GEOLOG, V3, P95; LIDGARD S, 1989, PALEOBIOLOGY, V15, P255, DOI 10.1017/S0094837300009441; LIDGARD S, 1993, PALEOBIOLOGY, V19, P352, DOI 10.1017/S0094837300000324; LUPIA R, IN PRESS BIOTIC RESP; McKinney F.K., 1989, BRYOZOAN EVOLUTION; MCNAUGHTON SJ, 1970, SCIENCE, V167, P131, DOI 10.1126/science.167.3915.131; PHILLIPS TL, 1984, INT J COAL GEOL, V3, P205, DOI 10.1016/0166-5162(84)90019-3; Sepkoski J.J. Jr, 1985, P11; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; SEPKOSKI JJ, 1988, PALEOBIOLOGY, V14, P221, DOI 10.1017/S0094837300011969; SEPKOSKI JJ, 1995, GLOBAL EVENTS EVENT, P35; SIGNOR PW, 1990, ANNU REV ECOL SYST, V21, P509, DOI 10.1146/annurev.es.21.110190.002453; SMITH AM, 1992, PALAEOGEOGR PALAEOCL, V93, P213, DOI 10.1016/0031-0182(92)90098-P; SMITH AM, 1994, OLSEN INT S, P177; Speijer RP, 1996, GEOL SOC SP, P343, DOI 10.1144/GSL.SP.1996.001.01.26; STAFF G, 1985, LETHAIA, V18, P209, DOI 10.1111/j.1502-3931.1985.tb00700.x; TAYLOR PD, 1988, EXTINCTION SURVIVAL, P99; THAYER CW, 1983, BIOTIC INTERACTIONS, P480; Upchurch G.R. Jr, 1989, P195; Vermeij G.J, 1987, EVOLUTION ESCALATION; Wilkinson L., 1990, SYSTAT SYSTEM STAT; WILSON E O, 1992	42	65	67	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					807	809		10.1126/science.281.5378.807	http://dx.doi.org/10.1126/science.281.5378.807			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694648				2022-12-01	WOS:000075295600044
J	Slepnev, VI; Ochoa, GC; Butler, MH; Grabs, D; De Camilli, P				Slepnev, VI; Ochoa, GC; Butler, MH; Grabs, D; De Camilli, P			Role of phosphorylation in regulation of the assembly of endocytic coat complexes	SCIENCE			English	Article							PROTEIN-KINASE-C; FROG NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE MEMBRANE; NERVE-TERMINALS; TRANSMITTER RELEASE; CLATHRIN; DYNAMIN; AMPHIPHYSIN; INHIBITOR; POTENT	Clathrin-mediated endocytosis involves cycles of assembly and disassembly of clathrin coat components and their accessory proteins. Dephosphorylation of rat brain extract was shown to promote the assembly of dynamin 1, synaptojanin 1, and amphiphysin into complexes that also included clathrin and AP-2, Phosphorylation of dynamin 1 and synaptojanin 1 inhibited their binding to amphiphysin, whereas phosphorylation of amphiphysin inhibited its binding to AP-2 and clathrin. Thus, phosphorylation regulates the association and dissociation cycle of the clathrin-based endocytic machinery, and calcium-dependent dephosphorylation of endocytic proteins could prepare nerve terminals for a burst of endocytosis.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Congress Ave, New Haven, CT 06510 USA.	pietro.decamilli@yale.edu			NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036251, R37NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Merisko E M, 1986, Pancreas, V1, P110, DOI 10.1097/00006676-198603000-00002; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; Ramjaun A. R., 1997, Molecular Biology of the Cell, V8, p93A; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHOOK WJ, 1985, P NATL ACAD SCI USA, V82, P8039, DOI 10.1073/pnas.82.23.8039; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	39	269	273	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					821	824		10.1126/science.281.5378.821	http://dx.doi.org/10.1126/science.281.5378.821			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694653				2022-12-01	WOS:000075295600049
J	Whybrew, K; Murray, M; Morley, C				Whybrew, K; Murray, M; Morley, C			Diagnosing fever by touch: observational study	BRITISH MEDICAL JOURNAL			English	Article							AXILLARY		Univ Cambridge, Dept Paediat, Neonatal Intens Care Unit, Cambridge CB2 2QQ, England	University of Cambridge	Morley, C (corresponding author), Univ Cambridge, Dept Paediat, Neonatal Intens Care Unit, Box 226, Cambridge CB2 2QQ, England.			Morley, Colin/0000-0001-5388-0214				CLARKE S, 1992, BRIT MED J, V304, P961, DOI 10.1136/bmj.304.6832.961; Einterz EM, 1997, LANCET, V350, P781, DOI 10.1016/S0140-6736(97)24037-7; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; Shann F, 1996, ARCH PEDIAT ADOL MED, V150, P74, DOI 10.1001/archpedi.1996.02170260078013	5	21	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					321	321		10.1136/bmj.317.7154.321	http://dx.doi.org/10.1136/bmj.317.7154.321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685279	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000075409500023
J	Duncan, SA; Navas, MA; Dufort, D; Rossant, J; Stoffel, M				Duncan, SA; Navas, MA; Dufort, D; Rossant, J; Stoffel, M			Regulation of a transcription factor network required for differentiation and metabolism	SCIENCE			English	Article							PYRUVATE-KINASE GENE; DEFINITIVE ENDODERM; EXPRESSION; MOUSE; INSULIN; HNF-3-BETA; NOTOCHORD; PROMOTER	Hepatocyte nuclear factors (HNFs) are a heterogeneous class of evolutionarily conserved transcription factors that are required for cellular differentiation and metabolism. Mutations in HNF-1 alpha and HNF-4 alpha genes impair insulin secretion and cause type 2 diabetes. Regulation of HNF-4/HNF-1 expression by HNF-3 alpha and HNF-3 beta was studied in embryoid bodies in which one or both HNF-3 alpha or HNF-3 beta alleles were inactivated. HNF-3 beta positively regulated the expression of HNF-4 alpha/HNF-1 alpha and their downstream targets, implicating a role in diabetes. HNF-3 beta was also necessary for expression of HNF-3 alpha. In contrast, HNF-3 alpha acts as a negative regulator of HNF-4 alpha/HNF-1 alpha demonstrating that HNF-3 alpha. and HNF-3 beta have antagonistic transcriptional regulatory functions in vivo. HNF-3 alpha does not appear to act as a classic biochemical repressor but rather exerts its negative effect by competing for HNF-3 binding sites with the more efficient activator HNF-3 beta. In addition, the HNF-3 alpha/HNF-3 beta ratio is modulated by the presence of insulin, providing evidence that the HNF network may have important roles in mediating the action of insulin.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Rockefeller University; Rockefeller University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stoffel, M (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.	stoffel@rockvax.rockefeller.edu		Stoffel, Markus/0000-0003-1304-5817; Dufort, Daniel/0000-0002-6477-596X; Duncan, Stephen/0000-0002-2507-7827; Navas, Maria Angeles/0000-0001-6858-2172				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DUNCAN S, UNPUB; Duncan SA, 1997, DEVELOPMENT, V124, P279; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LEMAIGRE FP, 1994, BIOCHEM J, V303, P1; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Nagy A., 1993, Gene targeting: a practical approach., P147; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; SASAKI H, 1993, DEVELOPMENT, V118, P47; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Tronche F., 1994, LIVER GENE EXPRESSIO; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Vaisse C, 1997, DIABETES, V46, P1364, DOI 10.2337/diabetes.46.8.1364; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	29	280	294	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					692	695		10.1126/science.281.5377.692	http://dx.doi.org/10.1126/science.281.5377.692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685261				2022-12-01	WOS:000075107900040
J	Huber, C; Wachtershauser, G				Huber, C; Wachtershauser, G			Peptides by activation of amino acids with CO on (Ni,Fe)S surfaces: Implications for the origin of life	SCIENCE			English	Article								In experiments modeling volcanic or hydrothermal settings amino acids were converted into their peptides by use of coprecipitated (Ni,Fe)S and CO in conjunction with H2S (or CH3SH) as a catalyst and condensation agent at 100 degrees C and pH 7 to 10 under anaerobic, aqueous conditions. These results demonstrate that amino acids can be activated under geochemically relevant conditions. They support a thermophilic origin of Life and an early appearance of peptides in the evolution of a primordial metabolism.	Tech Univ Munich, Dept Organ Chem & Biochem, D-85747 Munich, Germany	Technical University of Munich	Wachtershauser, G (corresponding author), Tal 29, D-80331 Munich, Germany.							BRACK A, 1984, ORIGINS LIFE EVOL B, V14, P229, DOI 10.1007/BF00933662; Bujdak J, 1996, J INORG BIOCHEM, V63, P119, DOI 10.1016/0162-0134(95)00186-7; Bujdak J, 1997, J MOL EVOL, V45, P457, DOI 10.1007/PL00006250; Fox S. W., 1977, MOL EVOLUTION ORIGIN; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; LAHAV N, 1978, SCIENCE, V201, P67, DOI 10.1126/science.663639; ORGEL LE, 1989, J MOL EVOL, V29, P465, DOI 10.1007/BF02602917; RABINOWI.J, 1969, NATURE, V224, P795, DOI 10.1038/224795a0; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHWENDINGER MG, 1995, INORG CHIM ACTA, V228, P207, DOI 10.1016/0020-1693(94)04186-Y; SHOCK EL, 1992, GEOCHIM COSMOCHIM AC, V56, P3481, DOI 10.1016/0016-7037(92)90392-V; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Williams RJP, 1997, CELL MOL LIFE SCI, V53, P816, DOI 10.1007/s000180050102	16	443	456	4	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					670	672		10.1126/science.281.5377.670	http://dx.doi.org/10.1126/science.281.5377.670			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685253				2022-12-01	WOS:000075107900032
J	Naoumov, NV; Petrova, EP; Thomas, MG; Williams, R				Naoumov, NV; Petrova, EP; Thomas, MG; Williams, R			Presence of a newly described human DNA virus (TTV) in patients with liver disease	LANCET			English	Article							HEPATITIS-G VIRUS; PARVOVIRUS B19; INFECTION; CLONING; AGENT	Background A newly described DNA virus, named transfusion-transmitted virus (TTV), was recently detected with high prevalence in Japanese patients with fulminant hepatitis end chronic liver disease of unknown aetiology. We investigated the presence of this virus in patients with liver disease in the UK to find out whether TTV infection is associated with liver damage. Methods We used semi-nested PCR to amplify TTV DNA from serum samples from 126 adults, of whom 72 were patients with a range of chronic liver diseases, 24 had spontaneous resolution of infection with hepatitis C virus (HCV), and 30 were normal controls. Direct DNA sequencing and phylogenetic analysis were used to characterise the TTV isolates. Findings We detected TTV DNA in 18 (25%) of the 72 patients with chronic liver disease, which was not different from the 10% prevalence in normal controls (p=0.15). The rate of TTV DNA was similar among patients with various liver diseases. The majority of TTV-positive cases had no biochemical or histological evidence of significant liver damage. TTV DNA sequencing of nine isolates showed the same genotypic groups as in Japan: three patients were infected with genotype 1, which showed 4% nucleotide divergence, and six patients were infected with genotype 2 with 15-27% divergence. Interpretation The high prevalence of active TTV infection in the general population, both in the UK and in Japan, and the lack of significant liver damage, suggest that TTV, similar to hepatitis G virus (HGV), may be an example of a human virus with no clear disease association.	UCL, Sch Med, Inst Hepatol, Dept Med, London WC1E 6HX, England; UCL, Sch Med, Dept Biol, London WC1E 6HX, England; UCL, Sch Med, Dept Anthropol, London WC1E 6HX, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Naoumov, NV (corresponding author), UCL, Sch Med, Inst Hepatol, Dept Med, London WC1E 6HX, England.	n.naoumov@ucl.ac.uk	Thomas, Mark G/A-2219-2012	Thomas, Mark G/0000-0002-2452-981X				ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; ANDERSON MJ, 1987, J VIROL METHODS, V17, P175, DOI 10.1016/0166-0934(87)90080-2; ANDERSON MJ, 1985, J INFECT DIS, V152, P257, DOI 10.1093/infdis/152.2.257; FELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hillingso JG, 1998, LANCET, V351, P955, DOI 10.1016/S0140-6736(00)80016-1; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; Yoto Y, 1996, LANCET, V347, P1563	14	262	273	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					195	197		10.1016/S0140-6736(98)04069-0	http://dx.doi.org/10.1016/S0140-6736(98)04069-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683209				2022-12-01	WOS:000074859800013
J	Clements, JL; Yang, B; Ross-Barta, SE; Eliason, SL; Hrstka, RF; Williamson, RA; Koretzky, GA				Clements, JL; Yang, B; Ross-Barta, SE; Eliason, SL; Hrstka, RF; Williamson, RA; Koretzky, GA			Requirement for the leukocyte-specific adapter protein SLP-76 for normal T-cell development	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; ALPHA-BETA; GENE; KINASE; INHIBITION; ACTIVATION; P56(LCK); MICE	The Leukocyte-specific adapter molecule SLP-76 (Src homology 2 domain-containing Leukocyte protein of 76 kilodaltons) is rapidly phosphorylated on tyrosine residues after receptor Ligation in several hematopoietically derived cell types. Mice made deficient for SLP-76 expression contained no peripheral T cells as a result of an early block in thymopoiesis. Macrophage and natural killer cell compartments were intact in SLP-76-deficient mice, despite SLP-76 expression in these lineages in wild-type mice. Thus, the SLP-76 adapter protein is required for normal-thymocyte development and plays a crucial role in translating signals mediated by pre-T cell receptors into distal biochemical events.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Koretzky, GA (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.		Koretzky, Gary/AAU-5381-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256, R37GM053256] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53256] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1995, ONCOGENE, V10, P1141; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHU KT, 1994, J BIOL CHEM, V269, P24095; CLEMENTS JA, UNPUB; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Hoffman ES, 1996, GENE DEV, V10, P948, DOI 10.1101/gad.10.8.948; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	25	357	363	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					416	419		10.1126/science.281.5375.416	http://dx.doi.org/10.1126/science.281.5375.416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665885				2022-12-01	WOS:000074918800048
J	Krause, PJ; Spielman, A; Telford, SR; Sikand, VK; McKay, K; Christianson, D; Pollack, RJ; Brassard, P; Magera, J; Ryan, R; Persing, DH				Krause, PJ; Spielman, A; Telford, SR; Sikand, VK; McKay, K; Christianson, D; Pollack, RJ; Brassard, P; Magera, J; Ryan, R; Persing, DH			Persistent parasitemia after acute babesiosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; BORRELIA-BURGDORFERI DNA; LYME-DISEASE; ANTIBIOTIC-TREATMENT; RAPID DIAGNOSIS; TRANSFUSION; MICROTI; INFECTIONS; STATE; FLUID	Background Babesiosis, a zoonosis caused by the protozoan Babesia microti, is usually nor treated when the symptoms are mild, because the parasitemia appears to be transient. However, the microscopical methods used to diagnose this infection are insensitive, and few infected people have been followed longitudinally. We compared the duration of parasitemia in people who had received specific antibabesial therapy with that in silently infected people who had not received specific therapy. Methods Forty-six babesia-infected subjects were identified from 1991 through 1996 in a prospective, community-based study designed to detect episodes of illness and of seroconversion among the residents of southeastern Connecticut and Block Island, Rhode island. Subjects with acute babesial illness were monitored every 3 months for up to 27 months by means of thin blood smears, Bab. microti polymerase-chain-reaction assays, serologic tests, and questionnaires. Results Babesial DNA persisted in the blood for a mean of 82 days in 24 infected subjects without specific symptoms who received no specific therapy. Babesial DNA persisted for 16 days in 22 acutely ill subjects who received clindamycin and quinine therapy (P = 0.03), of whom 9 had side effects from the treatment. Among the subjects who did not receive specific therapy, symptoms of babesiosis persisted for a mean of 114 days in five subjects with babesial DNA present for 3 or more months and for only 15 days in seven others in whom the DNA was detectable for less than 3 months (P<0.05); one subject had recrudescent disease after two years. Conclusions When left untreated, silent babesial infection may persist For months or even years. Although treatment with clindamycin and quinine reduces the duration of parasitemia, infection may still persist and recrudesce and side effects are common. Improved treatments are needed. (N Engl J Med 1998;339:160-5.) (C)1998, Massachusetts Medical Society.	Connecticut Childrens Med Ctr, Dept Pediat, Div Pediat Infect Dis, Hartford, CT 06106 USA; Univ Connecticut, Sch Med, Hartford, CT 06106 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA USA; Brown Univ, Sch Med, Dept Med, Providence, RI USA; Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Clin Microbiol, Mol Microbiol Lab, Rochester, MN 55905 USA	Connecticut Children's Medical Center; University of Connecticut; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University; Brown University; Mayo Clinic; Mayo Clinic	Krause, PJ (corresponding author), Connecticut Childrens Med Ctr, Dept Pediat, Div Pediat Infect Dis, Hartford, CT 06106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, R01AI042402] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32403, AI 41157, AI 42402] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BISHOP R, 1992, PARASITOLOGY, V104, P215, DOI 10.1017/S0031182000061655; CONRAD P, 1991, J AM VET MED ASSOC, V199, P601; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Falagas ME, 1996, CLIN INFECT DIS, V22, P809, DOI 10.1093/clinids/22.5.809; FIGUEROA JV, 1992, J CLIN MICROBIOL, V30, P2576, DOI 10.1128/JCM.30.10.2576-2582.1992; GELFAND JA, 1995, MANDELL DOUGLAS BENN, V2, P2497; GERBER MA, 1994, J INFECT DIS, V170, P231, DOI 10.1093/infdis/170.1.231; Herwaldt BL, 1997, J INFECT DIS, V175, P1259, DOI 10.1086/593812; KAIN KC, 1993, AM J TROP MED HYG, V49, P478, DOI 10.4269/ajtmh.1993.49.478; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2014, DOI 10.1128/JCM.34.8.2014-2016.1996; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2791, DOI 10.1128/JCM.34.11.2791-2794.1996; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; KRAUSE PJ, 1997, 46 ANN M AM SOC TROP, P247; KROGSTAD DJ, 1995, MANDELL DOUGLAS BENN, V2, P2415; MALAWISTA SE, 1994, J INFECT DIS, V170, P1312, DOI 10.1093/infdis/170.5.1312; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; MINTZ ED, 1991, TRANSFUSION, V31, P365, DOI 10.1046/j.1537-2995.1991.31491213305.x; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; ONG KR, 1990, LANCET, V336, P112, DOI 10.1016/0140-6736(90)91624-J; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; SMITH RP, 1986, JAMA-J AM MED ASSOC, V256, P2726, DOI 10.1001/jama.256.19.2726; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; Telford S. R. III, 1993, PARASIT PROTOZOA, V5, P1; TEUTSCH SM, 1980, AM J TROP MED HYG, V29, P738, DOI 10.4269/ajtmh.1980.29.738; Wittner M, 1996, AM J TROP MED HYG, V55, P219, DOI 10.4269/ajtmh.1996.55.219; WITTNER M, 1982, ANN INTERN MED, V96, P601, DOI 10.7326/0003-4819-96-5-601; 1990, MMWR MORB MORTAL WKL, V39, P19	32	208	210	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					160	165		10.1056/NEJM199807163390304	http://dx.doi.org/10.1056/NEJM199807163390304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664092				2022-12-01	WOS:000074782900004
J	Nagel, RL				Nagel, RL			A knockout of a transgenic mouse - Animal models of sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICE		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Nagel, RL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; Kaul DK, 1995, J CLIN INVEST, V96, P2845, DOI 10.1172/JCI118355; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; TRUDEL M, 1994, BLOOD, V84, P3189	5	24	36	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					194	195		10.1056/NEJM199807163390310	http://dx.doi.org/10.1056/NEJM199807163390310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664098				2022-12-01	WOS:000074782900010
J	Miesenbock, G; De Angelis, DA; Rothman, JE				Miesenbock, G; De Angelis, DA; Rothman, JE			Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins	NATURE			English	Article							SIMPLEX VIRUS VECTORS; FUSION EVENTS; MAST-CELLS; MUTATIONS; SIGNAL	In neural systems, information is often carried by ensembles of cells rather than by individual units. Optical indicators(1) provide a powerful means to reveal such distributed activity, particularly when protein-based and encodable in DNA(2-4): encodable probes can be introduced into cells, tissues, or transgenic organisms by genetic manipulation, selectively expressed in anatomically or functionally defined groups of cells, and, ideally, recorded in situ, without a requirement for exogenous cofactors, Here we describe sensors for secretion and neurotransmission that fulfill these criteria We have developed pH-sensitive mutants of green fluorescent protein ('pHluorins') by structure-directed combinatorial mutagenesis, with the aim of exploiting the acidic pH inside secretory vesicles(5,6) to monitor vesicle exocytosis and recycling. When linked to a vesicle membrane protein, pHluorins were sorted to secretory and synaptic vesicles and reported transmission at individual synaptic boutons, as well as secretion and fusion pore 'flicker' of single secretory granules.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Wood, David W/B-2992-2012; Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Miesenboeck, Gero/0000-0003-2940-3228				ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANDLER DE, 1980, J CELL BIOL, V86, P666, DOI 10.1083/jcb.86.2.666; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; LAWRENCE MS, 1995, P NATL ACAD SCI USA, V92, P7247, DOI 10.1073/pnas.92.16.7247; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Marconi P, 1996, P NATL ACAD SCI USA, V93, P11319, DOI 10.1073/pnas.93.21.11319; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; RAO M, 1997, J IMMUNOL, V159, P2815; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YU SS, 1993, J BIOL CHEM, V268, P337	27	1835	1887	9	311	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					192	195		10.1038/28190	http://dx.doi.org/10.1038/28190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671304				2022-12-01	WOS:000074705900057
J	Burman, WJ; Reves, RR; Cohn, DL				Burman, WJ; Reves, RR; Cohn, DL			The case for conservative management of early HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Denver Publ Hlth, Infect Dis AIDS Clin, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Burman, WJ (corresponding author), Denver Publ Hlth, Infect Dis AIDS Clin, 605 Bannock St, Denver, CO 80204 USA.	bburman@dhha.org						Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CARR A, 1998, 5 C RETR OPP INF FEB; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P889; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONDRA JH, 1996, 11 INT C AIDS JUL 7; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; GEISELER PJ, 1987, AM REV RESPIR DIS, V135, P3; GOUJARD C, 1998, 5 C RETR OPP INF FEB; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Lennox J. L., 1997, Clinical Infectious Diseases, V25, P397; MIEDEMA F, 1998, 5 C RETR OPP INF FEB; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN CLIN PRACT TR, 1997, GUID US ANT AG HIV I; PULLAR T, 1988, CLIN PHARMACOL THER, V44, P540, DOI 10.1038/clpt.1988.191; ROTH HP, 1978, CLIN PHARMACOL THER, V23, P361; RUBIO A, 1996, 3 INT C DRUG THER HI; Steger K. A., 1997, Clinical Infectious Diseases, V25, P444; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; WANG SA, 1998, CLIN INFECT DIS, V25, P444	26	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					93	95		10.1001/jama.280.1.93	http://dx.doi.org/10.1001/jama.280.1.93			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660372				2022-12-01	WOS:000074379400032
J	Schacker, T; Ryncarz, AJ; Goddard, J; Diem, K; Shaughnessy, M; Corey, L				Schacker, T; Ryncarz, AJ; Goddard, J; Diem, K; Shaughnessy, M; Corey, L			Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETERODUPLEX MOBILITY ASSAY; VIRAL EXPRESSION; PERIPHERAL-BLOOD; TYPE-1; TRANSMISSION; INFECTIONS; SEROCONVERSION; REPLICATION; ACTIVATION	Context.-Genital ulcer disease has been epidemiologically linked as a risk factor in the transmission of the human immunodeficiency virus 1 (HIV-1). While herpes simplex virus 2 (HSV-2) is the most common cause of genital ulcers, no study has systematically evaluated the frequency or titer of HIV-1 virus in HSV-2 lesions. Objective.-To compare lesional HIV-1 RNA levels during and after genital HSV-2 reactivation and to evaluate the frequency, titer, and duration of HIV-1 RNA shedding in lesions due to HSV-2. Design.-Convenience sample. Setting.-Sexually transmitted disease research clinic at the University of Washington, Seattle. Patients.-Twelve HIV-infected men with a history of symptomatic HSV-2 infection who underwent daily sampling of genital lesions for HIV-1 RNA by polymerase chain reaction assay and HSV-2 by culture. Main Outcome Measure.-Detection of lesional HIV RNA and HSV-2. Results.-HIV-1 RNA was detected from lesional swabs in 25 of 26 consecutively studied HSV-2 episodes and on 67% of days in which genital lesions were noted. The HIV-1 RNA titers in lesional swabs exceeded 10 000 copies/mL of swab sample in 75% of samples (range, 2.2-3.2 x 10(5) copies/mL of swab sample). HIV-1 RNA in genital lesion swabs was seen in persons with high and low titers of plasma HIV-1 RNA and was not associated with plasma HIV-1 RNA levels. Conclusions.-HIV-1 virions can consistently be detected in genital ulcers caused by HSV-2, which suggests that genital herpes infection likely increases the efficiency of the sexual transmission of HIV-1.	Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Lab Med, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis M115, POB 19024,1100 Fairview Ave N D3-100, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30371, U01 AI-35498, AI-01228] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT MA, 1989, J VIROL, V63, P1861, DOI 10.1128/JVI.63.5.1861-1868.1989; AUGENBRAUN M, 1995, ANN INTERN MED, V123, P845, DOI 10.7326/0003-4819-123-11-199512010-00006; AUGENBRAUN MH, 1994, INFECT DIS CLIN N AM, V8, P439; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; CAMERON DW, 1989, LANCET, V2, P403; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; CUNNINGHAM AL, 1985, J CLIN INVEST, V75, P226, DOI 10.1172/JCI111678; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, AIDS RES HUM RETROV, V11, P1081, DOI 10.1089/aid.1995.11.1081; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GOLDEN MP, 1992, J INFECT DIS, V166, P494, DOI 10.1093/infdis/166.3.494; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; KOELLE DM, 1994, J INFECT DIS, V169, P956, DOI 10.1093/infdis/169.5.956; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; OBRIEN WA, 1995, BLOOD, V86, P1082; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OFARRELL N, 1994, INT J STD AIDS, V5, P415, DOI 10.1177/095646249400500607; OSTROVE JM, 1987, J VIROL, V61, P3726, DOI 10.1128/JVI.61.12.3726-3732.1987; OTTEN MW, 1994, AIDS, V8, P549, DOI 10.1097/00002030-199404000-00020; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; Piot P, 1989, SEXUALLY TRANSMITTED, P711; RIOS Z, 1995, CELL MOL BIOL, V41, pS93; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WALD A, 1994, ANTIMICROB AGENTS CH, V38, P174, DOI 10.1128/AAC.38.2.174	42	240	244	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					61	66		10.1001/jama.280.1.61	http://dx.doi.org/10.1001/jama.280.1.61			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660365	Bronze			2022-12-01	WOS:000074379400025
J	Marzuk, PM; Tardiff, K; Leon, AC; Hirsch, CS; Portera, L; Iqbal, I; Nock, MK; Hartwell, N				Marzuk, PM; Tardiff, K; Leon, AC; Hirsch, CS; Portera, L; Iqbal, I; Nock, MK; Hartwell, N			Ambient temperature and mortality from unintentional cocaine overdose	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; 1980 HEAT-WAVE; RECREATIONAL COCAINE; CONSCIOUS DOG; ABUSE; HYPERTHERMIA; DEATH; INTOXICATION; RHABDOMYOLYSIS; LETHALITY	Context.-Hot weather taxes cardiovascular function and is associated with increased deaths from heart disease. Cocaine can cause hypertension, tachycardia, coronary vasospasm, arrhythmias, and increased core temperature. Objective.-To determine the association between mortality from cocaine overdose and hot weather. Setting.-New York, NY. Design.-Retrospective review of medical examiner cases from 1990 through 1995. Subjects.-All fatal unintentional cocaine overdoses from 1990 through 1992 (n=1382) and all hyperthermia deaths of cocaine users (n = 10) were used to identify a maximum daily temperature threshold above which mortality from cocaine intoxication increased. The study population consisted of all fatal unintentional cocaine overdoses from 1993 through 1995 (n = 2008) and 4 contemporaneous comparison groups that included fatal unintentional opiate overdoses (n = 793), all other fatal unintentional overdoses (n = 85), and a subset of homicides (n = 4638) and fatalities from motor vehicle crashes (n = 815). Main Outcome Measures.-The number of overdose deaths and the proportion of homicides and traffic fatalities with a positive cocaine toxicology test result on days with a maximum temperature above or below the temperature threshold. Results.-A threshold temperature of 31.1 degrees C (88 degrees F) was identified, above which the mean daily number of fatal cocaine overdoses increased steadily. On days with a maximum daily temperature of 31.1 degrees C (88 degrees F) or higher ("hot days"), the mean daily number of cocaine overdose deaths was 2.34 (SD = 1.68), which was 33% higher than the mean on days with a maximum temperature of less than 31.1 degrees C (88 degrees F) (mean=1.76 [SD=1.37] (P<.001). In contrast, the mean number of opiate overdose deaths per day was 0.81 (SD = 0.94) on hot days and 0.71 (SD = 0.86) on other days (P=.28). For other drug overdose deaths, the mean number of deaths per day was 0.08 (SD = 0.28) on hot days and 0.08 (SD = 0.28) on other days (P=.69). Among homicides, the proportion with a positive cocaine toxicology test result was 18.9% on hot days and 19.5% on other days (P=.69), and among traffic fatalities, the proportions with positive cocaine toxicology test results were 9.5% on hot days and 10.3% on other days (P=.91). Conclusions.-High ambient temperature is associated with a significant increase in mortality from cocaine overdose. Based on our comparison groups, the increase is not explained by changes in cocaine use among the general population. Although cocaine use is dangerous on all days, it appears to be even more dangerous on hot days.	Cornell Univ Med Coll, Dept Psychiat, Epidemiol Sect, New York, NY USA; Cornell Univ Med Coll, Dept Publ Hlth, New York, NY USA; Off Chief Med Examiner, New York, NY USA; NYU, Sch Med, Dept Forens Med, New York, NY USA	Cornell University; Cornell University; New York University	Marzuk, PM (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Dept Psychiat, 525 E 68th St, New York, NY 10021 USA.		Nock, Matthew/AAE-8330-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 06534] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERS C, 1995, MMWR-MORBID MORTAL W, V44, P465; APPLEGATE WB, 1981, J AM GERIATR SOC, V29, P337, DOI 10.1111/j.1532-5415.1981.tb01238.x; BAUWENS JE, 1989, WESTERN J MED, V150, P210; BUECHLEY RW, 1972, ENVIRON RES, V5, P85, DOI 10.1016/0013-9351(72)90022-9; CALLAWAY CW, 1994, ANN EMERG MED, V24, P68, DOI 10.1016/S0196-0644(94)70165-2; CATRAVAS JD, 1978, ARCH INT PHARMACOD T, V235, P328; CATRAVAS JD, 1981, J PHARMACOL EXP THER, V217, P350; CLARKE JF, 1972, ENVIRON RES, V5, P93, DOI 10.1016/0013-9351(72)90023-0; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; DARAS M, 1995, ACTA NEUROL SCAND, V92, P161; ELLIS FP, 1972, ENVIRON RES, V5, P1, DOI 10.1016/0013-9351(72)90019-9; FISCHMAN MW, 1976, ARCH GEN PSYCHIAT, V33, P983; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JONES TS, 1982, JAMA-J AM MED ASSOC, V247, P3327, DOI 10.1001/jama.247.24.3327; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1988, IMPACT PREDICTED CLI, V41; KOSTEN TR, 1988, AM J DRUG ALCOHOL AB, V14, P335, DOI 10.3109/00952998809001555; LOGHMANEE F, 1986, AM J FOREN MED PATH, V7, P246, DOI 10.1097/00000433-198607030-00012; MARZUK PM, 1995, NEW ENGL J MED, V332, P1753, DOI 10.1056/NEJM199506293322606; Marzuk PM, 1997, AM J DRUG ALCOHOL AB, V23, P221, DOI 10.3109/00952999709040943; *OFF APPL STUD, 1993, SMA PUBL; *OFF APPL STUD, 1996, SMA PUBL; *OFF APPL STUD, 1994, ANN EM ROOM DAT 19 1, pA12; ROBERTS JR, 1984, AM J EMERG MED, V2, P373, DOI 10.1016/0735-6757(84)90178-5; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; SEMANZA JC, 1996, NEW ENGL J MED, V335, P84; SPRANG CL, 1979, CHEST, V75, P362; WETLI CV, 1985, J FORENSIC SCI, V30, P873	31	75	77	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1795	1800		10.1001/jama.279.22.1795	http://dx.doi.org/10.1001/jama.279.22.1795			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628710	Green Published, Bronze			2022-12-01	WOS:000073998500031
J	Rosenmund, C; Stern-Bach, Y; Stevens, CF				Rosenmund, C; Stern-Bach, Y; Stevens, CF			The tetrameric structure of a glutamate receptor channel	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; ACID RECEPTORS; BINDING-SITES; RAT-BRAIN; DESENSITIZATION; CONDUCTANCE; LOCALIZATION; ACTIVATION; KINETICS; GLYCINE	The subunit stoichiometry of several ligand-gated ion channel receptors is still unknown. A counting method was developed to determine the number of subunits in one family of brain glutamate receptors, Successful application of this method in an HEK cell line provides evidence that ionotropic glutamate receptors share a tetrameric structure with the voltage-gated potassium channels. The average conductance of these channels depends on how many subunits are occupied by an agonist.	Salk Inst, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Max Planck Inst Biophys Chem, Workgrp Cellular Neurobiol, Gottingen, Germany; Hebrew Univ Jerusalem, Haddassah Dent Sch, Dept Anat & Embryol, Jerusalem, Israel	Howard Hughes Medical Institute; Salk Institute; Max Planck Society; Hebrew University of Jerusalem	Stevens, CF (corresponding author), Salk Inst, Howard Hughes Med Inst, La Jolla, CA 92093 USA.		Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 12961] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAPMAN L, 1997, BIOPHYS J, V72, P708; Clements JD, 1998, J NEUROSCI, V18, P119; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DUDEL J, 1990, BIOPHYS J, V57, P533, DOI 10.1016/S0006-3495(90)82569-8; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Mano I., 1996, Society for Neuroscience Abstracts, V22, P726; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; PREMKUMAR LS, 1997, J GEN PHYSIOL, V110, P48; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; Rosenmund C., 1996, Biophysical Journal, V70, pA251; RUIZ L, 1997, NATURE, V389, P389; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; SWANSON T, 1997, J NEUROSCI, V17, P58; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TAYLOR WR, 1995, J PHYSIOL-LONDON, V483, P567, DOI 10.1113/jphysiol.1995.sp020607; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; WU TY, 1994, BIOCHEM J, V300, P365, DOI 10.1042/bj3000365; YAMADA KA, 1993, J NEUROSCI, V13, P3904	35	608	626	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1596	1599		10.1126/science.280.5369.1596	http://dx.doi.org/10.1126/science.280.5369.1596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616121	Green Published			2022-12-01	WOS:000074061200039
J	Ridge, JP; Di Rosa, F; Matzinger, P				Ridge, JP; Di Rosa, F; Matzinger, P			A conditioned dendritic cell can be a temporal bridge between a CD4(+) T-helper and a T-killer cell	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; INVIVO; TOLERANCE; INDUCTION; RESPONSES; ABSENCE; REQUIREMENTS; GENERATION; ACTIVATION; MECHANISM	To generate an immune response, antigen-specific T-helper and T-killer cells must find each other and, because they cannot detect each other's presence, they are brought together by an antigen-loaded dendritic cell that displays antigens to both(1-3). This three-cell interaction, however, seems nearly impossible because all three cell types are rare and migratory. Here we provide a potential solution to this conundrum, We found that the three cells need not meet simultaneously but that the helper cell can first engage and 'condition' the dendritic cell, which then becomes empowered to stimulate a killer cell. The first step (help) can be bypassed by modulation of the surface molecule CD40, or by viral infection of dendritic cells. These results may explain the longstanding paradoxical observation that responses to some viruses are helper-independent, and they evoke the possibility that dendritic cells may take on different functions in response to different conditioning signals.	NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ridge, JP (corresponding author), NIAID, Ghost Lab, Sect T Cell Tolerance & Memory, Lab Cellular & Mol Immunol,NIH, Bldg 4 Room 111,9000 Rockville Pike, Bethesda, MD 20892 USA.	jridge@atlas.niaid.nih.gov	Di Rosa, Francesca/AAW-8612-2020; Di Rosa, Francesca/J-8116-2014	Di Rosa, Francesca/0000-0003-0252-9138; 				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BOOG CJP, 1985, NATURE, V318, P59, DOI 10.1038/318059a0; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HOU S, 1995, J VIROL, V69, P1429, DOI 10.1128/JVI.69.3.1429-1434.1995; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KATONA IM, 1991, J IMMUNOL, V146, P4215; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Liu LM, 1997, ADV EXP MED BIOL, V417, P375; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MITCHISON NA, 1987, EUR J IMMUNOL, V17, P1579, DOI 10.1002/eji.1830171109; NONACS R, 1992, J EXP MED, V176, P519, DOI 10.1084/jem.176.2.519; PALIARD X, 1988, J IMMUNOL, V141, P849; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; SAELAND S, 1993, J EXP MED, V178, P113, DOI 10.1084/jem.178.1.113; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; TRIPP RA, 1995, J IMMUNOL, V155, P2955; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WU Y, 1994, CURR BIOL, V4, P499, DOI 10.1016/S0960-9822(00)00110-X; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862; YONG JL, 1995, IMMUNITY, V2, P239	30	1945	2099	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					474	478		10.1038/30989	http://dx.doi.org/10.1038/30989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624003				2022-12-01	WOS:000074020000046
J	Weeks, JC; Cook, EF; O'Day, SJ; Petersen, LM; Wenger, N; Reding, D; Harrell, FE; Kussin, P; Dawson, NV; Connors, AF; Lynn, J; Phillips, RS				Weeks, JC; Cook, EF; O'Day, SJ; Petersen, LM; Wenger, N; Reding, D; Harrell, FE; Kussin, P; Dawson, NV; Connors, AF; Lynn, J; Phillips, RS			Relationship between cancer patients' predictions of prognosis and their treatment preferences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; BREAST-CANCER; SURVIVAL; LIFE; CARE; DECISIONS; DOCTORS; TRUTH	Context.-Previous studies have documented that cancer patients tend to overestimate the probability of long-term survival. If patient preferences about the trade-offs between the risks and benefits associated with alternative treatment strategies are based on inaccurate perceptions of prognosis, then treatment choices may not reflect each patient's true values. Objective.-To test the hypothesis that among terminally ill cancer patients an accurate understanding of prognosis is associated with a preference for therapy that focuses on comfort over attempts at life extension. Design.-Prospective cohort study. Setting.-Five teaching hospitals in the United States. Patients.-A total of 917 adults hospitalized with stage III or IV non-small cell lung cancer or colon cancer metastatic to liver in phases 1 and 2 of the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT), Main Outcome Measures.-Proportion of patients favoring life-extending therapy over therapy focusing on relief of pain and discomfort, patient and physician estimates of the probability of 6-month survival, and actual 6-month survival, Results.-Patients who thought they were going to live for at least 6 months were more likely (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.8-3.7) to favor life-extending therapy over comfort care compared with patients who thought there was at least a 10% chance that they would not live 6 months. This OR was highest (8.5; 95% CI, 3.0-24.0) among patients who estimated their 6-month survival probability at greater than 90% but whose physicians estimated it at 10% or less. Patients overestimated their chances of surviving 6 months, while physicians estimated prognosis quite accurately. Patients who preferred life-extending therapy were more likely to undergo aggressive treatment, but controlling for known prognostic factors, their 6-month survival was no better. Conclusions.-Patients with metastatic colon and lung cancer overestimate their survival probabilities and these estimates may influence their preferences about medical therapies.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Clin Epidemiol Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA; Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Div Biostat & Epidemiol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Case Western Reserve Univ, Dept Med, Metrohlth Med Ctr, Cleveland, OH 44106 USA; George Washington Univ, Ctr Improve Care Dying, Washington, DC USA; Beth Israel Hosp, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Marshfield Clinic; University of Virginia; Duke University; Case Western Reserve University; MetroHealth System; George Washington University; Harvard University; Beth Israel Deaconess Medical Center	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	jane_weeks@dci.harvard.edu		Connors, Alfred F./0000-0001-7123-3360				Bernheim JL, 1987, MONOGR SER EUR ORGAN, V17, P285; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Dawson N. V., 1995, JGIM, V10, P41; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FORROW L, 1988, JAMA-J AM MED ASSOC, V259, P3161, DOI 10.1001/jama.259.21.3161; GOODMAN LA, 1972, J AM STAT ASSOC, V67, P415, DOI 10.2307/2284396; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOLCOMBE RF, 1994, NEW ENGL J MED, V331, P811; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; MCQUELLON RP, 1995, J CLIN ONCOL, V13, P858, DOI 10.1200/JCO.1995.13.4.858; Mezey M, 1996, J AM GERIATR SOC, V44, P144, DOI 10.1111/j.1532-5415.1996.tb02430.x; MIYAJI NT, 1993, SOC SCI MED, V36, P249, DOI 10.1016/0277-9536(93)90008-R; MIYAJI NT, 1994, NEW ENGL J MED, V331, P810; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; PRONZATO P, 1994, SUPPORT CARE CANCER, V2, P242, DOI 10.1007/BF00365729; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; SINGER PA, 1995, SOC SCI MED, V41, P1517, DOI 10.1016/0277-9536(95)00057-E; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; STEELE GD, 1994, CANCER, V74, P1979, DOI 10.1002/1097-0142(19941001)74:7<1979::AID-CNCR2820740725>3.0.CO;2-J; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; YELLEN SB, 1996, 4 INT SOC BEH MED MA	31	887	890	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1709	1714		10.1001/jama.279.21.1709	http://dx.doi.org/10.1001/jama.279.21.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624023	Bronze			2022-12-01	WOS:000073878700031
J	Watson, P; Marcus, JN; Lynch, HT				Watson, P; Marcus, JN; Lynch, HT			Prognosis of BRCA1 hereditary breast cancer	LANCET			English	Editorial Material							CARCINOMA; MUTATION		Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA; St Lukes Hosp, Dept Pathol, Chesterfield, MO 63017 USA	Creighton University; Saint Luke's Hospital - Missouri	Watson, P (corresponding author), Creighton Univ, Sch Med, Dept Prevent Med, Omaha, NE 68178 USA.							Eisinger F, 1996, CANCER RES, V56, P471; GAMEL JW, 1995, CANCER, V76, P1009; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(97)89007-7; Lakhani SR, 1997, LANCET, V349, P1505; Marcus JN, 1997, CANCER-AM CANCER SOC, V80, P543, DOI 10.1002/(SICI)1097-0142(19970801)80:3+<543::AID-CNCR4>3.3.CO;2-R; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845	11	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					304	305		10.1016/S0140-6736(98)22005-8	http://dx.doi.org/10.1016/S0140-6736(98)22005-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652604				2022-12-01	WOS:000071864000002
J	Russmann, H; Shams, H; Poblete, F; Fu, YX; Galan, JE; Donis, RO				Russmann, H; Shams, H; Poblete, F; Fu, YX; Galan, JE; Donis, RO			Delivery of epitopes by the Salmonella type III secretion system for vaccine development	SCIENCE			English	Article							LYMPHOCYTES-T; TYPHIMURIUM; CELLS; IDENTIFICATION; IMMUNIZATION; RESPONSES; CARRIERS; VECTORS; STRAINS; GENE	Avirulent strains of Salmonella typhimurium are being considered as antigen delivery vectors. During its intracellular stage in the host, S. typhimurium resides within a membrane-bound compartment and is not an efficient inducer of class I-restricted immune responses. Viral epitopes were successfully delivered to the host-cell cytosol by using the type III protein secretion system of S. typhimurium. This resulted in class I-restricted immune responses that protected vaccinated animals against lethal infection. This approach may allow the efficient use of S. typhimurium as an antigen delivery system to control infections by pathogens that require this type of immune response for protection.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Nebraska System; University of Nebraska Lincoln	Galan, JE (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	galan@asterix.bio.sunysb.edu						ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; COLLAZO CM, 1995, MOL MICROBIOL, V15, P25, DOI 10.1111/j.1365-2958.1995.tb02218.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; CURTISS R, 1994, DEV BIOL STAND, V82, P23; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DECKHUT AM, 1993, J IMMUNOL, V151, P2658; Fu YX, 1998, J BACTERIOL, V180, P3393, DOI 10.1128/JB.180.13.3393-3399.1998; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GALAN JE, 1990, GENE, V94, P29, DOI 10.1016/0378-1119(90)90464-3; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1996, CELLULAR MOL BIOL, P2757; GAO XM, 1992, INFECT IMMUN, V60, P3780, DOI 10.1128/IAI.60.9.3780-3789.1992; Hackett Jim, 1993, Current Opinion in Biotechnology, V4, P611, DOI 10.1016/0958-1669(93)90085-B; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; KAREM KL, 1997, J GEN VIROL, V78, P27; Katz SL, 1997, LANCET, V350, P1767, DOI 10.1016/S0140-6736(97)05358-0; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; Lambert PH, 1996, DEV BIOL STAND, V87, P45; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; OSSEVOORT MA, 1995, J IMMUNOTHER, V18, P86, DOI 10.1097/00002371-199508000-00002; Paoletti E, 1996, P NATL ACAD SCI USA, V93, P11349, DOI 10.1073/pnas.93.21.11349; Ringrose JH, 1996, CLIN RHEUMATOL, V15, P79, DOI 10.1007/BF03342653; Rolph MS, 1997, CURR OPIN IMMUNOL, V9, P517, DOI 10.1016/S0952-7915(97)80104-5; Schlom J, 1996, BREAST CANCER RES TR, V38, P27, DOI 10.1007/BF01803781; Schmidt W, 1997, P NATL ACAD SCI USA, V94, P3262, DOI 10.1073/pnas.94.7.3262; SCHODEL F, 1995, DEV BIOL STAND, V84, P245; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; Vitiello A, 1996, J IMMUNOL, V157, P5555; Weiskirch LM, 1997, IMMUNOL REV, V158, P159, DOI 10.1111/j.1600-065X.1997.tb01002.x; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WUNDERLICH J, 1991, CURRENT PROTOCOLS IM; YANG DM, 1990, J IMMUNOL, V145, P2281; 1997, WHOVRDGEN9701	35	227	260	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					565	568		10.1126/science.281.5376.565	http://dx.doi.org/10.1126/science.281.5376.565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677200				2022-12-01	WOS:000075012300042
J	Torigoe, C; Inman, JK; Metzger, H				Torigoe, C; Inman, JK; Metzger, H			An unusual mechanism for ligand antagonism	SCIENCE			English	Article							T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; RECEPTOR LIGANDS; LEUKEMIA-CELLS; IGE; ANTIGEN; PHOSPHORYLATION; AGGREGATION; COMPLEXES; KINASE	The ratio of late to early events stimulated by the mast cell receptor for immunoglobulin E (IgE) correlated with the affinity of a ligand for the receptor-bound IgE. Because excess receptors clustered by a weakly binding ligand could hoard a critical initiating kinase, they prevented the outnumbered clusters engendered by the high-affinity ligands from launching the more complete cascade. A similar mechanism could explain the antagonistic action of some peptides on the activation of T cells.	NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Torigoe, C (corresponding author), NIAMSD, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA.							ALBER G, 1992, J IMMUNOL, V149, P2428; ASHMAN RF, 1969, J BIOL CHEM, V244, P3405; BARSUMIAN EL, 1985, CELL IMMUNOL, V90, P131, DOI 10.1016/0008-8749(85)90175-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS AM, 1995, INT ARCH ALLERGY IMM, V107, P547, DOI 10.1159/000237098; DAY LA, 1963, ANN NY ACAD SCI, V103, P611, DOI 10.1111/j.1749-6632.1963.tb53721.x; ELIOT CW, 1985, FOLKLORE FABLES, P27; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HABA S, 1991, J IMMUNOL METHODS, V138, P15, DOI 10.1016/0022-1759(91)90059-O; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; LIU FT, 1980, J IMMUNOL, V124, P2728; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; METZGER H, 1982, MOL IMMUNOL, V19, P1071, DOI 10.1016/0161-5890(82)90316-9; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; RACIOPPI L, 1995, CHEM IMMUNOL, V60, P79; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIN KE, 1980, J IMMUNOL METHODS, V37, P83, DOI 10.1016/0022-1759(80)90183-0; SUBRAMANIAN K, 1995, THESIS CORNELL U ITH; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; TORIGOE C, UNPUB; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; WOFSY C, 1997, J IMMUNOL, V159, P5985; WOLDEMUSSIE E, 1986, J IMMUNOL, V137, P1674; Wulfing C, 1997, J EXP MED, V185, P1815, DOI 10.1084/jem.185.10.1815; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	39	134	137	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					568	572		10.1126/science.281.5376.568	http://dx.doi.org/10.1126/science.281.5376.568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677201				2022-12-01	WOS:000075012300043
J	Young, A; Willatts, S				Young, A; Willatts, S			Controversies in management of acute brain trauma	LANCET			English	Editorial Material							CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; METABOLISM		Bristol Royal Infirm & Gen Hosp, Dept Anaesthesia, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary	Young, A (corresponding author), Bristol Royal Infirm & Gen Hosp, Dept Anaesthesia, Bristol BS2 8HW, Avon, England.		Young, Amber/H-2988-2018	Young, Amber/0000-0001-7205-492X				ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 1995, MAN SEV HEAD INJ; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DeWitt D S, 1995, New Horiz, V3, P376; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031	20	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	1998	352	9123					164	166		10.1016/S0140-6736(05)77803-X	http://dx.doi.org/10.1016/S0140-6736(05)77803-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683202				2022-12-01	WOS:000074859800006
J	Poon, B; Grovit-Ferbas, K; Stewart, SA; Chen, ISY				Poon, B; Grovit-Ferbas, K; Stewart, SA; Chen, ISY			Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; OPEN READING FRAME; PRODUCTIVE INFECTION; MUTATIONAL ANALYSIS; RHESUS-MONKEYS; TYPE-1; GENE; PROTEIN; MACROPHAGES; LYMPHOCYTES	Expression of human immunodeficiency virus-type 1 (HIV-1) Vpr after productive infection of T cells induces cell cycle arrest in the G(2) phase of the cell cycle. In the absence of de novo expression, HIV-1 Vpr packaged into virions still induced cell cycle arrest. Naturally noninfectious virus or virus rendered defective for infection by reverse transcriptase or protease inhibitors were capable of inducing Vpr-mediated cell cycle arrest. These results suggest a model whereby both infectious and noninfectious virions in vivo, such as those surrounding follicular dendritic cells, participate in immune suppression.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol & Med, AIDS Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, AIDS Inst, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Chen, ISY (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol & Med, AIDS Inst, Los Angeles, CA 90095 USA.		Stewart, Sheila A/C-5213-2012		NATIONAL CANCER INSTITUTE [R01CA070018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [CA70018] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; PHS HHS [T32/A107388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; BALLIET JW, 1994, VIROLOGY, V200, P623, DOI 10.1006/viro.1994.1225; BALOTTO CP, 1993, J EXP MED, V176, P1099; CAMERINI D, 1994, SCIENCE, V264, P1160, DOI 10.1126/science.7909961; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HOCH J, 1995, J VIROL, V69, P4807, DOI 10.1128/JVI.69.8.4807-4813.1995; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NALDINI L, 1996, P NATL ACAD SCI USA, V93, P11383; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; POON B, UNPUB; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Sambrook J., 1989, MOL CLONING; SHEARER GM, 1986, J IMMUNOL, V137, P2515; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; TENNERRACZ K, 1989, PROGR AIDS PATHOLOGY, P29; WAHREN B, 1987, J VIROL, V61, P2017, DOI 10.1128/JVI.61.6.2017-2023.1987; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265	50	165	166	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					266	269		10.1126/science.281.5374.266	http://dx.doi.org/10.1126/science.281.5374.266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657723				2022-12-01	WOS:000074714200052
J	Oda, Y; Kawasaki, K; Morita, M; Korn, H; Matsui, H				Oda, Y; Kawasaki, K; Morita, M; Korn, H; Matsui, H			Inhibitory long-term potentiation underlies auditory conditioning of goldfish escape behaviour	NATURE			English	Article							MAUTHNER CELL; STARTLE REFLEX; TRANSMISSION; SYNAPSES; RESPONSES; NETWORK	Long-term potentiation (LTP), the increase in synaptic strength evoked by high-frequency stimulation, is often considered to be a cellular model for learning and memory. The validity of this model depends on the assumptions that physiological stimuli can induce LTP in vivo and that the resulting: synaptic modifications correlate with behavioural changes. However, modifiable synapses are generally embedded deep in complex circuits. In contrast, the goldfish Mauthner (M)-cell and its afferent synapses are easily accessible for electrophysiological studies, and firing of this neuron is sufficient to trigger fast escape behaviour in response to sudden stimuli(1,2). We have previously shown that tetanic stimulation can induce LTP of the feedforward inhibitory synapses that control the excitability of the M-ceIl(3,4). Here we report that natural sensory stimulation can induce potentiation of this inhibitory connection that resembles the LTP induced by afferent tetanization. Furthermore, comparable acoustic stimulation produced a parallel decrease in the probability of the sound-evoked escape reflex Thus we demonstrate for the first time, to our knowledge, a behavioural role for the long-term synaptic strengthening of inhibitory synapses.	Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Osaka 5608531, Japan; Inst Pasteur, INSERM, U261, Biol Cellulaire & Mol Lab, F-75724 Paris, France	Osaka University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Oda, Y (corresponding author), Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Machikaneyama 1-3, Osaka 5608531, Japan.							ALJURE E, 1980, BRAIN RES, V188, P261, DOI 10.1016/0006-8993(80)90574-0; Blaxter J.H.S., 1988, P203; Brunskill R.W, 1978, ILLUSTRATED HDB VERN; Canfield JG, 1996, BRAIN BEHAV EVOLUT, V48, P137, DOI 10.1159/000113193; EATON RC, 1991, J EXP BIOL, V161, P469; EATON RC, 1988, J NEUROSCI, V8, P2758; FABER DS, 1975, BRAIN RES, V96, P349, DOI 10.1016/0006-8993(75)90746-5; FABER DS, 1988, J NEUROPHYSIOL, V60, P1982, DOI 10.1152/jn.1988.60.6.1982; FABER DS, 1982, J NEUROPHYSIOL, V48, P654, DOI 10.1152/jn.1982.48.3.654; FAY RR, 1995, BRAIN BEHAV EVOLUT, V46, P141, DOI 10.1159/000113267; FETCHO JR, 1991, BRAIN BEHAV EVOLUT, V37, P298, DOI 10.1159/000114367; FISHER TM, 1995, J NEUROSCI, V15, P762; FURUKAWA T, 1967, J NEUROPHYSIOL, V30, P1377, DOI 10.1152/jn.1967.30.6.1377; FURUKAWA T, 1963, J NEUROPHYSIOL, V26, P140, DOI 10.1152/jn.1963.26.1.140; GROVES P M, 1970, Psychological Review, V77, P419, DOI 10.1037/h0029810; KANDEL ER, 1978, GRASS LECT MONOGR J; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; ODA Y, 1995, J NEUROPHYSIOL, V74, P1056, DOI 10.1152/jn.1995.74.3.1056; RODGERS WL, 1963, J COMP PHYSIOL PSYCH, V56, P917, DOI 10.1037/h0039700; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; VU ET, 1993, J NEUROSCI, V13, P4379; Wilson MA, 1997, TRENDS NEUROSCI, V20, P102, DOI 10.1016/S0166-2236(96)01023-5; YANG XD, 1990, NATURE, V348, P542, DOI 10.1038/348542a0; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299; ZOTTOLI SJ, 1977, J EXP BIOL, V66, P243	27	69	69	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					182	185		10.1038/28172	http://dx.doi.org/10.1038/28172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671301				2022-12-01	WOS:000074705900054
J	Kaelin, WG				Kaelin, WG			Carcinogenesis - Another p53 Doppelganger?	SCIENCE			English	Editorial Material									Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Kaelin, WG (corresponding author), Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA.	William_Kaelin@dfci.harvard.edu						COLBRINIK D, 1996, GENE DEV, V10, P1633; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LECOUTER JE, COMMUNICATION; MARIN MC, COMMUNICATION; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; YANG A, COMMUNICATION	11	30	30	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					57	58		10.1126/science.281.5373.57	http://dx.doi.org/10.1126/science.281.5373.57			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9679018				2022-12-01	WOS:000074685800034
J	Wong, SS; Joselevich, E; Woolley, AT; Cheung, CL; Lieber, CM				Wong, SS; Joselevich, E; Woolley, AT; Cheung, CL; Lieber, CM			Covalently functionalized nanotubes as nanometre-sized probes in chemistry and biology	NATURE			English	Article							FORCE MICROSCOPY; CARBON NANOTUBES	Carbon nanotubes combine a range of properties that make them well suited for use as probe tips in applications such as atomic force microscopy (AFM)(1-3), Their high aspect ratio, for example, opens up the possibility of probing the deep crevices(4) that occur in microelectronic circuits, and the small effective radius of nanotube tips significantly improves the lateral resolution beyond what can be achieved using commercial silicon tips(5). Another characteristic feature of nanotubes is their ability to buckle elastically(4,6), which makes them very robust while limiting the maximum force that is applied to delicate organic and biological samples, Earlier investigations into the performance of nanotubes as scanning probe microscopy tips have focused on topographical imaging, but a potentially more significant issue is the question of whether nanotubes can be modified to create probes that can sense and manipulate matter at the molecular level(7), Here we demonstrate that nanotube tips with the capability of chemical and biological discrimination can be created with acidic functionality and by coupling basic or hydrophobic functionalities or biomolecular probes to the carboxyl groups that are present at the open tip ends. We have used these modified nanotubes as AFM tips to titrate the acid and base groups, to image patterned samples based on molecular interactions, and to measure the binding force between single protein-ligand pairs. As carboxyl groups are readily derivatized by a variety of reactions(8), the preparation of a wide range of functionalized nanotube tips should be possible, thus creating molecular probes with potential applications in many areas of chemistry and biology.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Cheung, Chin Li/B-8270-2013	Cheung, Chin Li/0000-0001-8210-2833; Joselevich, Ernesto/0000-0002-9919-0734				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Bodanszky M., 1994, PRACTICE PEPTIDE SYN; Bustamante C, 1997, CURR OPIN STRUC BIOL, V7, P709, DOI 10.1016/S0959-440X(97)80082-6; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; EVANS JF, 1977, J ELECTROANAL CHEM, V80, P409, DOI 10.1016/S0022-0728(77)80064-8; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; GILES MA, 1990, ANAL BIOCHEM, V184, P244; HIURA H, 1995, ADV MATER, V7, P275, DOI 10.1002/adma.19950070304; Keller D, 1996, NATURE, V384, P111, DOI 10.1038/384111a0; KUMARAMANICKAVEL G, 1994, NAT GENET, V8, P10, DOI 10.1038/ng0994-10; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; March J., 1992, ADV ORG CHEM, V4th; Marti A, 1995, LANGMUIR, V11, P4632, DOI 10.1021/la00012a009; McKendry R, 1998, NATURE, V391, P566, DOI 10.1038/35339; Noy A, 1998, LANGMUIR, V14, P1508, DOI 10.1021/la970948f; Noy A, 1997, ANNU REV MATER SCI, V27, P381, DOI 10.1146/annurev.matsci.27.1.381; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Vezenov DV, 1997, J AM CHEM SOC, V119, P2006, DOI 10.1021/ja963375m; WANDASS JH, 1987, J ELECTROCHEM SOC, V134, P2734, DOI 10.1149/1.2100278; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Wong SS, 1998, J AM CHEM SOC, V120, P603, DOI 10.1021/ja9737735; WONG SS, UNPUB J AM CHEM SOC	24	1342	1418	4	342	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					52	55		10.1038/27873	http://dx.doi.org/10.1038/27873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665127	Green Published			2022-12-01	WOS:000074579600044
J	McGarry, TJ; Kirschner, MW				McGarry, TJ; Kirschner, MW			Geminin, an inhibitor of DNA replication, is degraded during mitosis	CELL			English	Article							SISTER-CHROMATID SEPARATION; CELL-FREE-EXTRACTS; S-PHASE; LICENSING SYSTEM; MITOTIC CYCLINS; FISSION YEAST; XENOPUS; PROTEOLYSIS; PROTEIN; DESTRUCTION	We describe a novel 25 kDa protein, geminin, which inhibits DNA replication and is degraded during the mitotic phase of the cell cycle. Geminin has a destruction box sequence and is ubiquitinated anaphase-promoting complex (APC) in vitro. In synchronized HeLa cells, geminin is absent during G1 phase, accumulates during S, G2, and M phases, and disappears at the time of the metaphase-anaphase transition. Geminin inhibits DNA replication by preventing the incorporation of MCM complex into prereplication complex (preRC). We propose that geminin inhibits DNA replication during S, G2, and M phases and that geminin destruction at the metaphase-anaphase transition permits replication in the succeeding cell cycle.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							AMON A, 1994, CELL, V77, P4037; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUTCHISON CJ, 1993, CELL CYCLE PRACTICAL, P177; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Kay BK., 1991, XENOPUS LAEVIS PRACT, V36; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSTIG A, 1997, SCIENCE, V283, P83; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rowles A, 1997, CURR OPIN GENET DEV, V7, P152, DOI 10.1016/S0959-437X(97)80123-2; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Stern B, 1996, TRENDS GENET, V12, P345; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	42	707	724	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1043	1053		10.1016/S0092-8674(00)81209-X	http://dx.doi.org/10.1016/S0092-8674(00)81209-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635433	Bronze			2022-12-01	WOS:000074205700015
J	Duggan, AE; Tolley, K; Hawkey, CJ; Logan, RFA				Duggan, AE; Tolley, K; Hawkey, CJ; Logan, RFA			Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; THERAPY	Objective: To determine how small differences in the efficacy and cost of two antibiotic regimens to eradicate Helicobacter pylori can affect the overall cost effectiveness of H pylori eradication in duodenal ulcer disease. Design: A decision analysis to examine the cost effectiveness of eight H pylori eradication strategies for duodenal ulcer disease with and without C-13-urea breath testing to confirm eradication. Main outcome measures: Cumulative direct treatment costs per 100 patients with duodenal ulcer disease who were positive for H pylori. Results: In model 1 the strategy of omeprazole, clarithromycin, and metronidazole alone was the most cost effective of the four strategies assessed. The addition of the C-13-urea breath test and a second course of omeprazole, clarithromycin, and metronidazole achieved the highest eradication rate (97%) but was the most expensive (pound 62.63 per patient). The cost of each additional effective eradication was pound 589.00 (incremental cost per case) when compared with the cost of treating once only with omeprazole, clarithromycin, and metronidazole; equivalent to the cost of a patient receiving ranitidine for duodenal ulcer relapse for more than 15 years. Eradication strategies of omeprazole, amoxycillin, and metronidazole were less cost effective than omeprazole, clarithromycin, and metronidazole alone. in model 2 the addition of the C-13-urea breath test after treatment, and maintenance treatment, increased die cost of all the strategies and reduced the cost advantage of omeprazole, clarithromycin, and metronidazole alone. Conclusion: Small differences in efficacy can influence the comparative cost effectiveness of strategies for eradicating H pylori Of the strategies tested the most cost effective (omeprazole, clarithromycin, and metronidazole alone) was neither the least expensive (omeprazole, amoxycillin, and metronidazole alone) nor the most effective (omeprazole, clarithromycin, and metronidazole with further treatment for patients found positive for H pylori on C-13-urea breath testing). Cost effectiveness should be an important part of choosing an eradication strategy for H pylori.	Univ Nottingham, Dept Publ Hlth & Epidemiol, Nottingham NG7 2UH, England; Univ Nottingham, Div Gastroenterol, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Duggan, AE (corresponding author), Univ Nottingham, Dept Publ Hlth & Epidemiol, Nottingham NG7 2UH, England.			hobbs, richard/0000-0001-7976-7172				BELL GD, 1993, BR J MED EC, V6, P45; Carrere MO, 1997, PHARMACOECONOMICS, V11, P216, DOI 10.2165/00019053-199711030-00003; Johnston BJ, 1997, GUT, V41, pA166; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; LAMOULIATTE H, 1996, GASTROENTEROLOGY, V110, pA170; LOGAN RPH, 1996, CLIN CHALLENGES GAST, P42; MOAYYEDI P, 1995, EUR J GASTROEN HEPAT, V7, P835; PENSTON JG, 1993, ALIMENT PHARM THERAP, V7, P259; POUNDER RE, 1981, LANCET, V1, P29; PYM B, 1990, GASTROENTEROLOGY, V99, P27, DOI 10.1016/0016-5085(90)91225-U; SONNENBERG A, 1989, GASTROENTEROLOGY, V96, P1445, DOI 10.1016/0016-5085(89)90511-8; SONNENBERG A, 1996, GUT, V39, pA37; Sugden R., 1978, PRINCIPLES PRACTICAL; van der Hulst R W, 1996, Helicobacter, V1, P6	14	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1648	1654		10.1136/bmj.316.7145.1648	http://dx.doi.org/10.1136/bmj.316.7145.1648			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603748	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000074022700025
J	Smith, GD; Hart, C; Blane, D; Hole, D				Smith, GD; Hart, C; Blane, D; Hole, D			Adverse socioeconomic conditions in childhood and cause specific adult mortality: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; HELICOBACTER-PYLORI; CARDIOVASCULAR-DISEASE; LIVING-CONDITIONS; STOMACH-CANCER; SOCIAL-CLASS; RISK-FACTORS; EARLY-LIFE; MEN; ENGLAND	Objective: To investigate the association between social circumstances in childhood and mortality from various causes of death in adulthood. Design: Prospective observational study. Setting: 27 workplaces in the west of Scotland. Subjects: 5645 men aged 35-64 years at the time of examination. Main outcome measures: Death from various causes. Results: Men whose fathers had manual occupations when they were children were more likely as adults to have manual jobs and be living in deprived areas. Gradients in mortality fi-om coronary heart disease, stroke, lung cancer, stomach cancer, and respiratory disease were seen tall P < 0.05), generally increasing from men whose fathers had professional and managerial occupations (social class I and II) to those whose fathers had semiskilled and unskilled manual occupations (social class IV and V). Relative rates of mortality adjusted for age for men with fathers in manual versus non-manual occupations were 1.52 (95% confidence interval 1.24 to 1.87) for coronary heart disease, 1.83 (1.13 to 2.94) for stroke, 1.65 (1.12 to 2.43) for lung cancer, 2.06 (0.93 to 4.57) for stomach cancer, and 2.01 (1.17 to 3.48) for respiratory disease. Mortality from other cancers and accidental and violent death showed no association with fathers' social class. Adjustment for adult socioeconomic circumstances and risk factors did not alter results for mortality from stroke and stomach cancer, attenuated the increased risk of coronary heart disease and respiratory disease, and essentially eliminated the association with lung cancer. Conclusions: Adverse socioeconomic circumstances in childhood have a specific influence on mortality from stroke and stomach cancer in adulthood, which is not due to the continuity of social disadvantage throughout life. Deprivation in childhood influences risk of mortality from coronary heart disease and respiratory disease in adulthood, although an additive influence of adulthood circumstances is seen in these cases. Mortality from lung cancer, other cancer, and accidents and violence is predominantly influenced by risk factors that are related to social circumstances in adulthood.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Div Neurosci, London W6 8RP, England; Ruchill Hosp, W Scotland Canc Surveillance Unit, Glasgow G20 9NB, Lanark, Scotland	University of Bristol; University of Glasgow; Imperial College London; University of Glasgow	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; BURR ML, 1980, J EPIDEMIOL COMMUN H, V34, P93, DOI 10.1136/jech.34.2.93; COGGON D, 1990, BRIT J CANCER, V61, P573, DOI 10.1038/bjc.1990.128; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; HASTE H, 1990, BRIT MED J, V300, P289; KRIEGER N, IN PRESS AM J EPIDEM; KUH D, 1993, SOC HIST MED, V6, P101; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; MANN SL, 1992, J EPIDEMIOL COMMUNIT, V46, P256; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MURRAY M, 1962, ANN ASSOC AM GEOGR, V52, P130, DOI 10.1111/j.1467-8306.1962.tb00401.x; NOTKOLA V, 1985, SOC SCI MED, V21, P517, DOI 10.1016/0277-9536(85)90035-8; PAYNE G, 1987, EMPLOYMENT OPPORTUNI; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8; WATT GCM, 1995, SCOT MED J, V40, P108, DOI 10.1177/003693309504000403; WU JM, 1991, P 4 INT C COMB EFF E	29	432	438	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 30	1998	316	7145					1631	1635		10.1136/bmj.316.7145.1631	http://dx.doi.org/10.1136/bmj.316.7145.1631			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZR867	9603744	Green Submitted, Green Published, Green Accepted, Bronze			2022-12-01	WOS:000074022700019
J	Borg-Graham, LJ; Monier, C; Fregnac, Y				Borg-Graham, LJ; Monier, C; Fregnac, Y			Visual input evokes transient and strong shunting inhibition in visual cortical neurons	NATURE			English	Article							ORIENTATION SELECTIVITY; PYRAMIDAL CELLS; STRIATE CORTEX; CAT; MECHANISMS; EXCITATION; POTENTIALS; RESPONSES; SUMMATION; RAT	The function and nature of inhibition of neurons in the visual cortex have been the focus of both experimental and theoretical investigations(1-7), There are two ways in which inhibition can suppress synaptic excitation(2,8). In hyperpolarizing inhibition, negative and positive currents sum linearly to produce a net change in membrane potential. In contrast, shunting inhibition acts nonlinearly by causing an increase in membrane conductance; this divides the amplitude of the excitatory response. Visually evoked changes in membrane conductance have been reported to be nonsignificant or weak, supporting the hyperpolarization mode of inhibition(3,9-12). Here we present a new approach to studying inhibition that is based on in vivo whole-cell voltage clamping. This technique allows the continuous measurement of conductance dynamics during visual activation. We show, in neurons of cat primary visual cortex, that the response to optimally orientated flashed bars can increase the somatic input conductance to more than three times that of the resting state. The short latency of the visually evoked peak of conductance, and its apparent reversal potential suggest a dominant contribution from gamma-aminobutyric acid ((GABA)(A)) receptor-mediated synapses. We propose that nonlinear shunting inhibition may act during the initial stage of visual cortical processing, setting the balance between opponent 'On' and 'Off' responses in different locations of the visual receptive field.	CNRS, Inst Alfred Fessard, Equipe Cognisci, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Fregnac, Y (corresponding author), CNRS, Inst Alfred Fessard, Equipe Cognisci, Ave Terrasse, F-91198 Gif Sur Yvette, France.	fregnac@iaf.cnrs-gif.fr						ANDERSON JC, 1994, J COMP NEUROL, V341, P25, DOI 10.1002/cne.903410104; BARKER JL, 1988, J PHYSIOL-LONDON, V403, P41, DOI 10.1113/jphysiol.1988.sp017237; BERMAN NJ, 1991, J PHYSIOL-LONDON, V440, P697, DOI 10.1113/jphysiol.1991.sp018731; BERMAN NJ, 1989, J PHYSIOL-LONDON, V418, pP107; Bringuier V, 1997, J PHYSIOL-LONDON, V500, P751, DOI 10.1113/jphysiol.1997.sp022056; BUSH PC, 1994, J NEUROPHYSIOL, V71, P2183, DOI 10.1152/jn.1994.71.6.2183; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DEBANNE D, 1998, J PHYSL, V500, P523; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; DREIFUSS JJ, 1969, EXP BRAIN RES, V9, P137, DOI 10.1007/BF00238327; Eccles, 2013, PHYSL SYNAPSES; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KOCH C, 1990, J NEUROSCI, V10, P1728; KOCH C, 1985, MODELS VISUAL CORTEX, P408; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; Orban GA, 1984, STUDIES BRAIN FUNCTI, DOI DOI 10.1007/978-3-642-46469-0; PALMER LA, 1981, J NEUROPHYSIOL, V46, P260, DOI 10.1152/jn.1981.46.2.260; Rall W., 1964, NEURAL THEORY MODELI, P73; SHULZ D, 1993, SOC NEUR ABSTR, V19, P638; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; VOLGUSHEV M, 1993, VISUAL NEUROSCI, V10, P1151, DOI 10.1017/S0952523800010257; XING P, 1991, NEUROREPORT, V2, P485	29	505	514	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					369	373		10.1038/30735	http://dx.doi.org/10.1038/30735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620800				2022-12-01	WOS:000073883600055
J	McLatchie, LM; Fraser, NJ; Main, MJ; Wise, A; Brown, J; Thompson, N; Solari, R; Lee, MG; Foord, SM				McLatchie, LM; Fraser, NJ; Main, MJ; Wise, A; Brown, J; Thompson, N; Solari, R; Lee, MG; Foord, SM			RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor	NATURE			English	Article							GENE-RELATED-PEPTIDE; XENOPUS-OOCYTES; ADRENOMEDULLIN; IDENTIFICATION; CLONING; CELLS; EXPRESSION; BRAIN	Calcitonin-gene-related peptide (CORP) and adrenomedullin are related peptides with distinct pharmacological profiles. Here we show that a receptor with seven transmembrane domains, the calcitonin-receptor-like receptor (CRLR), can function as either a CORP receptor or an adrenomedullin receptor, depending on which members of a new family of single-transmembrane-domain proteins, which we have called receptor-activity-modifying proteins or RAMPs, are expressed. RAMPs are required to transport CRLR to the plasma membrane. RAMP1 presents the receptor at the cell surface as a mature glycoprotein and a CORP receptor. RAMP2-transported receptors are core-glycosylated and are adrenomedullin receptors.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Cell Biol Unit, Stevenage SG1 2NY, Herts, England	GlaxoSmithKline; GlaxoSmithKline	Foord, SM (corresponding author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Receptor Syst Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.							Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; Chen WJ, 1997, MOL PHARMACOL, V52, P1164, DOI 10.1124/mol.52.6.1164; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; FOORD SM, 1987, EUR J BIOCHEM, V170, P373, DOI 10.1111/j.1432-1033.1987.tb13710.x; GUILLEMARE E, 1994, PFLUG ARCH EUR J PHY, V428, P604, DOI 10.1007/BF00374584; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; KATO J, 1995, EUR J PHARM-MOLEC PH, V289, P383, DOI 10.1016/0922-4106(95)90117-5; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Luebke AE, 1996, P NATL ACAD SCI USA, V93, P3455, DOI 10.1073/pnas.93.8.3455; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Osajima A, 1996, EUR J PHARMACOL, V315, P319, DOI 10.1016/S0014-2999(96)00557-2; Owji AA, 1996, J NEUROCHEM, V67, P2172; Perry KJ, 1997, ENDOCRINOLOGY, V138, P3486, DOI 10.1210/en.138.8.3486; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P23, DOI 10.1016/0163-7258(92)90036-Y; SIMMONS D, 1988, J IMMUNOL, V141, P2797; STANGL D, 1991, BIOCHEMISTRY-US, V30, P8605, DOI 10.1021/bi00099a016; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; UEZONO Y, 1993, RECEPTOR CHANNEL, V1, P233; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; ZIMMERMANN U, 1995, PEPTIDES, V16, P421, DOI 10.1016/0196-9781(94)00195-C; Zimmermann U, 1996, BRAIN RES, V724, P238, DOI 10.1016/0006-8993(96)00337-X; ZIMMERMANN U, 1990, NEUROSCI LETT, V119, P195	27	1767	1860	0	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					333	339		10.1038/30666	http://dx.doi.org/10.1038/30666			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620797				2022-12-01	WOS:000073883600044
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Zeptomolar damage	SCIENCE			English	Editorial Material																		Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1101	1102						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9616083				2022-12-01	WOS:000073663600054
J	Henry, PD; Pacifico, A				Henry, PD; Pacifico, A			Altering molecular mechanisms to prevent sudden arrhythmic death	LANCET			English	Article							PLATELET-ACTIVATING-FACTOR; LEFT-VENTRICULAR DYSFUNCTION; ISCHEMIC-HEART-DISEASE; MYOCARDIAL REPERFUSION; ALPHA; ATHEROSCLEROSIS; INFLAMMATION; INFARCTION; RECEPTOR; BLOOD	Trials of drug treatment for prevention of sudden arrhythmic death have been disappointing, perhaps because suppressive therapy with arrhythmic agents fails to address the mechanisms leading; to electrophysiological failure. We propose that preventive treatment should pay more attention to molecular mechanisms responsible for the progression of cardiac disease to electrophysiological failure. Most sudden cardiac deaths occur in people with atherogenic dyslipidaemias. Our hypothesis is that the pathogenic molecular mechanisms of dyslipidaemias contribute directly to arrhythmogenesis. Proinflammatory-prothrombotic lipid-derived mediators that may play a part in arrhythmogenesis include phospholipids and leucotrienes acting through the platelet-activating-factor and peroxisome proliferator-activated-receptor pathways. There are drugs available to test the hypothesis of dyslipidaemias-specific prevention of electrophysiological failure.	Texas Arrhythmia Inst, Houston, TX 77030 USA		Henry, PD (corresponding author), Texas Arrhythmia Inst, Houston, TX 77030 USA.							[Anonymous], 1989, NEW ENGL J MED, V321, P406; ASAI K, 1993, ARTERIOSCLER THROMB, V13, P892, DOI 10.1161/01.ATV.13.6.892; Becker L, 1996, CARDIAC ARREST SCI P, P28; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FORNES P, 1994, ARCH MAL COEUR VAISS, V87, P319; Galea J, 1996, ARTERIOSCL THROM VAS, V16, P1000, DOI 10.1161/01.ATV.16.8.1000; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HERTUALLA SYY, 1993, P NATL ACAD SCI USA, V88, P5252; Hoffman BF, 1996, J CARDIOVASC ELECTR, V7, P120, DOI 10.1111/j.1540-8167.1996.tb00507.x; Jacobsen AN, 1996, CIRCULATION, V93, P23, DOI 10.1161/01.CIR.93.1.23; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; JuhanVague I, 1996, CIRCULATION, V94, P2057, DOI 10.1161/01.CIR.94.9.2057; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KLUFT C, 1988, THROMB HAEMOSTASIS, V59, P329; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; Matsumori A, 1997, CIRCULATION, V96, P1386, DOI 10.1161/01.CIR.96.5.1386; Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17, DOI 10.1152/ajpheart.1997.272.1.H17; PEDERSEN TR, 1994, LANCET, V344, P1383; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Prescott SM, 1996, JPN CIRC J, V60, P137, DOI 10.1253/jcj.60.137; RIALS SJ, 1995, CIRCULATION, V91, P426, DOI 10.1161/01.CIR.91.2.426; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Sakai A, 1997, ARTERIOSCL THROM VAS, V17, P310, DOI 10.1161/01.ATV.17.2.310; Schoonjans K, 1996, J LIPID RES, V37, P907; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; TAMURA K, 1994, CORONARY ARTERY DIS, V5, P267; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496; ZOLBE RG, 1997, CIRCADIAN RHYTHMS CA, P1	35	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 25	1998	351	9111					1276	1278		10.1016/S0140-6736(97)10049-6	http://dx.doi.org/10.1016/S0140-6736(97)10049-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643764				2022-12-01	WOS:000073283600043
J	Kaplan, EH				Kaplan, EH			Israel's ban on use of Ethiopians' blood: how many infectious donations were prevented?	LANCET			English	Editorial Material									Yale Univ, Sch Management, New Haven, CT 06520 USA	Yale University	Kaplan, EH (corresponding author), Yale Univ, Sch Management, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH056826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009531] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA09531] Funding Source: Medline; NIMH NIH HHS [P01-MH/DA-56826] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*CENT BUR STAT, 1995, STAT ABSTR ISR; Kaplan E H, 1995, Public Health Rev, V23, P215; KAPLAN EH, 1998, IN PRESS J ACQ IMM D; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Litvak E, 1997, MED DECIS MAKING, V17, P455, DOI 10.1177/0272989X9701700411; NAVON Y, 1996, SUMMONING CLARIFY BL; POLLACK S, 1993, ISRAEL J MED SCI, V29, P19; Satten GA, 1997, MATH BIOSCI, V141, P101, DOI 10.1016/S0025-5564(96)00185-X; SCHMEMANN S, 1996, NY TIMES        0129; SIEGEL J, 1996, JERUSALEM POST  0318; Siegel Judy, 1996, JERUSALEM POST  0206, P12; SLATER PE, 1993, ISRAEL J MED SCI, V29, P2; Vikhanski L, 1996, NAT MED, V2, P260, DOI 10.1038/nm0396-260; 1996, JERUSALEM POST  0129	14	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1127	1128		10.1016/S0140-6736(97)10356-7	http://dx.doi.org/10.1016/S0140-6736(97)10356-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660600				2022-12-01	WOS:000073090200047
J	Feldman, M; Cryer, B; Lee, E; Peterson, WL				Feldman, M; Cryer, B; Lee, E; Peterson, WL			Role of seroconversion in confirming cure of Helicobacter pylori infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTRITIS; SEROLOGY; HUMANS; ACID	Context.-The role of serologic testing to confirm cure of Helicobacter pylori infection after antimicrobial therapy is not completely defined. Objective.-To determine the utility of serologic testing in confirming cure of H pylori infection more than 1 year after therapy. Design.-A prospective, before-after interventional trial. Setting.-An outpatient clinical research laboratory in an academic, urban Veterans Affairs medical center. Participants.-Twenty-three otherwise healthy men and women with active H pylori infection demonstrated by gastric biopsy and with positive H pylori serologic findings. Intervention.-A 14-day course of bismuth, tetracycline, and metronidazole. Main Outcome Measures.-Determination of IgG serum antibodies to H pylori at baseline, 1 month, 3 months, and approximately 18 months after completion of therapy compared with serial gastric mucosal biopsy specimens with stains for H pylori and for histologic examination as the criterion standard. Results.-Fifteen (65%) of 23 subjects were cured of their H pylori infection as assessed by gastric biopsy, with elimination of gastritis; median antibody levels declined from 92.5 U/mL at baseline to undetectable levels at 18 months. The other 8 subjects (35%) were not cured and had persistent gastritis at 18 months; median antibody levels declined from 130.6 U/mL at baseline to 89.7 U/mL at 18 months. Sensitivity and specificity of seroconversion (from a positive to negative test result) in detecting cure of H pylori infection were 60% and 100%, respectively. Conclusion.-Undetectable antibody levels beyond the first year of therapy accurately confirm cure of H pylori infection in initially seropositive healthy subjects, with reasonable sensitivity.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, Dallas, TX 75235 USA; Dept Vet Affairs Med Ctr, Med Serv, Dallas, TX USA; Dept Vet Affairs Med Ctr, Lab Serv, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Feldman, M (corresponding author), Vet Adm Med Ctr, Med Serv 111, 4500 S Lancaster Rd, Dallas, TX 75216 USA.	feldman.mark@dallas.va.gov						Cryer B, 1996, GASTROINTEST ENDOSC, V44, P317, DOI 10.1016/S0016-5107(96)70171-2; CUTLER A, 1993, DIGEST DIS SCI, V38, P2262, DOI 10.1007/BF01299906; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; FELDMAN M, 1994, JAMA-J AM MED ASSOC, V272, P70; Feldman M, 1996, GASTROENTEROLOGY, V110, P1043, DOI 10.1053/gast.1996.v110.pm8612992; Graham DY, 1997, GASTROENTEROLOGY, V113, pS113, DOI 10.1016/S0016-5085(97)80023-6; Hopkins RJ, 1997, GASTROENTEROLOGY, V113, pS126, DOI 10.1016/S0016-5085(97)80026-1; Howden CW, 1997, GASTROENTEROLOGY, V113, pS107, DOI 10.1016/S0016-5085(97)80022-4; Lee J, 1997, GASTROENTEROLOGY, V113, pS99, DOI 10.1016/S0016-5085(97)80021-2; PETERSON WL, 1988, GASTROENTEROLOGY, V95, P1185, DOI 10.1016/0016-5085(88)90349-6; Unge P, 1997, GASTROENTEROLOGY, V113, pS131, DOI 10.1016/S0016-5085(97)80027-3; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	12	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					363	365		10.1001/jama.280.4.363	http://dx.doi.org/10.1001/jama.280.4.363			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686554	Bronze			2022-12-01	WOS:000074804200037
J	Neumann, CJ; Cohen, SM				Neumann, CJ; Cohen, SM			Boundary formation in Drosophila wing: Notch activity attenuated by the POU protein Nubbin	SCIENCE			English	Article							DORSAL/VENTRAL COMPARTMENT BOUNDARY; DORSAL-VENTRAL BOUNDARY; SPLIT COMPLEX GENES; VESTIGIAL GENE; EXPRESSION; SUPPRESSOR; ACTIVATION; RECEPTOR; SERRATE; SIGNAL	Cell interactions mediated by Notch-family receptors have been implicated in the specification of tissue boundaries in vertebrate and insect development, Although Notch Ligands are often widely expressed, tightly Localized activation of Notch is critical for the formation of sharp boundaries. Evidence is presented here that the POU domain protein Nubbin contributes to the formation of a sharp dorsoventral boundary in the Drosophila wing. Nubbin represses Notch-dependent target genes and sets a threshold for Notch activity that defines the spatial domain of boundary-specific gene expression.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				Averof M, 1997, NATURE, V385, P627, DOI 10.1038/385627a0; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cifuentes FJ, 1997, P NATL ACAD SCI USA, V94, P11405, DOI 10.1073/pnas.94.21.11405; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NG M, 1995, DEVELOPMENT, V121, P589; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	39	55	56	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					409	413		10.1126/science.281.5375.409	http://dx.doi.org/10.1126/science.281.5375.409			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665883				2022-12-01	WOS:000074918800046
J	Duda, RL				Duda, RL			Protein chainmail: Catenated protein in viral capsids	CELL			English	Article							RECOMBINANT BOVINE SOMATOTROPIN; VIRUS; HEAD; BACTERIOPHAGE-T4; RESOLUTION; SEQUENCE; SYSTEM	The capsid shells of bacteriophage HK97 and several other phages contain polypeptides that are covalently linked into complexes so large that they do not enter polyacrylamide gels after denaturation. The enormous apparent size of these protein complexes in HK97 derives from a novel protein topology. HK97 subunits cross-link via isopeptide bonds into oligomers that are closed rings of five or six members. However, polypeptides from neighboring pentamer and hexamer rings intertwine before the covalent cross-links form. As a result, adjacent protein rings catenate into a network similar to chainmail armor. In vitro linking and unlinking experiments provide strong support for the chainmail model, which explains the unusual properties of these bacteriophages and may apply to other macromolecular structures.	Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duda, RL (corresponding author), Univ Pittsburgh, Pittsburgh Bacteriophage Inst, Pittsburgh, PA 15260 USA.			Duda, Robert/0000-0002-9517-2731	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47795, R01 GM047795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Casjens SR, 1988, BACTERIOPHAGES, P1; CONWAY JF, 1995, J MOL BIOL, V253, P86, DOI 10.1006/jmbi.1995.0538; DHILLON EKS, 1980, J GEN VIROL, V50, P217, DOI 10.1099/0022-1317-50-1-217; DUDA RL, 1995, J MOL BIOL, V247, P636, DOI 10.1006/jmbi.1994.0169; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; FORD ME, 1998, IN PRESS J MOL BIOL; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; HERUTH DP, 1994, J BACTERIOL, V176, P3559, DOI 10.1128/JB.176.12.3559-3567.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIMBERGER RJ, 1994, J BACTERIOL, V176, P3631, DOI 10.1128/JB.176.12.3631-3637.1994; LUBBERS MW, 1995, APPL ENVIRON MICROB, V61, P4348, DOI 10.1128/AEM.61.12.4348-4356.1995; Murphy F.A., 1995, 6 REP INT COMM TAX V; OLSON AJ, 1983, J MOL BIOL, V171, P61, DOI 10.1016/S0022-2836(83)80314-3; POND FR, 1989, MICROBIOL REV, V53, P25, DOI 10.1128/MMBR.53.1.25-67.1989; POPA MP, 1991, J VIROL, V65, P3227, DOI 10.1128/JVI.65.6.3227-3237.1991; SCHAFER R, 1977, EUR J BIOCHEM, V73, P239, DOI 10.1111/j.1432-1033.1977.tb11312.x; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STEVEN AC, 1992, J MOL BIOL, V228, P870, DOI 10.1016/0022-2836(92)90871-G; TOU JS, 1993, J PROTEIN CHEM, V12, P237, DOI 10.1007/BF01026046; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; vanSinderen D, 1996, MOL MICROBIOL, V19, P1343, DOI 10.1111/j.1365-2958.1996.tb02478.x; VIOLAND BN, 1989, J PROTEIN CHEM, V8, P619, DOI 10.1007/BF01025602; Wikoff WR, 1998, VIROLOGY, V243, P113, DOI 10.1006/viro.1998.9040; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE ZH, 1995, J MOL BIOL, V253, P74, DOI 10.1006/jmbi.1995.0537	27	124	124	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					55	60		10.1016/S0092-8674(00)81221-0	http://dx.doi.org/10.1016/S0092-8674(00)81221-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674427	Bronze			2022-12-01	WOS:000074790800009
J	McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G				McQuillan, P; Pilkington, S; Allan, A; Taylor, B; Short, A; Morgan, G; Nielsen, M; Barrett, D; Smith, G			Confidential inquiry into quality of care before admission to intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL CARDIOPULMONARY ARREST; AVOIDABLE FACTORS; CARDIAC-ARREST; HEAD-INJURY; DOCTORS; CONSULTANTS; DEATHS; MANAGEMENT; PHYSICIANS; RESPONSES	Objective: To examine the prevalence, nature, causes, and consequences of suboptimal care before admission to intensive care units, and to suggest possible solutions. Design: Prospective confidential inquiry on the basis of structured interviews and questionnaires. Setting: A large district general hospital and a teaching hospital. Subjects: A cohort of 100 consecutive adult emergency admissions, 50 in each centre. Main outcome measures: Opinions of two external assessors on quality of care especially recognition, investigation, monitoring, and management of abnormalities of airway, breathing, and circulation, and oxygen therapy and monitoring. Results: Assessors agreed that 20 patients were well managed (group 1) and 54 patients received suboptimal care (group 2), Assessors disagreed on quality of management of 26 patients (group 3). The casemix and severity of illness, defined by the acute physiology and chronic health evaluation (APACHE II) score, were similar between centres and the three groups. In groups 1, 2, and 3 intensive care mortalities were 5 (25%), 26 (48%), and 6 (23%) respectively (P = 0.04) (group 1 versus group 2, P = 0.07). Hospital mortalities were 7 (35%), 30 (56%), and 8 (31%) (P = 0.07) and standardised hospital mortality ratios (95% confidence intervals) were 1.23 (0.49 to 2.54), 1.4 (0.94 to 2.0), and 1.26 (0.54 to 2.48) respectively. Admission to intensive care was considered late in 37 (69%) patients in group 2. Overall, a minimum of 4.5% and a maximum of 41% of admissions were considered potentially avoidable. Suboptimal care contributed to morbidity or mortality in most instances. The main causes of suboptimal care were failure of organisation, lack of knowledge, failure to appreciate clinical urgency, lack of supervision, and failure to seek advice. Conclusions: The management of airway breathing, and circulation, and oxygen therapy and monitoring in severely ill patients before admission to intensive care units may frequently be suboptimal. Major consequences may include increased morbidity and mortality and requirement for intensive care. Possible solutions include improved teaching, establishment of medical emergency teams, and widespread debate on the structure and process of acute care.	Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England; Southampton Gen Hosp, Intens Care Unit, Southampton SO16 6YD, Hants, England; Broomfield Hosp, Chelmsford CM1 7ET, Essex, England; Royal Cornwall Hosp, Truro TR1 3L, Cornwall, England; Univ Portsmouth, Sch Math Studies, Portsmouth PO1 2EG, Hants, England	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Southampton; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Royal Cornwall Hospital; University of Portsmouth	McQuillan, P (corresponding author), Queen Alexandra Hosp, Dept Intens Care Med, Portsmouth PO6 3LY, Hants, England.							ALLAN A, 1994, CLIN INTENSIVE CARE, V5, P152; Altman DG, 1991, PRACTICAL STAT MED R; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BOYD O, 1993, LANCET, V341, P1573, DOI 10.1016/0140-6736(93)90706-M; Capewell S, 1996, BRIT MED J, V312, P991; Daffurn K, 1994, Intensive Crit Care Nurs, V10, P115, DOI 10.1016/0964-3397(94)90007-8; DAVIES HTO, 1995, BRIT MED J, V311, P766, DOI 10.1136/bmj.311.7008.766; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; *DEPT HLTH UK, 1992, HLTH NAT; DILLNER L, 1995, BRIT MED J, V310, P757, DOI 10.1136/bmj.310.6982.757; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRANKLIN C, 1994, CRIT CARE MED, V22, P244, DOI 10.1097/00003246-199402000-00014; GEORGE AL, 1989, AM J MED, V87, P28; Goldhill DR, 1996, ANAESTHESIA, V51, P719, DOI 10.1111/j.1365-2044.1996.tb07882.x; GOULD TH, 1994, ANAESTHESIA, V49, P807; Hourihan F, 1995, CLIN INTENSIVE CARE, V6, P269, DOI DOI 10.3109/TCIC.6.6.269.272; JEFFREYS RV, 1981, LANCET, V2, P459; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE A, 1995, ANAESTH INTENS CARE, V23, P183, DOI 10.1177/0310057X9502300210; MATHER HM, 1995, BRIT MED J, V311, P1060, DOI 10.1136/bmj.311.7012.1060; MCGLOIN H, 1997, CLIN INTENSIVE CARE, V8, P104; MONTGOMERY H, 1994, BRIT MED J, V309, P1551, DOI 10.1136/bmj.309.6968.1551; MOSS F, 1995, BRIT MED J, V310, P925, DOI 10.1136/bmj.310.6984.925; *NAT CONF ENQ PER, 1993, NAT CONF ENQ PER DEA; PALAZZO M, 1993, LANCET, V342, P307; PAPPACHAN VJ, 1997, CLIN INTENSIVE CARE, V8, P97; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; POPE A, 1960, PENGUIN DICT QUOTATI; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; *ROYAL COLL PHYS L, 1996, FUT PATT CAR GEN SPE; *ROYAL COLL SURG E, 1985, REP WORK PART MAN PA; SAX FL, 1987, CRIT CARE MED, V15, P510, DOI 10.1097/00003246-198705000-00012; SCHEIN RMH, 1990, CHEST, V98, P1388, DOI 10.1378/chest.98.6.1388; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SIEGAL S, 1988, STAT BEHAV SCI; SMITH J, 1995, BRIT MED J, V310, P953, DOI 10.1136/bmj.310.6985.953; STONEHAM MD, 1994, LANCET, V344, P1339, DOI 10.1016/S0140-6736(94)90697-1; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNNELL RD, 1996, CLIN INTENSIVE CARE, V7, P55; 1994, REP CONF ENQ MAT DEA	42	602	622	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1853	1858						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632403				2022-12-01	WOS:000074686500015
J	Dale, DC; Liles, C				Dale, DC; Liles, C			How many neutrophils are enough?	LANCET			English	Editorial Material							FC-GAMMA-RIII; SITES		Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Dale, DC (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.							CROSBY WH, 1969, ARCH INTERN MED, V123, P722, DOI 10.1001/archinte.123.6.722; FLEIT HB, 1992, BLOOD, V79, P2721; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HOMBURG CHE, 1995, BLOOD, V85, P532; HUZINGA TWJ, 1990, J CLIN INVEST, V86, P416; HUZINGA TWJ, 1994, BRIT J HAEMATOL, V87, P459; INDIK ZK, 1995, BLOOD, V85, P532; Koene HR, 1998, BLOOD, V91, P1; KYLE RA, 1968, NEW ENGL J MED, V279, P1015, DOI 10.1056/NEJM196811072791902; McKenzie S E, 1998, Curr Opin Hematol, V5, P16, DOI 10.1097/00062752-199801000-00003	10	8	8	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1752	1753		10.1016/S0140-6736(05)78742-0	http://dx.doi.org/10.1016/S0140-6736(05)78742-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635945				2022-12-01	WOS:000074197600006
J	del Pozo, JC; Timpte, C; Tan, S; Callis, J; Estelle, M				del Pozo, JC; Timpte, C; Tan, S; Callis, J; Estelle, M			The ubiquitin-related protein RUB1 and auxin response in Arabidopsis	SCIENCE			English	Article							THALIANA; GENES	The AXR1 (auxin-resistant) protein, which has features of the ubiquitin-activating enzyme E1, is required for normal response to the plant hormone auxin in Arabidopsis thaliana. ECR1 functions together with AXR1 to activate members of the RUB/NEDD8 family of ubiquitin-related proteins. Extracts from mutant seedlings lacking AXR1 did not promote formation of the RUB-ECR1 thiolester, indicating that AXR1 is the major activity in this tissue. AXR1 was localized primarily to the nucleus of dividing and elongating cells, suggesting that the targets of RUB modification are nuclear. These results indicate that auxin response depends on RUB modification of one or more nuclear proteins.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Indiana University System; Indiana University Bloomington; University of California System; University of California Davis	Estelle, M (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		del Pozo, Juan C/K-7978-2014	del Pozo, Juan C/0000-0002-4113-457X; Callis, Judy/0000-0002-0622-078X	NIGMS NIH HHS [GM43644] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALLIS J, 1995, GENETICS, V139, P921; Cernac A, 1997, DEVELOPMENT, V124, P1583; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; EVANS ML, 1984, ENCY PLANT PHYSL, V10, P23; GRAY WM, IN PRESS CURR OPIN B; HAAS AL, 1997, FASEB J, V11, P125; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HANDELI S, COMMUNICATION; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; KLEE H, 1990, ANN REV PLANT PHYSL, V42, P1529; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; MAHAJAN R, 1997, CELL, V88, P197; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; PERKY SE, 1996, PLANT CELL, V8, P1977; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Tan S., UNPUB; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x	25	179	189	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1760	1763		10.1126/science.280.5370.1760	http://dx.doi.org/10.1126/science.280.5370.1760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624055				2022-12-01	WOS:000074197800044
J	Kume, T; Deng, KY; Winfrey, V; Gould, DB; Walter, MA; Hogan, BLM				Kume, T; Deng, KY; Winfrey, V; Gould, DB; Walter, MA; Hogan, BLM			The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus	CELL			English	Article							AUTOSOMAL-DOMINANT IRIDOGONIODYSGENESIS; TGF-BETA-SUPERFAMILY; FORK HEAD; RIEGER SYNDROME; PROTEINS; MEMBER; EMBRYO; MAINTENANCE; HNF-3-BETA; MESENCHYME	Mf1 encodes a forkhead/winged helix transcription factor expressed in many embryonic tissues, including prechondrogenic mesenchyme, periocular mesenchyme, meninges, endothelial cells, and kidney. Homozygous null Mf1(lacZ) mice die at birth with hydrocephalus, eye defects, and multiple skeletal abnormalities identical to those of the classical mutant, congenital hydrocephalus. We show that congenital hydrocephalos involves a point mutation in Mf1, generating a truncated protein lacking the DNA-binding domain. Mesenchyme cells from Mf1(lacZ) embryos differentiate poorly into cartilage in micromass culture and do not respond to added BMP2 and TGF beta 1. The differentiation of arachnoid cells in the mutant meninges is also abnormal. The human Mf1 homolog FREAC3 is a candidate gene for ocular dysgenesis and glaucoma mapping to chromosome 6p25-pter, and deletions of this region are associated with multiple developmental disorders, including hydrocephaly and eye defects.	Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Univ Alberta, Dept Opthalmol & Med Genet, Edmonton, AB T6G 2S2, Canada	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; University of Alberta	Hogan, BLM (corresponding author), Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALASHARI M, 1995, PEDIATR PATHOL LAB M, V15, P941, DOI 10.3109/15513819509027030; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CHEN JM, 1952, J ANAT, V86, P373; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHITAYAT D, 1987, American Journal of Medical Genetics, V26, P145, DOI 10.1002/ajmg.1320260122; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dou CL, 1997, NEURON, V18, P539, DOI 10.1016/S0896-6273(00)80296-2; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gould DB, 1997, AM J HUM GENET, V61, P765; GREEN MC, 1970, DEV BIOL, V23, P585, DOI 10.1016/0012-1606(70)90142-9; GRUNEBER.H, 1971, J EMBRYOL EXP MORPH, V25, P247; GRUNEBERG H, 1953, J GENET, V51, P327, DOI 10.1007/BF03023301; Gruneberg H, 1943, J GENET, V45, P1, DOI 10.1007/BF02982770; GRUNEBERG H, 1974, J EMBRYOL EXP MORPH, V31, P207; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hall BK, 1995, INT J DEV BIOL, V39, P881; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; Hogan B., 2014, MANIPULATING MOUSE E; Hong H.-K., 1995, American Journal of Human Genetics, V57, pA134; Huang RJ, 1997, ANAT EMBRYOL, V195, P435, DOI 10.1007/s004290050063; Iida K, 1997, DEVELOPMENT, V124, P4627; Jordan T, 1997, AM J HUM GENET, V61, P882, DOI 10.1086/514874; Kaestner KH, 1996, DEVELOPMENT, V122, P1751; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KELLY PC, 1989, CLIN GENET, V36, P204; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Labosky PA, 1996, GENOMICS, V34, P241, DOI 10.1006/geno.1996.0275; Labosky PA, 1997, DEVELOPMENT, V124, P1263; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Mears AJ, 1996, AM J HUM GENET, V59, P1321; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NODEN DM, 1988, DEVELOPMENT, V103, P121; ODA Y, 1984, J COMP NEUROL, V225, P448, DOI 10.1002/cne.902250310; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ohe Y, 1996, J NEUROCHEM, V67, P964; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SASAKI H, 1993, DEVELOPMENT, V118, P47; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SOLLOWAY MJ, 1998, IN PRESS DEV GENET; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; Storm EE, 1996, DEVELOPMENT, V122, P3969; Tanaka T, 1997, J BIOL CHEM, V272, P15789, DOI 10.1074/jbc.272.25.15789; TEPPERBERG JH, 1994, AM J HUM GENET SA119, V55; TOLMIE JLT, 1997, EMERY FRIMOINS PRINC, P2145; Walter MA, 1996, OPHTHALMOLOGY, V103, P1907, DOI 10.1016/S0161-6420(96)30408-9; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Wu SCY, 1998, MECH DEVELOP, V70, P3, DOI 10.1016/S0925-4773(97)00157-3; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; ZURCHER VL, 1990, AM J MED GENET, V35, P261, DOI 10.1002/ajmg.1320350223	62	291	297	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					985	996		10.1016/S0092-8674(00)81204-0	http://dx.doi.org/10.1016/S0092-8674(00)81204-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635428	Bronze			2022-12-01	WOS:000074205700010
J	Adolphs, R; Tranel, D; Damasio, AR				Adolphs, R; Tranel, D; Damasio, AR			The human amygdala in social judgment	NATURE			English	Article							FACIAL EXPRESSIONS; DAMAGE; RECOGNITION; LESIONS; EMOTION; FEAR	Studies in animals have implicated the amygdala in emotional(1-3) and social(4-6) behaviours, especially those related to fear and aggression. Although lesion(7-10) and functional imaging(11-13) studies in humans have demonstrated the amygdala's participation in recognizing emotional facial expressions, its role in human social behaviour has remained unclear. We report here our investigation into the hypothesis that the human amygdala is required for accurate social judgments of other individuals on the basis of their facial appearance. We asked three subjects with complete bilateral amygdala damage to judge faces of unfamiliar people with respect to two attributes important in real-life social encounters: approachability and trustworthiness. All three subjects judged unfamiliar individuals to be more approachable and more trustworthy than did control subjects. The impairment was most striking for faces to which normal subjects assign the most negative ratings: unapproachable and untrustworthy looking individuals. Additional investigations revealed that the impairment does not extend to judging verbal descriptions of people. The amygdala appears to be an important component of the neural systems that help retrieve socially relevant knowledge on the basis of facial appearance.	Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, Iowa City, IA 52242 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of Iowa; Salk Institute	Adolphs, R (corresponding author), Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, 200 Hawkins Dr, Iowa City, IA 52242 USA.	ralph-adolphs@uiowa.edu	Tudusciuc, Oana/C-1339-2011; Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389				ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; ANDERSON NH, 1968, J PERS SOC PSYCHOL, V9, P272, DOI 10.1037/h0025907; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DDAMASIO AR, 1995, NEUROSCIENTIST, V1, P19; Ekman P, 1976, PICTURES FACIAL AFFE; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; KLING A, 1979, EXP NEUROL, V66, P88, DOI 10.1016/0014-4886(79)90065-7; KLING A S, 1992, P353; LeDoux J.E., 1996, EMOTIONAL BRAIN; LEWICKI P, 1992, AM PSYCHOL, V47, P796, DOI 10.1037/0003-066X.47.6.796; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; NAHM FKD, 1993, NEUROPSYCHOLOGIA, V31, P727, DOI 10.1016/0028-3932(93)90125-J; ROSVOLD HE, 1954, J COMP PHYSIOL PSYCH, V47, P173, DOI 10.1037/h0058870; Saarni C., 1998, P237; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; TRANEL D, 1996, NEUROPSYCHOLOGICAL A, P81; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15	24	859	873	2	111	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					470	474		10.1038/30982	http://dx.doi.org/10.1038/30982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZR842	9624002				2022-12-01	WOS:000074020000045
J	Muhua, L; Adames, NR; Murphy, MD; Shields, CR; Cooper, JA				Muhua, L; Adames, NR; Murphy, MD; Shields, CR; Cooper, JA			A cytokinesis checkpoint requiring the yeast homologue of an APC binding protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SPINDLE ORIENTATION; GENE; MICROTUBULES; DYNEIN; MUTANT	Checkpoint controls ensure that events of the cell-division cycle are completed with fidelity and in the correct order. In budding yeast with a mutation in the motor protein dynein, the mitotic spindle is often misaligned and therefore slow to enter the neck between mother cell and budding daughter cell. When this occurs, cytokinesis (division of the cytoplasm into two) is delayed until the spindle is properly positioned(1). Here we describe mutations that abolish this delay, indicating the existence of a new checkpoint mechanism. One mutation lies in the gene encoding the yeast homologue of EB1, a human protein that binds the adenomatous polyposis coli (APC) protein, a tumour suppressor. EB1 is located on microtubules of the mitotic spindle and is important in spindle assembly. EB1 may therefore, by associating with microtubules, contribute to the sensor mechanism that activates the checkpoint. Another mutation affects Stt4, a phosphatidylinositol-4-OH kinase. Cold temperature is an environmental stimulus that causes misalignment of the mitotic spindle in yeast and appears to activate this checkpoint mechanism.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cooper, JA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.		Adames, Neil/S-1460-2017; Adames, Neil/C-8863-2012; Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047337] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047337, R01 GM047337-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; SU LK, 1995, CANCER RES, V55, P2972; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; Waddle JA, 1996, J CELL BIOL, V132, P861, DOI 10.1083/jcb.132.5.861; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	19	136	138	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					487	491		10.1038/31014	http://dx.doi.org/10.1038/31014			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624007	Green Accepted			2022-12-01	WOS:000074020000050
J	McNamee, D				McNamee, D			Cancer hopes and setbacks	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1450	1450		10.1016/S0140-6736(05)78868-1	http://dx.doi.org/10.1016/S0140-6736(05)78868-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605800				2022-12-01	WOS:000073707300006
J	Baron, JA; Gridley, G; Weiderpass, E; Nyren, O; Linet, M				Baron, JA; Gridley, G; Weiderpass, E; Nyren, O; Linet, M			Venous thromboembolism and cancer	LANCET			English	Article							PULMONARY-EMBOLISM; ORAL-CONTRACEPTIVES; OVARIAN-CANCER; THROMBOSIS; RISK; MALIGNANCY	Background Although cancer has been clearly associated with venous thromboembolism (VTE), many aspects of this relation are poorly understood, including the cancer sites most affected and the cancer risk during long-term follow-up. To clarify these relations, we carried out a large, population-based analysis of VTE and cancer risk. Methods Using the Swedish Inpatient Register and linkage to the nationwide Cancer Registry, we assessed cancer incidence during 1989 among 61 998 patients without a previous cancer diagnosis admitted to hospital between 1965 and 1983 for VTE. To measure possible increases in cancer risk, we computed standardised incidence ratios (SIRs) using Swedish national cancer rates for the period of the study. Findings At the time of thromboembolic admission or during the first year of follow-up, 2509 cancers were diagnosed (SIR 3.2, 95% CI 3.1-3.4). The SIR for polycythaemia vera was 12.9 (8.6-18.7), and the SIRs for cancers of the liver, pancreas, ovary, and brain, and for Hodgkin lymphoma also exceeded 5.0. Patients aged less than 65 years had higher SIRs than those who were older. In subsequent years, 6081 cancers were diagnosed (1.3, 1.3-1.3). Even 10 years or more after admission to hospital with VTE, cancer incidence had increased (1.3, 1.3-1.4). Interpretation At the time of VTE or in the first year afterwards, we found a large increase in the risk for diagnosis of virtually all cancers. In subsequent years, a persistent 30% increase in risk remains. Either premalignant change promotes thrombosis, or cancer and thrombosis share common risk factors.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; NCI, Div Canc Etiol, Epidemiol & Biostat Program, Bethesda, MD 20892 USA	Dartmouth College; Dartmouth College; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Baron, JA (corresponding author), DHMC, 7927 Rubin Bldg,1 Med Ctr Dr, Lebanon, NH 03756 USA.	John.Baron@Dartmouth.edu	Okutan, Oguzhan/I-8809-2016; Couturaud, Francis/Q-1366-2019; Weiderpass, Elisabete/M-4029-2016; Weiderpass, Elisabete/AAP-2747-2021	Okutan, Oguzhan/0000-0002-4660-1595; Couturaud, Francis/0000-0002-1855-8032; Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128	NCI NIH HHS [N01-CP-60538] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP060538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Adami HO, 1995, MUTAT RES-FUND MOL M, V333, P29, DOI 10.1016/0027-5107(95)00128-X; Baron JA, 1996, BRIT MED BULL, V52, P58, DOI 10.1093/oxfordjournals.bmb.a011533; BRESLOW NE, IARC SCI PUBLICATION, V82, P131; CARTER CJ, 1994, PROG CARDIOVASC DIS, V36, P423, DOI 10.1016/S0033-0620(94)80051-0; FEINLEIB M, 1972, MILBANK MEML FUND Q, V50, P123, DOI 10.2307/3349403; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GOLDHABER SZ, 1983, AM J MED, V74, P1023, DOI 10.1016/0002-9343(83)90805-7; GORE JM, 1982, ANN INTERN MED, V96, P556, DOI 10.7326/0003-4819-96-5-556; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HANKINSON SE, 1995, CANCER, V76, P284, DOI 10.1002/1097-0142(19950715)76:2<284::AID-CNCR2820760219>3.0.CO;2-5; MARNETT LJ, 1992, CANCER RES, V52, P5575; MATTSSON B, 1985, INT J EPIDEMIOL, V14, P64, DOI 10.1093/ije/14.1.64; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SAMKOFF JS, 1981, AM J EPIDEMIOL, V114, P488, DOI 10.1093/oxfordjournals.aje.a113214; SILVERSTEIN RL, 1992, NEW ENGL J MED, V327, P1163, DOI 10.1056/NEJM199210153271611; TOMATIS L, 1990, IARC SCI PUBL, V100, P169; TROUSSEAU A, 1872, LECT CLIN MED DEL HO, P282; TULINIUS H, 1991, AUTOPSY EPIDEMIOLOGY, P253; VESSEY MP, 1995, BRIT J CANCER, V71, P1340, DOI 10.1038/bjc.1995.260; WEISS N, 1995, LANCET, V346, P1570, DOI 10.1016/S0140-6736(95)91921-X; Willett WC, 1996, CANCER CAUSE CONTROL, V7, P178, DOI 10.1007/BF00115648; ZACHARSKI LR, 1992, SEMIN THROMB HEMOST, V18, P104, DOI 10.1055/s-2007-1002415; Zondervan KT, 1996, BRIT J CANCER, V73, P1291, DOI 10.1038/bjc.1996.247	27	375	398	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1077	1080		10.1016/S0140-6736(97)10018-6	http://dx.doi.org/10.1016/S0140-6736(97)10018-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660575	hybrid			2022-12-01	WOS:000073090200007
J	Northover, J				Northover, J			Realism or nihilism in bowel cancer follow-up?	LANCET			English	Editorial Material							COLORECTAL-CANCER; COLON-CANCER; CEA; COST		St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Imperial College London	Northover, J (corresponding author), St Marks Hosp, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England.							Audisio RA, 1996, ANN SURG ONCOL, V3, P349, DOI 10.1007/BF02305664; BRUINVELS DJ, 1995, EUR J SURG, V161, P827; COCHRANE JPS, 1980, BRIT MED J, V280, P593, DOI 10.1136/bmj.280.6214.593; FLETCHER RH, 1993, JAMA-J AM MED ASSOC, V270, P987, DOI 10.1001/jama.270.8.987; HAWARD R, 1997, IMPROVING OUTCOMES C; KIEVIT J, 1995, EUR J CANCER, V31A, P1222, DOI 10.1016/0959-8049(95)00155-C; MAKELA J, 1996, ARCH SURG-CHICAGO, V130, P1062; MARTIN EW, 1979, AM J SURG, V137, P167, DOI 10.1016/0002-9610(79)90137-5; MOERTEL C, 1978, JAMA-J AM MED ASSOC, V78, P1065; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; OHLSSON B, 1995, DIS COLON RECTUM, V38, P219; Schoemaker D, 1998, GASTROENTEROLOGY, V114, P7, DOI 10.1016/S0016-5085(98)70626-2; SUGARBAKER P, 1994, TUMORI, V31, P126; VIRGO KS, 1995, JAMA-J AM MED ASSOC, V273, P1837, DOI 10.1001/jama.273.23.1837	15	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1074	1076		10.1016/S0140-6736(05)79375-2	http://dx.doi.org/10.1016/S0140-6736(05)79375-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660572				2022-12-01	WOS:000073090200004
J	Dennis, DT; Meltzer, MI				Dennis, DT; Meltzer, MI			Antibiotic prophylaxis after tick bites	LANCET			English	Editorial Material							LYME-DISEASE; MISDIAGNOSIS; PREVENTION		CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA	Dennis, DT (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FT COLLINS,CO, USA.		Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472				Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; Seltzer EG, 1996, PEDIATR INFECT DIS J, V15, P762, DOI 10.1097/00006454-199609000-00003; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042	9	15	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1192		10.1016/S0140-6736(05)63449-6	http://dx.doi.org/10.1016/S0140-6736(05)63449-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652556				2022-12-01	WOS:A1997YD23800005
J	Reaich, D				Reaich, D			Odour perception in chronic renal disease	LANCET			English	Editorial Material											Reaich, D (corresponding author), S CLEVELAND HOSP,DEPT NEPHROL,MIDDLESBROUGH TS4 3BW,CLEVELAND,ENGLAND.							Griep MI, 1997, NEPHROL DIAL TRANSPL, V12, P2093, DOI 10.1093/ndt/12.10.2093; KOPPLE JD, 1994, J AM SOC NEPHROL, V5, P335	2	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 25	1997	350	9086					1191	1191		10.1016/S0140-6736(05)63448-4	http://dx.doi.org/10.1016/S0140-6736(05)63448-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD238	9652555				2022-12-01	WOS:A1997YD23800004
J	Haffner, SM; Lehto, S; Ronnemaa, T; Pyorala, K; Laakso, M				Haffner, SM; Lehto, S; Ronnemaa, T; Pyorala, K; Laakso, M			Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; MEN; POPULATIONS; IMPACT	Background Type 2 (non-insulin-dependent) diabetes is associated with a marked increase in the risk of coronary heart disease. It has been debated whether patients with diabetes who have not had myocardial infarctions should be treated as aggressively for cardiovascular risk factors as patients who have had myocardial infarctions. Methods To address this issue, we compared the seven-year incidence of myocardial infarction (fatal and nonfatal) among 1373 nondiabetic subjects with the incidence among 1059 diabetic subjects, all from a Finnish population-based study. Results The seven-year incidence rates of myocardial infarction in nondiabetic subjects with and without prior myocardial infarction at base line were 18.8 percent and 3.5 percent, respectively (P<0.001). The seven-year incidence rates of myocardial infarction in diabetic subjects with and without prior myocardial infarction at base line were 45.0 percent and 20.2 percent, respectively (P<0.001). The hazard ratio for death from coronary heart disease for diabetic subjects without prior myocardial infarction as compared with nondiabetic subjects with prior myocardial infarction was not significantly different from 1.0 (hazard ratio, 1.4; 95 percent confidence interval, 0.7 to 2.6) after adjustment for age and sex, suggesting similar risks of infarction in the two groups. After further adjustment for total cholesterol, hypertension, and smoking, this hazard ratio remained close to 1.0 (hazard ratio, 1.2; 95 percent confidence interval, 0.6 to 2.4). Conclusions Our data suggest that diabetic patients without previous myocardial infarction have as high a risk of myocardial infarction as nondiabetic patients with previous myocardial infarction. These data provide a rationale for treating cardiovascular risk factors in diabetic patients as aggressively as in nondiabetic patients with prior myocardial infarction. (N Engl J Med 1998;339:229-34.) (C) 1998, Massachusetts Medical Society.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Univ Kuopio, Dept Med, SF-70210 Kuopio, Finland; Turku Univ, Dept Med, Turku, Finland	University of Texas System; University of Texas Health San Antonio; University of Eastern Finland; University of Turku	Haffner, SM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Northe, Hilda/I-1916-2012; Greiver, Michelle/N-8764-2015	Northe, Hilda/0000-0002-8873-5014; Greiver, Michelle/0000-0001-8957-0285; Lehto, Seppo/0000-0003-0414-5285				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Amer Diabet Assoc, 1998, DIABETES CARE, V21, P179; [Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1998, AM HEART ASS 38 ANN; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V209, P3015; Haffner SM, 1997, DIABETES CARE, V20, P469, DOI 10.2337/diacare.20.4.469; HERLITZ J, 1992, CARDIOLOGY, V80, P237, DOI 10.1159/000175008; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; LAAKSO M, 1995, DIABETOLOGIA, V38, P487, DOI 10.1007/BF00410288; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Pyorala K, 1997, DIABETES CARE, V20, P1048; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; Rosengren A, 1997, EUR HEART J, V18, P754; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Walker A, 1981, STROKE S1, V12, P113; *WHO, 1983, PUBL WHO; Wingard DL., 1995, DIABETES AM, P429	26	4893	5115	0	193	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					229	234		10.1056/NEJM199807233390404	http://dx.doi.org/10.1056/NEJM199807233390404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673301				2022-12-01	WOS:000074918700004
J	Greenberg, DS				Greenberg, DS			Of human poundage	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					158	158		10.1016/S0140-6736(98)85078-2	http://dx.doi.org/10.1016/S0140-6736(98)85078-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672320				2022-12-01	WOS:000074775100071
J	Lorch, Y; Cairns, BR; Zhang, MC; Kornberg, RD				Lorch, Y; Cairns, BR; Zhang, MC; Kornberg, RD			Activated RSC-nucleosome complex and persistently altered form of the nucleosome	CELL			English	Article							YEAST SWI/SNF COMPLEX; DNA; TRANSCRIPTION; BINDING; DISPLACEMENT; DISRUPTION; INITIATION; HISTONES; PROTEIN	RSC, an abundant, essential chromatin-remodeling complex, related to SWI/SNF complex, binds nucleosomes and naked DNA with comparable affinities, as shown by gel shift analysis. The RSC-nucleosome complex is converted in the presence of ATP to a slower migrating form. This activated complex exhibits greatly increased susceptibility to endo- and exonucleases but retains a full complement of histones. Activation persists in the absence of ATP, and on removal of RSC, the nucleosome is released in an altered form, with a diminished electrophoretic mobility, greater sedimentation rate, and marked instability at elevated ionic strength. The reaction is reversible in the presence of RSC and ATP, with conversion of the altered form back to the nucleosome.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LORCH Y, 1994, P NATL ACAD SCI USA, V91, P11032, DOI 10.1073/pnas.91.23.11032; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PRUNELL A, 1977, COLD SPRING HARB SYM, V42, P103, DOI 10.1101/SQB.1978.042.01.011; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S	22	174	174	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					29	34		10.1016/S0092-8674(00)81218-0	http://dx.doi.org/10.1016/S0092-8674(00)81218-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674424	Bronze			2022-12-01	WOS:000074790800006
J	Ezekowitz, M				Ezekowitz, M			Antithrombotics for left-ventricular impairment?	LANCET			English	Editorial Material									Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06510 USA	Yale University	Ezekowitz, M (corresponding author), Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06510 USA.		Ezekowitz, Michael/AAJ-2543-2021					Al-Khadra AS, 1998, J AM COLL CARDIOL, V31, P749, DOI 10.1016/S0735-1097(98)00006-0; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; Loh E, 1997, NEW ENGL J MED, V336, P251, DOI 10.1056/NEJM199701233360403	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1904	1904		10.1016/S0140-6736(05)78610-4	http://dx.doi.org/10.1016/S0140-6736(05)78610-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654255	hybrid			2022-12-01	WOS:000074464700005
J	Tanaka, Y; Kanai, Y; Okada, Y; Nonaka, S; Takeda, S; Harada, A; Hirokawa, N				Tanaka, Y; Kanai, Y; Okada, Y; Nonaka, S; Takeda, S; Harada, A; Hirokawa, N			Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria	CELL			English	Article							ANTEROGRADE AXONAL-TRANSPORT; INTRACELLULAR-DISTRIBUTION; MICROTUBULE ORGANIZATION; ENDOPLASMIC-RETICULUM; ORGANELLE TRANSPORT; SUPERFAMILY PROTEIN; GOLGI-APPARATUS; NERVOUS-SYSTEM; RAT-BRAIN; IN-VIVO	Mouse kif5B gene was disrupted by homologous recombination. kif5B(-/-) mice were embryonic lethal with a severe growth retardation at 9.5-11.5 days postcoitum. To analyze the significance of this conventional kinesin heavy chain in organelle transport, we studied the distribution of major organelles in the extraembryonic cells. The null mutant cells impaired lysosomal dispersion, while brefeldin A could normally induce the breakdown of their Golgi apparatus. More prominently, their mitochondria abnormally clustered in the perinuclear region. This mitochondrial phenotype was reversed by an exogeneous expression of KIF5B, and a subcellular fractionation revealed that KIF5B is associated with mitochondria. These data collectively indicate that kinesin is essential for mitochondrial and lysosomal dispersion rather than for the Golgi-to-ER traffic in these cells.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan	University of Tokyo	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Tokyo 1130033, Japan.		Takeda, Sen/I-8462-2012; Kanai, Yoshimitsu/W-3486-2019; Nonaka, Shigenori/I-2132-2013; Okada, Yasushi/N-5067-2015	Takeda, Sen/0000-0001-7090-2139; Nonaka, Shigenori/0000-0002-8093-0325; Okada, Yasushi/0000-0003-2601-3689; Tanaka, Yosuke/0000-0001-5376-5726; Kanai, Yoshimitsu/0000-0002-0375-6853				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; BostUsinger L, 1997, EXP EYE RES, V64, P781, DOI 10.1006/exer.1996.0271; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brown NA, 1990, POSTIMPLANTATION MAM, P93; BURKHARDT JK, 1993, J CELL SCI, V104, P151; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Funakoshi T, 1996, J CELL BIOL, V133, P1347, DOI 10.1083/jcb.133.6.1347; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAESSMANN M, 1994, CELL BIOL LAB HDB, V3, P3; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HammAlvarez SF, 1997, EXP EYE RES, V64, P141, DOI 10.1006/exer.1996.0198; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HENSON JH, 1992, J CELL SCI, V103, P309; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; Hogan B., 2014, MANIPULATING MOUSE E; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Hurd DD, 1996, GENETICS, V142, P195; Hurd DD, 1996, GENETICS, V144, P1075; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; JELLALI A, 1994, CELL MOTIL CYTOSKEL, V28, P79, DOI 10.1002/cm.970280108; Johnson KJ, 1996, EUR J CELL BIOL, V69, P276; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; Lin SXH, 1996, CELL MOTIL CYTOSKEL, V34, P299; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MALEKZADEHHEMMAT K, 1993, CELL MOL BIOL, V39, P279; MARKS DL, 1994, J CELL SCI, V107, P2417; Meng YX, 1997, ENDOCRINOLOGY, V138, P1979, DOI 10.1210/en.138.5.1979; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKABE S, 1991, J NEUROSCI, V11, P1918; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Rodriguez A, 1996, J CELL BIOL, V134, P349, DOI 10.1083/jcb.134.2.349; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; Sambrook J., 1989, MOL CLONING LAB MANU; SATO K, 1986, MOL CELL BIOL, V6, P1032, DOI 10.1128/MCB.6.4.1032; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHMITZ F, 1994, EUR J CELL BIOL, V63, P77; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; Spector D. L., 1998, CELLS LAB MANUAL; Stearns T, 1997, J CELL BIOL, V138, P957, DOI 10.1083/jcb.138.5.957; Sturmer K, 1996, CELL TISSUE RES, V286, P547, DOI 10.1007/s004410050725; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; TANAHASHI S, 1992, FUSION ENG DES, V19, P269, DOI 10.1016/0920-3796(92)90035-3; TANAKA Y, 1995, J CELL SCI, V108, P1883; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; WATANABE A, 1993, GENE DEV, V7, P403; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; Yang ZH, 1997, GENOMICS, V45, P123, DOI 10.1006/geno.1997.4901; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112	81	480	489	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1147	1158		10.1016/S0092-8674(00)81459-2	http://dx.doi.org/10.1016/S0092-8674(00)81459-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657148	Bronze			2022-12-01	WOS:000074491100010
J	Gravil, JH; Al-Rawas, OA; Cotton, MM; Flanigan, U; Irwin, A; Stevenson, RD				Gravil, JH; Al-Rawas, OA; Cotton, MM; Flanigan, U; Irwin, A; Stevenson, RD			Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service	LANCET			English	Article							AIR-FLOW LIMITATION; CONTROLLED TRIAL; HEALTH WORKER; DISABILITY; IMPAIRMENT; DEPRESSION; COPD	Background Exacerbations of chronic obstructive pulmonary disease are a major cause of hospital admissions, but do not require intensive investigation or complex therapy. We investigated the suitability of home care for severe uncomplicated exacerbations. Methods Over 3.5 years we assessed 962 patients with exacerbations of chronic obstructive pulmonary disease after referral to a hospital respiratory department by their family physicians. All patients had chest radiographs, oxygen-saturation or arterial-gas analysis, spirometry, and physical assessment. Unless admission was thought to be essential, patients were allowed home with a customised treatment package. Each patient was visited daily by a respiratory nurse who monitored progress and treatment compliance and provided education and reassurance. Findings 145 (15%) of 962 required admission at initial referral and 115 (12%) were admitted later. 653 (68%) patients were managed entirely at home and 49 (5%) were referred inappropriately. One patient died at home. All patients had severe disease with a mean forced expiratory volume in 1 s of 1.02 L and 395 (41%) had required hospital admission in the previous year. Interpretation After formal assessment in a hospital respiratory unit, many patients with exacerbations of chronic obstructive pulmonary disease can be treated at home by respiratory nurses.	Royal Infirm, Dept Resp Med, Glasgow G31 2ER, Lanark, Scotland; Royal Alexandra Hosp, Palsley, England; Sultan Qaboos Univ, Coll Med, Muscat, Oman	Royal Infirmary of Edinburgh; Sultan Qaboos University	Stevenson, RD (corresponding author), Royal Infirm, Dept Resp Med, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.							COCKCROFT A, 1987, BRIT MED J, V294, P225, DOI 10.1136/bmj.294.6566.225; GIFT AG, 1993, HEART LUNG, V22, P289; HAGGERTY MC, 1991, CHEST, V100, P607, DOI 10.1378/chest.100.3.607; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; KELLNER R, 1992, GEN HOSP PSYCHIAT, V14, P20, DOI 10.1016/0163-8343(92)90022-3; LITTLEJOHNS P, 1991, THORAX, V46, P559, DOI 10.1136/thx.46.8.559; *LUNG ASTHM INF AG, 1992, SICK ABS RESP DIS; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SMALL SP, 1992, HEART LUNG, V21, P568	9	90	91	3	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1853	1855		10.1016/S0140-6736(97)11048-0	http://dx.doi.org/10.1016/S0140-6736(97)11048-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652670				2022-12-01	WOS:000074347100013
J	Jessop, DS				Jessop, DS			beta-endorphin in the immune system - mediator of pain and stress?	LANCET			English	Editorial Material									Univ Bristol, Div Med, Bristol BS2 8HW, Avon, England	University of Bristol	Jessop, DS (corresponding author), Univ Bristol, Div Med, Bristol BS2 8HW, Avon, England.							BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Carr DJJ, 1996, P SOC EXP BIOL MED, V213, P248; JESSOP DS, 1995, J NEUROIMMUNOL, V60, P29, DOI 10.1016/0165-5728(95)00049-8; JESSOP DS, 1998, CURR OPIN ENDOCRINOL, V5, P52; Karalis K, 1997, J NEUROIMMUNOL, V72, P131, DOI 10.1016/S0165-5728(96)00178-6; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5	9	23	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1828	1829		10.1016/S0140-6736(05)78799-7	http://dx.doi.org/10.1016/S0140-6736(05)78799-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652661				2022-12-01	WOS:000074347100004
J	Katoh-Fukui, Y; Tsuchiya, R; Shiroishi, T; Nakahara, Y; Hashimoto, N; Noguchi, K; Higashinakagawa, T				Katoh-Fukui, Y; Tsuchiya, R; Shiroishi, T; Nakahara, Y; Hashimoto, N; Noguchi, K; Higashinakagawa, T			Male-to-female sex reversal in M33 mutant mice	NATURE			English	Article							SRY-RELATED GENE; Y-CHROMOSOME; CAMPOMELIC DYSPLASIA; POLYCOMB PROTEIN; DROSOPHILA; MOUSE; EXPRESSION; DIFFERENTIATION; MUTATIONS; EMBRYOS	Polycomb genes in Drosophila maintain the repressed state of homeotic and other developmentally regulated genes(1-4) by mediating changes in higher-order chromatin structure(5-7). M33, a mouse homologue of Polycomb, was isolated by means of the structural similarity of its chromodomain(8). The fifth exon of M33 contains a region of homology shared by Drosophila and Xenopus(8,9). In Drosophila, its deletion results in the loss of Polycomb function(10). Here we have disrupted M33 in mice by inserting a poly(A) capture-type neo(r) targeting vector into its fifth exon. More than half of the resultant M33(cterm)/M33(cterm) mutant mice died before weaning, and survivors showed male-to-female sex reversal. Formation of genital ridges was retarded in both XX and XY M33(cterm)/M33(cterm) embryos. Gonadal growth defects appeared near the time of expression of the Y-chromosome-specific Sry gene(11), suggesting that M33 deficiency may cause sex reversal by interfering with steps upstream of Sry. M33(cterm)\M33(cterm) mice may be a valuable model in which to test opposing views regarding sex determination.	Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan; Natl Inst Genet, Mammalian Genet Lab, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Katoh-Fukui, Y (corresponding author), Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan.	kan@libra.ls.m-kagaku.co.jp	Katoh-Fukui, Yuko/Y-5383-2019	Katoh-Fukui, Yuko/0000-0001-6858-3693				Akasaka T, 1996, DEVELOPMENT, V122, P1513; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Burgoyne P.S., 1991, Seminars in Developmental Biology, V2, P277; CATTANACH BM, 1987, ANN NY ACAD SCI, V513, P27, DOI 10.1111/j.1749-6632.1987.tb24996.x; Core N, 1997, DEVELOPMENT, V124, P721; EICHER EM, 1983, J EXP ZOOL, V228, P297, DOI 10.1002/jez.1402280213; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MITTWOCH U, 1989, J THEOR BIOL, V137, P445, DOI 10.1016/S0022-5193(89)80039-6; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; NAGAMINE CM, 1992, MAMM GENOME, V3, P84, DOI 10.1007/BF00431251; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; REIJNEN MJ, 1995, MECH DEVELOP, V53, P35, DOI 10.1016/0925-4773(95)00422-X; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Uchida K, 1996, MAMM GENOME, V7, P481, DOI 10.1007/s003359900147; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0	30	233	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					688	692		10.1038/31482	http://dx.doi.org/10.1038/31482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641679				2022-12-01	WOS:000074289600054
J	Froelicher, VF; Lehmann, KG; Thomas, R; Goldman, S; Morrison, D; Edson, R; Lavori, P; Myers, J; Dennis, C; Shabetai, R; Do, D; Froning, J				Froelicher, VF; Lehmann, KG; Thomas, R; Goldman, S; Morrison, D; Edson, R; Lavori, P; Myers, J; Dennis, C; Shabetai, R; Do, D; Froning, J		Vet Affairs Cooperative Study Hlth Services 01	The electrocardiographic exercise test in a population with reduced workup bias: Diagnostic performance, computerized interpretation, and multivariable prediction	ANNALS OF INTERNAL MEDICINE			English	Article						exercise test; coronary angiography; sensitivity and specificity; coronary disease; image processing, computer assisted	CORONARY-ARTERY DISEASE; ST-SEGMENT DEPRESSION; PREVIOUS MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; TREADMILL SCORE; RATE ADJUSTMENT; RATE INDEX; ACCURACY; MEN; STANDARDS	Background: Empirical scores, computerized ST-segment measurements, and equations have been proposed as tools for improving the diagnostic performance of the exercise test. Objective: To compare the diagnostic utility of these scores, measurements, and equations with that of visual ST-segment measurements in patients with reduced workup bias. Design: Prospective analysis. Setting: 12 university-affiliated Veterans Affairs Medical Centers. Patients: 814 consecutive patients who presented with angina pectoris and agreed to undergo both exercise testing and coronary angiography. Measurements: Digital electrocardiographic recorders and angiographic calipers were used for testing at each site, and test results were sent to core laboratories. Results: Although 25% of patients had previously had testing, workup bias was reduced, as shown by comparison with a pilot study group. This reduction resulted in a sensitivity of 45% and a specificity of 85% for visual analysis. Computerized measurements and visual analysis had similar diagnostic power. Equations incorporating nonelectrocardiographic variables and either visual or computerized ST-segment measurement had similar discrimination and were superior to single ST-segment measurements. These equations correctly classified 5 more patients of every 100 tested (areas under the receiver-operating characteristic curve, 0.80 for equations and 0.68 for visual analysis; P < 0.001) in this population with a 50% prevalence of disease. Conclusions: Standard exercise tests had lower sensitivity but higher specificity in this population with reduced work-up bias than in previous studies. Computerized ST-segment measurements were similar to visual ST-segment measurements made by cardiologists. Considering more than ST-segment measurements can enhance the diagnostic power of the exercise test.	Palo Alto Vet Affairs Hlth Care Syst, Cardiol Div 111C, Palo Alto, CA 94304 USA		Froelicher, VF (corresponding author), Palo Alto Vet Affairs Hlth Care Syst, Cardiol Div 111C, 3801 Miranda Ave, Palo Alto, CA 94304 USA.			Froelicher, Victor/0000-0001-8831-4853				ASCOOP CA, 1977, BRIT HEART J, V39, P212; BERMAN JA, 1983, AM HEART J, V105, P60, DOI 10.1016/0002-8703(83)90279-X; BOBBIO M, 1991, CIRCULATION, V84, P1410, DOI 10.1161/01.CIR.84.3.1410; DECKERS JW, 1989, BRIT HEART J, V62, P438; DelCampo J, 1996, ANN NONINVAS ELECTRO, V1, P430; DETRANO R, 1987, J AM COLL CARDIOL, V10, P794, DOI 10.1016/S0735-1097(87)80272-3; DETRANO R, 1986, J AM COLL CARDIOL, V8, P836, DOI 10.1016/S0735-1097(86)80425-9; DETRY JMR, 1985, EUR HEART J, V6, P227, DOI 10.1093/oxfordjournals.eurheartj.a061846; Do D, 1997, CHEST, V111, P1742, DOI 10.1378/chest.111.6.1742; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; FROELICHER VF, 1993, EXERCISE HEART, P48; FRONING JN, 1988, J ELECTROCARDIOL, V21, pS141, DOI 10.1016/0022-0736(88)90082-9; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; HERBERT WG, 1991, AM HEART J, V122, P993, DOI 10.1016/0002-8703(91)90463-R; HOLLENBERG M, 1980, CIRCULATION, V61, P276, DOI 10.1161/01.CIR.61.2.276; LACHTERMAN B, 1990, CIRCULATION, V82, P44, DOI 10.1161/01.CIR.82.1.44; LACHTERMAN B, 1990, ANN INTERN MED, V112, P11, DOI 10.7326/0003-4819-112-1-11; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MIRANDA CP, 1992, AM J CARDIOL, V69, P303, DOI 10.1016/0002-9149(92)90224-M; MORISE AP, 1995, AM HEART J, V130, P741, DOI 10.1016/0002-8703(95)90072-1; MORISE AP, 1992, AM J CARDIOL, V69, P603, DOI 10.1016/0002-9149(92)90149-S; MORRIS CK, 1993, J AM COLL CARDIOL, V22, P175, DOI 10.1016/0735-1097(93)90832-L; MYERS J, 1994, AM J CARDIOL, V73, P591, DOI 10.1016/0002-9149(94)90340-9; OKIN PM, 1995, J AM COLL CARDIOL, V25, P1726, DOI 10.1016/0735-1097(95)00085-I; PHILBRICK JT, 1989, AM J CARDIOL, V64, P1117; PRUVOST P, 1987, EUR HEART J, V8, P1287, DOI 10.1093/oxfordjournals.eurheartj.a062215; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; RIBISL PM, 1993, AM J CARDIOL, V71, P546, DOI 10.1016/0002-9149(93)90509-B; RODRIGUEZ M, 1993, AM HEART J, V126, P752, DOI 10.1016/0002-8703(93)90443-D; SHEFFIELD LT, 1969, CIRCULATION, V40, P935, DOI 10.1161/01.CIR.40.6.935; SIMOONS ML, 1977, CIRCULATION, V56, P552, DOI 10.1161/01.CIR.56.4.552; SIMOONS ML, 1977, COMPUT BIOMED RES, V10, P483, DOI 10.1016/0010-4809(77)90023-4; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; Yamada H, 1997, PROG CARDIOVASC DIS, V39, P457, DOI 10.1016/S0033-0620(97)80040-0	36	146	151	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				965	+		10.7326/0003-4819-128-12_Part_1-199806150-00001	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625682				2022-12-01	WOS:000074201300001
J	Wu, YC; Horvitz, HR				Wu, YC; Horvitz, HR			The C-elegans cell corpse engulfment gene ced-7 encodes a protein similar to ABC transporters	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; VITRONECTIN RECEPTOR; ATP-BINDING; MACROPHAGE RECOGNITION; MULTIDRUG RESISTANCE; ADENYLATE KINASE; APOPTOTIC CELLS; P-GLYCOPROTEIN; BODY REGION; DEATH	The C. elegans gene ced-7 functions in the engulfment of cell corpses during programmed cell death. We report that the CED-7 protein has sequence similarity to ABC transporters, is broadly expressed during embryogenesis, and is localized to the plasma membrane. Mosaic analysis revealed that ced-7 functions in both dying cells and engulfing cells during the engulfment process. We propose that CED-7 functions to translocate molecules that mediate homotypic adhesion between the cell surfaces of the dying and engulfing cells. Like CED-7, the mammalian ABC transporter ABC1 has been implicated in the engulfment of cell corpses, suggesting that CED-7 and ABC1 may be functionally similar and that the molecular mechanism underlying cell corpse engulfment during programmed cell death may be conserved from nematodes to mammals.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Wu, Yi-Chun/F-7934-2012	Wu, Yi-Chun/0000-0002-8621-4098				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BRENNER S, 1974, GENETICS, V77, P71; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; CULOTTI JG, 1978, GENETICS, V90, P243; DUVALL E, 1985, IMMUNOLOGY, V56, P351; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; Guenther C, 1996, DEVELOPMENT, V122, P3509; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1995, GENETICS, V141, P989; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUVKUN G, 1989, GENETICS, V121, P501; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1991, CHEST, V99, pS6, DOI 10.1378/chest.99.3_Supplement.6S-a; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; [No title captured]	64	232	245	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					951	960		10.1016/S0092-8674(00)81201-5	http://dx.doi.org/10.1016/S0092-8674(00)81201-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635425	Green Submitted, Bronze			2022-12-01	WOS:000074205700007
J	Yoshikawa, S; Shinzawa-Itoh, K; Nakashima, R; Yaono, R; Yamashita, E; Inoue, N; Yao, M; Fei, MJ; Libeu, CP; Mizushima, T; Yamaguchi, H; Tomizaki, T; Tsukihara, T				Yoshikawa, S; Shinzawa-Itoh, K; Nakashima, R; Yaono, R; Yamashita, E; Inoue, N; Yao, M; Fei, MJ; Libeu, CP; Mizushima, T; Yamaguchi, H; Tomizaki, T; Tsukihara, T			Redox-coupled crystal structural changes in bovine heart cytochrome c oxidase	SCIENCE			English	Article							MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; RESOLUTION; BINDING; OXYGEN; REFINEMENT; DYNAMICS; SOLVENT	Crystal structures of bovine heart cytochrome c oxidase in the fully oxidized, fully reduced, azide-bound, and carbon monoxide-bound states were determined at 2.30, 2.35, 2.9, and 2.8 angstrom resolution, respectively. An aspartate residue apart from the O-2 reduction site exchanges its effective accessibility to the matrix aqueous phase for one to the cytosolic phase concomitantly with a significant decrease in the pK of its carboxyl group, on reduction of the metal sites. The movement indicates the aspartate as the proton pumping site. A tyrosine acidified by a covalently linked imidazole nitrogen is a possible proton donor for the O-2 reduction by the enzyme.	Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan; Japan Sci & Technol Corp, CREST, Himeji, Hyogo 6781297, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Kwansei Gakuin Univ, Fac Sci, Nishinomiya, Hyogo 662, Japan	University of Hyogo; Japan Science & Technology Agency (JST); Osaka University; Kwansei Gakuin University	Yoshikawa, S (corresponding author), Himeji Inst Technol, Dept Life Sci, Kamigohri Akoh, Himeji, Hyogo 6781297, Japan.		Yamashita, Eiki/V-6758-2019; yao, min/F-5287-2011	Yamashita, Eiki/0000-0002-4278-0039; yao, min/0000-0003-1687-5904				ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; ARGOS P, 1975, ACTA CRYSTALLOGR B, V32, P2975; BAKER GM, 1987, J BIOL CHEM, V262, P595; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRUDVIG GW, 1981, BIOCHEMISTRY-US, V20, P3912, DOI 10.1021/bi00516a039; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUEHNER M, 1974, J MOL BIOL, V82, P563, DOI 10.1016/0022-2836(74)90249-6; Capitanio N, 1997, BBA-BIOENERGETICS, V1318, P255, DOI 10.1016/S0005-2728(96)00143-0; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; Cotton FA, 1980, ADV INORGANIC CHEM C; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GIBSON QH, 1965, J BIOL CHEM, V240, P888; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kirichenko A, 1998, FEBS LETT, V423, P329, DOI 10.1016/S0014-5793(98)00117-3; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Puustinen A, 1997, BIOCHEMISTRY-US, V36, P13195, DOI 10.1021/bi971091o; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; Riistama S, 1997, FEBS LETT, V414, P275, DOI 10.1016/S0014-5793(97)01003-X; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANGELDE.BF, 1969, BIOCHIM BIOPHYS ACTA, V189, P1, DOI 10.1016/0005-2728(69)90219-9; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIKSTROM M, 1996, BIOCHIM BIOPHYS ACTA, V118, P106; WILLIAMS RJP, 1995, NATURE, V376, P643, DOI 10.1038/376643a0; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	39	950	964	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1723	1729		10.1126/science.280.5370.1723	http://dx.doi.org/10.1126/science.280.5370.1723			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624044				2022-12-01	WOS:000074197800033
J	Pal, B				Pal, B			Following up outpatients by telephone: pilot study	BRITISH MEDICAL JOURNAL			English	Article									S Manchester Univ Hosp NHS Trust, Withington Hosp, Manchester M20 2LR, Lancs, England	Wythenshawe Hospital NHS Foundation Trust	Pal, B (corresponding author), S Manchester Univ Hosp NHS Trust, Withington Hosp, Manchester M20 2LR, Lancs, England.	bpal@fs1.with.man.ac.uk						HALLAM L, 1991, BRIT MED J, V302, P629, DOI 10.1136/bmj.302.6777.629; Lattimer V, 1997, BRIT MED J, V314, P198; PAL B, 1996, BR J RHEUMATOL S1, V35, pA250; RAO JN, 1994, BRIT MED J, V309, P1527, DOI 10.1136/bmj.309.6968.1527; Wootton R, 1996, BRIT MED J, V313, P1375, DOI 10.1136/bmj.313.7069.1375	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1998	316	7145					1647	1647		10.1136/bmj.316.7145.1647	http://dx.doi.org/10.1136/bmj.316.7145.1647			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR867	9603747	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000074022700024
J	Blum, LN; Bresolin, LB; Williams, MA				Blum, LN; Bresolin, LB; Williams, MA			Heat-related illness during extreme weather emergencies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AMA, Council Sci Affairs, Chicago, IL 60611 USA	American Medical Association	Blum, LN (corresponding author), AMA, Council Sci Affairs, Chicago, IL 60611 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014					0	35	36	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1514	1514		10.1001/jama.279.19.1514	http://dx.doi.org/10.1001/jama.279.19.1514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN087	9605881				2022-12-01	WOS:000073608100008
J	Meier, CR; Jick, SS; Derby, LE; Vasilakis, C; Jick, H				Meier, CR; Jick, SS; Derby, LE; Vasilakis, C; Jick, H			Acute respiratory-tract infections and risk of first-time acute myocardial infarction	LANCET			English	Article							PHYSICAL EXERTION; CASE-CROSSOVER; ATHEROSCLEROSIS; INFLAMMATION; DISEASE; DEATH; ONSET	Background. There is growing interest in the role of infections in the aetiology of acute myocardial infarction (AMI). We undertook a large, population-based study to explore the association between risk of AMI and recent acute respiratory-tract infection Methods We used data from general practices in the UK (General Practice Research Database). Potential cases were people aged 75 years or younger, with no history of clinical risk factors, who had a first-time diagnosis of AMI between Jan 1, 1994, and Oct 31, 1996. Four controls were matched to each case on age, sex, and the practice attended. The date of the AMI in the case was defined as the index date. For both cases and controls the date of the last respiratory-tract infection before the index date was identified. We also did a case-crossover analysis of cases who had an acute respiratory-tract infection either before the index date or before an arbitrarily chosen date (1 year before AMI). Findings. In the case-control analysis of 1922 cases and 7649 matched controls, significantly more cases than controls had an acute respiratory-tract infection in the 10 days before the index date (54 [2.8%] vs 72 [0.9%]). The odds ratios, adjusted for smoking and body-mass index, for first-time AMI in association with an acute respiratory-tract infection 1-5, 6-10, 11-15, or 16-30 days before the index date (compared with participants who had no such infection during the preceding year) were 3.6 (95% CI 2.2-5.7), 2.3 (1.3-4.2), 1.8 (1.0-3.3), and 1.0 (0.7-1.6); (test for trend p < 0.01). The case-crossover analysis showed a relative risk of 2.7 (1.6-4.7) for AMI in relation to an acute respiratory-tract infection in the 10 days before the index date. Interpretation. Our findings suggest that in people without a history of clinical risk factors for AMI, acute respiratory-tract infections are associated with an increased risk of AMI for a period of about 2 weeks. We cannot, however, completely exclude the possibility of misdiagnosis bias, if prodromal symptoms of AMI were mistaken for respiratory-tract infection.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	Boston University	Meier, CR (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02173 USA.			Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992				Buja LM, 1996, CIRCULATION, V94, P872, DOI 10.1161/01.CIR.94.5.872; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Gullette ECD, 1997, JAMA-J AM MED ASSOC, V277, P1521, DOI 10.1001/jama.277.19.1521; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1996, PHARMACOTHERAPY, V16, P321; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; Mittleman MA, 1997, JAMA-J AM MED ASSOC, V277, P1558; NIEMINEN MS, 1993, EUR HEART J, V14, P12; PESONEN E, 1981, AM HEART J, V101, P512, DOI 10.1016/0002-8703(81)90150-2; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SPODICK DH, 1985, ANN INTERN MED, V102, P699, DOI 10.7326/0003-4819-102-5-699; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	28	300	313	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1467	1471		10.1016/S0140-6736(97)11084-4	http://dx.doi.org/10.1016/S0140-6736(97)11084-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605802	hybrid			2022-12-01	WOS:000073707300008
J	Dyson, S; Gurdon, JB				Dyson, S; Gurdon, JB			The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors	CELL			English	Article							GROWTH-FACTOR-BETA; XENOPUS EMBRYOS; SPEMANNS ORGANIZER; MAD PROTEINS; DROSOPHILA; HEDGEHOG; MESODERM; CELLS; THRESHOLDS; OOCYTES	Xenopus blastula cells activate different mesodermal genes as a concentration-dependent response to activin, which behaves like a morphogen. To understand how cells recognize morphogen concentration, we have bound naturally labeled activin to cells and related this to choice of gene activation. We find that the increasing occupancy of a single receptor type can cause cells to switch gene expression. Cells sense ligand concentration by the absolute number of occupied receptors per cell (100 and 300 molecules of bound activin induce Xbra and Xgsc, respectively, i.e., 2% and 6% of the total receptors) and not by a ratio of occupied to unoccupied receptors. The long duration of occupancy explains a previously described ratchet effect. Our results suggest a new concept of morphogen gradient formation and interpretation that is particularly well suited to the needs of early development.	Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Gurdon, JB (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armes NA, 1997, DEVELOPMENT, V124, P3797; Chang CB, 1997, DEVELOPMENT, V124, P827; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COLMAN A, 1979, CELL, V17, P517, DOI 10.1016/0092-8674(79)90260-5; DAWID IB, 1965, J MOL BIOL, V12, P581, DOI 10.1016/S0022-2836(65)80313-8; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Furriols M, 1996, DEVELOPMENT, V122, P2313; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1971, NATURE, V233, P177, DOI 10.1038/233177a0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HUSKENHINDI P, 1994, J BIOL CHEM, V269, P19380; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; Koenig JA, 1996, MOL PHARMACOL, V49, P351; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Natsume T, 1997, J BIOL CHEM, V272, P11535; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISHIMATSU SI, 1992, FEBS LETT, V303, P81, DOI 10.1016/0014-5793(92)80482-V; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Rothenberg EV, 1996, SCIENCE, V273, P78, DOI 10.1126/science.273.5271.78; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176	50	184	192	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					557	568		10.1016/S0092-8674(00)81185-X	http://dx.doi.org/10.1016/S0092-8674(00)81185-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604931	Bronze			2022-12-01	WOS:000073722200009
J	Boriack-Sjodin, PA; Margarit, SM; Bar-Sagi, D; Kuriyan, J				Boriack-Sjodin, PA; Margarit, SM; Bar-Sagi, D; Kuriyan, J			The structural basis of the activation of Ras by Sos	NATURE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EPIDERMAL GROWTH-FACTOR; GDP-GTP EXCHANGERS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL INTERACTION; MOLECULAR MECHANISM; EF-TU; PROTEIN; RESIDUES; COMPLEX	The crystal structure of human H-Ras complexed with the pas guanine-nucleotide-exchange-factor region of the Son of sevenless (Sos) protein has been determined at 2.8 Angstrom resolution. The normally tight interaction of nucleotides with pas is disrupted by Sos in two ways. First, the insertion into gas of an alpha-helix from Sos results in the displacement of the Switch 1 region of Ras, opening up the nucleotide-binding site. Second, side chains presented by this helix and by a distorted conformation of the Switch 2 region of pas alter title chemical environment of the binding site for the phosphate groups of the nucleotide and the associated magnesium ion, so that their binding is no longer favoured. Sos does not impede the binding sites for the base and the ribose of GTP or sop, so the Ras-Sos complex adopts a structure that allows nucleotide release and rebinding.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Rockefeller Univ, Labs Mol Biophys, 1230 York Ave, New York, NY 10021 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BERNSTEIN FC, 1978, ARCH BIOCHEM BIOPHYS, V185, P584, DOI 10.1016/0003-9861(78)90204-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; BRUNGER AT, IN PRESS ACTA CRYS D; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; LAI SHY, 1993, COMPUT IND ENG, V25, P13, DOI 10.1016/0360-8352(93)90209-G; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	46	581	590	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					337	343		10.1038/28548	http://dx.doi.org/10.1038/28548			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690470				2022-12-01	WOS:000074968800041
J	Yasuda, R; Noji, H; Kinosita, K; Yoshida, M				Yasuda, R; Noji, H; Kinosita, K; Yoshida, M			F-1-ATPase is a highly efficient molecular motor that rotates with discrete 120 degrees steps	CELL			English	Article							ESCHERICHIA-COLI F1-ATPASE; CATALYTIC SITE; MITOCHONDRIAL ATPASE; COOPERATIVITY; HYDROLYSIS	A single molecule of F-1-ATPase, a portion of ATP synthase, is by itself a rotary motor in which a central gamma subunit rotates against a surrounding cylinder made of alpha(3)beta(3) subunits. Driven by three catalytic beta s, each fueled with ATP, gamma makes discrete 120 degrees steps, occasionally stepping backward. The work done in each step is constant over a broad range of imposed load and is close to the free energy of hydrolysis of one ATP molecule.	Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	Keio University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Teikyo University	Kinosita, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER B, 1997, J BIOL CHEM, V272, P19621; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kagawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P247, DOI 10.1006/bbrc.1997.7574; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1997, FEBS LETT, V413, P55, DOI 10.1016/S0014-5793(97)00878-8; MUNEYUKI E, 1989, J BIOL CHEM, V264, P6092; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; SOUID AK, 1995, J BIOL CHEM, V270, P9074, DOI 10.1074/jbc.270.16.9074; STRYER L, 1995, BIOCHEMISTRY-US, P443; XIAO R, 1994, J BIOL CHEM, V269, P19232; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	37	668	680	4	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1117	1124		10.1016/S0092-8674(00)81456-7	http://dx.doi.org/10.1016/S0092-8674(00)81456-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657145	Bronze			2022-12-01	WOS:000074491100007
J	Arber, S; Barbayannis, FA; Hanser, H; Schneider, C; Stanyon, CA; Bernard, O; Caroni, P				Arber, S; Barbayannis, FA; Hanser, H; Schneider, C; Stanyon, CA; Bernard, O; Caroni, P			Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase	NATURE			English	Article							DEPOLYMERIZING FACTOR; ZINC-FINGER; IDENTIFICATION; PROTEIN; MOTIFS	Cell division, cell motility and the formation and maintenance of specialized structures in differentiated cells depend directly on the regulated dynamics of the actin cytoskeleton(1,2). To understand the mechanisms of these basic cellular processes, the signalling pathways that link external signals to the regulation of the actin cytoskeleton need to be characterized(2,3). Here we identify a pathway for the regulation of cofilin, a ubiquitous actin-binding protein that is essential for effective depolymerization of actin filaments(4-8). LIM-kinase 1, also known as KIZ, is a protein kinase with two amino-terminal LIM motifs(9-11) that induces stabilization of F-actin structures in transfected cells. Dominant-negative LIM-kinase1 inhibits the accumulation of the F-actin. Phosphorylation experiments in vivo and in vitro provide evidence that cofilin is a physiological substrate of LIM-kinase 1. Phosphorylation by LIM-kinase 1 inactivates cofilin, leading to accumulation of actin filaments. Constitutively active Rac augmented cofilin phosphorylation and LIM-kinase 1 autophosphorylation whereas phorbol ester inhibited these processes. Our results define a mechanism for the regulation of cofilin and hence of actin dynamics in vivo. By modulating the stability of actin cytoskeletal structures, this pathway should play a central role in regulating cell motility and morphogenesis.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Friedrich Miescher Institute for Biomedical Research; Walter & Eliza Hall Institute	Caroni, P (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Stanyon, Clem/AAM-5040-2020	Arber, Silvia/0000-0002-6261-250X; Stanyon, Clement/0000-0001-5030-6823				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; CALIER MF, 1997, J CELL BIOL, V136, P1307; DAVID IB, 1995, CR HEBD ACAD SCI, V318, P295; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; MICHISON TJ, 1996, CELL, V84, P371; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; NAGOAKA R, 1995, J CELL SCI, V108, P581; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; vonArx P, 1995, J CELL BIOL, V131, P1759, DOI 10.1083/jcb.131.6.1759; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4	22	1124	1143	2	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					805	809		10.1038/31729	http://dx.doi.org/10.1038/31729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655397				2022-12-01	WOS:000074433100054
J	Blennerhassett, M				Blennerhassett, M			Deadly charades	BRITISH MEDICAL JOURNAL			English	Article											Blennerhassett, M (corresponding author), Wyville Lodge, York YO62 4AQ, N Yorkshire, England.							Arnott SJ, 1996, LANCET, V348, P1049; KESEY K, 1973, ONE FLEW CUCKOOS NES	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1890	1891						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632414				2022-12-01	WOS:000074686500032
J	Korber, B; Theiler, J; Wolinsky, S				Korber, B; Theiler, J; Wolinsky, S			Limitations of a molecular clock applied to considerations of the origin of HIV-1	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; ENVELOPE GENES; GAG GENES; SEQUENCE; ISOLATE; RECOMBINATION; TRANSMISSION; INFECTIONS; EVOLUTION		Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Calif Los Alamos Natl Lab, Space & Remote Sensing Sci Grp NIS2, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Theoret Div T10, Los Alamos, NM 87545 USA	Northwestern University; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Wolinsky, S (corresponding author), Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA.		Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697; Korber, Bette/0000-0002-2026-5757	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI070001] Funding Source: NIH RePORTER; NIAID NIH HHS [3-Y01-AI-70001-13] Funding Source: Medline; NICHD NIH HHS [R01-HD-31756] Funding Source: Medline; PHS HHS [Y1-A1-4058-03] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BECKETT S, 1981, ILL SEEN ILL SAID, P76; Beddows S, 1998, J GEN VIROL, V79, P77, DOI 10.1099/0022-1317-79-1-77; BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Cao HY, 1997, J VIROL, V71, P8615, DOI 10.1128/JVI.71.11.8615-8623.1997; Carr JK, 1996, J VIROL, V70, P5935, DOI 10.1128/JVI.70.9.5935-5943.1996; CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR R, 1998, AIDS RES HUM RETROV, V72, P1552; Cornelissen M, 1996, J VIROL, V70, P8209, DOI 10.1128/JVI.70.11.8209-8212.1996; Delwart EL, 1997, J VIROL, V71, P7498, DOI 10.1128/JVI.71.10.7498-7508.1997; DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995; DIGHE PK, 1997, HUMAN RETROVIRUSES A, P74; DOMS RW, 1997, HIV MOL IMMUNOLOGY D, P1; DSOUZA MP, 1997, INFECT DIS, V175, P1056; ELGEN M, 1996, TRENDS MICROBIOL, V4, P216; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Ganeshan S, 1997, J VIROL, V71, P663, DOI 10.1128/JVI.71.1.663-677.1997; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GINSPARG P, 1905, COMMUNICATION; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; Gunthard HF, 1998, J VIROL, V72, P2422; HAMMOND J, 1997, HUMAN RETROVIRUSES 3, P206; Hillis David M., 1996, P515; HUET T, 1990, NATURE, V345, P356, DOI 10.1038/345356a0; Kanki P J, 1997, AIDS, V11 Suppl B, pS33; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KORBER B, UNPUB; Korber B T, 1995, AIDS, V9 Suppl A, pS5; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; KUIKEN CL, MOL EVOLUTION HIV; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; LEITNER T, 1997, HUMAN RETROVIRUSES 3, P25; LI WH, 1988, MOL BIOL EVOL, V5, P313; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; *LOS AL NAT LAB, 1997, THEOR BIOL BIOPH; LOUSSERTAJAKA I, 1995, J VIROL, V69, P5640, DOI 10.1128/JVI.69.9.5640-5649.1995; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; McCutchan FE, 1996, AIDS, V10, pS13; McCutchan FE, 1998, AIDS RES HUM RETROV, V14, P329, DOI 10.1089/aid.1998.14.329; MCCUTCHAN FE, 1998, P 5 ANN HIV DYN EV M, V5, P23; Moore J P, 1995, AIDS, V9 Suppl A, pS117; NEWTON I, 1947, PRINCIPIA, P6; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; OLSEN GJ, 1994, COMPUT APPL BIOSCI, V10, P41; PEETERS M, 1998, P 5 ANN HIV DYN EV M, V5, P73; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Press W.H, 1992, NUMERICAL RECIPES C, P666; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230; ROBERTSON DL, 1997, HUMAN RETROVIRUSES A, P25; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; Salminen MO, 1997, J VIROL, V71, P2647, DOI 10.1128/JVI.71.4.2647-2655.1997; SHARMA KD, 1994, HYDROL PROCESS, V8, P27, DOI 10.1002/hyp.3360080103; SHARP P, 1988, NATURE, V333, P315; Swofford David L., 1996, P407; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Zhu TF, 1998, NATURE, V391, P594, DOI 10.1038/35400	64	68	72	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1868	1871		10.1126/science.280.5371.1868	http://dx.doi.org/10.1126/science.280.5371.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669945				2022-12-01	WOS:000074323800041
J	Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V				Bernabei, R; Gambassi, G; Lapane, K; Landi, F; Gatsonis, C; Dunlop, R; Lipsitz, L; Steel, K; Mor, V		SAGE Study Grp	Management of pain in elderly patients with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME; GERIATRIC PAIN; PREVALENCE; RELIEF; ETHNICITY; RESIDENTS; PROGRAM; HOSPICE; SAMPLE; CARE	Context.-Cancer pain can be relieved with pharmacological agents as indicated by the World Health Organization (WHO). All too frequently pain management is reported to be poor. Objective.-To evaluate the adequacy of pain management in elderly and minority cancer patients admitted to nursing homes. Design.-Retrospective, cross-sectional study. Setting.-A total of 1492 Medicare-certified and/or Medicaid-certified nursing homes in 5 states participating in the Health Care Financing Administration's demonstration project, which evaluated the implementation of the Resident Assessment Instrument and its Minimum Data Set. Study Population.-A group of 13 625 cancer patients aged 65 years and older discharged from the hospital to any of the facilities from 1992 to 1995, Data were from the multilinked Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Main Outcome Measure.-Prevalence and predictors of daily pain and of analgesic treatment. Pain assessment was based on patients' report and was completed by a multidisciplinary team of nursing home personnel that observed, over a 7-day period, whether each resident complained or showed evidence of pain daily. Results.-A total of 4003 patients (24%, 29%, and 38% of those aged greater than or equal to 85 years, 75 to 84 years, and 65 to 74 years, respectively) reported daily pain. Age, gender, race, marital status, physical function, depression, and cognitive status were all independently associated with the presence of pain. Of patients with daily pain, 16% received a WHO level 1 drug, 32% a WHO level 2 drug, and only 26% received morphine. Patients aged 85 years and older were less likely to receive either weak opiates or morphine than those aged 65 to 74 years (13% vs 38%, respectively). More than a quarter of patients (26%) in daily pain did not receive any analgesic agent. Patients older than 85 years in daily pain were also more likely to receive no analgesia (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.13-1.73), Other independent predictors of failing to receive any analgesic agent were minority race (OR, 1.63; 95% CI, 1.18-2.26 for African Americans), low cognitive performance (OR, 1.23; 95% CI, 1.05-1.44), and the number of other medications received (Oc, 0.65; 95% CI, 0.5-0.84 for 11 or more medications). Conclusions.-Daily pain is prevalent among nursing home residents with cancer and is often untreated, particularly among older and minority patients.	Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Brown Univ, Dept Community Hlth, Providence, RI 02912 USA; Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA; Univ Cattolica Sacro Cuore, Ist Med Interna & Geriatria, Rome, Italy; St Christophers Hospice, London, England; Harvard Univ, Sch Med, Hebrew Rehabil Ctr Aged, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Hackensack, NJ USA; Hackensack Univ Med Ctr, Homecare Inst, Hackensack, NJ USA	Brown University; Brown University; Brown University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Harvard University; Harvard Medical School; Rutgers State University New Brunswick; Rutgers State University Medical Center; Hackensack University Medical Center	Gambassi, G (corresponding author), Brown Univ, Ctr Gerontol & Hlth Care Res, Box G-B213, Providence, RI 02912 USA.	Giovanni_Gambassi@brown.edu	Bernabei, Roberto/AAB-2704-2019	Bernabei, Roberto/0000-0002-9197-004X	PHS HHS [17C90428] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ball JK, 1996, MED CARE, V34, P970, DOI 10.1097/00005650-199609000-00008; Bernabei R, 1998, J AM GERIATR SOC, V46, P251, DOI 10.1111/j.1532-5415.1998.tb02553.x; BERNABEI R, IN PRESS J GERONTOL; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COHENMANSFIELD J, 1993, J GERONTOL, V48, pP96, DOI 10.1093/geronj/48.2.P96; CORRAN TM, 1994, PROG PAIN RES MANAG, V2, P895; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Elliott TE, 1997, J PAIN SYMPTOM MANAG, V13, P191, DOI 10.1016/S0885-3924(96)00275-8; Ferrell BA, 1995, J PAIN SYMPTOM MANAG, V10, P591, DOI 10.1016/0885-3924(95)00121-2; Fisher-Morris M, 1997, AGE AGEING, V26, P497, DOI 10.1093/ageing/26.6.497; FOLEY KM, 1995, J CLIN ONCOL, V13, P2149, DOI 10.1200/JCO.1995.13.9.2149; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Gambassi G, 1998, MED CARE, V36, P167, DOI 10.1097/00005650-199802000-00006; GOLDBERG RJ, 1986, J CHRON DIS, V39, P37, DOI 10.1016/0021-9681(86)90105-0; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; HIGGINSON I, 1994, SOC SCI MED, V38, P553, DOI 10.1016/0277-9536(94)90251-8; *I MED, 1997, APPR DEATH IMPR CAR, P51; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KWENTUS JA, 1985, GERIATRICS, V40, P48; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lindesay J, 1997, INT J GERIATR PSYCH, V12, P344, DOI 10.1002/(SICI)1099-1166(199703)12:3<344::AID-GPS504>3.0.CO;2-I; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; MELDING PS, 1991, PAIN, V46, P119, DOI 10.1016/0304-3959(91)90064-5; Mogil JS, 1997, PAIN, V70, P267, DOI 10.1016/S0304-3959(97)03333-2; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; PARMELEE PA, 1989, J GERONTOL, V44, pM22, DOI 10.1093/geronj/44.1.M22; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; PORTENOY RK, 1994, CANCER-AM CANCER SOC, V74, P907, DOI 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO;2-#; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; PORTENOY RK, 1992, ONCOLOGY, V2, P86; Porter FL, 1996, PAIN, V68, P413, DOI 10.1016/S0304-3959(96)03210-1; Repetto L, 1998, CANCER, V82, P760, DOI 10.1002/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.3.CO;2-D; Rischer JB, 1996, JOINT COMM J QUAL IM, V22, P683, DOI 10.1016/S1070-3241(16)30275-9; SAS, 2003, US GUID STAT; SCHECHTERN L, 1989, PEDIATR CLIN N AM, V36, P631; Scherder EJA, 1997, ALZ DIS ASSOC DIS, V11, P171, DOI 10.1097/00002093-199709000-00010; Schroll M, 1997, LANCET, V350, P604, DOI 10.1016/S0140-6736(05)63321-1; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41, P541, DOI 10.1111/j.1532-5415.1993.tb01892.x; SHAUGHNESSY PW, 1990, NEW ENGL J MED, V322, P21, DOI 10.1056/NEJM199001043220105; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; STEIN WM, 1993, J PAIN SYMPTOM MANAG, V8, P474, DOI 10.1016/0885-3924(93)90190-7; STJERNSWARD J, 1988, CANCER SURV, V7, P195; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Vallerand A H, 1997, Semin Oncol Nurs, V13, P16, DOI 10.1016/S0749-2081(97)80045-9; Yeager K A, 1997, Cancer Pract, V5, P39; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 1991, MINIMUM DATA SET PLU	57	759	776	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1877	1882		10.1001/jama.279.23.1877	http://dx.doi.org/10.1001/jama.279.23.1877			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634258	Bronze			2022-12-01	WOS:000074109700034
J	Climo, MW; Israel, DS; Wong, ES; Williams, D; Coudron, P; Markowitz, SM				Climo, MW; Israel, DS; Wong, ES; Williams, D; Coudron, P; Markowitz, SM			Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost	ANNALS OF INTERNAL MEDICINE			English	Article						clindamycin; Clostridium difficile; diarrhea; drug resistance, microbial; cost savings	TOXIN-ASSOCIATED DIARRHEA; AMINOGLYCOSIDE USAGE; RISK-FACTORS; SURVEILLANCE; RESISTANCE; COLITIS	Background: Widespread antibiotic use has been associated with increases in both bacterial resistance and nosocomial infection. Objective: To characterize the impact of hospital-wide clindamycin restriction on the incidence of Clostridium difficile-associated diarrhea and on antimicrobial prescribing practices. Design: Prospective, observational cohort study. Setting: University-affiliated Veterans Affairs Medical Center. Patients: Hospitalized patients with symptomatic diarrhea. Measurements: Clinical data on individual patients and data on antibiotic use were obtained from hospital pharmacy records. Hospital-wide use of antimicrobial agents was monitored. Isolates of C. difficile underwent antimicrobial susceptibility testing and molecular typing. Results: An outbreak of C. difficile-associated diarrhea was ca used by a clonal isolate of clindamycin-resistant C. difficile and was associated with increased use of clindamycin. Hospital-wide requirement of approval by an infectious disease consultant of clindamycin use led to an overall reduction in clindamycin use, a sustained reduction in the mean number of cases of C. difficile-associated diarrhea (11.5 cases/month compared with 3.33 cases/month; P < 0.001), and an increase in clindamycin susceptibility among C. difficile isolates (9% compared with 61%, P < 0.001). A parallel increase was noted in the use of and costs associated with other antibiotics with antianaerobic activity, including cefotetan, ticarcillin-clavulanate, and imipenem-cilastin. The hospital realized overall cost savings as a result of the decreased incidence of C. difficile-associated diarrhea. Conclusions: Hospital formulary restriction of clindamycin is an effective way to decrease the number of infections due to C. difficile. It can also lead to a return in clindamycin susceptibility among isolates and can effect cost savings to the hospital.	Virginia Commonwealth Univ Med Coll Virginia, Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	Climo, MW (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Hunter Holmes McGuire Vet Affairs Med Ctr, 1201 Broad Rock Blvd,Sect 111C, Richmond, VA 23249 USA.							BALLOW CH, 1992, DIAGN MICR INFEC DIS, V15, pS37; BAMBERGER DM, 1992, ARCH INTERN MED, V152, P554, DOI 10.1001/archinte.152.3.554; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1981, JOHNS HOPKINS MED J, V149, P6; BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; BETTS RF, 1984, ANN INTERN MED, V100, P219, DOI 10.7326/0003-4819-100-2-219; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; DONTA ST, 1980, J INFECT DIS, V141, P218, DOI 10.1093/infdis/141.2.218; FEKETY R, 1993, JAMA-J AM MED ASSOC, V1, P71; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1991, ANTIMICROB AGENTS CH, V35, P1284, DOI 10.1128/AAC.35.7.1284; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; JONES RN, 1992, DIAGN MICR INFEC DIS, V15, pS3; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KING JW, 1992, CLIN INFECT DIS, V14, P908, DOI 10.1093/clinids/14.4.908; KOFSKY P, 1991, DIS COLON RECTUM, V34, P244, DOI 10.1007/BF02090164; Maslow Joel N., 1993, P563; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MULLANY P, 1995, J ANTIMICROB CHEMOTH, V35, P305, DOI 10.1093/jac/35.2.305; OLSON MM, 1994, INFECT CONT HOSP EP, V15, P371; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; REINKE CM, 1994, AM J HOSP PHARM, V51, P1771, DOI 10.1093/ajhp/51.14.1771; RILEY TV, 1995, LANCET, V345, P455, DOI 10.1016/S0140-6736(95)90439-5; STRATTON CW, 1993, CLIN THER, V15, P12; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; YOUNG EJ, 1985, AM J MED SCI, V290, P223, DOI 10.1097/00000441-198512000-00001	27	185	189	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				989	+		10.7326/0003-4819-128-12_Part_1-199806150-00005	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625685				2022-12-01	WOS:000074201300004
J	Tachibana, K; Hirota, S; Iizasa, H; Yoshida, H; Kawabata, K; Kataoka, Y; Kitamura, Y; Matsushima, K; Yoshida, N; Nishikawa, S; Kishimoto, T; Nagasawa, T				Tachibana, K; Hirota, S; Iizasa, H; Yoshida, H; Kawabata, K; Kataoka, Y; Kitamura, Y; Matsushima, K; Yoshida, N; Nishikawa, S; Kishimoto, T; Nagasawa, T			The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract	NATURE			English	Article							BLOOD-VESSEL DEVELOPMENT; HIV-1 INFECTION; TYROSINE KINASE; ANGIOGENESIS; ENTRY; MICE; GENE; VASCULOGENESIS; LESTR/FUSIN; ENDOTHELIUM	Vascularization of organs generally occurs by remodelling of the preexisting vascular system during their differentiation and growth to enable them to perform their specific functions during development. The molecules required by early vascular systems, many of which are receptor tyrosine kinases and their ligands, have been defined by analysis of mutant mice(1-3). As most of these mice die during early gestation before many of their organs have developed, the molecules responsible for vascularization during organogenesis have not been identified. The cell-surface receptor CXCR4 (refs 4-6) is a seven-transmembrane-spanning, G-protein-coupled receptor for the CXC chemokine PBSF/SDF-1 (for pre-B-cell growth-stimulating factor/stromal-cell-derived factor), which is responsible for B-cell lymphopoiesis, bone-marrow myelopoiesis and cardiac ventricular septum formation(7). CXCR4 also functions as a co-receptor for T-cell-line tropic human immunodeficiency virus HIV-1 (ref. 8). Here we report that CXCR4 is expressed in developing vascular endothelial cells, and that mice lacking CXCR4 or PBSF/SDF-1 have defective formation of the large vessels supplying the gastrointestinal tract. In addition, mice lacking CXCR4 die in utero and are defective in vascular development, haematopoiesis and cardiogenesis, like mice lacking PBSF/SDF-1, indicating that CXCR4 is a primary physiological receptor for PBSF/SDF-1. We conclude that PBSF/SDF-1 and CXCR4 define a new signalling system for organ vascularization.	Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Immunol, Osaka 59002, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Div Social Med,Bunkyo Ku, Tokyo 113, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Sakyo Ku, Kyoto 606, Japan; Osaka Univ, Sch Med, Dept Med 3, Suita, Osaka 565, Japan	Osaka University; University of Tokyo; Kyoto University; Osaka University	Nagasawa, T (corresponding author), Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Immunol, 840 Murodo Cho, Osaka 59002, Japan.		Iizasa, Hisashi/A-9821-2012; Kishimoto, Tadamitsu/C-8470-2009	Nagasawa, Takashi/0000-0002-1085-0960; Yoshida, Hisahiro/0000-0001-6360-5988				Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; VECCHI A, 1994, EUR J CELL BIOL, V63, P247	30	1254	1336	0	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					591	594		10.1038/31261	http://dx.doi.org/10.1038/31261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634237				2022-12-01	WOS:000074150100056
J	Shafer, RW; Winters, MA; Palmer, S; Merigan, TC				Shafer, RW; Winters, MA; Palmer, S; Merigan, TC			Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients	ANNALS OF INTERNAL MEDICINE			English	Article							ZIDOVUDINE; INFECTION	Background: Drug resistance of HIV-1 is an obstacle to the long-term efficacy of antiretroviral therapy. Objective: To characterize reverse transcriptase and protease genes of multidrug-resistant HIV-1 isolates. Design: Descriptive case series. Setting: Academic medical center. Patients: Four consecutive patients with HIV-1 infection were selected because they had previously received many antiretroviral drugs and had not achieved plasma HIV-1 RNA suppression despite treatment with several three-drug combinations. Measurements: Reverse transcriptase sequencing, protease sequencing, and drug susceptibility testing of HIV-1. Results: Isolates of HIV-1 from the four patients shared seven protease mutations and eight reverse transcriptase mutations. These mutations were present in biological clones and at three time points in three of the patients. Susceptibility testing showed high-level resistance (30-fold to >100-fold) to zidovudine, lamivudine, saquinavir, indinavir, and nelfinavir and lower-level resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine. Conclusions: Simultaneous resistance to almost all available antiretroviral drugs may occur in HIV-1. The concordance and persistence of mutations in drug-resistant HIV-1 isolates suggest that some combinations of reverse transcriptase and protease mutations give the virus a selective advantage in the presence of various drug combinations.	Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA	Stanford University	Shafer, RW (corresponding author), Stanford Univ, Med Ctr, Div Infect Dis, Room S-156, Stanford, CA 94305 USA.	rshafer@cmgm.stanford.edu	Merigan, Thomas/AGQ-7464-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HERTOGS K, 1998, P 5 C RETR OPP INF C; LARDER B, 1996, 5 INT WORKSH HIV DRU, P61; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Myers GK, 1995, HUMAN RETROVIRUSES A; PALMER S, 1998, P 5 C RETR OPP INF C; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; SCHAPIRO JM, 1997, ANTIVIR THER S, P57; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; SHAFER RW, 1993, J VIROL METHODS, V41, P297, DOI 10.1016/0166-0934(93)90019-N; Shafer RW, 1997, J CLIN MICROBIOL, V35, P520, DOI 10.1128/JCM.35.2.520-522.1997; WINTERS MA, 1997, ANTIVIR THER S, P11; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	20	171	175	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					906	911		10.7326/0003-4819-128-11-199806010-00008	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634429				2022-12-01	WOS:000073808600005
J	Solomon, T; Kneen, R; Dung, NM; Khanh, VG; Thuy, TTN; Ha, DQ; Day, NPJ; Nisalak, A; Vaughn, DW; White, NJ				Solomon, T; Kneen, R; Dung, NM; Khanh, VG; Thuy, TTN; Ha, DQ; Day, NPJ; Nisalak, A; Vaughn, DW; White, NJ			Poliomyelitis-like illness due to Japanese encephalitis virus	LANCET			English	Article							GUILLAIN-BARRE-SYNDROME; NORTHERN CHINA; ANTIBODIES	Background Acute flaccid paralysis remains common among Vietnamese children despite a pronounced fall in the incidence of poliomyelitis. Methods During 1995, all 22 children presenting with acute flaccid paralysis to a referral centre in Ho Chi Mlnh City, Vietnam, had virological cultures and antibody measurements done on serum, cerebrospinal fluid, and faeces. A year later the children were reassessed and electrophysiological studies were done. Findings Wild poliovirus type 1 was isolated from the faeces of only one patient, and non-polio enteroviruses from three patients. 12 (55%) of the 22 children with acute flaccid paralysis had evidence of acute Japanese encephalitis virus (JEV) infection, compared with only one (1%) of 88 age-matched hospital controls (children with diphtheria; p<0.0001). Compared with JEV-negative patients, weakness in JEV-infected children was more rapid in onset, tended to be asymmetrical, but was less likely to involve the arms. All 12 children with JEV infection were febrile at the onset of weakness, seven had acute retention of urine, and ten had CSF pleiocytosis. Seven of eight JEV-negative patients met the case-definition of Guillain-Barre syndrome, compared with only one of 12 JEV-positive children. At follow-up, patients with JEV infection had greater disability and were more likely to have muscle wasting than were JEV-negative children. Nerve conduction and electromyographic studies indicated damage to the anterior horn cells. Interpretation JEV causes an acute flaccid paralysis in children that has similar clinical and pathological features to poliomyelitis. In endemic areas, children with acute flaccid paralysis should be investigated for evidence of JEV infection.	Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam; John Radcliffe Hosp, Ctr Trop Med & Infect Dis, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Inst Pasteur, Ho Chi Minh City, Vietnam; USA, Dept Virol, Med Component, Armed Forces Res Inst Med Sci, Bangkok, Thailand	University of Oxford; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	White, NJ (corresponding author), Cho Quan Hosp, Ctr Trop Dis, Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam.		White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	White, Nick/0000-0002-1897-1978; Solomon, Tom/0000-0001-7266-6547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASBURY AK, 1981, ANN NEUROL, V9, P1, DOI 10.1002/ana.410090703; Breinl A., 1918, MED J AUSTRALIA, V1, P209; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P169; BURKE DS, 1982, J CLIN MICROBIOL, V16, P1034, DOI 10.1128/JCM.16.6.1034-1042.1982; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P412; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; KUMAR R, 1991, INDIAN PEDIATR, V23, P1525; MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P; MISRA UK, 1994, J NEUROL NEUROSUR PS, V57, P1484, DOI 10.1136/jnnp.57.12.1484; PREVOT M., 1954, BULLL SOC PATHOL EXOT, V47, P490; Read SJ, 1997, J CLIN MICROBIOL, V35, P691, DOI 10.1128/JCM.35.3.691-696.1997; Solomon T., 1997, NEUROL INFECT EPIDEM, V2, P191; Tangermann RH, 1997, J INFECT DIS, V175, pS97, DOI 10.1093/infdis/175.Supplement_1.S97; *WHO, 1997, WEEKLY EPIDEMIOL REC, V5, P27; *WHO, 1993, AC ONS FLACC PAR; World Health Organization, 1992, MAN VIR INV POL; ZIMMERMAN HM, 1946, AM J PATHOL, V22, P965; 1993, MORBID MORTAL WEEKLY, V42, P1	20	186	191	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1094	1097		10.1016/S0140-6736(97)07509-0	http://dx.doi.org/10.1016/S0140-6736(97)07509-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660579				2022-12-01	WOS:000073090200011
J	Arant, BS				Arant, BS			Screening for urinary abnormalities: worth doing and worth doing well	LANCET			English	Editorial Material									Univ Tennessee, Coll Med, Dept Pediat, Chattanooga Unit, Chattanooga, TN 37403 USA	University of Tennessee System; University of Tennessee Health Science Center	Arant, BS (corresponding author), Univ Tennessee, Coll Med, Dept Pediat, Chattanooga Unit, Chattanooga, TN 37403 USA.							*AM AC PED, 1993, POL REF GUID COMPR G; DODGE WF, 1976, J PEDIATR-US, V88, P327, DOI 10.1016/S0022-3476(76)81012-8; Graff L, 1983, HDB ROUTINE URINALYS; Kaplan RE, 1997, PEDIATRICS, V100, P919, DOI 10.1542/peds.100.6.919; KUNIN CM, 1970, J INFECT DIS, V122, P382, DOI 10.1093/infdis/122.5.382; Linshaw MA, 1997, PEDIATRICS, V100, P1031, DOI 10.1542/peds.100.6.1031; LIPPMAN RW, 1957, URINE URINARY SEDIME	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					307	308		10.1016/S0140-6736(05)78344-6	http://dx.doi.org/10.1016/S0140-6736(05)78344-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652606				2022-12-01	WOS:000071864000004
J	Sattar, N; Hopkinson, ZEC; Greer, IA				Sattar, N; Hopkinson, ZEC; Greer, IA			Insulin-sensitising agents in polycystic-ovary syndrome	LANCET			English	Editorial Material							RESISTANCE		Univ Glasgow, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Univ NHS Trust, Glasgow G31 2ER, Lanark, Scotland	University of Glasgow; University of Glasgow	Sattar, N (corresponding author), Univ Glasgow, Dept Clin Biochem, Glasgow G31 2ER, Lanark, Scotland.			Sattar, Naveed/0000-0002-1604-2593				Acbay O, 1996, FERTIL STERIL, V65, P946, DOI 10.1016/S0015-0282(16)58266-1; CASIMIRRI F, 1997, INT J OBESITY S2, V21, pS61; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P524, DOI 10.1210/jc.82.2.524; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; Nestler JE, 1996, NEW ENGL J MED, V335, P617, DOI 10.1056/NEJM199608293350902; VANDERSPUY ZM, 1996, HUM REPROD, V11, P167; Velazquez E, 1997, OBSTET GYNECOL, V90, P392; Velazquez EM, 1997, METABOLISM, V46, P454, DOI 10.1016/S0026-0495(97)90066-4; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7	12	39	39	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					305	307		10.1016/S0140-6736(05)78345-8	http://dx.doi.org/10.1016/S0140-6736(05)78345-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652605				2022-12-01	WOS:000071864000003
J	Fienberg, AA; Hiroi, N; Mermelstein, PG; Song, WJ; Snyder, GL; Nishi, A; Cheramy, A; O'Callaghan, JP; Miller, DB; Cole, DG; Corbett, R; Haile, CN; Cooper, DC; Onn, SP; Grace, AA; Ouimet, CC; White, FJ; Hyman, SE; Surmeier, DJ; Girault, JA; Nestler, EJ; Greengard, P				Fienberg, AA; Hiroi, N; Mermelstein, PG; Song, WJ; Snyder, GL; Nishi, A; Cheramy, A; O'Callaghan, JP; Miller, DB; Cole, DG; Corbett, R; Haile, CN; Cooper, DC; Onn, SP; Grace, AA; Ouimet, CC; White, FJ; Hyman, SE; Surmeier, DJ; Girault, JA; Nestler, EJ; Greengard, P			DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission	SCIENCE			English	Article							NEOSTRIATAL NEURONS; BASAL GANGLIA; NUCLEUS-ACCUMBENS; CAUDATE-PUTAMEN; RAT STRIATUM; MUTANT MICE; RECEPTORS; COCAINE; D1; PHOSPHOPROTEIN	Dopaminergic neurons exert a major modulatory effect on the forebrain. Dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor. Mice generated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication. The results show that DARPP-32 plays a central role in regulating the efficacy of dopaminergic neurotransmission.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06519 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Univ Tennessee, Dept Anat & Neurobiol, Coll Med, Memphis, TN 38163 USA; Coll France, INSERM, U114, F-75005 Paris, France; Ctr Dis Control & Prevent, NIOSH, Morgantown, WV 26505 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Hoechst Marion Roussel Inc, Somerville, NJ 08807 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA	Rockefeller University; Yale University; University of Tennessee System; University of Tennessee Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Chicago Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; Florida State University	Fienberg, AA (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	fienba@rockvax.rockefeller.edu	anand, amit/A-7222-2009; Hiroi, Noboru/E-2215-2013; O'Callaghan, James/O-2958-2013; Miller, Diane/O-2927-2013; Girault, Jean-Antoine/F-7518-2013	Hiroi, Noboru/0000-0002-6846-5969; Girault, Jean-Antoine/0000-0002-7900-1705; Haile, Colin/0000-0001-8293-7291; Song, Wen-Jie/0000-0003-2909-3098	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008227, F31DA005794, P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10044, F31 DA005794, DA 08227] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE A, 1987, BRAIN RES, V418, P262, DOI 10.1016/0006-8993(87)90094-1; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; COLE DC, UNPUB; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; CORBETT R, UNPUB; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FLORAN B, 1990, NEUROSCI LETT, V116, P136, DOI 10.1016/0304-3940(90)90399-T; GALLI T, 1992, NEUROSCIENCE, V50, P769, DOI 10.1016/0306-4522(92)90203-E; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIRAULT JA, 1986, NEUROSCIENCE, V19, P1109, DOI 10.1016/0306-4522(86)90127-2; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KONRADI C, 1994, J NEUROSCI, V14, P5623; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Langley KC, 1997, NEUROSCIENCE, V78, P977, DOI 10.1016/S0306-4522(96)00583-0; Levine MS, 1996, J NEUROSCI, V16, P5870; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nishi A, 1997, J NEUROSCI, V17, P8147; NISHI A, UNPUB; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; ONN SP, UNPUB; OUIMET CC, 1990, J NEUROCYTOL, V19, P39, DOI 10.1007/BF01188438; OUIMET CC, 1984, J NEUROSCI, V4, P114; OUIMET CC, UNPUB; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; SHCIFFMAN SN, 1994, J PHYSIOL-LONDON, V483, P95; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Snyder G., 1996, Society for Neuroscience Abstracts, V22, P380; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SVENNINGSSON P, UNPUB; UCHIMURA N, 1986, BRAIN RES, V375, P368, DOI 10.1016/0006-8993(86)90760-2; WALAAS SI, 1983, NATURE, V301, P69; WHITE SR, 1995, BRAIN RES, V681, P167, DOI 10.1016/0006-8993(95)00309-E; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291	47	371	409	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					838	+		10.1126/science.281.5378.838	http://dx.doi.org/10.1126/science.281.5378.838			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694658				2022-12-01	WOS:000075295600054
J	Liu, Y; Merrow, M; Loros, JJ; Dunlap, JC				Liu, Y; Merrow, M; Loros, JJ; Dunlap, JC			How temperature changes reset a circadian oscillator	SCIENCE			English	Article							CLOCK MUTANTS; NEUROSPORA; LIGHT; PHASE; TIMELESS; ENTRAINMENT; FREQUENCY; PROTEIN; PERIOD	Circadian rhythms control many physiological activities. The environmental entrainment of rhythms involves the immediate responses of clock components. Levels of the clock protein FRQ were measured in Neurospora at various temperatures; at higher temperatures, the amount of FRQ oscillated around higher Levels. Absolute FRQ amounts thus identified different times at different temperatures, so temperature shifts corresponded to shifts in clock time without immediate synthesis or turnover of components. Moderate temperature changes could dominate Light-to-dark shifts in the influence of circadian timing. Temperature regulation of clock components could explain temperature resetting of rhythms and how single transitions can initiate rhythmicity from characteristic circadian phases.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Dunlap, JC (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	jay.c.dunlap@dartmouth.edu	Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457	NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aschoff J., 1981, BIOL RHYTHMS, P311; BARRETT RK, 1995, J NEUROSCI, V15, P5681; BellPedersen D, 1996, J GENET, V75, P387, DOI 10.1007/BF02966317; BRUCE VG, 1960, COLD SPRING HARB SYM, V25, P29, DOI 10.1101/SQB.1960.025.01.005; Bunning E, 1973, PHYSL CLOCK; BUNNING E, 1935, JB WISS BOT, V81, P411; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CZEISLER CA, 1978, THESIS STANFORD U; DHARMANANDA S, 1980, THESIS U CALIFORNIA; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Finlayson SA, 1998, PLANT PHYSIOL, V116, P17, DOI 10.1104/pp.116.1.17; FRANCIS CD, 1979, PLANT PHYSIOL, V64, P1000, DOI 10.1104/pp.64.6.1000; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; GOOCH VD, 1994, J BIOL RHYTHM, V9, P83, DOI 10.1177/074873049400900108; GOOCH VD, 1985, TEMPORAL ORDER, P232; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN P, 1995, SEMIN NEUROSCI, V7, P15, DOI 10.1016/1044-5765(95)90013-6; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Johnson C.H., 1990, ATLAS PHASE RESPONSE; KING PY, 1997, CELL, V89, P641; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; LAKINTHOMAS PI, 1991, J BIOL RHYTHM, V6, P281, DOI 10.1177/074873049100600401; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; MENAKER M, 1971, BIOCHRONOMETRY, P81; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; NAKASHIMA H, 1987, J INTERDISCIPL CYCLE, V18, P1; NJUS D, 1977, J COMP PHYSIOL, V117, P335, DOI 10.1007/BF00691559; PETERSON EL, 1980, J THEOR BIOL, V84, P281, DOI 10.1016/S0022-5193(80)80008-7; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; Pittendrigh CS, 1959, PHOTOPERIODISM RELAT, P475, DOI DOI 10.1177/0748730413516309; RENSING L, 1989, CHRONOBIOL INT, V6, P297, DOI 10.3109/07420528909056933; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Sidote D, 1998, MOL CELL BIOL, V18, P2004, DOI 10.1128/MCB.18.4.2004; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; SWEENEY B, 1968, INSECT PHYSL, V14, P669; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; UNDERWOOD H, 1987, Journal of Biological Rhythms, V2, P179, DOI 10.1177/074873048700200302; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Winfree A.T., 1980, GEOMETRY BIOL TIME, V8; Young MW, 1996, COLD SPRING HARB SYM, V61, P279	51	176	183	6	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					825	829		10.1126/science.281.5378.825	http://dx.doi.org/10.1126/science.281.5378.825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694654	Green Submitted			2022-12-01	WOS:000075295600050
J	Baecklund, E; Ekbom, A; Sparen, P; Feltelius, N; Klareskog, L				Baecklund, E; Ekbom, A; Sparen, P; Feltelius, N; Klareskog, L			Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							CANCER		Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17111 Stockholm, Sweden; Karolinska Inst, Dept Med, S-17111 Stockholm, Sweden	Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska Institutet	Baecklund, E (corresponding author), Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden.			Sparen, Par/0000-0002-5184-8971; Klareskog, Lars/0000-0001-9601-6186				GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; MYLLYKANGASLUOSUJARVI R, 1995, SCAND J RHEUMATOL, V24, P76, DOI 10.3109/03009749509099288; PRIOR P, 1984, ANN RHEUM DIS, V43, P128, DOI 10.1136/ard.43.2.128; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P988, DOI 10.1136/ard.47.12.988; SYMMONS DPM, 1985, AM J MED, V78, P22, DOI 10.1016/0002-9343(85)90241-4	5	303	308	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					180	181		10.1136/bmj.317.7152.180	http://dx.doi.org/10.1136/bmj.317.7152.180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9665898	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000075047800025
J	Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM				Simmonds, P; Davidson, F; Lycett, C; Prescott, LE; MacDonald, DM; Ellender, J; Yap, PL; Ludlam, CA; Haydon, GH; Gillon, J; Jarvis, LM			Detection of a novel DNA virus (TTV) in blood donors and blood products	LANCET			English	Article							HEPATITIS-C VIRUS; NON-A; HEMOPHILIA; DETERGENT; OUTBREAK; GLOBULIN; SOLVENT	Background A newly discovered DNA virus, transfusion-transmitted virus (TTV), has been implicated as a cause of post-transfusion hepatitis. We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which TTV contaminates blood products such as factor VIII and IX clotting factors. We also investigated the possible aetiological role of TTV in cryptogenic fulminant hepatic failure (FHF). Methods We extracted DNA from plasma of blood donors and patients with FHF, and from blood products (factor VIII and IX clotting-factor concentrates, immunoglobulin preparations). We detected TTV by PCR using primers from a conserved region in the TTV genome. Findings TTV viraemia was detected in 19 (1.9%) of 1000 non-remunerated regular blood donors. Infection occurred more frequently in older donors (mean age 53 years), compared with the age prolife of donors infected with hepatitis C virus and other parenterally-transmitted viruses. TTV contamination was found in ten (56%) of 18 batches of factor VIII and IX concentrate manufactured from such nonremunerated donors, and in seven (44%) of 16 batches of commercially available products. Whereas solvent or detergent treatment had little effect on the detection of TTV in factor VIII and IX by PCR, this virucidal step seemed to inactivate TTV infectivity. TTV infection was detected in four (19%) of 21 patients with FHF; in three cases, infection was detected at the onset of disease and could thus not be excluded from its aetiology. Interpretation TTV viraemia is frequent in the blood-donor population, and transmission of TTV through transfusion of blood components may have occurred extensively. Clinical assessment of infected donors and recipients of blood and blood products, and assessment of TTV's aetiological role in hepatic and extra-hepatic disease, are urgently needed.	Univ Edinburgh, Dept Med Microbiol, Edinburgh EH3 9HB, Midlothian, Scotland; Edinburgh & SE Scotland Blood Transfus Serv, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Haematol, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Royal Infirm Edinburgh, Dept Med, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Simmonds, P (corresponding author), Univ Edinburgh, Dept Med Microbiol, Teviot Pl, Edinburgh EH3 9HB, Midlothian, Scotland.			Simmonds, Peter/0000-0002-7964-4700				Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GARSON JA, 1990, LANCET, V335, P1473, DOI 10.1016/0140-6736(90)91510-H; Hanley JP, 1998, THROMB HAEMOSTASIS, V79, P291; Haydon GH, 1997, J VIRAL HEPATITIS, V4, P45, DOI 10.1046/j.1365-2893.1997.00122.x; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; KEDDA MA, 1995, HEPATOLOGY, V22, P1363, DOI 10.1002/hep.1840220504; KERNOFF PBA, 1985, BRIT J HAEMATOL, V60, P469, DOI 10.1111/j.1365-2141.1985.tb07444.x; LAWLOR E, 1994, VOX SANG, V67, P18, DOI 10.1111/j.1423-0410.1994.tb00968.x; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; Nishizawa T, 1997, BIOCHEM BIOPH RES CO, V241, P92, DOI 10.1006/bbrc.1997.7765; Okamoto H, 1998, HEPATOL RES, V10, P1, DOI 10.1016/S1386-6346(97)00123-X; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; Yap PL, 1996, CLIN EXP IMMUNOL, V104, P35, DOI 10.1111/cei.1996.104.s1.35	21	349	371	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					191	195		10.1016/S0140-6736(98)03056-6	http://dx.doi.org/10.1016/S0140-6736(98)03056-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683208				2022-12-01	WOS:000074859800012
J	Bowen, D; Rocheleau, TA; Blackburn, M; Andreev, O; Golubeva, E; Bhartia, R; ffrench-Constant, RH				Bowen, D; Rocheleau, TA; Blackburn, M; Andreev, O; Golubeva, E; Bhartia, R; ffrench-Constant, RH			Insecticidal toxins from the bacterium Photorhabdus luminescens	SCIENCE			English	Article							BACILLUS-THURINGIENSIS; XENORHABDUS; LARVAE; LEPIDOPTERA; HETERORHABDITIDAE; RESISTANCE; NEMATODES; MOTH	Transgenic plants expressing Bacillus thuringiensis (Bt) toxins are currently being deployed for insect control. In response to concerns about Bt resistance, we investigated a toxin secreted by a different bacterium Photorhabdus luminescens, which lives in the gut of entomophagous nematodes. In insects infected by the nematode, the bacteria are released into the insect hemocoel; the insect dies and the nematodes and bacteria replicate in the cadaver. The toxin consists of a series of four native complexes encoded by toxin complex loci tca, tcb, tcc, and tcd. Both tca and tcd encode complexes with high oral toxicity to Manduca sexta and therefore they represent potential alternatives to Bt for transgenic deployment.	Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	ffrench-Constant, RH (corresponding author), Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA.			Blackburn, Michael/0000-0001-5541-4831; ffrench-Constant, Richard/0000-0001-5385-9888; Bhartia, Rohit/0000-0002-1434-7481				AKHURST RJ, 1982, J GEN MICROBIOL, V128, P3061; BANNO Y, 1984, REV INFECT DIS S1, V6, P11; BOWEN D, 1995, THESIS U WISCONSIN M; BOWEN D, IN PRESS APPL ENV MI; CLARKE DJ, 1995, J INVERTEBR PATHOL, V66, P149, DOI 10.1006/jipa.1995.1078; DUNPHY GB, 1988, J GEN MICROBIOL, V134, P1017; DUNPHY GB, 1988, INT J PARASITOL, V18, P729, DOI 10.1016/0020-7519(88)90112-9; ENDO Y, 1980, J INVERTEBR PATHOL, V36, P90, DOI 10.1016/0022-2011(80)90140-8; ENSIGN JC, 1997, Patent No. 17432; GOTZ P, 1981, P R SOC LONDON B, V211, P330; GUINEY D, COMMUNICATION; HOFTE H, 1989, MICROBIOL REV, V53, P242; JOHNSON JL, 1990, CURR MICROBIOL, V20, P397, DOI 10.1007/BF02095867; KHAN A, 1977, J INVERTEBR PATHOL, V29, P253, DOI 10.1016/S0022-2011(77)80030-X; KINSINGER RA, 1979, ANN ENTOMOL SOC AM, V72, P787, DOI 10.1093/aesa/72.6.787; Libby SJ, 1997, INFECT IMMUN, V65, P1786, DOI 10.1128/IAI.65.5.1786-1792.1997; MCGAUGHEY WH, 1985, SCIENCE, V229, P193, DOI 10.1126/science.229.4709.193; McGaughey WH, 1998, NAT BIOTECHNOL, V16, P144, DOI 10.1038/nbt0298-144; PAUL VJ, 1981, J CHEM ECOL, V7, P589, DOI 10.1007/BF00987707; POINAR GO, 1977, NEMATOLOGICA, V23, P97, DOI 10.1163/187529277X00273; PURCELL JP, 1993, BIOCHEM BIOPH RES CO, V196, P1406, DOI 10.1006/bbrc.1993.2409; SCHMIDT TM, 1988, APPL ENVIRON MICROB, V54, P2793, DOI 10.1128/AEM.54.11.2793-2797.1988; SUTTER GR, 1967, J INVERTEBR PATHOL, V9, P90, DOI 10.1016/0022-2011(67)90048-1; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; YAMANAKA S, 1992, ARCH MICROBIOL, V158, P387; Yu CG, 1997, APPL ENVIRON MICROB, V63, P532, DOI 10.1128/AEM.63.2.532-536.1997	26	335	397	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2129	2132		10.1126/science.280.5372.2129	http://dx.doi.org/10.1126/science.280.5372.2129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641921				2022-12-01	WOS:000074435900049
J	Hart, MJ; Jiang, XJ; Kozasa, T; Roscoe, W; Singer, WD; Gilman, AG; Sternweis, PC; Bollag, G				Hart, MJ; Jiang, XJ; Kozasa, T; Roscoe, W; Singer, WD; Gilman, AG; Sternweis, PC; Bollag, G			Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by G alpha(13)	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE C-BETA-1; RAS; STATE; IDENTIFICATION; DEACTIVATION; SITE	Signaling pathways that link extracellular factors to activation of the monomeric guanosine triphosphatase (GTPase) Rho control cytoskeletal rearrangements and cell growth. Heterotrimeric guanine nucleotide-binding proteins (G proteins) participate in several of these pathways, although their mechanisms are unclear. The GTPase activities of two G protein alpha subunits, G alpha(12 )and G alpha(13), are stimulated by the Rho guanine nucleotide exchange factor p115 RhoGEF. Activated G alpha(13) bound tightly to p115 RhoGEF and stimulated its capacity to catalyze nucleotide exchange on Rho, In contrast, activated G alpha(12) inhibited stimulation by G alpha(13). Thus, p115 RhoGEF can directly link heterotrimeric G protein a subunits to regulation of Rho.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	sternwei@utsw.swmed.edu; bollag@onyx-pharm.com		Hart, Matthew/0000-0002-2683-480X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, R01GM031954] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31954, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, UNPUB; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Singer WD, 1996, J BIOL CHEM, V271, P4504; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	30	647	657	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2112	2114		10.1126/science.280.5372.2112	http://dx.doi.org/10.1126/science.280.5372.2112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641916				2022-12-01	WOS:000074435900044
J	Priscu, JC; Fritsen, CH; Adams, EE; Giovannoni, SJ; Paerl, HW; McKay, CP; Doran, PT; Gordon, DA; Lanoil, BD; Pinckney, JL				Priscu, JC; Fritsen, CH; Adams, EE; Giovannoni, SJ; Paerl, HW; McKay, CP; Doran, PT; Gordon, DA; Lanoil, BD; Pinckney, JL			Perennial Antarctic lake ice: An oasis for life in a polar desert	SCIENCE			English	Article								The permanent ice covers of Antarctic lakes in the McMurdo Dry Valleys develop liquid water inclusions in response to solar heating of internal aeolian-derived sediments. The ice sediment particles serve as nutrient (inorganic and organic)-enriched microzones for the establishment of a physiologically and ecologically complex microbial consortium capable of contemporaneous photosynthesis,.nitrogen fixation, and decomposition. The consortium is capable of physically and chemically establishing and modifying a relatively nutrient- and organic matter-enriched microbial "oasis" embedded in the lake ice cover.	Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA; Montana State Univ, Dept Civil Engn, Bozeman, MT 59717 USA; Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA; Univ Illinois, Chicago, IL 60607 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Oregon State University; University of North Carolina; University of North Carolina Chapel Hill; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Priscu, JC (corresponding author), Montana State Univ, Dept Biol Sci, Bozeman, MT 59717 USA.			Pinckney, James/0000-0002-6056-6511; Lanoil, Brian/0000-0001-8603-8330				Adams EE, 1998, ANTARCT RES SER, V72, P281; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; Clow GD, 1988, J CLIMATE, V1, P715, DOI 10.1175/1520-0442(1988)001<0715:COAPSR>2.0.CO;2; FELIP M, 1995, APPL ENVIRON MICROB, V61, P2394, DOI 10.1128/AEM.61.6.2394-2401.1995; FELSENSTEIN J, 1991, PHYLIP; FLETT RJ, 1976, CAN J MICROBIOL, V22, P43, DOI 10.1139/m76-006; FRITSEN CH, 1994, SCIENCE, V266, P782, DOI 10.1126/science.266.5186.782; Fritsen CH, 1998, J PHYCOL, V34, P587, DOI 10.1046/j.1529-8817.1998.340587.x; Fritsen CH, 1998, ANTARCT RES SER, V72, P269; LANE D.J., 1991, 16S 23S RRNA SEQUENC, P115, DOI DOI 10.1007/S00227-012-2133-0; MCKAY CP, 1989, REV GEOPHYS, V27, P189, DOI 10.1029/RG027i002p00189; MCKAY CP, 1992, ADV SPACE RES-SERIES, V12, P231, DOI 10.1016/0273-1177(92)90177-Y; MCKAY CP, 1985, NATURE, V313, P561, DOI 10.1038/313561a0; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; PAERL HW, 1979, LIMNOL OCEANOGR, V24, P1166, DOI 10.4319/lo.1979.24.6.1166; Parsons TR, 1984, MANUAL CHEM BIOL MET; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; Priscu JC, 1997, GLOBAL CHANGE BIOL, V3, P301, DOI 10.1046/j.1365-2486.1997.00147.x; PRISCU JC, UNPUB; REDFIELD AC, 1958, AM SCI, V46, P205; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALKI RK, 1988, SCIENCE, V239, P487; Wing K., 1993, ANTARCT J US, V28, P246	24	282	304	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2095	2098		10.1126/science.280.5372.2095	http://dx.doi.org/10.1126/science.280.5372.2095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641910				2022-12-01	WOS:000074435900038
J	Schwan, TG; Hinnebusch, BJ				Schwan, TG; Hinnebusch, BJ			Bloodstream- versus tick-associated variants of a relapsing fever bacterium	SCIENCE			English	Article							VARIABLE MAJOR PROTEINS; OUTER SURFACE PROTEIN; BORRELIA-HERMSII; ANTIGENIC VARIATION; BURGDORFERI; GENES; OSPC; CULTIVATION; SEQUENCE; EPITOPE	The relapsing fever spirochete, Borrelia hermsii, alternates infections between a mammal and a tick vector. Whether the spirochete changes;phenotypically in the different hosts was examined by allowing the tick vector Ornithodoros hermsi to feed on mice infected with serotype 7 or serotype 8 of B. hermsii. Upon infection of ticks, the spirochetal serotype-specific variable major proteins (Vmps) 7 and 8 became undetectable and were replaced by Vmp33. This switch from a bloodstream- to tick-associated phenotype could be induced in culture by a decrease in temperature. After tick-bite transmission back to mice, the process was reversed and the spirochetes resumed expression of the same Vmp present in the previous infectious blood meal.	NIAID, Microbial Struct & Funct Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schwan, TG (corresponding author), NIAID, Microbial Struct & Funct Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	tom_schwan@nih.gov						Barbour A G, 1987, Contrib Microbiol Immunol, V8, P125; Barbour A.G., 1985, GENOME REARRANGEMENT, P123; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BARBOUR AG, UNPUB; BARSTAD PA, 1985, J EXP MED, V161, P1302, DOI 10.1084/jem.161.6.1302; Cadavid D, 1997, INFECT IMMUN, V65, P3352, DOI 10.1128/IAI.65.8.3352-3360.1997; CARTER CJ, 1994, INFECT IMMUN, V62, P2792, DOI 10.1128/IAI.62.7.2792-2799.1994; Dworkin MS, 1998, CLIN INFECT DIS, V26, P122, DOI 10.1086/516273; Felsenfeld O., 1971, BORRELIA STRAINS VEC; HAJDUK SL, 1981, PARASITOLOGY, V83, P609, DOI 10.1017/S0031182000080574; Hinnebusch BJ, 1998, INFECT IMMUN, V66, P432, DOI 10.1128/IAI.66.2.432-440.1998; HINNEBUSCH BJ, UNPUB; KELLY R, 1971, SCIENCE, V173, P443, DOI 10.1126/science.173.3995.443; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; MARCONI RT, 1993, J CLIN MICROBIOL, V31, P2577, DOI 10.1128/JCM.31.10.2577-2583.1993; MARGOLIS N, 1994, GENE, V143, P105, DOI 10.1016/0378-1119(94)90613-0; MEIER JT, 1985, CELL, V41, P403, DOI 10.1016/S0092-8674(85)80013-1; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PLASTERK RHA, 1985, NATURE, V318, P257, DOI 10.1038/318257a0; PORCELLA SF, UNPUB; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; RESTREPO BI, 1994, CELL, V78, P867, DOI 10.1016/S0092-8674(94)90642-4; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; SCHWAN TG, 1989, INFECT IMMUN, V57, P3445, DOI 10.1128/IAI.57.11.3445-3451.1989; Schwan Tom G., 1995, P626; SOUTHERN PM, 1969, MEDICINE, V48, P129, DOI 10.1097/00005792-196903000-00002; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSKE B, 1993, INFECT IMMUN, V61, P2182, DOI 10.1128/IAI.61.5.2182-2191.1993	34	124	127	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1938	1940		10.1126/science.280.5371.1938	http://dx.doi.org/10.1126/science.280.5371.1938			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632392				2022-12-01	WOS:000074323800064
J	Lyznicki, JM; Doege, TC; Davis, RM; Williams, MA				Lyznicki, JM; Doege, TC; Davis, RM; Williams, MA		Am Med Assoc	Sleepiness, driving, and motor vehicle crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AUTOMOBILE ACCIDENTS; OPERATIONAL SETTINGS; DRIVER SLEEPINESS; MANAGING FATIGUE; SHIFT WORK; APNEA; NARCOLEPSY; DISORDERS; VIGILANCE; INSOMNIA	Objective.-To assess the contribution of driver sleepiness to highway crashes and review recent recommendations to change federal hours-of-service regulations for commercial motor vehicle drivers. Data Sources.-Information was derived from a search of the MEDLINE, Transportation Research information Service (TRIS), and Bibliographic Electronic Databases of Sleep (BEDS) databases from 1975 through 1997 and from manual review of the reference lists in relevant journal articles, government publications, conference proceedings, and textbooks. Data Synthesis.-Driver sleepiness is a causative factor in 1% to 3% of all US motor vehicle crashes. Surveys of the prevalence of sleepy behavior in drivers suggest that sleepiness may be a more common cause of highway crashes than is reflected in these estimates. About 96% of sleep-related crashes involve passenger vehicle drivers and 3% involve drivers of large trucks. Risk factors include youth, shift work, alcohol and other drug use, over-the-counter and prescription medications, and sleep disorders. Conclusions.-Increased awareness of the relationship between sleepiness and motor vehicle crashes will promote the health and safely of drivers and highway users. Physicians can contribute by encouraging good sleep habits, recognizing and treating sleep-related problems, and counseling patients about the risks of driving while sleepy. To protect public health and safety, the American Medical Association recommends continued research on devices and technologies to detect the signs of sleepiness and prevent the deterioration of driver alertness and performance. Educational programs about the risks of falling asleep while driving are needed for physicians, the public, and commercial truck drivers.	Amer Med Assoc, Council Sci Affairs, Chicago, IL 60610 USA	American Medical Association	Lyznicki, JM (corresponding author), Amer Med Assoc, Council Sci Affairs, 515 N State St, Chicago, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014				*AA FDN TRAFF SAF, 1985, REP DET EV ROL FAT H; AKERSTEDT T, 1994, J SLEEP RES, V3, P152, DOI 10.1111/j.1365-2869.1994.tb00122.x; Akerstedt T, 1995, J SLEEP RES, V4, P15, DOI 10.1111/j.1365-2869.1995.tb00221.x; AKERSTEDT T, 1988, SLEEP, V11, P17, DOI 10.1093/sleep/11.1.17; ALDRICH MS, 1989, SLEEP, V12, P487, DOI 10.1093/sleep/12.6.487; ALDRICH MS, 1990, NEW ENGL J MED, V323, P389; American Psychiatric Association, 1994, DIAGN CRIT DSM 4; American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; [Anonymous], 1995, FACT AFF FAT HEAV TR, V1-2; BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BEILOCK R, 1995, ACCIDENT ANAL PREV, V27, P33, DOI 10.1016/0001-4575(94)00042-K; Braver Elisa R., 1992, Journal of Public Health Policy, V13, P341, DOI 10.2307/3342733; BROWN ID, 1994, HUM FACTORS, V36, P298, DOI 10.1177/001872089403600210; Brown ID, 1997, ACCIDENT ANAL PREV, V29, P525, DOI 10.1016/S0001-4575(97)00032-8; BROWN ID, 1993, ALCOHOL DRUGS DRIVIN, V9, P239; *CAN MED ASS, 1991, PHYS GUID DRIV EX; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P869; Chaska B, 1996, AM FAM PHYSICIAN, V53, P247; CORFITSEN MT, 1994, ACCIDENT ANAL PREV, V26, P617, DOI 10.1016/0001-4575(94)90023-X; Culebras A, 1996, CLIN HDB SLEEP DISOR; DEMENT WC, 1993, JAMA-J AM MED ASSOC, V269, P1548, DOI 10.1001/jama.269.12.1548; Dement WC, 1997, NEW ENGL J MED, V337, P783, DOI 10.1056/NEJM199709113371111; Dinges DF, 1995, J SLEEP RES, V4, P4, DOI 10.1111/j.1365-2869.1995.tb00220.x; Dinges DF, 1997, SLEEP, V20, P267; DOEGE TC, 1986, MED CONDITIONS AFFEC; Evans Leonard, 1991, TRAFFIC SAFETY DRIVE; *EXP PAN DRIV FAT, 1997, DROWS DRIV AUT CRASH; *FED HIGHW ADM, 1995, 1995 TRUCK BUS SAF S; FINDLEY L, 1995, CHEST, V108, P619, DOI 10.1378/chest.108.3.619; FINDLEY LJ, 1989, NEW ENGL J MED, V320, P868; FINDLEY LJ, 1988, AM REV RESPIR DIS, V138, P337, DOI 10.1164/ajrccm/138.2.337; GENGO FM, 1990, J ALLERGY CLIN IMMUN, V86, P1034, DOI 10.1016/S0091-6749(05)80250-7; George CFP, 1996, SLEEP, V19, P711, DOI 10.1093/sleep/19.9.711; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; GOLD DR, 1992, AM J PUBLIC HEALTH, V82, P1011, DOI 10.2105/AJPH.82.7.1011; HARTENBAUM NP, 1997, DOT MED EXAMINATION; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; HERTZ RP, 1988, ACCIDENT ANAL PREV, V20, P431, DOI 10.1016/0001-4575(88)90041-3; Horne JA, 1996, PSYCHOPHYSIOLOGY, V33, P306, DOI 10.1111/j.1469-8986.1996.tb00428.x; Horne JA, 1995, J SLEEP RES, V4, P23, DOI 10.1111/j.1365-2869.1995.tb00222.x; HUBLIN C, 1994, SLEEP, V17, pS7, DOI 10.1093/sleep/17.suppl_8.S7; Itoi A, 1993, CAN DRIVERS AVOID FA; KANEKO T, 1992, ACCIDENT ANAL PREV, V24, P437, DOI 10.1016/0001-4575(92)90055-N; KNIPLING RR, 1996, 15 INT TECHN C ENH S; KNIPLING RR, 1994, INT VEH HIGHW SOC AM; Knipling RR., 1994, CRASHES FATALITIES R; KNIPLING RR, 1995, ANN M ASS ADV AUT ME; KOELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233, DOI 10.1007/BF02245951; Kryger M, 1994, PRINCIPLES PRACTICE; Kupfer DJ, 1997, NEW ENGL J MED, V336, P341, DOI 10.1056/NEJM199701303360506; LAUBER JK, 1988, SLEEP, V11, P503; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; Maycock G, 1997, ACCIDENT ANAL PREV, V29, P453, DOI 10.1016/S0001-4575(97)00024-9; McCartt AT, 1996, ACCIDENT ANAL PREV, V28, P511, DOI 10.1016/0001-4575(96)00021-8; McCartt AT, 1997, ASS ADV AUT MED 41 A; Mitler MM, 1997, NEW ENGL J MED, V337, P755, DOI 10.1056/NEJM199709113371106; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; *NAT COM SLEEP DIS, 1993, WAK AM NAT SLEEP AL; *NAT SAF COUNC, 1909, ACC FACTS; *NAT SAF COUNC TRA, 1991, NCHRP SYNTH, V191; *NAT SLEEP FDN, 1997, US CONT SHOULD RUMBL; *NAT TRANSP SAF BO, 1990, NTSBSS9001 NAT TRANS, V1; Neutel C. Ineke, 1995, Annals of Epidemiology, V5, P239; OGILVIE RD, 1989, SLEEP, V12, P458, DOI 10.1093/sleep/12.5.458; OHANLON JF, 1986, DRUGS DRIVING; OHANLON JF, 1995, 75 ANN M TRANSP RES; Pack AI, 1995, ACCIDENT ANAL PREV, V27, P769, DOI 10.1016/0001-4575(95)00034-8; Pack AM, 1995, J SLEEP RES, V24, P452; PAKOLA SJ, 1995, SLEEP, V18, P787, DOI 10.1093/sleep/18.9.787; PARTINEN M, 1994, PRINCIPLES PRACTICE; Pary R, 1996, POSTGRAD MED, V100, P195, DOI 10.3810/pgm.1996.11.117; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; Reyner LA, 1998, SLEEP, V21, P46; ROEHRS T, 1994, ALCOHOL CLIN EXP RES, V18, P154, DOI 10.1111/j.1530-0277.1994.tb00896.x; Rosa RR, 1997, PLAIN LANGUAGE SHIFT, P97; Rosekind MR, 1996, BEHAV MED, V21, P157, DOI 10.1080/08964289.1996.9933753; Rosekind MR, 1996, BEHAV MED, V21, P166, DOI 10.1080/08964289.1996.9933754; ROSEN RC, 1993, SLEEP, V16, P249, DOI 10.1093/sleep/16.3.249; STOOHS RA, 1995, CHEST, V107, P1275, DOI 10.1378/chest.107.5.1275; STOOHS RA, 1994, SLEEP, V17, P619; STROHL KP, 1994, AM J RESP CRIT CARE, V150, P1463; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; *US C, 1991, PUBL US C; WANG JS, 1993, ASS ADV AUT MED 40 A; WANG JS, 1994, DOT PUBLICATION; WEBB WB, 1995, SLEEP, V18, P276, DOI 10.1093/sleep/18.4.276; Williamson AM, 1996, ACCIDENT ANAL PREV, V28, P709, DOI 10.1016/S0001-4575(96)00044-9; WYLIE CD, 1996, FHWA PUBLICATION; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1996, FED REG, V61, P57251	91	289	313	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1998	279	23					1908	1913		10.1001/jama.279.23.1908	http://dx.doi.org/10.1001/jama.279.23.1908			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZT653	9634264				2022-12-01	WOS:000074109700040
J	Andes, GM				Andes, GM			Mark Twain's cat	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Andes, GM (corresponding author), 51 Hunthurst Circle, Worcester, MA 01602 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1043	1044		10.7326/0003-4819-128-12_Part_1-199806150-00019	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00019			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625670				2022-12-01	WOS:000074201300014
J	Ridker, PM; Miletich, JP; Buring, JE; Ariyo, AA; Price, DT; Manson, JE; Hill, JA				Ridker, PM; Miletich, JP; Buring, JE; Ariyo, AA; Price, DT; Manson, JE; Hill, JA			Factor V Leiden mutation as a risk factor for recurrent pregnancy loss	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; VENOUS THROMBOSIS; RESISTANCE; THROMBOPHILIA; THROMBOEMBOLISM	Background: Recurrent pregnancy loss may result from hypercoagulability. Objective: To determine whether women with factor V Leiden mutation, a common inherited defect of coagulation, are at increased risk for recurrent pregnancy loss. Design: Case-control study. Setting: University hospital. Patients: 113 consecutive women referred for evaluation of recurrent spontaneous abortion (case-patients) and 437 postmenopausal women with at least one successful pregnancy and no history of pregnancy loss (controls). An additional survey of 387 postmenopausal women with at least one pregnancy loss was also conducted. Measurements: Prevalence of factor V Leiden mutation determined by a second-generation screening test for resistance to activated protein C with genetic confirmation of all borderline and low-value results. Results: Prevalence of the factor V Leiden mutation was greater among case-patients (8.0%) than among controls (3.7%) (odds ratio, 2.3 [95% CI, 1.0 to 5.2]; P = 0.050). In the subgroup of case-patients with three or more pregnancy losses and no successful pregnancies, prevalence of the mutation was 9.0% (odds ratio, 2.6 [CI, 1.0 to 6.7]; P = 0.048). Among the additional women surveyed, the prevalence of the mutation in those with three or more pregnancy losses (7.5%) was almost identical to that in case-patients. Thus, in all evaluated women with several pregnancy losses, the prevalence of factor V Leiden was increased 2.2-fold (P = 0.026). Conclusion: These data are compatible with the hypothesis that factor V Leiden mutation may play a role in some cases of unexplained recurrent pregnancy loss.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Washington Univ, Med Ctr, St Louis, MO USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL)	Ridker, PM (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; CUMMING AM, 1995, BRIT J HAEMATOL, V90, P725, DOI 10.1111/j.1365-2141.1995.tb05610.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DizonTownson DS, 1997, AM J OBSTET GYNECOL, V176, P883, DOI 10.1016/S0002-9378(97)70615-X; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Grisaru D, 1996, AM J OBSTET GYNECOL, V174, P801, DOI 10.1016/S0002-9378(96)70478-7; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HILL JA, 1994, CURRENT PROBLEMS OBS, V4, P116; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Ridker PM, 1997, CIRCULATION, V95, P1777; SVENSSON PJ, 1998, NEW ENGL J MED, V330, P517; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	23	165	167	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1998	128	12	1				1000	1003		10.7326/0003-4819-128-12_Part_1-199806150-00007	http://dx.doi.org/10.7326/0003-4819-128-12_Part_1-199806150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU474	9625662				2022-12-01	WOS:000074201300006
J	Kunkele, KP; Heins, S; Dembowski, M; Nargang, FE; Benz, R; Thieffry, M; Walz, J; Lill, R; Nussberger, S; Neupert, W				Kunkele, KP; Heins, S; Dembowski, M; Nargang, FE; Benz, R; Thieffry, M; Walz, J; Lill, R; Nussberger, S; Neupert, W			The preprotein translocation channel of the outer membrane of mitochondria	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN IMPORT RECEPTOR; GENERAL INSERTION PORE; PRECURSOR PROTEINS; ESCHERICHIA-COLI; NEUROSPORA-CRASSA; SECRETORY PROTEINS; CATIONIC CHANNEL; CELL VIABILITY; COMPLEX	The preprotein translocase of the outer membrane of mitochondria (TOM complex) facilitates the recognition, insertion, and translocation of nuclear-encoded mitochondrial preproteins. We have purified the TOM complex from Neurospora crassa and analyzed its composition and functional properties. The TOM complex contains a cation-selective high-conductance channel. Upon reconstitution into liposomes, it mediates integration of proteins into and translocation across the lipid bilayer. TOM complex particles have a diameter of about 138 Angstrom, as revealed by electron microscopy and image analysis; they contain two or three centers of stain-filled openings, which we interpret as pores with an apparent diameter of about 20 Angstrom. We conclude that the structure reported here represents the protein-conducting channel of the mitochondrial outer membrane.	Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, D-80336 Munich, Germany; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; CNRS, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; Univ Wurzburg, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany; Philipps Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany	University of Munich; University of Alberta; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Wurzburg; Max Planck Society; Philipps University Marburg	Kunkele, KP (corresponding author), Univ Munich, Inst Physiol Chem Phys Biochem & Zellbiol, Goethestr 33, D-80336 Munich, Germany.		Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720; Benz, Roland/0000-0002-9510-9265; Nussberger, Stephan/0000-0003-3619-4452; Lill, Roland/0000-0002-8345-6518				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; COURT DA, 1995, CAN J BOT, V73, pS193; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Dekker PJT, 1996, BIOL CHEM, V377, P535; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; FEVRE F, 1994, BIOPHYS J, V66, P1887, DOI 10.1016/S0006-3495(94)80982-8; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANK J, 1982, J MOL BIOL, V161, P134, DOI 10.1016/0022-2836(82)90282-0; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOPING IS, 1995, FEBS LETT, V373, P45; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HALLERMAYER G, 1974, H-S Z PHYSIOL CHEM, V355, P279, DOI 10.1515/bchm2.1974.355.1.279; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Haucke V, 1997, TRENDS CELL BIOL, V7, P103, DOI 10.1016/S0962-8924(96)10052-0; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hille B, 1992, IONIC CHANNELS EXCIT, P291; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; IWAHASHI J, 1994, J BIOCHEM-TOKYO, V116, P156, DOI 10.1093/oxfordjournals.jbchem.a124488; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; NAKAI M, 1995, FEBS LETT, V357, P202; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; Sebald W, 1979, Methods Enzymol, V55, P144; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	75	311	315	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					1009	1019		10.1016/S0092-8674(00)81206-4	http://dx.doi.org/10.1016/S0092-8674(00)81206-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635430	Bronze			2022-12-01	WOS:000074205700012
J	Liu, QA; Hengartner, MO				Liu, QA; Hengartner, MO			Candidate adaptor protein CED-6 promotes the engulfment of apoptotic cells in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PHOSPHOTYROSINE INTERACTION DOMAIN; RECEPTOR-MEDIATED PHAGOCYTOSIS; VITRONECTIN RECEPTOR; MACROPHAGE RECOGNITION; SIGNAL-TRANSDUCTION; GENETIC MOSAICS; SH3 DOMAINS; PTB DOMAIN; DEATH	The rapid engulfment (phagocytosis) of cells undergoing programmed cell death (apoptosis) is a fundamental biological process that is not well understood. Here we report the cloning and functional characterization of ced-6, a gene specifically required for the engulfment of apoptotic cells in the nematode C. elegans. The CED-6 protein contains a phosphotyrosine binding domain at its N terminus and a proline/serine-rich region in its C-terminal half. Genetic mosaic analysis demonstrates that ced-6 acts within engulfing cells. We also show that ced-6 can promote the engulfment of cells at both early and late stages of apoptosis. Our data suggest that CED-6 is an adaptor molecule acting in a signal transduction pathway that specifically mediates the recognition and engulfment of apoptotic cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Hengartner, MO (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Liu, Alison/0000-0002-4636-0920; Hengartner, Michael/0000-0002-7584-596X; Liu (liu qiong), Alison/0000-0003-0171-6441	NIGMS NIH HHS [GM-52540] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052540] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BIANCO C, 1975, J EXP MED, V141, P1278, DOI 10.1084/jem.141.6.1278; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRENNER S, 1974, GENETICS, V77, P71; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS RE, 1991, GENETICS, V129, P79; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HEDGECOCK EM, 1995, GENETICS, V141, P989; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERMAN RK, 1984, GENETICS, V108, P165; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Hodgkin J, 1997, C ELEGANS, P881; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLASS M, 1976, DEV BIOL, V52, P1, DOI 10.1016/0012-1606(76)90002-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lockshin R. A, 1981, CELL DEATH BIOL PATH, P79; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mello C, 1995, METHOD CELL BIOL, P452; Metchnikoff E, 1983, LECT COMP PATHOLOGY; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; ROSENBLUTH RE, 1985, GENETICS, V109, P493; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Sun AY, 1997, GENETICS, V147, P1077; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; [No title captured]	64	164	176	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					961	972		10.1016/S0092-8674(00)81202-7	http://dx.doi.org/10.1016/S0092-8674(00)81202-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635426	Bronze, Green Accepted			2022-12-01	WOS:000074205700008
J	Moore, MS; DeZazzo, J; Luk, AY; Tully, T; Singh, CM; Heberlein, U				Moore, MS; DeZazzo, J; Luk, AY; Tully, T; Singh, CM; Heberlein, U			Ethanol intoxication in Drosophila: Genetic and pharmacological evidence for regulation by the cAMP signaling pathway	CELL			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; MUTANT MICE LACKING; MUSHROOM BODIES; PREFERENTIAL EXPRESSION; A RECEPTORS; ALCOHOL; MEMORY; DUNCE; MELANOGASTER	Upon exposure to ethanol, Drosophila display behaviors that are similar to ethanol intoxication in rodents and humans. Using an inebriometer to measure ethanol-induced loss of postural control, we identified cheapdate, a mutant with enhanced sensitivity to ethanol. Genetic and molecular analyses revealed that cheapdate is an allele of the memory mutant amnesiac. amnesiac has been postulated to encode a neuropeptide that activates the cAMP pathway. Consistent with this, we find that enhanced ethanol sensitivity of cheapdate can be reversed by treatment with agents that increase cAMP levels or PKA activity. Conversely, genetic or pharmacological reduction in PKA activity results in increased sensitivity to ethanol. Taken together, our results provide functional evidence for the involvement of the cAMP signal transduction pathway in the behavioral response to intoxicating levels of ethanol.	Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94110 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	Moore, MS (corresponding author), Univ Calif San Francisco, Gallo Ctr, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010035, F32AA005482] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10035, F32 AA05482] Funding Source: Medline; NINDS NIH HHS [T32 NS07067] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Buck KJ, 1996, BEHAV GENET, V26, P313, DOI 10.1007/BF02359387; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; COHAN FM, 1986, GENETICS, V114, P145; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; DAVIS RL, 1981, J CELL BIOL, V90, P101, DOI 10.1083/jcb.90.1.101; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; GORDON AS, 1992, G PROTEINS, V8, P191; GRANT KA, 1995, CLIN NEUROSCI, V3, P155; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Iourgenko V, 1997, FEBS LETT, V413, P104, DOI 10.1016/S0014-5793(97)00891-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOHLER JD, 1977, GENETICS, V85, P259; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; QUI Y, 1991, J MOL BIOL, V222, P553; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHUCKIT MA, 1988, ARCH GEN PSYCHIAT, V45, P211; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P184; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WEBER KE, 1988, INEBRIOMETER, V67, P91; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301	39	365	371	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					997	1007		10.1016/S0092-8674(00)81205-2	http://dx.doi.org/10.1016/S0092-8674(00)81205-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635429	Green Submitted, Bronze			2022-12-01	WOS:000074205700011
J	Krasnopolsky, VA; Mumma, MJ; Gladstone, GR				Krasnopolsky, VA; Mumma, MJ; Gladstone, GR			Detection of atomic deuterium in the upper atmosphere of Mars	SCIENCE			English	Article							INNER SOLAR-SYSTEM; MARTIAN ATMOSPHERE; LYMAN-ALPHA; TERRESTRIAL PLANETS; CHARGE-TRANSFER; WATER; D/H; EVOLUTION; IONS; ABUNDANCE	High-resolution spectroscopy of Mars' atmosphere with the Hubble Space Telescope revealed the deuterium Lyman alpha line at an intensity of 23 +/- 6 rayleighs. This measured intensity corresponds to HD/H-2 = 1.5 +/- 0.6 x 10(-4), which is smaller by a factor of 11 than HDO/H2O. This indicates that fractionation of HD/H-2 relative to that of HDO/H2O is not kinetically controlled by the rates of formation and destruction of H-2 and HD but is thermodynamically controlled by the isotope exchange HD + H2O <-> HDO + H-2. Molecular hydrogen is strongly depleted in deuterium relative to water on Mars because of the very long lifetime of H-2 (1200 years). The derived isotope fractionation corresponds to an estimate of a planetwide reservoir of water ice about 5 meters thick that is exchangeable with the atmosphere.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Catholic University of America	Krasnopolsky, VA (corresponding author), NASA, Goddard Space Flight Ctr, Code 6902, Greenbelt, MD 20771 USA.		Krasnopolsky, Vladimir/L-5085-2013; mumma, michael j/I-2764-2013	mumma, michael j/0000-0003-4627-750X				Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; AJELLO JM, 1987, ASTROPHYS J, V317, P964, DOI 10.1086/165345; ANDERSON DE, 1974, J GEOPHYS RES, V79, P1513, DOI 10.1029/JA079i010p01513; ANICICH VG, 1993, J PHYS CHEM REF DATA, V22, P1469, DOI 10.1063/1.555940; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; Bertaux J. L., 1992, SCI HUBBLE SPACE TEL, P459; Bjoraker G. L., 1989, B AM ASTRON SOC, V21, P991; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CLARKE JT, 1995, ASTROPHYS J, V448, P893, DOI 10.1086/176018; DEMORE WB, 1994, JPL PUBL, V9426; DONAHUE TM, 1995, NATURE, V374, P432, DOI 10.1038/374432a0; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Gurvich L.V., 1989, THERMODYNAMIC PROPER, V4th; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Hanson W. B., 1977, Journal of Geophysical Research, V82, P4351, DOI 10.1029/JS082i028p04351; HUNTEN DM, 1993, SCIENCE, V259, P915, DOI 10.1126/science.259.5097.915; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1994, NATURE, V370, P328, DOI 10.1038/370328a0; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; Kieffer L. J., 1969, Atomic Data, V1, P19, DOI 10.1016/S0092-640X(69)80020-3; Krasnopolsky V. A., 1986, PHOTOCHEMISTRY ATMOS; KRASNOPOLSKY VA, 1995, J GEOPHYS RES-PLANET, V100, P3263, DOI 10.1029/94JE03283; Krasnopolsky VA, 1997, J GEOPHYS RES-PLANET, V102, P6525, DOI 10.1029/96JE03766; KRASNOPOLSKY VA, 1993, ICARUS, V101, P313, DOI 10.1006/icar.1993.1027; KRASNOPOLSKY VA, 1994, ICARUS, V109, P337, DOI 10.1006/icar.1994.1098; KRASNOPOLSKY VA, 1993, ICARUS, V101, P33, DOI 10.1006/icar.1993.1003; Krasnopolsky VA, 1996, J GEOPHYS RES-SPACE, V101, P15765, DOI 10.1029/96JA01080; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LEMAIRE P, 1978, ASTROPHYS J, V223, pL55, DOI 10.1086/182727; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MELOSH HJ, 1989, NATURE, V338, P487, DOI 10.1038/338487a0; MERLIVAT L, 1967, TELLUS, V19, P122, DOI 10.1111/j.2153-3490.1967.tb01465.x; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; NAKAI Y, 1987, ATOM DATA NUCL DATA, V37, P69, DOI 10.1016/0092-640X(87)90005-2; NEWMAN JH, 1982, PHYS REV A, V25, P2976, DOI 10.1103/PhysRevA.25.2976; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; STUMPNER W, 1998, ANN GEOPHYS S111, V16, pC1002; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WU FM, 1980, ASTROPHYS J, V239, P389, DOI 10.1086/158119; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9; Yung YL, 1998, SCIENCE, V280, P1545, DOI 10.1126/science.280.5369.1545; ZHANG MHG, 1993, J GEOPHYS RES-PLANET, V98, P3311, DOI 10.1029/92JE02229	45	94	93	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1576	1580		10.1126/science.280.5369.1576	http://dx.doi.org/10.1126/science.280.5369.1576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616115				2022-12-01	WOS:000074061200033
J	Zimetbaum, PJ; Kim, KY; Josephson, ME; Goldberger, AL; Cohen, DJ				Zimetbaum, PJ; Kim, KY; Josephson, ME; Goldberger, AL; Cohen, DJ			Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; electrocardiography, ambulatory; time factors; arrhythmia; palpitations		Background: Continuous-loop event recorders are widely used for the evaluation of palpitations, but the optimal duration of monitoring is unknown. Objective: To determine the yield, timing, and incremental cost-effectiveness of each week of event monitoring for palpitations. Design: Prospective cohort study. Patients: 105 consecutive outpatients referred for the placement of a continuous-loop event recorder for the evaluation of palpitations. Measurements: Diagnostic yield, incremental cost, and cost-effectiveness for each week of monitoring. Results: The diagnostic yield of continuous-loop event recorders was 1.04 diagnoses per patient in week 1, 0.15 diagnoses per patient in week 2, and 0.01 diagnoses per patient in week 3 and beyond. Over time, the cost effectiveness ratio increased from $98 per new diagnosis in week 1 to $576 per new diagnosis in week 2 and $5832 per new diagnosis in week 3. Conclusions: In patients referred for evaluation of palpitations, the diagnostic yield of continuous-loop event recording decreases rapidly after 2 weeks of monitoring. A 2-week monitoring period is reasonably cost-effective for most patients and should be the standard period for continuous-loop event recording for the evaluation of palpitations.	Bath Israel Deaconess Med Ctr, Cardiovasc Div GZ435, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cohen, DJ (corresponding author), Bath Israel Deaconess Med Ctr, Cardiovasc Div GZ435, 330 Brookline Ave, Boston, MA 02115 USA.							DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Fogel RI, 1997, AM J CARDIOL, V79, P207, DOI 10.1016/S0002-9149(96)00717-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kinlay S, 1996, ANN INTERN MED, V124, P16, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00003; KRAHN AD, 1995, CIRCULATION, V92, P1819, DOI 10.1161/01.CIR.92.7.1819; REIFFEL JA, 1991, J ELECTROCARDIOL, V24, P165, DOI 10.1016/0022-0736(91)90007-9	7	87	91	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					890	+		10.7326/0003-4819-128-11-199806010-00002	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634426				2022-12-01	WOS:000073808600002
J	Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ				Brown, RH; Cruikshank, DP; Pendleton, Y; Veeder, GJ			Identification of water ice on the Centaur 1997 CU26	SCIENCE			English	Article							SHORT-PERIOD COMETS; OUTER SOLAR-SYSTEM; OPTICAL-CONSTANTS; KUIPER BELT; OBJECTS	Spectra of the Centaur 1997 CU26 were obtained at the Keck Observatory on 27 October 1997 (universal time). The data show strong absorptions at 1.52 and 2.03 micrometers attributable to water ice on the surface of 1997 CU26. The reflectance spectrum of 1997 CU26 is matched by the spectrum of a mixture of low-temperature particulate water ice and spectrally featureless but otherwise red-colored material. Water ice dominates the Spectrum of 1997 CU26, whereas methane or methane-like hydrocarbons apparently dominate the spectrum of the Kuiper belt object 1993 SC, perhaps indicating different origins, thermal histories, or both for these two objects.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Arizona; University of Arizona; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Brown, RH (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							BELL JF, 1988, LUNAR PLANET SCI, V19, P57; Brown RH, 1997, SCIENCE, V276, P937, DOI 10.1126/science.276.5314.937; CRUIKSHANK DP, 1997, STARDUST PLANETESIMA; CRUIKSHANK DP, UNPUB; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; GLADMAN B, 1990, ASTRON J, V100, P1680, DOI 10.1086/115628; Hapke B, 1993, REMOTE GEOCHEMICAL A, P31; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; Irwin M, 1995, ASTRON J, V110, P3082, DOI 10.1086/117749; Jewitt D, 1996, ASTRON J, V112, P1225, DOI 10.1086/118093; JEWITT DC, UNPUB; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; LUU J, 1994, ICARUS, V109, P133, DOI 10.1006/icar.1994.1081; Luu JX, 1998, ASTROPHYS J, V494, pL117, DOI 10.1086/311172; Matthews M. S., 1989, ASTEROIDS, VII; SAGAN C, 1984, SATURN, P788; TOON OB, 1994, J GEOPHYS RES-ATMOS, V99, P25631, DOI 10.1029/94JD02388; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; [No title captured]; 1997, 31010 MIN PLAN	21	44	44	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1430	1432		10.1126/science.280.5368.1430	http://dx.doi.org/10.1126/science.280.5368.1430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603731				2022-12-01	WOS:000073883400054
J	Villa, A; Santagata, S; Bozzi, F; Giliani, S; Frattini, A; Imberti, L; Gatta, LB; Ochs, HD; Schwarz, K; Notarangelo, LD; Vezzoni, P; Spanopoulou, E				Villa, A; Santagata, S; Bozzi, F; Giliani, S; Frattini, A; Imberti, L; Gatta, LB; Ochs, HD; Schwarz, K; Notarangelo, LD; Vezzoni, P; Spanopoulou, E			Partial V(D)J recombination activity leads to Omenn syndrome	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-E PRODUCTION; COMBINED IMMUNE-DEFICIENCY; T-CELLS; LYMPHOCYTES-T; SCID MICE; DNA; RAG-1; SEQUENCE; GENES	Genomic rearrangement of the antigen receptor loci is initiated by the two lymphoid-specific proteins Rag-1 and Rag-2. Null mutations in either of the two proteins abrogate initiation of V(D)J recombination and cause severe combined immunodeficiency with complete absence of mature B and T rymphocytes. We report here that patients with Omenn syndrome, a severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T cells, hypereosinophilia, and high IgE levels, bear missense mutations in either the Rag-1 or Rag-2 genes that result in partial activity of the two proteins. Two of the amino acid substitutions map within the Rag-1 homeodomain and decrease DNA binding activity, while three others lower the efficiency of Rag-1/Rag-2 interaction. These findings provide evidence to indicate that the immunodeficiency manifested in patients with Omenn syndrome arises from mutations that decrease the efficiency of V(D)J recombination.	CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, I-20090 Segrate, Milano, Italy; Mt Sinai Sch Med, Ruttenberg Canc Ctr, Howard Hughes Med Inst, New York, NY 10029 USA; Spedali Civili, Dept Paediat, I-25123 Brescia, Italy; Univ Brescia, I-25123 Brescia, Italy; Spedali Civili, Terzo Lab Anal, I-25123 Brescia, Italy; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Univ Ulm, Dept Transfus Med, D-89070 Ulm, Germany	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Washington; University of Washington Seattle; Ulm University	Vezzoni, P (corresponding author), CNR, Ist Tecnol Biomed Avanzate, Dept Human Genome & Multifactorial Dis, Via Fratelli Cervi 93, I-20090 Segrate, Milano, Italy.		Santagata, Sandro/A-7714-2009; Vezzoni, Paolo/K-3197-2018; Giliani, Silvia/AAX-8843-2020; Vezzoni, Paolo/R-3416-2019; Notarangelo, Luigi D/F-9718-2016; Frattini, Annalisa/B-7684-2015; Bozzi, Fabio Luigi/H-6091-2017	Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Frattini, Annalisa/0000-0002-1166-3091; Bozzi, Fabio Luigi/0000-0003-0729-1288; Vezzoni, Paolo/0000-0002-6382-3923; Imberti, Luisa/0000-0002-2075-8391; Villa, Anna/0000-0003-4428-9013; Santagata, Sandro/0000-0002-7528-9668	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040191] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40191] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline; Telethon [E.0495, E.0668] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon)		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Arden Bernhard, 1995, Immunogenetics, V42, P455; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bernstein RM, 1996, P NATL ACAD SCI USA, V93, P9454, DOI 10.1073/pnas.93.18.9454; BETTINARDI A, 1992, J IMMUNOL METHODS, V146, P71, DOI 10.1016/0022-1759(92)90050-4; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; Brugnoni D, 1997, EUR J IMMUNOL, V27, P2765, DOI 10.1002/eji.1830271104; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Chilosi M, 1996, EUR J IMMUNOL, V26, P329, DOI 10.1002/eji.1830260209; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; GOMEZ L, 1995, J PEDIATR-US, V127, P76, DOI 10.1016/S0022-3476(95)70260-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GU Y, 1997, IMMUNITY, V7, P853; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Harville TO, 1997, J CLIN IMMUNOL, V17, P322, DOI 10.1023/A:1027330800085; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Imberti L, 1997, BLOOD, V89, P2822, DOI 10.1182/blood.V89.8.2822; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Leu TMJ, 1997, IMMUNITY, V7, P303, DOI 10.1016/S1074-7613(00)80532-4; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Livak F, 1996, J EXP MED, V184, P419, DOI 10.1084/jem.184.2.419; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACHE CJ, 1994, ANN HEMATOL, V69, P85, DOI 10.1007/BF01698488; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, J IMMUNOL, V158, P2202; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Nagawa F, 1998, MOL CELL BIOL, V18, P655, DOI 10.1128/MCB.18.1.655; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; ROLDAN EQ, 1995, IMMUNOGENETICS, V41, P91; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SANTAGATA S, 1998, IN PRESS J BIOL CHEM; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SILVER DP, 1994, THESIS MIT CAMBRIDGE; Sottini A, 1996, HUM IMMUNOL, V48, P12, DOI 10.1016/0198-8859(96)00087-0; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WeisGarcia F, 1997, MOL CELL BIOL, V17, P6379, DOI 10.1128/MCB.17.11.6379; WEN L, 1994, NATURE, V369, P654, DOI 10.1038/369654a0; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	67	325	338	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					885	896		10.1016/S0092-8674(00)81448-8	http://dx.doi.org/10.1016/S0092-8674(00)81448-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630231	Bronze			2022-12-01	WOS:000073956700023
J	Hinuma, S; Habata, Y; Fujii, R; Kawamata, Y; Hosoya, N; Fukusumi, S; Kitada, C; Masuo, Y; Asano, T; Matsumoto, H; Sekiguchi, M; Kurokawa, T; Nishimura, O; Onda, H; Fujino, M				Hinuma, S; Habata, Y; Fujii, R; Kawamata, Y; Hosoya, N; Fukusumi, S; Kitada, C; Masuo, Y; Asano, T; Matsumoto, H; Sekiguchi, M; Kurokawa, T; Nishimura, O; Onda, H; Fujino, M			A prolactin-releasing peptide in the brain	NATURE			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; COUPLED RECEPTOR; PITUITARY-GLAND; GROWTH-HORMONE; CELL-LINE; RAT; SECRETION; CLONING; EXPRESSION; INVITRO	Hypothalamic peptide hormones regulate the secretion of most of the anterior pituitary hormones, that is, growth hormone, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone and adrenocorticotropin(1,2). These peptides do not regulate the secretion of prolactin(1,2), at least in a specific manner, however. The peptides act through specific receptors, which are referred to as seven-transmembrane-domain receptors or G-protein-coupled receptors(3-7). Although prolactin is important in pregnancy and lactation in mammals, and is involved in the development of the mammary glands and the promotion of milk synthesis(8,9), a specific prolactin-releasing hormone has remained unknown. Here we identify a potent candidate for such a hormone. We first proposed that there may still be unknown peptide hormone factors that control pituitary function through seven-transmembrane-domain receptors. We isolated the complementary DNA encoding an 'orphan' receptor (that is, one for which the ligand is unknown). This receptor, hGR3, is specifically expressed in the human pituitary. We then searched for the hGR3 Ligand in the hypothalamus and identified a new peptide. which shares no sequence similarity with known peptides and proteins, as an endogenous ligand. We show that this ligand is a potent prolactin-releasing factor for rat anterior pituitary cells; we have therefore named this peptide prolactin-releasing peptide.	Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, Ibaraki, Osaka 3004293, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Ibaraki, Osaka 3004293, Japan; Takeda Chem Ind Ltd, Pharmaceut Dev Div, Ibaraki, Osaka 3004293, Japan	Takeda Chemical Industries; Takeda Chemical Industries; Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Pharmaceut Discovery Res Div, Discovery Res Labs 1, 10 Wadai, Ibaraki, Osaka 3004293, Japan.	Hinuma_Shuji@takeda.co.jp		Kawamata, Yuji/0000-0001-5652-4899				CANONICO PL, 1983, NEUROENDOCRINOLOGY, V37, P212, DOI 10.1159/000123545; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; Cox KJA, 1997, J NEUROSCI, V17, P1197; DROUHAULT R, 1994, NEUROENDOCRINOLOGY, V60, P179, DOI 10.1159/000126749; Erfurth EM, 1996, HORM METAB RES, V28, P599, DOI 10.1055/s-2007-979861; FRANTZ AG, 1978, NEW ENGL J MED, V298, P201, DOI 10.1056/NEJM197801262980408; Hammond PJ, 1996, J NEUROENDOCRINOL, V8, P457, DOI 10.1046/j.1365-2826.1996.04747.x; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; HURBAINKOSMATH I, 1990, IN VITRO CELL DEV B, V26, P431; HYDE JF, 1987, ENDOCRINOLOGY, V121, P1531, DOI 10.1210/endo-121-4-1531; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KOENIG JI, 1989, TOXICOL PATHOL, V17, P256, DOI 10.1177/019262338901700204; KOYAMA N, 1994, J BIOTECHNOL, V32, P273, DOI 10.1016/0168-1656(94)90213-5; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; Mayo KE, 1996, ANN NY ACAD SCI, V805, P184, DOI 10.1111/j.1749-6632.1996.tb17483.x; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MIYAMOTO Y, 1994, BBA-GENE STRUCT EXPR, V1218, P297, DOI 10.1016/0167-4781(94)90181-3; NAKAGAWA S, 1994, J AM CHEM SOC, V116, P5513, DOI 10.1021/ja00091a083; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; REICHLIN S, 1989, TOXICOL PATHOL, V17, P250, DOI 10.1177/019262338901700203; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; RIVIER C, 1977, ENDOCRINOLOGY, V100, P751, DOI 10.1210/endo-100-3-751; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SAMSON WK, 1986, ENDOCRINOLOGY, V119, P554, DOI 10.1210/endo-119-2-554; SAMSON WK, 1980, PEPTIDES, V1, P325, DOI 10.1016/0196-9781(80)90010-8; SHIOTA K, 1984, ACTA ENDOCRINOL-COP, V106, P71, DOI 10.1530/acta.0.1060071; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WELCH SK, 1995, BIOCHEM BIOPH RES CO, V209, P606, DOI 10.1006/bbrc.1995.1543	29	482	524	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1998	393	6682					272	276		10.1038/30515	http://dx.doi.org/10.1038/30515			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607765				2022-12-01	WOS:000073761000055
J	Reichardt, HM; Kaestner, KH; Tuckermann, J; Kretz, O; Wessely, O; Bock, R; Gass, P; Schmid, W; Herrlich, P; Angel, P; Schutz, G				Reichardt, HM; Kaestner, KH; Tuckermann, J; Kretz, O; Wessely, O; Bock, R; Gass, P; Schmid, W; Herrlich, P; Angel, P; Schutz, G			DNA binding of the glucocorticoid receptor is not essential for survival	CELL			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTORS; RESPONSE ELEMENT; FUNCTIONAL ANTAGONISM; THYMOCYTE APOPTOSIS; PROTEIN-INTERACTION; POSSIBLE MECHANISM; GENE-EXPRESSION; MESSENGER-RNA; C-JUN	Transcriptional regulation by the glucocorticoid receptor (GR) is essential for survival. Since the GR can influence transcription both through DNA-binding-dependent and -independent mechanisms, we attempted to assess their relative importance in vivo. In order to separate these modes of action, we introduced the point mutation A458T into the GR by gene targeting using the Cre/loxP system. This mutation impairs dimerization and therefore GRE-dependent transactivation while functions that require cross-talk with other transcription factors, such as transrepression of AP-1-driven genes, remain intact. In contrast to GR(-/-) mice, these mutants termed GR(dim) are viable, revealing the in vivo relevance of DNA-binding-independent activities of the GR.	German Canc Res Ctr, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Univ Saarland, Inst Anat, D-66421 Homburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Saarland University; Helmholtz Association; Karlsruhe Institute of Technology	Schutz, G (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 1, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Reichardt, Holger/AAF-3048-2020; Piris, Miguel A/AAP-1445-2020	Reichardt, Holger/0000-0003-4647-057X; Piris, Miguel A/0000-0001-5839-3634; Kretz, Oliver/0000-0003-1152-5956				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BOCK R, 1991, ACTA HISTOCHEM, V91, P201, DOI 10.1016/S0065-1281(11)80277-1; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GACK S, 1994, J BIOL CHEM, V269, P10363; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; IMAI E, 1993, J BIOL CHEM, V268, P5353; JIANG W, 1989, INT J DEV NEUROSCI, V7, P513, DOI 10.1016/0736-5748(89)90010-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1996, MOL MED, V2, P735, DOI 10.1007/BF03401657; ROSS ME, 1990, J NEUROSCI, V10, P520; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Wilkinson DG, 1992, SITU HYBRIDIZATION P; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	48	870	919	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					531	541		10.1016/S0092-8674(00)81183-6	http://dx.doi.org/10.1016/S0092-8674(00)81183-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604929	hybrid			2022-12-01	WOS:000073722200007
J	Thomas, MJ; Platas, AA; Hawley, DK				Thomas, MJ; Platas, AA; Hawley, DK			Transcriptional fidelity and proofreading by RNA polymerase II	CELL			English	Article							DNA-REPLICATION FIDELITY; ELONGATION-FACTOR TFIIS; SACCHAROMYCES-CEREVISIAE; KINETIC MECHANISM; FACTOR-SII; CLEAVAGE; COMPLEXES; SITES; TERMINATION; EXONUCLEASE	We have addressed whether the intrinsic 3'-->15' nuclease activity of human RNA polymerase II (pol II) can proofread during transcription in vitro. In the presence of SII, a protein that stimulates the nuclease activity, pol II quantitatively removed misincorporated nucleotides from the nascent transcript during rapid chain extension. The basis of discrimination between the correct and incorrect base was the slow addition of the next nucleotide to the mismatched terminus. Incorporation of inosine monophosphate inhibited next nucleotide addition by a similar magnitude as a mismatched base. We used this finding to demonstrate that addition of SII to a transcription reaction dramatically altered the RNA base content, reflecting the stable incorporation of more "correct" (GMP) and fewer "incorrect" (IMP) nucleotides.	Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Dept Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Hawley, DK (corresponding author), Univ Oregon, Inst Mol Biol, Dept Chem, Eugene, OR 97403 USA.							ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAMBERLIN M, 1974, ENZYMES, P333; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KAHN JD, 1989, J MOL BIOL, V205, P291, DOI 10.1016/0022-2836(89)90342-2; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KIRKWOOD TBL, 1986, ACCURACY MOL PROCESS; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LIBBY RT, 1991, MOL MICROBIOL, V5, P999, DOI 10.1111/j.1365-2958.1991.tb01872.x; LO KY, 1976, J BIOL CHEM, V251, P2480; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; NAKANISHI Y, 1981, FEBS LETT, V130, P69, DOI 10.1016/0014-5793(81)80667-9; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; TAMURA H, 1980, J BIOCHEM-TOKYO, V88, P1475, DOI 10.1093/oxfordjournals.jbchem.a133117; Umehara T, 1997, J BIOCHEM-TOKYO, V121, P598, DOI 10.1093/oxfordjournals.jbchem.a021627; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	45	199	202	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					627	637		10.1016/S0092-8674(00)81191-5	http://dx.doi.org/10.1016/S0092-8674(00)81191-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604937	Bronze			2022-12-01	WOS:000073722200015
J	Gho, M; Schweisguth, F				Gho, M; Schweisguth, F			Frizzled signalling controls orientation of asymmetric sense organ precursor cell divisions in Drosophila	NATURE			English	Article							NUMB PROTEIN; NOTCH; MECHANISMS; ENCODES; DOMAINS; FATES; GENE	During metazoan development, cell-fate diversity is brought about, in part, by asymmetric cell divisions(1). In Drosophila, bristle mechanosensory organs are composed of four different cells that originate from a single precursor cell, pI, after two rounds of asymmetric division(2). At each division, distinct fates are conferred on sister cells by the asymmetric segregation ofNumb, a negative regulator of Notch signalling(3-6). Here we show that the orientation of the mitotic spindles and the localization of the Numb crescent follow a stereotyped pattern. Mitosis of pI is orientated parallel eo the anteroposterior axis of the fly. We show that signalling mediated by the Frizzled receptor polarizes pi along this axis, thereby specifying the orientation of the mitotic spindle and positioning the Numb crescent. The mitoses of the two cells produced by mitosis of pI are orientated parallel and orthogonal, respectively, to the division axis of pI. This difference in cell-division orientation is largely independent of the identity of the secondary precursor cells, and is regulated by Frizzled-independent mechanisms.	Ecole Normale Super, Lab Genet Dev Drosophile, URA 1857,46 Rue Ulm, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Gho, M (corresponding author), Ecole Normale Super, Lab Genet Dev Drosophile, URA 1857,46 Rue Ulm, F-75005 Paris, France.	mgho@wotan.ens.fr						ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; BATE CM, 1978, HDB SENSORY PHYSL, P1; EMERY JF, 1995, DEVELOPMENT, V121, P3549; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gho M, 1996, DEVELOPMENT, V122, P1673; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P398; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jones KH, 1996, GENETICS, V142, P205; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; USUI K, 1993, ROUX ARCH DEV BIOL, V203, P151, DOI 10.1007/BF00365054; Wang SW, 1997, DEVELOPMENT, V124, P4435	22	187	189	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					178	181		10.1038/30265	http://dx.doi.org/10.1038/30265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603522				2022-12-01	WOS:000073619900051
J	Dandona, L; Dandona, R; Naduvilath, TJ; McCarty, CA; Nanda, A; Srinivas, M; Mandal, P; Rao, GN				Dandona, L; Dandona, R; Naduvilath, TJ; McCarty, CA; Nanda, A; Srinivas, M; Mandal, P; Rao, GN			Is current eye-care-policy focus almost exclusively on cataract adequate to deal with blindness in India?	LANCET			English	Article							VISUAL-ACUITY; BALTIMORE	Background India's National Programme for Control of Blindness focuses almost exclusively on cataract, based on a national survey done in the 1980s which reported that cataract caused 80% of the blindness in India, No current population-based data on the causes of blindness in India are available, We assessed the rate and causes of blindness in an urban population in southern India. Methods We selected 2954 participants by stratified, random, cluster, systematic sampling from Hyderabad city. Eligible participants were interviewed and given a detailed ocular assessment, including visual acuity, refraction, slitlamp biomicroscopy, applanation intraocular pressure, gonioscopy, dilatation, grading of cataract, stereoscopic fundus assessment, and automated-threshold visual fields. Findings 2522 participants, including 1399 aged 30 years or more, were assessed. 49 participants tall aged greater than or equal to 30 years) were blind (presenting distance visual acuity <6/60 or central visual field <20 degrees in the better eye). The rate of blindness among those aged 30 years or more, adjusted for age and sex, was 3.08% ([95% CI 1.95-4.21]), Causes included cataract (29.7%), retinal disease (17.1%), corneal disease (15.4%), refractive error (12.5%), glaucoma (12.1%), and optic atrophy (11.0%). 15.7% of the blindness caused by visual-field constriction would have been missed without visual-field examination. Also without visual-field and detailed dilated-fundus assessments, blindness attributed to cataract would have been overestimated by up to 75.8%. If the use of cataract surgery in this urban population was half that found in this study, which simulates the situation in rural India, cataract would have caused 51.8% (39.4-64.2) of blindness, significantly less than the 80% accepted by current policy. Interpretation Much of the blindness in this Indian population was due to non-cataract causes. The previous national survey did not include detailed dilated-fundus assessment and visual-field examination which could have led to overestimation of cataract as a cause of blindness in India. Policy-makers in India should encourage well-designed population-based epidemiological studies from which to develop a comprehensive long-term policy on blindness in addition to dealing with cataract.	LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Hyderabad 500034, Andhra Pradesh, India; Univ Melbourne, Dept Ophthalmol, Epidemiol Res Unit, Melbourne, Vic, Australia	L. V. Prasad Eye Institute; University of Melbourne	Dandona, L (corresponding author), LV Prasad Eye Inst, Publ Hlth Ophthalmol Serv, Rd 2 Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.			Naduvilath, Thomas/0000-0001-8813-2048; McCarty, Catherine/0000-0003-1089-0142; Dandona, Rakhi/0000-0003-0926-788X				Attebo K, 1996, OPHTHALMOLOGY, V103, P357; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035; *DAN ASS NAT PROGR, 1997, RAP ASS CAT BLINDN P, P10; Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514; Dandona Lalit, 1998, Indian Journal of Ophthalmology, V46, P93; Dandona Rakhi, 1997, Indian Journal of Ophthalmology, V45, P251; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; *GOV IND DIR GEN H, 1993, PRES STAT NAT PROGR; *HUMPHR INSTR INC, 1974, HUMPHR FIELD AN 2 US; *INT ARM EP STUD G, 1995, OLK, V39, P367; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; MOHAN M, 1992, PRESENT STATUS NATL, P79; OLK RJ, 1993, DIABETIC RETINOPATHY, P3; PRADESH A, 1995, CENSUS INDIA 1991; *REG GEN CENS COMM, 1992, CENS IND 1991 FIN PO; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; SCHEIE HG, 1957, ARCH OPHTHALMOL-CHIC, V58, P510, DOI 10.1001/archopht.1957.00940010526005; SHAFFER R N, 1960, Trans Am Acad Ophthalmol Otolaryngol, V64, P112; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Taylor H, 1988, LENS RES, V5, P175; Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0; *WHO, 1973, INT STAT CLASS DIS R, V518, P10; 1994, HDB STAT HYDERABAD D	27	115	119	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1312	1316		10.1016/S0140-6736(97)09509-3	http://dx.doi.org/10.1016/S0140-6736(97)09509-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643793				2022-12-01	WOS:000073439400008
J	Grant, RM; Abrams, DI				Grant, RM; Abrams, DI			Not all is dead in HIV-1 graveyard	LANCET			English	Editorial Material							LYMPHOCYTES		Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; Univ Calif San Francisco, AIDS Program, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Grant, RM (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.			Grant, Robert/0000-0002-0851-7085				Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 31	1998	351	9099					308	309		10.1016/S0140-6736(05)78343-4	http://dx.doi.org/10.1016/S0140-6736(05)78343-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV794	9652607				2022-12-01	WOS:000071864000005
J	Boutros, M; Paricio, N; Strutt, DI; Mlodzik, M				Boutros, M; Paricio, N; Strutt, DI; Mlodzik, M			Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling	CELL			English	Article							TISSUE POLARITY; DROSOPHILA EYE; BETA-CATENIN; IN-VIVO; PROTEIN; GENE; WNT; XENOPUS; EMBRYOGENESIS; CONSERVATION	Frizzled family proteins have been described as receptors of Wnt signaling molecules. In Drosophila, the two known Frizzled proteins are associated with distinct developmental processes. Genesis of epithelial planar polarity requires Frizzled, whereas Dfz2 affects morphogenesis by wingless-mediated signaling. Dishevelled is required in both signaling pathways. Here, we use genetic and overexpression assays to show that Dishevelled activates JNK cascades. Rescue analysis reveals different protein domain requirements in Dishevelled far the two pathways; the C-terminal DEP domain is essential to rescue planar polarity defects and induce JNK signaling. Furthermore, the planar polarity-specific dsh(1) allele is mutated in the DEP domain. Our results indicate that different Wnt/Fz signals activate distinct intracellular pathways, and Dishevelled discriminates among them by distinct domain interactions.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mlodzik, M (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Paricio, Nuria/K-2184-2014; Strutt, David/E-6196-2010; Boutros, Michael/C-3566-2008	Paricio, Nuria/0000-0001-7193-2532; Strutt, David/0000-0001-8185-4515; Boutros, Michael/0000-0002-9458-817X				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1994, GENETICS, V137, P1; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; AXELROD JD, 1998, IN PRESS GENES DEV; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Fahmy O. G., 1959, DIS, V33, P83; Fehon RG, 1997, GENETICS, V146, P245; GUBB D, 1993, DEVELOPMENT, P269; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MOON RT, 1993, DEVELOPMENT, V119, P97; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; XU T, 1993, DEVELOPMENT, V117, P1223; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZHENG L, 1995, DEVELOPMENT, V121, P3045; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	61	651	658	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 10	1998	94	1					109	118		10.1016/S0092-8674(00)81226-X	http://dx.doi.org/10.1016/S0092-8674(00)81226-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674432	Bronze			2022-12-01	WOS:000074790800014
J	Kortemme, T; Ramirez-Alvarado, M; Serrano, L				Kortemme, T; Ramirez-Alvarado, M; Serrano, L			Design of a 20-amino acid, three-stranded beta-sheet protein	SCIENCE			English	Article							SIDE-CHAIN INTERACTIONS; NMR-SPECTROSCOPY; HELICAL PROTEIN; AMINO-ACIDS; QUANTUM NMR; CONFORMATION; POLYPEPTIDE; SEQUENCE; PEPTIDE; VALUES	20-residue protein (named Betanova) forming a monomeric, three-stranded, antiparallel beta sheet was designed using a structural backbone template and an iterative hierarchical approach. Structural and physicochemical characterization show that the beta-sheet conformation is stabilized by specific tertiary interactions and that the protein exhibits a cooperative two-state folding-unfolding transition, which is a hallmark of natural proteins. The Betanova molecule constitutes a tractable model system to aid in the understanding of beta-sheet formation, including beta-sheet aggregation and amyloid fibril formation.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Kortemme, T (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Kortemme@EMBL-Heidelberg.DE; Ramirez@EMBL-Heidelberg.DE	Serrano, Luis/B-3355-2013	Serrano, Luis/0000-0002-5276-1392; Ramirez-Alvarado, Marina/0000-0003-2325-6773; Kortemme, Tanja/0000-0002-8494-680X				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; Dahiyat BI, 1997, J MOL BIOL, V273, P789, DOI 10.1006/jmbi.1997.1341; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; deAlba E, 1996, FOLD DES, V1, P133, DOI 10.1016/S1359-0278(96)00022-3; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; Ilyina E, 1997, BIOCHEMISTRY-US, V36, P5245, DOI 10.1021/bi963064o; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jones DT, 1996, PROTEINS, V24, P502, DOI 10.1002/(SICI)1097-0134(199604)24:4<502::AID-PROT9>3.0.CO;2-F; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; KORTEMMA T, UNPUB; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MACIAS MJ, COMMUNICATION; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prieto J, 1997, J MOL BIOL, V268, P760, DOI 10.1006/jmbi.1997.0984; RamirezAlvarado M, 1997, J MOL BIOL, V273, P898, DOI 10.1006/jmbi.1997.1347; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; RAMIREZALVARADO M, UNPUB; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; Schenck HL, 1998, J AM CHEM SOC, V120, P4869, DOI 10.1021/ja973984+; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; STONEHOUSE J, 1995, J MAGN RESON SER A, V112, P43, DOI 10.1006/jmra.1995.1008; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205; Wuthrich K., 1986, NMR PROTEINS NUCL AC	46	296	306	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1998	281	5374					253	256		10.1126/science.281.5374.253	http://dx.doi.org/10.1126/science.281.5374.253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657719				2022-12-01	WOS:000074714200048
J	Sun, ZX; Hsiao, J; Fay, DS; Stern, DF				Sun, ZX; Hsiao, J; Fay, DS; Stern, DF			Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint	SCIENCE			English	Article							CELL-CYCLE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEIN-KINASE; BUDDING YEAST; REPLICATION; MITOSIS; GENE; TRANSCRIPTION; THREONINE	The Rad53 protein kinase of Saccharomyces cerevisiae is required for checkpoints that prevent cell division in cells with damaged or incompletely replicated DNA, The Rad9 protein was phosphorylated in response to DNA damage, and phosphorylated Rad9 interacted with the COOH-terminal forkhead homology-associated (FHA) domain of Rad53, Inactivation of this domain abolished DNA damage-dependent Rad53 phosphorylation, G(2)/M cell cycle phase arrest, and increase of RNR3 transcription but did not affect replication inhibition-dependent Rad53 phosphorylation, Thus, Rad53 integrates DNA damage signals by coupling with phosphorylated Rad9, The hitherto uncharacterized FHA domain appears to be a modular protein-binding domain.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Dept Biol, New Haven, CT 06511 USA	Yale University; Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,Room BML 342, New Haven, CT 06520 USA.	Stern@biomed.med.yale.edu						ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; EMILI A, IN PRESS MOL CELL; Fay DS, 1997, CURR GENET, V31, P97, DOI 10.1007/s002940050181; GARDNER R, UNPUB; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; REYNOLDS A, 1991, CURRENT PROTOCOLS MO, V2; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sun Z., UNPUB; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	30	323	331	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					272	274		10.1126/science.281.5374.272	http://dx.doi.org/10.1126/science.281.5374.272			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657725				2022-12-01	WOS:000074714200054
J	Ahmed, Y; Hayashi, S; Levine, A; Wieschaus, E				Ahmed, Y; Hayashi, S; Levine, A; Wieschaus, E			Regulation of armadillo by a Drosophila APC inhibits neuronal apoptosis during retinal development	CELL			English	Article							SEGMENT POLARITY GENE; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; CELL-DEATH; PIGMENT EPITHELIUM; CONGENITAL HYPERTROPHY; MOLECULAR ANALYSIS; GARDNERS-SYNDROME; 4TH CHROMOSOME	We find that inactivation of a Drosophila homolog of the tumor suppressor APC (D-APC) causes retinal neuronal degeneration and pigment cell hypertrophy, a phenotype remarkably similar to that found in humans with germline APC mutations. Retinal degeneration in the D-APC mutant results from apoptotic cell death, which accompanies a defect in neuronal differentiation. Reduction in the Drosophila beta-catenin, Armadillo (Arm), rescues the differentiation defect and prevents apoptosis in the D-APC mutant, while Arm overexpression mimics D-APC inactivation. A mutation in dTCF, the DNA-binding protein required in Arm-mediated signal transduction, can eliminate the cell death without rescuing the differentiation defect in D-APC mutants. Uncoupling of these two Arm-induced processes suggests a novel role for the Arm/dTCF complex in the activation of apoptosis.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA	Princeton University; Howard Hughes Medical Institute; Princeton University	Wieschaus, E (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; BUETTNER H, 1975, AM J OPHTHALMOL, V79, P177, DOI 10.1016/0002-9394(75)90069-0; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLIFFORD RJ, 1989, GENETICS, V123, P771; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LOCKE J, 1994, MOL GEN GENET, V243, P234, DOI 10.1007/BF00280321; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reddy GV, 1997, DEVELOPMENT, V124, P703; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; STEITZ MC, 1998, IN PRESS DEV BIOL, V197; STRATER J, 1995, GUT, V37, P819, DOI 10.1136/gut.37.6.819; SUGIYAMA H, 1994, J FOOD HYG SOC JPN, V35, P13, DOI 10.3358/shokueishi.35.13; TRABOULSI EI, 1990, ARCH OPHTHALMOL-CHIC, V108, P525, DOI 10.1001/archopht.1990.01070060073052; TRABOULSI EI, 1990, AM J OPHTHALMOL, V110, P550, DOI 10.1016/S0002-9394(14)77880-8; TZEPACZ C, 1997, J BIOL CHEM, V272, P21681; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WOLFF T, 1991, DEVELOPMENT, V113, P825; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	58	193	196	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1171	1182		10.1016/S0092-8674(00)81461-0	http://dx.doi.org/10.1016/S0092-8674(00)81461-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657150	Bronze			2022-12-01	WOS:000074491100012
J	Ciosk, R; Zachariae, W; Michaelis, C; Shevchenko, A; Mann, M; Nasmyth, K				Ciosk, R; Zachariae, W; Michaelis, C; Shevchenko, A; Mann, M; Nasmyth, K			An ESP1/PDS1 complex regulates loss of sister chromatid cohesion at the metaphase to anaphase transition in yeast	CELL			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DNA-REPLICATION; FISSION YEAST; POLYACRYLAMIDE GELS; NUCLEAR DIVISION; S-PHASE; MITOSIS; CYCLIN	Cohesion between sister chromatids during G2 and M phases depends on the "cohesin" protein Scc1p (Mcd1p). Loss of cohesion at the metaphase to anaphase transition is accompanied by Scc1p's dissociation from chromatids, which depends on proteolysis of Pds1p mediated by a ubiquitin protein ligase called the anaphase promoting complex (APC). We show that destruction of Pds1p is the APC's sole role in triggering Scc1p's dissociation from chromatids and that Pds1p forms a stable complex with a 180 kDa protein called Esp1p, which is essential for the dissociation of Scc1p from sister chromatids and for their separation. We propose that the APC promotes sister separation not by destroying cohesins but instead by liberating the "sister-separating" Esp1 protein from its inhibitor Pds1p.	Res Inst Mol Pathol, A-1030 Vienna, Austria; European Mol Biol Lab, D-69012 Heidelberg, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); European Molecular Biology Laboratory (EMBL)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Ciosk, Rafal/L-7327-2013; Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Ciosk, Rafal/0000-0003-2234-6216; Nasmyth, Kim/0000-0001-7030-4403				BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LIANG H, 1993, EXP CELL RES, V204, P110, DOI 10.1006/excr.1993.1015; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MICHAELIS C, 1997, CELL, V91, P32; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rose M, 1990, LAB COURSE MANUAL ME; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM M, 1996, ANAL CHEM, V66, P1; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	42	504	519	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1067	1076		10.1016/S0092-8674(00)81211-8	http://dx.doi.org/10.1016/S0092-8674(00)81211-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635435	Bronze			2022-12-01	WOS:000074205700017
J	Mullins, RJ; Mann, NC; Hedges, JR; Worrall, W; Helfand, M; Zechnich, AD; Jurkovich, GJ				Mullins, RJ; Mann, NC; Hedges, JR; Worrall, W; Helfand, M; Zechnich, AD; Jurkovich, GJ			Adequacy of hospital discharge status as a measure of outcome among injured patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 18-22, 1997	WASHINGTON, D.C.	Soc Acad Emergency Med			TRAUMA SYSTEM; MAJOR TRAUMA; MORTALITY; DEATH; CARE; COMORBIDITIES; INSTITUTION; DATABASES; ACCURACY; BIAS	Context.-Crude mortality rates at the time of hospital discharge are commonly used to assess the quality of care provided to patients hospitalized following trauma. Objectives.-To evaluate the adequacy of hospital death rates as an outcome measure following trauma and to determine the influence of noninjury illness as a cause of hospital death and the frequency of postdischarge death. Design.-Retrospective cohort analyses using hospital discharge data for injured patients cross-linked to death certificate data that provided 1 year of followup for all patients discharged alive. Patients.-A total of 90 048 injured patients admitted to all acute care hospitals in the state of Washington from 1991 through 1993 and discharged with at least 1 diagnosis coded in the International Classification of Diseases, Ninth Revision, Clinical Modification to indicate trauma. Main Outcome Measures.-Death in the hospital and death within 30 days of hospital discharge. Results.-Among 1912 injured patients with in-hospital deaths, 825 death certificates (43%) listed a noninjury cause of death, The overall mortality rate at hospital discharge was 21.2 per 100 000 hospitalized injured patients, and was 12.1 per 100 000 for trauma deaths and 9.1 per 100 000 for those designated as nontrauma deaths. Patients with trauma-related death designations were younger (mean age, 51.5 years vs 77.9 years), had shorter lengths of stay (median stay, 2 days vs 5 days), and sustained more severe injures (P<.001). Including the 1273 deaths that occurred within 30 days of hospital discharge increased rates for trauma-designated deaths to 14.1 per 100 000 and increased rates for nontrauma-designated deaths to 21.3 per 100 000. Conclusions.-Hospital discharge death rates are incomplete measures of death frequency for injured patients. Designation of the cause of death, especially among older, hospitalized, injured patients often reflects preexisting medical conditions. Adequate assessment of mortality following trauma requires measurement of the frequency of death following hospital discharge.	Oregon Hlth & Sci Univ, Sch Med, Dept Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Med, Div Hlth Informat & Outcomes Res, Portland, OR 97201 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle	Mullins, RJ (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Surg, L223A,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	mullinsr@ohsu.edu	Hedges, Jerris/AAC-1847-2021		PHS HHS [R49/CCR-006283] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RN, 1997, MON VITAL STAT REP, V45, P17; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DEYO RA, 1994, SPINE, V19, pS2083; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GARNICK DW, 1995, HEALTH SERV RES, V29, P679; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; JONES DR, 1982, INT J EPIDEMIOL, V11, P276, DOI 10.1093/ije/11.3.276; JONES JM, 1995, J TRAUMA, V38, P123, DOI 10.1097/00005373-199501000-00029; Kleinbaum D, 1996, SURVIVAL ANAL SELF L; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; MULLINS RJ, 1995, J TRAUMA, V39, P941, DOI 10.1097/00005373-199511000-00020; NORUSIS MJ, 1996, SPSS VERSION 6 01 WI; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; POLLOCK DA, 1993, JAMA-J AM MED ASSOC, V269, P1525, DOI 10.1001/jama.269.12.1525; ROMANO PS, 1992, AM J EPIDEMIOL, V136, P863, DOI 10.1093/aje/136.7.863; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; Winer B.J., 1971, STAT PRINCIPLES EXPT	25	101	101	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1727	1731		10.1001/jama.279.21.1727	http://dx.doi.org/10.1001/jama.279.21.1727			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZQ544	9624026	Bronze			2022-12-01	WOS:000073878700034
J	Mason, AL; Xu, LZ; Guo, LS; Munoz, S; Jaspan, JB; Bryer-Ash, M; Cao, Y; Sander, DM; Shoenfeld, Y; Ahmed, A; Van de Water, J; Gershwin, ME; Garry, RF				Mason, AL; Xu, LZ; Guo, LS; Munoz, S; Jaspan, JB; Bryer-Ash, M; Cao, Y; Sander, DM; Shoenfeld, Y; Ahmed, A; Van de Water, J; Gershwin, ME; Garry, RF			Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; HEPATITIS-C VIRUS; LIVER-TRANSPLANTATION; SJOGRENS-SYNDROME; GRAVES-DISEASE; AUTOANTIBODIES; RECURRENCE; PROTEINS; PARTICLE	Background Retroviruses have been implicated in the aetiology of various autoimmune diseases. We used immunoblots as a surrogate test to find out whether retroviruses play a part in the development of primary biliary cirrhosis. Methods We did western blot tests for HIV-1 and the human intracisternal A-type particle (HIAP), on serum samples from 77 patients with primary biliary cirrhosis, 126 patients with chronic liver disease, 48 patients with systemic lupus erythematosus, and 25 healthy volunteers. Findings HIV-1 p24 gag seroreactivity was found in 27 (35%) of 77 patients with primary biliary cirrhosis, 14 (29%) of 48 patients with systemic lupus erythematosus, 14 (50%) of 28 patients with chronic viral hepatitis, and nine (39%) of 23 patients with either primary sclerosing cholangitis or biliary atresia, compared with only one (4%) of 24 patients with alcohol-related liver disease or alpha(1)-antitrypsin-deficiency liver disease, and only one (4%) of 25 healthy volunteers (p=0.003). Western blot reactivity to more than two HIAP proteins was found in 37 (51%) of patients with primary biliary cirrhosis, in 28 (58%) of patients with systemic lupus erythematosus, in 15 (20%) of patients with chronic viral hepatitis, and in four (17%) of those with other biliary diseases. None of the 23 patients with either alcohol-related liver disease or alpha(1)-antitrypsin deficiency, and only one of the healthy controls showed the same reactivity to HIAP proteins (p<0.0001). Our results showed a strong association between HIAP seroreactivity and the detection of autoantibodies to double-stranded DNA. HIAP seroreactivity was also strongly associated with the detection of mitochondrial, nuclear, and extractable nuclear antigens. Interpretation The HIV-1 and HIAP antibody reactivity found in patients with primary biliary cirrhosis and other biliary disorders may be attributable either to an autoimmune response to antigenically related cellular proteins or to an immune response to uncharacterised viral proteins that share antigenic determinants with these retroviruses.	Alton Ochsner Med Fdn & Ochsner Clin, Sect Gastroenterol & Hepatol, New Orleans, LA 70121 USA; Albert Einstein Med Ctr, Ctr Liver Dis, Philadelphia, PA 19141 USA; Tulane Univ, Med Ctr, Sch Med, Dept Med, New Orleans, LA USA; Tulane Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, New Orleans, LA USA; Univ Tennessee, Coll Med, Dept Med, Memphis, TN USA; Chaim Sheba Med Ctr, Dept Med B, Autoimmune Dis Res Unit, IL-52621 Tel Hashomer, Israel; Specialty Labs Inc, Santa Monica, CA USA; Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA USA	Ochsner Health System; Yeshiva University; Tulane University; Tulane University; University of Tennessee System; University of Tennessee Health Science Center; Chaim Sheba Medical Center; University of California System; University of California Davis	Mason, AL (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Richard Freeman Res Inst, 1520 Jefferson Highway, New Orleans, LA 70121 USA.		Mason, Andrew/D-2938-2013	Mason, Andrew/0000-0002-0470-9522; Garry, Robert/0000-0002-5683-3250	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039588, R01DK039588] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10862-03] Funding Source: Medline; NIDDK NIH HHS [DK39588] Funding Source: Medline; PHS HHS [A101467-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKA N, 1995, CLIN DIAGN LAB IMMUN, V2, P469, DOI 10.1128/CDLI.2.4.469-472.1995; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHA S, 1993, P NATL ACAD SCI USA, V90, P2527, DOI 10.1073/pnas.90.6.2527; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; DORNER T, 1994, SCAND J GASTROENTERO, V29, P655, DOI 10.3109/00365529409092488; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GARRY RF, 1995, RETROVIRUSES THEIR R; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; Jaspan JB, 1996, J CLIN ENDOCR METAB, V81, P2271, DOI 10.1210/jc.81.6.2271; JASPAN JB, 1995, AUTOIMMUNITY, V20, P135, DOI 10.3109/08916939509001938; KONIKOFF F, 1989, HEPATO-GASTROENTEROL, V36, P341; MUNOZ SJ, 1988, GASTROENTEROLOGY, V94, pA574; NEUBERGER J, 1982, NEW ENGL J MED, V306, P1, DOI 10.1056/NEJM198201073060101; Perron H, 1997, P NATL ACAD SCI USA, V94, P7583, DOI 10.1073/pnas.94.14.7583; PIRISI M, 1994, SCAND J GASTROENTERO, V29, P942; RODRIGUEZCUARTERO A, 1994, INFECTION, V22, P415, DOI 10.1007/BF01715500; Sherlock S, 1993, PRIMARY BILIARY CIRR; SWAAK T, 1985, ANN RHEUM DIS, V44, P245, DOI 10.1136/ard.44.4.245; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; TALAL N, 1990, ARTHRITIS RHEUM, V33, P741; VANDEWATER J, 1989, NEW ENGL J MED, V320, P1377, DOI 10.1056/NEJM198905253202104; VandeWater J, 1996, HEPATOLOGY, V24, P1079	22	125	129	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1620	1624		10.1016/S0140-6736(97)10290-2	http://dx.doi.org/10.1016/S0140-6736(97)10290-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620716				2022-12-01	WOS:000074026600009
J	Rosen, RC				Rosen, RC			Sildenafil: medical advance or media event?	LANCET			English	Editorial Material							IMPOTENCE		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rosen, RC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA.							ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Burnett AL, 1998, GERIATRICS, V53, P34; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141, DOI 10.1038/sj.ijir.3900269; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Laumann E.O., 2000, SOCIAL ORG SEXUALITY; LUE TF, 1990, WORLD J UROL, V8, P67, DOI 10.1007/BF01576350; Moreland RB, 1998, LIFE SCI, V62, pPL309, DOI 10.1016/S0024-3205(98)00158-1; Rosen RC, 1996, CLIN PSYCHOL REV, V16, P497, DOI 10.1016/0272-7358(96)00032-3; TAUB HC, 1993, UROLOGY, V42, P698, DOI 10.1016/0090-4295(93)90538-L	12	28	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1998	351	9116					1599	1600		10.1016/S0140-6736(05)77682-0	http://dx.doi.org/10.1016/S0140-6736(05)77682-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620710				2022-12-01	WOS:000074026600003
J	Peet, DJ; Turley, SD; Ma, WZ; Janowski, BA; Lobaccaro, JMA; Hammer, RE; Mangelsdorf, DJ				Peet, DJ; Turley, SD; Ma, WZ; Janowski, BA; Lobaccaro, JMA; Hammer, RE; Mangelsdorf, DJ			Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; 7-ALPHA-HYDROXYLASE GENE; HYPERCHOLESTEROLEMIA; BIOSYNTHESIS; PATHWAY; LIVER; FLUX; DIFFERENTIATION; SUPERFAMILY; ACTIVATION	We demonstrate that mice lacking the oxysterol receptor, LXR alpha, lose their ability to respond normally to dietary cholesterol and are unable to tolerate any amount of cholesterol in excess of that which they synthesize de novo. When fed diets containing cholesterol, LXR alpha (-/-) mice fair to induce transcription of the gene encoding cholesterol 7 alpha-hydroxylase (Cyp7a), the rate-limiting enzyme in bile acid synthesis. This defect is associated with a rapid accumulation of large amounts of cholesterol in the liver that eventually leads to impaired hepatic function. The regulation of several other crucial lipid metabolizing genes is also altered in LXR alpha (-/-) mice. These results demonstrate the existence of a physiologically significant feed-forward regulatory pathway for sterol metabolism and establish the role of LXR alpha as the major sensor of dietary cholesterol.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.		Peet, Daniel/AAE-6698-2020; Lobaccaro, Jean-Marc A./U-1928-2019; Lobaccaro, Jean-Marc/Q-3926-2019	Peet, Daniel/0000-0002-6085-8936; Lobaccaro, Jean-Marc/0000-0001-9890-2392; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL009610, R01HL009610] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYOSHI T, 1986, J LIPID RES, V27, P915; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUCOLO G, 1973, CLIN CHEM, V19, P476; Carey Martin C., 1994, P719; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; COHEN BI, 1977, J LIPID RES, V18, P223; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LAVY U, 1977, J LIPID RES, V18, P232; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SHEFER S, 1991, J BIOL CHEM, V266, P2693; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Turley SD, 1997, HEPATOLOGY, V25, P797, DOI 10.1002/hep.510250403; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; UCHIDA K, 1980, J BIOCHEM, V87, P187, DOI 10.1093/oxfordjournals.jbchem.a132724; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILLY PJ, 1998, HORMONES SIGNALING, V1, P307; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	43	1196	1275	1	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					693	704		10.1016/S0092-8674(00)81432-4	http://dx.doi.org/10.1016/S0092-8674(00)81432-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630215	Bronze			2022-12-01	WOS:000073956700007
J	Brown, P				Brown, P			BSE: the final resting place	LANCET			English	Editorial Material							SURVIVAL; VARIANT		NINDS, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINDS, Cent Nervous Syst Studies Lab, Bethesda, MD 20892 USA.							BROWN P, 1990, J INFECT DIS, V161, P467, DOI 10.1093/infdis/161.3.467; BROWN P, 1991, LANCET, V337, P269, DOI 10.1016/0140-6736(91)90873-N; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Palsson P. A., 1979, Slow transmissible diseases of the nervous system. Volume 1., P357; Scrimgeour EM, 1996, VET REC, V139, P219; Taylor David M., 1996, P105; Wells GAH, 1998, VET REC, V142, P103, DOI 10.1136/vr.142.5.103; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	10	19	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1146	1147		10.1016/S0140-6736(05)79115-7	http://dx.doi.org/10.1016/S0140-6736(05)79115-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643681				2022-12-01	WOS:000073220200003
J	Gray, NS; Wodicka, L; Thunnissen, AMWH; Norman, TC; Kwon, SJ; Espinoza, FH; Morgan, DO; Barnes, G; LeClerc, S; Meijer, L; Kim, SH; Lockhart, DJ; Schultz, PG				Gray, NS; Wodicka, L; Thunnissen, AMWH; Norman, TC; Kwon, SJ; Espinoza, FH; Morgan, DO; Barnes, G; LeClerc, S; Meijer, L; Kim, SH; Lockhart, DJ; Schultz, PG			Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors	SCIENCE			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; GENE-EXPRESSION; YEAST; TRANSCRIPTION; PROTEIN; ANALOGS	Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the adenosine triphosphate- binding site of the human cyclin-dependent kinase 2 (CDK2). By iterating chemical Library synthesis and biological screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified. The structural basis for the binding affinity and selectivity was determined by analysis of a three-dimensional crystal structure of a CDK2-inhibitor complex. The cellular effects of these compounds were characterized in mammalian cells and yeast. In the Latter case the effects were characterized on a genome-wide scale by monitoring changes in messenger RNA Levels in treated cells with high-density oligonucleotide probe arrays. Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may Lead to the development of new therapeutics.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Affymetrix, Santa Clara, CA 95051 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; CNRS, Biol Stn, F-29682 Roscoff, France	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Affymetrix; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS)	Schultz, PG (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Thunnissen, Andy-Mark/A-1777-2010; MEIJER, Laurent/ABE-7465-2021	Thunnissen, Andy-Mark/0000-0002-1915-9850; , laurent/0000-0003-3511-4916; Morgan, David/0000-0001-8753-4416				ANDREWS B, 1997, MOL CELL BIOL, V17, P1212; BACKES BJ, 1994, J AM CHEM SOC, V116, P11171, DOI 10.1021/ja00103a048; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; Gray NS, 1997, TETRAHEDRON LETT, V38, P1161, DOI 10.1016/S0040-4039(97)00014-2; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/0968-0004(96)10048-7; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Norman TC, 1996, J AM CHEM SOC, V118, P7430, DOI 10.1021/ja9614934; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Timblin BK, 1997, MOL MICROBIOL, V26, P981, DOI 10.1046/j.1365-2958.1997.6352004.x; Timblin BK, 1996, GENETICS, V143, P57; TOYOTA A, 1993, HETEROCYCLES, V36, P1625, DOI 10.3987/COM-93-6371; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wahl MC, 1997, TRENDS BIOCHEM SCI, V22, P97, DOI 10.1016/S0968-0004(97)01004-9; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; 1368002	30	783	844	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					533	538		10.1126/science.281.5376.533	http://dx.doi.org/10.1126/science.281.5376.533			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677190	Green Submitted			2022-12-01	WOS:000075012300032
J	Caraballo, RS; Giovino, GA; Pechacek, TF; Mowery, PD; Richter, PA; Strauss, WJ; Sharp, DJ; Eriksen, MP; Pirkle, JL; Maurer, KR				Caraballo, RS; Giovino, GA; Pechacek, TF; Mowery, PD; Richter, PA; Strauss, WJ; Sharp, DJ; Eriksen, MP; Pirkle, JL; Maurer, KR			Racial and ethnic differences in serum cotinine levels of cigarette smokers - Third National Health and Nutrition Examination Survey, 1988-1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; NONMENTHOL CIGARETTES; WHITE SMOKERS; YOUNG-ADULTS; SELF-REPORT; NICOTINE; EXPOSURE; MENTHOL; METABOLISM; CHILDREN	Context.-Cotinine, a metabolite of nicotine, is a marker of exposure to tobacco smoke. Previous studies suggest that non-Hispanic blacks have higher levels of serum cotinine than non-Hispanic whites who report similar levels of cigarette smoking. Objective.-To investigate differences in levels of serum cotinine in black, white, and Mexican American cigarette smokers in the US adult population. Design.-Third National Health and Nutrition Examination Survey, 1988-1991. Participants.-A nationally representative sample of persons aged 17 years or older who participated in the survey. Outcome Measures.-Serum cotinine levels by reported number of cigarettes smoked per day and by race and ethnicity. Results.-A total of 7182 subjects were involved in the study; 2136 subjects reported smoking at least 1 cigarette in the last 5 days, Black smokers had cotinine concentrations substantially higher at all levels of cigarette smoking than did white or Mexican American smokers (P<.001). Serum cotinine levels for blacks were 125 nmol/L (22 ng/mL) (95% confidence interval [CI], 79-176 nmol/L. [14-31 ng/mL]) to 539 nmol/L (95 ng/mL) (95% CI, 289-630 nmol/L [51-111 ng/mL]) higher than for whites and 136 nmol/L (24 ng/mL) (95% CI, 85-182 nmol/L [15-32 ng/mL]) to 641 nmol/L (113 ng/mL) (95% CI, 386-897 nmol/L [68-158 ng/mL]I) higher than for Mexican Americans, These differences do not appear to be attributable to differences in environmental tobacco smoke exposure or in number of cigarettes smoked. Conclusions.-To our knowledge, this study provides the first evidence from a national study that serum cotinine levels are higher among black smokers than among white or Mexican American smokers. If higher cotinine levels among blacks indicate higher nicotine intake or differential pharmacokinetics and possibly serve as a marker of higher exposure to cigarette carcinogenic components, they may help explain why blacks find it harder to quit and are more likely to experience higher rates of lung cancer than white smokers.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Battelle Mem Inst, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Bethesda, MD USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Caraballo, RS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, 4770 Buford Hwy NE, Atlanta, GA 30341 USA.							Ahijevych K, 1996, PHARMACOL BIOCHEM BE, V53, P355, DOI 10.1016/0091-3057(95)02034-9; ARMITAGE AK, 1975, BRIT MED J, V4, P313, DOI 10.1136/bmj.4.5992.313; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; BENOWITZ NL, 1994, J PHARMACOL EXP THER, V268, P296; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; Bernert JT, 1997, CLIN CHEM, V43, P2281; CASKEY NH, 1993, PHARMACOL BIOCHEM BE, V46, P259, DOI 10.1016/0091-3057(93)90350-3; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P671; Centers for Disease Control and Prevention (CDC), 1993, MMWR-MORBID MORTAL W, V42, P504; Clark PI, 1996, ANN EPIDEMIOL, V6, P483, DOI 10.1016/S1047-2797(96)00049-X; Clark PI, 1996, CHEST, V110, P1194, DOI 10.1378/chest.110.5.1194; COULTAS DB, 1988, AM REV RESPIR DIS, V137, P810, DOI 10.1164/ajrccm/137.4.810; CRAWFORD FG, 1994, J NATL CANCER I, V86, P1398, DOI 10.1093/jnci/86.18.1398; ENGLISH PB, 1994, AM J PUBLIC HEALTH, V84, P1439, DOI 10.2105/AJPH.84.9.1439; HENNINGFIELD JE, 1990, AM J PUBLIC HEALTH, V80, P1040, DOI 10.2105/AJPH.80.9.1040; HERNING RI, 1983, CLIN PHARMACOL THER, V33, P84, DOI 10.1038/clpt.1983.12; ISAAC PF, 1972, NATURE, V236, P308, DOI 10.1038/236308a0; JARVIK ME, 1994, PHYSIOL BEHAV, V56, P563, DOI 10.1016/0031-9384(94)90302-6; Knight JM, 1996, CHEST, V109, P446, DOI 10.1378/chest.109.2.446; LEADERER BP, 1991, ENVIRON SCI TECHNOL, V25, P770, DOI 10.1021/es00016a023; MCCARTHY WJ, 1992, AM J PUBLIC HEALTH, V82, P1171, DOI 10.2105/AJPH.82.8.1171; MCCARTHY WJ, 1995, AM J PUBLIC HEALTH, V85, P67, DOI 10.2105/AJPH.85.1.67; Miller BA, 1996, NIH PUBLICATION, V96-4104; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; PEREZSTABLE EJ, 1995, PREV MED, V24, P171, DOI 10.1006/pmed.1995.1031; PEREZSTABLE EJ, 1990, AM J PUBLIC HEALTH, V80, P1057, DOI 10.2105/AJPH.80.9.1057; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; SHAH BV, 1995, SOFTWARE SURVEY DATA; TURNER JAM, 1977, BMJ-BRIT MED J, V2, P1387, DOI 10.1136/bmj.2.6099.1387; *US DEP HHS, 1989, RED HLTH CONS SMOK 2; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; WAGENKNECHT LE, 1990, AM J PUBLIC HEALTH, V80, P1053, DOI 10.2105/AJPH.80.9.1053; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; Wagenknecht LE, 1992, AM J PUBLIC HEALTH, V82, P1173	37	374	375	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					135	139		10.1001/jama.280.2.135	http://dx.doi.org/10.1001/jama.280.2.135			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669785				2022-12-01	WOS:000074608400027
J	Koltover, I; Salditt, T; Radler, JO; Safinya, CR				Koltover, I; Salditt, T; Radler, JO; Safinya, CR			An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery	SCIENCE			English	Article							GENE-TRANSFER; EXPRESSION; MEMBRANES; SERIES	A two-dimensional columnar phase in mixtures of DNA complexed with cationic liposomes has been found in the Lipid composition regime known to be significantly more efficient at transfecting mammalian cells in culture compared to the lamellar (L-alpha(subset of)) structure of cationic liposome-DNA complexes. The structure, derived from synchrotron x-ray diffraction, consists of DNA coated by cationic lipid monolayers and arranged on a two-dimensional hexagonal lattice (H-parallel to(subset of)). Two membrane-altering pathways induce the L-alpha(subset of) --> H-parallel to(subset of) transition: one where the spontaneous curvature of the Lipid monolayer is driven negative, and another where the membrane bending rigidity is lowered with a new class of helper-lipids. Optical microscopy revealed that the L-alpha(subset of) complexes bind stably to anionic vesicles (models of cellular membranes), whereas the more transfectant H-parallel to(subset of) complexes are unstable and rapidly fuse and release DNA upon adhering to anionic vesicles.	Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Biochem & Mol Biol Program, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Safinya, CR (corresponding author), Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA.		Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489				BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Dan N, 1998, BBA-BIOMEMBRANES, V1369, P34, DOI 10.1016/S0005-2736(97)00171-5; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; Felgner PL, 1997, SCI AM, V276, P102, DOI 10.1038/scientificamerican0697-102; Friedmann T, 1997, SCI AM, V276, P96; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; GUTTMAN GD, 1993, J PHYS II, V3, P1411, DOI 10.1051/jp2:1993210; HARRINGTON JJ, 1997, NAT GENET, V15, P21994; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; KOLTOVER I, UNPUB; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LIN AL, UNPUB; May S, 1997, BIOPHYS J, V73, P2427, DOI 10.1016/S0006-3495(97)78271-7; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; Roush W, 1997, SCIENCE, V276, P38, DOI 10.1126/science.276.5309.38; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; Salditt T, 1997, PHYS REV LETT, V79, P2582, DOI 10.1103/PhysRevLett.79.2582; SEDDON JM, 1989, BIOCHIM BIOPHYS ACTA, V1031, P1; SZLEIFER I, 1988, PHYS REV LETT, V60, P1966, DOI 10.1103/PhysRevLett.60.1966; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	27	1116	1152	11	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					78	81		10.1126/science.281.5373.78	http://dx.doi.org/10.1126/science.281.5373.78			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651248				2022-12-01	WOS:000074685800040
J	Venn, A; Lewis, S; Cooper, M; Hill, J; Britton, J				Venn, A; Lewis, S; Cooper, M; Hill, J; Britton, J			Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Venn, A (corresponding author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.		Britton, John R/G-9705-2011					ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; LUYT DK, 1993, BMJ-BRIT MED J, V306, P1386, DOI 10.1136/bmj.306.6889.1386; SCHACHTER J, 1976, J ALLERGY CLIN IMMUN, V57, P342, DOI 10.1016/0091-6749(76)90091-9; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368	5	78	80	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1998	316	7149					1945	1946		10.1136/bmj.316.7149.1945	http://dx.doi.org/10.1136/bmj.316.7149.1945			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY568	9641931	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000074636700026
J	Neufeld, TP; de la Cruz, AFA; Johnston, LA; Edgar, BA				Neufeld, TP; de la Cruz, AFA; Johnston, LA; Edgar, BA			Coordination of growth and cell division in the Drosophila wing	CELL			English	Article							GENETIC-CONTROL; CYCLIN-E; S-PHASE; TRANSLATION INITIATION; RETINOBLASTOMA PROTEIN; DEVELOPMENTAL CONTROL; EXPRESSION; PROLIFERATION; YEAST; G(1)	In most tissues, cell division is coordinated with increases in mass (i.e., growth). To understand this coordination, we altered rates of division in cell clones or compartments of the Drosophila wing and measured the effects on growth. Constitutive overproduction of the transcriptional regulator dE2F increased expression of the S- and M-phase initiators Cyclin E and String (Cdc25), thereby accelerating cell proliferation. Loss of dE2F or overproduction of its corepressor, RBF, retarded cell proliferation. These manipulations altered cell numbers over a 4- to 5-fold range but had little effect on clone or compartment sizes. Instead, changes in cell division rates were offset by changes in cell size. We infer that dE2F and RBF function specifically in cell cycle control, and that cell cycle acceleration is insufficient to stimulate growth. Variations in dE2F activity could be used to coordinate cell division with growth.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Edgar, BA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	Neufeld, Thomas/0000-0001-5659-4811; JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017373] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017373-04, GM51186, F32 GM017373, GM17373, F32 GM017373-03, R01 GM051186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDERSSON S, 1994, GENETICS, V137, P513; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; Bryant PJ, 1996, BIOESSAYS, V18, P781, DOI 10.1002/bies.950181003; Burke R, 1996, DEVELOPMENT, V122, P2261; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GONZALEZGAITAN M, 1994, MECH DEVELOP, V46, P183, DOI 10.1016/0925-4773(94)90070-1; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON LA, 1998, IN PRESS NATURE; Karim FD, 1998, DEVELOPMENT, V125, P1; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Milan M, 1996, P NATL ACAD SCI USA, V93, P11687, DOI 10.1073/pnas.93.21.11687; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; MITCHISON JM, 1971, BIOL CELL CYCLE; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WATSON KL, 1994, J CELL SCI, P19; Weigmann K, 1997, DEVELOPMENT, V124, P3555; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	69	618	622	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1183	1193		10.1016/S0092-8674(00)81462-2	http://dx.doi.org/10.1016/S0092-8674(00)81462-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657151	Bronze			2022-12-01	WOS:000074491100013
J	Wang, ZY; Tobin, EM				Wang, ZY; Tobin, EM			Constitutive expression of the CIRCADIAN CLOCK ASSOCIATED 1 (CCA1) gene disrupts circadian rhythms and suppresses its own expression	CELL			English	Article							ARABIDOPSIS; PLANTS; PHYTOCHROME; FREQUENCY; PROTEINS; PROMOTER; INCREASE; WHEAT	The CIRCADIAN CLOCK ASSOCIATED 1 (CCA1) gene encodes a MYB-related transcription factor involved in the phytochrome induction of a light-harvesting chlorophyll alb-protein (Lhcb) gene. Expression of the CCA1 gene is transiently induced by phytochrome and oscillates with a circadian rhythm. Constitutive expression of CCA1 protein in transgenic plants abolished the circadian rhythm of several genes with dramatically different phases. These plants also had longer hypocotyls and delayed flowering, developmental processes regulated by light and the circadian clock. Furthermore, the expression of both endogenous CCA1 and the related LHY gene was suppressed. Our results suggest that CCA1 is a part of a feedback loop that is closely associated with the circadian clock in Arabidopsis.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tobin, EM (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.		Wang, Zhi-Yong/E-3810-2012; Rosa, Bruce/F-6393-2010	Wang, Zhi-Yong/0000-0003-4602-3390; 	NIGMS NIH HHS [GM-23167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson S, 1996, TRENDS PLANT SCI, V1, P51, DOI 10.1016/S1360-1385(96)80029-X; Anderson SL, 1997, PLANT CELL, V9, P1727, DOI 10.1105/tpc.9.10.1727; ANDERSON SL, 1995, P NATL ACAD SCI USA, V92, P1500, DOI 10.1073/pnas.92.5.1500; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; B?nning E., 1936, BER DEUT BOT GES, V54, P590, DOI DOI 10.1038/424033A; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; CARPENTER CD, 1994, PLANT PHYSIOL, V104, P1015, DOI 10.1104/pp.104.3.1015; Carre IA, 1995, PLANT CELL, V7, P2039, DOI 10.2307/3870149; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DAMERVAL C, 1986, ELECTROPHORESIS, V7, P52, DOI 10.1002/elps.1150070108; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Heintzen C, 1997, P NATL ACAD SCI USA, V94, P8515, DOI 10.1073/pnas.94.16.8515; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; Johnson Carl Hirschie, 1994, Seminars in Cell Biology, V5, P355, DOI 10.1006/scel.1994.1042; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KENIGSBUCH D, 1995, PLANT PHYSIOL, V108, P1023, DOI 10.1104/pp.108.3.1023; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kolar C, 1998, PLANT J, V13, P563, DOI 10.1046/j.1365-313X.1998.00048.x; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; LECHARNY A, 1984, PHYSIOL PLANTARUM, V60, P437, DOI 10.1111/j.1399-3054.1984.tb06089.x; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; MCCLUNG CR, 1994, ARABIDOPSIS THALIANA, P615; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; Millar AJ, 1997, BIOESSAYS, V19, P209, DOI 10.1002/bies.950190306; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; NAGY F, 1993, P NATL ACAD SCI USA, V90, P6290, DOI 10.1073/pnas.90.13.6290; PIECHULLA B, 1993, PLANT MOL BIOL, V22, P533, DOI 10.1007/BF00015982; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Somers DE, 1998, DEVELOPMENT, V125, P485; Stirland JA, 1996, P ROY SOC B-BIOL SCI, V263, P345, DOI 10.1098/rspb.1996.0053; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thomas B., 1996, PHOTOPERIODISM PLANT; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x; ZENG H, 1997, NATURE, V380, P129; Zhong HH, 1997, PLANT CELL, V9, P947, DOI 10.1105/tpc.9.6.947; Zhong HH, 1996, MOL GEN GENET, V251, P196	45	738	793	5	124	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1207	1217		10.1016/S0092-8674(00)81464-6	http://dx.doi.org/10.1016/S0092-8674(00)81464-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657153	Bronze			2022-12-01	WOS:000074491100015
J	Goedert, JJ; Cote, TR; Virgo, P; Scoppa, SM; Kingma, DW; Gail, MH; Jaffe, ES; Biggar, RJ				Goedert, JJ; Cote, TR; Virgo, P; Scoppa, SM; Kingma, DW; Gail, MH; Jaffe, ES; Biggar, RJ		AIDS-Canc Match Study Grp	Spectrum of AIDS-associated malignant disorders	LANCET			English	Article							EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; TESTICULAR CANCER; HODGKINS-DISEASE; LYMPHOMAS; INFECTION; TUMOR; RISK	Background To clarify which types of cancer result from AIDS, we compared the cancer experiences of people with AIDS with those of the general population by matching population-based cancer and AIDS registries in the USA and Puerto Rico. Methods We used a probabilistic matching algorithm to compare names, birth dates, and, where available, social-security numbers of 98 336 people with AIDS and 1 125 098 people with cancer aged less than 70 years. We defined AIDS-related cancers as those with both significantly raised incidence post-AIDS and increasing prevalence from 5 years pre-AIDS to 2 years post-AIDS. Findings Among people with AIDS, we found 7028 cases of Kaposi's sarcoma (KS), 1793 of non-Hodgkin lymphoma (NHL), and 712 other cases of histologically defined cancer. Incidence rates among people with AIDS were increased 310-fold for KS, 113-fold for NHL, and l.9-fold (95% CI 1.5-2.3) for other cancers. Of 38 malignant disorders other than KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold), multiple myeloma (4.5-fold), brain cancer (3.5-fold), and seminoma (2.9-fold) were raised and increasing significantly (p<0.02) from the pre-AIDS to the post-AIDS period. Interpretation Interpretation is complicated by screening and shared risk factors, such as sexual behaviour and cigarette smoking. However, our data indicate that AIDS leads to a significantly increased risk of Hodgkin's disease, multiple myeloma, brain cancer, and seminoma. Immunological failure to control herpes or other viral infections may contribute to these malignant diseases.	NCI, Viral Epidemiol Branch, Rockville, MD USA; NCI, Pathol Lab, Bethesda, MD 20892 USA; Comp Sci Corp, Rockville, MD USA; Informat Management Serv Inc, Silver Spring, MD USA; NCI, Biostat Branch, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Goedert, JJ (corresponding author), 6130 Execut Blvd,Suite 434, Rockville, MD 20852 USA.		Jaffe, Elaine/G-8981-2014		NCI NIH HHS [N01-CP-40521, YO1-CP-0003-01, N01-CP-40514] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMANN AJ, 1993, J ACQ IMMUN DEF SYND, V6, P1224; [Anonymous], 1996, IARC MON EV CARC RIS; ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; Biggar RJ, 1996, INT J CANCER, V68, P754; *CDCP, 1996, HIV AIDS SURV REP, V8, P18; COTE TR, 1995, PREV MED, V24, P375, DOI 10.1006/pmed.1995.1061; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DAY NE, 1984, BIOMETRICS, V40, P1, DOI 10.2307/2530739; DICTOR M, 1988, INT J CANCER, V42, P346, DOI 10.1002/ijc.2910420307; Fizazi K, 1996, EUR J CANCER, V32A, P1812, DOI 10.1016/0959-8049(96)00167-0; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GOEDERT JJ, 1995, LANCET, V346, P257, DOI 10.1016/S0140-6736(95)91309-2; HEINZER H, 1993, EUR UROL, V24, P271; *IARC, 1998, IARC MON EV CARC RIS, V70; *IARC, 1995, IARC MON EV CARC RIS, V64; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kingma DW, 1996, AM J SURG PATHOL, V20, P1511, DOI 10.1097/00000478-199612000-00011; KINGMA DW, 1994, AM J SURG PATHOL, V18, P48, DOI 10.1097/00000478-199401000-00005; KINLEN LJ, 1996, CANC EPIDEMIOLOGY PR, P532; LONDON WT, 1996, CANC EPIDEMIOLOGY PR, P772; LYTER DW, 1995, J CLIN ONCOL, V13, P2540, DOI 10.1200/JCO.1995.13.10.2540; LYTER DW, 1996, P AM SOC CLIN ONCOL, V15, P852; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; Melbye M, 1996, BRIT J CANCER, V73, P995, DOI 10.1038/bjc.1996.194; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; MUELLER N, 1988, INT J CANCER, V41, P399, DOI 10.1002/ijc.2910410314; Mueller NE, 1996, CANC EPIDEMIOLOGY PR, P893; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Parravicini C, 1997, SCIENCE, V278, P1969, DOI 10.1126/science.278.5345.1969; Percy C., 1990, INT CLASSIFICATION D; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Ries L, 1994, NIH PUBLICATION, V94-2789; Yu MC, 1996, CANC EPIDEMIOLOGY PR, P603	37	530	544	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1833	1839		10.1016/S0140-6736(97)09028-4	http://dx.doi.org/10.1016/S0140-6736(97)09028-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652666				2022-12-01	WOS:000074347100009
J	Ott, A; Slooter, AJC; Hofman, A; van Harskamp, F; Witteman, JCM; Van Broeckhoven, C; van Duijn, CM; Breteler, MMB				Ott, A; Slooter, AJC; Hofman, A; van Harskamp, F; Witteman, JCM; Van Broeckhoven, C; van Duijn, CM; Breteler, MMB			Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study	LANCET			English	Article							VASCULAR DEMENTIA; CIGARETTE-SMOKING; BLOOD-PRESSURE; MENTAL STATE; ASSOCIATION; DIAGNOSIS	Background Previous studies suggested a protective effect of smoking on Alzheimer's disease, but most were case-control studies based on prevalent cases. The findings of prospective studies on the association between smoking and the risk of dementia are inconclusive. Methods We did a population-based follow-up study of elderly people who were initially free of dementia. 6870 people aged 55 years and older agreed to take part. Smoking history was taken at baseline and participants were classified as never smokers, former smokers, and current smokers. During follow-up, we recorded all incident cases of dementia, We used never smokers as the reference category to calculate relative risks of dementia and Alzheimer's disease by Cox proportional hazards regression, after adjustment for age, sex, education, and alcohol intake. We also examined modification of risk by age, sex, and the apolipoprotein E (APOE) genotype. Findings During mean follow-up of 2.1 (range 1.5-3.4) years, 146 incident cases of dementia were detected, of which 105 were Alzheimer's disease. Compared with never smokers, smokers had an increased risk of dementia (relative risk 2.2 [95% CI 1.3-3.6]) and Alzheimer's disease (2.3 [1.3-4.1]). Smoking was a strong risk factor for Alzheimer's disease in individuals without the APOE epsilon 4 allele (4.6 [1.5-14.2]), but had no effect in participants with this allele (0.6 [0.1-4.8]). Interpretation Smoking was associated with a doubling of the risk of dementia and Alzheimer's disease. Our finding that carriers of the APOE epsilon 4 had no increased risk of dementia suggests an interaction between smoking and the APOE epsilon 4 genotype in the aetiology of Alzheimer's disease.	Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Neurol, NL-3000 DR Rotterdam, Netherlands; Univ Antwerp VIB, Born Bunge Fdn,Dept Biochem, Neurogenet Lab, B-2020 Antwerp, Belgium	Erasmus University Rotterdam; Erasmus University Rotterdam; Flanders Institute for Biotechnology (VIB); University of Antwerp	Breteler, MMB (corresponding author), Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	breteler@epib.fgg.eur.nl	Van Broeckhoven, Christine/G-8362-2017; Van Broeckhoven, Christine/M-7853-2019; Breteler, Monique M.B./J-5058-2014	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; Breteler, Monique M.B./0000-0002-0626-9305				American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BARTECCHI CE, 1994, NEW ENGL J MED, V330, P907, DOI 10.1056/NEJM199403313301307; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; CRUICKSHANK JM, 1989, J HUM HYPERTENS, V3, P443; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geleijnse JM, 1996, J HYPERTENS, V14, P737, DOI 10.1097/00004872-199606000-00009; GORELICK PB, 1993, ARCH NEUROL-CHICAGO, V50, P714, DOI 10.1001/archneur.1993.00540070034011; HACHINSKI V, 1992, LANCET, V340, P645; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LEE PN, 1994, NEUROEPIDEMIOLOGY, V13, P131, DOI 10.1159/000110372; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEYER JS, 1988, J NEUROL NEUROSUR PS, V51, P1489, DOI 10.1136/jnnp.51.12.1489; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; PRINCE M, 1994, NEUROLOGY, V44, P97; RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	29	365	386	1	36	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1840	1843		10.1016/S0140-6736(97)07541-7	http://dx.doi.org/10.1016/S0140-6736(97)07541-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652667				2022-12-01	WOS:000074347100010
J	Lumer, ED; Friston, KJ; Rees, G				Lumer, ED; Friston, KJ; Rees, G			Neural correlates of perceptual rivalry in the human brain	SCIENCE			English	Article							BINOCULAR-RIVALRY; VISUAL-PERCEPTION; ATTENTION; CORTEX; MECHANISMS; NEGLECT; FMRI; LOBE	When dissimilar images are presented to the two eyes, perception alternates spontaneously between each monocular view, a phenomenon called binocular rivalry. Functional brain imaging in humans was used to study the neural basis of these subjective perceptual changes. Cortical regions whose activity reflected perceptual transitions included extrastriate areas of the ventral visual pathway, and parietal and frontal regions that have been implicated in spatial attention; whereas the extrastriate areas were also engaged by nonrivalrous perceptual changes, activity in the frontoparietal cortex was specifically associated with perceptual alternation only during rivalry. These results suggest that frontoparietal areas play a central role in conscious perception, biasing the content of visual awareness toward abstract internal representations of visual scenes, rather than simply toward space.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England	University of London; University College London	Lumer, ED (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.	elumer@fil.ion.ucl.ac.uk	Rees, Geraint/C-1493-2008; Friston, Karl/D-9230-2011	Rees, Geraint/0000-0002-9623-7007; Friston, Karl/0000-0001-7984-8909	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrews TJ, 1997, P NATL ACAD SCI USA, V94, P9905, DOI 10.1073/pnas.94.18.9905; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Crick F, 1996, NATURE, V379, P485, DOI 10.1038/379485a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; HELMHOLTZ, 1911, TREATISE PHYSL OPTIC; Holmes AP, 1997, NEUROIMAGE, V5, pS480; HUMPHREYS GW, 1994, NATURE, V372, P357, DOI 10.1038/372357a0; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; Josephs O, 1997, HUM BRAIN MAPP, V5, P243, DOI 10.1002/(SICI)1097-0193(1997)5:4<243::AID-HBM7>3.0.CO;2-3; Kanwisher N, 1997, J NEUROSCI, V17, P4302; LANSING RW, 1964, SCIENCE, V146, P1325, DOI 10.1126/science.146.3649.1325; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0; LOGOTHETIS NK, 1996, ANNU REV NEUROSCI, V19, P557; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; POGGIO GF, 1988, J NEUROSCI, V8, P4531; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; SCALAIDHE SPO, 1997, SCIENCE, V278; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; VANESSEN DC, 1994, NEURON, V13, P1, DOI 10.1016/0896-6273(94)90455-3; WALKER P, 1978, PSYCHOL BULL, V85, P376, DOI 10.1037/0033-2909.85.2.376; Wolfe JM, 1996, NATURE, V380, P587, DOI 10.1038/380587a0	41	544	550	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1930	1934		10.1126/science.280.5371.1930	http://dx.doi.org/10.1126/science.280.5371.1930			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632390				2022-12-01	WOS:000074323800062
J	Kwong, PD; Wyatt, R; Robinson, J; Sweet, RW; Sodroski, J; Hendrickson, WA				Kwong, PD; Wyatt, R; Robinson, J; Sweet, RW; Sodroski, J; Hendrickson, WA			Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CRYSTAL-STRUCTURE; TRANSMEMBRANE GLYCOPROTEIN; VARIABLE REGIONS; ATOMIC-STRUCTURE; BINDING; RESOLUTION; FRAGMENT; AIDS; HEMAGGLUTININ	The entry of human Immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the Immune system. We have solved the X-ray crystal structure at 2.5 Angstrom resolution of an HIV-1 gp120 core complexed with a two-domain fragment of human con and an antigen-binding fragment of a neutralizing antibody that blocks chemokine-receptor binding. The structure reveals a cavity-laden CD4-gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion. Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to Intervene.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA	Columbia University; Columbia University; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; GlaxoSmithKline	Hendrickson, WA (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.	wayne@convex.hhmi.columbia.edu			NIGMS NIH HHS [R01 GM034102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Binley JM, 1998, AIDS RES HUM RETROV, V14, P191, DOI 10.1089/aid.1998.14.191; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KWONG PD, UNPUB J BIOL CHEM; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLSHEVSKY U, 1990, J VIROL, V64; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PROFY AT, 1990, J IMMUNOL, V144, P4641; RIZZUTO C, IN PRESS SCIENCE; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	50	2391	2568	2	320	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					648	659		10.1038/31405	http://dx.doi.org/10.1038/31405			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641677	Green Accepted			2022-12-01	WOS:000074289600043
J	Dowsett, M				Dowsett, M			Improved prognosis for biomarkers in breast cancer	LANCET			English	Editorial Material							EXPRESSION		Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Dowsett, M (corresponding author), Royal Marsden NHS Trust, Acad Dept Biochem, London SW3 6JJ, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ABE O, 1992, LANCET, V339, P71; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARTLETT K, 1993, LANCET, V341, P1293; Bast RC, 1998, J CLIN ONCOL, V16, P793; DRESSLER LG, 1992, J NATL CANCER I MONO, V11, P167; *EARL BREAST CANC, 1992, LANCET, V339, P1; ELLEDGE RM, 1993, ANNU REV MED, V44, P201, DOI 10.1146/annurev.me.44.020193.001221; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Ellis PA, 1997, LANCET, V349, P849, DOI 10.1016/S0140-6736(05)61752-7; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Makris A, 1998, BREAST CANCER RES TR, V48, P11, DOI 10.1023/A:1005973529921; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; TIETILAINEN T, 1996, J CANC RES ONCOL, V122, P687	16	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 13	1998	351	9118					1753	1754		10.1016/S0140-6736(05)78743-2	http://dx.doi.org/10.1016/S0140-6736(05)78743-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635946				2022-12-01	WOS:000074197600007
J	Rogers, A; Entwistle, V; Pencheon, D				Rogers, A; Entwistle, V; Pencheon, D			Managing demand - A patient led NHS: Managing demand at the interface between lay and primary care	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; MEDICATION; SERVICES; ILLNESS		Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, NHS Ctr Reviews & Disseminat, York YO1 5DD, N Yorkshire, England; Univ Forvie Site, Inst Publ Hlth, Cambridge CB2 2SR, England	University of Manchester; University of York - UK; University of Cambridge	Rogers, A (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.		Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				ALONZO AA, 1984, SOC SCI MED, V19, P499, DOI 10.1016/0277-9536(84)90045-5; ANCTIL B, 1996, JOINT COMMISSION J Q, V2, P345; BALXTER M, 1986, J ROY COLL GEN PRACT, V33, P256; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Coulter A, 1997, J Health Serv Res Policy, V2, P112; DEAN K, 1986, SOC SCI MED, V22, P275, DOI 10.1016/0277-9536(86)90076-6; DEAN K, 1986, HLTH PROMOTION, V2, P133; EYLES J, 1990, SOCIAL EFFECTS HLTH; FLEMING GV, 1984, MED CARE, V22, P950, DOI 10.1097/00005650-198410000-00007; Free C, 1998, BRIT MED J, V316, P380, DOI 10.1136/bmj.316.7128.380; FREWER LJ, 1994, PUBLIC UNDERST SCI, V2, P112; Gurwitz JH, 1995, HEALTH SERV RES, V30, P672; Hassell K, 1997, FAM PRACT, V14, P498, DOI 10.1093/fampra/14.6.498; HOPTON JL, 1995, BRIT MED J, V310, P1369, DOI 10.1136/bmj.310.6991.1369; JESSON J, 1994, ETHNIC MINORITY CONS, P66; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; PEARSON M, 1993, HEALTH SOC CARE COMM, V1, P11; ROGERS A, IN PRESS HLTH PLACE; ROGERS A, IN PRESS DEMANDING P; *SECR STAT HLTH, 1998, NEW NHS; Shipman C, 1997, FAM PRACT, V14, P503, DOI 10.1093/fampra/14.6.503; STACEY M, 1984, ECON IND DEMOCRACY, V5, P157, DOI 10.1177/0143831X8452002	24	37	37	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1816	+		10.1136/bmj.316.7147.1816	http://dx.doi.org/10.1136/bmj.316.7147.1816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZV258	9624078	Green Published			2022-12-01	WOS:000074286300035
J	Cullum, CM; Rosenberg, RN				Cullum, CM; Rosenberg, RN			Memory loss - When is it Alzheimer disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE		Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Alzheimers Dis Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cullum, CM (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Cullum, C. Munro/AAC-2496-2019	Cullum, C. Munro/0000-0001-9706-5465	NIA NIH HHS [P30-AG-12300-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, Neurology, V47, P592; Bonte FJ, 1997, RADIOLOGY, V202, P793, DOI 10.1148/radiology.202.3.9051035; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Cullum C M, 1995, J Int Neuropsychol Soc, V1, P100; CULLUM CM, 1993, J CLIN EXP NEUROPSYC, V15, P321, DOI 10.1080/01688639308402566; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geldmacher DS, 1997, NEUROLOGY, V48, pS2, DOI 10.1212/WNL.48.5_Suppl_6.2S; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; NAUGLE RI, 1998, INTRO CLIN NEUROPSYC; Rosenberg RN, 1997, JAMA-J AM MED ASSOC, V278, P1282, DOI 10.1001/jama.278.15.1282; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.1997.03550160083043	13	8	8	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1689	1690		10.1001/jama.279.21.1689	http://dx.doi.org/10.1001/jama.279.21.1689			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624014				2022-12-01	WOS:000073878700010
J	Cadigan, KM; Fish, MP; Rulifson, EJ; Nusse, R				Cadigan, KM; Fish, MP; Rulifson, EJ; Nusse, R			Wingless repression of Drosophila frizzled 2 expression shapes the wingless morphogen gradient in the wing	CELL			English	Article							IMAGINAL DISKS; SIGNALING PATHWAY; NERVOUS-SYSTEM; BODY PATTERN; CELL FATE; HEDGEHOG; PROTEIN; POLARITY; RECEPTOR; ENCODES	In Drosophila wing imaginal discs, the Wingless (Wg) protein acts as a morphogen, emanating from the dorsal/ventral (D/V) boundary of the disc to directly define cell identities along the D/V axis at short and long range. Here, we show that high levels of a Wg receptor, Drosophila frizzled 2 (Dfz2), stabilize Wg, allowing it to reach cells far from its site of synthesis. Wg signaling represses Dfz2 expression, creating a gradient of decreasing Wg stability moving toward the D/V boundary. This repression of Dfz2 is crucial for the normal shape of Wg morphogen gradient as well as the response of cells to the Wg signal. In contrast to other ligand-receptor relationships where the receptor limits diffusion of the ligand, Dfz2 broadens the range of Wg action by protecting it from degradation.	Stanford Univ, Med Ctr, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Med Ctr, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Cadigan, Ken/0000-0003-2431-1703				BAKER NE, 1988, DEVELOPMENT, V102, P489; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1996, DEVELOPMENT, V122, P2801; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; COUSO JP, 1994, DEVELOPMENT, V120, P621; Freeman M, 1997, DEVELOPMENT, V124, P261; Golembo M, 1996, DEVELOPMENT, V122, P223; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Pai LM, 1997, DEVELOPMENT, V124, P2255; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; SLACK JMW, 1987, EGG EMBRYO REGIONAL; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	58	265	268	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					767	777		10.1016/S0092-8674(00)81438-5	http://dx.doi.org/10.1016/S0092-8674(00)81438-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630221	Bronze			2022-12-01	WOS:000073956700013
J	Probst, FJ; Fridell, RA; Raphael, Y; Saunders, TL; Wang, AH; Liang, Y; Morell, RJ; Touchman, JW; Lyons, RH; Noben-Trauth, K; Friedman, TB; Camper, SA				Probst, FJ; Fridell, RA; Raphael, Y; Saunders, TL; Wang, AH; Liang, Y; Morell, RJ; Touchman, JW; Lyons, RH; Noben-Trauth, K; Friedman, TB; Camper, SA			Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene	SCIENCE			English	Article							HAIR-CELLS; MOUSE; GENE; ALIGNMENT; ACTIN	The shaker-2 mouse mutation, the homolog of human DFNB3, causes deafness and circling behavior. A bacterial artificial chromosome (BAC) transgene from the shaker-2 critical region corrected the vestibular defects, deafness, and inner ear morphology of shaker-2 mice. An unconventional myosin gene, Myo15, was discovered by DNA sequencing of this BAG. Shaker-2 mice were found to have an amino acid substitution at a highly conserved position within the motor domain of this myosin, Auditory hair cells of shaker-2 mice have very short stereocilia and a long actin-containing protrusion extending from their basal end. This histopathology suggests that Myo15 is necessary for actin organization in the hair cells of the cochlea.	NIDOCD, NIH, Rockville, MD 20850 USA; Michigan State Univ, Grad Program Genet, E Lansing, MI 48824 USA; Univ Michigan, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA; Natl Human Genome Res Inst, Bethesda, MD 20892 USA; NIH, Intramural Sequencing Ctr, Rockville, MD 20850 USA; Univ Michigan, DNA Sequencing Core Facil, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Michigan State University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan	Camper, SA (corresponding author), Univ Michigan, Dept Human Genet, 4701 MSRB 111,1500 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	scamper@umich.edu	Morell, Robert James/Q-2042-2019	Camper, Sally/0000-0001-8556-3379; Morell, Robert/0000-0003-1537-7356; Saunders, Thom/0000-0003-2015-101X	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002407] Funding Source: NIH RePORTER; NIDCD NIH HHS [Z01 DC 02407, Z01 DC 00038, Z01 DC 00035] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; DEOL MS, 1954, J GENET, V52, P562, DOI 10.1007/BF02985081; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOBROVOLSKAIA-ZAVASDKAIA N., 1928, ARCH BIOL, V38, P457; FRIEDMAN TB, 1995, NAT GENET, V9, P86, DOI 10.1038/ng0195-86; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hogan B., 2014, MANIPULATING MOUSE E; KOHMAN D, 1998, 21 MIDW RES M ASS RE; Liang Y, 1998, AM J HUM GENET, V62, P904, DOI 10.1086/301786; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; PROBST, UNPUB; RAPHAEL Y, 1994, HEARING RES, V76, P173, DOI 10.1016/0378-5955(94)90098-1; RAPHAEL Y, 1991, CELL MOTIL CYTOSKEL, V18, P215, DOI 10.1002/cm.970180307; Self T, 1998, DEVELOPMENT, V125, P557; Snell GD, 1939, J HERED, V30, P447, DOI 10.1093/jhered/30.10.447; SOBIN A, 1982, ARCH OTO-RHINO-LARYN, V236, P1, DOI 10.1007/BF00464051; SOBIN A, 1981, ADV OTORHINOLARYNGOL, V25, P12; STEEL K, COMMUNICATION; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wakabayashi Y, 1997, BIOCHEM BIOPH RES CO, V234, P107, DOI 10.1006/bbrc.1997.6595; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILSON REK, 1997, ANAL DNA, P398	30	322	337	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1444	1447		10.1126/science.280.5368.1444	http://dx.doi.org/10.1126/science.280.5368.1444			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603735				2022-12-01	WOS:000073883400058
J	Wang, AH; Liang, Y; Fridell, RA; Probst, FJ; Wilcox, ER; Touchman, JW; Morton, CC; Morell, RJ; Noben-Trauth, K; Camper, SA; Friedman, TB				Wang, AH; Liang, Y; Fridell, RA; Probst, FJ; Wilcox, ER; Touchman, JW; Morton, CC; Morell, RJ; Noben-Trauth, K; Camper, SA; Friedman, TB			Association of unconventional myosin MYO15 mutations with human nonsyndromic deafness DFNB3	SCIENCE			English	Article							GENE; MOUSE	DFNB3, a locus for nonsyndromic sensorineural recessive deafness, maps to a 3-centimorgan interval on human chromosome 17p11.2, a region that shows conserved synteny with mouse shaker-2. A human unconventional myosin gene, MYO15, was identified by combining functional and positional cloning approaches in searching for shaker-2 and DFNB3. MYO15 has at least 50 exons spanning 36 kilobases. Sequence analyses of these exons in affected individuals from three unrelated DFNB3 families revealed two missense mutations and one nonsense mutation that cosegregated with congenital recessive deafness.	NIDOCD, Genet Mol Lab, NIH, Rockville, MD 20850 USA; Michigan State Univ, Grad Program Genet, E Lansing, MI 48824 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; NIH, Intramural Sequencing Ctr, Rockville, MD 20850 USA; NIH, Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Michigan State University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Friedman, TB (corresponding author), NIDOCD, Genet Mol Lab, NIH, Rockville, MD 20850 USA.	tfriedman@pop.nidcd.nih.gov	Morell, Robert James/Q-2042-2019	Morell, Robert/0000-0003-1537-7356; Camper, Sally/0000-0001-8556-3379	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003402] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC 03402, Z01 DC 00035-01, Z01 DC 00038-01] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen K-S, 1996, MENTAL RETARD DEV DI, V2, P122; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Crozet F, 1997, GENOMICS, V40, P332, DOI 10.1006/geno.1996.4526; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRIEDMAN TB, 1995, NAT GENET, V9, P86, DOI 10.1038/ng0195-86; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Liang Y, 1998, AM J HUM GENET, V62, P904, DOI 10.1086/301786; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Maquat LE, 1996, AM J HUM GENET, V59, P279; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NANCE WE, 1975, OTOLARYNG CLIN N AM, V8, P19; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; PUSTELL J, 1984, NUCLEIC ACIDS RES, V12, P643, DOI 10.1093/nar/12.1Part2.643; Sellers JR, 1996, J MUSCLE RES CELL M, V17, P7, DOI 10.1007/BF00140320; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; VANCAMP G, 1998, HEREDITARY HEARING L; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILSON REK, 1997, ANAL DNA, P398	35	330	341	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1447	1451		10.1126/science.280.5368.1447	http://dx.doi.org/10.1126/science.280.5368.1447			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603736	Green Submitted			2022-12-01	WOS:000073883400059
J	Wheeler, GL; Jones, MA; Smirnoff, N				Wheeler, GL; Jones, MA; Smirnoff, N			The biosynthetic pathway of vitamin C in higher plants	NATURE			English	Article							ASCORBIC-ACID BIOSYNTHESIS; L-SORBOSONE; L-FUCOSE; DEHYDROGENASE; METABOLISM; GALACTOSE; MANNOSE; ENZYME; ROOTS; LEAF	Vitamin C (L-ascorbic acid) has important antioxidant and metabolic functions in both plants and animals, but humans, and a few other animal species, have lost the capacity to synthesize it(1). Plant-derived ascorbate is thus the major source of vitamin C in the human diet. Although the biosynthetic pathway of L-ascorbic acid in animals is well understood(2), the plant pathway has remained unknown(3)-one of the few primary plant metabolic pathways for which this is the case. L-ascorbate is abundant in plants (found at concentrations of 1-5 mM in leaves and 25 mM in chloroplasts(3,4)) and may have roles in photosynthesis and transmembrane electron transport(3-5). We found that D-mannose and I.-galactose are efficient precursors for ascorbate synthesis and are interconverted by GDP-D-mannose-3,5-epimerase. We have identified an enzyme in pea and Arabidopsis thaliana, L-galactose dehydrogenase, that catalyses oxidation of L-galactose to L-galactono-1,4-lactone. We propose an ascorbate biosynthesis pathway involving GDP-D-mannose, GDP-L-galactose, L-galactose and L-galactono-1,4-lactone, and have synthesized ascorbate from GDP-D-mannose by way of these intermediates in vitro. The definition of this biosynthetic pathway should allow engineering of plants for increased ascorbate production, thus increasing their nutritional value and stress tolerance.	Univ Exeter, Sch Biol Sci, Hatherly Labs, Exeter EX4 4PS, Devon, England	University of Exeter	Smirnoff, N (corresponding author), Univ Exeter, Sch Biol Sci, Hatherly Labs, Prince Wales Rd, Exeter EX4 4PS, Devon, England.	N.Smirnoff@exeter.ac.uk	Wheeler, Glen L/E-5034-2011; Smirnoff, Nicholas/GZN-1978-2022	Smirnoff, Nicholas/0000-0001-5630-5602				ANDREWS MA, 1989, CARBOHYD RES, V194, P1, DOI 10.1016/0008-6215(89)85001-3; BARBER GA, 1971, ARCH BIOCHEM BIOPHYS, V147, P619, DOI 10.1016/0003-9861(71)90420-6; BARBER GA, 1979, J BIOL CHEM, V254, P7600; BAYDOUN EAH, 1988, J PLANT PHYSIOL, V132, P484, DOI 10.1016/S0176-1617(88)80068-3; BURNS J. J., 1967, Metabolic Pathways, V1, P394; CHEN YT, 1953, BIOCHEM J, V55, P821, DOI 10.1042/bj0550821; Conklin PL, 1996, P NATL ACAD SCI USA, V93, P9970, DOI 10.1073/pnas.93.18.9970; Conklin PL, 1997, PLANT PHYSIOL, V115, P1277, DOI 10.1104/pp.115.3.1277; CONTER PF, 1984, CAN J MICROBIOL, V30, P753, DOI 10.1139/m84-115; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; Feingold D. S., 1982, ENCY PLANT PHYSL A, V13A, P3; Foyer C. H., 1993, ANTIOXIDANTS HIGHER, P31; GHEBREGZABHER M, 1976, J CHROMATOGR, V127, P133, DOI 10.1016/S0021-9673(00)80168-5; HARRIS GC, 1986, PLANT PHYSIOL, V82, P1081, DOI 10.1104/pp.82.4.1081; HOREMANS N, 1994, PLANT PHYSIOL, V104, P1455, DOI 10.1104/pp.104.4.1455; Kim ST, 1996, BBA-PROTEIN STRUCT M, V1297, P1, DOI 10.1016/0167-4838(96)00077-5; LOEWUS FA, 1987, CRC CR REV PLANT SCI, V5, P101, DOI 10.1080/07352688709382235; LOEWUS FA, 1963, PHYTOCHEMISTRY, V2, P109, DOI 10.1016/S0031-9422(00)82971-4; LOEWUS MW, 1990, PLANT PHYSIOL, V94, P1492, DOI 10.1104/pp.94.3.1492; MAIER E, 1982, METHOD ENZYMOL, V89, P176; MAPSON LW, 1956, BIOCHEM J, V64, P13, DOI 10.1042/bj0640013; MAPSON LW, 1958, BIOCHEM J, V68, P395, DOI 10.1042/bj0680395; NISHIKIMI M, 1994, J BIOL CHEM, V269, P13685; OBA K, 1995, J BIOCHEM, V117, P120, DOI 10.1093/oxfordjournals.jbchem.a124697; ROBERTS RM, 1973, PHYTOCHEMISTRY, V12, P2679, DOI 10.1016/0031-9422(73)85079-4; ROBERTS RM, 1971, ARCH BIOCHEM BIOPHYS, V145, P685, DOI 10.1016/S0003-9861(71)80029-2; SAITO K, 1990, PLANT PHYSIOL, V94, P1496, DOI 10.1104/pp.94.3.1496; SCHACHTER H, 1969, J BIOL CHEM, V244, P4785; Smirnoff N, 1996, ANN BOT-LONDON, V78, P661, DOI 10.1006/anbo.1996.0175	29	769	915	7	166	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					365	369		10.1038/30728	http://dx.doi.org/10.1038/30728			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620799				2022-12-01	WOS:000073883600054
J	Colasanti, J; Yuan, Z; Sundaresan, V				Colasanti, J; Yuan, Z; Sundaresan, V			The indeterminate gene encodes a zinc finger protein and regulates a leaf-generated signal required for the transition to flowering in maize	CELL			English	Article							FLORAL MERISTEM IDENTITY; SHOOT APICAL MERISTEM; NICOTIANA-TABACUM; ARABIDOPSIS; TIME; MORPHOGENESIS; PATTERNS; HOMOLOG; CLONING; PLANTS	Flowering in plants is a consequence of the transition of the shoot apex from vegetative to reproductive growth in response to environmental and internal signals. The indeterminate 1 gene (id1) controls the transition to flowering in maize. We show by cloning the id1 gene that it encodes a protein with zinc finger motifs, suggesting that the id1 gene product functions as a transcriptional regulator of the floral transition, id1 mRNA expression studies and analyses of transposon-induced chimeric plants indicate that id1 acts non-cell-autonomously to regulate the production of a transmissible signal in the leaf that elicits the transformation of the shoot apex to reproductive development. These results provide molecular and genetic data consistent with the florigen hypothesis derived from classical plant physiology studies.	Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	United States Department of Agriculture (USDA); University of California System; University of California Berkeley; Cold Spring Harbor Laboratory; National University of Singapore	Colasanti, J (corresponding author), Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA.			Sundaresan, Venkatesan/0000-0002-4670-0630				Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BATTEY NH, 1990, BOT REV, V56, P162, DOI 10.1007/BF02858534; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Chen J., 1994, MAIZE HDB, P526, DOI [10.1007/978-1-4612-2694-9_85, DOI 10.1007/978-1-4612-2694-9_85]; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COLASANTI J, 1991, P NATL ACAD SCI USA, V88, P3377, DOI 10.1073/pnas.88.8.3377; COLASANTI J, 1992, MAIZE GENET COOP NEW, V66, P30; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; DAWE RK, 1990, DEV BIOL, V142, P233, DOI 10.1016/0012-1606(90)90167-H; FISHER JE, 1972, BOT GAZ, V133, P78, DOI 10.1086/336618; GALINAT WC, 1951, AM J BOT, V38, P38, DOI 10.2307/2437990; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; Irish E, 1997, PLANT J, V11, P63, DOI 10.1046/j.1365-313X.1997.11010063.x; IRISH EE, 1991, DEVELOPMENT, V112, P891; IRISH EE, 1988, PLANTA, V175, P9, DOI 10.1007/BF00402876; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D., 1991, MOL PLANT PATHOLOGY, P163; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KUHN C, 1995, MOL GEN GENET, V247, P759, DOI 10.1007/BF00290408; Lang A., 1965, ENCYCL PLANT PHYSIOL, VVolume XV/1, P1380; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MARTIENSSEN RA, 1989, EMBO J, V8, P1633, DOI 10.1002/j.1460-2075.1989.tb03553.x; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; McClintock B., 1949, CARNEGIE I WASHINGTO, V48, P142; MCCLINTOCK B, 1955, CARNEGIE I WASH YB, V54, P242; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; McDaniel CN, 1996, PLANT J, V9, P55, DOI 10.1046/j.1365-313X.1996.09010055.x; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; ONEILL SD, 1992, PHOTOCHEM PHOTOBIOL, V56, P789, DOI 10.1111/j.1751-1097.1992.tb02235.x; Pouteau S, 1997, DEVELOPMENT, V124, P3343; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Scott L, 1996, GENETICS, V142, P237; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SINGER SR, 1986, DEV BIOL, V118, P587, DOI 10.1016/0012-1606(86)90028-X; SINGLETON WR, 1946, J HERED, V37, P61, DOI 10.1093/oxfordjournals.jhered.a105582; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X	43	221	255	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					593	603		10.1016/S0092-8674(00)81188-5	http://dx.doi.org/10.1016/S0092-8674(00)81188-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604934	Bronze			2022-12-01	WOS:000073722200012
J	Fauman, EB; Cogswell, JP; Lovejoy, B; Rocque, WJ; Holmes, W; Montana, VG; Piwnica-Worms, H; Rink, MJ; Saper, MA				Fauman, EB; Cogswell, JP; Lovejoy, B; Rocque, WJ; Holmes, W; Montana, VG; Piwnica-Worms, H; Rink, MJ; Saper, MA			Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; P34CDC2; TRANSITION; P34(CDC2); MECHANISM; RHODANESE; MITOSIS	Cdc25 phosphatases activate the cell division kinases throughout the cell cycle. The 2.3 Angstrom structure of the human Cdc25A catalytic domain reveals a small alpha/beta domain with a fold unlike previously described phosphatase structures but identical to rhodanese, a sulfur-transfer protein. Only the active-site loop, containing the Cys-(X)(5)-Arg motif, shows similarity to the tyrosine phosphatases. In some crystals, the catalytic Cys-430 forms a disulfide bond with the invariant Cys-384, suggesting that Cdc25 may be self-inhibited during oxidative stress. Asp-383, previously proposed to be the general acid, instead serves a structural role, forming a conserved buried salt-bridge. We propose that Glu-431 may act as a general acid. Structure-based alignments suggest that the noncatalytic domain of the MAP kinase phosphatases will share this topology, as will ACR2, a eukaryotic arsenical resistance protein.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Glaxo Wellcome Inc, Dept Funct Genet, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, Howard Hughes Med Inst, St Louis, MO 63110 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Howard Hughes Medical Institute; Washington University (WUSTL)	Fauman, EB (corresponding author), Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.		Fauman, Eric/AAC-8275-2020; Piwnica-Worms, Helen/C-5214-2012	Fauman, Eric/0000-0002-9739-0249	NIAID NIH HHS [AI34095] Funding Source: Medline; NIGMS NIH HHS [GM47017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gladysheva T, 1996, J BIOL CHEM, V271, P33256, DOI 10.1074/jbc.271.52.33256; Gliubich F, 1996, J BIOL CHEM, V271, P21054, DOI 10.1074/jbc.271.35.21054; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Ramponi G, 1997, BBA-PROTEIN STRUCT M, V1341, P137, DOI 10.1016/S0167-4838(97)00087-3; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Wysocki R, 1997, J BIOL CHEM, V272, P30061, DOI 10.1074/jbc.272.48.30061; Xu X, 1996, J BIOL CHEM, V271, P5118; Yamauchi A, 1997, BLOOD, V89, P4092, DOI 10.1182/blood.V89.11.4092; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	51	262	268	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					617	625		10.1016/S0092-8674(00)81190-3	http://dx.doi.org/10.1016/S0092-8674(00)81190-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604936	Bronze			2022-12-01	WOS:000073722200014
J	Fisk, GJ; Thummel, CS				Fisk, GJ; Thummel, CS			The DHR78 nuclear receptor is required for ecdysteroid signaling during the onset of Drosophila metamorphosis	CELL			English	Article							STEROID-HORMONE ECDYSONE; RETINOID-X-RECEPTOR; BROAD-COMPLEX; GENE-EXPRESSION; MANDUCA-SEXTA; MOLECULAR ANALYSIS; PUPAL DEVELOPMENT; TOBACCO HORNWORM; SALIVARY-GLANDS; INDUCIBLE GENE	Pulses of ecdysteroids direct Drosophila through its life cycle by activating stage- and tissue-specific genetic regulatory hierarchies. Here we show that an orphan nuclear receptor, DHR78, functions at the top of the ecdysteroid regulatory hierarchies. Null mutations in DHR78 lead to lethality during the third larval instar with defects in ecdysteroid-triggered developmental responses. Consistent with these phenotypes, DHR78 mutants fail to activate the mid-third instar regulatory hierarchy that prepares the animal for metamorphosis. DHR78 protein is bound to many ecdysteroid-regulated puff loci, suggesting that DHR78 directly regulates puff gene expression. In addition, ectopic expression of DHR78 has no effects on development, indicating that its activity is regulated posttranslationally. We propose that DHR78 is a ligand-activated receptor that plays a central role in directing the onset of Drosophila metamorphosis.	Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Thummel, CS (corresponding author), Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA.				NIGMS NIH HHS [5T32GM07464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AJ, 1994, METHOD CELL BIOL, V44, P565, DOI 10.1016/S0091-679X(08)60932-2; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ANDREW DJ, 1994, DROSOPHILA MELANOGAS, P354; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; BELYAEVA ES, 1980, CHROMOSOMA, V81, P281, DOI 10.1007/BF00285954; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; BERREUR P, 1984, GEN COMP ENDOCR, V54, P76, DOI 10.1016/0016-6480(84)90201-6; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOLLENBACHER WE, 1975, DEV BIOL, V44, P46, DOI 10.1016/0012-1606(75)90375-9; BOYD L, 1991, DEVELOPMENT, V112, P981; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CALVEZ B, 1976, FEBS LETT, V71, P57, DOI 10.1016/0014-5793(76)80898-8; Champlin DT, 1998, DEVELOPMENT, V125, P269; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CLEVER U, 1964, SCIENCE, V146, P794, DOI 10.1126/science.146.3645.794; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; DAVIES MJ, 1995, CARDIOL ELDER, V3, P161; DIBELLO PR, 1991, GENETICS, V129, P385; DOMINICK OS, 1985, J EXP BIOL, V117, P45; FISK GJ, 1995, P NATL ACAD SCI USA, V92, P10604, DOI 10.1073/pnas.92.23.10604; FLETCHER JC, 1995, GENETICS, V141, P1025; FLETCHER JC, 1995, DEVELOPMENT, V121, P1455; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Gilbert Lawrence I., 1996, P59; GUAY PS, 1991, GENETICS, V129, P169; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HENRICH VC, 1994, DEV BIOL, V165, P38, DOI 10.1006/dbio.1994.1232; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; Horner M., 1997, DROS INF SERV, V80, P35; IMAM F, 1996, THESIS STANFORD U ST; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KARIM FD, 1993, DEVELOPMENT, V118, P977; Karim FD, 1996, GENETICS, V143, P315; KARLSON P, 1984, BIOSYNTHESIS METABOL, P162; KISS I, 1988, GENETICS, V118, P247; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U ST; KOOLMAN J, 1980, PROGR ECDYSONE RES, V7, P187; KOZLOVA T, 1998, IN PRESS GENETICS; Lam GT, 1997, DEVELOPMENT, V124, P1757; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Manning G., 1993, DEV DROSOPHILA MELAN, V1, P609; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; MOUGNEAU E, 1993, MOL CELL BIOL, V13, P184, DOI 10.1128/MCB.13.1.184; NAKANISHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2971, DOI 10.1073/pnas.80.10.2971; NOIROT C, 1982, INSECT ULTRASTRUCTUR, V1, P351; OHTAKI T, 1986, J INSECT PHYSIOL, V32, P635, DOI 10.1016/0022-1910(86)90093-4; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; RESTIFO LL, 1992, ROUX ARCH DEV BIOL, V201, P221, DOI 10.1007/BF00188753; RICHARDS G, 1981, BIOL REV, V56, P501, DOI 10.1111/j.1469-185X.1981.tb00358.x; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; Riddiford L., 1993, DEV DROSOPHILA MELAN, V2, P899; RIDDIFORD LM, 1978, GEN COMP ENDOCR, V34, P438, DOI 10.1016/0016-6480(78)90284-8; RIDDIFORD LM, 1986, DEV BIOL, V118, P82, DOI 10.1016/0012-1606(86)90075-8; Russell SRH, 1996, GENETICS, V144, P159; RYERSE JS, 1978, J INSECT PHYSIOL, V24, P541, DOI 10.1016/0022-1910(78)90056-2; SCHWARTZ MB, 1984, DEV BIOL, V103, P85, DOI 10.1016/0012-1606(84)90010-1; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SLATIS HM, 1959, GENETICS, V44, P536; SLITER TJ, 1992, GENETICS, V130, P555; SMITH WA, 1982, J INSECT PHYSIOL, V28, P797, DOI 10.1016/0022-1910(82)90141-X; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; SUTHERLAND JD, 1995, P NATL ACAD SCI USA, V92, P7966, DOI 10.1073/pnas.92.17.7966; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; TALBOT WS, 1993, THESIS STANFORD U ST; Thummel CS, 1996, TRENDS GENET, V12, P306, DOI 10.1016/0168-9525(96)10032-9; Thummel CS, 1992, DROS INF SERV, V71, P150; Urness LD, 1995, EMBO J, V14, P6239, DOI 10.1002/j.1460-2075.1995.tb00314.x; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; Wassarman P., 1997, ADV DEV BIO, P81; White KP, 1997, SCIENCE, V276, P114, DOI 10.1126/science.276.5309.114; WIGGLESWORTH VB, 1976, INSECT DEV, V8, P186; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; ZELHOF AC, 1995, MOL CELL BIOL, V15, P6736; ZELHOF AC, 1995, P NATL ACAD SCI USA, V92, P10477, DOI 10.1073/pnas.92.23.10477	86	49	49	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					543	555		10.1016/S0092-8674(00)81184-8	http://dx.doi.org/10.1016/S0092-8674(00)81184-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604930	Bronze			2022-12-01	WOS:000073722200008
J	Saad, Z; Bramwell, VHC; Wilson, SM; O'Malley, FP; Jeacock, J; Chambers, AF				Saad, Z; Bramwell, VHC; Wilson, SM; O'Malley, FP; Jeacock, J; Chambers, AF			Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases	LANCET			English	Article							EXTRACELLULAR-MATRIX; PREMENOPAUSAL WOMEN; CATHEPSIN-L; CYCLE; SURGERY; CELLS; DEGRADATION; SURVIVAL; ACID	Background Retrospective studies show significant improvements in survival among women who had breast cancer resected during the luteal phase of their menstrual cycle compared with the follicular phase. We hypothesised that tumour tissue would show cyclical changes in expression of genes whose products might contribute to metastatic potential. Methods We studied 32 premenopausal women with operable breast cancer. We assayed hormones to define more accurately the menstrual phase during which surgery was done. We used northern blot analysis of RNA from fresh-frozen tumour specimens to study the patterns of expression of genes for proteolytic enzymes (cysteine proteinase cathepsin L and aspartyl proteinase cathepsin D; matrix metalloproteinases MMP-9 and MMP-2), tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2, and TP53. Results There was a significantly higher level of expression of RNA for cathepsin L, MMP-9, and TP53 (p=0.005, 0.03, 0.03, respectively) in tumours that were resected during the follicular and periovulatory phases of the menstrual cycle than at other times in the cycle. A similar but nonsignificant trend was seen for MMP-2 and cathepsin D. A non-significant trend in the opposite direction was seen for TIMP-1 and TIMP-2. Interpretation We found that tumour expression of genes that may contribute to proliferative capacity and metastatic potential can change in breast cancer during the course of the menstrual cycle. The finding could provide a molecular explanation for the reports of improved survival in some breast-cancer patients whose tumours were removed during the luteal phase of the menstrual cycle. Larger studies are required to extend our study, assess mechanisms of gene regulation, and verify any relevant influence in long-term survival.	London Reg Canc Ctr, London, ON N6A 4L6, Canada; London Hlth Sci Ctr, London, ON, Canada; Univ Manchester, Sch Nursing, Manchester, Lancs, England	Western University (University of Western Ontario); London Health Sciences Centre; University of Manchester	Saad, Z (corresponding author), Hope Hosp, Stott Lane, Salford M6 8HD, Lancs, England.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123; Winstanley, Julie/0000-0002-9353-6757				AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; BRIOZZO P, 1988, CANCER RES, V48, P3688; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; FERGUSON JE, 1992, CELL TISSUE RES, V268, P167, DOI 10.1007/BF00338066; Hrushesky W., 1996, Breast Cancer Research and Treatment, V41, P272; HRUSHESKY WJM, 1989, LANCET, V2, P949; JARVIS PM, 1980, ANN NY ACAD SCI, V464, P152; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; LEIS HP, 1991, BREAST, P331; LEVINE M, 1996, P AN M AM SOC CLIN, V15, P99; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; POWLES TJ, 1991, LANCET, V337, P1604; PRICE JE, 1990, CANCER RES, V50, P717; RADVIN PM, 1993, BREAST CANC RES TREA, V24, P219; RAGETH JC, 1991, ANN ONCOL, V2, P269, DOI 10.1093/oxfordjournals.annonc.a057935; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; SAAD Z, 1994, BRIT J SURG, V81, P217, DOI 10.1002/bjs.1800810219; SAINSBURY R, 1991, LANCET, V338, P391; SENIE RT, 1991, ANN INTERN MED, V115, P337, DOI 10.7326/0003-4819-115-5-337; SORSDAHL K, 1994, CANCER DETECT PREV, V18, P179; Thomssen C, 1995, CLIN CANCER RES, V1, P741; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; VERONESI U, 1994, LANCET, V343, P1544	27	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 18	1998	351	9110					1170	1173		10.1016/S0140-6736(97)07498-9	http://dx.doi.org/10.1016/S0140-6736(97)07498-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ483	9643688				2022-12-01	WOS:000073220200010
J	Kuroda, S; Fukata, M; Nakagawa, M; Fujii, K; Nakamura, T; Ookubo, T; Izawa, I; Nagase, T; Nomura, N; Tani, H; Shoji, I; Matsuura, Y; Yonehara, S; Kaibuchi, K				Kuroda, S; Fukata, M; Nakagawa, M; Fujii, K; Nakamura, T; Ookubo, T; Izawa, I; Nagase, T; Nomura, N; Tani, H; Shoji, I; Matsuura, Y; Yonehara, S; Kaibuchi, K			Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion	SCIENCE			English	Article							BINDING PROTEIN; ALPHA-CATENIN; BETA-CATENIN; IDENTIFICATION; FAMILY; RHO; INTERLEUKIN-3; PLAKOGLOBIN; ACTIVATION; FILOPODIA	The small guanosine triphosphatases (GTPases) Cdc42 and Rad regulate E-cadherin-mediated cell-cell adhesion. IQGAP1, a target: of Cdc42 and Rac1,was localized with E-cadherin and beta-catenin at sites of cell-cell contact in mouse L Fibroblasts expressing E-cadherin (EL cells), and interacted with E-cadherin and beta-catenin both in vivo and in vitro. IQGAP1 induced the dissociation of alpha-catenin from a cadherin-catenin complex in vitro and in vivo. Overexpression of IQGAP1 in EL cells, but not in L cells expressing an E-cadherin-alpha-catenin chimeric protein, resulted in a decrease in E-cadherin-mediated cell-cell adhesive activity. Thus, IQGAP1, acting downstream of Cdc42 and Rac1, appears to regulate cell-cell adhesion through the cadherin-catenin pathway.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Japan Sci & Technol, PRESTO, Inheritance & Variat Grp, Kyoto 6190237, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Cent Lab Key Technol, Kirin Brewery, Yokohama 2360004, Japan; Kazusa DNA Res Inst, Kazusa CDNA Res Grp, Kisarazu 2920812, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 1620052, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068397, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Hiroshima University; Kirin Brewery Company Limited; Kazusa DNA Research Institute; National Institute of Infectious Diseases (NIID); Kyoto University	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		Shoji, Ikuo/Y-7079-2019; Fukata, Masaki/AAZ-2476-2021; KURODA, SHINYA/G-4961-2014	Shoji, Ikuo/0000-0002-0730-4379; Fukata, Masaki/0000-0001-5200-9806; 				Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; KURODA S, UNPUB; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; YONEHARA S, 1990, INT IMMUNOL, V2, P143, DOI 10.1093/intimm/2.2.143	27	409	425	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					832	835		10.1126/science.281.5378.832	http://dx.doi.org/10.1126/science.281.5378.832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694656				2022-12-01	WOS:000075295600052
J	Brown, P				Brown, P			On the origins of BSE	LANCET			English	Editorial Material									NINDS, NIH, CNS Studies Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINDS, NIH, CNS Studies Lab, Bethesda, MD 20892 USA.							Taylor DM, 1998, VET REC, V143, P6, DOI 10.1136/vr.143.1.6; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	3	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 25	1998	352	9124					252	253		10.1016/S0140-6736(05)60255-3	http://dx.doi.org/10.1016/S0140-6736(05)60255-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690401				2022-12-01	WOS:000074974500004
J	Roland, M; van Tulder, M				Roland, M; van Tulder, M			Should radiologists change the way they report plain radiography of the spine?	LANCET			English	Editorial Material									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands	University of Manchester; Vrije Universiteit Amsterdam	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 6PL, Lancs, England.		van Tulder, Maurits/AAB-9785-2022	van Tulder, Maurits/0000-0002-7589-8471				*AG HLTH CAR POL R, 1994, AC LOW BACK PROBL AD; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326; HAPLIN SF, 1991, BRIT MED J, V303, P813; KELLGREN JH, 1963, ATLAS STANDARD RADIO, V2, P20; ROSEN M, 1995, BACK PAIN; *ROYAL COLL RAD, 1995, MAK BEST US DEP RAD; SuarezAlmazor ME, 1997, JAMA-J AM MED ASSOC, V277, P1782, DOI 10.1001/jama.277.22.1782; vanTulder MW, 1997, SPINE, V22, P427, DOI 10.1097/00007632-199702150-00015; WADDELL G, 1996, LOW BACK PAIN EVIDEN	13	41	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 18	1998	352	9123					229	230		10.1016/S0140-6736(97)11499-4	http://dx.doi.org/10.1016/S0140-6736(97)11499-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101FW	9683228				2022-12-01	WOS:000074859800044
J	Emanuel, EJ; Battin, MP				Emanuel, EJ; Battin, MP			What are the potential cost savings from legalizing physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERMINAL CANCER-PATIENTS; ACTIVE EUTHANASIA; MEDICAL DECISIONS; MANAGED DEATH; DATA SHOW; LAST YEAR; CARE; LIFE; END; ATTITUDES		Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA; Univ Utah, Dept Philosophy, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Internal Med, Div Med Eth, Salt Lake City, UT USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Epidemiol & Control, Ctr Outcomes & Policy Res, 44 Binney St, Boston, MA 02115 USA.							Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DORONZIO JC, 1993, NY TIMES        0608, pA25; Emanuel EJ, 1998, MINN LAW REV, V82, P983; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fireman BH, 1997, HEALTH CARE FINANC R, V18, P51; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRYE A, 1994, WASHINGTON POST 0102, pC3; Ginzberg E, 1980, Inquiry, V17, P293; GODEC MS, 1993, WASHINGTON POST 0502, pC3; KASS LR, 1989, PUBLIC INTEREST, V94, P25; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LAPUMA J, 1995, ARCH INTERN MED, V155, P1553, DOI 10.1001/archinte.1995.00430140133014; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LONG SH, 1984, INQUIRY-J HEALTH CAR, V21, P315; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MURPHY DJ, 1993, ARCH INTERN MED, V153, P1641, DOI 10.1001/archinte.153.14.1641; *NAT HOSP ORG, 1995, AN COST SAV MED HOSP; PETERSON PG, 1996, AM GROW UP IT GROWS, P176; RILEY G, 1987, INQUIRY-J HEALTH CAR, V24, P233; Riley G F, 1989, Health Care Financ Rev, V11, P1; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SCHROEDER SA, 1981, JAMA-J AM MED ASSOC, V245, P1446, DOI 10.1001/jama.245.14.1446; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; SPECTOR WD, 1984, INQUIRY-J HEALTH CAR, V21, P328; SULMASY DP, 1995, ARCH INTERN MED, V155, P133, DOI 10.1001/archinte.155.2.133; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; van der Maas PJ, 1992, HEALTH POLICY, V22, P1	42	53	53	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					167	172		10.1056/NEJM199807163390306	http://dx.doi.org/10.1056/NEJM199807163390306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZZ922	9664094				2022-12-01	WOS:000074782900006
J	de Beaufort, AJ; Pelikan, DMV; Elferink, JGR; Berger, HM				de Beaufort, AJ; Pelikan, DMV; Elferink, JGR; Berger, HM			Effect of interleukin 8 in meconium on in-vitro neutrophil chemotaxis	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; ASPIRATION SYNDROME; INHIBITION; IL-8; INFLAMMATION; FLUID	Background Pneumonitis, characterised by large numbers of neutrophils in the lung, is an important feature of the meconium aspiration syndrome. The mechanism underlying the neutrophil influx is not known. We have investigated whether meconium has chemotactic activity and whether such activity is related to the presence of interleukin 8. Methods The chemotactic activity of meconium on neutrophils from newborn infants was assessed in a Boyden-chamber assay. Interleukin 8 and formyl-methionyl-leucyl-phenylalanine (f-MLP) served as positive controls. Inhibition of chemotaxis was assessed with monoclonal antibody to interleukin 8. The interleukin-8 concentration was measured by ELISA. Findings Sterile meconium suspension from seven unrelated newborn babies increased migration of neutrophils from neonates in comparison with random migration (79, 72, 70, 50, 58, 88 mu m vs 46 mu m; p<0,001). This effect was greatest at a meconium concentration of 5 g/L, although differences between samples from individual babies were observed. Interleukin 8 was present in all meconium suspensions (480-3980 ng/L). Anti-interleukin-8 inhibited neutrophil migration. Interpretation Interleukin 8 is present in meconium and it induces chemotaxis of neutrophils in vitro. This mechanism may have a role in the pathogenesis of pneumonitis in meconium aspiration syndrome.	Leiden Univ, Med Ctr, Dept Pediat, Neonatal Unit, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Biochem Med, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Beaufort, AJ (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Neonatal Unit, POB 9600, NL-2300 RC Leiden, Netherlands.			de Beaufort, Arnout Jan/0000-0003-1990-2672				BERGER HM, 1994, J R COLL PHYSICIANS, V1, P24; CLARK P, 1995, AM J OBSTET GYNECOL, V173, P1301, DOI 10.1016/0002-9378(95)91375-0; DAVEY AM, 1993, PEDIATR PULM, V16, P101, DOI 10.1002/ppul.1950160205; DIRKES K, 1995, J PEDIATR SURG, V30, P979, DOI 10.1016/0022-3468(95)90325-9; Elferink JGR, 1997, BRIT J PHARMACOL, V121, P643, DOI 10.1038/sj.bjp.0701167; ELFERINK JGR, 1993, EUR J PHARM-MOLEC PH, V246, P157, DOI 10.1016/0922-4106(93)90093-O; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Jones CA, 1996, PEDIATR RES, V39, P966, DOI 10.1203/00006450-199606000-00007; KATZ VL, 1992, AM J OBSTET GYNECOL, V166, P171, DOI 10.1016/0002-9378(92)91856-6; Miller EJ, 1996, CRIT CARE MED, V24, P1448, DOI 10.1097/00003246-199609000-00004; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; Olah KS, 1996, J REPROD IMMUNOL, V32, P89, DOI 10.1016/S0165-0378(96)00990-4; Perks B., 1997, European Respiratory Journal Supplement, V10, p303S; PERLMAN EJ, 1989, HUM PATHOL, V20, P701, DOI 10.1016/0046-8177(89)90159-7; RAPPAPORT S, 1950, SCIENCE, V85, P715; Soukka H, 1997, PEDIATR PULM, V23, P205, DOI 10.1002/(SICI)1099-0496(199703)23:3<205::AID-PPUL6>3.0.CO;2-M; SUN B, 1993, ACTA PAEDIATR, V82, P182, DOI 10.1111/j.1651-2227.1993.tb12635.x; TYLER DC, 1978, PEDIATRICS, V62, P454; Yokoi K, 1997, LAB INVEST, V76, P375; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	21	65	65	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					102	105		10.1016/S0140-6736(98)85013-7	http://dx.doi.org/10.1016/S0140-6736(98)85013-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672275				2022-12-01	WOS:000074775100013
J	Katayama, T; Kubota, T; Kurokawa, K; Crooke, E; Sekimizu, K				Katayama, T; Kubota, T; Kurokawa, K; Crooke, E; Sekimizu, K			The initiator function of DnaA protein is negatively regulated by the sliding clamp of the E-coli chromosomal replicase	CELL			English	Article							POLYMERASE-III HOLOENZYME; IN-VITRO REPLICATION; ESCHERICHIA-COLI; BETA-SUBUNIT; ENZYMATIC REPLICATION; ORIGIN REGION; MUTANT; SEQA; GENE; PURIFICATION	The beta subunit of DNA polymerase III is essential far negative regulation of the initiator protein, DnaA. DnaA inactivation occurs through accelerated hydrolysis of ATP bound to DnaA; the resulting ADP-DnaA fails to initiate replication. The ability of beta subunit to promote DnaA inactivation depends on its assembly as a sliding clamp on DNA and must be accompanied by a partially purified factor, IdaB protein. DnaA inactivation in the presence of IdaB and DNA polymerase III is further stimulated by DNA synthesis, indicating close linkage between initiator inactivation and replication. In vivo, DnaA predominantly takes on the ADP form in a beta subunit-dependent manner. Thus, the initiator is negatively regulated by action of the replicase, a mechanism that may be key to effective control of the replication cycle.	Kyushu Univ, Fac Pharmaceut Sci, Dept Microbiol, Fukuoka 8128582, Japan; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Kyushu University; Georgetown University	Katayama, T (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Dept Microbiol, Fukuoka 8128582, Japan.			Katayama, Tsutomu/0000-0001-9994-1684	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700, R21GM049700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49700, R01 GM049700] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRENDLER T, 1995, EMBO J, V14, P4083, DOI 10.1002/j.1460-2075.1995.tb00080.x; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CROOKE E, 1995, CELL, V82, P877, DOI 10.1016/0092-8674(95)90020-9; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; Crooke E, 1995, METHOD ENZYMOL, V262, P500; CROOKE E, 1992, J BIOL CHEM, V267, P16779; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; ECHOLS H, 1961, J MOL BIOL, V3, P425, DOI 10.1016/S0022-2836(61)80055-7; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1996, EMBO J, V15, P2313, DOI 10.1002/j.1460-2075.1996.tb00585.x; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1997, MOL MICROBIOL, V25, P661, DOI 10.1046/j.1365-2958.1997.5001872.x; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; LASKEN RS, 1987, J BIOL CHEM, V262, P1720; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MIKI T, 1978, MOL GEN GENET, V158, P217, DOI 10.1007/BF00267192; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOZAKI N, 1988, J BIOL CHEM, V263, P14176; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; SAKAKIBARA Y, 1980, MOL GEN GENET, V178, P541, DOI 10.1007/BF00337859; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	66	261	263	0	80	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1998	94	1					61	71		10.1016/S0092-8674(00)81222-2	http://dx.doi.org/10.1016/S0092-8674(00)81222-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	100AB	9674428	hybrid			2022-12-01	WOS:000074790800010
J	Iiri, T; Farfel, Z; Bourne, HR				Iiri, T; Farfel, Z; Bourne, HR			G-protein diseases furnish a model for the turn-on switch	NATURE			English	Article							HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; BETA-GAMMA; GTP HYDROLYSIS; ALPHA-SUBUNIT; TRANSDUCIN; RHODOPSIN; MECHANISM; ACTIVATION; G(I-ALPHA-1)	How does a trimeric a protein on the inside of a cell membrane respond to activation by a transmembrane receptor? G-protein mutations in patients with hypertension and inherited endocrine disorders enhance or block signals from stimulated receptors. In combination with three-dimensional crystal structures and results from biochemical experiments, the phenotypes produced by these mutations suggest a model for the molecular activation mechanism that relays hormonal and sensory signals transmitted by many transmembrane receptors.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Tel Aviv Univ, Biochem Pharmacol Lab, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Med E, IL-52621 Tel Hashomer, Israel	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	h_bourne@quickmail.ucsf.edu						Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P9998; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; IIRI T, 1998, NAT GENET, V18, P45; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Stratton HF, 1996, MOL CELL BIOL, V16, P6325; SUNAHARA RK, 1997, GSA SCI, V278, P1943; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WEST RE, 1985, J BIOL CHEM, V260, P4428	45	161	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					35	38		10.1038/27831	http://dx.doi.org/10.1038/27831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665125				2022-12-01	WOS:000074579600039
J	Luzuriaga, K; Sullivan, JL				Luzuriaga, K; Sullivan, JL			Prevention and treatment of pediatric HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; ZIDOVUDINE TREATMENT; TRANSMISSION; TYPE-1; INFANT		Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Sullivan, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Suite 318,Biotech II,373 Plantat St, Worcester, MA 01605 USA.	John.Sullivan@banyan.ummed.edu						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CDCP, 1998, MMWR MORB MORTAL WKL, V47; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; Ho DD, 1997, J CLIN INVEST, V99, P2565, DOI 10.1172/JCI119443; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; LIDINJANSSON G, 1994, PEDIATRICS, V94, P815; LUZURIAGA K, 1993, J INFECT DIS, V167, P1008, DOI 10.1093/infdis/167.5.1008; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Luzuriaga K, 1996, JAMA-J AM MED ASSOC, V275, P1360; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MIROCHNICK M, IN PRESS J INFECT DI; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1019; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; *UNAIDS WHO WORK G, 1998, GLOB HIV AIDS EP EST; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911	22	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					17	18		10.1001/jama.280.1.17	http://dx.doi.org/10.1001/jama.280.1.17			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660351				2022-12-01	WOS:000074379400010
J	Shishido, E; Takeichi, M; Nose, A				Shishido, E; Takeichi, M; Nose, A			Drosophila synapse formation: Regulation by transmembrane protein with leu-rich repeats, CAPRICIOUS	SCIENCE			English	Article							ADHESION MOLECULE; NERVOUS-SYSTEM; MOTOR AXONS; MOTONEURONS; EMBRYO; SUBSET; GENES	Upon reaching the target region, neuronal growth cones transiently search through potential targets and form synaptic connections with only a subset of these. The capricious (caps) gene may regulate these processes in Drosophila. caps encodes a transmembrane protein with leucine-rich repeats (LRRs). During the formation of neuromuscular synapses, caps is expressed in a small number of synaptic partners, including muscle 12 and the motorneurons that innervate it. Loss-of-function and ectopic expression of caps alter the target specificity of muscle 12 motorneurons, indicating a role for caps in selective synapse formation.	Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 6068502, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University	Nose, A (corresponding author), Univ Tokyo, Sch Sci, Dept Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138654, Japan.	nose@bio.phys.s.u-tokyo.ac.jp	Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378; Shishido, Emiko/0000-0002-2474-1343				BATE M, 1995, NEURON, V15, P513, DOI 10.1016/0896-6273(95)90141-8; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V201, P194, DOI 10.1007/BF00188752; JIA XX, 1993, J NEUROBIOL, V24, P1025, DOI 10.1002/neu.480240804; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kose H, 1997, DEVELOPMENT, V124, P4143; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; Landgraf M, 1997, J NEUROSCI, V17, P9642; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; Nose A, 1997, DEVELOPMENT, V124, P1433; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Raghavan S, 1997, NEURON, V18, P873, DOI 10.1016/S0896-6273(00)80327-X; Rose D, 1997, DEVELOPMENT, V124, P1561; SHISHIDO E, UNPUB; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Yoshihara M, 1997, J NEUROSCI, V17, P8408; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	30	97	99	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2118	2121		10.1126/science.280.5372.2118	http://dx.doi.org/10.1126/science.280.5372.2118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641918				2022-12-01	WOS:000074435900046
J	Choi, SK; Lee, JH; Zoll, WL; Merrick, WC; Dever, TE				Choi, SK; Lee, JH; Zoll, WL; Merrick, WC; Dever, TE			Promotion of Met-tRNA(i)(Met) binding to ribosomes by yIF2, a bacterial IF2 homolog in yeast	SCIENCE			English	Article							INITIATION FACTOR-II; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL-INITIATION; SHUTTLE VECTORS; CHROMOSOME-I; START-SITE; GENE; SEQUENCE; IDENTIFICATION; SELECTION	Delivery of the initiator methionine transfer RNA (Met-tRNA(i)(Met)) to the ribosome is a key step in the initiation of protein synthesis. Previous results have indicated that this step is catalyzed by the structurally dissimilar translation factors in prokaryotes and eukaryotes-initiation factor 2 (IF2) and eukaryotic initiation factor 2 (eIF2), respectively. A bacterial IF2 homolog has been identified in both eukaryotes and archaea. By using a combination of molecular genetic and biochemical studies, the Saccharomyces cerevisiae IF2 homolog is shown to function in general translation initiation by promoting Met-tRNA(i)(Met) binding to ribosomes. Thus, the mechanism of protein synthesis in eukaryotes and prokaryotes is more similar than was previously realized.	NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University	Dever, TE (corresponding author), NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	NIGMS NIH HHS [GM08056] Funding Source: Medline; PHS HHS [26796] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS SL, 1975, J BIOL CHEM, V250, P9083; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ASTROM SU, 1993, J MOL BIOL, V233, P43, DOI 10.1006/jmbi.1993.1483; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DIEHL BE, 1991, GENETICS, V127, P287; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; HERSHEY JWB, 1991, TRANSLATION EUKARYOT, P353; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick W.C., 1975, J BIOL CHEM, V250, P1107; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; SIKORSKI RS, 1989, GENETICS, V122, P19; SUTRAVE P, 1994, GENE, V146, P209, DOI 10.1016/0378-1119(94)90294-1; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; WICKNER RB, 1994, METH MOL G, V3, P141; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	33	112	114	2	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1757	1760		10.1126/science.280.5370.1757	http://dx.doi.org/10.1126/science.280.5370.1757			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624054				2022-12-01	WOS:000074197800043
J	Sweitzer, SM; Hinshaw, JE				Sweitzer, SM; Hinshaw, JE			Dynamin undergoes a GTP-dependent conformational change causing vesiculation	CELL			English	Article							PROTEIN-KINASE-C; MEDIATED ENDOCYTOSIS; ACIDIC PHOSPHOLIPIDS; BINDING-SITE; SH3 DOMAINS; DROSOPHILA; SHIBIRE; IDENTIFICATION; MUTATIONS	The dynamin family of GTPases is essential for receptor-mediated endocytosis and synaptic vesicle recycling, and it has recently been shown to play a role in vesicle formation from the trans-Golgi network. Dynamin is believed to assemble around the necks of clathrin-coated pits and assist in pinching vesicles from the plasma membrane. This role would make dynamin unique among GTPases in its ability to act as a mechanochemical enzyme. Data presented here demonstrate that purified recombinant dynamin binds to a lipid bilayer in a regular pattern to form helical tubes that constrict and vesiculate upon GTP addition. This suggests that dynamin alone is sufficient for the formation of constricted necks of coated pits and supports the hypothesis that dynamin is the force-generating molecule responsible for membrane fission.	NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sweitzer, SM (corresponding author), NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA.							Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Omata W, 1997, BIOCHEM BIOPH RES CO, V241, P401, DOI 10.1006/bbrc.1997.7810; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	39	526	534	2	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					1021	1029		10.1016/S0092-8674(00)81207-6	http://dx.doi.org/10.1016/S0092-8674(00)81207-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635431	Bronze			2022-12-01	WOS:000074205700013
J	Moore, LR; Rocap, G; Chisholm, SW				Moore, LR; Rocap, G; Chisholm, SW			Physiology and molecular phylogeny of coexisting Prochlorococcus ecotypes	NATURE			English	Article							SKELETONEMA-COSTATUM BACILLARIOPHYCEAE; DIVINYL CHLOROPHYLL-A; NORTH-ATLANTIC OCEAN; COMMUNITY STRUCTURE; GENETIC DIVERSITY; SEQUENCE-ANALYSIS; SEA; SYNECHOCOCCUS; PICOPLANKTON; DISTRIBUTIONS	The cyanobacterium Prochlorococcus(1,2) is the dominant oxygenic phototroph in the tropical and subtropical regions of the world's (1,3,4). It can grow at a range of depths over which light oceans intensities can vary by up to 4 orders of magnitude. This broad depth distribution has been hypothesized to stem from the coexistence of genetically different populations adapted for growth at high-and low-light intensities(4-6). Here we report direct evidence supporting this hypothesis, which has been generated by isolating and analysing distinct co-occurring populations of Prochlorococcus at two locations in the North Atlantic. Go-isolates from the same water sample have very different light-dependent physiologies, one growing maximally at light intensities at which the other is completely photoinhibited. Despite this ecotypic differentiation, the co-isolates have 97% similarity in their 16S ribosomal RNA sequences, demonstrating that molecular microdiversity, commonly observed in microbial systems(7-12), can be due to the coexistence of closely related, physiologically distinct populations. The coexistence and distribution of multiple ecotypes permits the survival of the population as a whole over a broader range of environmental conditions than would be possible for a homogeneous population.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT Woods Hole Oceanog Inst Joint Program Oceanog, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, 48-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	chisholm@mit.edu		Chisholm, Sallie/0000-0003-1480-2445; Moore, Lisa/0000-0002-4114-1518; Rocap, Gabrielle/0000-0001-7253-611X				Amann R, 1996, J BACTERIOL, V178, P3496, DOI 10.1128/jb.178.12.3496-3500.1996; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; CAMPBELL L, 1993, DEEP-SEA RES PT I, V40, P2043, DOI 10.1016/0967-0637(93)90044-4; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; CHISHOLM SW, 1992, ARCH MICROBIOL, V157, P297, DOI 10.1007/BF00245165; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; FUHRMAN JA, 1993, APPL ENVIRON MICROB, V59, P1294, DOI 10.1128/AEM.59.5.1294-1302.1993; GALLAGHER JC, 1982, J PHYCOL, V18, P148, DOI 10.1111/j.0022-3646.1982.00148.x; GALLAGHER JC, 1980, J PHYCOL, V16, P464; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GOERICKE R, 1993, MAR ECOL PROG SER, V101, P307, DOI 10.3354/meps101307; JEFFREY SW, 1975, BIOCHEM PHYSIOL PFL, V167, P191, DOI 10.1016/s0015-3796(17)30778-3; Maidak BL, 1997, NUCLEIC ACIDS RES, V25, P109, DOI 10.1093/nar/25.1.109; MOORE LR, 1995, MAR ECOL PROG SER, V116, P259, DOI 10.3354/meps116259; MOORE LR, UNPUB LIMNOL OCEANOG; OLSON RJ, 1988, DEEP-SEA RES, V35, P425, DOI 10.1016/0198-0149(88)90019-2; OLSON RJ, 1990, DEEP-SEA RES, V37, P1033, DOI 10.1016/0198-0149(90)90109-9; PALENIK B, 1994, APPL ENVIRON MICROB, V60, P3212, DOI 10.1128/AEM.60.9.3212-3219.1994; Partensky F, 1996, DEEP-SEA RES PT I, V43, P1191, DOI 10.1016/0967-0637(96)00056-8; PARTENSKY F, 1993, PLANT PHYSIOL, V101, P285, DOI 10.1104/pp.101.1.285; PLATT T, 1980, J MAR RES, V38, P687; Scanlan DJ, 1996, EUR J PHYCOL, V31, P1, DOI 10.1080/09670269600651131; Shimada A, 1996, MAR BIOL, V127, P15, DOI 10.1007/BF00993639; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Toledo G, 1997, APPL ENVIRON MICROB, V63, P4298, DOI 10.1128/AEM.63.11.4298-4303.1997; Urbach E, 1998, J MOL EVOL, V46, P188, DOI 10.1007/PL00006294; VELDHUIS MJW, 1993, NETH J SEA RES, V31, P135, DOI 10.1016/0077-7579(93)90003-B; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; Waterbury J.B., 1986, PHOTOSYNTHETIC PICOP, P71	29	562	577	3	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					464	467		10.1038/30965	http://dx.doi.org/10.1038/30965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624000				2022-12-01	WOS:000074020000043
J	Schoenberger, SP; Toes, REM; van der Voort, EIH; Offringa, R; Melief, CJM				Schoenberger, SP; Toes, REM; van der Voort, EIH; Offringa, R; Melief, CJM			T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions	NATURE			English	Article							CD40 LIGAND; DENDRITIC CELLS; ANTITUMOR IMMUNITY; DEFICIENT MICE; CLASS-II; ACTIVATION; DISRUPTION; INDUCTION; ANTIGENS; MOLECULE	Although in vivo priming of CD8(+) cytotoxic T lymphocytes (CTLs) generally requires the participation of CD4(+) T-helper lymphocytes(1,2), the nature of the 'help' provided to CTLs is unknown(3). One widely held view is that help for CTLs is mediated by cytokines produced by T-helper cells activated in proximity to the CTL precursor at the surface of an antigen-presenting cell (APC)(4). An alternative theory is that, rather than being directly supplied to the CTL by the helper cell, help is delivered through activation of the APC, which can then prime the CTL directly(5). CD40 and its ligand, CD40L, may activate the APC to allow CTL priming. CD40L is expressed on the surface of activated CD4(+) T-helper cells and is involved in their activation and in the development of their effector functions(6,7). Ligation of CD40 on the surface of APCs such as dendritic cells, macrophages and B cells greatly increases their antigen-presentation and co-stimulatory capacity(8-11). Here we report that signalling through CD40 can replace CD4(+) T-helper cells in priming of helper-dependent CD8(+) CTL responses. Blockade of CD40L inhibits CTL priming; this inhibition is overcome by signalling through CD40. CD40-CD40L interactions are therefore vital in the delivery of T-cell help for CTL priming.	Univ Leiden Hosp, Dept Immunohematol, NL-2333 AZ Leiden, Netherlands; Univ Leiden Hosp, Blood Bank, NL-2333 AZ Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Schoenberger, SP (corresponding author), Univ Leiden Hosp, Dept Immunohematol, POB 9600, NL-2333 AZ Leiden, Netherlands.	sps@liai.org		Toes, Rene/0000-0002-9618-6414				Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; HUSMANN LA, 1988, ANN NY ACAD SCI, V532, P158, DOI 10.1111/j.1749-6632.1988.tb36335.x; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KENNEDY MK, 1994, EUR J IMMUNOL, V24, P116, DOI 10.1002/eji.1830240118; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Mackey MF, 1997, CANCER RES, V57, P2569; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Shinde S, 1996, J IMMUNOL, V157, P2764; SIMPSON E, 1977, IMMUNOL REV, V35, P59, DOI 10.1111/j.1600-065X.1977.tb00235.x; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Stout RD, 1996, J IMMUNOL, V156, P8; Toes REM, 1996, CANCER RES, V56, P3782; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	29	1914	2013	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					480	483		10.1038/31002	http://dx.doi.org/10.1038/31002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624005				2022-12-01	WOS:000074020000048
J	Das, S; Sasaki, YF; Rothe, T; Premkumar, LS; Takasu, M; Crandall, JE; Dikkes, P; Conner, DA; Rayudu, PV; Cheung, W; Chen, HSV; Lipton, SA; Nakanishi, N				Das, S; Sasaki, YF; Rothe, T; Premkumar, LS; Takasu, M; Crandall, JE; Dikkes, P; Conner, DA; Rayudu, PV; Cheung, W; Chen, HSV; Lipton, SA; Nakanishi, N			Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A	NATURE			English	Article							LONG-TERM POTENTIATION; DENDRITIC SPINES; REGIONAL EXPRESSION; RAT-BRAIN; CHANNEL; PLASTICITY; CLONING	The NMDA (N-methyl-D-aspartate) subclass of glutamate receptor(1) is essential for the synaptic plasticity thought to underlie learning and memory(2-4) and for synaptic refinement during development(5,6). It is currently believed that the NMDA receptor (NMDAR) is a heteromultimeric channel comprising the ubiquitous NR1 subunit and at least one regionally localized NR2 subunit(7-11). Here we report the characterization of a regulatory NMDAR subunit, NR3A (formerly termed NMDAR-L or chi-1), which is expressed primarily during brain development(12,13) NR3A co-immunoprecipitates with receptor subunits NR1 and NR2 in cerebrocortical extracts. In single-channel recordings from Xenopus oocytes, addition of NR3A to NR1 and NR2 leads to the appearance of a smaller unitary conductance, Genetic knockout of NR3A in mice results in enhanced NMDA responses and increased dendritic spines in early postnatal cerebrocortical neurons. These data suggest that NR3A is involved in the development of synaptic elements by modulating NMDAR activity.	Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dev Neurosci Div, Waltham, MA 02254 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Boston Children's Hospital	Nakanishi, N (corresponding author), Brigham & Womens Hosp, Cerebrovasc & Neurosci Res Inst, Neurosurg Serv, 75 Francis St, Boston, MA 02115 USA.	slipton@rics.bwh.harvard.edu; nnakanis@warren.med.harvard.edu	Sasaki, Yasnory/L-7065-2018; Das, Saumya/R-7644-2019	Sasaki, Yasnory/0000-0003-2614-7038; Posina, Venkata Rayudu/0000-0002-3040-9224; Das, Saumya/0000-0002-4521-4606; Lipton, Stuart/0000-0002-3490-1259				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CIABARRA AM, 1995, J NEUROSCI, V15, P6498; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kossel AH, 1997, J NEUROSCI, V17, P9634; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Papa M, 1996, NEUROSCIENCE, V71, P1005, DOI 10.1016/0306-4522(95)00490-4; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; ROGERS SW, 1991, J NEUROSCI, V11, P2713; SEGAL M, 1995, TRENDS NEUROSCI, V18, P468, DOI 10.1016/0166-2236(95)92765-I; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; STERN P, 1994, J PHYSIOL-LONDON, V476, P391, DOI 10.1113/jphysiol.1994.sp020140; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; SUCHER NJ, 1995, J NEUROSCI, V15, P6509; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680	29	473	501	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1998	393	6683					377	381		10.1038/30748	http://dx.doi.org/10.1038/30748			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620802				2022-12-01	WOS:000073883600057
J	Sit, TL; Vaewhongs, AA; Lommel, SA				Sit, TL; Vaewhongs, AA; Lommel, SA			RNA-mediated trans-activation of transcription from a viral RNA	SCIENCE			English	Article							NECROTIC MOSAIC-VIRUS; INFECTIOUS TRANSCRIPTS; SUBGENOMIC RNA; PLANTS; INVITRO; REGION	The red clover necrotic mosaic virus genome is composed of two single-stranded RNA components, RNA-1 and RNA-2. The viral capsid protein is translated from a subgenomic RNA (sgRNA) that is transcribed from genomic RNA-1, Here, a 34-nucleotide sequence in RNA-2 is shown to be required for transcription of sgRNA. Mutations that prevent base-pairing between the RNA-1 subgenomic promoter and the 34-nucleotide trans-activator prevent expression of a reporter gene. A model is proposed in which direct binding of RNA-2 to RNA-1 trans-activates sgRNA synthesis. This RNA-mediated regulation of transcription is unusual among RNA viruses, which typically rely on protein regulators.	N Carolina State Univ, Dept Plant Pathol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Lommel, SA (corresponding author), N Carolina State Univ, Dept Plant Pathol, Box 7616, Raleigh, NC 27695 USA.	steve_lommel@ncsu.edu		Sit, Tim/0000-0001-7302-823X				Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CRESPI MD, 1994, EMBO J, V13, P5099, DOI 10.1002/j.1460-2075.1994.tb06839.x; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Gallie DR, 1996, PLANT MOL BIOL, V32, P145, DOI 10.1007/BF00039381; GE ZM, 1993, P JPN ACAD B-PHYS, V69, P113, DOI 10.2183/pjab.69.113; GE ZM, 1992, J GEN VIROL, V73, P2483, DOI 10.1099/0022-1317-73-9-2483; Giesman-Cookmeyer D., 1995, PATHOGENESIS HOST SP, V3, P157; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; KENDALL TL, 1992, J GEN VIROL, V73, P2479, DOI 10.1099/0022-1317-73-9-2479; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; Liebhaber S A, 1997, Nucleic Acids Symp Ser, P29; Miller WA, 1997, SEMIN VIROL, V8, P3, DOI 10.1006/smvy.1997.0101; MILLER WA, 1985, NATURE, V313, P68, DOI 10.1038/313068a0; MILLER WS, COMMUNICATION; Scholthof HB, 1996, ANNU REV PHYTOPATHOL, V34, P299, DOI 10.1146/annurev.phyto.34.1.299; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; SIT TL, UNPUB; VAEWHONGS AA, 1995, VIROLOGY, V212, P607, DOI 10.1006/viro.1995.1518; XIONG ZG, 1991, VIROLOGY, V182, P388, DOI 10.1016/0042-6822(91)90687-7; Zavriev SK, 1996, VIROLOGY, V216, P407, DOI 10.1006/viro.1996.0076; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	24	174	177	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					829	832		10.1126/science.281.5378.829	http://dx.doi.org/10.1126/science.281.5378.829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694655				2022-12-01	WOS:000075295600051
J	Sato, K; Wickner, W				Sato, K; Wickner, W			Functional reconstitution of Ypt7p GTPase and a purified vacuole SNARE complex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ALKALINE-PHOSPHATASE; ALPHA-SNAP; PROTEIN; FUSION; TRANSPORT; DOCKING; INHERITANCE; SYNTAXIN-1	Membrane trafficking has heretofore been studied with intact organelles. Here, fusion-competent proteoliposomes were reconstituted from a yeast vacuole detergent extract. Homotypic vacuole fusion requires many membrane proteins, including the Ypt7p guanosine triphosphatase and a "SNARE complex" with Vam3p and Nyv1p. Proteoliposomes from extracts immunodepleted of either Vam3p or Ypt7p could not fuse, but vesicles reconstituted from a mixture of these depleted extracts had restored fusion activity. Purified preassembled vacuolar SNARE complex, when reconstituted with a SNARE-depleted extract, was fully functional for fusion. Thus, solubilized integral membrane components can be reconstituted for priming, docking, and fusion steps of organelle trafficking.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.							CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; KANEKO Y, 1987, GENE, V58, P137; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SATO K, UNPUB; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; YAMADA H, 1989, J BIOL CHEM, V264, P1723; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	23	38	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	1998	281	5377					700	702		10.1126/science.281.5377.700	http://dx.doi.org/10.1126/science.281.5377.700			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9685264				2022-12-01	WOS:000075107900043
J	Keenan, RJ; Freymann, DM; Walter, P; Stroud, RM				Keenan, RJ; Freymann, DM; Walter, P; Stroud, RM			Crystal structure of the signal sequence binding subunit of the signal recognition particle	CELL			English	Article							METHIONINE-RICH DOMAIN; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; DNA RECOGNITION; PEPTIDE COMPLEX; GTP HYDROLYSIS; 4.5S RNA; SRP; CALMODULIN	The crystal structure of the signal sequence binding subunit of the signal recognition particle (SRP) from Thermus aquaticus reveals a deep groove bounded by a flexible loop and lined with side chains of conserved hydrophobic residues. The groove defines a flexible, hydrophobic environment that is likely to contribute to the structural plasticity necessary for SRP to bind signal sequences of different lengths and amino acid sequence. The structure also reveals a helix-turn-helix motif containing an arginine-rich alpha helix that is required for binding to SRP RNA and is implicated in forming the core of an extended RNA binding surface.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Keenan, RJ (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015; Freymann, Douglas/0000-0002-5231-8841; Keenan, Robert/0000-0003-1466-0889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032384, R01GM032384, R01GM024485] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09270] Funding Source: Medline; NIGMS NIH HHS [GM-32384, GM-24485] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; BRUNGER AT, 1996, XPLOR VERSION 3843; CHUPRINA VP, 1993, J MOL BIOL, V234, P446, DOI 10.1006/jmbi.1993.1598; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurita K, 1996, J BIOL CHEM, V271, P13140, DOI 10.1074/jbc.271.22.13140; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lentzen G, 1996, RNA, V2, P244; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MILLER MS, 1994, INT J ONCOL, V4, P5; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; NICHOLLS A, 1992, GRASP MANUAL; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Schmitz U, 1996, RNA, V2, P1213; STEITZ TA, 1982, P NATL ACAD SCI-BIOL, V79, P3097, DOI 10.1073/pnas.79.10.3097; Takamatsu H, 1997, EUR J BIOCHEM, V248, P575, DOI 10.1111/j.1432-1033.1997.00575.x; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	63	227	229	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1998	94	2					181	191		10.1016/S0092-8674(00)81418-X	http://dx.doi.org/10.1016/S0092-8674(00)81418-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695947	Bronze, Green Published			2022-12-01	WOS:000075020100007
J	Pivniouk, V; Tsitsikov, E; Swinton, P; Rathbun, G; Alt, FW; Geha, RS				Pivniouk, V; Tsitsikov, E; Swinton, P; Rathbun, G; Alt, FW; Geha, RS			Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76	CELL			English	Article							T-CELL DEVELOPMENT; TYROSINE KINASE; MUTANT MICE; ALPHA-BETA; LYMPHOCYTE DEVELOPMENT; THYMIC SELECTION; TCR-BETA; B-CELLS; GENE; DIFFERENTIATION	The adaptor protein SLP-76 is expressed in T lymphocytes and myeloid cells and is a substrate for ZAP-70 and Syk. We generated a SLP-76 null mutation in mice by homologous recombination in embryonic stem cells to evaluate the role of SLP-76 in T cell development and activation. SLP-76-deficient mice exhibited subcutaneous and intraperitoneal hemorrhaging and impaired viability. Analysis of lymphoid cells revealed a profound block in thymic development with absence of double-positive CD4(+)8(+) thymocytes and of peripheral T cells. This block could not be overcome by in vivo treatment with anti-CD3. V-D-J rearrangement of the TCR beta locus was not obviously affected. B cell development was normal. These results indicate that SLP-76 collects all pre-TCR signals that drive the development and expansion of double-positive thymocytes.	Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute	Geha, RS (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aifantis I, 1997, IMMUNITY, V7, P601, DOI 10.1016/S1074-7613(00)80381-7; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ardouin L, 1998, J EXP MED, V187, P105, DOI 10.1084/jem.187.1.105; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; daSilva AJ, 1997, BIOCHEM SOC T, V25, P361, DOI 10.1042/bst0250361; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fehling HJ, 1997, IMMUNITY, V6, P703, DOI 10.1016/S1074-7613(00)80446-X; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hollander GA, 1996, P NATL ACAD SCI USA, V93, P4994, DOI 10.1073/pnas.93.10.4994; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; LEVELT CN, 1995, IMMUNITY, V3, P215, DOI 10.1016/1074-7613(95)90091-8; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WALLACE VA, 1995, EUR J IMMUNOL, V25, P1312, DOI 10.1002/eji.1830250527; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	53	317	323	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					229	238		10.1016/S0092-8674(00)81422-1	http://dx.doi.org/10.1016/S0092-8674(00)81422-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695951	Bronze			2022-12-01	WOS:000075020100011
J	Liefers, GJ; Cleton-Jansen, AM; van de Velde, CJH; Hermans, J; van Krieken, JHJM; Cornelisse, CJ; Tollenaar, RAEM				Liefers, GJ; Cleton-Jansen, AM; van de Velde, CJH; Hermans, J; van Krieken, JHJM; Cornelisse, CJ; Tollenaar, RAEM			Micrometastases and survival in stage II colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; LYMPH-NODE MICROMETASTASES; PROGNOSTIC-SIGNIFICANCE; REVERSE-TRANSCRIPTASE; GENETIC DIAGNOSIS; ALLELIC LOSS; TUMOR-CELLS; CARCINOMA; IDENTIFICATION; THERAPY	Background Standard treatment of colorectal cancer includes adjuvant chemotherapy for patients with stage III disease (defined by the presence of lymphnode metastases), but not for patients with stage II tumors (who have no lymph-node metastases). However, 20 percent of patients with stage II tumors die of recurrent disease. We investigated whether the detection of micrometastases can be used to identify patients with stage II disease who are at high risk for recurrence. Methods We analyzed 192 lymph nodes from 26 consecutive patients with stage II colorectal cancer, using a carcinoembryonic antigen-specific nested reverse-transcriptase polymerase chain reaction. Five-year follow-up information was obtained on all patients. Observed and adjusted survival rates were assessed in the patients with and the patients without micrometastases. Results Micrometastases were detected in one or more lymph nodes from 14 of 26 patients (54 percent). The adjusted five-year survival rate (for which only cancer-related deaths were considered) was 50 percent in this group, whereas in the 12 patients without micrometastases, the survival rate was 91 percent (P=0.02 by the log-rank test). The observed five-year survival rates were 36 percent and 75 percent, respectively (P=0.03). The groups were similar with respect to age, sex, tumor side (location in relation to the flexura lienalis), degree of tumor differentiation (grade), and diameter of the primary tumor. Conclusions Molecular detection of micrometastases is a prognostic tool in stage II colorectal cancer. (N Engl J Med 1998;339:223-8.) (C)1998, Massachusetts Medical Society.	Leiden Univ, Med Ctr, Dept Surg K6R, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Tollenaar, RAEM (corresponding author), Leiden Univ, Med Ctr, Dept Surg K6R, POB 9600, NL-2300 RC Leiden, Netherlands.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040				Adell G, 1996, EUR J SURG, V162, P637; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX DR, 1972, J R STAT SOC B, V34, P187; CUTAIT R, 1991, DIS COLON RECTUM, V34, P917, DOI 10.1007/BF02049708; GERHARD M, 1994, J CLIN ONCOL, V12, P725, DOI 10.1200/JCO.1994.12.4.725; GOLDHIRSCH A, 1990, LANCET, V335, P1565; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; Gunn J, 1996, LAB INVEST, V75, P611; HAYASHI N, 1994, CANCER RES, V54, P3853; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; International Union Against Cancer (UICC), 1997, J CLIN PATHOL; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; JASS JR, 1986, HISTOPATHOLOGY, V10, P437, DOI 10.1111/j.1365-2559.1986.tb02497.x; JEFFERS MD, 1994, J PATHOL, V172, P183, DOI 10.1002/path.1711720205; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MORI M, 1995, CANCER RES, V55, P3417; Nakamori S, 1997, DIS COLON RECTUM, V40, pS29, DOI 10.1007/BF02062017; NEUMAIER M, 1995, GENE, V159, P43, DOI 10.1016/0378-1119(94)00522-T; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; SCHOENFELD A, 1994, CANCER RES, V54, P2986; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; SHIVELY JE, 1985, CRC CR REV ONCOL-HEM, V2, P355, DOI 10.1016/S1040-8428(85)80008-1; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G	31	528	556	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1998	339	4					223	228		10.1056/NEJM199807233390403	http://dx.doi.org/10.1056/NEJM199807233390403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	102HQ	9673300				2022-12-01	WOS:000074918700003
J	Winkleby, MA; Kraemer, HC; Ahn, DK; Varady, AN				Winkleby, MA; Kraemer, HC; Ahn, DK; Varady, AN			Ethnic and socioeconomic differences in cardiovascular disease risk factors - Findings for women from the third national health and nutrition examination survey, 1988-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; STANFORD 5-CITY PROJECT; NON-HISPANIC WHITES; MEXICAN-AMERICANS; UNITED-STATES; COMMUNITY INTERVENTION; SOCIAL INEQUALITIES; PREVALENCE; MORTALITY	Context.-Cardiovascular disease (CVD) risk factors are higher among ethnic minority women than among white women in the United States. However, because ethnic minority women are disproportionately poor, socioeconomic status (SES) may substantially explain these risk factor differences. Objective.-To determine whether differences in CVD risk factors by ethnicity could be attributed to differences in SES. Design.-Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Setting.-Eighty-nine mobile examination centers. Participants.-A total of 1762 black, 1481 Mexican American, and 2023 white women, aged 25 to 64 years, who completed both the home questionnaire and medical examination. Main Outcome Measures.-Ethnicity and years of education (SES) in relation to systolic blood pressure, cigarette smoking, body mass index (BMI, a measure of weight in kilograms divided by the square of height in meters), physical inactivity, non-high-density lipoprotein cholesterol (non-HDL-C [the difference between total cholesterol and HDL-C]), and non-insulin-dependent diabetes mellitus. Results.-As expected, most CVD risk factors were higher among ethnic minority women than among white women. After adjusting for years of education, highly significant differences in blood pressure, BMI, physical inactivity, and diabetes remained for both black and Mexican American women compared with white women (P<.001). In addition, women of lower SES from each of the 3 ethnic groups had significantly higher prevalences of smoking and physical inactivity and higher levels of BMI and non-HDL-C than women of higher SES (P<.001). Conclusions.-These findings provide the greatest evidence to date of higher CVD risk factors among black and Mexican American women than among white women of comparable SES. The striking differences by both ethnicity and SES underscore the critical need to improve screening, early detection, and treatment of CVD-related conditions for black and Mexican American women, as well as for women of lower SES in all ethnic groups.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Winkleby, MA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 1000 Welch Rd, Palo Alto, CA 94304 USA.	marilyn_winkleby@scrdp.stanford.edu			NHLBI NIH HHS [1-RO3-HL-57100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL057100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Anderson NB, 1995, HEALTH PSYCHOL, V14, P589, DOI 10.1037/0278-6133.14.7.589; ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; BOYKO EJ, 1991, DIABETES, V40, P509, DOI 10.2337/diabetes.40.4.509; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CARLETON RA, 1995, AM J PUBLIC HEALTH, V85, P777, DOI 10.2105/AJPH.85.6.777; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; COWIE CC, 1993, AM J EPIDEMIOL, V137, P719, DOI 10.1093/oxfordjournals.aje.a116732; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; DAY JC, 1996, P251130 US BUR CENS; DIEHL AK, 1989, ADV INTERNAL MED, V34, P79; DIEZROUX AV, 1995, AM J EPIDEMIOL, V141, P960, DOI 10.1093/oxfordjournals.aje.a117363; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FINUCANE TE, 1990, J GEN INTERN MED, V5, P120, DOI 10.1007/BF02600511; FORTMANN SP, 1995, AM J EPIDEMIOL, V142, P576, DOI 10.1093/oxfordjournals.aje.a117678; FRANCO LJ, 1985, AM J EPIDEMIOL, V121, P684, DOI 10.1093/aje/121.5.684; FRANK E, 1992, JAMA-J AM MED ASSOC, V268, P1566, DOI 10.1001/jama.268.12.1566; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gidding SS, 1996, AM J CARDIOL, V78, P304, DOI 10.1016/S0002-9149(96)00282-2; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GINZBERG E, 1991, JAMA-J AM MED ASSOC, V265, P238, DOI 10.1001/jama.265.2.238; Goff DC, 1997, CIRCULATION, V95, P1433; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAFFNER SM, 1993, HYPERTENSION, V21, P83, DOI 10.1161/01.HYP.21.1.83; HAMMAN RF, 1989, AM J EPIDEMIOL, V129, P295, DOI 10.1093/oxfordjournals.aje.a115134; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; HENDEE WR, 1991, JAMA-J AM MED ASSOC, V265, P248; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KAUTZ JA, 1981, CIRCULATION, V64, P730, DOI 10.1161/01.CIR.64.4.730; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KELSEY JL, 1986, METHODS OBSERVATIONA; KRIEGER N, 1993, AM J PUBLIC HEALTH, V83, P1086, DOI 10.2105/AJPH.83.8.1086; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUMANYIKA SK, 1993, ANN INTERN MED, V119, P650, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00005; LIAO Y, 1995, PUBLIC HEALTH REP, V110, P572; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LUEPKER RV, 1993, CIRCULATION, V88, P2172, DOI 10.1161/01.CIR.88.5.2172; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; LYNCH J, 1995, CIRCULATION, V92, P1786, DOI 10.1161/01.CIR.92.7.1786; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; Marilyn, 1994, LATINO HLTH US GROWI, P23; MARIN G, 1993, PUBLIC HEALTH REP, V108, P546; MARMOT MG, 1986, LANCET, V2, P274; MARTIN DC, 1993, STAT MED, V12, P329, DOI 10.1002/sim.4780120315; MCDOWELL A, 1981, VITAL HLTH STAT, V1; MILLER HW, 1977, VITAL HLTH STAT, V1; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; Mitchell BD, 1996, CIRCULATION, V94, P2159, DOI 10.1161/01.CIR.94.9.2159; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; *NAT HEART LUNG BL, 1995, C SOC STAT CARD HLTH; NAUMBURG EH, 1993, J FAM PRACTICE, V36, P425; *PHS, 1990, DHHS PUBL; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; PUGH JA, 1988, J GEN INTERN MED, V3, P331, DOI 10.1007/BF02595790; Ramirez AG, 1996, PUBLIC HEALTH REP, V111, P25; REESE JW, 1977, HEW CDC PUBLICATION; REYNES JF, 1993, AM J PREV MED, V9, P365, DOI 10.1016/S0749-3797(18)30689-5; SHAH BV, 1991, SUDAAN USERS MANUAL; SHEA S, 1991, AM J EPIDEMIOL, V134, P567, DOI 10.1093/oxfordjournals.aje.a116130; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SORLIE PD, 1993, JAMA-J AM MED ASSOC, V270, P2464, DOI 10.1001/jama.270.20.2464; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; Stafford RS, 1997, J AM COLL CARDIOL, V29, P139, DOI 10.1016/S0735-1097(96)00441-X; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; Syme SL, 1996, ANN EPIDEMIOL, V6, P463, DOI 10.1016/S1047-2797(96)00097-X; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEPT HHS, 1989, DHHS PUBL, pCH6; VEGA WA, 1994, ANNU REV PUBL HEALTH, V15, P39, DOI 10.1146/annurev.pu.15.050194.000351; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WENNEKER MB, 1987, JAMA-J AM MED ASSOC, V261, P253; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; Winkleby MA, 1997, ANN EPIDEMIOL, V7, pS96, DOI 10.1016/S1047-2797(97)80012-9; Winkleby MA, 1997, J CLIN EPIDEMIOL, V50, P645, DOI 10.1016/S0895-4356(97)00020-6; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Winkleby MA, 1996, PREV MED, V25, P203, DOI 10.1006/pmed.1996.0047	87	438	441	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					356	362		10.1001/jama.280.4.356	http://dx.doi.org/10.1001/jama.280.4.356			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	100FC	9686553	Bronze			2022-12-01	WOS:000074804200036
J	Nightingale, SL				Nightingale, SL			Proposal published on dissemination of information on unapproved uses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1998	280	1					12	12		10.1001/jama.280.1.12	http://dx.doi.org/10.1001/jama.280.1.12			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW145	9660348				2022-12-01	WOS:000074379400005
J	Kozasa, T; Jiang, XJ; Hart, MJ; Sternweis, PM; Singer, WD; Gilman, AG; Bollag, G; Sternweis, PC				Kozasa, T; Jiang, XJ; Hart, MJ; Sternweis, PM; Singer, WD; Gilman, AG; Bollag, G; Sternweis, PC			p115 RhoGEF, a GTPase activating protein for G alpha(12) and G alpha(13)	SCIENCE			English	Article							ALPHA-SUBUNITS; DBL FAMILY; PURIFICATION; INHIBITION; CLONING; CELLS; RGS4	Members of the regulators of G protein signaling (RGS) family stimulate the intrinsic guanosine triphosphatase (GTPase) activity of the alpha subunits of certain heterotrimeric guanine nucleotide-binding proteins (G proteins). The guanine nucleotide exchange factor (GEF) for Rho, p115 RhoGEF, has an amino-terminal region with similarity to RGS proteins. Recombinant p115 RhoGEF and a fusion protein containing the amino terminus of p115 had specific activity as GTPase activating proteins toward the alpha subunits of the G proteins G(12) and G(13), but not toward members of the G(s), G(i), or G(q) subfamilies of G alpha proteins. This GEF may act as an intermediary in the regulation of Rho proteins by G(13) and G(12).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kozasa, T (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.	tohru.kozasa@email.swmed.edu; bollag@onyx-pharm.com; slernwei@utsw.swmed.edu		Hart, Matthew/0000-0002-2683-480X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM031954, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497, GM31954] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; INGI T, IN PRESS J NEUROSCI; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KOZASA T, UNPUB; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	35	708	716	3	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2109	2111		10.1126/science.280.5372.2109	http://dx.doi.org/10.1126/science.280.5372.2109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641915				2022-12-01	WOS:000074435900043
J	Yamaoka, S; Courtois, G; Bessia, C; Whiteside, ST; Weil, R; Agou, F; Kirk, HE; Kay, RJ; Israel, A				Yamaoka, S; Courtois, G; Bessia, C; Whiteside, ST; Weil, R; Agou, F; Kirk, HE; Kay, RJ; Israel, A			Complementation cloning of NEMO, a component of the I kappa B kinase complex essential for NF-kappa B activation	CELL			English	Article							VIRUS TYPE-I; RAT FIBROBLASTS; TAX PROTEIN; EXPRESSION; PATHWAY	We have characterized a flat cellular variant of HTLV-1 Tax-transformed rat fibroblasts, 5R, which is unresponsive to all tested NF-kappa B activating stimuli, and we report here its genetic complementation. The recovered full-length cDNA encodes a 48 kDa protein, NEMO (NF-kappa B Essential MOdulator), which contains a putative leucine zipper motif. This protein is absent from 5R cells, is part of the high molecular weight I kappa B kinase complex, and is required for its formation. In vitro, NEMO can homodimerize and directly interacts with IKK-2. The NEMO cDNA was also able to complement another NF-kappa B-unresponsive cell line, 1.3E2, in which the protein is also absent, allowing us to demonstrate that this factor is required not only for Tax but also for LPS, PMA, and IL-1 stimulation of NF-kappa B activity.	Inst Pasteur, Unite Biol Mol Express Gen, CNRS, URA 1773, F-75724 Paris 15, France; Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS, URA 1773, F-75724 Paris, France; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 606, Japan	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; British Columbia Cancer Agency; Kyoto University	Yamaoka, S (corresponding author), Inst Pasteur, Unite Biol Mol Express Gen, CNRS, URA 1773, 25 Rue Dr Roux, F-75724 Paris 15, France.		, AGOU/GXA-2760-2022	Weil, Robert/0000-0001-5235-0932; COURTOIS, Gilles/0000-0003-3117-9595				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; PYSZNIAK AM, 1994, J IMMUNOL, V152, P5241; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	28	917	965	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 26	1998	93	7					1231	1240		10.1016/S0092-8674(00)81466-X	http://dx.doi.org/10.1016/S0092-8674(00)81466-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657155	Bronze			2022-12-01	WOS:000074491100017
J	Wainberg, MA; Friedland, G				Wainberg, MA; Friedland, G			Public health implications of antiretroviral therapy and HIV drug resistance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ZIDOVUDINE-RESISTANCE; HETEROSEXUAL TRANSMISSION; TYPE-1 RNA; IN-VIVO; SEROPOSITIVE INDIVIDUALS; GENITAL SECRETIONS; SEMINAL PLASMA; INFECTION	Widespread use of antiretroviral agents and increasing occurrence of human immunodeficiency virus (HIV) strains resistant to these drugs have given rise to a number of important issues. Some of these concerns are distinct from the obvious question of the relationship between drug resistance and treatment failure and have potentially widespread public health implications. The relevant issues include but are not limited to the following. (1) frequency with which drug-resistant virus may be transmitted via sexual, intravenous, or mother-to-child routes; (2) ability of drug-resistant variants to be transmitted, a question that relates, in part, to the relative fitness of such strains; (3) effectiveness of antiviral therapy in diminishing viral burden in both blood and genital secretions, and whether this may be compromised in persons harboring resistant virus; and (4) importance of patient adherence to antiviral therapy and its relationship to sustained reduction in viral load to minimize the appearance in and transmission of drug-resistant virus from both blood and genital secretions. Thus, prevention of both development of HIV drug resistance as well as transmission of drug-resistant variants is a central issue of public: health importance. Unless this topic is appropriately addressed, the likelihood is that drug-resistant variants of HIV, if able to successfully replicate, will sustain the epidemic and limit the effectiveness of antiviral therapy.	McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada; Yale Univ, Sch Med, AIDS Program, New Haven, CT USA	McGill University; Yale University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdwa@musica.mcgill.ca						Albrecht H, 1998, AIDS, V12, P333; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bayer R, 1997, IMPLICATIONS OF ANTIRETROVIRAL TREATMENTS, P95; BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121; Byrn RA, 1997, LANCET, V350, P1141, DOI 10.1016/S0140-6736(97)24042-0; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P468; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; COLGROVE R, 1998, 5 C RETR OPP INF CHI; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONWAY B, 1997, INT WORKSH HIV DRUG; CONWAY B, 1996, 3 INT C DRUG THER HI; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; CORELLI RL, 1991, DICP ANN PHARMAC, V25, P1374; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DEEKS S, 1998, 5 C RETR OPP INF CHI; Delwart EL, 1998, J VIROL, V72, P617, DOI 10.1128/JVI.72.1.617-623.1998; DEOLIVEIRA CF, 1998, 5 C RETR OPP INF CHI; deRonde A, 1996, AIDS, V10, P231, DOI 10.1097/00002030-199602000-00017; Doyon L, 1996, J VIROL, V70, P3763, DOI 10.1128/JVI.70.6.3763-3769.1996; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ERON J, 1998, 5 C RETR OPP INF CHI; EVANS JS, 1998, 5 C RETR OPP INF CHI; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; GRIFFITH S, 1990, BRIT J GEN PRACT, V40, P114; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HART C, 1998, 5 C RETR OPP INF CHI; Haynes RB, 1996, LANCET, V348, P383; Haynes RB, 1979, COMPLIANCE HLTH CARE; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOESLEY C, 1998, 5 C RETR OPP INF CHI; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; Ickovics JR, 1997, J CLIN EPIDEMIOL, V50, P385, DOI 10.1016/S0895-4356(97)00041-3; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; JAPOUR AJ, 1995, J INFECT DIS, V171, P1172, DOI 10.1093/infdis/171.5.1172; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KATZENSTEIN DA, 1992, J ACQ IMMUN DEF SYND, V5, P107; Kotler DP, 1998, AIDS, V12, P597, DOI 10.1097/00002030-199806000-00008; KRAVCIK S, 1998, 5 C RETR OPP INF CHI; KROODSMA KL, 1994, J INFECT DIS, V170, P1292, DOI 10.1093/infdis/170.5.1292; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; LENNOX J, 1997, 4 C RETR OPP INF WAS; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MAYERS D, 1997, INT WORKSH HIV DRUG; MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MONTANER JSG, 1995, ANN INTERN MED, V123, P561, DOI 10.7326/0003-4819-123-8-199510150-00001; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MOORE RD, 1997, 37 INT C ANT AG CHEM; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; MUMA RD, 1995, AIDS CARE, V7, P439, DOI 10.1080/09540129550126399; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; NIJHUIS M, 1997, INT WORKSH HIV DRUG; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; O'Brien M K, 1992, Med Care Rev, V49, P435, DOI 10.1177/002570879204900403; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; POMERANTZ R, 1998, 5 C RETR OPP INF CHI; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541; Quigg M, 1997, AIDS, V11, P835; Ragni MV, 1998, J ACQ IMMUN DEF SYND, V17, P42, DOI 10.1097/00042560-199801010-00006; RASHEED S, 1995, J REPROD MED, V40, P747; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rubio A, 1997, AIDS, V11, P1184, DOI 10.1097/00002030-199709000-00016; Sackett DL, 1979, COMPLIANCE HLTH CARE; SALOMON H, 1995, ANTIVIR CHEM CHEMOTH, V6, P222, DOI 10.1177/095632029500600404; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; UVIN CU, 1998, 5 C RETR OPP INF CHI; VERNAZZA L, 1998, 5 C RETR OPP INF CHI; Vernazza PL, 1996, J VIROL METHODS, V56, P33, DOI 10.1016/0166-0934(95)01899-9; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; VUTHIPONGSE P, 1998, MMWR-MORBID MORTAL W, V47, P151; WAHLBERG J, 1994, J INFECT DIS, V169, P611, DOI 10.1093/infdis/169.3.611; WAINBERG M, 1996, 3 INT C DRUG THER HI; WALL TL, 1995, DRUG ALCOHOL DEPEN, V37, P261, DOI 10.1016/0376-8716(94)01080-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Williams A, 1997, AIDS Clin Care, V9, P51; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu C, 1997, J INFECT DIS, V176, P941, DOI 10.1086/516539; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	110	375	388	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1998	279	24					1977	1983		10.1001/jama.279.24.1977	http://dx.doi.org/10.1001/jama.279.24.1977			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU945	9643862				2022-12-01	WOS:000074252100035
J	Geiger, H; Sick, S; Bonifer, C; Muller, AM				Geiger, H; Sick, S; Bonifer, C; Muller, AM			Globin gene expression is reprogrammed in chimeras generated by injecting adult hematopoietic stem cells into mouse blastocysts	CELL			English	Article							YOLK-SAC; DEVELOPMENTAL REGULATION; EMBRYO; MICE; FETUSES; REGION; LOCUS; SPLANCHNOPLEURA; DIFFERENTIATION; CULTURE	To elucidate whether the differentiation capacity of hematopoietic stem cells (HSCs) is influenced by specific microenvironments, adult mouse bone marrow-derived HSCs were injected into mouse blastocysts. Embryos developing from injected blastocysts contained donor-derived cells at various developmental stages, and progeny of the stem cells were detected in hematopoietic tissues. Thus, HSCs derived from an adult animal survive after injection into blastocysts and are able to participate in hematopoietic development. We further find that the erythroid progeny of transplanted adult HSCs express embryonic/fetal-type globin genes and, conversely, that embryonic and fetal progenitor cells transplanted into adult recipients transcribe the adult-type globin gene. Thus, the developmental potential of adult HSCs is evidently more plastic than previously thought, and the developmental stage of the hematopoietic microenvironment controls the developmental fate of transplanted progenitor cells.	Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Max Planck Society; University of Freiburg	Muller, AM (corresponding author), Max Planck Inst Immunobiol, D-79108 Freiburg, Germany.		Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BLANCHET JP, 1982, DEV GENET, V3, P197, DOI 10.1002/dvg.1020030303; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Faust N, 1997, EXP HEMATOL, V25, P432; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; FLEISCHMAN RA, 1984, J EXP MED, V159, P731, DOI 10.1084/jem.159.3.731; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARDNER RL, 1985, J EMBRYOL EXP MORPH, V88, P349; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HERZENBERG LA, 1992, ANN NY ACAD SCI, V651, P1; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; LANSDORP PM, 1994, BLOOD CELLS, V20, P376; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1971, HAEMOPOIETIC CELLS, P172; MORRIS L, 1991, DEVELOPMENT, V112, P517; MOUCHIROUD G, 1981, BLOOD, V57, P586; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OKADA S, 1992, BLOOD, V80, P3044; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; Tanosaki R, 1997, BRIT J HAEMATOL, V98, P1017, DOI 10.1046/j.1365-2141.1997.2983115.x; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; VanZant G, 1997, EXP HEMATOL, V25, P187; WEISSMAN IL, 1976, COLD SPRING HARB SYM, V41, P9, DOI 10.1101/SQB.1977.041.01.005; Yoder MC, 1997, P NATL ACAD SCI USA, V94, P6776, DOI 10.1073/pnas.94.13.6776; ZANJANI ED, 1982, NATURE, V295, P244, DOI 10.1038/295244a0	45	105	112	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1998	93	6					1055	1065		10.1016/S0092-8674(00)81210-6	http://dx.doi.org/10.1016/S0092-8674(00)81210-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635434	Bronze			2022-12-01	WOS:000074205700016
J	Nowak, MA; Sigmund, K				Nowak, MA; Sigmund, K			Evolution of indirect reciprocity by image scoring	NATURE			English	Article							TIT-FOR-TAT; PRISONERS-DILEMMA; COOPERATION	Darwinian evolution has to provide an explanation for cooperative behaviour. Theories of cooperation are based on kin selection (dependent on genetic relatedness)(1,2), group selection(3-5) and reciprocal altruism(6-9). The idea of reciprocal altruism usually involves direct reciprocity: repeated encounters between the same individuals allow for the return of an altruistic act by the recipient(10-16). Here we present a new theoretical framework, which is based on indirect reciprocity(17) and does not require the same two individuals ever to meet again, individual selection can nevertheless favour cooperative strategies directed towards recipients that have helped others in the past. Cooperation pays because it confers the image of a valuable community member to the cooperating individual. We present computer simulations and analytic models that specify the conditions required for evolutionary stability(18) of indirect reciprocity. We show that the probability of knowing the 'image' of the recipient must exceed the cost-to-benefit ratio of the altruistic act. We propose that the emergence of indirect reciprocity was a decisive step for the evolution of human societies.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Univ Vienna, Inst Math, A-1090 Vienna, Austria	University of Oxford; University of Vienna	Nowak, MA (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	martin.nowak@zoo.ox.ac.uk	Nowak, Martin A/A-6977-2008					Alexander RD, 1987, BIOL MORAL SYSTEMS; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod Robert K., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Binmore Ken, 1992, FUN GAMES TEXT GAME, P29; BOYD R, 1989, SOC NETWORKS, V11, P213, DOI 10.1016/0378-8733(89)90003-8; Buss L. W., 1987, EVOLUTION INDIVIDUAL; DUGATKIN LA, 1992, TRENDS ECOL EVOL, V7, P202, DOI 10.1016/0169-5347(92)90074-L; ESHEL I, 1972, THEOR POPUL BIOL, V3, P258, DOI 10.1016/0040-5809(72)90003-2; FRANK SA, 1995, J THEOR BIOL, V176, P403, DOI 10.1006/jtbi.1995.0208; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hofbauer J., 1998, EVOLUTIONARY GAMES P, DOI 10.1017/CBO9781139173179; Krebs J.R., 1987, BEHAV ECOL, Vsecond; Marler P, 1996, IBIS, V138, P26; MAY RM, 1987, NATURE, V327, P15, DOI 10.1038/327015a0; Maynard Smith J., 1982, pi; Michod R.E., 1985, P95; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; NOWAK MA, UNPUB J THEOR BIOL; PECK JR, 1986, AM NAT, V127, P209, DOI 10.1086/284479; POLLOCK G, 1992, J THEOR BIOL, V159, P25, DOI 10.1016/S0022-5193(05)80765-9; Sudgen R, 1986, EC RIGHTS COOPERATIO; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Williams G.C., 1971, GROUP SELECTION; WILSON DS, 1994, BEHAV BRAIN SCI, V17, P585, DOI 10.1017/S0140525X00036104; Wilson E.O., 1975, P1; Zahavi A., 1999, HANDICAP PRINCIPLE M	30	1515	1555	7	288	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					573	577		10.1038/31225	http://dx.doi.org/10.1038/31225			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634232				2022-12-01	WOS:000074150100051
J	Wagner, A				Wagner, A			On being eighty	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1766	1766		10.1001/jama.279.22.1766-a	http://dx.doi.org/10.1001/jama.279.22.1766-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628693				2022-12-01	WOS:000073998500001
J	Nightingale, SL				Nightingale, SL			Viagra approval information on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-01	WOS:000073878700004
J	Ye, WL; Shimamura, K; Rubenstein, JLR; Hynes, MA; Rosenthal, A				Ye, WL; Shimamura, K; Rubenstein, JLR; Hynes, MA; Rosenthal, A			FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPRESSION DOMAINS; SONIC HEDGEHOG; FLOOR PLATE; TYROSINE-HYDROXYLASE; MOUSE EMBRYO; RAT-BRAIN; MIDBRAIN; INDUCTION; DIFFERENTIATION	During development, distinct classes of neurons are specified in precise locations along the dorso-ventral and anterior-posterior axes of the neural tube. We provide evidence that intersections of Shh, which is expressed along the ventral neural tube, and FGF8, which is locally produced at the mid/hindbrain boundary and in the rostral forebrain, create induction sites for dopaminergic neurons in the midbrain and forebrain. The same intersection, when preceded by a third signal, FGF4, which is expressed in the primitive streak, defines an inductive center for hindbrain 5-HT neurons. These findings illustrate that cell patterning in the neural plate is a multistep process in which early inducers, which initially divide the neural plate into crude compartments, are replaced by multiple local organizing centers, which specify distinct neuronal cell types within these compartments.	Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA	Roche Holding; Genentech; University of California System; University of California San Francisco	Rosenthal, A (corresponding author), Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA.			Hynes, Mary/0000-0001-6623-6727; Ye, Weilan/0000-0002-6219-3982	NIMH NIH HHS [K02 MH01046-01.18.] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001046] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cox WG, 1995, DEVELOPMENT, V121, P4349; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Foley AC, 1997, DEVELOPMENT, V124, P2983; GARDNER CA, 1991, DEVELOPMENT, V113, P1037; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HORGER BA, 1995, J NEUROCHEM, V65, P770; Houart C, 1998, NATURE, V391, P788, DOI 10.1038/35853; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LAWSON KA, 1992, CIBA F SYMP, V165, P3; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; NISWANDER L, 1992, DEVELOPMENT, V114, P755; PLACZEK M, 1993, DEVELOPMENT, V117, P205; Pownall ME, 1996, DEVELOPMENT, V122, P3881; RESIBOIS A, 1992, NEUROSCIENCE, V46, P101, DOI 10.1016/0306-4522(92)90012-Q; ROGERS JH, 1992, BRAIN RES, V587, P203, DOI 10.1016/0006-8993(92)90998-O; ROWITCH DH, 1995, MECH DEVELOP, V52, P3, DOI 10.1016/0925-4773(95)00380-J; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SASAKI H, 1993, DEVELOPMENT, V118, P47; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; Smidt MP, 1997, P NATL ACAD SCI USA, V94, P13305, DOI 10.1073/pnas.94.24.13305; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; Storey KG, 1998, DEVELOPMENT, V125, P473; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	57	703	737	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					755	766		10.1016/S0092-8674(00)81437-3	http://dx.doi.org/10.1016/S0092-8674(00)81437-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630220	Bronze			2022-12-01	WOS:000073956700012
J	Tybjaerg-Hansen, A; Steffensen, R; Meinertz, H; Schnohr, P; Nordestgaard, BG				Tybjaerg-Hansen, A; Steffensen, R; Meinertz, H; Schnohr, P; Nordestgaard, BG			Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL DEFECTIVE APOLIPOPROTEIN-B-100; RECEPTOR-BINDING; CHOLESTEROL; B-100; PRAVASTATIN; PREVENTION	Background Familial hypercholesterolemia leads to premature ischemic heart disease and is often caused by mutations in the gene for the low-density lipoprotein receptor. Mutations in the apolipoprotein B gene, which encodes a ligand for this receptor, may also result in this phenotype, Methods We studied the genotypes of 9255 women and men from the general population, 948 patients with ischemic heart disease, and 36 patients with familial hypercholesterolemia, all from Denmark, for three mutations in the apolipoprotein B gene: Arg3500Gln, Arg3531Cys, and Arg3500Trp. Results The prevalence of heterozygotes in the general population was 0.08 percent (95 percent confidence interval, 0.03 to 0.16 percent) for both the Arg3500Gln and the Arg3531Cys mutations, and 0.00 percent (95 percent confidence interval, 0.00 to 0.18 percent) for the Arg3500Trp mutation. Among carriers of the Arg3500Gln mutation, cholesterol levels were significantly higher than among noncarriers in the general population - by 100 mg per deciliter (2.6 mmol per liter) among carriers in the general population, 154 mg per deciliter (4.0 mmol per liter) among patients with ischemic heart disease, and 172 mg per deciliter (4.5 mmol per liter) among patients with familial hypercholesterolemia. Heterozygous carriers of the Arg3500Gln mutation were significantly more common among patients with ischemic heart disease (odds ratio, 7.0; 95 percent confidence interval, 2.2 to 22; P=0.003) and patients with familial hypercholesterolemia (odds ratio, 78; 95 percent confidence interval, 16 to 388; P=0.001) than in the general population. Heterozygous carriers of the Arg3531Cys mutation in the general population did not have higher-than-normal plasma cholesterol levels or an increased risk of ischemic heart disease (odds ratio; 1.4; 95 percent confidence interval, 0.2 to 11; P=0.54), Conclusions The Arg3500Gln mutation in the apolipoprotein B gene, which is responsible for familial defective apolipoprotein B-100 and is present in approximately 1 in 1000 persons in Denmark, causes severe hypercholesterolemia and increases the risk of ischemic heart disease. (C) 1998, Massachusetts Medical Society.	Univ Copenhagen, Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark; Univ Copenhagen, Rigshosp, Natl Univ Hosp, Dept Med B,Div Cardiol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Natl Univ Hosp, Copenhagen City Heart Study, DK-2100 Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Tybjaerg-Hansen, A (corresponding author), Herlev Univ Hosp, Dept Clin Biochem 54M1, Herlev Ringvej 75, DK-2730 Herlev, Denmark.		Nordestgaard, Borge Gronne/ABF-1310-2020					AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P541, DOI 10.1111/j.1651-2227.1979.tb05052.x; ARMITAGE P, 1987, STAT METHODS MED RES, P67; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAFFNEY D, 1995, ARTERIOSCL THROM VAS, V15, P1025, DOI 10.1161/01.ATV.15.8.1025; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; *GRAPHP SOFTW, 1995, STATM VERS 1 0; HANSEN PS, 1994, CLIN CHIM ACTA, V230, P101, DOI 10.1016/0009-8981(94)90093-0; HANSEN PS, 1991, J LIPID RES, V32, P1229; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; Julian DG, 1997, EUR HEART J, V18, P394; Ludwig EH, 1997, J LIPID RES, V38, P1361; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; Nordestgaard BG, 1997, CIRCULATION, V96, P1737, DOI 10.1161/01.CIR.96.6.1737; PEDERSEN TR, 1994, LANCET, V344, P1383; PULLINGER CR, 1995, J CLIN INVEST, V95, P1225, DOI 10.1172/JCI117772; PYORALA K, 1994, EUR HEART J, V15, P1300; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; SPSS, 1996, SPSS BAS 7 0 WIND US; Talmud PJ, 1996, ATHEROSCLEROSIS, V125, P135, DOI 10.1016/0021-9150(96)05838-8; TybjaergHansen A, 1997, J CLIN INVEST, V99, P3034, DOI 10.1172/JCI119499; TYBJAERGHANSEN A, 1995, SCAND J CLIN LAB INV, V55, P57; TYBJAERGHANSEN A, 1992, ATHEROSCLEROSIS, V96, P91, DOI 10.1016/0021-9150(92)90056-M; Wenham PR, 1997, ATHEROSCLEROSIS, V129, P185, DOI 10.1016/S0021-9150(96)06029-7; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323	30	150	154	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1998	338	22					1577	1584		10.1056/NEJM199805283382203	http://dx.doi.org/10.1056/NEJM199805283382203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ350	9603795	Bronze			2022-12-01	WOS:000073852400003
J	Wieczorek, E; Brand, M; Jacq, X; Tora, L				Wieczorek, E; Brand, M; Jacq, X; Tora, L			Function of TAF(II)-containing complex without TBP in transcription by RNA polymerase II	NATURE			English	Article							TATA-BINDING PROTEIN; ESTROGEN-RECEPTOR; TFIID COMPLEX; ACTIVATION FUNCTIONS; PROMOTER; PURIFICATION; INITIATION; EXPRESSION; DROSOPHILA; SUBUNITS	Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex. Assembly of this complex(1,2) is thought to be nucleated exclusively by the sequence-specific binding of the TFIID transcription factor complex, which is composed of the TATA-binding protein (TBP) and TBP-associated factors (TAF(II)s) (refs 3, 4), to the different promoters. Here we isolate and characterize a new multiprotein complex that does not contain either TBP or a TBP-like factor but is composed of several TAF(II)s and other proteins. This complex can replace TFIID on both TATA-containing and TATA-lacking promoters in in vitro transcription assays. Moreover, an anti-TBP antibody that inhibits TBP- and TFIID-dependent transcription does not inhibit activity of this new complex. These results indicate that TBP-free RNA polymerase II mediated transcription may be able to occur in mammalian cells and that multiple preinitiation complexes may play an important role in regulating gene expression.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.		Tora, Laszlo/E-9999-2018; Wieczorek, Elżbieta/GXZ-9842-2022	Tora, Laszlo/0000-0001-7398-2250; 				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BOAM DS, 1995, J BIOL CHEM, V270, P487; BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Chang MP, 1997, NUCLEIC ACIDS RES, V25, P4861, DOI 10.1093/nar/25.24.4861; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P85; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LAVIGNE AC, 1996, J BIOL CHEM, V271, P774; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	29	220	228	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					187	191		10.1038/30283	http://dx.doi.org/10.1038/30283			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603525				2022-12-01	WOS:000073619900054
J	Rockey, DC; Koch, J; Cello, JP; Sanders, LL; McQuaid, K				Rockey, DC; Koch, J; Cello, JP; Sanders, LL; McQuaid, K			Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL-CANCER; CHEMICAL-TESTS; NEGATIVE COLONOSCOPY; RECTAL EXAMINATION; UPPER ENDOSCOPY; CR-51 METHOD; SENSITIVITY; MORTALITY; DISEASE; POLYPS	Background Although bleeding lesions anywhere in the gastrointestinal tract can cause a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gastrointestinal and colonic lesions is unknown. Methods During a period of 30 months, we prospectively studied all patients with at least one stool specimen containing fecal occult blood who were referred for further evaluation. Fecal occult blood was detected by standard guaiac-based tests of stool specimens obtained as part of routine screening or of stool obtained by digital rectal examination. Patients with documented iron-deficiency anemia or active gastrointestinal bleeding were excluded from the study. All participants had a detailed history taken and underwent colonoscopy, followed by esophagogastroduodenoscopy. Results Of the 409 patients with fecal occult blood who were referred, 310 were potentially eligible to participate, and 248 (mean age, 61 years; range, 40 to 89) were studied; 40 percent were women. We identified lesions consistent with occult bleeding in 119 patients (48 percent); in 71 bleeding lesions were found in the upper gastrointestinal tract, and in 54 they were identified in the colon. Six patients had abnormalities in both areas. The most common upper gastrointestinal lesions were esophagitis (23 patients), gastric ulcer (14), gastritis (12), and duodenal ulcer (10). Thirty patients with lesions in the upper gastrointestinal tract were long-term users of aspirin, ethanol, nonsteroidal antiinflammatory drugs, or a combination of these substances. The most com mon colonic lesions were adenomas more than 1.0 cm in diameter (29 patients), carcinoma (13), colitis (5), and vascular ectasia (5). Although the overall sensitivity of symptoms for the detection of gastrointestinal lesions was low, logistic-regression analysis demonstrated that the presence of symptoms in the upper gastrointestinal tract was associated with the detection of lesions in the upper gastrointestinal tract (odds ratio, 2.6; 95 percent confidence interval, 1.4 to 4.7). In both patients with symptoms and those without symptoms, the prevalence of lesions in the upper gastrointestinal tract was greater than or equal to that of colonic lesions. Conclusions In a group of patients with positive fecal occult-blood tests who were referred for further evaluation, from which those with iron-deficiency anemia and active bleeding had been excluded, up per gastrointestinal lesions were identified more frequently than colonic lesions. (N Engl J Med 1998; 339:153-9.) (C)1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Liver Res Lab, Sands Bldg,Rm 334,Res Dr,Box 3038, Durham, NC 27710 USA.							AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; BRINT SL, 1993, SOUTHERN MED J, V86, P601, DOI 10.1097/00007611-199306000-00001; CHEN YK, 1993, AM J GASTROENTEROL, V88, P2026; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P245, DOI 10.1080/00365521.1984.12005716; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P235, DOI 10.1080/00365521.1984.12005715; EISNER MS, 1991, ARCH INTERN MED, V151, P2180, DOI 10.1001/archinte.151.11.2180; Ferguson A, 1996, GUT, V38, P120, DOI 10.1136/gut.38.1.120; GELLER AJ, 1993, AM J GASTROENTEROL, V88, P1184; Greenberg PD, 1996, AM J MED, V100, P598, DOI 10.1016/S0002-9343(96)00009-5; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; HSIA PC, 1992, AM J GASTROENTEROL, V87, P1571; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; Kleinbaum D.G., 1988, STUDENTS PARTIAL SOL; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANCE P, 1993, GASTROENTEROLOGY, V104, P1852, DOI 10.1016/0016-5085(93)90669-4; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Lieberman D, 1996, LANCET, V348, P1463, DOI 10.1016/S0140-6736(05)65886-2; LIEBERMAN DA, 1990, ARCH INTERN MED, V150, P740; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; Marks RD, 1997, GASTROENTEROLOGY, V112, pA29; MORRIS DW, 1976, AM J DIG DIS, V21, P845, DOI 10.1007/BF01072075; OSTROW JD, 1973, AM J DIG DIS, V18, P930, DOI 10.1007/BF01072436; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Rockey D, 1997, GASTROENTEROLOGY, V112, pA40; SAS Institute, 1990, SAS STAT US GUID, V2; SONTAG SJ, 1992, GASTROENTEROLOGY, V102, P109, DOI 10.1016/0016-5085(92)91790-B; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; STROEHLEIN JR, 1976, AM J DIG DIS, V21, P841, DOI 10.1007/BF01072074; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; YOUNG GP, 1993, JAMA-J AM MED ASSOC, V270, P451, DOI 10.1001/jama.1993.03510040055022; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	37	138	141	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1998	339	3					153	159		10.1056/NEJM199807163390303	http://dx.doi.org/10.1056/NEJM199807163390303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ922	9664091				2022-12-01	WOS:000074782900003
J	Arias, IM				Arias, IM			New genetics of inheritable jaundice and cholestatic liver disease	LANCET			English	Editorial Material									Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Arias, IM (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.							BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Jansen P L, 1995, Prog Liver Dis, V13, P125; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; ZHANG X, 1997, HEPATOLOGY, V26, pA69	9	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					82	83		10.1016/S0140-6736(98)85004-6	http://dx.doi.org/10.1016/S0140-6736(98)85004-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672268				2022-12-01	WOS:000074775100004
J	Martin, RM; Kapoor, KV; Wilton, LV; Mann, RD				Martin, RM; Kapoor, KV; Wilton, LV; Mann, RD			Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study	BRITISH MEDICAL JOURNAL			English	Article									Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; Univ Southampton, Fac Med Hlth & Biol Sci, Sch Med, Southampton SO16 7PX, Hants, England	University of Southampton	Martin, RM (corresponding author), Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.							BELTON KJ, 1995, BRIT J CLIN PHARMACO, V39, P223, DOI 10.1111/j.1365-2125.1995.tb04440.x; BEM JL, 1988, BRIT MED J, V296, P1319, DOI 10.1136/bmj.296.6632.1319; *JOINT FORM COMM, 1997, BRIT NATL FORMULARY, P10; LUMLEY C E, 1986, Pharmaceutical Medicine (London), V1, P205; RAWLINS MD, 1993, BR J CLIN PHARM, V35, P590	5	129	136	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					119	120		10.1136/bmj.317.7151.119	http://dx.doi.org/10.1136/bmj.317.7151.119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657787	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000075081700022
J	Husband, DJ				Husband, DJ			Malignant spinal cord compression: prospective study of delays in referral and treatment	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DIAGNOSIS	Objectives: To examine the delay in presentation diagnosis, and treatment of malignant spinal cord compression and to define the effect of this delay on motor and bladder function at the time of treatment Design: Prospective study of all new patients presenting to a regional cancer centre with this condition. Setting: Regional cancer centre. Subjects: 301 consecutive patients. Main outcome measures: Interval from onset of symptoms to presentation and treatment, delay at each stage of referral, and functional deterioration. Results: The median (range) delay from onset of symptoms of spinal cord compression to treatment was 14 (0-840) days. Of the total delay 3 (0-300) days were accounted for by patients, 3 (0-330) days by general practitioners, 4 (0-794) days by the district general hospital, and 0 (0-114) days by the treatment unit Initial presentation to the regional cancer centre with symptoms of malignant spinal cord compression led to a significant reduction in delay to treatment and improved functional status at the time of treatment Deterioration of motor or bladder function greater than or equal to 1 grade occurred at the general practice stage in 28% (57) and 18% (36) of patients, the general hospital stage in 36% (83) and 29% (66), and the treatment unit stage in 6% (19) and 5% (15), respectively. Conclusions: Unacceptable delay in diagnosis, investigation, and referral occurs in most patients with malignant spinal cord compression and results in preventable loss of function before treatment Improvement in the outcome of such patients requires earlier diagnosis and treatment.	Clatterbridge Ctr Oncol, Wirral L63 4JY, Merseyside, England	Clatterbridge Cancer Centre	Husband, DJ (corresponding author), Clatterbridge Ctr Oncol, Wirral L63 4JY, Merseyside, England.							BACH F, 1990, ACTA NEUROCHIR, V107, P37, DOI 10.1007/BF01402610; BOOGERD W, 1993, CANCER TREAT REV, V19, P129, DOI 10.1016/0305-7372(93)90031-L; BYRNE TN, 1995, NEUROLOGICAL COMPLIC, P23; CAMPBELL MJ, 1989, STAT CONFIDENCE; Delaney TF, 1993, CANC PRINCIPLES PRAC, P2118; FINDLAY GFG, 1984, J NEUROL NEUROSUR PS, V47, P761, DOI 10.1136/jnnp.47.8.761; GILBERT RW, 1978, ANN NEUROL, V3, P40, DOI 10.1002/ana.410030107; JOHNSTON RA, 1993, J NEUROL NEUROSUR PS, V56, P1046, DOI 10.1136/jnnp.56.10.1046; Posner J.B., 1995, NEUROLOGICAL COMPLIC; SIEGEL S, 1988, NONPARAMETRIC STAT	10	112	116	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					18	21		10.1136/bmj.317.7150.18	http://dx.doi.org/10.1136/bmj.317.7150.18			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9651261	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000075081600017
J	Schott, JJ; Benson, DW; Basson, CT; Pease, W; Silberbach, GM; Moak, JP; Maron, BJ; Seidman, CE; Seidman, JG				Schott, JJ; Benson, DW; Basson, CT; Pease, W; Silberbach, GM; Moak, JP; Maron, BJ; Seidman, CE; Seidman, JG			Congenital heart disease caused by mutations in the transcription factor NKX2-5	SCIENCE			English	Article							MOLECULAR-CLONING; TINMAN; GENES	Mutations in the gene encoding the homeobox transcription factor NKX2-5 were found to cause nonsyndromic, human congenital heart disease. A dominant disease locus associated with cardiac malformations and atrioventricular conduction abnormalities was mapped to chromosome 5q35, where NKX2-5, a Drosophila tinman homolog, is located. Three different NKX2-5 mutations were identified. Two are predicted to impair binding of NKX2-5 to target DNA, resulting in haploinsufficiency, and a third potentially augments target-DNA binding. These data indicate that NKX2-5 is important for regulation of septation during cardiac morphogenesis and for maturation and maintenance of atrioventricular node function throughout life.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harrisburg Hosp, Harrisburg, PA 17104 USA; Oregon Hlth Sci Univ, Div Pediat Cardiol, Portland, OR 97201 USA; Childrens Natl Med Ctr, Div Pediat Cardiol, Washington, DC 20010 USA; Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Oregon Health & Science University; Children's National Health System; Minneapolis Heart Institute Foundation	Seidman, JG (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.		Schott, jean-Jacques/F-8842-2013	Schott, jean-Jacques/0000-0002-9578-9475				Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BASSON CT, 1995, CIRCULATION, V91, P1326, DOI 10.1161/01.CIR.91.5.1326; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BODMER R, 1993, DEVELOPMENT, V118, P719; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HOFFMAN JIE, 1990, PEDIATR CLIN N AM, V37, P25; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kostrzewa M, 1996, HUM GENET, V97, P399, DOI 10.1007/BF02185781; Li QY, 1997, NAT GENET, V15, P21; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MOORE KL, 1998, DEV HUMAN CLIN ORIEN, P349; MOORMAN AFM, 1994, TRENDS CARDIOVAS MED, V4, P257, DOI 10.1016/1050-1738(94)90029-9; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PEASE WE, 1976, CIRCULATION, V53, P759, DOI 10.1161/01.CIR.53.5.759; Schott JJ, UNPUB; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; Turbay D, 1996, MOL MED, V2, P86, DOI 10.1007/BF03402205	19	958	997	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					108	111		10.1126/science.281.5373.108	http://dx.doi.org/10.1126/science.281.5373.108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651244				2022-12-01	WOS:000074685800049
J	Hutton, M; Lendon, CL; Rizzu, P; Baker, M; Froelich, S; Houlden, H; Pickering-Brown, S; Chakraverty, S; Isaacs, A; Grover, A; Hackett, J; Adamson, J; Lincoln, S; Dickson, D; Davies, P; Petersen, RC; Stevens, M; de Graaff, E; Wauters, E; van Baren, J; Hillebrand, M; Joosse, M; Kwon, JM; Nowotny, P; Che, LK; Norton, J; Morris, JC; Reed, LA; Trojanowski, J; Basun, H; Lannfelt, L; Neystat, M; Fahn, S; Dark, F; Tannenberg, T; Dodd, PR; Hayward, N; Kwok, JBJ; Schofield, PR; Andreadis, A; Snowden, J; Craufurd, D; Neary, D; Owen, F; Oostra, BA; Hardy, J; Goate, A; van Swieten, J; Mann, D; Lynch, T; Heutink, P				Hutton, M; Lendon, CL; Rizzu, P; Baker, M; Froelich, S; Houlden, H; Pickering-Brown, S; Chakraverty, S; Isaacs, A; Grover, A; Hackett, J; Adamson, J; Lincoln, S; Dickson, D; Davies, P; Petersen, RC; Stevens, M; de Graaff, E; Wauters, E; van Baren, J; Hillebrand, M; Joosse, M; Kwon, JM; Nowotny, P; Che, LK; Norton, J; Morris, JC; Reed, LA; Trojanowski, J; Basun, H; Lannfelt, L; Neystat, M; Fahn, S; Dark, F; Tannenberg, T; Dodd, PR; Hayward, N; Kwok, JBJ; Schofield, PR; Andreadis, A; Snowden, J; Craufurd, D; Neary, D; Owen, F; Oostra, BA; Hardy, J; Goate, A; van Swieten, J; Mann, D; Lynch, T; Heutink, P			Association of missense and 5 '-splice-site mutations in tau with the inherited dementia FTDP-17	NATURE			English	Article							PROTEIN-TAU; ALZHEIMERS-DISEASE; LOCALIZATION; PARKINSONISM; COMPLEX; GENE; RNA	Thirteen families have been described with an autosomal dominantly inherited dementia named frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)(1-9), historically termed Pick's disease(10). Most FTDP-17 cases show neuronal and/or glial inclusions that stain positively with antibodies raised against the microtubule-associated protein Tau, although the Tau pathology varies considerably in both its quantity (or severity) and characteristics(1-8,12). Previous studies have mapped the FTDP-17 locus to a 2-centimorgan region on chromosome 17q21.11; the tau gene also lies within this region. We have now sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon in. The splice-site mutations all destabilize a potential stem-loop structure which is probably involved in regulating the alternative splicing of exon10 (ref. 13). This causes more frequent usage of the 5' splice site and an increased proportion of tan transcripts that include exon 10. The increase in exon 10(+) messenger RNA will increase the proportion of Tau containing four microtubule-binding repeats, which is consistent with the neuropathology described in several families with FTDP-17 (refs 12, 14).	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Erasmus Univ, Dept Clin Genet, Rotterdam, Netherlands; Erasmus Univ, Dept Neurol, Rotterdam, Netherlands; Karolinska Inst, Inst Clin Neurophysiol & Family Med, Geriatr Med Sect, S-14186 Huddinge, Sweden; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester M13 9PT, Lancs, England; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Mayo Clin, Rochester, MN 56007 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Princess Alexandra Hosp, Dept Psychiat, Woolloongabba, Qld 4102, Australia; Mater Misericordiae Hosp, Dept Anat Pathol, Brisbane, Qld 4101, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Queensland Inst Med Res, Human Genet Lab, Herston, Qld 4029, Australia; Garvan Inst Med Res, Sydney, NSW 2010, Australia; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Dept Biomed Sci, Waltham, MA 02154 USA; Manchester Royal Infirm, Dept Neurol, Manchester M13 9WL, Lancs, England; St Marys Hosp, Dept Clin Genet, Manchester M13 0GH, Lancs, England; Univ Manchester, Dept Pathol Sci, Manchester M13 9PT, Lancs, England	Mayo Clinic; Washington University (WUSTL); Erasmus University Rotterdam; Erasmus University Rotterdam; Karolinska Institutet; University of Manchester; Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic; Washington University (WUSTL); University of Pennsylvania; Columbia University; University of Queensland; QIMR Berghofer Medical Research Institute; Garvan Institute of Medical Research; University of Manchester; University of Manchester; University of Manchester	Hutton, M (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	hutton.michael@mayo.edu; heutink@kgen.fgg.eut.nl	Hardy, John/C-2451-2009; Lynch, Timothy/M-1316-2019; hayward, nicholas k/C-1367-2015; Craufurd, David/G-5277-2013; Morris, John C/A-1686-2012; de Graaff, Esther/D-3287-2011; Houlden, Henry J/C-1532-2008; hayward, nick/AAV-8802-2020; Pickering-Brown, Stuart/D-4008-2009; Dodd, Peter Ronald/A-4865-2010; Schofield, Peter/C-9669-2011	Hardy, John/0000-0002-3122-0423; hayward, nicholas k/0000-0003-4760-1033; Houlden, Henry J/0000-0002-2866-7777; Pickering-Brown, Stuart/0000-0003-1561-6054; Dodd, Peter Ronald/0000-0001-5970-0181; Goate, Alison/0000-0002-0576-2472; Snowden, Julie/0000-0002-3976-4310; Dickson, Dennis W/0000-0001-7189-7917; Kwok, John/0000-0001-9574-6195; Heutink, Peter/0000-0001-5218-1737; Schofield, Peter/0000-0003-2967-9662; van Swieten, John/0000-0001-6278-6844				ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Baker M, 1997, ANN NEUROL, V42, P794, DOI 10.1002/ana.410420516; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Conrad C, 1997, ANN NEUROL, V41, P277, DOI 10.1002/ana.410410222; CONSTANT.J, 1974, EUR NEUROL, V11, P208, DOI 10.1159/000114320; Dark F, 1997, AUST NZ J PSYCHIAT, V31, P139, DOI 10.3109/00048679709073812; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Froelich S, 1997, AM J MED GENET, V74, P380, DOI 10.1002/(SICI)1096-8628(19970725)74:4<380::AID-AJMG8>3.0.CO;2-T; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Heutink P, 1997, ANN NEUROL, V41, P150, DOI 10.1002/ana.410410205; Higgins JJ, 1998, NEUROLOGY, V50, P270, DOI 10.1212/WNL.50.1.270; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; Murrell JR, 1997, AM J HUM GENET, V61, P1131, DOI 10.1086/301594; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; Yamaoka LH, 1996, AM J HUM GENET, V59, P1306	28	2714	2807	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					702	705		10.1038/31508	http://dx.doi.org/10.1038/31508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641683				2022-12-01	WOS:000074289600058
J	Wang, JL; Liu, R; Hawkins, M; Barzilai, N; Rossetti, L				Wang, JL; Liu, R; Hawkins, M; Barzilai, N; Rossetti, L			A nutrient-sensing pathway regulates leptin gene expression in muscle and fat	NATURE			English	Article							INSULIN-RESISTANCE; OBESE GENE; IN-VIVO; HEXOSAMINE BIOSYNTHESIS; GLUCOSE-TRANSPORT; HUMANS; ADIPOSITY; PRODUCT; PROTEIN; MICE	Leptin, the protein encoded by the obese (ob) gene, is synthesized and released in response to increased energy storage in adipose tissue(1-4). However, it is still not known how incoming energy is sensed and transduced into increased expression of the ob gene. The hexosamine biosynthetic pathway is a cellular 'sensor' of energy availability(5-8) and mediates the effects of glucose on the expression of several gene products(9-12). Here we provide evidence for rapid activation of ob gene expression in skeletal muscle by glucosamine. Increased tissue concentrations of the end product of the hexosamine biosynthetic pathway, UDP-N-acetylglucosamine (UDP-GlcNAc), result in rapid and marked increases in leptin messenger RNA and protein levels (although these levels were much lower than those in fat). Plasma leptin levels and leptin mRNA and protein levels in adipose tissue also increase. Most important, stimulation of leptin synthesis is reproduced by either hyperglycaemia or hyperlipidaemia, which also increase tissue levels of UDP-N-acetylglucosamine in conscious rodents(7). Finally, incubation of 3T3-L1 pre-adipocytes and L6 myocytes with glucosamine rapidly induces ob gene expression. Our findings are the first evidence of inducible leptin expression in skeletal muscle and unveil an important biochemical Link between increased availability of nutrients and leptin expression.	Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Liu, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu						Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Kolaczynski JW, 1996, DIABETES, V45, P699, DOI 10.2337/diabetes.45.5.699; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988; Wang JL, 1997, DIABETES, V46, P325; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	636	662	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1998	393	6686					684	688		10.1038/31474	http://dx.doi.org/10.1038/31474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641678				2022-12-01	WOS:000074289600053
J	Wyatt, R; Kwong, PD; Desjardins, E; Sweet, RW; Robinson, J; Hendrickson, WA; Sodroski, JG				Wyatt, R; Kwong, PD; Desjardins, E; Sweet, RW; Robinson, J; Hendrickson, WA; Sodroski, JG			The antigenic structure of the HIV gp120 envelope glycoprotein	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; NEUTRALIZING ANTIBODIES; CD4 BINDING; RECEPTOR; EPITOPE; CELLS; RETROVIRUS; EXPOSURE; REGION	The human immunodeficiency virus HIV-1 establishes persistent infections in humans which lead to acquired immunodeficiency syndrome (AIDS). The HIV-1 envelope glycoproteins, gp120 and gp41, are assembled into a trimeric complex that mediates virus entry into target cells(1). HIV-1 entry depends on the sequential interaction of the gp120 exterior envelope glycoprotein with the receptors on the cell, CD4 and members of the chemokine receptor family(2-4). The gp120 glycoprotein, which can be shed from the envelope complex, elicits both virus-neutralizing and non-neutralizing antibodies during natural infection. Antibodies that lack neutralizing activity are often directed against the gp120 regions that are occluded on the assembled trimer and which are exposed only upon shedding(5,6). Neutralizing antibodies, by contrast, must access the functional envelope glycoprotein complex(7) and typically recognize conserved or variable epitopes near the receptor-binding regions(8-11). Here we describe the spatial organization of conserved neutralization epitopes on gp120, using epitope maps in conjunction with the X-ray crystal structure of a ternary complex that includes a gp120 core, CD4 and a neutralizing antibody(12). A large fraction of the predicted accessible surface of gp120 in the trimer is composed of variable, heavily glycosylated core and loop structures that surround the receptor-binding regions. Understanding the structural basis for the ability of HIV-1 to evade the humoral immune response should assist in the design of a vaccine.	Harvard Univ, Sch Med, Charles A Dana Res Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA; Tulane Univ, Med Ctr, Dept Pediat, New Orleans, LA 70112 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Columbia University; Howard Hughes Medical Institute; GlaxoSmithKline; Tulane University	Sodroski, JG (corresponding author), Harvard Univ, Sch Med, Charles A Dana Res Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.							ALLEN J, 1983, SCIENCE, V228, P1091; BINLEY J, 1997, AIDS RES HUM RETROV, V14, P191; Cao J, 1997, J VIROL, V71, P9808, DOI 10.1128/JVI.71.12.9808-9812.1997; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUNG MSC, 1992, J VIROL, V66, P848, DOI 10.1128/JVI.66.2.848-856.1992; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; Karlsson GB, 1997, J VIROL, V71, P4218, DOI 10.1128/JVI.71.6.4218-4225.1997; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MOORE JP, 1994, J VIROL, V68, P8350, DOI 10.1128/JVI.68.12.8350-8364.1994; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; MYERS G, 1996, HUMAN RETROVIRUSES A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POSNER MR, 1991, J IMMUNOL, V146, P4325; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; WATKINS BA, 1993, J VIROL, V67, P7493, DOI 10.1128/JVI.67.12.7493-7500.1993; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995	30	1041	1115	2	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					705	711		10.1038/31514	http://dx.doi.org/10.1038/31514			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641684	Bronze			2022-12-01	WOS:000074289600059
J	Brewster, R; Lee, J; Altaba, ARI				Brewster, R; Lee, J; Altaba, ARI			Gli/Zic factors pattern the neural plate by defining domains of cell differentiation	NATURE			English	Article							NEUROGENESIS; XENOPUS; INDUCTION; ECTODERM; EMBRYOS; PROTEIN; CREST; TUBE	Three cell types differentiate in the early frog neural plate: neural crest at the lateral edges, floorplate at the midline and primary neurons in three bilateral stripes. Floorplate cells and ventral neurons are induced by Sonic hedgehog(1,2) (Shh) and neural crest and dorsal. neurons are induced by epidermal factors such as bone morphogenetic proteins (BMPs)(3). Neurogenesis in a subset of cells within the stripes involves lateral inhibition(4). However, the process by which pools of precursors are defined in stereotypic domains in response to inductive signals is unknown. Here we show that frog Zic2 encodes a zinc-finger transcription factor of the Gli superfamily which is expressed in stripes that alternate with those in which primary neurons differentiate and overlap the domains of floorplate and neural crest progenitors. Zic2 inhibits neurogenesis and induces neural crest differentiation. Conversely, Gli proteins are widely expressed, induce neurogenesis and inhibit neural crest differentiation. Zic2 is therefore a vertebrate pre-pattern gene, encoding anti-neurogenic and crest-inducing functions that counteract the neurogenic but not the floorplate-inducing activity of Gli proteins. We propose that the combined function of Gli/Zic genes responds to inductive signals and induces patterned neural cell differentiation.	NYU, Med Ctr, Dept Cell Biol, Skirball Inst,Dev Genet Program, New York, NY 10016 USA	New York University	Altaba, ARI (corresponding author), NYU, Med Ctr, Dept Cell Biol, Skirball Inst,Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	ria@saturn.med.nyu.edu		Ruiz i Altaba, Ariel/0000-0003-2292-3933				Altaba AR, 1996, MECH DEVELOP, V60, P207, DOI 10.1016/S0925-4773(96)00618-1; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; ARUGA J, 1994, J NEUROCHEM, V63, P1880; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Baker NE, 1997, CURR BIOL, V7, P122, DOI 10.1016/S0960-9822(06)00056-X; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; ESSEX LJ, 1993, DEV DYNAM, V198, P108, DOI 10.1002/aja.1001980205; FERREIRO B, 1994, DEVELOPMENT, V120, P3649; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lee J, 1997, DEVELOPMENT, V124, P2537; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mizuseki K, 1998, DEVELOPMENT, V125, P579; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2	23	196	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					579	583		10.1038/31242	http://dx.doi.org/10.1038/31242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634234				2022-12-01	WOS:000074150100053
J	Venter, JC; Adams, MD; Sutton, GG; Kerlavage, AR; Smith, HO; Hunkapiller, M				Venter, JC; Adams, MD; Sutton, GG; Kerlavage, AR; Smith, HO; Hunkapiller, M			Shotgun sequencing of the human genome	SCIENCE			English	Article							MAP; PROJECT; TAGS; DNA		TIGR, Rockville, MD 20850 USA; Perkin Elmer Appl Biosyst, Foster City, CA 94404 USA	J. Craig Venter Institute; Thermo Fisher Scientific; Applied Biosystems	Venter, JC (corresponding author), TIGR, Rockville, MD 20850 USA.			Kerlavage, Anthony/0000-0002-3954-9653				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMS MD, 1995, NATURE S, V37, P3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FRASER CM, IN PRESS SCIENCE; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; GREEN E, 1997, GENOME RES, V7, P410; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sutton G.G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	22	222	244	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1540	1542		10.1126/science.280.5369.1540	http://dx.doi.org/10.1126/science.280.5369.1540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9644018				2022-12-01	WOS:000074061200021
J	Cruickshanks, KJ; Klein, R; Klein, BEK; Wiley, TL; Nondahl, DM; Tweed, TS				Cruickshanks, KJ; Klein, R; Klein, BEK; Wiley, TL; Nondahl, DM; Tweed, TS			Cigarette smoking and hearing loss - The epidemiology of hearing loss study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEAVER-DAM EYE; RECEPTORS	Context.-Clinical studies have suggested that cigarette smoking may be associated with hearing loss, a common condition affecting older adults. Objective.-To evaluate the association between smoking and hearing loss. Design.-Population-based, cross-sectional study. Setting.-Community of Beaver Dam, Wis. Participants.-Adults aged 48 to 92 years. Of 4541 eligible subjects, 3753 (83%) participated in the hearing study. Main Outcome Measures.-The examination included otoscopy, screening tympanometry, and pure-tone air-conduction and bone-conduction audiometry, Smoking history was ascertained by self-report. Hearing loss was defined as a pure-tone average (0.5, 1, 2, and 4 kHz) greater than 25-dB hearing level in the worse ear. Results.-After adjusting for other factors, current smokers were 1.69 times as likely to have a hearing loss as nonsmokers (95% confidence interval, 1.31-2.17), This relationship remained for those without a history of occupational noise exposure and in analyses excluding those with non-age-related hearing loss. There was weak evidence of a dose-response effect. Nonsmoking participants who lived with a smoker were more likely to have a hearing loss than those who were not exposed to a household member who smoked (odds ratio, 1.94; 95% confidence interval, 1.01-3.74). Conclusions.-These data suggest that environmental exposures may play a role in age-related hearing loss. If longitudinal studies confirm these findings, modification of smoking habits may prevent or delay age-related declines in hearing sensitivity.	Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA; Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Cruickshanks, KJ (corresponding author), Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,460 WARF, Madison, WI 53705 USA.	cruickshanks@epi.ophth.wisc.edu	Legarth, Jonas/A-9156-2012		NATIONAL INSTITUTE ON AGING [R01AG011099] Funding Source: NIH RePORTER; NEI NIH HHS [EY0694] Funding Source: Medline; NIA NIH HHS [AG11099] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM NAT STAND I, 1989, ANSI PUBL; *AM NAT STAND I, 1991, ANSI PUBL; [Anonymous], 1978, ASHA, V20, P297; Blanchet C, 1996, J NEUROSCI, V16, P2574; Brant L J, 1996, J Am Acad Audiol, V7, P152; CAMPBELL JA, 1988, P SURV RES METH SECT, P549; CRUICKSHANKS KJ, IN PRESS AM J EPIDEM; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; Guth PS, 1996, HEARING RES, V98, P1, DOI 10.1016/0378-5955(96)00031-7; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Jarvis J F, 1967, J Laryngol Otol, V81, P63, DOI 10.1017/S0022215100066779; Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5; LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049; LYONS JA, 1992, J TRAUMA STRESS, V5, P111, DOI 10.1002/jts.2490050112; MAFFEL G, 1962, ARCHIV OTOLARYNGOL, V75, P386; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCARTNEY JS, 1994, NEUROTOXICOL TERATOL, V16, P269, DOI 10.1016/0892-0362(94)90048-5; *NAT CTR HLTH STAT, 1967, VITAL HLTH STAT 10, V34, P11; *NAT STRAT RES PLA, 1996, HEAR HEAR IMP, P33; Nondahl D M, 1996, J Am Acad Audiol, V7, P251; ROSEN S, 1962, ANN OTO RHINOL LARYN, V71, P727, DOI 10.1177/000348946207100313; SHAPIRO SL, 1965, EYE EAR NOSE THROAT, V44, P94; SIEGELAUB AB, 1974, ARCH ENVIRON HEALTH, V29, P107, DOI 10.1080/00039896.1974.10666542; Weiss W, 1970, Med Times, V98, P84; WESTON T E, 1964, J Laryngol Otol, V78, P273, DOI 10.1017/S0022215100062071; Wiley T L, 1996, J Am Acad Audiol, V7, P260; ZELMAN S, 1973, JAMA-J AM MED ASSOC, V223, P920, DOI 10.1001/jama.1973.03220080050016	27	263	277	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1715	1719		10.1001/jama.279.21.1715	http://dx.doi.org/10.1001/jama.279.21.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624024	Bronze			2022-12-01	WOS:000073878700032
J	Nightingale, SL				Nightingale, SL			Web site for "year 2000" information on biomedical equipment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	10	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1684	1684		10.1001/jama.279.21.1684	http://dx.doi.org/10.1001/jama.279.21.1684			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ544	9624011				2022-12-01	WOS:000073878700006
J	Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB				Penninx, BWJH; Guralnik, JM; Ferrucci, L; Simonsick, EM; Deeg, DJH; Wallace, RB			Depressive symptoms and physical decline in community-dwelling older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; IMMUNE-SYSTEM; DISABILITY; PERFORMANCE; ANXIETY; FALLS; CARE	Context.-Significant symptoms of depression are common in the older community-dwelling population. Although depressive symptoms and disability may commonly occur in the same person, whether depressive symptoms contribute to subsequent functional decline has not been elucidated, Objective.-To determine whether depressive symptoms in older persons increase the risk of subsequent decline in physical function as measured by objective performance-based tests. Design.-A 4-year prospective cohort study. Setting.-The communities of Iowa and Washington counties, Iowa. Participants.-A total of 1286 persons aged 71 years and older who completed a short battery of physical performance tests in 1988 and again 4 years later. Main Outcome Measures.-Baseline depressive symptoms were assessed by the Center for Epidemiological Studies Depression Scale. Physical performance tests included an assessment of standing balance, a timed 2.4-m (8-ft) walk, and a timed test of 5 repetitions of rising from a chair and sitting down. Results.-After adjustment far baseline performance score, health status, and sociodemographic factors, increasing levels of depressive symptoms were predictive of greater decline in physical performance over 4 years (odds ratio for decline in those with depressed mood vs those without, 1.55; 95% confidence interval [CI], 1.02-2.34), Even among those at the high end of the functional spectrum, who reported no disability, the severity of depressive symptoms predicted subsequent decline in physical performance (odds ratio for decline, 1.03; 95% CI, 1.00-1.08). Conclusions.-This study provides evidence that older persons who report depressive symptoms are at higher risk of subsequent physical decline, These results suggest that prevention or reduction of depressed mood could play a role in reducing functional decline in older persons.	NIA, Epidemiol Demogr & Biometry Program, Bethesda, MD 20892 USA; INRCA Florence, Dept Geriatr, Florence, Italy; Vrije Univ Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Vrije Univ Amsterdam, Dept Psychiat, Amsterdam, Netherlands; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); IRCCS INRCA; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Iowa	Guralnik, JM (corresponding author), NIA, Epidemiol Demogr & Biometry Program, Gateway Bldg,Suite 3C-309,7201 Wisconsin Ave, Bethesda, MD 20892 USA.	jg48s@nih.gov	Simonsick, Eleanor/W-6864-2019; Penninx, Brenda WJH/S-7627-2017	Penninx, Brenda WJH/0000-0001-7779-9672	NIA NIH HHS [N01-AG-0215, N01-AG-02107, N01-AG-02106] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000215, N01AG002106, N01AG002107] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BARSKY AJ, 1988, PSYCHOSOM MED, V50, P510, DOI 10.1097/00006842-198809000-00007; Beekman ATF, 1995, J AFFECT DISORDERS, V36, P65, DOI 10.1016/0165-0327(95)00061-5; Beekman ATF, 1997, PSYCHOL MED, V27, P231, DOI 10.1017/S0033291796003510; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CRESS ME, 1995, J AM GERIATR SOC, V43, P93, DOI 10.1111/j.1532-5415.1995.tb06372.x; CRONBACH LJ, 1970, PSYCHOL BULL, V74, P68, DOI 10.1037/h0029382; Gallo JJ, 1997, J AM GERIATR SOC, V45, P570, DOI 10.1111/j.1532-5415.1997.tb03089.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1989, J GERONTOL, V44, pM141, DOI 10.1093/geronj/44.5.M141; GURALNIK JM, 1994, AGING-CLIN EXP RES, V6, P303, DOI 10.1007/BF03324256; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; HUISIANI BA, 1980, J COMMUNITY PSYCHOL, V8, P20; *HYP DET FOLL UP P, 1977, JAMA-J AM MED ASSOC, V237, P2385; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kempen GIJM, 1996, J GERONTOL B-PSYCHOL, V51, pP254, DOI 10.1093/geronb/51B.5.P254; Kohout FJ, 1993, J AGING HEALTH, V5, P79; KRONFOL Z, 1984, LANCET, V1, P1026; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; MILLER AH, 1993, ANN MED, V25, P481, DOI 10.3109/07853899309147316; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; ORMEL J, 1993, AM J PUBLIC HEALTH, V83, P385, DOI 10.2105/AJPH.83.3.385; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSOW I, 1966, J GERONTOL, V39, P686; SEEMAN TE, 1994, J GERONTOL, V49, pM97, DOI 10.1093/geronj/49.3.M97; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; *SPSS INC, 1993, SPSS ADV STAT REF GU; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TURNER RJ, 1988, J HEALTH SOC BEHAV, V29, P23, DOI 10.2307/2137178; Unutzer J, 1997, JAMA-J AM MED ASSOC, V277, P1618, DOI 10.1001/jama.277.20.1618; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; *WHO, 1977, MAN INT STAT CLASS D; WINOGRAD CH, 1994, J AM GERIATR SOC, V42, P743, DOI 10.1111/j.1532-5415.1994.tb06535.x	42	579	588	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1998	279	21					1720	1726		10.1001/jama.279.21.1720	http://dx.doi.org/10.1001/jama.279.21.1720			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZQ544	9624025				2022-12-01	WOS:000073878700033
J	Chiang, CW; Lo, SK; Ko, YS; Cheng, NJ; Lin, PJ; Chang, CH				Chiang, CW; Lo, SK; Ko, YS; Cheng, NJ; Lin, PJ; Chang, CH			Predictors of systemic embolism in patients with mitral stenosis - A prospective study	ANNALS OF INTERNAL MEDICINE			English	Article						embolism; mitral valve stenosis; anticoagulants; atrial fibrillation; balloon dilation	PRESSURE HALF-TIME; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; SPONTANEOUS ECHO CONTRAST; ATRIAL-FIBRILLATION; VALVE DISEASE; COMMISSUROTOMY; COMPLICATIONS; PREVENTION; ACCURACY; CATHETER	Background: Most studies of the predictors of systemic embolism in patients with mitral stenosis have been retrospective. Objective: To prospectively study factors associated with systemic embolism in mitral stenosis. Design: Prospective cohort study. Setting: University-affiliated medical institution with 3000 beds. Patients: 534 consecutive patients with a mitral valve area of 2.0 cm(2) or less; 132 patients were in sinus rhythm, and 402 were in atrial fibrillation. Measurements: Nine clinical and 10 echocardiographic variables were assessed for prediction of systemic embolism over a mean (+/- SD) follow-up of 36.9 +/- 22.5 months. Diagnosis of systemic embolism was based on symptoms and signs (sudden onset of peripheral arterial ischemic or neurologic manifestations without prodromes) and on findings on computed tomography, angiography, and surgery. Results: For patients in sinus rhythm, age (relative risk [RR], 1.12 [95% CI, 1.04 to 1.21]), the presence of a left atrial thrombus (RR, 37.1 [CI, 2.82 to 487.8]), mitral valve area (RR, 16.9 [CI, 1.53 to 187.0]), and the presence of significant aortic regurgitation (RR, 22.4 [CI, 2.72 to 184.8]) were positively associated with embolism. For patients in atrial fibrillation, previous embolism (RR, 3.11 [CI, 1.66 to 5.85]) was positively associated with embolism; percutaneous balloon mitral commissurotomy (RR, 0.37 [CI, 0.18 to 0.79]) was a negative predictor. Conclusions: It may be prudent to give anticoagulants not only to patients in atrial fibrillation and patients with previous systemic embolism but also to those showing a left atrial thrombus or significant aortic regurgitation on echocardiography. Early percutaneous balloon mitral commissurotomy may also help prevent systemic embolism in patients with mitral stenosis.	Chang Gung Univ, Chang Gung Mem Hosp, Cardiovasc Div 1, Taipei 105, Taiwan; Deaking Univ, Burwood, Vic, Australia	Chang Gung Memorial Hospital; Chang Gung University; Deakin University	Chiang, CW (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Cardiovasc Div 1, 199 Tung Hwa N Rd, Taipei 105, Taiwan.			LO, Sing Kai/0000-0001-8401-1759				[Anonymous], 1986, Arch Neurol, V43, P71; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; CASELLA L, 1964, ARCH INTERN MED, V114, P773, DOI 10.1001/archinte.1964.03860120085008; Chiang C W, 1992, Changgeng Yi Xue Za Zhi, V15, P72; CHIANG CW, 1994, CHEST, V106, P396, DOI 10.1378/chest.106.2.396; CHIANG CW, 1988, AM HEART J, V115, P908, DOI 10.1016/0002-8703(88)90899-X; CHIANG CW, 1987, J ULTRAS MED, V6, P525; Chiang CW, 1998, AM J CARDIOL, V81, P515, DOI 10.1016/S0002-9149(97)00943-0; Cooper J W, 1989, J Am Soc Echocardiogr, V2, P56; COULSHED N, 1970, BRIT HEART J, V32, P26; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; Dixon WJ, 1990, BMDP STAT SOFTWARE M; EASTON JD, 1980, STROKE, V11, P433, DOI 10.1161/01.STR.11.5.433; HATLE L, 1979, CIRCULATION, V60, P1096, DOI 10.1161/01.CIR.60.5.1096; HORSTKOTTE D, 1991, EUR HEART J, V12, P55, DOI 10.1093/eurheartj/12.suppl_B.55; HUNG JS, 1991, AM J CARDIOL, V67, P854, DOI 10.1016/0002-9149(91)90619-V; HWANG JJ, 1992, AM J CARDIOL, V70, P769, DOI 10.1016/0002-9149(92)90557-F; ILICETO S, 1985, AM J CARDIOL, V55, P603, DOI 10.1016/0002-9149(85)90267-X; INOUE K, 1984, J THORAC CARDIOV SUR, V87, P394; Loyd D, 1988, J Am Soc Echocardiogr, V1, P313; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, LANCET, V1, P175; PEVERILL RE, 1995, CIRCULATION, V92, P96; RICHARDS KL, 1986, CIRCULATION, V73, P964, DOI 10.1161/01.CIR.73.5.964; ROY D, 1986, AM HEART J, V112, P1039, DOI 10.1016/0002-8703(86)90318-2; RUIZ CE, 1990, AM J CARDIOL, V65, P473, DOI 10.1016/0002-9149(90)90813-G; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SELVIN S, 1995, PRACTICAL BIOSTATIST, P124; SIGEL B, 1981, INVEST RADIOL, V16, P71, DOI 10.1097/00004424-198101000-00013; SMITH MD, 1986, CIRCULATION, V73, P100, DOI 10.1161/01.CIR.73.1.100; THOMAS JD, 1987, J AM COLL CARDIOL, V10, P923, DOI 10.1016/S0735-1097(87)80290-5; VAHANIAN A, 1989, AM J CARDIOL, V63, P847, DOI 10.1016/0002-9149(89)90055-6	33	101	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					885	+		10.7326/0003-4819-128-11-199806010-00001	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634425				2022-12-01	WOS:000073808600001
J	Zhu, JY; Shibasaki, F; Price, R; Guillemot, JC; Yano, T; Dotsch, V; Wagner, G; Ferrara, P; McKeon, F				Zhu, JY; Shibasaki, F; Price, R; Guillemot, JC; Yano, T; Dotsch, V; Wagner, G; Ferrara, P; McKeon, F			Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1	CELL			English	Article							NF-KAPPA-B; SUBSTRATE DETERMINANTS; MOLECULAR-CLONING; PROTEIN-KINASE; GENE FAMILY; CALCINEURIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; ACTIVATION	T cell activation requires the import of NF-AT transcription factors to the nucleus, a process promoted by calcineurin-dependent dephosphorylation and inhibited by poorly understood protein kinases. Here, we report the identification of two protein kinases that oppose NF-AT4 nuclear import. Casein kinase I alpha directly binds and phosphorylates NF-AT4, resulting in the inhibiton of NF-AT4 nuclear translocation. MEKK1 indirectly suppresses NF-AT4 nuclear import by stabilizing the interaction between NF-AT4 and CKI alpha. CKI alpha thus acts to establish an intramolecular masking of the nuclear location signal on NF-AT4, while MEKK1 augments this mechanism, and may further provide a link to signal transduction pathways regulating NF-AT4.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Sanofi Biorech, F-31676 Labege, France	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Sanofi-Aventis; Sanofi France	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HO U, 1997, P NATL ACAD SCI USA, V94, P581; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kusuda J, 1996, GENOMICS, V32, P140, DOI 10.1006/geno.1996.0091; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	34	261	266	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					851	861		10.1016/S0092-8674(00)81445-2	http://dx.doi.org/10.1016/S0092-8674(00)81445-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630228	Bronze			2022-12-01	WOS:000073956700020
J	Stenzl, A; Ninkovic, M; Kolle, D; Napp, R; Anderl, H; Bartsch, G				Stenzl, A; Ninkovic, M; Kolle, D; Napp, R; Anderl, H; Bartsch, G			Restoration of voluntary emptying of the bladder by transplantation of innervated free skeletal muscle	LANCET			English	Article							NEUROGENIC BLADDER; DETRUSOR-MYOPLASTY	Background. On the basis of studies with animals and experience with functioning muscle transfer in plastic surgery, we have developed a surgical technique to restore detrusor function for patients with bladder acontractility in whom there is no treatment alternative. Methods. Three patients (aged 26 years, 28 years, and 68 years) with bladder acontractility as a result of spinal-cord injury (two patients) and chronic overdistension (one patient), who required catheterisation for bladder emptying for 5 years, 2 years, and 2 years, respectively, took part in our study. The patients were treated with microneurovascular free transfer of autologous latissimus dorsi muscle to the bladder to restore detrusor function. Follow-up included clinical and urodynamic evaluation, colour doppler sonography, intravenous urography, and flow-mode computerised tomography. Findings. The three patients voluntarily emptied their bladders at 16 weeks, 16 weeks, and 30 weeks after surgery, respectively. There was no need for further catheterisation throughout the follow-up period. On urodynamic assessment at 12 months after the operation bladder capacity was found to be 600 mt, 600 mt, and 650 mL, residual urinary volume 0 mL, 50 mL, 90 mL, and maximum flow rate 26 mL/s, 25 mL/s, and 18 mL/s, respectively. Activity at the transplanted latissimus dorsi was confirmed by ultrasonography and flow-mode computerised tomography. Interpretation. Microneurovascular free transfer of latissimus dorsi muscle to functionally restore a deficient detrusor muscle has proved to be successful for the three patients in our study. This technique may also be an option to restore the function of other smooth-muscle organs.	Univ Innsbruck, Med Ctr, Dept Urol, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Plast Surg, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Gynaecol, A-6020 Innsbruck, Austria; Univ Innsbruck, Med Ctr, Dept Radiodiagnost 2, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	Stenzl, A (corresponding author), Univ Innsbruck, Med Ctr, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	arnulf.stenzl@uibk.ac.at						BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; BRINDLEY GS, 1990, PARAPLEGIA, V28, P469, DOI 10.1038/sc.1990.63; CARPENTIER A, 1985, LANCET, V1, P1267; CHANCELLOR MB, 1994, LANCET, V343, P669, DOI 10.1016/S0140-6736(94)92661-1; CHANCELLOR MB, 1994, NEUROUROL URODYNAM, V13, P547, DOI 10.1002/nau.1930130509; MANKTELOW R, 1985, RECENT ADV PLASTIC S, P123; MANKTELOW RT, 1989, ANN PLAS SURG, V22, P275, DOI 10.1097/00000637-198904000-00001; MESSING EM, 1985, J UROLOGY, V134, P1202, DOI 10.1016/S0022-5347(17)47687-7; Ninkovic M, 1997, PLAST RECONSTR SURG, V100, P402, DOI 10.1097/00006534-199708000-00020; NINKOVIC M, 1994, BRIT J PLAST SURG, V47, P185, DOI 10.1016/0007-1226(94)90052-3; Ninkovic M, 1998, PLAST RECONSTR SURG, V101, P971, DOI 10.1097/00006534-199804040-00013; RUSSELL RC, 1986, PLAST RECONSTR SURG, V78, P336, DOI 10.1097/00006534-198609000-00009; Stenzl A, 1997, J UROLOGY, V157, P1103, DOI 10.1016/S0022-5347(01)65150-4; TANAGHO EA, 1988, J UROLOGY, V140, P1331, DOI 10.1016/S0022-5347(17)42038-6; Wechselberger G, 1997, J RECONSTR MICROSURG, V13, P125, DOI 10.1055/s-2007-1000228; ZHANG YH, 1990, J UROLOGY, V144, P1194	16	35	38	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 16	1998	351	9114					1483	1485		10.1016/S0140-6736(97)10005-8	http://dx.doi.org/10.1016/S0140-6736(97)10005-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605805				2022-12-01	WOS:000073707300011
J	Arner, P				Arner, P			Not all fat is alike	LANCET			English	Editorial Material							REGIONAL ADIPOSITY		Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden	Karolinska Institutet	Arner, P (corresponding author), Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden.			Arner, Peter/0000-0002-6208-6220				ABATE N, 1995, PROG LIPID RES, V34, P53, DOI 10.1016/0163-7827(94)00006-8; ARNER P, 1996, DIABETES REV, V4, P450; Bjorntorp P, 1998, HDB OBESITY, P573; BLUM WF, 1997, LEPTIN VOICE ADIPOSE, P1; Frayn KN, 1996, CLIN SCI, V90, P243, DOI 10.1042/cs0900243; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; Lefebvre AM, 1998, DIABETES, V47, P98, DOI 10.2337/diabetes.47.1.98; Montague CT, 1997, DIABETES, V46, P342, DOI 10.2337/diabetes.46.3.342; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; VANHARMELEN V, IN PRESS DIABETES	10	132	134	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 2	1998	351	9112					1301	1302		10.1016/S0140-6736(05)79052-8	http://dx.doi.org/10.1016/S0140-6736(05)79052-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643790				2022-12-01	WOS:000073439400005
J	Catalano, SM; Shatz, CJ				Catalano, SM; Shatz, CJ			Activity-dependent cortical target selection by thalamic axons	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; VISUAL-CORTEX; RETINOTECTAL PROJECTION; SUBPLATE NEURONS; CONNECTIONS; RAT; TETRODOTOXIN; MORPHOLOGY; NEOCORTEX; CIRCUITS	Connections in the developing nervous system are thought to be formed initially by an activity-independent process of axon pathfinding and target selection and subsequently refined by neural activity. Blockade of sodium action potentials by intracranial infusion of tetrodotoxin in cats during the early period when axons from the Lateral geniculate nucleus (LCN) were in the process of selecting visual cortex as their target altered the pattern and precision of this thalamocortical projection. The majority of LCN neurons, rather than projecting to visual cortex, elaborated a significant projection within the subplate of cortical areas normally bypassed. Those axons that did project to their correct target were topographically disorganized. Thus, neural activity is required for initial targeting decisions made by thalamic axone as they traverse the subplate,	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Catalano, SM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Catalano, Susan/0000-0001-7278-3233	NEI NIH HHS [EY02838, EY06491] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; BOLZ J, 1992, J NEUROSCI, V12, P3054, DOI 10.1523/JNEUROSCI.12-08-03054.1992; Campbell G, 1997, VISUAL NEUROSCI, V14, P779, DOI 10.1017/S0952523800012724; CATALANO SM, UNPUB; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; DALVA MB, 1994, J NEUROSCI, V14, P3588; DECARLOS JA, 1992, J NEUROSCI, V12, P1194; FRIAUF E, 1990, J NEUROSCI, V10, P2601; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; GHOSH A, 1992, J NEUROSCI, V12, P39; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GOODMAN CS, 1993, NEURON S, V10, P77; HERRMANN K, 1995, P NATL ACAD SCI USA, V92, P11244, DOI 10.1073/pnas.92.24.11244; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KONIG N, 1975, ANAT EMBRYOL, V148, P73, DOI 10.1007/BF00315564; KOSTOVIC I, 1980, J NEUROCYTOL, V9, P219, DOI 10.1007/BF01205159; KRISTT DA, 1979, ANAT EMBRYOL, V157, P217, DOI 10.1007/BF00305161; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; OLSON MD, 1994, J NEUROSCI, V14, P208; SCHMIDT JT, 1990, J NEUROBIOL, V21, P900, DOI 10.1002/neu.480210608; SHATZ CJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P472, DOI 10.1001/archopht.1993.01090040064031; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; VALVERDE F, 1989, J COMP NEUROL, V290, P118, DOI 10.1002/cne.902900108	27	194	200	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					559	562		10.1126/science.281.5376.559	http://dx.doi.org/10.1126/science.281.5376.559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677198				2022-12-01	WOS:000075012300040
J	Johnson, PR; Swanson, R; Rakhilina, L; Hochstrasser, M				Johnson, PR; Swanson, R; Rakhilina, L; Hochstrasser, M			Degradation signal masking by heterodimerization of MAT alpha 12 and MATa1 blocks their mutual destruction by the ubiquitin-proteasome pathway	CELL			English	Article							HOMEO DOMAIN; HOMEODOMAIN PROTEINS; IN-VIVO; YEAST; REPRESSOR; ALPHA-2; DNA; MUTAGENESIS; SEQUENCES; CHAINS	Proteolysis by the ubiquitin-proteasome pathway is often regulated, but the mechanisms underlying such regulation remain ill-defined. In Saccharomyces cerevisiae, cell type is controlled by the MAT transcription factors. The alpha 2 repressor is a known ubiquitin pathway substrate in cu haploid cells. We show that a1 is rapidly degraded in a haploids. In a/alpha diploids, alpha 2 and a1 are stabilized by heterodimerization. Association depends on N-terminal coiled-coil interactions between al and alpha 2. Residues in alpha 2 important for these interactions overlap a critical determinant of an alpha 2 degradation signal, which we delimit by extensive mutagenesis. Our data provide a detailed description of a natural ubiquitin-dependent degradation signal and point to a molecular mechanism for regulated turnover in which proteolytic signals are differentially masked in alternative multiprotein complexes.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Hochstrasser, M (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.			Hochstrasser, Mark/0000-0002-1131-5484	NIGMS NIH HHS [GM07183, GM46904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046904, T32GM007183, R37GM046904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HARASHIMA S, 1989, MOL CELL BIOL, V9, P4523, DOI 10.1128/MCB.9.10.4523; HO YC, 1994, EMBO J, V13, P1403; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kopski KM, 1997, GENETICS, V147, P409; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486	35	136	139	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					217	227		10.1016/S0092-8674(00)81421-X	http://dx.doi.org/10.1016/S0092-8674(00)81421-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695950	Bronze			2022-12-01	WOS:000075020100010
J	Chen, QJ; Fernandez, V; Sundstrom, A; Schlichtherle, M; Datta, S; Hagblom, P; Wahlgren, M				Chen, QJ; Fernandez, V; Sundstrom, A; Schlichtherle, M; Datta, S; Hagblom, P; Wahlgren, M			Developmental selection of var gene expression in Plasmodium falciparum	NATURE			English	Article							HUMAN CEREBRAL MALARIA; INFECTED ERYTHROCYTES; ANTIGENIC VARIATION; PROTEINS; CYTOADHERENCE; PHENOTYPES; ADHERENCE; DIVERSE; FAMILY	The protozoan Plasmodium falciparum causes lethal malaria(1). Adhesion of erythrocytes infected with P. falciparum to vascular endothelium and to uninfected red blood cells (rosetting) maybe involved in the pathogenesis of severe malaria(2-4). The binding is mediated by the antigenically variant erythrocyte-membrane-protein-1 (PfEMP-1)(5-8), which is encoded by members of the P. falciparum var gene famjily(9,10). The control of expression and switching of var genes seems to lack resemblance.to mechanisms operating in variant gene families of other microbial pathogens(11,12). Here we show that multiple, distinct var gene transcripts (about 24 or more) can be detected by reverse transcription and polymerase chain reaction in bulk cultures of the rosetting parasite FCR3S1.2, despite the adhesive homogeneity of the cultures. We also detected several var transcripts in single erythrocytes infected with a ring-stage parasite of FCR3S1.2, and found that different var genes are transcribed simultaneously from several chromosomes in the same cell. In contrast, we detected only one var transcript, FCR3S1.2 var-1, which encodes the rosetting PfEMP-1 protein(13), in individual rosette-adhesive trophozoite-infected cells, and we found only one PfEMP-1 type at the erythrocyte surface by labelling with (125)iodine and immunoprecipitation. We conclude that a single P. falciparum parasite simultaneously transcribes multiple var genes but, through a developmentally regulated process, selects only one PfEMP-1 to reach the surface of the host cell.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Swedish Inst Infect Dis Control, S-17177 Stockholm, Sweden; Changchun Univ Agr & Anim Sci, Changchun 130062, Peoples R China; Astra Res Ctr, Bangalore, Karnataka, India	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Jilin University	Wahlgren, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.							Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998; GUPTA S, 1994, P NATL ACAD SCI USA, V91, P3715, DOI 10.1073/pnas.91.9.3715; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; PIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835; VANSCHRAVENDIJK MR, 1991, BLOOD, V78, P226	24	259	265	3	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					392	395		10.1038/28660	http://dx.doi.org/10.1038/28660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690477				2022-12-01	WOS:000074968800057
J	Yablonski, D; Kuhne, MR; Kadlecek, T; Weiss, A				Yablonski, D; Kuhne, MR; Kadlecek, T; Weiss, A			Uncoupling of nonreceptor tyrosine kinases from PLC-gamma 1 in an SLP-76-deficient T cell	SCIENCE			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; GENE-EXPRESSION; ACTIVATION; PHOSPHORYLATION; SLP-76; PROTEIN; PHOSPHOPROTEIN; GRB2	Activation of nonreceptor protein tyrosine kinases (PTKs) is essential for T cell receptor (TCR) responsiveness; however, the function of individual PTK substrates is often uncertain. A mutant T cell Line was isolated that Lacked expression of SLP-76 (SH2 domain-containing Leukocyte protein of 76 kilodaltons), a hematopoietically expressed adaptor protein and PTK substrate. SLP-76 was not required for TCR-induced tyrosine phosphorylation of most proteins, but was required for optimal tyrosine phosphorylation and activation of phospholipase C-gamma l (PLC-gamma l), as well as Ras pathway activation. TCR-inducible gene expression was dependent on SLP-76. Thus, coupling of TCR-regulated PTKs to downstream signaling pathways requires SLP-76.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, Box 0795, San Francisco, CA 94143 USA.			Yablonski, Deborah/0000-0003-2979-0440; Kadlecek, Theresa/0000-0002-1020-8169	NATIONAL CANCER INSTITUTE [R01CA072531] Funding Source: NIH RePORTER; NCI NIH HHS [CA72531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fang N, 1996, J IMMUNOL, V157, P3769; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; ZHANG R, 1995, NATURE, V374, P471; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	32	357	363	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					413	416		10.1126/science.281.5375.413	http://dx.doi.org/10.1126/science.281.5375.413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665884				2022-12-01	WOS:000074918800047
J	Mauceri, HJ; Hanna, NN; Beckett, MA; Gorski, DH; Staba, MJ; Stellato, KA; Bigelow, K; Heimann, R; Gately, S; Dhanabal, M; Soff, GA; Sukhatme, VP; Kufe, DW; Weichselbaum, RR				Mauceri, HJ; Hanna, NN; Beckett, MA; Gorski, DH; Staba, MJ; Stellato, KA; Bigelow, K; Heimann, R; Gately, S; Dhanabal, M; Soff, GA; Sukhatme, VP; Kufe, DW; Weichselbaum, RR			Combined effects of angiostatin and ionizing radiation in antitumour therapy	NATURE			English	Article							ANGIOGENESIS; CANCER; SUPPRESSION; CARCINOMA; DISEASE; AGENTS	Angiogenesis, the formation of new capillaries from pre-existing vessels, is essential for tumour progression(1-5). Angiostatin, a proteolytic fragment of plasminogen(6) that was first isolated from the serum and urine of tumour-bearing mice(7), inhibits angiogenesis and thereby growth of primary(8) and metastatic(7,9,10) tumours. Radiotherapy is important in the treatment of many human cancers, but is often unsuccessful because of tumour cell radiation resistance(11,12). Here we combine radiation with angiostatin to target tumour vasculature that is genetically stable and therefore less likely to develop resistance(13-15). The results show an antitumour interaction between ionizing radiation and angiostatin for four distinct tumour types, at doses of radiation that are used in radiotherapy. The combination produced no increase in toxicity towards normal tissue. In vitro studies show that radiation and angiostatin have combined cytotoxic effects on endothelial cells, but not tumour cells. In vivo studies show that these agents, in combination, target the tumour vasculature. Our results provide support for combining ionizing radiation with angiostatin to improve tumour eradication without increasing deleterious effects.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Chicago; University of Chicago; University of Chicago; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Weichselbaum, RR (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.	rrw@rover.uchicago.edu	Gorski, David/AAE-6399-2022; Sukhatme, Vikas/W-2776-2019	Gorski, David/0000-0002-9805-6699; 				Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOULDS G, 1985, INT J CLIN PHARM RES, V2, P79; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HANAHAN D, 1996, J NATL CANCER I, V88, P1091; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kakeji Y, 1997, INVEST NEW DRUG, V15, P39, DOI 10.1023/A:1005718628223; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Sim BKL, 1997, CANCER RES, V57, P1329; TEICHER BA, 1992, CANCER RES, V52, P6702; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V14, P907, DOI 10.1016/0360-3016(88)90013-2; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684	15	608	639	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					287	291		10.1038/28412	http://dx.doi.org/10.1038/28412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685160				2022-12-01	WOS:000074851900051
J	Shih, DM; Gu, LJ; Xia, YR; Navab, M; Li, WF; Hama, S; Castellani, LW; Furlong, CE; Costa, LG; Fogelman, AM; Lusis, AJ				Shih, DM; Gu, LJ; Xia, YR; Navab, M; Li, WF; Hama, S; Castellani, LW; Furlong, CE; Costa, LG; Fogelman, AM; Lusis, AJ			Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; POLYMORPHISM	Serum paraoxonase (PON1) is an esterase that is associated with high-density lipoproteins (HDLs) in the plasma; it is involved in the detoxification of organophosphate insecticides such as parathion and chlorpyrifos(1-3). PON1 may also confer protection against coronary artery disease by destroying pro-inflammatory oxidized lipids present in oxidized low-density lipoproteins (LDLs)(4-8). To study the role of PON1 in vivo we created PON1-knockout mice by gene targeting. Compared with their wild-type littermates, PON1-deficient mice were extremely sensitive to the toxic effects of chlorpyrifos oxon, the activated form of chlorpyrifos, and were more sensitive to chlorpyrifos itself. HDLs isolated from PON1-deficient mice were unable to prevent LDL oxidation in a co-cultured cell model of the artery wall, and both HDLs and LDLs isolated from PON1-knockout mice were more susceptible to oxidation by co-cultured cells than the lipoproteins from wild-type littermates. When fed on a high-fat, high-cholesterol diet, PON1-null mice were more susceptible to atherosclerosis than their wild-type littermates.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lusis, AJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, 47-123 CHS, Los Angeles, CA 90095 USA.							COSTA LG, 1990, TOXICOL APPL PHARM, V103, P66, DOI 10.1016/0041-008X(90)90263-T; Davies HG, 1996, NAT GENET, V14, P334, DOI 10.1038/ng1196-334; Heinecke JW, 1998, AM J HUM GENET, V62, P20, DOI 10.1086/301691; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; LI WF, 1993, J TOXICOL ENV HEALTH, V40, P337, DOI 10.1080/15287399309531798; LI WF, 1995, TOXICOL LETT, V76, P219, DOI 10.1016/0378-4274(95)80006-Y; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MURPHY SD, 1980, TOXICOLOGY BASIC SCI, P357; Navab M, 1997, J CLIN INVEST, V99, P2005, DOI 10.1172/JCI119369; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; SMOLEN A, 1991, DRUG METAB DISPOS, V19, P107; TAFURI J, 1987, ANN EMERG MED, V16, P193, DOI 10.1016/S0196-0644(87)80015-X; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359	17	913	950	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					284	287		10.1038/28406	http://dx.doi.org/10.1038/28406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685159				2022-12-01	WOS:000074851900050
J	Vaizey, CJ; Kamm, MA; Gold, DM; Bartram, CI; Halligan, S; Nicholls, RJ				Vaizey, CJ; Kamm, MA; Gold, DM; Bartram, CI; Halligan, S; Nicholls, RJ			Clinical, physiological, and radiological study of a new purpose-designed artificial bowel sphincter	LANCET			English	Article							FECAL INCONTINENCE; ANAL INCONTINENCE	Background Studies of the use of artificial urinary sphincters for faecal incontinence have led to refinement and adaptation of such sphincters to the anatomy of the anal region. We aimed to test this new device. Methods Six women, median age 53 (range 32-58) years, who were unsuitable for sphincter repair, had an artificial bowel sphincter implanted as a one-stage procedure without colostomy cover. Clinical assessment, physiological testing, and endosonography were done before and after the operation. Plain radiography, three-dimensional endosonography, and magnetic-resonance imaging were done after the operation, to define its anatomical location. Results Median follow-up was 10 (range 5-13) months and the device was functional in five patients. In one patient, the device was removed after ulceration through the skin, Of the patients with intact devices, Wexner incontinence scores improved from a median of 19 (18-20) of 20 before the operation, to 3 (0-6) of 20 after the operation, Median anal pressure at rest significantly increased from 60 (range 30-80) cm H2O to 110 (100-120) cm H2O, Functional anal-canal length varied after the operation from 3.3 cm to 3.8 cm. There was no significant change in the maximum tolerated volume of the rectum (140 [80-230] vs 100 [75-250] mt), or rectal compliance (2.9 [2.8-6.0] cm H2O/mL vs 3.5 [2.3-7.3] cm H2O/mL). All the imaging techniques accurately located the implant relative to the anal canal and pelvic floor in each patient. Interpretation The new artificial bowel sphincter provided a good functional result in five of the six patients, the surgical procedure was straightforward, and the maximum resting anal pressure rose without affecting rectal function. The ease of visualisation of such implants in situ should aid simple management of complications, should they arise.	St Marks Hosp, Dept Physiol, London EC1V 2PS, England; St Marks Hosp, Dept Radiol, London EC1V 2PS, England; St Marks Hosp, Dept Surg, London EC1V 2PS, England	Imperial College London; Imperial College London; Imperial College London	Nicholls, RJ (corresponding author), St Marks Hosp, Dept Surg, Northwick Pk,Watford Rd, Harrow HA1 3UJ, Middx, England.		Halligan, Steve/C-5875-2009	Halligan, Steve/0000-0003-0632-5108; Gold, Darren/0000-0003-4478-9747				BAETEN CGMI, 1995, NEW ENGL J MED, V332, P1600, DOI 10.1056/NEJM199506153322403; CHRISTIANSEN J, 1989, DIS COLON RECTUM, V32, P432, DOI 10.1007/BF02563699; CHRISTIANSEN J, 1987, LANCET, V1, P244; Geerdes BP, 1996, DIS COLON RECTUM, V39, P912, DOI 10.1007/BF02053991; JORGE JMN, 1993, SOUTH MED J, V86, P924, DOI 10.1097/00007611-199308000-00016; KAMM MA, 1990, DIS COLON RECTUM, V33, P419, DOI 10.1007/BF02156270; KIFF ES, 1984, BRIT J SURG, V71, P614, DOI 10.1002/bjs.1800710817; Lehur PA, 1996, DIS COLON RECTUM, V39, P1352, DOI 10.1007/BF02054523; LEO ME, 1993, J UROLOGY, V150, P1412, DOI 10.1016/S0022-5347(17)35793-2; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; NEILL ME, 1981, BRIT J SURG, V68, P531, DOI 10.1002/bjs.1800680804; Scott F B, 1973, Urology, V1, P252; Wong WD, 1996, DIS COLON RECTUM, V39, P1345	13	82	85	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 11	1998	352	9122					105	109		10.1016/S0140-6736(97)11427-1	http://dx.doi.org/10.1016/S0140-6736(97)11427-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672276				2022-12-01	WOS:000074775100014
J	Welch, MD; Rosenblatt, J; Skoble, J; Portnoy, DA; Mitchison, TJ				Welch, MD; Rosenblatt, J; Skoble, J; Portnoy, DA; Mitchison, TJ			Interaction of human Arp2/3 complex and the Listeria monocytogenes ActA protein in actin filament nucleation	SCIENCE			English	Article							HOST-CELL ACTIN; PROLINE-RICH REGION; SACCHAROMYCES-CEREVISIAE; OWN CYTOSKELETON; FOCAL ADHESION; MOTILITY; GENE; POLYMERIZATION; MOVEMENT; PROFILIN	Actin filament assembly at the cell surface of the pathogenic bacterium Listeria monocytogenes requires the bacterial ActA surface protein and the host cell Arp2/3 complex. Purified Arp2/3 complex accelerated the nucleation of actin polymerization in vitro, but pure ActA had no effect. However, when combined, the Arp2/3 complex and ActA synergistically stimulated the nucleation of actin filaments. This mechanism of activating the host Arp2/3 complex at the L. monocytogenes surface may be similar to the strategy used by cells to control Arp2/3 complex activity and hence the spatial and temporal distribution of actin polymerization.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; University of California System; University of California Berkeley	Welch, MD (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868	NIAID NIH HHS [AI26919] Funding Source: Medline; NIGMS NIH HHS [GM48027] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 1996, EMBO J, V15, P6426, DOI 10.1002/j.1460-2075.1996.tb01034.x; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Huang ME, 1996, YEAST, V12, P839, DOI 10.1002/(SICI)1097-0061(199607)12:9<839::AID-YEA982>3.3.CO;2-#; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; LEESMILLER JP, 1992, P NATL ACAD SCI USA, V89, P80, DOI 10.1073/pnas.89.1.80; Machesky LM, 1997, BIOCHEM J, V328, P105; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1992, J CELL BIOL, V118, P71, DOI 10.1083/jcb.118.1.71; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; WELCH MD, 1998, METHODS ENZYMOL, V298; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5	41	409	437	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					105	108		10.1126/science.281.5373.105	http://dx.doi.org/10.1126/science.281.5373.105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651243				2022-12-01	WOS:000074685800048
J	Rainey, PB; Travisano, M				Rainey, PB; Travisano, M			Adaptive radiation in a heterogeneous environment	NATURE			English	Article							EVOLUTION; ADAPTATION; BACTERIA; DIVERSIFICATION; POLYMORPHISM; POPULATIONS; DIVERGENCE; TESTS	Successive adaptive radiations have played a pivotal role in the evolution of biological diversity(1-3). The effects of adaptive radiation are often seen(4-6), but the underlying causes are difficult to disentangle and remain unclear(7-9). Here we examine directly the role of ecological opportunity and competition in driving genetic diversification. We use the common aerobic bacterium Pseudomonas fluorescens(10), which evolves rapidly under novel environmental conditions to generate a large repertoire of mutants(11-13). When provided with ecological opportunity (afforded by spatial structure), identical populations diversify morphologically, but when ecological opportunity is restricted there is no such divergence. In spatially structured environments, the evolution of variant morphs follows a predictable sequence and we show that competition among the newly evolved niche-specialists maintains this variation. These results demonstrate that the elementary processes of mutation and selection alone are suifficient to promote rapid proliferation of new designs and support the theory that trade-offs in competitive ability drive adaptive radiation(14,15).	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Rainey, PB (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	prainey@worf.molbiol.ox.ac.uk	Travisano, Michael/AAI-4809-2020; Rainey, Paul/A-3207-2008	Rainey, Paul/0000-0003-0879-5795				ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; ATWOOD KC, 1951, P NATL ACAD SCI USA, V37, P146, DOI 10.1073/pnas.37.3.146; Bell G, 1997, HEREDITY, V78, P498, DOI 10.1038/hdy.1997.78; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; CHARLESWORTH B, 1982, EVOLUTION, V46, P16; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; DOBZHANSKY T, 1972, SCIENCE, V177, P664, DOI 10.1126/science.177.4050.664; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Gould S.J., 1989, WONDERFUL LIFE BURGE; Grant P.R., 1986, ECOLOGY EVOLUTION DA; Haldane JBS., 1932, CAUSES EVOLUTION; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HEDRICK PW, 1986, ANNU REV ECOL SYST, V17, P535; HOPF FA, 1993, EVOL ECOL, V7, P142, DOI 10.1007/BF01239385; KLEIN D, 1993, NATURE, V364, P330, DOI 10.1038/364330a0; KORONA R, 1994, P NATL ACAD SCI USA, V91, P9037, DOI 10.1073/pnas.91.19.9037; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; MORRIS SC, 1979, SCI AM, V241, P122, DOI 10.1038/scientificamerican0779-122; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Otte D., 1989, SPECIATION ITS CONSE; Rainey PB, 1996, MOL MICROBIOL, V19, P521, DOI 10.1046/j.1365-2958.1996.391926.x; Rainey PB, 1993, ADV MICROB ECOL, P263; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; SHAPRIO JA, 1986, BACTERIA BIOL PSEUDO, P27; TAPER MT, 1994, OXFORD SURVEYS EVOLU, V8, P63; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Turner PE, 1996, ECOLOGY, V77, P2119, DOI 10.2307/2265706	30	860	878	3	424	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1998	394	6688					69	72		10.1038/27900	http://dx.doi.org/10.1038/27900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665128				2022-12-01	WOS:000074579600049
J	Roingeard, P; Brand, D				Roingeard, P; Brand, D			Budding of human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHU Tours, F-37044 Tours, France	CHU Tours	Roingeard, P (corresponding author), CHU Tours, F-37044 Tours, France.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1998	339	1					32	32		10.1056/NEJM199807023390106	http://dx.doi.org/10.1056/NEJM199807023390106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZX285	9647877				2022-12-01	WOS:000074500000006
J	Tzivion, G; Luo, ZJ; Avruch, J				Tzivion, G; Luo, ZJ; Avruch, J			A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity	NATURE			English	Article							14-3-3-PROTEINS; ACTIVATION; C-RAF-1; IDENTIFICATION; PATHWAY; BINDING	cRaf-1 is a mitogen-activated protein kinase that is the main effector recruited by GTP-bound Ras in order to activate the MAP kinase pathway(1). Inactive Raf is found in the cytosol in a complex with Hsp90, Hsp50 (Cdc37)(2,3) and the 14-3-3 proteins(4). GTP-bound Ras binds Raf and is necessary but not sufficient for the stable activation of Raf that occurs in response to serum, epidermal growth factor, platelet-derived growth factor or insulin(5-8). These agents cause a two- to threefold increase in overall phosphorylation of Raf on serine/threonine residues(8,9), and treatment of cRaf-1 with protein (serine/threonine) phosphatases can deactivate it, at least partially(10). The role of 14-3-3 proteins in the regulation of Raf's kinase activity is uncertain(4,11) and is investigated here. Active Raf can be almost completely deactivated in vitro by displacement of 14-3-3 using synthetic phosphopeptides. Deactivation can be substantially reversed by addition of purified recombinant bacterial 14-3-3; however, Raf must have been previously activated in vivo to be reactivated by 14-3-3 in vitro. The ability of 14-3-3 to support Raf activity is dependent on phosphorylation of serine residues on Raf and on the integrity of the 14-3-3 dimer; mutant monomeric forms of 14-3-3, although able to bind Raf in vivo, do not enable Raf to be activated in vivo or restore Raf activity after displacement of 14-3-3 in vitro. The 14-3-3 protein is not required to induce dimerization of Raf, We propose that dimeric 14-3-3 is needed both to maintain Raf in an inactive state in the absence of GTP-bound Ras and to stabilize an active conformation of Raf produced during activation in vivo.	Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.	avruch@helix.mgh.harvard.edu	Tzivion, Guri/D-8954-2011; Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KNOCKEL L, 1997, GENE DEV, V11, P1140; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; STANCATO LE, 1995, J BIOL CHEM, V268, P21711; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUEN KL, 1995, ONCOGENE, V11, P825; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	383	391	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					88	92		10.1038/27938	http://dx.doi.org/10.1038/27938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665134				2022-12-01	WOS:000074579600055
J	Pocovi, M; Cenarro, A; Civeira, F; Torralba, MA; Perez-Calvo, JI; Mozas, P; Giraldo, P; Giralt, M; Myers, RH; Cupples, LA; Ordovas, JM				Pocovi, M; Cenarro, A; Civeira, F; Torralba, MA; Perez-Calvo, JI; Mozas, P; Giraldo, P; Giralt, M; Myers, RH; Cupples, LA; Ordovas, JM			beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia	LANCET			English	Article							HIGH-DENSITY-LIPOPROTEIN; ASHKENAZI JEWS; CHOLESTEROL; MUTATION; POPULATION; IDENTIFICATION; FREQUENCIES; GENOTYPE; DNA	Background Gaucher's disease is the most common lysosomal storage disorder, caused by deficiency of glucocerebrosidase resulting from homozygosity for any of several mutations of the glucocerebrosidase gene locus. Affected people have decreased concentrations of LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C). We assessed the association between mutations in the glucocerebrosidase locus and hypo-alpha-lipoproteinaemia. Methods We studied 258 people from 43 unrelated Spanish families. 57 participants were affected, 137 were nonaffected carriers, and 64 were non-carriers. We determined glucocerebrosidase genotypes and measured plasmid lipids, apolipoproteins A-I, B, and E, and leucocyte glucocerebrosidase activity. Findings The most common glucocerebrosidase mutations were N37OS (45%), L444P (23%), and G377S (5%). Deletions and recombinants accounted for another 5%, and point mutations in exons 5, 6, 9, and 10 were present in 12%, Affected participants had lower LDL-C and HDL-C concentrations than non-affected carriers (p<0.001) and non-carriers (p<0 001). HDL-C values were also significantly different between the non-affected carriers and non-carriers. Mutations at this locus may account for as much as 19.5% of the genetic variability in HDL-C in the population studied. Interpretation Heterozygosity for these mutations at the glucocerebrosidase locus does not result in clinical expression of Gaucher's disease but can decrease HDLC concentrations, Given the high frequency of these mutations, the glucocerebrosidase locus might lead to familial low alpha-lipoproteinaemia in up to 2% of the general population and be one of the most common known genetic causes of HDL-C.	Univ Zaragoza, Fac Sci, Dept Biochem Mol & Cellular Biol, E-50009 Zaragoza, Spain; Univ Hosp, Dept Internal Med, Zaragoza, Spain; Hosp Miguel Servet, Dept Internal Med, Zaragoza, Spain; Hosp Miguel Servet, Dept Haematol, Zaragoza, Spain; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Publ Hlth, Boston, MA 02118 USA; Tufts Univ, Lipid Metab Lab JM HNRCA, Boston, MA 02111 USA	University of Zaragoza; Miguel Servet University Hospital; Miguel Servet University Hospital; Miguel Servet University Hospital; Boston University; Boston University; Tufts University; United States Department of Agriculture (USDA)	Ordovas, JM (corresponding author), Tufts Univ, JM USDA Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.	ordovas_li@hnrc.tufts.edu	Calvo, Juan Ignacio Pérez/I-4194-2019; MOZAS, PILAR/AAR-8624-2021; Ordovas, Jose/B-8727-2013	Calvo, Juan Ignacio Pérez/0000-0003-2361-9941; Ordovas, Jose/0000-0002-7581-5680; Myers, Richard/0000-0002-8365-2674	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AMARAL O, 1993, BIOCHEM MED METAB B, V49, P97, DOI 10.1006/bmmb.1993.1011; BEUTLER E, 1990, CLIN CHIM ACTA, V194, P161, DOI 10.1016/0009-8981(90)90130-K; BEUTLER E, 1994, HUM MUTAT, V4, P212, DOI 10.1002/humu.1380040307; BEUTLER E, 1991, NEW ENGL J MED, V325, P1354; BEUTLER E, 1994, MOL MED, V1, P82, DOI 10.1007/bf03403534; BEUTLER E, 1993, AM J HUM GENET, V52, P85; Beutler E., 1995, METABOLIC MOL BASES, P2641; BOERWINKLE E, 1987, ANN HUM GENET, V51, P211, DOI 10.1111/j.1469-1809.1987.tb00874.x; Cormand B, 1997, HUM GENET, V100, P75, DOI 10.1007/s004390050468; DeMarchi JM, 1996, HUM MUTAT, V8, P116; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; GINSBERG H, 1984, CLIN GENET, V26, P109; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRABOWSKI GA, 1993, ADV HUM GENET, V21, P377; LACERDA L, 1994, CLIN GENET, V45, P298; LAUBSCHER KH, 1994, HUM MUTAT, V3, P411, DOI 10.1002/humu.1380030418; LE NA, 1988, METABOLISM, V37, P240, DOI 10.1016/0026-0495(88)90102-3; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MIDDLETONPRICE HR, 1988, HUM GENET, V79, P283, DOI 10.1007/BF00366253; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MISTRY PK, 1995, LANCET, V346, P982, DOI 10.1016/S0140-6736(95)91680-6; *NIH, 1995, GAUCH DIS CURR ISS D; RAGHAVAN SS, 1980, AM J HUM GENET, V32, P158; UCHIYAMA A, 1994, HUM MOL GENET, V3, P1183, DOI 10.1093/hmg/3.7.1183; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	27	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1919	1923		10.1016/S0140-6736(97)09490-7	http://dx.doi.org/10.1016/S0140-6736(97)09490-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654259	hybrid			2022-12-01	WOS:000074464700009
J	Benke, TA; Luthi, A; Isaac, JTR; Collingridge, GL				Benke, TA; Luthi, A; Isaac, JTR; Collingridge, GL			Modulation of AMPA receptor unitary conductance by synaptic activity	NATURE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; EXCITATORY AMINO-ACIDS; HIPPOCAMPAL-NEURONS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; SILENT SYNAPSES; BRAIN-SLICES; GLUTAMATE; CHANNELS	Activity-dependent alteration in synaptic strength is a fundamental property of the vertebrate central nervous system and is thought to underlie learning and memory. The most extensively studied model of activity-dependent synaptic plasticity is longterm potentiation (LTP) of glutamate-responsive (glutamatergic) synapses, a widespread phenomenon involving multiple mechanisms(1). The best characterized form of LTP occurs in the CA1 region of the hippocampus, in which LTP is initiated by transient activation of NMDA (N-methyl-D-aspartate) receptors and is expressed as a persistent increase in synaptic transmission through AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole pionate) receptors(2). This increase is due, at least in part, to a postsynaptic modification of AMPA-receptor function(3); this modification could be caused by an increase in the number of receptors, their open probability, their kinetics or their single-channel conductance. Here we show that the induction of LTP in the CA1 region of the hippocampus is often associated with an increase in single-channel conductance of AMPA receptors. This shows that elementary channel properties can be rapidly modified by synaptic activity and provides an insight into one molecular mechanism by which glutamatergic synapses can alter their strength.	Univ Bristol, Sch Med Sci, Dept Anat, Bristol BS8 1TD, Avon, England	University of Bristol	Collingridge, GL (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, Univ Walk, Bristol BS8 1TD, Avon, England.		collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLAY JR, 1983, BIOPHYS J, V42, P151, DOI 10.1016/S0006-3495(83)84381-1; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HINES M, 1984, INT J BIOMED COMPUT, V15, P69, DOI 10.1016/0020-7101(84)90008-4; HOMES WR, 1990, J NEUROPHYSIOL, V63, P1148; Isaac JTR, 1996, P NATL ACAD SCI USA, V93, P8710, DOI 10.1073/pnas.93.16.8710; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAJOR G, 1994, J NEUROSCI, V14, P4613; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; SHRIKE AM, 1997, J NEUROPHYSIOL, V78, P2682; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	30	397	411	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					793	797		10.1038/31709	http://dx.doi.org/10.1038/31709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655394				2022-12-01	WOS:000074433100051
J	Choo, V				Choo, V			Outlook for sexually transmitted diseases	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Choo, V (corresponding author), Lancet, London WC1B 3SL, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1832	1832		10.1016/S0140-6736(05)78803-6	http://dx.doi.org/10.1016/S0140-6736(05)78803-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652665				2022-12-01	WOS:000074347100008
J	Marshall, SJ				Marshall, SJ			On being a ginseng connoisseur	LANCET			English	Editorial Material																			0	1	1	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1898	1898		10.1016/S0140-6736(05)78859-0	http://dx.doi.org/10.1016/S0140-6736(05)78859-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652710				2022-12-01	WOS:000074347100072
J	Welch, AM; Semlitsch, RD; Gerhardt, HC				Welch, AM; Semlitsch, RD; Gerhardt, HC			Call duration as an indicator of genetic quality in male gray tree frogs	SCIENCE			English	Article							ACOUSTIC CRITERIA; HYLA-VERSICOLOR; FEMALE CHOICE; LIFE-HISTORY; MATE CHOICE; SELECTION; VARIABILITY; BEHAVIOR; GROWTH; BUFO	The "good genes" hypothesis predicts that mating preferences enable females to select mates of superior genetic quality. The genetic consequences of the preference shown by female gray tree frogs for long-duration calls were evaluated by comparing the performance of maternal half-siblings sired by males with different call durations. Offspring of male gray tree frogs that produced long calls showed better performance during larval and juvenile stages than did offspring of males that produced short calls. These data suggest that call duration can function as a reliable indicator of heritable genetic quality.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Welch, AM (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.			Semlitsch, Raymond/0000-0002-7999-5762				BERVEN KA, 1983, AM ZOOL, V23, P85; Falconer DS, 1996, INTRO QUANTITATIVE G; FELLERS GM, 1979, COPEIA, P286, DOI 10.2307/1443416; Gerhardt HC, 1996, BEHAV ECOL, V7, P7, DOI 10.1093/beheco/7.1.7; GERHARDT HC, 1991, ANIM BEHAV, V42, P615, DOI 10.1016/S0003-3472(05)80245-3; GERHARDT HC, 1995, ANIM BEHAV, V50, P1187; Gosner K. L., 1960, Herpetologica, V16, P183; Grafe U, 1997, COPEIA, P356, DOI 10.2307/1447755; HOWARD RD, 1994, EVOLUTION, V48, P1286, DOI 10.1111/j.1558-5646.1994.tb05313.x; Kirkpatrick M, 1997, P NATL ACAD SCI USA, V94, P1282, DOI 10.1073/pnas.94.4.1282; KLUMP GM, 1987, NATURE, V326, P286, DOI 10.1038/326286a0; KRENZ JD, UNPUB; MITCHELL SL, 1990, EVOLUTION, V44, P502, DOI 10.1111/j.1558-5646.1990.tb05935.x; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; RITKE ME, 1990, J HERPETOL, V24, P135, DOI 10.2307/1564220; RUNKLE LS, 1994, BEHAV ECOL, V5, P318, DOI 10.1093/beheco/5.3.318; Semlitsch RD, 1996, EVOL ECOL, V10, P531, DOI 10.1007/BF01237883; Semlitsch RD, 1997, EVOLUTION, V51, P1249, DOI 10.1111/j.1558-5646.1997.tb03972.x; SEMLITSCH RD, 1994, BEHAV ECOL SOCIOBIOL, V34, P19; Sokal R., 1981, BIOMETRY; SULLIVAN BK, 1992, ANIM BEHAV, V44, P733, DOI 10.1016/S0003-3472(05)80299-4; WELLS KD, 1986, BEHAV ECOL SOCIOBIOL, V19, P9, DOI 10.1007/BF00303837; WILBUR HM, 1973, SCIENCE, V182, P1305, DOI 10.1126/science.182.4119.1305; WOODWARD BD, 1986, AM NAT, V128, P58, DOI 10.1086/284539; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	26	346	354	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1928	1930		10.1126/science.280.5371.1928	http://dx.doi.org/10.1126/science.280.5371.1928			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9632389				2022-12-01	WOS:000074323800061
J	Li, P; Zhuo, M				Li, P; Zhuo, M			Silent glutamatergic synapses and nociception in mammalian spinal cord	NATURE			English	Article							LONG-TERM POTENTIATION; NUCLEI RETICULARIS-GIGANTOCELLULARIS; SUBSTANTIA GELATINOSA NEURONS; SUPERFICIAL DORSAL HORN; DESCENDING FACILITATION; PARS-ALPHA; RAT; INFLAMMATION; PLASTICITY; TRANSMISSION	Neurons in the superficial dorsal horn of the spinal cord are important for conveying sensory information from the periphery to the central nervous system(1,2). Some synapses between primary afferent fibres and spinal dorsal horn neurons may be inefficient or silent(3). Ineffective sensory transmission could result from a small postsynaptic current that fails to depolarize the cell to threshold for an action potential or from a cell with a normal postsynaptic current but an increased threshold for action potentials. Here we show that some cells in the superficial dorsal horn of the lumbar spinal cord have silent synapses: they do not respond unless the holding potential is moved from -70 mV to +40 mV. Serotonin (5-hydroxytryptamine, 5-HT), an important neurotransmitter of the raphe-spinal projecting pathway, transforms silent glutamatergic synapses into functional ones. Therefore, transformation of silent glutamatergic synapses may serve as a cellular mechanism for central plasticity in the spinal cord.	Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Zhuo, M (corresponding author), Washington Univ, Dept Anesthesiol, Campus Box 8054, St Louis, MO 63110 USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241				BEYER WH, 1968, HDB TABLES PROBABILI; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.ne.14.030191.001251; GEBHART GF, 1990, BRAINSTEM MECH BEHAV, P315; HARRIS JA, 1996, NEUROSCIENCE, V14, P7; Hori Y, 1996, J PHYSIOL-LONDON, V492, P867, DOI 10.1113/jphysiol.1996.sp021352; HYLDEN JLK, 1989, PAIN, V37, P229, DOI 10.1016/0304-3959(89)90135-8; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; LopezGarcia JA, 1996, EUR J NEUROSCI, V8, P2188, DOI 10.1111/j.1460-9568.1996.tb00740.x; Maccaferri G, 1996, J NEUROSCI, V16, P5334; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MENETREY D, 1982, PAIN, V13, P343, DOI 10.1016/0304-3959(82)90003-3; Paxinos G., 1998, RAT BRAIN STEROTAXIC; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TODD AJ, 1994, J NEUROSCI, V14, P774; WALL PD, 1977, PHILOS T R SOC B, V278, P361, DOI 10.1098/rstb.1977.0048; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; YOSHIMURA M, 1990, J PHYSIOL-LONDON, V430, P315, DOI 10.1113/jphysiol.1990.sp018293; Zhuo M, 1997, J NEUROPHYSIOL, V78, P746, DOI 10.1152/jn.1997.78.2.746; ZHUO M, 1991, BRAIN RES, V550, P35, DOI 10.1016/0006-8993(91)90402-H; ZHUO M, 1992, J NEUROPHYSIOL, V67, P1599, DOI 10.1152/jn.1992.67.6.1599	29	212	225	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					695	698		10.1038/31496	http://dx.doi.org/10.1038/31496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641681				2022-12-01	WOS:000074289600056
J	Eudy, JD; Weston, MD; Yao, SF; Hoover, DM; Rehm, HL; Ma-Edmonds, M; Yan, D; Ahmad, I; Cheng, JJ; Ayuso, C; Cremers, C; Davenport, S; Moller, C; Talmadge, CB; Beisel, KW; Tamayo, M; Morton, CC; Swaroop, A; Kimberling, WJ; Sumegi, J				Eudy, JD; Weston, MD; Yao, SF; Hoover, DM; Rehm, HL; Ma-Edmonds, M; Yan, D; Ahmad, I; Cheng, JJ; Ayuso, C; Cremers, C; Davenport, S; Moller, C; Talmadge, CB; Beisel, KW; Tamayo, M; Morton, CC; Swaroop, A; Kimberling, WJ; Sumegi, J			Mutation of a gene encoding a protein with extracellular matrix motifs in usher syndrome type IIa	SCIENCE			English	Article							SYNDROME TYPE-I; ALPORT SYNDROME; LOCALIZATION; IDENTIFICATION; CHROMOSOME-11	Usher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2. Three biologically important mutations in Usher syndrome type IIa patients were identified in a gene (USH2A) isolated from this critical region. The USH2A gene encodes a protein with a predicted size of 171.5 kilodaltons that has laminin epidermal growth factor and fibronectin type III motifs; these motifs are most commonly observed in proteins comprising components of the basal lamina and extracellular matrixes and in cell adhesion molecules.	Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Boys Town Natl Res Hosp, Dept Genet, Omaha, NE 68131 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA; Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, Omaha, NE 68198 USA; Fdn Jimenez Diaz, E-28003 Madrid, Spain; Univ Nijmegen, Sint Radboudziekenhuis, NL-6500 NB Nijmegen, Netherlands; Univ Hosp RIL, Ear Nose & Throat Clin, S-58180 Linkoping, Sweden; Univ Javeriana, Unidad Genet Clin, Bogota, Colombia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol & Pathol, Boston, MA 02115 USA	University of Nebraska System; University of Nebraska Medical Center; Boys Town National Research Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; Radboud University Nijmegen; Pontificia Universidad Javeriana; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sumegi, J (corresponding author), Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.	jsumegi@mail.unmc.edu	Cremers, C.W.R.J./L-4254-2015	Swaroop, Anand/0000-0002-1975-1141; Tamayo, Martha Lucia/0000-0001-8297-3970; Ayuso, Carmen/0000-0002-9242-7065; Rehm, Heidi L./0000-0002-6025-0015	NEI NIH HHS [EY07003] Funding Source: Medline; NIDCD NIH HHS [5PO1 DC01813-05, DC03402] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC001813, R01DC003402] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BOUGHMAN JA, 1983, BRIT J OPHTHALMOL, V67, P449, DOI 10.1136/bjo.67.7.449; Chaib H, 1997, HUM MOL GENET, V6, P27, DOI 10.1093/hmg/6.1.27; DAHL SP, 1993, J MED GENET, V30, P843, DOI 10.1136/jmg.30.10.843; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; EUDY JD, UNPUB; HALLGREN B, 1959, ACTA PSYCHIAT SCAN S, V138; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; Kimberling W J, 1995, J Am Acad Audiol, V6, P63; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; OGDEN TE, 1994, RETINA, P58; PIASSA L, 1986, ARCH OPHTHALMOL-CHIC, V1041, P1336; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Rosenberg T, 1997, CLIN GENET, V51, P314; SANKILA EM, 1995, HUM MOL GENET, V4, P93, DOI 10.1093/hmg/4.1.93; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SoussiYanicostas N, 1996, J CELL SCI, V109, P1749; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; Sumegi J, 1996, GENOMICS, V35, P79, DOI 10.1006/geno.1996.0325; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Vielmetter J, 1997, GENOMICS, V41, P414, DOI 10.1006/geno.1997.4688; Wayne S, 1996, HUM MOL GENET, V5, P1689, DOI 10.1093/hmg/5.10.1689; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	27	290	300	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1753	1757		10.1126/science.280.5370.1753	http://dx.doi.org/10.1126/science.280.5370.1753			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624053				2022-12-01	WOS:000074197800042
J	Shann, F				Shann, F			Pneumococcal vaccine: time for another controlled trial	LANCET			English	Editorial Material							RESPIRATORY-TRACT INFECTIONS; PAPUA-NEW-GUINEA; CHILDREN		Royal Childrens Hosp, Intens Care Unit, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Melbourne, Vic 3052, Australia.		Shann, Frank/C-9510-2011					AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Goldblatt D, 1993, Immunodeficiency, V4, P47; Kayhty H, 1996, EMERG INFECT DIS, V2, P289, DOI 10.3201/eid0204.9604; LEHMANN D, 1991, ANN TROP PAEDIATR, V11, P247, DOI 10.1080/02724936.1991.11747510; POMAT WS, 1994, INFECT IMMUN, V62, P1848, DOI 10.1128/IAI.62.5.1848-1853.1994; RILEY ID, 1986, LANCET, V2, P877; TEMPLE K, 1991, PEDIATR INFECT DIS J, V10, P386, DOI 10.1097/00006454-199105000-00008; Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006; *WHO, 1997, TECHN REV GROUP M JU, P32; *WHO, 1995, WORLD HLTH REP 1995, P9; WITT CS, 1991, CLIN EXP IMMUNOL, V83, P219, DOI 10.1111/j.1365-2249.1991.tb05618.x; Woolfson A, 1997, B WORLD HEALTH ORGAN, V75, P453; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	14	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1600	1601		10.1016/S0140-6736(05)77683-2	http://dx.doi.org/10.1016/S0140-6736(05)77683-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620711				2022-12-01	WOS:000074026600004
J	Struhl, G; Adachi, A				Struhl, G; Adachi, A			Nuclear access and action of notch in vivo	CELL			English	Article							DEVELOPING DROSOPHILA EYE; EPIDERMAL GROWTH-FACTOR; OF-FUNCTION MUTATIONS; SPLIT COMPLEX GENES; ACTIVATES TRANSCRIPTION; SIGNAL-TRANSDUCTION; RECEPTOR; PROTEIN; EXPRESSION; SUPPRESSOR	The Drosophila Notch (N) gene encodes a conserved single-pass transmembrane receptor that transduces extracellular signals controlling cell fate. Here, we present evidence that the intracellular domain of Notch gains access to the nucleus in response to ligand, possibly through a mechanism involving proteolytic cleavage and release from the remainder of the protein. In addition, our results suggest that signal transduction by Notch depends on the ability of the intracellular domain, particularly the portion containing the CDC10 repeats, to reach the nucleus and to participate in the transcriptional activation of downstream target genes.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Eastman DS, 1997, MOL CELL BIOL, V17, P5620, DOI 10.1128/MCB.17.9.5620; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FISHER AL, 1998, IN PRESS GENES DEV; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1998, IN PRESS GENES DEV; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wang SW, 1997, DEVELOPMENT, V124, P4435; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	40	630	651	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1998	93	4					649	660		10.1016/S0092-8674(00)81193-9	http://dx.doi.org/10.1016/S0092-8674(00)81193-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604939	hybrid			2022-12-01	WOS:000073722200017
J	May, A; Bahra, A; Buchel, C; Frackowiak, RSJ; Goadsby, PJ				May, A; Bahra, A; Buchel, C; Frackowiak, RSJ; Goadsby, PJ			Hypothalamic activation in cluster headache attacks	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; ORBITAL PHLEBOGRAPHY; ANGINA-PECTORIS; PAIN; MIGRAINE; FIBERS; BRAIN	Background Cluster headache, one of the most severe pain syndromes in human beings, is usually described as a vascular headache. However, the striking circadian rhythmicity of this strictly half-sided pain syndrome cannot be readily explained by the vascular hypothesis. We aimed to assess changes in regional cerebral blood flow (rCBF) in patients with cluster headache. Methods We used positron emission tomography (PET) to assess the changes in rCBF, as an index of synaptic activity, during nitroglycerin-induced cluster headache attacks in nine patients who had chronic cluster headache. Eight patients who had cluster headache but were not in the bout acted as a control group. Findings In the acute pain slate, activation was seen in the ipsilateral inferior hypothalamic grey matter, the contralateral ventroposterior thalamus, the anterior cingulate cortex, and bilaterally in the insulae. Activation in the hypothalamus was seen solely in the pain state and was not seen in patients who have cluster headache but were out of the bout. Interpretation Our findings establish central nervous system dysfunction in the region of the hypothalamus as the primum movens in the pathophysiology of cluster headache. We suggest that a radical reappraisal of this type of headache is needed and that it should in general terms, be regarded as a neurovascular headache, to give equal weight to the pathological and physiological mechanisms that are at work.	UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Univ London, Dept Clin Neurol, London, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London	May, A (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.	amay@ion.ucl.ac.uk	Goadsby, Peter J/Z-1970-2019; Frackowiak, Richard S/I-1809-2013; Goadsby, Peter J/B-2267-2009; Frackowiak, Richard/H-4383-2011	Goadsby, Peter J/0000-0003-3260-5904; Frackowiak, Richard/0000-0002-3151-822X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOVIM G, 1992, HEADACHE, V32, P408; BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHAZOT G, 1984, CEPHALALGIA, V4, P213, DOI 10.1046/j.1468-2982.1984.0404213.x; EKBOM K, 1968, ARCH NEUROL-CHICAGO, V19, P487, DOI 10.1001/archneur.1968.00480050057005; EKBOM K, 1970, ACTA NEUROL SCAND, V46, P225, DOI 10.1111/j.1600-0404.1970.tb05618.x; EKEROT CF, 1991, J PHYSIOL-LONDON, V441, P257, DOI 10.1113/jphysiol.1991.sp018750; FANCIULLACCI M, 1995, PAIN, V60, P119, DOI 10.1016/0304-3959(94)00097-X; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GOADSBY PJ, 1987, AM J PHYSIOL, V253, pR270, DOI 10.1152/ajpregu.1987.253.2.R270; GOADSBY PJ, 1994, BRAIN, V117, P427, DOI 10.1093/brain/117.3.427; GOADSBY PJ, 1991, HEADACHE, V31, P365, DOI 10.1111/j.1526-4610.1991.hed3106365.x; GOADSBY PJ, 1997, HEADACHE; GOADSBY PJ, 1988, BASIC MECHANISMS HEA, P413; HANNERZ J, 1987, CEPHALALGIA, V7, P207, DOI 10.1046/j.1468-2982.1987.0703207.x; HARDEBO JE, 1994, HEADACHE, V34, P125, DOI 10.1111/j.1526-4610.1994.hed3403125.x; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; Hsieh JC, 1996, PAIN, V67, P59, DOI 10.1016/0304-3959(96)03066-7; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; ISLER H, 1993, CEPHALALGIA, V13, P172, DOI 10.1046/j.1468-2982.1993.1303172.x; KUDROW L, 1987, CEPHALALGIA, V7, P197, DOI 10.1046/j.1468-2982.1987.0703197.x; KUNKLE EC, 1952, T AM NEUROL ASSOC, P240; LEONE M, 1990, CEPHALALGIA, V10, P235, DOI 10.1046/j.1468-2982.1990.1005235.x; May A, 1998, PAIN, V74, P61, DOI 10.1016/S0304-3959(97)00144-9; Mesulam M. M., 1985, INSULA REIL MAN MONK; MINOSHIMA S, 1995, J CEREB BLOOD FLOW M, V15, P859; NELSON RF, 1978, HEADACHE, V18, P265, DOI 10.1111/j.1526-4610.1978.hed1805265.x; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; WEILLER C, 1995, NAT MED, V1, P658, DOI 10.1038/nm0795-658	32	777	791	2	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					275	278		10.1016/S0140-6736(98)02470-2	http://dx.doi.org/10.1016/S0140-6736(98)02470-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690407				2022-12-01	WOS:000074974500010
J	Slaytor, EK; Ward, JE				Slaytor, EK; Ward, JE			How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets	BRITISH MEDICAL JOURNAL			English	Article									Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Newtown, NSW 2042, Australia		Ward, JE (corresponding author), Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Locked Bag 8, Newtown, NSW 2042, Australia.	jward@nah.rpa.cs.nsw.gov.au						BAINES C, 1992, CAN MED J ASS, V142, P2147; CURRY SJ, 1993, PREV MED, V22, P350, DOI 10.1006/pmed.1993.1029; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; McCormick J, 1996, J CLIN EPIDEMIOL, V49, P619, DOI 10.1016/0895-4356(96)00039-X; ROBERTS MM, 1989, BRIT MED J, V299, P1153, DOI 10.1136/bmj.299.6708.1153	5	110	112	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					263	264		10.1136/bmj.317.7153.263	http://dx.doi.org/10.1136/bmj.317.7153.263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PG	9677220	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000075081900027
J	Gregg, EW; Cauley, JA; Seeley, DG; Ensrud, KE; Bauer, DC				Gregg, EW; Cauley, JA; Seeley, DG; Ensrud, KE; Bauer, DC		Study of Osteoporotic Fractures Res Grp	Physical activity and osteoporotic fracture risk in older women	ANNALS OF INTERNAL MEDICINE			English	Article						osteoporosis, postmenopausal; exercise; fracture; physical fitness; falls, accidental	BONE-MINERAL DENSITY; HIP FRACTURE; POSTMENOPAUSAL WOMEN; EXERCISE; CALCIUM	Background: Physical activity has been related to enhanced bone mass and improved physical functioning and thus may reduce the risk for osteoporotic fracture. Objective: To determine whether higher levels of physical activity are related to lower incidence of hip, wrist, and vertebral fractures. Design: Prospective cohort study. Setting: Four clinical centers in Baltimore, Maryland; Portland, Oregon; Minneapolis, Minnesota; and the Monongahela Valley, Pennsylvania. Participants: 9704 nonblack women 65 years of age or older. Measurements: Physical activity was assessed by questionnaire at baseline. Hip and wrist fractures were followed for an average of 7.6 years. The incidence of vertebral fracture was determined morphometrically by using radiography at baseline and an average of 3.7 years later. Results: Higher levels of leisure time, sport activity, and household chores and fewer hours of sitting daily were associated with a significantly reduced relative risk for hip fracture after adjustment for age, dietary factors, falls at baseline, and functional and health status. Very active women (fourth and fifth quintiles) had a statistically significant 36% reduction in hip fractures (relative risk, 0.64 [95% CI, 0.45 to 0.89]) compared with the least active women (lowest quintile). The intensity of physical activity was also related to fracture risk: Moderately to vigorously active women had statistically significant reductions of 42% and 33% in risk for hip and vertebral fractures, respectively, compared with inactive women. Total physical activity, hours of household chores per day, and hours of sitting per day were not significantly associated with wrist or vertebral fractures. Conclusions: Among older community-dwelling women, physical activity is associated with a reduced risk for hip fracture but not wrist or vertebral fracture.	Univ Vermont, Coll Med, Burlington, VT USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Minnesota, Vet Affairs Med Ctr, Minneapolis, MN USA	University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Gregg, EW (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, 4770 Buford Highway NE,Mailstop K-10, Atlanta, GA 30341 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036; Gregg, Edward/0000-0003-2381-6822	NIADDK NIH HHS [1-R01-AM35584] Funding Source: Medline; NIAMS NIH HHS [1-R01-AR35582, 1-R01-AR35583] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035583, R01AR035582] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baudoin C, 1996, BONE, V18, pS149, DOI 10.1016/8756-3282(95)00496-3; BLACK DM, 1995, J BONE MINER RES, V10, P890; BLACK DM, 1992, J BONE MINER RES, V7, P639; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; CHILIBECK PD, 1995, SPORTS MED, V19, P103, DOI 10.2165/00007256-199519020-00003; CHRISTIANSEN C, 1991, AM J MED, V90, P107; COUPLAND C, 1993, J EPIDEMIOL COMMUN H, V47, P441, DOI 10.1136/jech.47.6.441; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; Grisso JA, 1997, AM J EPIDEMIOL, V145, P786, DOI 10.1093/oxfordjournals.aje.a009171; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MELTON LJ, 1995, J BONE MINER RES, V10, P175; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NEVITT MC, 1992, FALLS BALANCE GAIT D; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Paganini-Hill A, 1991, Epidemiology, V2, P16; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023; Smith EL, 1996, BONE, V18, pS45, DOI 10.1016/8756-3282(95)00379-7; Snow-Harter C, 1991, Exerc Sport Sci Rev, V19, P351; SOROCK GS, 1988, J GERONTOL, V43, pM134, DOI 10.1093/geronj/43.5.M134; Stevens JA, 1997, ANN EPIDEMIOL, V7, P54, DOI 10.1016/S1047-2797(96)00110-X; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889	33	246	251	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					81	88		10.7326/0003-4819-129-2-199807150-00002	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669990				2022-12-01	WOS:000074852000001
J	Berkenkamp, S; Kirpekar, F; Hillenkamp, F				Berkenkamp, S; Kirpekar, F; Hillenkamp, F			Infrared MALDI mass spectrometry of large nucleic acids	SCIENCE			English	Article							IONS; RNA; PCR	Mass spectrometry has become an increasingly important tool of high accuracy, efficiency, and speed for the routine analysis of nucleic acids. To make it useful for large-scale sequencing of genomic material as required for example in genotyping and clinical diagnosis, it is necessary to find approaches that allow the analysis of sequences much larger than the 100 nucleotides currently possible. Matrix-assisted laser desorption/ionization (MALDI) mass spectra of synthetic DNA, restriction enzyme fragments of plasmid DNA, and RNA transcripts up to a size of 2180 nucleotides are reported. The demonstrated mass accuracy of 1 percent or better and the sample requirement of a few femtomoles or Less surpass all currently available techniques for the analysis of large nucleic acids. DNA and RNA can be analyzed with only a limited investment in sample purification.	Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Odense Univ, Dept Mol Biol, DK-5230 Odense M, Denmark	University of Munster; University of Southern Denmark	Hillenkamp, F (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48149 Munster, Germany.	hillenk@uni-muenster.de		Kirpekar, Finn/0000-0003-1901-2266				Berkenkamp S, 1997, RAPID COMMUN MASS SP, V11, P1399; CHEN RD, 1995, ANAL CHEM, V67, P1159, DOI 10.1021/ac00103a004; Fuerstenau SD, 1995, RAPID COMMUN MASS SP, V9, P1528, DOI 10.1002/rcm.1290091513; HOPERT A, 1993, J IMMUNOL METHODS, V164, P91, DOI 10.1016/0022-1759(93)90279-G; KIRPEKAR F, 1994, NUCLEIC ACIDS RES, V22, P3866, DOI 10.1093/nar/22.19.3866; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LIMBACH PA, 1995, J AM SOC MASS SPECTR, V6, P27, DOI 10.1016/1044-0305(94)00086-F; Little DP, 1997, ANAL CHEM, V69, P4540, DOI 10.1021/ac970758+; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Muddiman DC, 1996, ANAL CHEM, V68, P3705, DOI 10.1021/ac960689j; Naito Y, 1997, J AM SOC MASS SPECTR, V8, P737, DOI 10.1016/S1044-0305(97)00083-4; Nordhoff E, 1996, MASS SPECTROM REV, V15, P67, DOI 10.1002/(SICI)1098-2787(1996)15:2<67::AID-MAS1>3.0.CO;2-8; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; NUI S, 1998, J AM SOC MASS SPECTR, V9, P1; Ross PL, 1997, ANAL CHEM, V69, P3966, DOI 10.1021/ac970312t	15	181	205	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	1998	281	5374					260	262		10.1126/science.281.5374.260	http://dx.doi.org/10.1126/science.281.5374.260			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ286	9657721				2022-12-01	WOS:000074714200050
J	Levine, D; Grossberg, R; Tilton, R; Banks, P; Rosenfeld, A				Levine, D; Grossberg, R; Tilton, R; Banks, P; Rosenfeld, A			Are current regulations for approval of in vitro diagnostic devices adequate?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TESTS		New England Pediat LLP, Stamford, CT 06902 USA; Carolinas Med Ctr, New Britain, CT USA		Levine, D (corresponding author), New England Pediat LLP, 166 W Broad St,Suite 103, Stamford, CT 06902 USA.	ARosen45@aol.com						ALPERT S, 1998, SUBM 510K CHANG EX D; *AM AC PED, 1997, 1997 REED BOOK REP C, V199, P329; BANKS PM, 1993, HUM PATHOL, V24, P1153, DOI 10.1016/0046-8177(93)90208-X; BONE RC, 1995, CRIT CARE MED, V23, P1756; BURLINGTON DB, 1997, FDA PUBLIC HLTH ADVI; BURLINGTON DB, 1997, FDA SAFETY ALERT RIS; DOSHI ML, 1986, AM J PUBLIC HEALTH, V76, P512, DOI 10.2105/AJPH.76.5.512; Genel M, 1997, PEDIATRICS, V99, P597, DOI 10.1542/peds.99.4.597; LEVINE D, 1994, PEDIATRICS, V94, P892; Levine D, 1997, PEDIATRICS, V100, P267, DOI 10.1542/peds.100.2.267; RHEINSTEIN PH, 1993, AM FAM PHYSICIAN, V48, P636; SAVAGE RA, 1994, HUM PATHOL, V25, P548, DOI 10.1016/0046-8177(94)90131-7; *US DEP HHS, 1992, REV CRIT IN VITR DIA, P1; WAGNER L, 1997, ARCH PATHOL LAB MED, V121, P539; Wilson M, 1997, J CLIN MICROBIOL, V35, P3112, DOI 10.1128/JCM.35.12.3112-3115.1997; 1997, NY TIEMS        0724, pA20	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					187	189		10.1001/jama.280.2.187	http://dx.doi.org/10.1001/jama.280.2.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY321	9669797				2022-12-01	WOS:000074608400038
J	Berenson, GS; Srinivasan, SR; Bao, WH; Newman, WP; Tracy, RE; Wattigney, WA				Berenson, GS; Srinivasan, SR; Bao, WH; Newman, WP; Tracy, RE; Wattigney, WA		Bogaulas Heart Study	Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; INSULIN-RESISTANCE; SYNDROME-X; HYPERTENSION; NECROPSY; OBESITY; YOUTH	Background In adults, cardiovascular risk factors reinforce each other in their effect on cardiovascular events. However, information is scant on the relation of multiple risk factors to the extent of asymptomatic atherosclerosis in young people. Methods We performed autopsies on 204 young persons 2 to 39 years of age, who had died from various causes, principally trauma. Data on antemortem risk factors were available for 93 of these persons, who were the focus of this study. We correlated risk factors with the extent of atherosclerosis in the aorta and coronary arteries. Results The extent of fatty streaks and fibrous plaques in the aorta and coronary arteries increased with age. The association between fatty streaks and fibrous plaques was much stronger in the coronary arteries (r=0.60, P<0.001) than in the aorta (r=0.23, P=0.03). Among the cardiovascular risk factors, body-mass index, systolic and diastolic blood pressure, and serum concentrations of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, as a group, were strongly associated with the extent of lesions in the aorta and coronary arteries (canonical correlation [a measure of the association between groups of variables]: r=0.70; P<0.001). In addition, cigarette smoking increased the percentage of the intimal surface involved with fibrous plaques in the aorta (1.22 percent in smokers vs. 0.12 percent in nonsmokers, P=0.02) and fatty streaks in the coronary vessels (8.27 percent vs. 2.89 percent, P=0.04). The effect of multiple risk factors on the extent of atherosclerosis was quite evident. Subjects with 0, 1, 2, and 3 or 4 risk factors had, respectively, 19.1 percent, 30.3 percent, 37.9 percent, and 35.0 percent of the intimal surface covered with fatty streaks in the aorta (P for trend=0.01). The comparable figures for the coronary arteries were 1.3 percent, 2.5 percent, 7.9 percent, and 11.0 percent, respectively, for fatty streaks (P for trend=0.01) and 0.6 percent, 0.7 percent, 2.4 percent, and 7.2 percent for collagenous fibrous plaques (P for trend=0.003). Conclusions These findings indicate that as the number of cardiovascular risk factors increases, so does the severity of asymptomatic coronary and aortic atherosclerosis in young people. (C) 1998, Massachusetts Medical Society.	Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	Tulane University; Louisiana State University System	Berenson, GS (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, 1501 Canal St,14th Fl, New Orleans, LA 70112 USA.		Robles-Sardin, Alma E/M-7714-2015; tracy, richard/L-6072-2019; Hrafnkelsson, Hannes/C-8490-2011	Robles-Sardin, Alma E/0000-0003-2044-7793; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032194] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL038844, R01HL038844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38844] Funding Source: Medline; NICHD NIH HHS [HD-32194] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAO WH, 1994, ARCH INTERN MED, V154, P1842; Bao WH, 1996, CIRCULATION, V93, P54, DOI 10.1161/01.CIR.93.1.54; Berenson G.S., 1986, CAUSATION CARDIOVASC; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; Berenson GSM C.A., 1980, CARDIOVASCULAR RISK; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; GUZMAN MA, 1968, LAB INVEST, V18, P479; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HUNTER SMD, 1980, PREV MED, V9, P701; KANNEL WB, 1988, AM J CARDIOL, V62, P1109, DOI 10.1016/0002-9149(88)90558-9; KANNEL WB, 1987, NIH PUBL; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KHOURY P, 1980, AM J EPIDEMIOL, V112, P524, DOI 10.1093/oxfordjournals.aje.a113022; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P2222, DOI 10.1161/01.ATV.15.12.2222; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; MCGILL HC, 1995, ARTERIOSCL THROM VAS, V15, P431, DOI 10.1161/01.ATV.15.4.431; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBERTS WC, 1990, AM J CARDIOL, V66, P121, DOI 10.1016/0002-9149(90)90751-L; ROBERTS WC, 1989, AM J CARDIOL, V64, P324, DOI 10.1016/0002-9149(89)90528-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAS Institute, 1990, SAS US GUID STAT VER; SMOAK CG, 1987, AM J EPIDEMIOL, V125, P364, DOI 10.1093/oxfordjournals.aje.a114543; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; TEJADA C, 1968, LAB INVEST, V18, P509; WEBBER LS, 1979, PREV MED, V8, P407, DOI 10.1016/0091-7435(79)90018-5	30	2666	2784	1	136	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1650	1656		10.1056/NEJM199806043382302	http://dx.doi.org/10.1056/NEJM199806043382302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614255				2022-12-01	WOS:000073978000002
J	Watts, DJ; Strogatz, SH				Watts, DJ; Strogatz, SH			Collective dynamics of 'small-world' networks	NATURE			English	Article							PULSE-COUPLED OSCILLATORS; SYNCHRONIZATION; DISEASE; SPREAD; CHAOS	Networks of coupled dynamical systems have been used to model biological oscillators(1-4), Josephson junction arrays(5,6), excitable media(7), neural networks(8-10), spatial games(11), genetic control networks(12) and many other self-organizing systems. Ordinarily, the connection topology is assumed to be either completely regular or completely random. But many biological, technological and social networks lie somewhere between these two extremes. Here we explore simple models of networks that can be tuned through this middle ground: regular networks 'rewired' to introduce increasing amounts of disorder. We find that these systems can be highly clustered, like regular lattices, yet have small characteristic path lengths, like random graphs. We call them 'small-world' networks, by analogy with the small-world phenomenon(13,14) (popularly known as six degrees of separation(15)). The neural network of the worm Caenorhabditis elegans, the power grid of the western United States, and the collaboration graph of film actors are shown to be small-world networks. Models of dynamical systems with small-world coupling display enhanced signal-propagation speed, computational power, and synchronizability. In particular, infectious diseases spread more easily in small-world networks than in regular lattices.	Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA	Cornell University	Watts, DJ (corresponding author), Columbia Univ, Paul F Lazarsfeld Ctr Social Sci, 812 SIPA Bldg,420 W118 St, New York, NY 10027 USA.		Watts, Duncan J/J-6483-2012; Xie, Jianjun/D-9838-2012; Strogatz, Steven H/A-1641-2014	Strogatz, Steven H/0000-0003-2923-3118				ABBOTT LF, 1993, PHYS REV E, V48, P1483, DOI 10.1103/PhysRevE.48.1483; Achacoso T, 1992, AYS NEUROANATOMY C E; [Anonymous], 1990, 6 DEGREES SEPARATION; [Anonymous], 1994, SOCIAL NETWORK ANAL, DOI DOI 10.1017/CBO9780511815478; Axelrod Robert K., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BLYTHE SP, 1991, MATH BIOSCI, V107, P379, DOI 10.1016/0025-5564(91)90015-B; BOLLABAS B, 1985, RANDOM GRAPHS; BRAIMAN Y, 1995, NATURE, V378, P465, DOI 10.1038/378465a0; Bressloff PC, 1997, PHYS REV LETT, V79, P2791, DOI 10.1103/PhysRevLett.79.2791; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; Das R, 1994, LECT NOTES COMPUT SC, V866, P344; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Hess G, 1996, ECOLOGY, V77, P1617, DOI 10.2307/2265556; HOPFIELD JJ, 1995, P NATL ACAD SCI USA, V92, P6655, DOI 10.1073/pnas.92.15.6655; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Kochen Manfred, 1989, SMALL WORLD; Kretzschmar M, 1996, MATH BIOSCI, V133, P165, DOI 10.1016/0025-5564(95)00093-3; Kuramoto, 1984, SPRINGER SERIES SYNE; LONGINI IM, 1988, MATH BIOSCI, V90, P367, DOI 10.1016/0025-5564(88)90075-2; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Phadke AG., 2009, COMPUTER RELAYING PO; SATTENSPIEL L, 1988, MATH BIOSCI, V90, P341, DOI 10.1016/0025-5564(88)90074-0; STROGATZ SH, 1993, SCI AM, V269, P102, DOI 10.1038/scientificamerican1293-102; Wiesenfeld K, 1996, PHYSICA B, V222, P315, DOI 10.1016/0921-4526(96)85057-5; Winfree A.T., 2001, GEOMETRY BIOL TIME, DOI [10.1007/978-1-4757-3484-3, DOI 10.1007/978-1-4757-3484-3]	27	25863	27949	234	4360	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					440	442		10.1038/30918	http://dx.doi.org/10.1038/30918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9623998				2022-12-01	WOS:000074020000035
J	Li, DY; Brooke, B; Davis, EC; Mecham, RP; Sorensen, LK; Boak, BB; Eichwald, E; Keating, MT				Li, DY; Brooke, B; Davis, EC; Mecham, RP; Sorensen, LK; Boak, BB; Eichwald, E; Keating, MT			Elastin is an essential determinant of arterial morphogenesis	NATURE			English	Article							ATHEROSCLEROSIS; DISRUPTION; CELLS; GENE	Elastin, the main component of the extracellular matrix of arteries, was thought to have a purely structural role(1). Disruption of elastin was believed to lead to dissection of arteries(2,3), but we showed that mutations in one allele encoding elastin cause a human disease in which arteries are blocked, namely, supravalvular aortic stenosis(4,5). Here we define the role of elastin in arterial development and disease by generating mice that lack elastin. These mice die of an obstructive arterial disease, which results from subendothelial cell proliferation and reorganization of smooth muscle. These cellular changes are similar to those seen in atherosclerosis. However, lack of elastin is not associated with endothelial damage, thrombosis or inflammation, which occur in models of atherosclerosis. Haemodynamic stress is not associated with arterial obstruction in these mice either, as the disease still occurred in arteries that were isolated in organ culture and therefore not subject to haemodynamic stress. Disruption of elastin is enough to induce subendothelial proliferation of smooth muscle and may contribute to obstructive arterial disease. Thus, elastin has an unanticipated regulatory function during arterial development, controlling proliferation of smooth muscle and stabilizing arterial structure.	Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84112 USA; Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Washington University (WUSTL)	Li, DY (corresponding author), Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT 84112 USA.		Davis, Elaine/F-3449-2012					Bittar, 1993, ADV MOL CELL BIOL, P133, DOI [10.1016/S1569-2558(08)60201-5, DOI 10.1016/S1569-2558(08)60201-5]; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langille BL, 1997, TRENDS CARDIOVAS MED, V7, P111, DOI 10.1016/S1050-1738(97)00005-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; OWENS GK, 1995, PHYSIOL REV, V75, P487; PROSSER IW, 1989, AM J PATHOL, V135, P1073; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; TERPIN T, 1987, CAN J PHYSIOL PHARM, V65, P395, DOI 10.1139/y87-066; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Thompson RW, 1996, CURR OPIN CARDIOL, V11, P504, DOI 10.1097/00001573-199609000-00010	18	560	586	0	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					276	280		10.1038/30522	http://dx.doi.org/10.1038/30522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607766				2022-12-01	WOS:000073761000056
J	Kanopka, A; Muhlemann, O; Petersen-Mahrt, S; Estmer, C; Ohrmalm, C; Akusjarvi, G				Kanopka, A; Muhlemann, O; Petersen-Mahrt, S; Estmer, C; Ohrmalm, C; Akusjarvi, G			Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins	NATURE			English	Article							PRE-MESSENGER-RNA; PHOSPHORYLATION; TRANSCRIPTION; INFECTION; SITES; LEVEL	SR proteins are a family of essential splicing factors required for early recognition of splice sites during spliceosome assembly(1,2). They also function as alternative RNA splicing factors when overexpressed in vivo or added in excess to extracts in vitro(1,2). SR proteins are highly phosphorylated in vivo, a modification that is required for their function in spliceosome assembly(3,4) and splicing catalysis(5,6). Here we show that SR proteins purified from late adenovirus-infected cells are inactivated as splicing enhancer or splicing repressor proteins by virus-induced dephosphorylation. We further show that the virus-encoded protein E4-ORF4 activates dephosphorylation by protein phosphatase 2A of HeLa SR proteins and converts their splicing properties into that of SR proteins purified from late adenovirus-infected cells. Taken together, our results suggest that E4-ORF4 is an important factor controlling the temporal shift in adenovirus alternative RNA splicing,We conclude that alternative pre-mRNA splicing, like many other biological processes, is regulated by reversible protein phosphorylation.	Univ Uppsala, BMC, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Uppsala University	Akusjarvi, G (corresponding author), Univ Uppsala, BMC, Dept Med Biochem & Microbiol, Box 582, S-75123 Uppsala, Sweden.			Ohrmalm, Christina/0000-0002-3287-3549				Ausubel F.M., 1995, CURRENT PROTOCOLS MO; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; CAO W, 1997, RNA, V3, P1; FU XD, 1995, RNA, V1, P663; HIMMELSPACH M, 1995, RNA, V1, P794; IMPERIALE M, 1995, CURR TOP MICROBIOL, P139; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; MUHLEMANN O, 1995, J VIROL, V69, P7324; MULLER U, 1992, J VIROL, V66, P5867; OHMAN K, 1993, VIROLOGY, V194, P50, DOI 10.1006/viro.1993.1234; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	19	165	169	2	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					185	187		10.1038/30277	http://dx.doi.org/10.1038/30277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603524				2022-12-01	WOS:000073619900053
J	Birck, C; Poch, O; Romier, C; Ruff, M; Mengus, G; Lavigne, AC; Davidson, I; Moras, D				Birck, C; Poch, O; Romier, C; Ruff, M; Mengus, G; Lavigne, AC; Davidson, I; Moras, D			Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by atypical evolutionary conserved motifs also found in the SPT3 family	CELL			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TFIID COMPLEX; MULTIPLE INTERACTIONS; BINDING PROTEIN; TBP; ACTIVATION; SUBUNITS	Determination of the crystal structure of the human Tap-associated factor (hTAF(II))28/hTAF(II)18 heterodimer shows that these TAF(II)s form a novel histone-like pair in the TFIID complex. The histone folds in hTAF(II)28 and hTAF(II)18 were not predicted from their primary sequence, indicating that these TAF(II)s define a novel family of atypical histone fold sequences. The TAF(II)18 and TAF(II)28 histone fold moths are also present in the N- and C-terminal regions of the SPT3 proteins, suggesting that the histone fold in SPT3 may be reconstituted by intramolecular rather than classical intermolecular interactions. The;existence of additional histone-like pairs in both the TFIID and SAGA complexes shows that the histone fold is a more commonly used motif for mediating TAF-TAF interactions than previously believed.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Moras, D (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163,CU Strasbourg, F-67404 Illkirch, France.		ruff, marc/J-3011-2013; Lavigne, Anne-Claire/O-8805-2015	ruff, marc/0000-0001-5451-6377; Romier, Christophe/0000-0002-3680-935X; MENGUS, Gabrielle/0000-0002-2844-1778; Davidson, Irwin/0000-0001-5533-1171				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; BRUNGER AT, 1992, XPLOR VERSION 3 1; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Burley SK, 1997, CURR OPIN STRUC BIOL, V7, P94, DOI 10.1016/S0959-440X(97)80012-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gribskov M, 1996, METHOD ENZYMOL, V266, P198; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klebanow ER, 1997, J BIOL CHEM, V272, P9436; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Roberts SM, 1997, GENETICS, V147, P451; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SLESAREV AI, 1998, NUCLEIC ACIDS RES, V26, P247; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	53	118	130	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					239	249		10.1016/S0092-8674(00)81423-3	http://dx.doi.org/10.1016/S0092-8674(00)81423-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695952	Bronze			2022-12-01	WOS:000075020100012
J	Kersh, EN; Shaw, AS; Allen, PM				Kersh, EN; Shaw, AS; Allen, PM			Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation	SCIENCE			English	Article							PROTEIN-TYROSINE KINASES; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; MICE LACKING; TCR-ZETA; MURINE THYMOCYTES; CYTOPLASMIC TAIL; PARTIAL AGONISTS; MHC COMPLEXES; CHAIN	The T cell receptor (TCR) alpha beta heterodimer interacts with its ligands with high specificity, but surprisingly Low affinity. The role of the zeta component of the murine TCR in contributing to the Fidelity of antigen recognition was examined. With sequence-specific phosphotyrosine antibodies, it was found that zeta undergoes a series of ordered phosphorylation events upon TCR engagement. Completion of phosphorylation steps is dependent on the nature of the TCR ligand. Thus, the phosphorylation steps establish thresholds for T cell activation. This study documents the sophisticated molecular events that follow the engagement of a low-affinity receptor.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Allen, PM (corresponding author), Washington Univ, Sch Med, Ctr Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	allen@immunology.wustl.edu						Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Combadiere B, 1996, J EXP MED, V183, P2109, DOI 10.1084/jem.183.5.2109; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; GRAKOUI A, UNPUB; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KERSH EN, UNPUB; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LaFace DM, 1997, J IMMUNOL, V158, P2057; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Lin SY, 1997, J EXP MED, V185, P707, DOI 10.1084/jem.185.4.707; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SHINKAI Y, 1995, IMMUNITY, V2, P401; Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; SHORES EW, 1963, CURR OPIN IMMUNOL, V9380, P97; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Smith JA, 1997, J EXP MED, V185, P1413, DOI 10.1084/jem.185.8.1413; Sousa CRE, 1996, J EXP MED, V184, P149, DOI 10.1084/jem.184.1.149; Stone JD, 1997, J IMMUNOL, V158, P5773; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; van Oers NSC, 1998, J IMMUNOL, V160, P163; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; Vely F, 1997, EUR J IMMUNOL, V27, P3010, DOI 10.1002/eji.1830271138; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; Wiest DL, 1996, IMMUNITY, V4, P495, DOI 10.1016/S1074-7613(00)80415-X; Yamazaki T, 1997, J IMMUNOL, V158, P1634	59	266	275	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1998	281	5376					572	575		10.1126/science.281.5376.572	http://dx.doi.org/10.1126/science.281.5376.572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677202				2022-12-01	WOS:000075012300044
J	Xie, T; Spradling, AC				Xie, T; Spradling, AC			decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary	CELL			English	Article							BETA SIGNALING PATHWAY; BAG-OF-MARBLES; DPP RECEPTORS; THICK VEINS; I RECEPTORS; PROTEIN; GENE; PATTERN; TRANSCRIPTION; MELANOGASTER	Stem cells are thought to occupy special local environments, or niches, established by neighboring cells that give them the capability for self-renewal. Each ovariole in the Drosophila ovary contains two germline stem cells surrounded by a group of differentiated somatic cells that express hedgehog and wingless. Here we show that the BMP2/4 homolog decapentaplegic (dpp) is specifically required to maintain female germline stem cells and promote their division. Overexpression of dpp blocks germline stem cell differentiation. Conversely, mutations in dpp or its receptor (saxophone) accelerate stem cell loss and retard stem cell division. We constructed mutant germline stem cell clones to show that the dpp signal is directly received by germline stem cells. Thus, dpp signaling helps define a niche that controls germline stem cell proliferation.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Spradling, AC (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.				Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; BAKER D, 1992, GENE DEV, V6, P2312; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Burke R, 1996, DEVELOPMENT, V122, P2261; BYERS TJ, 1987, J CELL BIOL, V105, P2103, DOI 10.1083/jcb.105.5.2103; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen EH, 1997, DEVELOPMENT, V124, P205; Das P, 1998, DEVELOPMENT, V125, P1519; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; DECUEVAS M, 1998, IN PRESS DEVELOPMENT; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; Forbes A, 1998, DEVELOPMENT, V125, P679; Forbes AJ, 1996, DEVELOPMENT, V122, P3283; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hudson JB, 1998, DEVELOPMENT, V125, P1407; HURSH DA, 1993, DEVELOPMENT, V117, P1211; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIANG L, 1994, DEVELOPMENT, V120, P1201; Lin HF, 1997, ANNU REV GENET, V31, P455, DOI 10.1146/annurev.genet.31.1.455; Lin HF, 1997, DEVELOPMENT, V124, P2463; Manseau L, 1997, DEV DYNAM, V209, P310, DOI 10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA6>3.3.CO;2-O; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Matunis E, 1997, DEVELOPMENT, V124, P4383; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; MCKEARIN DM, 1990, GENE DEV, V4, P2242, DOI 10.1101/gad.4.12b.2242; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Ohlstein B, 1997, DEVELOPMENT, V124, P3651; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; Penton A, 1997, SCIENCE, V275, P203, DOI 10.1126/science.275.5297.203; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Spradling AC, 1997, COLD SPRING HARB SYM, V62, P25; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Twombly V, 1996, DEVELOPMENT, V122, P1555; Wharton K, 1996, GENETICS, V142, P493; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU T, 1993, DEVELOPMENT, V117, P1223; Zaccai M, 1996, ZYGOTE, V4, P159, DOI 10.1017/S096719940000304X; Zhao GQ, 1996, GENE DEV, V10, P1657, DOI 10.1101/gad.10.13.1657; Zhao GQ, 1998, DEVELOPMENT, V125, P1103	61	510	523	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 24	1998	94	2					251	260		10.1016/S0092-8674(00)81424-5	http://dx.doi.org/10.1016/S0092-8674(00)81424-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	104NF	9695953	Bronze			2022-12-01	WOS:000075020100013
J	Garrett, TPJ; McKern, NM; Lou, MZ; Frenkel, MJ; Bentley, JD; Lovrecz, GO; Elleman, TC; Cosgrove, LJ; Ward, CW				Garrett, TPJ; McKern, NM; Lou, MZ; Frenkel, MJ; Bentley, JD; Lovrecz, GO; Elleman, TC; Cosgrove, LJ; Ward, CW			Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor	NATURE			English	Article							ALANINE-SCANNING MUTAGENESIS; ALPHA-SUBUNIT; BINDING DOMAIN; GENE; DETERMINANTS; SPECIFICITY; SITE	The type-1 insulin-like growth-factor receptor (IGF-1R) and insulin receptor (IR) are closely related members of the tyrosine-kinase receptor superfamily. IR is essential for glucose homeostasis, whereas IGF-1R is involved in both normal growth and development and malignant transformation. Homologues of these receptors are found in animals as simple as cnidarians. The epidermal growth-factor receptor (EGFR) family is closely related to the IR family and has significant sequence identity to the extracellular portion we describe here. We now present the structure of the first three domains of IGF-1R (L1-Cys-rich-L2) determined to a 2.4 Angstrom resolution. The L domains each consist of a single-stranded right-handed beta-helix. The Cys-rich region is composed of eight disulphide-bonded modules, seven of which form a rod-shaped domain with modules associated in an unusual manner. The three domains surround a central space of sufficient size to accommodate a ligand molecule. Although the fragment (residues 1-462) does not bind ligand, many of the determinants responsible for hormone binding and ligand specificity map to this central site. This structure therefore shows how the IR subfamily might interact with their ligands.	CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Biomol Res Inst, Parkville, Vic 3052, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Ward, CW (corresponding author), CSIRO, Div Mol Sci, 343 Royal Parade, Parkville, Vic 3052, Australia.	tom.barrett@bioresi.com.au; colin.ward@molsci.csiro.au	Lovrecz, George/H-8602-2013; Cosgrove, Leah J/A-7764-2010	Cosgrove, Leah J/0000-0002-8340-4291				BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; BAYNE ML, 1988, J BIOL CHEM, V264, P11004; BRUNGER AT, 1996, XPLOR REFERENCE MANU; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HOLM I, 1993, J MOL BIOL, V233, P125; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KUROSE T, 1994, J BIOL CHEM, V269, P29190; McKern NM, 1997, PROTEIN SCI, V6, P2663; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; NAKAE J, 1995, J BIOL CHEM, V270, P22017, DOI 10.1074/jbc.270.37.22017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROACH P, 1994, DIABETES, V43, P1096, DOI 10.2337/diabetes.43.9.1096; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1993, J BIOL CHEM, V268, P3044; Steele RE, 1996, DEV GENES EVOL, V206, P247, DOI 10.1007/s004270050050; STEIGEMAN W, 1974, THESIS TU MUNICH; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; TAYLOR S, 1994, ENDOCR REV, V2, P58; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7	30	221	244	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1998	394	6691					395	399		10.1038/28668	http://dx.doi.org/10.1038/28668			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690478				2022-12-01	WOS:000074968800058
J	de Groen, PC; Barry, JA; Schaller, WJ				de Groen, PC; Barry, JA; Schaller, WJ			Applying World Wide Web technology to the study of patients with rare diseases	ANNALS OF INTERNAL MEDICINE			English	Article								Randomized, controlled trials of sporadic diseases are rarely conducted. Recent developments in communication technology, particularly the World Wide Web, allow efficient dissemination and exchange of information. However, software for the identification of patients with a ra re disease and subsequent data entry and analysis in a secure Web database are currently not available. To study cholangiocarcinoma, a rare cancer of the bile ducts, we developed a computerized disease tracing system coupled with a database accessible on the Web. The tracing system scans computerized information systems on a daily basis and forwards demographic information on patients with bile duct abnormalities to an electronic mailbox. If informed consent is given, the patient's demographic and preexisting medical information available in medical database servers are electronically forwarded to a UNIX research database. Information from further patient-physician interactions and procedures is also entered into this database. The database is equipped with a Web user interface that allows data entry from various platforms (PC-compatible, Macintosh, and UNIX workstations) anywhere inside or outside our institution. To ensure patient confidentiality and data security, the database includes all security measures required for electronic medical records. The combination of a Web-based disease tracing system and a database has broad applications, particularly for the integration of clinical research within clinical practice and for the coordination of multicenter trials.	Mayo Clin & Mayo Fdn, Div Gastroenterol, Rochester, MN 55905 USA	Mayo Clinic	de Groen, PC (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol, 200 1st St SW, Rochester, MN 55905 USA.							Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Sirica A. E., 1997, BILIARY PANCREATIC D, P229; WALL L, 1996, PROGRAMMING PERL	3	20	29	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1998	129	2					107	113		10.7326/0003-4819-129-2-199807150-00009	http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	101CL	9669969				2022-12-01	WOS:000074852000006
J	Versteege, I; Sevenet, N; Lange, J; Rousseau-Merck, MF; Ambros, P; Handgretinger, R; Aurias, A; Delattre, O				Versteege, I; Sevenet, N; Lange, J; Rousseau-Merck, MF; Ambros, P; Handgretinger, R; Aurias, A; Delattre, O			Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer	NATURE			English	Article							MALIGNANT RHABDOID TUMOR; SWI/SNF COMPLEX; BINDING; STIMULATION; PROTEIN; KIDNEY; SNF5	Malignant rhabdoid tumours (MRTs) are extremely aggressive cancers of early childhood. They can occur in various locations, mainly the kidney, brain and soft tissues(1,2). Cytogenetic and molecular analyses have shown that the deletion of region 11.2 of the long arm of chromosome 22 (22q11.2) is a recurrent genetic characteristic of MRTs, indicating that this locus may encode a tumour suppressor gene(3-8). Here we map the most frequently deleted part of chromosome 22q11.2 from a panel of 13 MRT cell lines. We observed six homozygous deletions that delineate the smallest region of overlap between the cell lines. This region is found in the hSNF5/3INI1 gene, which encodes a member of the chromatin-remodelling SWI/SNF multiprotein complexes(9-12). We analysed the sequence of hSNF5/INI1 and found frameshift or nonsense mutations of this gene in six other cell lines. These truncating mutations of one allele were associated with the loss of the other allele. Identical alterations were observed in corresponding primary tumour DNAs but not in matched constitutional DNAs, indicating that they had been acquired somatically. The observation of bi-allelic alterations of hSNF5/INI1 in MRTs suggests that loss-of-function mutations of hSNF5/INI1 contribute to oncogenesis.	Inst Curie, Sect Rech, Lab Pathol Mol Canc, F-75248 Paris 05, France; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Tubingen, Kinderklin, D-72070 Tubingen, Germany	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Saint Anna Children's Hospital; Eberhard Karls University of Tubingen	Delattre, O (corresponding author), Inst Curie, Sect Rech, Lab Pathol Mol Canc, 26 Rue Ulm, F-75248 Paris 05, France.	delattre@curie.fr	Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; delattre, olivier/0000-0002-8730-2276				Biegel JA, 1996, GENE CHROMOSOME CANC, V16, P94, DOI 10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOUGLASS EC, 1990, GENE CHROMOSOME CANC, V2, P210, DOI 10.1002/gcc.2870020308; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FORT DW, 1994, GENE CHROMOSOME CANC, V11, P146, DOI 10.1002/gcc.2870110303; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; HANDGRETINGER R, 1990, CANCER RES, V50, P2177; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LYNCH HT, 1983, CANCER-AM CANCER SOC, V52, P290, DOI 10.1002/1097-0142(19830715)52:2<290::AID-CNCR2820520216>3.0.CO;2-L; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1998, EMBO J, V16, P101; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARHAM DM, 1994, AM J SURG PATHOL, V18, P1010, DOI 10.1097/00000478-199410000-00005; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; SHASHI V, 1994, GENE CHROMOSOME CANC, V10, P49, DOI 10.1002/gcc.2870100108; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SOULIE J, 1986, CANCER GENET CYTOGEN, V21, P117, DOI 10.1016/0165-4608(86)90037-3; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WICK MR, 1995, SEMIN DIAGN PATHOL, V12, P233	28	1116	1159	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1998	394	6689					203	206		10.1038/28212	http://dx.doi.org/10.1038/28212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671307				2022-12-01	WOS:000074705900060
J	Gureje, O; Von Korff, M; Simon, GE; Gater, R				Gureje, O; Von Korff, M; Simon, GE; Gater, R			Persistent pain and well-being - A World Health Organization study in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BACK-PAIN; PSYCHOLOGICAL-PROBLEMS; DEPRESSION; DISABILITY; SYMPTOMS; ILLNESS	Context.-There is little information on the extent of persistent pain across cultures. Even though pain is a common reason for seeking health care, information on the frequency and impacts of persistent pain among primary care patients is inadequate. Objective.-To assess the prevalence and impact of persistent pain among primary care patients. Design and Setting.-Survey data were collected from representative samples of primary care patients as part of the World Health Organization Collaborative Study of Psychological Problems in General Health Care, conducted in 15 centers in Asia, Africa, Europe, and the Americas. Participants.-Consecutive primary care attendees between the age of majority (typically 18 years) and 65 years were screened (n = 25 916) and stratified random samples interviewed (n = 5438). Main Outcome Measures.-Persistent pain, defined as pain present most of the time for a period of 6 months or more during the prior year, and psychological illness were assessed by the Composite International Diagnostic interview, Disability was assessed by the Groningen Social Disability Schedule and by activity-limitation days in the prior month. Results.-Across all 15 centers, 22% of primary care patients reported persistent pain, but there was wide variation in prevalence rates across centers (range, 5.5%-33.0%). Relative to patients without persistent pain, pain sufferers were more likely to have an anxiety or depressive disorder (adjusted odds ratio [OR], 4, 14, 95% confidence interval [CI], 3.52-4.86), to experience significant activity limitations (adjusted OR, 1.63; 95% CI, 1.41-1.89), and to have unfavorable health perceptions (adjusted OR, 1.26; 95% CI, 1.07-1.49), The relationship between psychological disorder and persistent pain was observed in every center, while the relationship between disability and persistent pain was inconsistent across centers. Conclusions.-Persistent pain was a commonly reported health problem among primary care patients and was consistently associated with psychological illness across centers. Large variation in frequency and the inconsistent relationship between persistent pain and disability across centers suggests caution in drawing conclusions about the role of culture in shaping responses to persistent pain when comparisons are based on patient samples drawn from a limited number of health care settings in each culture.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Coll Hosp, Dept Psychiat, Ibadan, Nigeria; Withington Hosp, Dept Psychiat, Manchester M20 8LR, Lancs, England	Group Health Cooperative; University of Ibadan; University College Hospital, Ibadan	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave, Seattle, WA 98101 USA.		Gureje, Oye/J-1183-2014	Gureje, Oye/0000-0003-0094-5947; VonKorff, Michael/0000-0001-5386-8477	NIDCR NIH HHS [DE08773-10] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; Bates M S, 1995, Med Anthropol, V16, P141; Goldberg D., 1988, USERS GUIDE GEN HLTH; LERESCHE L, IN PRESS HDB PAIN SY; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; MOORE R, 1990, PSYCHOSOM MED, V52, P171, DOI 10.1097/00006842-199003000-00005; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011; ROMANO JM, 1985, PSYCHOL BULL, V97, P18, DOI 10.1037/0033-2909.97.1.18; ROY R, 1984, COMPR PSYCHIAT, V25, P96, DOI 10.1016/0010-440X(84)90027-0; SANDERS SH, 1992, CLIN J PAIN, V8, P317, DOI 10.1097/00002508-199212000-00006; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; SCHAPPERT SM, 1992, VITAL HLTH STAT, V18; TURK DC, 1988, J CONSULT CLIN PSYCH, V56, P233, DOI 10.1037/0022-006X.56.2.233; USTN TB, 1995, MENTAL ILLNESS GEN H; Von Korff M., 1995, MENTAL ILLNESS GEN H; VONKORFF A, 1988, PAIN, V32, P173; VONKORFF M, 1993, PAIN, V55, P251, DOI 10.1016/0304-3959(93)90154-H; VonKorff M, 1996, J CLIN EPIDEMIOL, V49, P297, DOI 10.1016/0895-4356(95)00512-9; VonKorff M, 1996, BRIT J PSYCHIAT, V168, P101, DOI 10.1192/S0007125000298474; VONKORFFM, 1992, PAIN, V50, P133; *WHO, 1989, WHO PUBL; WIERSMA D, 1988, INT J REHABIL RES, V11, P213, DOI 10.1097/00004356-198809000-00001; World Health Organization, 1992, INT STAT CLASS DIS	24	966	1000	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1998	280	2					147	151		10.1001/jama.280.2.147	http://dx.doi.org/10.1001/jama.280.2.147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZY321	9669787	Bronze			2022-12-01	WOS:000074608400029
J	Fiorillo, CD; Williams, JT				Fiorillo, CD; Williams, JT			Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons	NATURE			English	Article							CEREBELLAR GRANULE CELLS; VENTRAL TEGMENTAL AREA; EXCITATORY AMINO-ACID; SYNAPTIC POTENTIALS; RAT; RECEPTORS; CONDUCTANCE; BRAIN; CA-2+-ATPASE; ACTIVATION	Rapid information transfer within the brain depends on chemical signalling between neurons that is mediated primarily by glutamate and GABA (gamma-aminobutyric acid), acting at ionotropic receptors to cause excitatory or inhibitory postsynaptic potentials (EPSPs or IPSPs), respectively. In addition, synaptically released glutamate acts on metabotropic receptors to excite neurons on a slower timescale through second-messenger cascades, including phosphoinositide hydrolysis'. We now report a unique IPSP mediated by the activation of metabotropic glutamate receptors. Tn ventral midbrain dopamine neurons, activation of metabotropic glutamate receptors (mGluR1) mobilized calcium from caffeine/ryanodine-sensitive stores and increased an apamin-sensitive potassium conductance. The underlying potassium conductance and dependence on calcium stores set this IPSP apart from the slow IPSPs described so far(2-4). The mGluR-induced hyperpolarization was dependent on brief exposure to agonist, because prolonged application of exogenous agonist desensitized the hyperpolarization and caused the more commonly reported depolarization(1,5,6). The rapid rise and brief duration of synaptically released glutamate in the extracellular space can therefore mediate a rapid excitation through activation of ionotropic receptors, followed by inhibition through the mGluR1 receptor. Thus the idea that glutamate is solely an excitatory neurotransmitter must be replaced with a more complex view of its dual function in synaptic transmission.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Williams, JT (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Fiorillo, Christopher Dante/C-1718-2011	Fiorillo, Christopher/0000-0002-7232-9505				BRABET I, 1995, NEUROPHARMACOLOGY, V34, P895, DOI 10.1016/0028-3908(95)00079-L; CAMERON DL, 1993, NATURE, V366, P344, DOI 10.1038/366344a0; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; Johnson SW, 1997, NEUROSCI LETT, V231, P13, DOI 10.1016/S0304-3940(97)00508-9; JOHNSON SW, 1992, J NEUROSCI, V12, P2000; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; KALIVAS PW, 1995, J NEUROSCI, V15, P5379, DOI 10.1523/jneurosci.15-07-05379.1995; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; KOLINSKI CM, INPRESS NEUROSCIENCE; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; MARTIN LJ, 1992, NEURON, V9, P259, DOI 10.1016/0896-6273(92)90165-A; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MERCURI NB, 1993, NEUROSCIENCE, V56, P399, DOI 10.1016/0306-4522(93)90341-C; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; PAN ZZ, 1989, J NEUROPHYSIOL, V62, P481, DOI 10.1152/jn.1989.62.2.481; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; ROUSSEAU E, 1987, AM J PHYSIOL, V253, P364; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shen KZ, 1997, EUR J NEUROSCI, V9, P48, DOI 10.1111/j.1460-9568.1997.tb01352.x; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SHIRASAKI T, 1994, J PHYSIOL-LONDON, V475, P439, DOI 10.1113/jphysiol.1994.sp020084; SURPRENANT A, 1987, J PHYSIOL-LONDON, V382, P87, DOI 10.1113/jphysiol.1987.sp016357; TESTA CM, 1994, J NEUROSCI, V14, P3005; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	30	226	232	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					78	82		10.1038/27919	http://dx.doi.org/10.1038/27919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665131				2022-12-01	WOS:000074579600052
J	Flick, KE; Jurica, MS; Monnat, RJ; Stoddard, BL				Flick, KE; Jurica, MS; Monnat, RJ; Stoddard, BL			DNA binding and cleavage by the nuclear intron-encoded homing endonuclease I-PpoI	NATURE			English	Article							CRYSTAL-STRUCTURE; FINGER DOMAIN; MINOR-GROOVE; ZINC-FINGER; PROTEIN; RECOGNITION; COMPLEX; FAMILY; MOTIF	Homing endonucleases are a diverse collection of proteins that are encoded by genes with mobile, self-splicing introns(1-3). They have also been identified in self-splicing inteins (protein introns)(4). These enzymes promote the movement of the DNA sequences that encode them from one chromosome location to another; they do this by making a site-specific double-strand break at a target site in an allele that lacks the corresponding mobile intron(3). The target sites recognized by these small endonucleases are generally long (14-44 base pairs). Four families of homing endonucleases have been identified, including the LAGLIDADG, the His-Cys box, the GIY-YIG and the H-N-H endonucleases(1). The first identified His-Cys box homing endonuclease was I-PpoI from the slime mould Physarum polycephalum(5,6). Its gene resides in one of only a few nuclear introns known to exhibit genetic mobility(7). Here we report the structure of the I-PpoI homing endonuclease bound to homing-site DNA determined to 1.8 Angstrom resolution. I-PpoI displays an elongated fold of dimensions 25 x 35 x 80 Angstrom, with mixed (alpha/beta topology. Each I-PpoI monomer contains three antiparallel beta-sheets flanked by two long ol-helices and a long carboxy-terminal tail, and is stabilized by two bound zinc ions 15 Angstrom apart. The enzyme possesses a new zinc-bound fold and endonuclease active site. The structure has been determined in both uncleaved substrate and cleaved product complexes.	Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	bstoddar@fred.fhcrc.org						BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELFORT M, 1995, J BACTERIOL, V177, P3897, DOI 10.1128/jb.177.14.3897-3903.1995; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; *DAR LAB, 1979, 4 CCP4 SERC UK COLL; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; ELLISON EL, 1993, MOL CELL BIOL, V13, P7531, DOI 10.1128/MCB.13.12.7531; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVERETT RD, 1993, J MOL BIOL, V234, P1038, DOI 10.1006/jmbi.1993.1657; FLICK KE, 1997, PROTEIN SCI, V6, P1; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; JOHANSEN S, 1993, NUCLEIC ACIDS RES, V21, P4405, DOI 10.1093/nar/21.18.4405; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LASKOWSKI RJ, 1993, J APPL CRYSTALLOGR, V26, P383; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; 1996, QUANTA96 XRAY STRUCT	27	187	197	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					96	101		10.1038/27952	http://dx.doi.org/10.1038/27952			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665136				2022-12-01	WOS:000074579600057
J	Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T; Takahashi, T; Chiba, S; Yazaki, Y; Matsumoto, K; Hirai, H				Kurokawa, M; Mitani, K; Irie, K; Matsuyama, T; Takahashi, T; Chiba, S; Yazaki, Y; Matsumoto, K; Hirai, H			The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3	NATURE			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; TRANSFORMING ACTIVITY; MYELOID-LEUKEMIA; BLASTIC CRISIS; EXPRESSION; PROTEIN; GENE; ACTIVATION; RECEPTOR; DOMAIN	Evi-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells(1-5). Evi-1 has two zinc-finger domains, one with seven repeats of a zinc-finger motif and one with three repeats(6), and it has characteristics of a transcriptional regulator(7,8). Although Evi-1 is thought to be able to promote growth and to block differentiation in some cell types(9-11), its biological functions are poorly understood. Here we study the mechanisms that underlie oncogenesis induced by Evi-1 by investigating whether Evi-1 perturbs signalling through transforming growth factor-beta (TGF-beta), one of the most studied growth-regulatory factors, which inhibits proliferation of a wide range of cell types(12). We show that Evi-1 represses TGF-beta signalling and antagonizes the growth-inhibitory effects of TGF-beta. Two separate regions of Evi-1 are responsible for this repression; one of these regions is the first zinc-finger domain. Through this domain, Evi-1 interacts with Smad3, an intracellular mediator of TGF-beta signalling(13), thereby suppressing the transcriptional activity of Smad3, These results define a new function of Evi-1 as a repressor of signalling through TGF-beta.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1138655, Japan; Nagoya Univ, Fac Sci, Dept Biol Mol, Chikusa Ku, Nagoya, Aichi 46401, Japan	University of Tokyo; Nagoya University	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.			Takahashi, Tokiharu/0000-0002-5785-8660				Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; KUROKAWA M, 1995, ONCOGENE, V11, P833; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lopingco MC, 1996, CURR TOP MICROBIOL, V211, P211; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	29	298	312	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					92	96		10.1038/27945	http://dx.doi.org/10.1038/27945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665135				2022-12-01	WOS:000074579600056
J	Bieber, D; Ramer, SW; Wu, CY; Murray, WJ; Tobe, T; Fernandez, R; Schoolnik, GK				Bieber, D; Ramer, SW; Wu, CY; Murray, WJ; Tobe, T; Fernandez, R; Schoolnik, GK			Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli	SCIENCE			English	Article							OUTER-MEMBRANE PROTEINS; BUNDLE-FORMING PILUS; TISSUE-CULTURE CELLS; LOCALIZED ADHERENCE; TWITCHING MOTILITY; BINDING PROTEINS; GENETIC-LOCUS; PLASMID; SEROTYPES; PATHOGENESIS	Type IV bundle-forming pill of enteropathogenic Escherichia coli are required for the localized adherence and autoaggregation phenotypes, Whether these pill are also required for virulence was tested in volunteers by inactivating bfpA or bfpT (perA) encoding, respectively, the pilus subunit and the bfp operon transcriptional activator. Both mutants caused significantly less diarrhea. Mutation of the bfpF nucleotide-binding domain Caused increased piliation, enhanced localized adherence, and abolished the twitching motility-dispersal phase of the autoaggregation phenotype. The bfpF mutant colonized the human intestine but was about 200-fold less virulent. Thus, BfpF is required for dispersal from the bacterial aggregate and for full virulence.	Stanford Univ, Med Ctr, Sch Med, Dept Med,Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med,Stanford Program Vaccine Res, Dept Microbiol & Immunol, Stanford, CA 94305 USA; San Jose State Univ, Dept Biol Sci, San Jose, CA 95912 USA; Univ Tokyo, Inst Med Sci, Dept Bacteriol, Tokyo, Japan	Stanford University; Stanford University; California State University System; San Jose State University; University of Tokyo	Schoolnik, GK (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Med,Div Infect Dis & Geog Med, Stanford, CA 94305 USA.	ml.gks@forsythe.stanford.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK052038] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00070] Funding Source: Medline; NIAID NIH HHS [1RO1-AI39521] Funding Source: Medline; NIDDK NIH HHS [1RO3-DK52038] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANATHA RP, 1998, INFECT IMMUN, V66, P122; BALDINI MM, 1983, J PEDIATR GASTR NUTR, V2, P534, DOI 10.1097/00005176-198302030-00023; BALDINI MM, 1986, INFECT IMMUN, V52, P334, DOI 10.1128/IAI.52.1.334-336.1986; BIEBER D, UNPUB; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Donnenberg Michael S., 1995, P709; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOMEZDUARTE OG, 1995, INFECT IMMUN, V63, P1767; HENRICHSEN J, 1983, ANNU REV MICROBIOL, V37, P81, DOI 10.1146/annurev.mi.37.100183.000501; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HILL SM, 1991, GUT, V32, P154, DOI 10.1136/gut.32.2.154; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; JERSE AE, 1991, INFECT IMMUN, V59, P3869, DOI 10.1128/IAI.59.11.3869-3875.1991; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LAUER P, 1993, MOL MICROBIOL, V8, P357, DOI 10.1111/j.1365-2958.1993.tb01579.x; LEVINE MM, 1985, J INFECT DIS, V152, P550, DOI 10.1093/infdis/152.3.550; Manning PA, 1997, GENE, V192, P1; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NATARO JP, 1985, INFECT IMMUN, V48, P378, DOI 10.1128/IAI.48.2.378-383.1985; NATARO JP, 1987, INFECT IMMUN, V55, P2370, DOI 10.1128/IAI.55.10.2370-2377.1987; Puente JL, 1996, MOL MICROBIOL, V20, P87, DOI 10.1111/j.1365-2958.1996.tb02491.x; Ramer SW, 1996, J BACTERIOL, V178, P6555, DOI 10.1128/jb.178.22.6555-6563.1996; ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441; SCALETSKY ICA, 1984, INFECT IMMUN, V45, P534, DOI 10.1128/IAI.45.2.534-536.1984; SOHEL I, 1993, MOL MICROBIOL, V7, P563, DOI 10.1111/j.1365-2958.1993.tb01147.x; Sohel I, 1996, J BACTERIOL, V178, P2613, DOI 10.1128/jb.178.9.2613-2628.1996; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x; Swanson J., 1989, MOBILE DNA, P743; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; TAYLOR CJ, 1986, J PEDIATR GASTR NUTR, V5, P70, DOI 10.1097/00005176-198601000-00013; Tobe T, 1996, MOL MICROBIOL, V21, P963, DOI 10.1046/j.1365-2958.1996.531415.x; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; VUOPIOVARKILA J, 1991, J EXP MED, V174, P1167, DOI 10.1084/jem.174.5.1167; WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V	45	362	367	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2114	2118		10.1126/science.280.5372.2114	http://dx.doi.org/10.1126/science.280.5372.2114			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641917				2022-12-01	WOS:000074435900045
J	Xu, ZY; Sato, K; Wickner, W				Xu, ZY; Sato, K; Wickner, W			LMA1 binds to vacuoles at Sec18p (NSF), transfers upon ATP hydrolysis to a t-SNARE (Vam3p) complex, and is released during fusion	CELL			English	Article							PROTEIN DISULFIDE-ISOMERASE; SACCHAROMYCES-CEREVISIAE; ALPHA-SNAP; ESCHERICHIA-COLI; IN-VITRO; YEAST; INHERITANCE; SEGREGATION; THIOREDOXIN; MEMBRANE	Vacuole fusion requires Sec18p (NSF), Sec17p (alpha-SNAP), Ypt7p (GTP binding protein), Vam3p (t-SNARE), Nyv1p (V-SNARE), and LMA1 (low M-r activity 1, a heterodimer of thioredoxin and I-2(B)). LMA1 requires Sec18p for saturable, high-affinity binding to vacuoles, and Sec18p "priming" ATPase requires both Sec17p and LMA1. Either the sec18-1 mutation and deletion of I-2(B), or deletion of both I-2(B), and p13 (an I-2(B) homolog) causes a striking synthetic vacuole fragmentation phenotype. Upon Sec18p ATP hydrolysis, LMA1 transfers to (and stabilizes) a Vam3p complex. LMA1 is released from vacuoles in a phosphatase-regulated reaction. This LMA1 cycle explains how priming by Sec18p is coupled to t-SNARE stabilization and to fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.				NIAMS NIH HHS [T32AR07576] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ausubel F, 1997, SHORT PROTOCOLS MOL; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUBER HE, 1986, J BIOL CHEM, V261, P5006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MAIER K, 1979, J BIOL CHEM, V254, P8491; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NICOLSON TA, 1995, J CELL BIOL, V130, P835, DOI 10.1083/jcb.130.4.835; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHU P, 1991, EUR J BIOCHEM, V197, P1, DOI 10.1111/j.1432-1033.1991.tb15874.x; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	44	75	80	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1125	1134		10.1016/S0092-8674(00)81457-9	http://dx.doi.org/10.1016/S0092-8674(00)81457-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657146	Bronze			2022-12-01	WOS:000074491100008
J	Shen, HM; Peters, A; Baron, B; Zhu, XD; Storb, U				Shen, HM; Peters, A; Baron, B; Zhu, XD; Storb, U			Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes	SCIENCE			English	Article							IMMUNOGLOBULIN GENES; NUCLEOTIDE-SEQUENCE; INTRON ENHANCER; ELEMENTS; LYMPHOMA; REGION; LOCUS	Immunoglobulin (Ig) genes are hypermutated in B lymphocytes that are the precursors to memory B cells. The mutations are linked to transcription initiation, but non-Ig promoters are permissible for the mutation process; thus, other genes expressed in mutating B cells may also be subject to somatic hypermutation. Significant mutations were not observed in c-MYC, S14, or alpha-fetoprotein (AFP) genes, but BCL-6 was highly mutated in a large proportion of memory B cells of normal individuals. The mutation pattern was similar to that of Ig genes.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60617 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60617 USA; Univ Chicago, Dept Pathol, Chicago, IL 60617 USA; Univ Chicago, Dept Med, Chicago, IL 60617 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Storb, U (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60617 USA.			zhu, xiangdong/0000-0002-5627-8082	NIGMS NIH HHS [GM07183, GM38649] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; KLEIN U, 1994, J EXP MED, V180, P1383, DOI 10.1084/jem.180.4.1383; Klotz EL, 1996, J IMMUNOL, V157, P4458; Migliazza A., 1997, Blood, V90, p177A; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MUELLER J, 1995, P NATL ACAD SCI USA, V92, P6577; Newton JS, 1996, EUR J IMMUNOL, V26, P811, DOI 10.1002/eji.1830260413; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Storb U, 1996, CURR OPIN IMMUNOL, V8, P206, DOI 10.1016/S0952-7915(96)80059-8; Storb U, 1998, CURR TOP MICROBIOL, V229, P11; STORB U, IN PRESS BIOL GERMIN; STORB U, UNPUB; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239	22	438	443	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 12	1998	280	5370					1750	1752		10.1126/science.280.5370.1750	http://dx.doi.org/10.1126/science.280.5370.1750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZU446	9624052				2022-12-01	WOS:000074197800041
J	Irvine, WM; Bergin, DA; Dickens, JE; Jewitt, D; Lovell, AJ; Matthews, HE; Schloerb, FP; Senay, M				Irvine, WM; Bergin, DA; Dickens, JE; Jewitt, D; Lovell, AJ; Matthews, HE; Schloerb, FP; Senay, M			Chemical processing in the coma as the source of cometary HNC	NATURE			English	Article							ABUNDANCE RATIO; HCN	The discovery of hydrogen isocyanide (HNC) in comet Hyakutake with an abundance (relative to hydrogen cyanide, KCN) similar to that seen in dense interstellar clouds raised the possibility that these molecules might be surviving interstellar material(1). The preservation of material from the Sun's parent molecular cloud would provide important constraints on the processes that took place in the protostellar nebula. But another possibility is that HNC is produced by photochemical processes in the coma, which means that its abundance could not be used as a direct constraint on conditions in the early Solar System. Here we show that the HNC/HCN ratio determined for comet Hale-Bopp varied with heliocentric distance in a way that matches the predictions of models of gas-phase chemical production of HNC in the coma, but cannot be explained if the HNC molecules were coming from the comet's nucleus. We conclude that HNC forms mainly by chemical reactions in the coma, and that such reactions need to be considered when attempting to deduce the composition of the nucleus from observations of the coma.	Univ Massachusetts, Five Coll Radio Astron Observ, Amherst, MA 01003 USA; Smithsonian Astrophys Observ, Cambridge, MA 02138 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Ottawa, ON K1A 0R6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA	University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Smithsonian Institution; University of Hawaii System; National Research Council Canada	Irvine, WM (corresponding author), Univ Massachusetts, Five Coll Radio Astron Observ, 619 LGRC, Amherst, MA 01003 USA.							Bergin EA, 1997, ASTROPHYS J, V486, P316, DOI 10.1086/304510; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BIVER N, IN PRESS EARTH MOON; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; FESTOU MC, 1993, ASTRON ASTROPHYS REV, V5, P37, DOI 10.1007/BF00872923; Fomenkova M. N., 1997, Astronomical Society of the Pacific Conference Series, V122, P415; GOLDSMITH PF, 1986, ASTROPHYS J, V310, P383, DOI 10.1086/164692; GOLDSMITH PF, 1981, ASTROPHYS J, V249, P524, DOI 10.1086/159312; HERBST E, 1978, ASTROPHYS J, V222, P508, DOI 10.1086/156163; HIROTA T, IN PRESS ASTROPHYS J; IRVINE WH, IN PRESS FARADAY DIS, V109; Irvine WM, 1996, NATURE, V383, P418, DOI 10.1038/383418a0; IRVINE WM, 1997, ESA, P277; LOVAS FJ, 1992, J PHYS CHEM REF DATA, V21, P181, DOI 10.1063/1.555920; Lovell AJ, 1998, ASTROPHYS J, V497, pL117, DOI 10.1086/311288; LOVELL AJ, IN PRESS EARTH MOON; MUMMA MJ, 1993, PROTOSTARS PLANETS, V3, P1177; Notesco G, 1997, ICARUS, V126, P336, DOI 10.1006/icar.1996.5654; OLOFSSON H, 1982, ASTRON ASTROPHYS, V107, P128; RODGERS SD, IN PRESS ASTROPHYS J; SCHMIDT HU, 1988, COMPUT PHYS COMMUN, V49, P17, DOI 10.1016/0010-4655(88)90214-7; Shiba Y, 1998, J CHEM PHYS, V108, P698, DOI 10.1063/1.475443; TACCONIGARMAN LE, 1990, ASTROPHYS J, V364, P672, DOI 10.1086/169450; WINK J, IN PRESS EARTH MOON; IN PRESS EARTH MOON	26	64	64	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					547	550		10.1038/31171	http://dx.doi.org/10.1038/31171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634231				2022-12-01	WOS:000074150100043
J	Glover, DW; Maron, BJ				Glover, DW; Maron, BJ			Profile of preparticipation cardiovascular screening for high school athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUDDEN-DEATH; YOUNG-ADULTS; DISEASE; ECHOCARDIOGRAPHY; CARDIOMYOPATHY	Context.-Sudden death in young competitive athletes due to unsuspected cardiovascular disease has heightened concern and interest in the preparticipation screening available to high school athletes in the United States. Objective.-To assess the potential adequacy of the preparticipation screening process for detecting or increasing the suspicion of cardiovascular abnormalities. Design.-Current guidelines and requirements for implementation of preparticipation screening from each of the high school jurisdictions in the 50 states and the District of Columbia were analyzed and compared with the 1996 American Heart Association (AHA) consensus panel guidelines on screening. Outcome Measures.-Items contained on preparticipation screening questionnaires; the examiners designated to perform screening. Results.-Eight states (16%) have no approved history and physical examination questionnaires to guide examiners, including 1 state without a formal screening requirement. Of the remaining 43 states, several items relevant to cardiac-related problems were frequently omitted from the questionnaires, Exertional dyspnea or chest pain, prior limitation from sports, family history of heart disease, or Marian syndrome were included in 0% to 56% of the state forms. Specific cardiovascular items on physical examination were included in forms from only 5% to 37% of states, including documentation of a heart murmur, irregular heart rhythm, peripheral pulses, or stigmata of Marfan syndrome. Seventeen (40%) of 43 states had history and physical questionnaires judged to be most adequate with at least 9 of the 13 AHA recommendations, whereas 12 states (28%) were least adequate with 4 or less of these recommended items. Therefore, a total of 20 (40%) of the 51 states have no approved history and physical examination questionnaires, or formal screening requirement, or forms that were judged to be inadequate. In addition to physicians, 21 states also permit nurses or physician assistants to administer examinations, and 11 states specifically provide for practitioners with limited cardiovascular training (such as chiropractors). Conclusions.-Preparticipation athletic screening for cardiovascular disease with standard history and physical examination, as presently employed in US high schools, is highly dependent on the state-approved questionnaires, which frequently are abbreviated and may be inadequate; is implemented by a variety of health care workers with varying levels of expertise; and may be severely limited in its power to detect potentially lethal cardiovascular abnormalities. These observations should represent an impetus for change and improvement in the preparticipation cardiovascular screening process for high school athletes.	St Lukes Hosp, Ambulatory Care Div, Kansas City, MO USA; Minneapolis Heart Inst Fdn, Minneapolis, MN USA	Saint Luke's Hospital - Missouri; Minneapolis Heart Institute Foundation	Maron, BJ (corresponding author), 920 E 28th St,Suite 40, Minneapolis, MN 55407 USA.							BHARATI S, 1986, J AM COLL CARDIOL, V8, P1096, DOI 10.1016/S0735-1097(86)80387-4; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; CORRADO D, 1997, CIRCULATION S1, V96, P152; Feinstein RA, 1994, CLIN J SPORT MED, V3, P149; Fuller CM, 1997, MED SCI SPORT EXER, V29, P1131, DOI 10.1097/00005768-199709000-00003; LACORTE MA, 1989, CLIN CARDIOL, V12, P41; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; Liberthson RR, 1996, NEW ENGL J MED, V334, P1039, DOI 10.1056/NEJM199604183341607; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; Maron BJ, 1996, CIRCULATION, V94, P850, DOI 10.1161/01.CIR.94.4.850; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARON BJ, 1996, CIRCULATION, V94, P388; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; MARSALESE DL, 1989, J AM COLL CARDIOL, V14, P422, DOI 10.1016/0735-1097(89)90197-6; MURRY PM, 1995, AM J CARDIOL, V76, P849, DOI 10.1016/S0002-9149(99)80244-6; SMITH DM, 1997, PREPARTICIPATION PHY, P1; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WEIDENBENER EJ, 1995, CLIN J SPORT MED, V5, P86, DOI 10.1097/00042752-199504000-00003; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6	25	119	119	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1998	279	22					1817	1819		10.1001/jama.279.22.1817	http://dx.doi.org/10.1001/jama.279.22.1817			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR635	9628714	Bronze			2022-12-01	WOS:000073998500035
J	Mdluli, K; Slayden, RA; Zhu, YQ; Ramaswamy, S; Pan, X; Mead, D; Crane, DD; Musser, JM; Barry, CE				Mdluli, K; Slayden, RA; Zhu, YQ; Ramaswamy, S; Pan, X; Mead, D; Crane, DD; Musser, JM; Barry, CE			Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; ACYL CARRIER PROTEIN; DRUG-RESISTANCE; CELL-GROWTH; FATTY-ACID; TARGET; INHA; MUTATIONS; KATG; BIOSYNTHESIS	Although isoniazid (isonicotinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive. In response to INH treatment, saturated hexacasanoic acid (C26:0) accumulated on a 12-kilodalton acyl carrier protein (AcpM) that normally carried mycolic acid precursors as long as C50. A protein species purified from INH-treated Mycobacterium tuberculosis was shown to consist of a covalent complex of INH, AcpM, and a beta-ketoacyl acyl carrier protein synthase, KasA. Amino acid-altering mutations in the KasA protein were identified in INH-resistant patient isolates that lacked other mutations associated with resistance to this drug.	NIAID, Rocky Mt Labs, Intracellular Parasites Lab, TB Res Unit,NIH, Hamilton, MT 59840 USA; Baylor Coll Med, Dept Pathol, Inst Study Bacterial Pathogenesis, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine	Barry, CE (corresponding author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, TB Res Unit,NIH, Hamilton, MT 59840 USA.		Slayden, Richard/AAV-2582-2021; Barry, Clifton E/ABE-7992-2020; Barry, Clifton E/H-3839-2012; Slayden, Richard/O-8626-2016	Slayden, Richard/0000-0001-6857-7277; Barry, Clifton E/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Slayden, Richard/0000-0001-6857-7277	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004, Z01AI000783] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI37004] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187, DOI 10.1128/AAC.40.9.2187; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; MDLULI K, UNPUB; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; OBrien KL, 1996, MOL CELL PROBE, V10, P1, DOI 10.1006/mcpr.1996.0001; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TAKAYAMA K, 1974, AM REV RESPIR DIS, V110, P43; TAKAYAMA K, 1979, ANTIBIOTICS, V1, P98; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	28	345	364	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1607	1610		10.1126/science.280.5369.1607	http://dx.doi.org/10.1126/science.280.5369.1607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616124				2022-12-01	WOS:000074061200042
J	Morris, JS; Ohman, A; Dolan, RJ				Morris, JS; Ohman, A; Dolan, RJ			Conscious and unconscious emotional learning in the human amygdala	NATURE			English	Article							BLOOD-FLOW; DISCRIMINATION; RECOGNITION; MECHANISMS; ACTIVATION; EXPRESSION; RESPONSES; IMAGES; FACES	If subjects are shown an angry face as a target visual stimulus for less than forty milliseconds and are then immediately shown an expressionless mask, these subjects report seeing the mask but not the target. However, an aversively conditioned masked target can elicit an emotional response from subjects without being consciously perceived(1,2). Here we study the mechanism of this unconsciously mediated emotional learning. We measured neural activity in volunteer subjects who were presented with two angry faces, one of which, through previous classical conditioning, was associated with a burst of white noise. In half of the trials, the subjects' awareness of the angry faces was prevented by backward masking with a neutral face. A significant neural response was elicited in the right, but not left, amygdala to masked presentations of the conditioned angry face. Unmasked presentations of the same face produced enhanced neural activity in the left, but not right, amygdala. Our results indicate that, first, the human amygdala can discriminate between stimuli solely on the basis of their acquired behavioural significance, and second, this response is lateralized according to the subjects' level of awareness of the stimuli.	Wellcome Dept Cognit Neurol, London WC1N 3BG, England; Karolinska Hosp, Dept Clin Neurosci, Psychiat & Psychol Sect, S-17176 Stockholm, Sweden; Royal Free Hosp, London NW3 2DF, England; UCL Hosp, Sch Med, London NW3 2DF, England	University of London; University College London; Karolinska Institutet; Karolinska University Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School	Dolan, RJ (corresponding author), Wellcome Dept Cognit Neurol, Queen Sq, London WC1N 3BG, England.		anand, amit/A-7222-2009	Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adolphs R, 1997, LEARN MEMORY, V4, P291, DOI 10.1101/lm.4.3.291; Babinsky R, 1993, Behav Neurol, V6, P167, DOI 10.3233/BEN-1993-6310; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; DAVIS M, 1992, P255; DEKOSKY ST, 1980, BRAIN LANG, V9, P206, DOI 10.1016/0093-934X(80)90141-8; Ekman P, 1976, PICTURES FACIAL AFFE; Esteves F., 1994, COGNITION EMOTION, V9, P99; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GAZZANIGA MS, 1983, ANN NEUROL, V13, P536, DOI 10.1002/ana.410130511; GAZZANIGA MS, 1995, COGNITIVE NEUROSCIEN, P1049; GUR RC, 1994, BRAIN COGNITION, V25, P271, DOI 10.1006/brcg.1994.1036; HUGDAHL K, 1995, NEUROREPORT, V6, P1723, DOI 10.1097/00001756-199509000-00005; Kapp BS, 1984, NEUROPSYCHOLOGY MEMO, P473; KLINGER MR, 1995, J EXP PSYCHOL LEARN, V21, P569, DOI 10.1037/0278-7393.21.3.569; LABAR KS, 1995, J NEUROSCI, V15, P6846; LADAVAS E, 1993, COGNITION EMOTION, V7, P95, DOI 10.1080/02699939308409179; LeDoux J.E., 1996, EMOTIONAL BRAIN; LEONARD CM, 1985, BEHAV BRAIN RES, V15, P159, DOI 10.1016/0166-4328(85)90062-2; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris JS, 1997, P ROY SOC B-BIOL SCI, V264, P769, DOI 10.1098/rspb.1997.0109; OHMAN A, 1994, J ABNORM PSYCHOL, V103, P231, DOI 10.1037/0021-843X.103.2.231; STONE VS, 1995, NEUROPSYCHOLOGIA, V34, P23; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009; Whalen PJ, 1998, J NEUROSCI, V18, P411; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	30	1242	1279	4	150	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 4	1998	393	6684					467	470		10.1038/30976	http://dx.doi.org/10.1038/30976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZR842	9624001	Green Submitted			2022-12-01	WOS:000074020000044
J	Harris, AL				Harris, AL			Are angiostatin and endostatin cures for cancer?	LANCET			English	Editorial Material							SUPPRESSION; DORMANCY		Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Oxford OX3 9DS, England	University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Oxford OX3 9DS, England.		Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brem S, 1998, Angiogenesis, V2, P9, DOI 10.1023/A:1009068807898; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Harris Adrian L., 1997, Lancet (North American Edition), V349, P13; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OREILLY MS, 1997, INVEST NEW DRUGS, V1, P5; Pezzella F, 1997, AM J PATHOL, V151, P1417; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sim BKL, 1997, CANCER RES, V57, P1329	16	36	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 30	1998	351	9116					1598	1599		10.1016/S0140-6736(98)22022-8	http://dx.doi.org/10.1016/S0140-6736(98)22022-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR900	9620709				2022-12-01	WOS:000074026600002
J	Ryan, EA				Ryan, EA			Pancreas transplants: for whom?	LANCET			English	Editorial Material							QUALITY-OF-LIFE; KIDNEY-TRANSPLANTATION; DIABETES-MELLITUS; MORTALITY		Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ryan, EA (corresponding author), Univ Alberta, Dept Med, Div Endocrinol, Edmonton, AB T6G 2S2, Canada.							Alejandro R, 1997, DIABETES, V46, P1983, DOI 10.2337/diabetes.46.12.1983; Bloom RD, 1997, TRANSPLANTATION, V64, P1689, DOI 10.1097/00007890-199712270-00010; Busing M, 1997, EXP CLIN ENDOCR DIAB, V105, P92; Gruessner RWG, 1997, TRANSPLANTATION, V64, P1572, DOI 10.1097/00007890-199712150-00011; Kendall DM, 1997, DIABETES, V46, P249, DOI 10.2337/diabetes.46.2.249; Kinkhabwala M, 1996, AM J SURG, V171, P516, DOI 10.1016/S0002-9610(97)89613-4; Korbutt GS, 1996, J CLIN INVEST, V97, P2119, DOI 10.1172/JCI118649; Landgraf R, 1996, DIABETOLOGIA, V39, P1415, DOI 10.1007/s001250050593; LARSEN JL, 1992, DIABETES CARE, V15, P35, DOI 10.2337/diacare.15.1.35; Manske CL, 1995, LANCET, V346, P1658, DOI 10.1016/S0140-6736(95)92838-3; Martinenghi S, 1997, DIABETES CARE, V20, P272, DOI 10.2337/diacare.20.3.272; NAVARRO X, 1990, DIABETES, V39, P802, DOI 10.2337/diabetes.39.7.802; Piehlmeier W, 1996, EUR J SURG, V162, P933; Stratta RJ, 1997, DIABETES CARE, V20, P362, DOI 10.2337/diacare.20.3.362; SUTHERLAND DER, 1997, CURRENT THERAPY ENDO, P496	15	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1072	1073		10.1016/S0140-6736(98)22015-0	http://dx.doi.org/10.1016/S0140-6736(98)22015-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660570				2022-12-01	WOS:000073090200002
J	Bastian, H; Keirse, MJNC; Lancaster, PAL				Bastian, H; Keirse, MJNC; Lancaster, PAL			Perinatal death associated with planned home birth in Australia: population based study	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY	Objective: To assess the risk of perinatal death in planned home births in Australia. Design: Comparison of data an planned home births during 1985-90, notified to Homebirth Australia, with national data on perinatal deaths and outcomes of home births internationally. Results: 50 perinatal deaths occurred in 7002 planned home births in Australia during 1985-90: 7.1 per 1000 (95% confidence interval 5.2 to 9.1) according to Australian definitions and 6.4 per 1000 (4.6 to 8.3) according to World Health Organisation definitions. The perinatal death rate in infants weighing more than 2500 g was higher than the national average (5.7 versus 3.6 per 1000: relative risk 1.6; 1.1 to 2.4) as were intrapartum deaths not due to malformations or immaturity (2.7 versus 0.9 per 1000: 3.0; 1.9 to 4.8). More than half (52%) of the deaths were associated with intrapartum asphyxia. Conclusions: Australian home births carried a high death rate compared with both all Australian births ana home births elsewhere. The two largest contributors to the excess mortality were underestimation of the risks associated with post-term birth, twin pregnancy and breech presentation, and a lack of response to fetal distress.	Flinders Univ S Australia, Flinders Med Ctr, Dept Obstet & Gynaecol, Adelaide, SA 5100, Australia; Univ New S Wales, Australian Inst Hlth & Welf, Natl Perinatal Stat Unit, Sydney, NSW 2052, Australia	Flinders Medical Centre; Flinders University South Australia; University of New South Wales Sydney	Bastian, H (corresponding author), POB 569, Blackwood, SA 5051, Australia.	hilda.bastian@flinders.edu.au		Bastian, Hilda/0000-0001-8544-7386				Anderson RE, 1995, J NURSE-MIDWIFERY, V40, P483, DOI 10.1016/0091-2182(95)00051-8; Barron SL, 1996, BRIT MED J, V313, P1306; BASTIAN H, 1992, HOME BIRTHS AUSTR 19; BASTIAN H, 1990, HOME BIRTHS AUSTR 19; CHAMBERLAIN G, 1996, HOME BIRTHS REPORT 1; Gardner M. J., 1989, STAT CONFIDENCE; Gulbransen G, 1997, NEW ZEAL MED J, V110, P87; LECKYTHOMPSON M, 1989, CELEBRATING REVOLUTI, P43; Lumley J, 1985, Aust Fam Physician, V14, P1104; Macfarlane A, 1996, BRIT MED J, V312, P754; MEHLMADRONA L, 1997, NURSE MIDWIFERY, V42, P91; *MIDIRS NHS CTR RE, 1997, INF CHOIC WOM; *MIDIRS NHS CTR RE, 1997, INF CHOIC PROF; ODENT M, 1991, MOTHERING, V58, P80; TEW M, 1995, SAFER CHILDBIRTH CRI, P311; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; WIEGERS TA, 1996, BRIT MED J, V313, P1276; WOODCOCK HC, EPIDEMIOLOGICAL STUD; *ZIEK, 1987, VERL IND 1987 FIN RE	19	82	83	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					384	388						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9694754				2022-12-01	WOS:000075409600025
J	Itescu, S; Tung, TCM; Burke, EM; Weinberg, AD; Mancini, D; Michler, RE; Suciu-Foca, NM; Rose, EA				Itescu, S; Tung, TCM; Burke, EM; Weinberg, AD; Mancini, D; Michler, RE; Suciu-Foca, NM; Rose, EA			An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients	LANCET			English	Article							SOLID-ORGAN TRANSPLANTATION; ANTI-HLA ANTIBODIES; HEART-TRANSPLANTATION; ALLOGRAFT-REJECTION; LUNG-TRANSPLANTATION; SURVIVAL; MICROCHIMERISM; CELLS	Background Transplant-related coronary-artery disease (TCAD) develops frequently in cardiac-allograft recipients, and limits long-term survival. We examined the relation between this disorder and cumulative frequency of high-grade rejection, and investigated whether concomitant use of three immunological factors at the time of a low-grade endomyocardial biopsy can predict progression to high-grade rejection. Methods We investigated the relation between the cumulative annual frequency of high-grade rejection and TCAD in 198 recipients of cardiac transplantation between 1992 and 1996 by means of Kaplan-Meier actuarial life-tables. Endomyocardial biopsy, lymphocyte-growth assays, and anti-HLA antibody measurements were compiled over 12 months in 102 patients during their first post-transplant year. We calculated predictive values for high-grade rejection within 90 days by chi(2), Kaplan Meier survival curves, and by multivariable logistic regression analyses. Findings We found a direct correlation between cumulative annual frequency of rejection and TCAD onset with highest risk in those with more than 0.75 rejections per year (p=0.0002). After a low-grade endomyocardial biopsy (0 or 1A), one or more donor-recipient HLA-DR matches protected against high-grade rejections (p<0.001). Among individuals with one or two DR matches, the negative predictive value for progression from a low-grade biopsy to a high-grade rejection was 87% in the presence of a negative lymphocyte-growth assay. Among individuals with no DR matches, the presence of either lymphocyte-growth assay or IgG anti-major-histocompatibility complex (MHC) class II antibodies was independently associated With high probability of progression to rejection (64% and 68%, respectively, p<0.0005). When both assays were positive, concomitantly with a low-grade endomyocardial biopsy, the positive predictive value for progression to a high-grade rejection was 86% (p<0.0001). For endomyocardial-biopsy grades 1B or 2, a positive lymphocyte-growth assay alone was associated with high-grade rejection in 100% of cases. Interpretation Use of an algorithm combining three immunological factors at the time of a low-grade endomyocardial biopsy enables prospective stratification of cardiac transplant recipients into risk categories for progression to high-grade rejection. Low-risk individuals require fewer biopsies, moderate-risk individuals require an ongoing schedule of surveillance biopsies, and high-risk individuals require rational organisation of interventional strategies aimed at preventing rejection. Additional predictive factors are needed to identify moderate-risk individuals who will progress to rejection. Ultimately, successful intervention may have an impact on the subsequent complication of TCAD.	Columbia Univ, Coll Phys & Surg, Dept Surg, New York, NY 10032 USA	Columbia University	Itescu, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Surg, 622 W 168th St,PH 14 W, New York, NY 10032 USA.	si5@columbia.edu						BILLINGHAM ME, 1990, J HEART TRANSPLANT, V9, P272; Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117; CONSTANZONORDIN MR, 1992, J HEART LUNG TRANSPL, V11, pS90; Creemers P, 1997, NEPHRON, V75, P166, DOI 10.1159/000189526; DEMATTOS AM, 1994, TRANSPLANTATION, V57, P626; FISCHER PE, 1995, J HEART LUNG TRANSPL, V14, P1156; GEORGE JF, 1995, J HEART LUNG TRANSPL, V14, P856; HALL T S, 1986, Journal of Heart Transplantation, V5, P419; HESS ML, 1983, CIRCULATION, V68, P94; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; ITESCU S, 1998, IN PRESS CIRCULATION; JARCHO J, 1994, J HEART LUNG TRANSPL, V13, P583; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEMKES BM, 1992, J HEART LUNG TRANSPL, V11, pS221; KEOGH A, 1995, J HEART LUNG TRANSPL, V14, P444; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KORMOS R, 1992, J HEART LUNG TRANSPL, V11, pS104; Krieger NR, 1996, J EXP MED, V184, P2013, DOI 10.1084/jem.184.5.2013; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIU Z, 1993, J EXP MED, V177, P1643, DOI 10.1084/jem.177.6.1643; Liu ZR, 1996, J CLIN INVEST, V98, P1150, DOI 10.1172/JCI118898; MAMULA MJ, 1993, IMMUNOL TODAY, V14, P151, DOI 10.1016/0167-5699(93)90274-O; MARKUS PM, 1993, CELL TRANSPLANT, V2, P345, DOI 10.1177/096368979300200418; REED EF, 1996, TRANSPLANTATION, V61, P556; RIZEQ MN, 1994, J HEART LUNG TRANSPL, V13, P862; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, pS120; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SMITH JD, 1992, TRANSPLANTATION, V53, P1358, DOI 10.1097/00007890-199206000-00034; SMITH JD, 1995, LANCET, V346, P1318, DOI 10.1016/S0140-6736(95)92341-1; Starzl T E, 1994, Prog Liver Dis, V12, P191; SUCIUFOCA N, 1991, TRANSPLANTATION, V51, P716, DOI 10.1097/00007890-199103000-00033; Tugulea S, 1997, TRANSPLANTATION, V64, P842, DOI 10.1097/00007890-199709270-00009; VALENTINE H, 1991, J HEART LUNG TRANSPL, V10, P757; Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4; White JA, 1995, J HEART LUNG TRANSPL, V14, P1052; WINTERS GL, 1995, CIRCULATION, V91, P1975, DOI 10.1161/01.CIR.91.7.1975; WISENBERG G, 1987, AM J CARDIOL, V60, P130, DOI 10.1016/0002-9149(87)90999-4; ZAVAZAVA N, 1993, TISSUE ANTIGENS, V42, P20, DOI 10.1111/j.1399-0039.1993.tb02161.x; ZEEVI A, 1995, TRANSPLANTATION, V59, P616	40	48	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1998	352	9124					263	270		10.1016/S0140-6736(98)09475-6	http://dx.doi.org/10.1016/S0140-6736(98)09475-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103TT	9690405				2022-12-01	WOS:000074974500008
J	Nelles, J; Fuhrer, A; Hirsbrunner, HP; Harding, TW				Nelles, J; Fuhrer, A; Hirsbrunner, HP; Harding, TW			Provision of syringes: the cutting edge of harm reduction in prison?	BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS-DRUG-USERS; HEPATITIS-C VIRUS; HIV-INFECTION; AUSTRALIAN PRISON; RISK BEHAVIOR; NEEDLE; AIDS; PREVALENCE; EXCHANGE; PENITENTIARY		Univ Bern, Psychiat Serv, Dept East, CH-3000 Bern 60, Switzerland; Univ Geneva, Inst Med Legale, CH-1211 Geneva, Switzerland	University of Bern; University of Geneva	Nelles, J (corresponding author), Univ Bern, Psychiat Serv, Dept East, CH-3000 Bern 60, Switzerland.							ANON C, 1995, REV ESP ENFERM DIG, V87, P505; BREWER TF, 1992, AIDS, V6, P623, DOI 10.1097/00002030-199207000-00002; Council of Europe, 1993, R936 COUNC EUR; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DOLAN K, 1995, AIDS, V9, P825, DOI 10.1097/00002030-199508000-00001; DOLAN K, 1994, MED J AUSTRALIA, V160, P734, DOI 10.5694/j.1326-5377.1994.tb125930.x; DOLAN K, 1997, STRATEGIES DRUGS AID, P213; DUBOISARBER F, 1991, EVALUATION AIDS PRAV; FORD PM, 1995, CAN MED ASSOC J, V153, P1605; Frischer M, 1996, LANCET, V347, P768, DOI 10.1016/S0140-6736(96)90121-X; Gaiter J, 1996, AM J PUBLIC HEALTH, V86, P1201, DOI 10.2105/AJPH.86.9.1201; Gaube J, 1993, Gesundheitswesen, V55, P246; HARDING TW, 1997, HARM REDUCTION PRISO, P161; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; Mahon N, 1996, AM J PUBLIC HEALTH, V86, P1211, DOI 10.2105/AJPH.86.9.1211; MARTIN G S, 1990, AIDS Care, V2, P275, DOI 10.1080/09540129008257740; MEYENBERG R, 1996, INFEKTIONSPROPHYLAXE; MYERS T, 1995, ADDICTION, V90, P217, DOI 10.1111/j.1360-0443.1995.tb01039.x; Nelles J., 1997, HARM REDUCTION PRISO, P239; NELLES J, 1997, KURZEVALUATION PILOT; NELLES J, 1997, HARM REDUCTION PRISO; Nelles J., 1995, DRUG HIV PREVENTION; NELLES J, 1997, INT J DRUG POLICY, V1, P2; PAPE U, 1996, 54 KRIM FORSCH NIED; Polych C, 1995, MENS HLTH ILLNESS GE, P139; STARK K, 1995, SCAND J INFECT DIS, V27, P331, DOI 10.3109/00365549509032726; STARK K, 1995, ADDICTION, V90, P1367, DOI 10.1111/j.1360-0443.1995.tb03554.x; STEPHENS RC, 1991, AM J PUBLIC HEALTH, V81, P568, DOI 10.2105/AJPH.81.5.568; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; THOMAS PA, 1994, AIDS PRISON; VLAHOV D, 1993, EUR J EPIDEMIOL, V9, P566, DOI 10.1007/BF00209538; *WHO, 1993, GLOB PROGR AIDS WHO; 1995, LANCET, V346, P1397	35	31	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					270	273		10.1136/bmj.317.7153.270	http://dx.doi.org/10.1136/bmj.317.7153.270			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PG	9677225	Green Published			2022-12-01	WOS:000075081900031
J	Brenner, RA; Simons-Morton, BG; Bhaskar, B; Mehta, N; Melnick, VL; Revenis, M; Berendes, HW; Clemens, JD				Brenner, RA; Simons-Morton, BG; Bhaskar, B; Mehta, N; Melnick, VL; Revenis, M; Berendes, HW; Clemens, JD			Prevalence and predictors of the prone sleep position among inner-city infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; PROGRAM; COHORT; HEALTH; RISK; SIDS; BACK; CARE	Context.-The prone sleep position is associated with an increased risk of sudden infant death syndrome (SIDS), but few studies have assessed factors associated with the choice of infant sleep position. Objectives.-To describe infant sleep position in a cohort of infants born to predominantly low-income, inner-city mothers and to identify predictors of the prone sleep position in this population. Design.-Prospective birth cohort study. Patients and Setting.-Three hundred ninety-four mother-infant dyads, systematically selected from 3 District of Columbia hospitals between August 1995 and September 1996, Mothers were interviewed shortly after delivery and again at 3 to 7 months postpartum. Main Outcome Measures.-Position in which infants were placed for sleep on the night prior to the 3- to 7-month interview. Results.-At 3 to 7 months of age, 157 infants (40%) were placed for sleep in the prone position. Independent predictors of prone sleep position included poverty (odds ratio [OR], 1.81; 95% confidence interval [CI], 1.10-2.99), black race (OR, 2.06; 95% CI, 1.05-4.04), presence of infant's grandmother in the home (OR, 1.83; 95% CI, 1.11-3.00), and intent, as measured shortly after delivery, to place the infant in the prone position (OR, 2.28; 95% CI, 1.44-3.60), Importantly, of the 43 mothers who observed their infants in the prone sleep position while in the hospital, 40 (93%) intended to place their infants prone at home. Conclusions.-A substantial proportion of infants in this predominantly low-income population were placed in the prone sleep position. Educational efforts should address both initial intentions and reinforcement of the correct sleep position, once initiated. Hospitals should ensure that healthy newborn infants are placed in the supine sleep position during the postpartum hospital stay.	NICHHD, Div Epidemiol Stat & Prevent Res, Bethesda, MD 20892 USA; Res Triangle Inst, Rockville, MD USA; Georgetown Univ Hosp, Div Neonatol, Washington, DC 20007 USA; Univ Dist Columbia, Dept Biol & Environm Sci, Washington, DC USA; Childrens Natl Med Ctr, Dept Neonatol, Washington, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Research Triangle Institute; Georgetown University; University of the District of Columbia; Children's National Health System	Brenner, RA (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, 6100 Execut Blvd,Room 7B03, Bethesda, MD 20892 USA.	BrennerR@nih.gov		Simons-Morton, Bruce/0000-0003-1099-6617	NICHD NIH HHS [U18-HD30447, U18-HD30450, U18-HD30458] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U18HD030458, U18HD030450, U18HD030447] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1996, FED REGISTER, V61, P8286; Bandura A., 1986, SOCIAL FDN THOUGHT A; BATES AS, 1995, JAMA-J AM MED ASSOC, V272, P1105; BURD L, 1994, PUBLIC HEALTH REP, V109, P446; CHESSARE JB, 1995, PEDIATRICS, V96, P893; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; ELLEN JM, 1995, PEDIATR EMERG CARE, V11, P223, DOI 10.1097/00006565-199508000-00008; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Hiley CMH, 1995, ARCH DIS CHILD, V73, P496, DOI 10.1136/adc.73.6.496; Johnson CM, 1996, PEDIATRICS, V98, P163; KAHN A, 1993, PEDIATRICS, V91, P1112; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; Kemp JS, 1996, SLEEP, V19, pS263, DOI 10.1093/sleep/19.suppl_10.S263; MARKESTAD T, 1995, ACTA PAEDIATR, V84, P375, DOI 10.1111/j.1651-2227.1995.tb13653.x; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; PONSONBY AL, 1995, ARCH DIS CHILD, V72, P204, DOI 10.1136/adc.72.3.204; Ray BJ, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e12; Rogers E., 1983, DIFFUSION INNOVATION; Sawczenko A, 1996, SLEEP, V19, pS267; Taylor JA, 1996, ARCH PEDIAT ADOL MED, V150, P834, DOI 10.1001/archpedi.1996.02170330060010; Taylor JA, 1996, J PEDIATR-US, V128, P626, DOI 10.1016/S0022-3476(96)80126-0; TUOHY PG, 1993, ARCH DIS CHILD, V69, P664, DOI 10.1136/adc.69.6.664; WILLINGER M, 1995, PEDIATR ANN, V24, P358, DOI 10.3928/0090-4481-19950701-07; Willinger M, 1998, JAMA-J AM MED ASSOC, V280, P329, DOI 10.1001/jama.280.4.329; WILLINGER M, 1994, PEDIATRICS, V93, P814; WILLINGER M, 1995, JAMA-J AM MED ASSOC, V273, P818, DOI 10.1001/jama.273.10.818	34	85	86	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1998	280	4					341	346		10.1001/jama.280.4.341	http://dx.doi.org/10.1001/jama.280.4.341			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	100FC	9686551	Bronze			2022-12-01	WOS:000074804200034
J	Ghosh, S; Drummond, HE; Ferguson, A				Ghosh, S; Drummond, HE; Ferguson, A			Neglect of growth and development in the clinical monitoring of children and teenagers with inflammatory bowel disease: review of case records	BRITISH MEDICAL JOURNAL			English	Article									Western Gen Hosp, Dept Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Ferguson, A (corresponding author), Western Gen Hosp, Dept Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							BARTON JR, 1989, BRIT MED J, V298, P865, DOI 10.1136/bmj.298.6677.865; KURTZ Z, 1996, SERVICES YOUNG PEOPL, P141	2	14	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1998	317	7151					120	121		10.1136/bmj.317.7151.120	http://dx.doi.org/10.1136/bmj.317.7151.120			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PE	9657788	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000075081700023
J	Gonzalez-Crespo, S; Abu-Shaar, M; Torres, M; Martinez, C; Mann, RS; Morata, G				Gonzalez-Crespo, S; Abu-Shaar, M; Torres, M; Martinez, C; Mann, RS; Morata, G			Antagonism between extradenticle function and Hedgehog signalling in the developing limb	NATURE			English	Article							HUMAN PROTOONCOGENE PBX1; LONG-RANGE ACTION; DISTAL-LESS; MORPHOGEN GRADIENT; DROSOPHILA EMBRYO; LEG DEVELOPMENT; GENE ACTIVITY; WINGLESS; PROTEIN; PATTERN	The Drosophila homeobox gene extradenticle (exd) encodes a highly conserved cofactor of Hox proteins(1-3). exd activity is regulated post-translationally by a mechanism involving nuclear translocation(4,5); only nuclear Exd protein is functional. The exd gene is required for patterning of the proximal region of the leg(6,7), whereas patterning of the distal region requires signalling by the Wingless (Wg) and Decapentaplegic (Dpp)(8,9) proteins, which are in turn activated by Hedgehog (Hh)(10). Here we show that exd function and Dpp/Wg signalling are antagonistic and divide the leg into two mutually exclusive domains. In the proximal domain, exd activity prevents cells from responding to Dpp and Wg, Conversely, in the distal domain, exd function is suppressed by the Dpp/Wg response gene Distal-less (Dll), which prevents the nuclear transport of Exd, We also found that the product of a murine homologue of exd (Pbx1) is regulated at the subcellular level, and that its pattern of nuclear localization in the mouse limb resembles that of Exd in the Drosophila leg. These findings suggest that the division of the limb into two antagonistic domains, as defined by exd (Pbx1) function and Hh signalling, may be a general feature of limb development.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrat Program Cellular Mol & Biophys Stud, New York, NY 10032 USA; Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Columbia University; Columbia University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Morata, G (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain.		Torres, Miguel/CAG-0003-2022; Torres, Miguel/A-7388-2013	Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767; Morata, Gines/0000-0003-3274-5173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510, R01GM058575] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510, R01 GM058575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspland SE, 1997, DEVELOPMENT, V124, P741; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIAZBENJUMES FJ, 1994, NATURE, V32, P175; Fuse N, 1996, DEVELOPMENT, V122, P1059; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Goto S, 1997, DEVELOPMENT, V124, P125; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MARDON G, 1994, DEVELOPMENT, V120, P3473; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Torres M, 1995, DEVELOPMENT, V121, P4057; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	29	129	130	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					196	200		10.1038/28197	http://dx.doi.org/10.1038/28197			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671305				2022-12-01	WOS:000074705900058
J	Iwata, S; Lee, JW; Okada, K; Lee, JK; Iwata, M; Rasmussen, B; Link, TA; Ramaswamy, S; Jap, BK				Iwata, S; Lee, JW; Okada, K; Lee, JK; Iwata, M; Rasmussen, B; Link, TA; Ramaswamy, S; Jap, BK			Complete structure of the 11-subunit bovine mitochondrial cytochrome bc(1) complex	SCIENCE			English	Article							IRON-SULFUR PROTEIN; C REDUCTASE; PROCESSING PEPTIDASE; BC1 COMPLEX; BEEF-HEART; UBIQUINOL; OXIDOREDUCTASE; OXIDATION; BINDING; SITE	Mitochondrial cytochrome bc(1) complex performs two functions: It is a respiratory multienzyme complex and it recognizes a mitochondrial targeting presequence. Refined crystal structures of the 11-subunit bc(1) complex from bovine heart reveal full views of this bifunctional enzyme. The "Rieske" iron-sulfur protein subunit shows significant conformational changes in different crystal forms, suggesting a new electron transport mechanism of the enzyme. The mitochondrial targeting presequence of the "Rieske" protein (subunit 9) is lodged between the two "core" subunits at the matrix side of the complex. These "core" subunits are related to the matrix processing peptidase, and the structure unveils how mitochondrial targeting presequences are recognized.	Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden; Univ Frankfurt Klinikum, ZBC, D-60590 Frankfurt, Germany; Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France	Uppsala University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Swedish University of Agricultural Sciences; Goethe University Frankfurt; Goethe University Frankfurt Hospital; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)	Iwata, S (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	iwata@xray.bmc.uu.se; BKJap@lbl.gov	Subramanian, Ramaswamy/Q-8671-2019	Subramanian, Ramaswamy/0000-0002-6709-190X				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1997, IN PRESS P 9 INT S P; DENG K, 1996, BIOPHYS J, V72, pA319; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM CH, 1983, J BIOL CHEM, V258, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LINK TA, 1997, BIOINORG CHEM, P312; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MUKAI K, 1985, J BIOCHEM-TOKYO, V98, P1417, DOI 10.1093/oxfordjournals.jbchem.a135409; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Robinson, 1982, CYCLOTRONS CYTOCHROM, P263, DOI 10.1016/B978-0-12-397580-5.50026-0; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1998, BIOCHIM BIOPHYS ACTA, V1365, P261; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1991, J BIOL CHEM, V266, P6416; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	50	1032	1068	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1998	281	5373					64	71		10.1126/science.281.5373.64	http://dx.doi.org/10.1126/science.281.5373.64			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651245				2022-12-01	WOS:000074685800037
J	Rae, C; Lee, MA; Dixon, RM; Blamire, AM; Thompson, CH; Styles, P; Talcott, J; Richardson, AJ; Stein, JF				Rae, C; Lee, MA; Dixon, RM; Blamire, AM; Thompson, CH; Styles, P; Talcott, J; Richardson, AJ; Stein, JF			Metabolic abnormalities in developmental dyslexia detected by H-1 magnetic resonance spectroscopy	LANCET			English	Article							DEFICITS; CHILDREN	Background Neurological and physiological deficits have been reported in the brain in developmental dyslexia. The temporoparietal cortex has been directly implicated in dyslexic dysfunction, and substantial indirect evidence suggests that the cerebellum is also implicated. We wanted to find out whether the neurological and physiological deficits manifested as biochemical changes in the brain. Methods We obtained localised proton magnetic resonance spectra bilaterally from the temporo-parietal cortex and cerebellum of 14 well-defined dyslexic men and 15 control men of similar age. Findings We found biochemical differences between dyslexic men and controls in the left temporo-parietal lobe (ratio of choline-containing compounds [Cho] to N-acetylaspartate [NA] p less than or equal to 0.01) and right cerebellum (Cho/NA, p less than or equal to 0.01; creatine [Cre] to NA p less than or equal to 0.05; (not significant). We found lateral biochemical differences in dyslexic men in both these brain regions (Cho/NA in temporo-parietal lobe, left vs right, p less than or equal to 0.01; Cre/NA in cerebellum, left vs right, p less than or equal to 0.001). We found no such lateral differences in controls. There was no significant relation between the degree of contralateral chemical difference and handedness in dyslexic or control men. Interpretation We suggest that the observed differences reflect changes in cell density in the temporo-parietal lobe in developmental dyslexia and that the altered cerebral structural symmetry in dyslexia is associated with abnormal development of cells or intracellular connections or both. The cerebellum is biochemically asymmetric in dyslexic men, indicating altered development of this organ. These differences provide direct evidence of the involvement of the cerebellum in dyslexic dysfunction.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; John Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England; Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Sydney; University of Oxford; Radcliffe Infirmary; University of Oxford	Rae, C (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.	crae@biochem.usyd.edu.au	Thompson, Campbell/E-2885-2010; Blamire, Andrew/AAU-6100-2021; Rae, Caroline/B-7537-2008	Thompson, Campbell/0000-0002-5164-3327; Rae, Caroline/0000-0003-0673-8084; Richardson, Alex/0000-0001-5650-4409; Blamire, Andrew/0000-0002-8749-1257				ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BRADLEY L, 1978, NATURE, V271, P746, DOI 10.1038/271746a0; CASTLES A, 1993, COGNITION, V47, P149, DOI 10.1016/0010-0277(93)90003-E; Eden GF, 1996, NATURE, V382, P66, DOI 10.1038/382066a0; FAWCETT AJ, 1992, PERCEPT MOTOR SKILL, V75, P507, DOI 10.2466/pms.1992.75.2.507; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; GALABURDA AM, 1985, ANN NEUROL, V18, P222, DOI 10.1002/ana.410180210; HIER DB, 1978, ARCH NEUROL-CHICAGO, V35, P90, DOI 10.1001/archneur.1978.00500260028005; LARSEN JP, 1990, BRAIN LANG, V39, P289, DOI 10.1016/0093-934X(90)90015-9; LIVINGSTONE MS, 1991, P NATL ACAD SCI USA, V88, P7943, DOI 10.1073/pnas.88.18.7943; LOVEGROVE WJ, 1980, NEUROPSYCHOLOGIA, V18, P111, DOI 10.1016/0028-3932(80)90093-7; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; NICOLSON RI, 1995, P ROY SOC B-BIOL SCI, V259, P43, DOI 10.1098/rspb.1995.0007; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; Rae C, 1996, P ROY SOC B-BIOL SCI, V263, P1061, DOI 10.1098/rspb.1996.0156; RAMSEY JM, 1992, ARCH NEUROL-CHICAGO, V49, P527; SNOWLING MJ, 1987, DYXLEXIA COGNITIVE D; Stein J, 1997, TRENDS NEUROSCI, V20, P147, DOI 10.1016/S0166-2236(96)01005-3; STEIN JF, 1992, PHYSIOL REV, V72, P967, DOI 10.1152/physrev.1992.72.4.967; TALLAL P, 1980, BRAIN LANG, V9, P182, DOI 10.1016/0093-934X(80)90139-X; TEDESCHI G, 1995, NEUROLOGY, V45, P1384, DOI 10.1212/WNL.45.7.1384; TRACEY I, 1995, LANCET, V345, P1260, DOI 10.1016/S0140-6736(95)90923-0; VAN IJZENDOORN MH, 1994, READ RES QUART, V29, P267; WILSHER CR, 1987, J CLIN PSYCHOPHARM, V7, P230	25	138	138	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1849	1852		10.1016/S0140-6736(97)99001-2	http://dx.doi.org/10.1016/S0140-6736(97)99001-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652669				2022-12-01	WOS:000074347100012
J	Stell, IM; Gransden, WR				Stell, IM; Gransden, WR			Simple tests for septic bursitis: comparative study	BRITISH MEDICAL JOURNAL			English	Article									Guys Hosp, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust	Stell, IM (corresponding author), Univ London Kings Coll Hosp, Kings Healthcare NHS Trust, Dept Accid & Emergency, London SE5 9RS, England.							FREEMONT AJ, 1991, ANN RHEUM DIS, V50, P101, DOI 10.1136/ard.50.2.101; HO G, 1979, ARCH INTERN MED, V139, P1269, DOI 10.1001/archinte.139.11.1269; RADDATZ DA, 1987, J RHEUMATOL, V14, P1160; VONESSEN R, 1986, ANN RHEUM DIS, V45, P454, DOI 10.1136/ard.45.6.454; ZIMMERMANN B, 1995, SEMIN ARTHRITIS RHEU, V24, P391, DOI 10.1016/S0049-0172(95)80008-5	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1998	316	7148					1877	1877						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632407	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000074686500024
J	Cavert, W; Hase, AT				Cavert, W; Hase, AT			A National Tissue Bank to track HIV eradication and immune reconstitution	SCIENCE			English	Editorial Material									Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Cavert, W (corresponding author), Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hauptman PJ, 1997, NEW ENGL J MED, V336, P422, DOI 10.1056/NEJM199702063360607; Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; McArthur JC, 1997, ANN NEUROL, V42, P689, DOI 10.1002/ana.410420504; *OFF AIDS RES ADV, 1996, REP NIH AIDS RES PRO; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARKER NG, 1998, NAT MED, V4, P208; Price RW, 1997, ANN NEUROL, V42, P675, DOI 10.1002/ana.410420502; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	16	10	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1998	280	5371					1865	1866		10.1126/science.280.5371.1865	http://dx.doi.org/10.1126/science.280.5371.1865			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669943				2022-12-01	WOS:000074323800039
J	Bennett, SRM; Carbone, FR; Karamalis, F; Flavell, RA; Miller, JFAP; Heath, WR				Bennett, SRM; Carbone, FR; Karamalis, F; Flavell, RA; Miller, JFAP; Heath, WR			Help for cytotoxic-T-cell responses is mediated by CD40 signalling	NATURE			English	Article							CD40-CD40 LIGAND INTERACTION; ANTIBODY-RESPONSES; HUMAN MONOCYTES; CD8(+) CTL; MICE; ACTIVATION; INDUCTION; INVIVO; LYMPHOCYTES; REQUIREMENT	Cytotoxic T lymphocytes (CTLs) which carry the CD8 antigen recognize antigens that are presented on target cells by the class I major histocompatibility complex. CTLs are responsible for the killing of antigen-bearing target cells, such as virus-infected cells. Although CTL effecters can act alone when killing target cells, their differentiation from naive CD8-positive T cells is often dependent on 'help' from CD4-positive helper T (T-H) cells(1-4).Furthermore, for effective CTL priming, this help must be provided in a cognate manner, such that both the T-H cell and the CTL recognize antigen on the same antigen-presenting cell(2,4). One explanation for this requirement is that T-H cells are needed to convert the antigen-presenting cell into a cell that is fully competent to prime CTL5. Here we show that signalling through CD40 on the antigen-presenting cells can replace the requirement for T-H cells, indicating that T-cell 'help', at least for generation of CTLs by cross-priming, is mediated by signalling through CD40 on the antigen-presenting cell.	PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia; PO Royal Brisbane Hosp, Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Herston, Qld 4029, Australia; Monash Med Sch, Prahran, Vic 3181, Australia; Yale Univ, Immunol Sect, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Monash University; Yale University; Howard Hughes Medical Institute; Yale University	Carbone, FR (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Immunol, Melbourne, Vic 3050, Australia.		Carbone, Francis/ABF-2141-2020	Heath, William/0000-0001-9670-259X				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; BUTLER RM, 1987, NATURE, V328, P77; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; Guo Y, 1996, J EXP MED, V184, P955, DOI 10.1084/jem.184.3.955; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Ke Y, 1996, J IMMUNOL, V156, P916; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KIENER PA, 1995, J IMMUNOL, V155, P4917; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; ROY M, 1993, J IMMUNOL, V151, P2497; Sad S, 1997, EUR J IMMUNOL, V27, P914, DOI 10.1002/eji.1830270417; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Shinde S, 1996, J IMMUNOL, V157, P2764; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235; Whitmire JK, 1996, J VIROL, V70, P8375, DOI 10.1128/JVI.70.12.8375-8381.1996; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	30	1698	1780	0	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1998	393	6684					478	480		10.1038/30996	http://dx.doi.org/10.1038/30996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZR842	9624004				2022-12-01	WOS:000074020000047
J	Ahsan, H; Neugut, AI; Garbowski, GC; Jacobson, JS; Forde, KA; Treat, MR; Waye, JD				Ahsan, H; Neugut, AI; Garbowski, GC; Jacobson, JS; Forde, KA; Treat, MR; Waye, JD			Family history of colorectal adenomatous polyps and increased risk for colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; adenomatous polyposis coli; age factors; colonoscopy; risk factors	NONPOLYPOSIS COLON-CANCER; FIRST-DEGREE RELATIVES; LARGE BOWEL; TUMORS; SUSCEPTIBILITY; INHERITANCE; DISEASE; HABITS; AGE	Background: The risk for colorectal cancer among family members of patients with colorectal cancer is well established, but the risk among family members of patients with colorectal adenomas is less well established. Objective: To examine the risk for colorectal cancer among first-degree relatives of patients with adenoma compared with that among first-degree relatives of controls without adenoma. Design: Reconstructed cohort study. Setting: Three university-based colonoscopy practices in New York City. Patients: 1554 first-degree relatives of 244 patients with newly diagnosed adenomas and 2173 first-degree relatives of 362 endoscopically normal controls. Measurements: Structured interviews were used to obtain family history. Adjusted relative risks (RR) were estimated from Cox proportional hazards regression models. Results: The risk for colorectal cancer was elevated (RR, 1.74 [95% CI, 1.24 to 2.45]) among first-degree relatives of patients with newly diagnosed adenomas compared with the risk among first-degree relatives of controls. This increased risk was the same for parents (RR, 1.58 [CI, 1.07 to 2.34]) and siblings (RR, 1.58 [CI, 0.81 to 3.08]). First-degree relatives of patients with adenomas did not have elevated risk for other cancers. The risk for colorectal cancer among family members increased with decreasing age at diagnosis of adenoma in probands. Among first-degree relatives of patients who were 50 years of age or younger when the adenoma was diagnosed, the risk was more than four times greater (RR, 4.36 [CI, 2.24 to 8.51]) than that among first-degree relatives of patients who were older than 60 years of age when the adenoma was diagnosed. Conclusions: First-degree relatives of patients with newly diagnosed adenomas, particularly of patients who are 50 years of age or younger at diagnosis, are at increased risk for colorectal cancer and should undergo screening similar to that recommended for relatives of patients with colorectal cancer.	Columbia Presbyterian Med Ctr, Div Oncol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Dept Surg, New York, NY 10032 USA; Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; Columbia Univ, Sch Publ Hlth, New York, NY 10027 USA; Mt Sinai Sch Med, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai	Neugut, AI (corresponding author), Columbia Presbyterian Med Ctr, Div Oncol, 630 W 168th St, New York, NY 10032 USA.	ain1@columbia.edu			NCI NIH HHS [5T32-CA09529-11A1, R01-CA37196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009529, R01CA037196] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN J, 1995, AM J EPIDEMIOL, V141, P863, DOI 10.1093/oxfordjournals.aje.a117522; BAZZOLI F, 1995, GASTROENTEROLOGY, V109, P783, DOI 10.1016/0016-5085(95)90385-2; BONELLI L, 1988, INT J CANCER, V41, P513; BOUTRON MC, 1995, GUT, V37, P830, DOI 10.1136/gut.37.6.830; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DELEON MP, 1987, CANCER, V60, P2848, DOI 10.1002/1097-0142(19871201)60:11<2848::AID-CNCR2820601141>3.0.CO;2-F; FISHER G, 1989, MED J AUSTRALIA, V150, P22, DOI 10.5694/j.1326-5377.1989.tb136314.x; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GROSSMAN S, 1988, GASTROENTEROLOGY, V94, P395, DOI 10.1016/0016-5085(88)90427-1; GUILLEM JG, 1988, AM J GASTROENTEROL, V83, P271; GUILLEM JG, 1992, DIS COLON RECTUM, V35, P523, DOI 10.1007/BF02050530; HALL NR, 1994, BRIT J SURG, V81, P1485, DOI 10.1002/bjs.1800811029; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; KATO I, 1990, JPN J CANCER RES, V81, P115, DOI 10.1111/j.1349-7006.1990.tb02536.x; KATO I, 1990, JPN J CANCER RES, V81, P1101, DOI 10.1111/j.1349-7006.1990.tb02520.x; KHOURY MJ, 1995, EPIDEMIOLOGY, V6, P511, DOI 10.1097/00001648-199509000-00009; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUNE GA, 1991, NUTR CANCER, V16, P25, DOI 10.1080/01635589109514137; KUNE GA, 1989, WORLD J SURG, V13, P124, DOI 10.1007/BF01671173; LeMarchand L, 1996, AM J EPIDEMIOL, V144, P1122, DOI 10.1093/oxfordjournals.aje.a008890; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; NEUGUT AI, 1993, AM J GASTROENTEROL, V88, P1179; NEUGUT AI, 1993, CANCER EPIDEM BIOMAR, V2, P159; NEUGUT AI, 1993, ANN INTERN MED, V118, P91, DOI 10.7326/0003-4819-118-2-199301150-00002; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Winawer SJ, 1996, NEW ENGL J MED, V334, P82, DOI 10.1056/NEJM199601113340204	34	108	109	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					900	+		10.7326/0003-4819-128-11-199806010-00006	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634428				2022-12-01	WOS:000073808600004
J	Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; DuBois, RN				Tsujii, M; Kawano, S; Tsuji, S; Sawaoka, H; Hori, M; DuBois, RN			Cyclooxygenase regulates angiogenesis induced by colon cancer cells	CELL			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; MICROVASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR; EXPRESSION; DIFFERENTIATION; MODULATION; MIGRATION; MATRIX; MODEL	To explore the role of cyclooxygenase (COX) in endothelial cell migration and angiogenesis, we have used two in vitro model systems involving coculture of endothelial cells with colon carcinoma cells. COX-2-overexpressing cells produce prostaglandins, proangiogenic factors, and stimulate both endothelial migration and tube formation, while control cells have little activity. The effect is inhibited by antibodies to combinations of angiogenic factors, by NS-398 (a selective COX-2 inhibitor), and by aspirin. NS-398 does not inhibit production of angiogenic factors or angiogenesis induced by COX-2-negative cells. Treatment of endothelial cells with aspirin or a COX-1 antisense oligonucleotide inhibits COX-1 activity/expression and suppresses tube formation. Cyclooxygenase regulates colon carcinoma-induced angiogenesis by two mechanisms: COX-2 can modulate production of angiogenic factors by colon cancer cells, while COX-1 regulates angiogenesis in endothelial cells.	Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Osaka Univ, Sch Med, Dept Med 1, Osaka 5650871, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Osaka University	Tsujii, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, VA Med Ctr, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NIDDK NIH HHS [DK-47297] Funding Source: Medline; NCEH CDC HHS [NIEHS-00267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCEH CDC HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220; Breyer MD, 1996, J AM SOC NEPHROL, V7, P8; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; DuBois RN, 1996, CANCER RES, V56, P733; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.0.CO;2-7; Kawamori T, 1998, CANCER RES, V58, P409; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; MASUDA E, 1992, AM J PHYSIOL, V262, pG785, DOI 10.1152/ajpgi.1992.262.5.G785; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; Seed MP, 1997, CANCER RES, V57, P1625; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; SKOBE M, 1997, NAT MED, V3, P122; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WILLIAMS CS, 1997, J CLIN INVEST, V100, P1; Yamazaki K, 1996, IN VIVO, V10, P459; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	35	2029	2225	0	91	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 29	1998	93	5					705	716		10.1016/S0092-8674(00)81433-6	http://dx.doi.org/10.1016/S0092-8674(00)81433-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZR264	9630216	Bronze			2022-12-01	WOS:000073956700008
J	Kemp, M				Kemp, M			Hyde's horrors	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.							Darwin C., 1872, EXPRESS EMOT MAN, DOI [10.1037/10001-000, DOI 10.1037/10001-000]; Stevenson Robert Louis, 1886, STRANGE CASE DR JEKY	2	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1998	393	6682					219	219		10.1038/30370	http://dx.doi.org/10.1038/30370			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZP513	9607757	Bronze			2022-12-01	WOS:000073761000032
J	Boysen, G; Truelsen, T				Boysen, G; Truelsen, T			Looking beyond first-ever stroke incidence	LANCET			English	Editorial Material							RISK-FACTORS; RACE		Bispebjerg Hosp, Dept Neurol, DK-1399 Copenhagen K, Denmark; Kommune Hosp, Inst Prevent Med, DK-1399 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital	Boysen, G (corresponding author), Bispebjerg Hosp, Dept Neurol, DK-1399 Copenhagen K, Denmark.		Truelsen, Thomas/AAY-1549-2020					*AM HEART ASS, 1997, HEART STROK STAT UPD; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Brown RD, 1996, STROKE, V27, P373; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; Heyman A, 1971, STROKE, V2, P509, DOI 10.1161/01.STR.2.6.509; HORNER RD, 1991, STROKE, V22, P1497, DOI 10.1161/01.STR.22.12.1497; KITTNER SJ, 1990, JAMA-J AM MED ASSOC, V264, P1267, DOI 10.1001/jama.264.10.1267; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; RESCH JA, 1970, ATHEROSCLEROSIS, V12, P401, DOI 10.1016/0021-9150(70)90044-4; SACCO RL, 1995, NEUROLOGY, V45, P659, DOI 10.1212/WNL.45.4.659; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4	11	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 11	1998	351	9109					1073	1074		10.1016/S0140-6736(05)79374-0	http://dx.doi.org/10.1016/S0140-6736(05)79374-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH269	9660571				2022-12-01	WOS:000073090200003
J	Marx, SO; Ondrias, K; Marks, AR				Marx, SO; Ondrias, K; Marks, AR			Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors)	SCIENCE			English	Article							II-III-LOOP; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; DIHYDROPYRIDINE RECEPTOR; REGIONS	Excitation-contraction coupling in skeletal muscle requires the release of intracellular calcium ions (Ca2+) through ryanodine receptor (RyR1) channels in the sarcoplasmic reticulum. Half of the RyR1 channels are activated by voltage-dependent Ca2+ channels in the plasma membrane, In planar Lipid bilayers, RyR1 channels exhibited simultaneous openings and closings, termed "coupled gating." Addition of the channel accessory protein FKBP12 induced coupled gating, and removal of FKBP12 uncoupled channels, Coupled gating provides a mechanism by which RyR1 channels that are not associated with voltage-dependent Ca2+ channels can be regulated.	Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Cardiol,Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Circulatory Physiol,Dept Med, New York, NY 10032 USA; Slovak Acad Sci, Inst Mol Physiol & Genet, SK-83334 Bratislava, Slovakia; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Slovak Academy of Sciences; Columbia University	Marks, AR (corresponding author), Columbia Univ, Coll Phys & Surg, Mol Cardiobiol Program, Div Cardiol,Dept Med, New York, NY 10032 USA.			Ondrias, Karol/0000-0001-8329-3563	FOGARTY INTERNATIONAL CENTER [R03TW000949] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056180] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00949] Funding Source: Medline; NHLBI NIH HHS [R01HL56180] Funding Source: Medline; PHS HHS [R01A139794] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MARX SO, UNPUB; MILLER C, 1986, ION CHANNL RECONSTIT, P3; Ondrias K, 1996, SOC GEN PHY, V51, P29; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0	20	350	362	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					818	821		10.1126/science.281.5378.818	http://dx.doi.org/10.1126/science.281.5378.818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9694652				2022-12-01	WOS:000075295600048
J	Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R				Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R			Identification of patients with atrial fibrillation in general practice: a study of screening methods	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle Upon Tyne, Sch Clin Med Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England	Newcastle University - UK	Sudlow, M (corresponding author), Univ Newcastle Upon Tyne, Sch Clin Med Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Mark.Sudlow@ncl.ac.uk		Kenny, Rose Anne/0000-0002-9336-8124				Cuckle HS, 1984, ANTENATAL NEONATAL S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	5	51	52	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					327	328		10.1136/bmj.317.7154.327	http://dx.doi.org/10.1136/bmj.317.7154.327			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9685281	Green Published			2022-12-01	WOS:000075409500025
J	Smith, H; Gooding, S; Brown, R; Frew, A				Smith, H; Gooding, S; Brown, R; Frew, A			Evaluation of readability and accuracy of information leaflets in general practice for patients with asthma	BRITISH MEDICAL JOURNAL			English	Article									Univ Southampton, Wessex Primary Care Res Network, Southampton SO16 5ST, Hants, England; Wilton Hlth Ctr, Wilton SP2 0HT, England; Univ Med, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Smith, H (corresponding author), Univ Southampton, Wessex Primary Care Res Network, Southampton SO16 5ST, Hants, England.		Kelly, Frank J/C-6125-2009; Smith, Helen E/M-2449-2016	Kelly, Frank J/0000-0003-2558-8392; Smith, Helen E/0000-0003-1883-6124				*BAS SKILLS AG, 1992, MAK READ EAS; Carey S, 1997, ADULT LITERACY BRITA; ESTEY A, 1991, PATIENT EDUC COUNS, V18, P165, DOI 10.1016/0738-3991(91)90008-S; ESTEY A, 1996, PATIENT EDUC COUNS, V30, P205; MCLAUGHLIN GH, 1969, J READING, V12, P639; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	6	60	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1998	317	7153					264	265		10.1136/bmj.317.7153.264	http://dx.doi.org/10.1136/bmj.317.7153.264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	105PG	9677221	Green Accepted, Green Published			2022-12-01	WOS:000075081900028
J	Dobbins, AC; Jeo, RM; Fiser, J; Allman, JM				Dobbins, AC; Jeo, RM; Fiser, J; Allman, JM			Distance modulation of neural activity in the visual cortex	SCIENCE			English	Article							RESPONSE PROPERTIES; PRESTRIATE CORTEX; VIEWING DISTANCE; EYE POSITION; NEURONS; MONKEY; AREA; DEPTH; SIZE; STEREOPSIS	Humans use distance information to scale the size of objects. Earlier studies demonstrated changes in neural response as a function of gaze direction and gaze distance in the dorsal visual cortical pathway to parietal cortex. These findings have been interpreted as evidence of the parietal pathway's role in spatial representation. Here, distance-dependent: changes in neural response were also found to be common in neurons in the ventral pathway leading to inferotemporal cortex of monkeys, This result implies that the information necessary for object and spatial scaling is common to all visual cortical areas.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ So Calif, Los Angeles, CA 90089 USA	California Institute of Technology; University of Southern California	Dobbins, AC (corresponding author), Univ Alabama, Dept Biomed Engn, Vis Sci Res Ctr, Birmingham, AL 35294 USA.		Fiser, József/A-2877-2009	Fiser, Jozsef/0000-0002-7064-0690				Aguirre GK, 1997, J NEUROSCI, V17, P2512; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; BARBUR JL, 1987, CLIN VISION SCI, V2, P131; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; COLLETT TS, 1991, PERCEPTION, V20, P733, DOI 10.1068/p200733; DOBBINS E, UNPUB; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GALLETTI C, 1989, J NEUROSCI, V9, P1112; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280, DOI 10.1152/jn.1995.73.1.280; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Holway AH, 1941, AM J PSYCHOL, V54, P21, DOI 10.2307/1417790; HUMPHREY N, 1969, Q J EXP PSYCHOL, V21, P255; LEIBOWIT.H, 1966, J OPT SOC AM, V56, P1120, DOI 10.1364/JOSA.56.001120; Milner D., 1995, VISUAL BRAIN ACTION; NAKAYAMA K, 1990, VISION RES, V30, P1811, DOI 10.1016/0042-6989(90)90161-D; PETERSEN SE, 1980, BRAIN RES, V197, P507, DOI 10.1016/0006-8993(80)91137-3; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SAKATA H, 1980, J NEUROPHYSIOL, V43, P1654, DOI 10.1152/jn.1980.43.6.1654; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; TROTTER Y, 1992, SCIENCE, V257, P1279, DOI 10.1126/science.1519066; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1977, EXP BRAIN RES, V27, P251; WALLACH H, 1963, AM J PSYCHOL, V76, P404, DOI 10.2307/1419781; WEYAND TG, 1993, J NEUROPHYSIOL, V69, P2258, DOI 10.1152/jn.1993.69.6.2258; WISE SP, 1988, SCIENCE, V242, P736, DOI 10.1126/science.3187520; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	27	86	86	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					552	555		10.1126/science.281.5376.552	http://dx.doi.org/10.1126/science.281.5376.552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9677196				2022-12-01	WOS:000075012300038
J	Wang, LY; Kaczmarek, LK				Wang, LY; Kaczmarek, LK			High-frequency firing helps replenish the readily releasable pool of synaptic vesicles	NATURE			English	Article							AUDITORY BRAIN-STEM; TRAPEZOID BODY; TRANSMITTER RELEASE; MEDIAL NUCLEUS; DEPRESSION; CELLS; ORGANIZATION; HIPPOCAMPUS; PARVALBUMIN; CALRETININ	Synapses in the central nervous system undergo various short- and long-term changes in their strength(1-3), but it is often difficult to distinguish whether presynaptic or postsynaptic mechanisms are responsible for these changes. Using patch-clamp recording from giant synapses in the mouse auditory brainstem(4-7), we show here that short-term synaptic depression can be largely attributed to rapid depletion of a readily releasable pool of vesicles. Replenishment of this pool is highly dependent on the recent history of synaptic activity. High-frequency stimulation of presynaptic terminals significantly enhances the rate of replenishment. Broadening the presynaptic action potential with the potassium-channel blocker tetraethylammonium, which increases Ca2+ entry, further enhances the rate of replenishment. As this increase can be suppressed by the Ca2+-channel blocker Cd2+ or by the Ca2+ buffer EGTA, we conclude that Ca2+ influx through voltage-gated Ca2+ channels is the key signal that dynamically regulates the refilling of che releasable pool of synaptic vesicles in response to different patterns of inputs.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Toronto, Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada	Yale University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	Kaczmarek@Yale.edu						BARNESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387, DOI 10.1113/jphysiol.1995.sp020974; BETZ WJ, 1970, J PHYSIOL-LONDON, V206, P629, DOI 10.1113/jphysiol.1970.sp009034; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Borst JGG, 1996, NATURE, V383, P431, DOI 10.1038/383431a0; BROWNELL WE, 1975, BRAIN RES, V94, P413, DOI 10.1016/0006-8993(75)90226-7; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; GUINAN JJ, 1972, INT J NEUROSCI, V4, P147, DOI 10.3109/00207457209164756; HANKEL AW, 1996, CURR OPIN NEUROBIOL, V6, P350; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; Isaacson JS, 1996, J NEUROPHYSIOL, V76, P1566, DOI 10.1152/jn.1996.76.3.1566; KUSANO K, 1975, J PHYSIOL-LONDON, V245, P13, DOI 10.1113/jphysiol.1975.sp010832; KUWABARA N, 1991, J COMP NEUROL, V314, P684, DOI 10.1002/cne.903140405; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lohmann C, 1996, J COMP NEUROL, V367, P90, DOI 10.1002/(SICI)1096-9861(19960325)367:1<90::AID-CNE7>3.0.CO;2-E; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MOREST D K, 1968, Zeitschrift fuer Anatomie und Entwicklungsgeschichte, V127, P201, DOI 10.1007/BF00526129; PARKER D, 1995, J NEUROPHYSIOL, V74, P529, DOI 10.1152/jn.1995.74.2.529; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VATER M, 1994, J COMP NEUROL, V341, P534, DOI 10.1002/cne.903410409; vonGersdorff H, 1997, J NEUROSCI, V17, P8137; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WANG LY, 1997, SOC NEUR ABSTR, V25, P365; WU SH, 1993, HEARING RES, V68, P189, DOI 10.1016/0378-5955(93)90123-I; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	456	463	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					384	388		10.1038/28645	http://dx.doi.org/10.1038/28645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690475				2022-12-01	WOS:000074968800055
J	Mach, F; Schonbeck, U; Sukhova, GK; Atkinson, E; Libby, P				Mach, F; Schonbeck, U; Sukhova, GK; Atkinson, E; Libby, P			Reduction of atherosclerosis in mice by inhibition of CD40 signalling	NATURE			English	Article							ENDOTHELIAL-CELLS; LIGAND INTERACTIONS; LYMPHOCYTES-T; GP39; HYPERCHOLESTEROLEMIA; PATHOGENESIS; MACROPHAGES; PREVENTION; EXPRESSION; LESIONS	Increasing amounts of evidence support the involvement of inflammation and immunity in atherogenesis(1-4), but mediators of communication between the major cell types in atherosclerotic plaques are poorly defined. Cells in human atherosclerotic lesions express the immune mediator CD40 and its ligand CD40L (also known as CD154 or gp39)(5). The interaction of CD40 with CD40L figures prominently in both humoral and cell-mediated immune responses(6). CD4OL-positive T cells accumulate in atheroma(5), and, by virtue of their early appearance, persistence and localization at sites of lesion growth and complication, activated T cells may coordinate important aspects of atherogenesis(7-9). Interruption of CD40L-CD40 signalling by administration of an anti-CD40L antibody Limits experimental autoimmune diseases such as collagen-induced arthritis, lupus nephritis, acute or chronic graft-versus-host disease, multiple sclerosis and thyroiditis(10-14). Ligation of CD40 on atheroma-associated cells in vitro activates functions related to atherogenesis, including induction of proinflammatory cytokines(5), matrix metalloproteinases(15,16), adhesion molecules(17-19) and tissue factor(16,20). However, the role of CD40 signalling in atherogenesis in vivo remains unknown. Here we determine whether interruption of CD40 signalling influences atherogenesis in vivo in hyperlipidaemic mice, Treatment with antibody against mouse CD40L limited atherosclerosis in mice lacking the receptor for low-density lipoprotein that had been fed a high-cholesterol diet for 12 weeks. This antibody reduces the size of aortic atherosclerotic lesions by 59% and their lipid content by 79%, Furthermore, atheroma of mice treated with anti-CD40L antibody contained significantly fewer macrophages (64%) and T lymphocytes (70%), and exhibited decreased expression of vascular cell adhesion molecule-1. These data support the involvement of inflammatory pathways in atherosclerosis and indicate a role for CD40 signalling during atherogenesis in hyperlipidaemic mice.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Cardiovasc Div,Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Libby, P (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Cardiovasc Div,Vasc Med & Atherosclerosis Unit, 221 Longwood Ave, Boston, MA 02115 USA.	plibby@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X				Carayanniotis G, 1997, IMMUNOLOGY, V90, P421, DOI 10.1111/j.1365-2567.1997.00421.x; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DURIE FH, 1993, SCIENCE, V261, P1328, DOI 10.1126/science.7689748; EMESON EE, 1988, AM J PATHOL, V130, P369; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; HANSSON GK, 1988, ATHEROSCLEROSIS, V72, P135, DOI 10.1016/0021-9150(88)90074-3; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lichtman A. H., 1997, FASEB Journal, V11, pA154; Lichtman AH, 1996, AM J PATHOL, V149, P351; Lu LN, 1997, TRANSPLANTATION, V64, P1808, DOI 10.1097/00007890-199712270-00031; Mach F, 1997, CIRCULATION, V96, P396; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MACH F, IN PRESS ATHEROSCLER; MOHAN C, 1995, J IMMUNOL, V154, P1470; Roselaar SE, 1996, ARTERIOSCL THROM VAS, V16, P1013, DOI 10.1161/01.ATV.16.8.1013; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schonbeck U, 1997, CIRC RES, V81, P448, DOI 10.1161/01.RES.81.3.448; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; Zhou XH, 1996, AM J PATHOL, V149, P359	29	720	781	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1998	394	6689					200	203		10.1038/28204	http://dx.doi.org/10.1038/28204			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ203	9671306				2022-12-01	WOS:000074705900059
J	McEwen, AS; Keszthelyi, L; Spencer, JR; Schubert, G; Matson, DL; Lopes-Gautier, R; Klassen, KP; Johnson, TV; Head, JW; Geissler, P; Fagents, S; Davies, AG; Carr, MH; Breneman, HH; Belton, MJS				McEwen, AS; Keszthelyi, L; Spencer, JR; Schubert, G; Matson, DL; Lopes-Gautier, R; Klassen, KP; Johnson, TV; Head, JW; Geissler, P; Fagents, S; Davies, AG; Carr, MH; Breneman, HH; Belton, MJS			High-temperature silicate volcanism on Jupiter's moon Io	SCIENCE			English	Article							GALILEAN SATELLITES; INTERNAL STRUCTURE; TOPOGRAPHY; SPECTRA; SYSTEM	Infrared wavelength observations of lo by the Galileo spacecraft show that at Least 12 different vents are erupting lavas that are probably hotter than the highest temperature basaltic eruptions on Earth today. In at least one case, the eruption near Pillan Patera, two independent instruments on Galileo show that the lava temperature must have exceeded 1700 kelvin and may have reached 2000 kelvin. The most likely explanation is that these lavas are ultramafic (magnesium-rich) silicates, and this idea-is supported by the tentative identification of magnesium-rich orthopyroxene in Lava flows associated with these high-temperature hot spots.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA; Lowell Observ, Flagstaff, AZ 86001 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; US Geol Survey, Menlo Park, CA 94025 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA	University of Arizona; University of California System; University of California Los Angeles; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Brown University; Arizona State University; Arizona State University-Tempe; United States Department of the Interior; United States Geological Survey; National Optical Astronomy Observatory	McEwen, AS (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA.	mcewen@lplarizona.edu	Fagents, Sarah/B-3983-2014; Lopes, Rosaly M.C./D-1608-2016; Davies, Ashley/S-5588-2018	Lopes, Rosaly M.C./0000-0002-7928-3167; Kestay, Laszlo/0000-0003-1879-4331; Davies, Ashley/0000-0003-1747-8142				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BELTON MJS, 1992, SPACE SCI REV, V60, P413, DOI 10.1007/BF00216864; Bevington P. R., 1969, DATA REDUCTION ERROR; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; CARR MH, 1986, J GEOPHYS RES-SOLID, V91, P3521, DOI 10.1029/JB091iB03p03521; CARR MH, IN PRESS ICARUS; DAVIES AG, 1998, LUNAR PLANET SCI, V29; GARCIA MO, 1995, GEOPHYS MONOGR SER, V92, P219; GASKELL RW, 1988, GEOPHYS RES LETT, V15, P581, DOI 10.1029/GL015i006p00581; Hall A, 1987, IGNEOUS PETROLOGY; HEAD JW, 1992, GEOCHIM COSMOCHIM AC, V56, P2155, DOI 10.1016/0016-7037(92)90183-J; HEIKEN G, 1991, LUNAR SORUCEBOOK USE; HERZBERG C, 1992, J GEOPHYS RES-SOL EA, V97, P4521, DOI 10.1029/91JB03066; Hess P. C, 1989, ORIGINS IGNEOUS ROCK; JOHNSON ML, 1990, GEOPHYS RES LETT, V17, P981, DOI 10.1029/GL017i007p00981; JOHNSON TV, 1988, SCIENCE, V242, P1280, DOI 10.1126/science.242.4883.1280; Keszthelyi L, 1997, GEOPHYS RES LETT, V24, P2463, DOI 10.1029/97GL01368; Keszthelyi L, 1997, ICARUS, V130, P437, DOI 10.1006/icar.1997.5837; KLAASEN KP, 1984, OPT ENG, V23, P334, DOI 10.1117/12.7973290; KLASSEN KP, 1997, OPT ENG, V36, P3001; LopesGautier R, 1997, GEOPHYS RES LETT, V24, P2439, DOI 10.1029/97GL02662; LUNINE JI, 1985, ICARUS, V64, P345, DOI 10.1016/0019-1035(85)90060-0; MATSON DL, 1998, LUNAR PLANET SCI, V29; McEwen AS, 1997, GEOPHYS RES LETT, V24, P2443, DOI 10.1029/97GL01956; MCEWEN AS, 1989, NASA SP494, P11; MCEWEN AS, IN PRESS ICARUS; Morse S. A., 1980, BASALTS PHASE DIAGRA; NASH DB, 1990, SATELLITES, P629; Pearl J.S., 1982, SATELLITES JUPITER, P724; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; ROSS MN, 1990, ICARUS, V85, P309, DOI 10.1016/0019-1035(90)90119-T; Rothery DA, 1996, J GEOPHYS RES-PLANET, V101, P26131, DOI 10.1029/96JE02864; SCHABER GG, 1982, SATELLITES JUPITER, P556; SEGATZ M, 1988, ICARUS, V75, P187, DOI 10.1016/0019-1035(88)90001-2; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; Spencer JR, 1997, GEOPHYS RES LETT, V24, P2451, DOI 10.1029/97GL02591; Stansberry JA, 1997, GEOPHYS RES LETT, V24, P2455, DOI 10.1029/97GL02593; THOMAS PE, IN PRESS; VEEDER GJ, 1994, J GEOPHYS RES-PLANET, V99, P17095, DOI 10.1029/94JE00637	40	159	161	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					87	90		10.1126/science.281.5373.87	http://dx.doi.org/10.1126/science.281.5373.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651251				2022-12-01	WOS:000074685800043
J	DePace, AH; Santoso, A; Hillner, P; Weissman, JS				DePace, AH; Santoso, A; Hillner, P; Weissman, JS			A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROTEIN; PSI(+); URE3	The yeast [PSI+] factor propagates by a prion-like mechanism involving self-replicating Sup35p amyloids. We identified multiple Sup35p mutants that either are poorly recruited into, or cause curing of, wildtype amyloids in vivo. In vitro, these mutants showed markedly decreased rates of amyloid formation, strongly supporting the protein-only prion hypothesis. Kinetic analysis suggests that the prion state replicates by accelerating slow conformational changes rather than by providing stable nuclei. Strikingly, our mutations map exclusively within a short glutamine/asparagine-rich region of Sup35p, and all but one occur at polar residues. Even after replacement of this region with polyglutamine, Sup35p retains its ability to form amyloids. These and other considerations suggest similarities between the prion-like propagation of [PSI+] and polyglutamine-mediated pathogenesis of several neurodegenerative diseases.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.			Weissman, Jonathan/0000-0003-2445-670X				Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BRIEHL RW, 1980, NATURE, V288, P622, DOI 10.1038/288622a0; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; JAHLEM P, 1998, MOL CELL, V1, P595; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Lazo ND, 1998, BIOCHEMISTRY-US, V37, P1731, DOI 10.1021/bi971016d; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	38	326	329	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1998	93	7					1241	1252		10.1016/S0092-8674(00)81467-1	http://dx.doi.org/10.1016/S0092-8674(00)81467-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZX217	9657156	Bronze			2022-12-01	WOS:000074491100018
J	Nabarro, DN; Tayler, EM				Nabarro, DN; Tayler, EM			The "Roll Back Malaria" campaign	SCIENCE			English	Editorial Material									Dept Int Dev, London SW1E 5JL, England		Nabarro, DN (corresponding author), Dept Int Dev, 94 Victoria St, London SW1E 5JL, England.	d-nabarro@dfid.gtnet.gov.uk						Butler D, 1997, NATURE, V390, P209, DOI 10.1038/36663; Mons B, 1998, SCIENCE, V279, P498, DOI 10.1126/science.279.5350.498; *WHO HLTH ORG, 1993, GLOB STRAT MAL CONTR; *WHO HLTH ORG AFR, AFR IN MAL CONTR 21, P98	4	114	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1998	280	5372					2067	2068		10.1126/science.280.5372.2067	http://dx.doi.org/10.1126/science.280.5372.2067			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9669961				2022-12-01	WOS:000074435900028
J	Nomura, M; Li, E				Nomura, M; Li, E			Smad2 role in mesoderm formation, left-right patterning and craniofacial development	NATURE			English	Article							SIGNALING PATHWAYS; NODAL EXPRESSION; GENE; MOUSE; GASTRULATION; PROTEINS; MUTATION; ACTIVIN	Signalling by the transforming growth factor-p (TGF-P) superfamily of proteins depends on the phosphorylation and activation of SMAD proteins by heteromeric complexes of ligand-specific type I and type II receptors with serine/threonine-kinase activity(1). The vertebrate SMAD family includes at least nine members, of which Smad2 has been shown to mediate signalling by activin and TGF-beta(2-5). In Xenopus, Smad2 can induce dorsal mesoderm, mimicking Vg-1, activin and nodal(2,4), Here we investigate the function of Smad2 in mammalian development by generating two independent Smad2 mutant alleles in mice by gene targeting, We show that homozygous mutant embryos fail to form an organized egg cylinder and lack mesoderm, like mutant mice lacking nodal(6,7) or ActRIB the gene encoding the activin type-I receptor(8). About 20 per cent of Smad2 heterozygous embryos have severe gastrulation defects and lack mandibles or eyes, indicating that the gene dosage of Smad2 is critical for signalling. Mice trans-heterozygous for both Smad2 and nodal mutations display a range of phenotypes, including gastrulation defects, complex craniofacial abnormalities such as cyclopia, and defects in left-right patterning, indicating that Smad2 may mediate nodal signalling in these developmental processes. Our results show that Smad2 function is essential for early development and for several patterning processes in mice.	Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp E,Cardiovasc Res Ctr, Charlestown, MA 02129 USA	Harvard University	Li, E (corresponding author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp E,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.							Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOGAN B, 1994, MANIPULATING MOUSE E, P51; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JONES CM, 1995, DEVELOPMENT, V121, P3651; Kaufman M.H., 1992, ATLAS MOUSE DEV; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, IN SITU HYBRIDIXATIO; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	496	520	4	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1998	393	6687					786	790		10.1038/31693	http://dx.doi.org/10.1038/31693			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW652	9655392				2022-12-01	WOS:000074433100049
J	Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S				Michaelsson, K; Baron, JA; Farahmand, BY; Johnell, O; Magnusson, C; Persson, PG; Persson, I; Ljunghall, S		Swedish Hip Fracture Study Grp	Hormone replacement therapy and risk of hip fracture: population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; BONE-DENSITY; ESTROGEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREVENTION; AGE	Objective: To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. Design: Population based case-control study. Setting: Six counties in Sweden. Subjects: 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. Main outcome measure: Use of hormone replacement therapy. Results: Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01), For every year of therapy the overall risk decreased by 6% (3% to 9%): 4%, (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously with a duration of use more than five years, was associated with all odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (-7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with skin patches gave similar risk estimates as oral regimens. Conclusions: Recent use of hormone replacement therapy is required for optimum fracture protection, but therapy can bt started several years after the menopause. The protective effect increases with duration of use, and an oestrogen-sparing effect is achieved when progestins are included in the regimen.	Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Stockholm Cty Council, Dept Epidemiol, S-17176 Stockholm, Sweden; Malmo Gen Hosp, Dept Orthopaed, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Dartmouth College; Dartmouth College; Karolinska Institutet; Stockholm County Council; Uppsala University; Uppsala University Hospital	Michaelsson, K (corresponding author), Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden.	Karl.Michaelsson@ortopedi.uu.se	Michaelsson, Karl/AAM-9094-2021	Michaelsson, Karl/0000-0003-2815-1217; Magnusson, Cecilia/0000-0002-8567-6725	NINR NIH HHS [NR 1 RO 1 CA58427] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1985, LANCET, V2, P800; Christiansen C, 1990, Osteoporos Int, V1, P7; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GALLAGHER JC, 1991, AM J MED, V90, P171; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Hammar ML, 1996, OBSTET GYNECOL, V88, P955; HEANEY RP, 1992, J INTERN MED, V231, P169, DOI 10.1111/j.1365-2796.1992.tb00520.x; HILLARD TC, 1991, CALCIFIED TISSUE INT, V49, pS55, DOI 10.1007/BF02555090; HORSMAN A, 1983, NEW ENGL J MED, V309, P1405, DOI 10.1056/NEJM198312083092301; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; MELTON LJ, 1987, BONE MINER, V2, P321; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P412, DOI 10.1016/S0002-9378(97)70207-2; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140-6736(97)90007-6; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	28	201	206	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 20	1998	316	7148					1858	1863						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ013	9632404				2022-12-01	WOS:000074686500016
J	Richardson, S; Grimwood, K; Gorrell, R; Palombo, E; Barnes, G; Bishop, R				Richardson, S; Grimwood, K; Gorrell, R; Palombo, E; Barnes, G; Bishop, R			Extended excretion of rotavirus after severe diarrhoea in young children	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSE; CELL-CULTURE; SERUM; INFECTION; GASTROENTERITIS; ENTERITIS	Background Rotaviruses are the major cause of severe childhood diarrhoea. Knowledge of the natural history of infection, including duration of intestinal virus shedding, is important in the understanding of transmission, sources of infection, and immune responses. Methods We carried out a study of rotavirus excretion in 37 children admitted to hospital with severe rotavirus diarrhoea. Sequential faecal specimens were collected from each child during 100 days of surveillance, and screened for rotavirus by EIA and by amplification of genome double-stranded RNA by reverse-transcription PCR. IgA coproantibody was estimated by EIA. Findings Duration of rotavirus excretion ranged from 4 to 57 days after onset of diarrhoea. Excretion ceased within 10 days in 16 (43%) children, and within 20 days in 26 (70%) children. Extended excretion was detected for 25-57 days in the remaining 11 (30%) children owing mainly to continued excretion of the primary infecting strain. Extended excretion was significantly associated with antirotavirus IgA coproantibody boosts during 100 days of surveillance (p=0.001, log-rank test), and with recurrence of mild diarrhoea symptoms during convalescence (p=0.006, Fisher's exact test). Interpretation Severe rotavirus disease in young children may be followed by extended excretion of rotavirus. The risk of transmission to others may be greater than previously believed. Extended excretion could also explain some cases of the postgastroenteritis syndrome.	Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Melbourne, Vic, Australia; Wellington Sch Med, Dept Paediat & Child Hlth, Wellington S, New Zealand	Royal Children's Hospital Melbourne; University of Otago	Bishop, R (corresponding author), Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Flemington Rd, Parkville, Vic 3052, Australia.	bishop@cryptic.rch.unimelb.edu.au	Palombo, Enzo/AAV-8632-2021; Grimwood, Keith/F-9334-2011; Gorrell, Rebecca/H-5259-2019; Gorrell, Rebecca/J-1454-2012	Palombo, Enzo/0000-0001-5889-1393; Gorrell, Rebecca/0000-0003-0728-3325; Grimwood, Keith/0000-0003-3174-9834				ALBERT MJ, 1984, J MED VIROL, V13, P377, DOI 10.1002/jmv.1890130409; BASS DM, 1991, DIARRHOEAL DIS, P139; BEARDS GM, 1984, J CLIN MICROBIOL, V19, P248, DOI 10.1128/JCM.19.2.248-254.1984; BISHOP R, 1990, MED VIROL, V9, P85; CHIARINI A, 1983, J GEN VIROL, V64, P1101, DOI 10.1099/0022-1317-64-5-1101; COULSON BS, 1990, J CLIN MICROBIOL, V28, P1367, DOI 10.1128/JCM.28.6.1367-1374.1990; COULSON BS, 1987, J CLIN MICROBIOL, V25, P509, DOI 10.1128/JCM.25.3.509-515.1987; COULSON BS, 1989, J VIROL METHODS, V26, P53, DOI 10.1016/0166-0934(89)90074-8; DAVIDSON GP, 1975, LANCET, V1, P242; DAVIDSON GP, 1983, INFECT IMMUN, V40, P447, DOI 10.1128/IAI.40.2.447-452.1983; EIDEN JJ, 1988, PEDIATR INFECT DIS J, V7, P564; ESTES MK, 1980, ARCH VIROL, V65, P187, DOI 10.1007/BF01317330; GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GRIMWOOD K, 1988, J CLIN MICROBIOL, V26, P732, DOI 10.1128/JCM.26.4.732-738.1988; GUARINO A, 1995, J PEDIATR GASTR NUTR, V20, P173, DOI 10.1097/00005176-199502000-00006; HJELT K, 1985, J PEDIATR GASTR NUTR, V4, P60, DOI 10.1097/00005176-198502000-00012; Kapikian A.Z., 1996, FIELDS VIROLOGY, P1657; KILBOURNE ED, 1973, J INFECT DIS, V128, P668, DOI 10.1093/infdis/128.5.668; KRAFT LISBETH M., 1961, PROC ANIMAL CARE PANEL, V11, P125; MISRA V, 1980, ICN UCLA S MOL CELL, V18, P727; NAGAYOSHI S, 1980, EUR J PEDIATR, V134, P99, DOI 10.1007/BF01846024; PALOMBO EA, 1993, ARCH VIROL, V133, P323, DOI 10.1007/BF01313772; RIEPENHOFFTALTY M, 1981, J MED VIROL, V8, P215, DOI 10.1002/jmv.1890080309; STALS F, 1984, J MED VIROL, V4, P333; VESIKARI T, 1981, ACTA PAEDIATR SCAND, V70, P717, DOI 10.1111/j.1651-2227.1981.tb05774.x; WARD RL, 1986, J INFECT DIS, V154, P871, DOI 10.1093/infdis/154.5.871; WARD RL, 1984, J CLIN MICROBIOL, V19, P748, DOI 10.1128/JCM.19.6.748-753.1984; WILDE J, 1991, LANCET, V337, P323, DOI 10.1016/0140-6736(91)90945-L; WILDE J, 1992, J INFECT DIS, V166, P507, DOI 10.1093/infdis/166.3.507; XU L, 1990, J VIROL METHODS, V27, P29, DOI 10.1016/0166-0934(90)90143-4	31	95	100	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 20	1998	351	9119					1844	1848		10.1016/S0140-6736(97)11257-0	http://dx.doi.org/10.1016/S0140-6736(97)11257-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV842	9652668				2022-12-01	WOS:000074347100011
J	Kurtzhals, JAL; Adabayeri, V; Goka, BQ; Akanmori, BD; Oliver-Commey, JO; Nkrumah, FK; Behr, C; Hviid, L				Kurtzhals, JAL; Adabayeri, V; Goka, BQ; Akanmori, BD; Oliver-Commey, JO; Nkrumah, FK; Behr, C; Hviid, L			Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM MALARIA; SERUM LEVELS; BONE-MARROW; IFN-GAMMA; IN-VITRO; CHILDREN; ANEMIA; IL-10; DISEASE	Background Severe anaemia is a major complication of malaria but little is known about its pathogenesis. Experimental models have implicated tumour necrosis factor (TNF) in induction of bone-marow suppression and eythrophagocytosis. Conversely, interleukin 10 (IL-10), which mediates feed-back regulation of TNF, stimulates bone-marrow function in vitro and counteracts anaemia in mice. We investigated the associations of these cytokines with malarial anaemia. Methods We enrolled 175 African children with malaria into two studies in 1995 and 1996. In the first study, children were classified as having severe anaemia (n=10), uncomplicated malaria (n=26), or cerebral anaemia (n=41). In the second study, patients were classified as having cerebral malaria (n=33) or being fully conscious (n=65), and the two groups were subdivided by measured haemoglobin as normal (>110 g/L), moderate anaemia (60-90 g/L), and severe anaemia (<50 g/L). IL-10 and TNF concentrations were measured by ELISA in plasma samples from all patients. Findings IL-10 concentrations were significantly lower in patients with severe anaemia than in all other groups. In 1995, geometric mean plasma IL-10 in patients with severe anaemia was 270 pg/mL (95% CI 152-482) compared with 725 pg/mL (465-1129) in uncomplicated malaria and 966 pg/mL (612-1526) in cerebral malaria (p<0.03). In 1996, fully conscious patients with severe anaemia also had significantly lower IL-10 concentrations than all other groups, including cerebral-malaria patients with severe anaemia and all patients with moderate anaemia (p<0.001). In both studies, TNF concentrations were significantly higher in cerebral malaria than in fully conscious patients (p<0.01). By contrast, the ratio of TNF to IL-10 was significantly higher in fully conscious patients with severe anaemia than in all other groups (p<0.001). Interpretation Our findings identify severe malarial anaemia as a distinct disorder in which insufficient IL-10 response to high TNF concentrations may have a central role.	Noguchi Mem Inst Med Res, Immunol Unit, Legon, Ghana; Korle Bu Teaching Hosp, Dept Child Hlth, Accra, Ghana; Copenhagen Univ Hosp, RHIMA Ctr, Ctr Medlocal Parisitol, Copenhagen, Denmark; Univ Copenhagen, Inst Med Microbiol & Immunol, DK-1168 Copenhagen, Denmark; Inst Pasteur, Unite Immunol Mol Parasites, CNRS, URA 1960, Paris, France	University of Ghana; University of Copenhagen; University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kurtzhals, JAL (corresponding author), Rigshosp, Dept M7641, DK-2200 Copenhagen N, Denmark.	jkcmp@ncs.com.gh	Kurtzhals, Jorgen/Y-3799-2019; Hviid, Lars/G-3705-2012; Kurtzhals, Jorgen AL/I-8921-2012	Kurtzhals, Jorgen/0000-0003-2760-8713; Hviid, Lars/0000-0002-1698-4927; 				ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x; CLARK IA, 1988, BRIT J HAEMATOL, V70, P99, DOI 10.1111/j.1365-2141.1988.tb02440.x; Clark IA, 1996, ADV PARASIT, V37, P1, DOI 10.1016/S0065-308X(08)60218-3; DAVIS TME, 1990, J CLIN INVEST, V86, P793, DOI 10.1172/JCI114776; ECKWALANGA M, 1994, P NATL ACAD SCI USA, V91, P8097, DOI 10.1073/pnas.91.17.8097; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; HO M, 1995, J INFECT DIS, V172, P838, DOI 10.1093/infdis/172.3.838; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; Jakobsen PH, 1996, CLIN EXP IMMUNOL, V105, P69, DOI 10.1046/j.1365-2249.1996.d01-718.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MALEFYT RD, 1991, J EXP MED, V174, P1209; McHugh S, 1996, EUR J IMMUNOL, V26, P1260, DOI 10.1002/eji.1830260612; MOLDAWER LL, 1989, FASEB J, V3, P1637, DOI 10.1096/fasebj.3.5.2784116; MOLYNEUX ME, 1989, Q J MED, V71, P441; Mordmuller BG, 1997, EUR CYTOKINE NETW, V8, P29; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; PEYRON F, 1994, CLIN EXP IMMUNOL, V95, P300, DOI 10.1111/j.1365-2249.1994.tb06527.x; PHILLIPS RE, 1992, BAILLIERE CLIN HAEM, V5, P315, DOI 10.1016/S0950-3536(11)80022-3; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; RALPH P, 1992, J IMMUNOL, V148, P808; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; TAVERNE J, 1994, IMMUNOLOGY, V82, P397; Tsukahara H, 1997, BLOOD, V90, P473; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; VANDERPOLL T, 1994, J EXP MED, V180, P1985, DOI 10.1084/jem.180.5.1985; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; VANVLASSELAER P, 1995, CLIN ORTHOP RELAT R, P103; Wang CQ, 1996, J CELL PHYSIOL, V166, P305, DOI 10.1002/(SICI)1097-4652(199602)166:2<305::AID-JCP8>3.0.CO;2-T; Waruiru CM, 1996, T ROY SOC TROP MED H, V90, P152, DOI 10.1016/S0035-9203(96)90120-0; WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734; WENISCH C, 1995, CLIN IMMUNOL IMMUNOP, V74, P115, DOI 10.1006/clin.1995.1017; WICKRAMASINGHE SN, 1987, BRIT J HAEMATOL, V66, P295, DOI 10.1111/j.1365-2141.1987.tb06913.x; YAP GS, 1994, INFECT IMMUN, V62, P357, DOI 10.1128/IAI.62.2.357-362.1994	36	248	252	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1998	351	9118					1768	1772		10.1016/S0140-6736(97)09439-7	http://dx.doi.org/10.1016/S0140-6736(97)09439-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZU444	9635949				2022-12-01	WOS:000074197600010
J	Arnsten, AFT				Arnsten, AFT			Research: Neuroscience - The biology of being frazzled	SCIENCE			English	Editorial Material							PREFRONTAL CORTEX; DOPAMINE TURNOVER; AMYGDALA; MODULATION; STRESS; RAT		Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06520 USA	Yale University	Arnsten, AFT (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	amy_arnsten@qm.yale.edu						AGGLETON JP, 1992, AMYGDALA; Arnsten AFT, 1998, ARCH GEN PSYCHIAT, V55, P362, DOI 10.1001/archpsyc.55.4.362; Arnsten AFT, 1997, PHARMACOL BIOCHEM BE, V58, P55, DOI 10.1016/S0091-3057(96)00477-7; Cahill L, 1997, ANN NY ACAD SCI, V821, P238, DOI 10.1111/j.1749-6632.1997.tb48283.x; CAHILL L, IN PRESS TRENDS NEUR; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; DAVIS M, 1994, BRAIN RES, V664, P207, DOI 10.1016/0006-8993(94)91972-0; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; Goldstein LE, 1996, J NEUROSCI, V16, P4787; LAMONT EW, IN PRESS BRAIN RES; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; MAZURE CM, 1995, DOES STRESS CUASE PS; Murphy BL, 1996, P NATL ACAD SCI USA, V93, P1325, DOI 10.1073/pnas.93.3.1325; PACKARD MG, 1994, P NATL ACAD SCI USA, V91, P8477, DOI 10.1073/pnas.91.18.8477; Stuss D.T., 1986, FRONTAL LOBES; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; Yang CR, 1996, J NEUROSCI, V16, P1922; Zahrt J, 1997, J NEUROSCI, V17, P8528	19	207	210	6	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1998	280	5370					1711	1712		10.1126/science.280.5370.1711	http://dx.doi.org/10.1126/science.280.5370.1711			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZU446	9660710				2022-12-01	WOS:000074197800028
J	Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG				Cole, ST; Brosch, R; Parkhill, J; Garnier, T; Churcher, C; Harris, D; Gordon, SV; Eiglmeier, K; Gas, S; Barry, CE; Tekaia, F; Badcock, K; Basham, D; Brown, D; Chillingworth, T; Connor, R; Davies, R; Devlin, K; Feltwell, T; Gentles, S; Hamlin, N; Holroyd, S; Hornby, T; Jagels, K; Krogh, A; McLean, J; Moule, S; Murphy, L; Oliver, K; Osborne, J; Quail, MA; Rajandream, MA; Rogers, J; Rutter, S; Seeger, K; Skelton, J; Squares, R; Squares, S; Sulston, JE; Taylor, K; Whitehead, S; Barrell, BG			Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence	NATURE			English	Article							ANTIGEN; RESISTANCE; SURVIVAL; LEPRAE; REPEAT; SEARCH; CELLS; GENES; DNA	Countless millions of people have died from tuberculosis, a chronic infectious disease caused by the tubercle bacillus. The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, has been determined and analysed in order to improve our understanding of the biology of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions. The genome comprises 4,411,529 base pairs, contains around 4,000 genes, and has a very high guanine + cytosine content that is reflected in the biased amino-acid content of the proteins. M. tuberculosis differs radically from other bacteria in that a very large portion of its coding capacity is devoted to the production of enzymes involved in lipogenesis and lipolysis, and to two new families of glycine-rich proteins with a repetitive structure that may represent a source of antigenic variation.	Sanger Ctr, Hinxton CB10 1SA, England; Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Mol Levures, F-75724 Paris 15, France; NIAID, TB Res Unit, Intracellular Parasites Lab, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA; Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark	Wellcome Trust Sanger Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Technical University of Denmark	Barrell, BG (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	stcole@pasteur.fr; barrell@sanger.ac.uk	Salami, Aysan/AAZ-6730-2020; Brosch, Roland/AAZ-3850-2021; Parkhill, Julian/G-4703-2011; Barry, Clifton E/ABE-7992-2020; Tekaia, Fredj/H-4553-2012; Azadbakht, Morteza/ABA-2569-2020; Barry, Clifton E/H-3839-2012; Quail, michael/ABE-6131-2020; Choobkar, Saeed/AAA-3212-2020; Brosch, Roland/ABB-4108-2021; Krogh, Anders/M-1541-2014	Brosch, Roland/0000-0003-2587-3863; Parkhill, Julian/0000-0002-7069-5958; Barry, Clifton E/0000-0002-2927-270X; Azadbakht, Morteza/0000-0001-8103-3506; Barry, Clifton E/0000-0002-2927-270X; Tekaia, Fredj/0000-0003-1934-2396; Gordon, Stephen/0000-0002-4833-5542; Murphy, Lee/0000-0001-6467-7449; Davies, Robert/0000-0002-9983-1378; Krogh, Anders/0000-0002-5147-6282	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission)		ABOUZEID C, 1991, INFECT IMMUN, V59, P2712, DOI 10.1128/IAI.59.8.2712-2718.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727; Av-Gay Y., 1997, MICROB COMP GENOMICS, V2, P63, DOI DOI 10.1089/OMI.1.1997.2.63; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; BARRY CE, IN PRESS PROG LIPID; BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bloom Barry R., 1994, P531; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Brennan Patrick J., 1994, P271; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Chan J, 1994, TUBERCULOSIS PATHOGE, P271; COLE ST, 1995, EUR RESPIR J, V8, pS701; COLE ST, 1994, FEMS MICROBIOL REV, V14, P139, DOI 10.1016/0168-6445(94)90003-5; Cole ST, 1998, NOVART FDN SYMP, V217, P160, DOI 10.1002/0470846526.ch12; Collins DM, 1996, TRENDS MICROBIOL, V4, P426, DOI 10.1016/0966-842X(96)10066-4; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; GOBIN J, 1995, P NATL ACAD SCI USA, V92, P5189, DOI 10.1073/pnas.92.11.5189; HERMANS PWM, 1992, J BACTERIOL, V174, P4157, DOI 10.1128/jb.174.12.4157-4165.1992; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KROGH A, 1994, NUCLEIC ACIDS RES, V22, P4768, DOI 10.1093/nar/22.22.4768; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Minnikin D.E., 1982, BIOL MYCOBACTERIA, V1, P95; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; RATLEDGE CR, 1982, BIOL MYCOBACTERIA, P53; Riley M., 1996, ESCHERICHIA COLI SAL, P2118; ROBERTSON BD, 1992, TRENDS GENET, V8, P422, DOI 10.1016/0168-9525(92)90325-X; Smith DR, 1997, GENOME RES, V7, P802, DOI 10.1101/gr.7.8.802; SNIDER DE, 1994, TUBERCULOSIS PATHOGE, P2; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; VEGALOPEZ F, 1993, INFECT IMMUN, V61, P2145; Wheeler Paul R., 1994, P353; YOUNG DB, 1997, NEW GENERATION VACCI, P631	50	6150	10743	19	702	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1998	393	6685					537	+		10.1038/31159	http://dx.doi.org/10.1038/31159			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634230	Bronze			2022-12-01	WOS:000074150100041
J	Jones, TW; Porter, P; Sherwin, RS; Davis, EA; O'Leary, P; Frazer, F; Byrne, G; Stick, S; Tamborlane, WV				Jones, TW; Porter, P; Sherwin, RS; Davis, EA; O'Leary, P; Frazer, F; Byrne, G; Stick, S; Tamborlane, WV			Decreased epinephrine responses to hypoglycemia during sleep	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; NOCTURNAL HYPOGLYCEMIA; HORMONAL COUNTERREGULATION; GLUCOSE COUNTERREGULATION; SUBSEQUENT HYPOGLYCEMIA; INSULIN THERAPY; NERVE ACTIVITY; HUMANS	Background In patients with type I diabetes mellitus, hypoglycemia occurs commonly during sleep and is frequently asymptomatic. This raises the question of whether sleep is associated with reduced counterregulatory-hormone responses to hypoglycemia. Methods We studied the counterregulatory-hormone responses to insulin-induced hypoglycemia in eight adolescent patients with type I diabetes and six age-matched normal subjects when they were awake during the day, asleep at night, and awake at night. In each study, the plasma glucose concentration was stabilized for 60 minutes at approximately 100 mg per deciliter (5.6 mmol per liter) and then reduced to 50 mg per deciliter (2.8 mmol per liter) and maintained at that concentration for 40 minutes. Plasma free insulin, epinephrine, norepinephrine, cortisol, and growth hormone were measured frequently during each study. Sleep was monitored by polysomnography. Results The plasma glucose and free insulin concentrations were similar in both groups during all studies. During the studies when the subjects were asleep, no one was awakened during the hypoglycemic phase, but during the final 30 minutes of the studies when the subjects were awake both the patients with diabetes and the normal subjects had symptoms of hypoglycemia. In the patients with diabetes, plasma epinephrine responses to hypoglycemia were blunted when they were asleep (mean [+/-SE] peak plasma epinephrine concentration, 70+/-14 pg per milliliter [382+/-76 pmol per liter]; P=0.3 for the comparison with base line), as compared with when they were awake during the day or night (238+/-39 pg per milliliter [1299+/-213 pmol per liter], P=0.004 for the comparison with base line, and 296+/-60 pg per milliliter [1616+/-327 pmol per liter], P=0.004, respectively). The patients' plasma norepinephrine responses were also reduced during sleep, whereas their plasma cortisol concentrations did not increase and their plasma growth hormone concentrations increased, slightly. The patterns of counterregulatory-hormone responses in the normal subjects were similar. Conclusions Sleep impairs counterregulatory-hormone responses to hypoglycemia in patients with diabetes and normal subject. (C) 1998, Massachusetts Medical Society.	Princess Margaret Hosp Children, Dept Endocrinol & Diabet, Perth, WA 6001, Australia; Princess Margaret Hosp Children, Dept Resp Med, Perth, WA 6001, Australia; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	University of Western Australia; University of Western Australia; Yale University; Yale University	Jones, TW (corresponding author), Princess Margaret Hosp Children, Dept Endocrinol & Diabet, Box D184, Perth, WA 6001, Australia.		Porter, Paul/R-2362-2018; Stick, Stephen/O-5683-2014; Stick, Stephen/GZG-7584-2022; Stick, Stephen/AAA-5945-2021	Porter, Paul/0000-0001-9051-589X; Stick, Stephen/0000-0002-5386-8482; O'Leary, Peter/0000-0001-9375-0801; Jones, Timothy/0000-0002-7989-1998; Davis, Elizabeth/0000-0003-4244-5473	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06020, RR00125] Funding Source: Medline; PHS HHS [10495] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; BENDTSON I, 1993, ACTA ENDOCRINOL-COP, V128, P109, DOI 10.1530/acta.0.1280109; BOLLI G, 1983, DIABETES, V32, P134, DOI 10.2337/diabetes.32.2.134; CADUFF F, 1989, SCHWEIZ MED WSCHR, V119, P9; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; CRYER PE, 1994, DIABETES CARE, V17, P734, DOI 10.2337/diacare.17.7.734; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; Davis EA, 1997, DIABETES CARE, V20, P22, DOI 10.2337/diacare.20.1.22; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; GALE EAM, 1979, LANCET, V1, P1049; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HORNYAK M, 1991, BRAIN, V114, P1281, DOI 10.1093/brain/114.3.1281; Kryger M, 1994, PRINCIPLES PRACTICE; Maggs DG, 1997, DIABETES, V46, P70, DOI 10.2337/diabetes.46.1.70; OKADA H, 1991, NEUROLOGY, V41, P1961, DOI 10.1212/WNL.41.12.1961; Porter PA, 1996, ARCH DIS CHILD, V75, P120, DOI 10.1136/adc.75.2.120; SHALWITZ RA, 1990, J PEDIATR-US, V116, P685, DOI 10.1016/S0022-3476(05)82648-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMONSON DC, 1985, ANN INTERN MED, V103, P184, DOI 10.7326/0003-4819-103-2-184; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233	20	181	181	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1998	338	23					1657	1662		10.1056/NEJM199806043382303	http://dx.doi.org/10.1056/NEJM199806043382303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZR451	9614256	Bronze			2022-12-01	WOS:000073978000003
J	Altare, F; Durandy, A; Lammas, D; Emile, JF; Lamhamedi, S; Le Deist, F; Drysdale, P; Jouanguy, E; Doffinger, R; Bernaudin, F; Jeppsson, O; Gollob, JA; Meinl, E; Segal, AW; Fischer, A; Kumararatne, D; Casanova, JL				Altare, F; Durandy, A; Lammas, D; Emile, JF; Lamhamedi, S; Le Deist, F; Drysdale, P; Jouanguy, E; Doffinger, R; Bernaudin, F; Jeppsson, O; Gollob, JA; Meinl, E; Segal, AW; Fischer, A; Kumararatne, D; Casanova, JL			Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency	SCIENCE			English	Article							IFN-GAMMA PRODUCTION; HUMAN T-CELLS; INFECTION; CYTOKINE; RESISTANCE; COMPLEX; PROTEIN; MICE	In humans, interferon gamma (IFN-gamma) receptor deficiency leads to a predisposition to mycobacterial infections and impairs the formation of mature granulomas. Interleukin-12 (IL-12) receptor deficiency was found in otherwise healthy individuals with mycobacterial infections. Mature granulomas were seen, surrounded by T cells and centered with epithelioid and multinucleated giant cells, yet reduced IFN-gamma concentrations were found to be secreted by activated natural killer and T cells. Thus, IL-12-dependent IFN-gamma secretion in humans seems essential in the control of mycobacterial infections, despite the formation of mature granulomas due to IL-12-independent IFN-gamma secretion.	Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France; UCL, Dept Med, London WC1 E6JJ, England; Univ Erlangen Nurnberg, D-91054 Erlangen, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Hosp, Dept Pediat, S-14501 Norsborg, Sweden; Ctr Hosp Intercommunal, Serv Pediat, F-94010 Creteil, France; Hop Paul Brousse, Serv Anatomopathol, F-94804 Villejuif, France; Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; University of Erlangen Nuremberg; Harvard University; Dana-Farber Cancer Institute; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; University of Birmingham	Casanova, JL (corresponding author), Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France.	casanova@ceylan.necker.fr	Casanova, Jean-Laurent/I-3418-2017; altare, frederic/K-8664-2015; Jouanguy, Emmanuelle/H-7901-2017; Durandy, Anne/H-7475-2017	altare, frederic/0000-0002-5077-4616; Jouanguy, Emmanuelle/0000-0002-7358-9157; Durandy, Anne/0000-0001-7706-8466; Meinl, Edgar/0000-0002-2570-6785; Casanova, Jean-Laurent/0000-0002-7782-4169; Segal, Anthony/0000-0001-7602-9043				Altare F, 1998, AM J HUM GENET, V62, P723, DOI 10.1086/301750; ALTARE F, 1997, RES INFECT DIS B I P, V95, P143; ANDERSON P, 1990, J IMMUNOL, V144, P574; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CASANOVA JL, 1995, LANCET, V346, P581, DOI 10.1016/S0140-6736(95)91421-8; Casanova JL, 1996, PEDIATRICS, V98, P774; CASANOVA JL, IN PRESS PRIMARY IMM; CHUA AO, 1994, J IMMUNOL, V153, P128; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; de Jong R, 1998, SCIENCE, V280, P1435; deJong R, 1997, J IMMUNOL, V159, P786; Emile JF, 1997, J PATHOL, V181, P25, DOI 10.1002/(SICI)1096-9896(199701)181:1<25::AID-PATH747>3.0.CO;2-Z; Frucht DM, 1996, J IMMUNOL, V157, P411; Gollob JA, 1997, EUR J IMMUNOL, V27, P647, DOI 10.1002/eji.1830270311; Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Jouanguy E, 1997, J INTERF CYTOK RES, V17, P583, DOI 10.1089/jir.1997.17.583; JOUANGUY E, UNPUB; Kohno K, 1997, J IMMUNOL, V158, P1541; Lamhamedi S, 1998, INT J MOL MED, V1, P415; LEDEIST F, 1987, J IMMUNOL, V138, P423; LEVIN M, 1995, LANCET, V345, P79, DOI 10.1016/S0140-6736(95)90059-4; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mattner F, 1997, INFECT IMMUN, V65, P4378, DOI 10.1128/IAI.65.11.4378-4383.1997; Mattner F, 1996, EUR J IMMUNOL, V26, P1553, DOI 10.1002/eji.1830260722; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; MEINL E, 1995, IMMUNOL TODAY, V16, P55, DOI 10.1016/0167-5699(95)80087-5; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; Modlin RL, 1995, RES IMMUNOL, V146, P526, DOI 10.1016/0923-2494(96)83027-6; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PierreAudigier C, 1997, CLIN INFECT DIS, V24, P982, DOI 10.1093/clinids/24.5.982; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Romani L, 1997, CLIN MICROBIOL REV, V10, P611, DOI 10.1128/CMR.10.4.611; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Wu CY, 1997, J IMMUNOL, V159, P1658	39	649	666	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1998	280	5368					1432	1435		10.1126/science.280.5368.1432	http://dx.doi.org/10.1126/science.280.5368.1432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603732				2022-12-01	WOS:000073883400055
J	Astin, JA				Astin, JA			Why patients use alternative medicine - Results of a national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEMENTARY MEDICINE; UNITED-STATES; CARE; PRACTITIONERS; SOMATIZATION; PREVALENCE; THERAPIES; ATTITUDES; BEHAVIORS; DOCTORS	Context.-Research both in the United States and abroad suggests that significant numbers of people are involved with various forms of alternative medicine. However, the reasons for such use are, at present, poorly understood. Objective.-To investigate possible predictors of alternative health care use. Methods.-Three primary hypotheses were tested. People seek out these alternatives because (1) they are dissatisfied in some way with conventional treatment; (2) they see alternative treatments as offering more personal autonomy and control over health care decisions; and (3) the alternatives are seen as more compatible with the patients' values, worldview, or beliefs regarding the nature and meaning of health and illness. Additional predictor variables explored included demographics and health status. Design.-A written survey examining use of alternative health care, health status, values, and attitudes toward conventional medicine. Multiple logistic regression analyses were used in an effort to identify predictors of alternative health care use. Setting and Participants.-A total of 1035 individuals randomly selected from a panel who had agreed to participate in mail surveys and who live throughout the United States. Main Outcome Measure.-Use of alternative medicine within the previous year. Results.-The response rate was 69%. The following variables emerged as predictors of alternative health care use: more education (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.1-1.3); poorer health status (OR, 1.3, 95% CI, 1.1-1.5); a holistic orientation to health (OR, 1.4; 95% CI, 1.1-1.9); having had a transformational experience that changed the person's worldview (OR, 1.8; 95% CI, 1.3-2.5); any of the following health problems: anxiety (OR, 3.1; 95% CI, 1.6-6.0); back problems (OR, 2.3; 95% CI, 1.7-3.2); chronic pain (OR, 2.0; 95% CI, 1.1-3.5); urinary tract problems (OR, 2.2; 95% CI, 1.3-3.5); and classification in a cultural group identifiable by their commitment to environmentalism, commitment to feminism, and interest in spirituality and personal growth psychology (OR, 2.0; 95% CI, 1.4-2.7). Dissatisfaction with conventional medicine did not predict use of alternative medicine. Only 4.4% of those surveyed reported relying primarily on alternative therapies. Conclusion.-Along with being more educated and reporting poorer health status, the majority of alternative medicine users appear to be doing so not so much as a result of being dissatisfied with conventional medicine but largely because they find these health care alternatives to be more congruent with their own values, beliefs, and philosophical orientations toward health and life.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA	Stanford University	Astin, JA (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, 730 Welch Rd, Palo Alto, CA 94304 USA.							AVINA RL, 1978, WESTERN J MED, V128, P366; BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; Bernstein JH, 1997, SOC SCI MED, V44, P1341, DOI 10.1016/S0277-9536(97)84076-2; BORKAN J, 1994, J FAM PRACTICE, V39, P545; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHARLTON BG, 1993, J ROY SOC MED, V86, P125; DEAN K, 1981, SOC SCI MED-MED SOC, V15, P673, DOI 10.1016/0271-7123(81)90091-2; Dimmock S, 1996, CLIN RHEUMATOL, V15, P478, DOI 10.1007/BF02229645; Duggan R M, 1995, Altern Ther Health Med, V1, P28; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Fuller Robert, 1989, ALTERNATIVE MED AM R; FURNHAM A, 1988, SOC SCI MED, V26, P685, DOI 10.1016/0277-9536(88)90060-3; FURNHAM A, 1993, BRIT J CLIN PSYCHOL, V32, P237, DOI 10.1111/j.2044-8260.1993.tb01051.x; FURNHAM A, 1994, J CLIN PSYCHOL, V50, P458, DOI 10.1002/1097-4679(199405)50:3<458::AID-JCLP2270500318>3.0.CO;2-V; JENSEN P, 1990, ACTA DERM-VENEREOL, V70, P425; KLEINMAN A, 1984, ALTERNATIVE MED POPU; Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337; Kuhn TS., 1970, STRUCTURE SCI REVOLU, P174; LEVIN JS, 1986, SOC SCI MED, V23, P889, DOI 10.1016/0277-9536(86)90217-0; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McGuire Meredith, 1988, RITUAL HEALING SUBUR; Millar WJ, 1997, CAN J PUBLIC HEALTH, V88, P154, DOI 10.1007/BF03403879; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Ostrow MJ, 1997, J ACQ IMMUN DEF SYND, V15, P115, DOI 10.1097/00042560-199706010-00003; OTHS K, 1994, CULT MED PSYCHIAT, V18, P83, DOI 10.1007/BF01384878; PERKIN MR, 1994, J ROY SOC MED, V87, P523; RAY PH, 1997, AM DEMOGRAPHICS  FEB; RAY PH, IN PRESS CULTURAL CR; RIESMANN F, 1994, SOC POLICY       SPR, P53; SALMON JW, 1984, ALTERNATIVE MED POPU; SUTHERLAND LR, 1994, J CLIN GASTROENTEROL, V19, P194, DOI 10.1097/00004836-199410000-00004; Vincent C, 1996, BRIT J CLIN PSYCHOL, V35, P37, DOI 10.1111/j.2044-8260.1996.tb01160.x	34	1897	1941	7	228	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1998	279	19					1548	1553		10.1001/jama.279.19.1548	http://dx.doi.org/10.1001/jama.279.19.1548			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZN087	9605899	Bronze			2022-12-01	WOS:000073608100033
J	Lees, KR				Lees, KR			Does neuroprotection improve stroke outcome?	LANCET			English	Editorial Material							DOUBLE-BLIND; TRIAL		Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.							Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bath P, 1997, BRIT MED J, V315, P1167; CANDELISE L, 1995, LANCET, V346, P1509; Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6; Diener HC, 1998, CEREBROVASC DIS, V8, P172, DOI 10.1159/000015847; Diener HC, 1996, STROKE, V27, P76, DOI 10.1161/01.STR.27.1.76; DONNAN GA, 1995, LANCET, V345, P578; Dyker Alexander G., 1997, Stroke, V28, P233; Grotta J, 1997, STROKE, V28, P2338, DOI 10.1161/01.STR.28.12.2338; Hommel M, 1996, NEW ENGL J MED, V335, P145; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; MUIR KW, 1996, CEREBROVASC DIS, V6; Ronning OM, 1998, STROKE, V29, P58, DOI 10.1161/01.STR.29.1.58; Sandercock P, 1997, LANCET, V349, P1569; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303	18	47	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1998	351	9114					1447	1448		10.1016/S0140-6736(05)78865-6	http://dx.doi.org/10.1016/S0140-6736(05)78865-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP017	9605797				2022-12-01	WOS:000073707300003
J	Evrard, YA; Lun, Y; Aulehla, A; Gan, L; Johnson, RL				Evrard, YA; Lun, Y; Aulehla, A; Gan, L; Johnson, RL			lunatic fringe is an essential mediator of somite segmentation and patterning	NATURE			English	Article							SIGNALING MOLECULE; GENE FAMILY; EXPRESSION; NOTCH1; REGION; CELLS	The gene lunatic fringe encodes a secreted factor with significant sequence similarity to the Drosophila gene fringe(1-5). fringe has been proposed to function as a boundary-specific signalling molecule in the wing imaginal disc, where it is required to localize signalling activity by the protein Notch to the presumptive wing margin(3,6). By targeted disruption in mouse embryos, we show here that lunatic fringe is likewise required for boundary formation. lunatic fringe mutants fail to form boundaries between individual GRAPHICS somites, the initial segmental unit of the vertebrate trunk. Hn addition, the normal alternating rostral-caudal pattern of the semitic mesoderm is disrupted, suggesting that intersomitic boundary formation and rostral-caudal patterning of somites are mechanistically Linked by a process that requires lunatic fringe activity. As a result, the derivatives of the somitic mesoderm, especially the axial skeleton, are severely disorganized in lunatic fringe mutants. Taken together our results demonstrate an essential function for a vertebrate fringe homologue and suggest a model in which lunatic fringe modulates Notch signalling in the segmental plate to regulate somitogenesis and rostral-caudal patterning of somites simultaneously.	Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Johnson, RL (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.			Aulehla, Alexander/0000-0003-3487-9239				BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Christ B, 1998, ANAT EMBRYOL, V197, P1; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; CONLON RA, 1995, DEVELOPMENT, V121, P1533; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gossler A, 1998, CURR TOP DEV BIOL, V38, P225; Hogan B., 2014, MANIPULATING MOUSE E; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jen WC, 1997, DEVELOPMENT, V124, P1169; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Mansouri A, 1997, DEV DYNAM, V210, P53, DOI 10.1002/(SICI)1097-0177(199709)210:1<53::AID-AJA6>3.0.CO;2-0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; STERN CD, 1987, DEVELOPMENT, V99, P261; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; WILLIAMS R, 1995, MECH DEVELOP, V53, P357, DOI 10.1016/0925-4773(95)00451-3; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	28	340	350	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1998	394	6691					377	381		10.1038/28632	http://dx.doi.org/10.1038/28632			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103QF	9690473				2022-12-01	WOS:000074968800053
J	Hertz, M; Kouskoff, V; Nakamura, T; Nemazee, D				Hertz, M; Kouskoff, V; Nakamura, T; Nemazee, D			V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling	NATURE			English	Article							POSITIVE SELECTION; GERMINAL-CENTERS; CELLS; DEATH; THYMOCYTES; TOLERANCE; APOPTOSIS	In lymphocytes, DNA recombinations that generate the antigen-receptor genes can sometimes be reinduced in receptor-bearing cells in a process called receptor editing, which modifies the specificity of the receptor for antigen. In immature B lymphocytes, B-cell antigen receptor (BCR) signalling stimulates immune tolerance by receptor editing(1-5). More mature splenic B cells can also be induced to undergo V(D)J recombination, which generates diversity in the immune system, either by immunization with foreign proteins(6-9) or by stimulation in vitro with interleukin-4 and lipopolysaccharides(8-10). Here we show that immune tolerance is unlikely to induce V(D)J recombination in mature B cells, because BCR ligation actively inhibits V(D)J recombination induced by interleukin-ii and lipopolysaccharide. Furthermore, immunization of immunoglobulin transgenic mice with ligands of varying avidities for the BCR showed that low-avidity antigen could induce strong V(D)J recombination, whereas non-binding or high-avidity ligands could not. These data suggest that V(D)J recombination induced during the immune response modifies the antigen receptors of B cells with weak, but not strong, reactivity to antigen, potentially rescuing cells with improved receptor affinity and promoting their contribution to the immune response. Thus BCR signalling regulates V(D)J recombination in both tolerance and immunity, but in strikingly different ways.	Natl Jewish Med & Res Ctr, Div Basic Sci, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Tokyo, Inst Med Sci, Dept Infect Dis & Appl Immunol, Minato Ku, Tokyo 108, Japan	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Tokyo	Nemazee, D (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, Dept Pediat, Denver, CO 80206 USA.				NIAID NIH HHS [R01 AI033608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hertz M, 1997, IMMUNITY, V6, P429, DOI 10.1016/S1074-7613(00)80286-1; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1998, J EXP MED, V187, P795, DOI 10.1084/jem.187.5.795; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KOUSKOFF V, UNPUB J EXP MED; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MARRACK P, 1993, IMMUNOL REV, V133, P119, DOI 10.1111/j.1600-065X.1993.tb01513.x; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; PAPAVASILIOU E, 1997, SCIENCE, V278, P298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009	24	106	110	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1998	394	6690					292	295		10.1038/28419	http://dx.doi.org/10.1038/28419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	101CK	9685161	Green Accepted			2022-12-01	WOS:000074851900052
J	Senn, S				Senn, S			In the blood: proposed new requirements for registering generic drugs	LANCET			English	Editorial Material							BIOEQUIVALENCE		UCL, Dept Stat Sci, London WC1E 6BT, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Senn, S (corresponding author), UCL, Dept Stat Sci, Mortimer St, London WC1E 6BT, England.		Senn, Stephen J/A-8101-2008; Senn, Stephen/B-2903-2013	Senn, Stephen/0000-0002-7558-8473				ANDERSON S, 1990, J PHARMACOKINET BIOP, V18, P259, DOI 10.1007/BF01062202; *FDA, 1997, IN IV BIOEQ STUD BAS; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Senn S., 2021, STAT ISSUES DRUG DEV; Senn S, 1993, CROSS OVER TRIALS CL, V2nd; SHEINER LB, 1992, STAT MED, V11, P1777, DOI 10.1002/sim.4780111311; Steinijans V. W., 1993, Clinical Research and Regulatory Affairs, V10, P203, DOI 10.3109/10601339309079568; Steinijans V. W., 1995, DRUG INF J, V29, P1055	9	29	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 11	1998	352	9122					85	86						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZZ859	9672271				2022-12-01	WOS:000074775100007
J	Henry, GL; Melton, DA				Henry, GL; Melton, DA			Mixer, a homeobox gene required for endoderm development	SCIENCE			English	Article							MESSENGER-RNA; XENOPUS EMBRYOS; TGF-BETA; SPEMANNS-ORGANIZER; EXPRESSION; INDUCTION; LAEVIS; MESODERM; SEQUENCE; PROTEINS	An expression cloning strategy in Xenopus laevis was used to isolate a homeobox-containing gene, Mixer, that can cause embryonic cells to form endoderm. Mixer transcripts are found specifically in the prospective endoderm of gastrula, which coincides with the time and place that endodermal cells become histologically distinct and irreversibly determined. Loss-of-function studies with a dominant inhibitory mutant demonstrate that Mixer activity is required for endoderm development. In particular, the expression of Sox17 alpha and Sox17 beta, two previously identified endodermal determinants, require Mixer function. Together, these data suggest that Mixer is an embryonic transcription factor involved in specifying the endodermal germ layer.	Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Melton, DA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Howard Hughes Med Inst, 7 Divin Ave, Cambridge, MA 02138 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BAUER DV, 1994, DEVELOPMENT, V120, P1179; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GORDON JI, 1983, J BIOL CHEM, V258, P3356; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HENRY G, UNPUB; Henry GL, 1996, DEVELOPMENT, V122, P1007; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; KESSLER DA, UNPUB; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Mead PE, 1996, NATURE, V382, P357, DOI 10.1038/382357a0; Okada T. S., 1954, Memoirs of the College of Science Kyoto, V20B, P157; Okada T. S., 1954, Memoirs of the College of Science Kyoto, V21B, P1; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SMITH JC, 1991, CELL, V71, P731; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; TAKATA CHINAKI, 1960, EMBRYOLOGIA, V5, P38, DOI 10.1111/j.1440-169X.1960.tb00265.x; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WRIGHT CVE, 1988, DEVELOPMENT, V105, P787	35	167	179	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 3	1998	281	5373					91	96		10.1126/science.281.5373.91	http://dx.doi.org/10.1126/science.281.5373.91			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZZ009	9651252				2022-12-01	WOS:000074685800044
J	Seidemann, E; Zohary, E; Newsome, WT				Seidemann, E; Zohary, E; Newsome, WT			Temporal gating of neural signals during performance of a visual discrimination task	NATURE			English	Article							AREA MT; FUNCTIONAL-PROPERTIES; RESPONSE PROPERTIES; ATTENTION; MACAQUE; DIRECTION; NEURONS; MONKEY; MICROSTIMULATION; ORGANIZATION	The flow of neural signals within the cerebral cortex must be subject to multiple controls as behaviour unfolds in time. In a visual discrimination task that includes a delay period, the transmission of sensory signals to circuitry that mediates memory, decision-making and motor-planning must be governed closely by 'filtering' or 'gating' mechanisms so that extraneous events occurring before, during or after presentation of the critical visual stimulus have little or no effect on the subject's behavioural responses. Here we study one such mechanism physiologically by applying electrical microstimulation(1-3) to columns of directionally selective neurons in the middle temporal visual area(4-9) at varying times during single trials of a direction-discrimination task. The behavioural effects of microstimulation varied strikingly according to the timing of delivery within the trial, indicating that signals produced by microstimulation may be subject to active 'gating'. Our results show several important features of this gating process: first, signal flow is modulated upwards on onset of the visual stimulus and downwards, typically with a slower time course, after stimulus offset; second, gating efficacy can be modified by behavioural training; and third, gating is implemented primarily downstream of the middle temporal visual area.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA; Hebrew Univ Jerusalem, Inst Life Sci, Dept Neurobiol, IL-91904 Jerusalem, Israel	Howard Hughes Medical Institute; Stanford University; Stanford University; Hebrew University of Jerusalem	Seidemann, E (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019	Seidemann, Eyal/0000-0003-2841-5948				ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; CORBETTA M, 1991, J NEUROSCI, V11, P2383; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Cox DR, 2018, ANAL BINARY DATA; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DUBNER R, 1971, BRAIN RES, V35, P528, DOI 10.1016/0006-8993(71)90494-X; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2190; MOUNTCASTLE VB, 1984, DYNAMIC ASPECTS NEOC, P159; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302	19	60	60	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1998	394	6688					72	75		10.1038/27906	http://dx.doi.org/10.1038/27906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZY030	9665129				2022-12-01	WOS:000074579600050
J	Phoolcharoen, W				Phoolcharoen, W			HIV/AIDS prevention in Thailand: Success and challenges	SCIENCE			English	Editorial Material							YOUNG MEN; NORTHERN THAILAND; INFECTION		Minist Publ Hlth, Dept Communicable Dis Control, Amphur Muang Nonthaburi 11000, Thailand	Ministry of Public Health - Thailand	Phoolcharoen, W (corresponding author), Minist Publ Hlth, Dept Communicable Dis Control, Tivanont Rd, Amphur Muang Nonthaburi 11000, Thailand.							*ARM MED SC RES I, 1998, REP HIV PREV RAT NEW; CARR JK, 1994, J ACQ IMMUN DEF SYND, V7, P1270; Celentano DD, 1996, JAMA-J AM MED ASSOC, V275, P122, DOI 10.1001/jama.275.2.122; CELENTANO DD, 1993, AIDS, V7, P1647, DOI 10.1097/00002030-199312000-00016; Epidemiology Division, 1998, REP HIV SER SENT SUR; FORD NJ, 1994, AIDS CARE, V6, P517, DOI 10.1080/09540129408258667; FRERICHS R, 1995, J PUBLIC HLTH, V8, P20; HAVANON N, 1993, STUD FAMILY PLANN, V24, P1, DOI 10.2307/2939210; KHAMBOONRUANG C, 1996, 10 INT C AIDS VANC C; Lyttleton C, 1996, Med Anthropol, V16, P363; Mills S, 1997, AIDS, V11, pS43; *NAT EC SOC DEV BO, 1998, EST UN RES 1997 EC C; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; PORAPAKKHAM Y, 1996, AIDSCAP POLICY WORKI; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; Sawanpanyalert P, 1996, J INFECT DIS, V174, P870, DOI 10.1093/infdis/174.4.870; SITTITRAL W, 1992, THAI SEXUAL BEHAV; Sugisaki Shigemitsu, 1998, 1998 HARV AS BUS C H; [No title captured]	19	50	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1873	1874		10.1126/science.280.5371.1873	http://dx.doi.org/10.1126/science.280.5371.1873			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669947				2022-12-01	WOS:000074323800043
J	Zhou, W; King, WM				Zhou, W; King, WM			Premotor commands encode monocular eye movements	NATURE			English	Article							PONTINE RETICULAR-FORMATION; ALERT MONKEYS; NEURONS; ABDUCENS	Binocular coordination of eye movements is essential for stereopsis (depth perception) and to prevent double vision. More than a century ago, Hering and Helmholtz debated the neural basis of binocular coordination. Helmholtz(1) believed that each eye is controlled independently and that binocular coordination is learned, Hering(2) believed that both eyes are innervated by common command signals that yoke the eye movements (Hering's law of equal innervation). Here we provide evidence that Hering's law is unlikely to be correct. We show that premotor neurons in the paramedian pontine reticular formation that were thought to encode conjugate(3-6) velocity commands for saccades (rapid eye movements) actually encode monocular commands for either right or left eye saccades, However, 66% of the abducens motor neurons, which innervate the ipsilateral lateral rectus muscle, fire as a result of movements of either eye. The distribution of sensitivity to ipsilateral and contralateral eye movements across the abducens motor neuron pool may provide a basis for learning binocular coordination in infancy and adapting it throughout life.	Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Zhou, W (corresponding author), Univ Mississippi, Med Ctr, Dept Neurol, 2500 N State St, Jackson, MS 39216 USA.			King, Michael/0000-0002-7848-6595				FUCHS AF, 1970, J NEUROPHYSIOL, V33, P382, DOI 10.1152/jn.1970.33.3.382; FUCHS AF, 1985, ANNU REV NEUROSCI, V8, P307, DOI 10.1146/annurev.ne.08.030185.001515; Helmholtz J. A., 1910, TREATISE PHYSL OPTIC; HENN V, 1976, BRAIN RES, V108, P307, DOI 10.1016/0006-8993(76)90188-8; Henn V, 1982, Hum Neurobiol, V1, P87; HENN V, 1973, J NEUROPHYSIOL, V36, P115, DOI 10.1152/jn.1973.36.1.115; Hering E., 1977, THEORY BINOCULAR VIS; KELLER EL, 1974, J NEUROPHYSIOL, V37, P316, DOI 10.1152/jn.1974.37.2.316; King W. M., 1997, Society for Neuroscience Abstracts, V23, P1559; LUSCHEI ES, 1972, J NEUROPHYSIOL, V35, P445, DOI 10.1152/jn.1972.35.4.445; MAYS LE, 1984, J NEUROPHYSIOL, V52, P743, DOI 10.1152/jn.1984.52.4.743	11	159	161	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1998	393	6686					692	695		10.1038/31489	http://dx.doi.org/10.1038/31489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV288	9641680				2022-12-01	WOS:000074289600055
J	Casari, G; De Fusco, M; Ciarmatori, S; Zeviani, M; Mora, M; Fernandez, P; De Michele, G; Filla, A; Cocozza, S; Marconi, R; Durr, A; Fontaine, B; Ballabio, A				Casari, G; De Fusco, M; Ciarmatori, S; Zeviani, M; Mora, M; Fernandez, P; De Michele, G; Filla, A; Cocozza, S; Marconi, R; Durr, A; Fontaine, B; Ballabio, A			Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; CELL-ADHESION; GENE; FAMILY; LOCUS; LINKAGE; COMPLEX; MEMBER; YEAST	Hereditary spastic paraplegia (HSP) is characterized by progressive weakness and spasticity of the lower limbs due to degeneration of corticospinal axons. We found that patients from a chromosome 16q24.3-linked HSP family are homozygous for a 9.5 kb deletion involving a gene encoding a novel protein, named Paraplegin. Two additional Paraplegin mutations, both resulting in a frameshift, were found in a complicated and in a pure form of HSP. Paraplegin is highly homologous to the yeast mitochondrial ATPases, AFG3, RCA1, and YME1, which have both proteolytic and chaperon-like activities at the inner mitochondrial membrane. Immunofluorescence analysis and import experiments showed that Paraplegin localizes to mitochondria. Analysis of muscle biopsies from two patients carrying Paraplegin mutations showed typical signs of mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type disorders.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Natl Neurol Inst C Besta, I-20132 Milan, Italy; Univ Naples Federico II, CNR, Dept Neurol, I-80136 Naples, Italy; Univ Naples Federico II, CNR, Dept Mol & Cellular Biol Pathol, I-80136 Naples, Italy; Univ Naples Federico II, CNR, CEOS, I-80136 Naples, Italy; Misericordia Hosp, Dept Neurol, I-58100 Grosseto, Italy; Hop La Pitie Salpetriere, Federat Neurol, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, F-75013 Paris, France; Univ Vita Salute, I-20132 Milan, Italy; Childrens Hosp Bambino Gesu, I-00165 Rome, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); IRCCS Istituto Neurologico Besta; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Vita-Salute San Raffaele University; IRCCS Bambino Gesu	Ballabio, A (corresponding author), Telethon Inst Genet & Med, I-20132 Milan, Italy.		De Fusco, Maurizio/AAN-7358-2020; Zeviani, Massimo/AAU-2632-2021; Cocozza, Sergio/F-6488-2010; Zeviani, Massimo/K-2891-2014; Silva, Patricio Fernandez/U-2256-2017; BALLABIO, Andrea/AAL-2672-2020; Casari, Giorgio/J-3070-2018; Mora, Marina/J-2883-2018	Zeviani, Massimo/0000-0002-9067-5508; Silva, Patricio Fernandez/0000-0001-8971-7355; BALLABIO, Andrea/0000-0003-1381-4604; Casari, Giorgio/0000-0002-0115-8980; Mora, Marina/0000-0002-5765-2320	Telethon [767, TGM06S01, TGM97000] Funding Source: Medline	Telethon(Fondazione Telethon)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS PW, 1984, LAB INVEST, V50, P147; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BONNEAU D, 1993, J MED GENET, V30, P381, DOI 10.1136/jmg.30.5.381; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMICHELE G, 1998, IN PRESS AM J HUM GE; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Durbin H, 1997, P NATL ACAD SCI USA, V94, P14578, DOI 10.1073/pnas.94.26.14578; DURBIN H, 1994, GENOMICS, V19, P181, DOI 10.1006/geno.1994.1038; DURR A, 1994, NEUROLOGY, V44, P1274, DOI 10.1212/WNL.44.7.1274; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FILLA A, 1992, J NEUROL, V239, P351, DOI 10.1007/BF00867594; Fink JK, 1997, CURR OPIN NEUROL, V10, P313, DOI 10.1097/00019052-199708000-00006; FINK JK, 1995, AM J HUM GENET, V56, P188; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIGLI GL, 1993, AM J MED GENET, V45, P711, DOI 10.1002/ajmg.1320450610; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARDING AE, 1981, J MED GENET, V18, P436, DOI 10.1136/jmg.18.6.436; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HENTATI A, 1994, HUM MOL GENET, V3, P1263, DOI 10.1093/hmg/3.8.1263; IOANNOU PA, 1996, CURRENT PROTOCOLS HU, P1; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KELMAN Z, 1993, ONCOGENE, V8, P37; KOYAMA K, 1993, GENOMICS, V16, P264, DOI 10.1006/geno.1993.1173; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LizcanoGil LA, 1997, AM J MED GENET, V68, P1, DOI 10.1002/(SICI)1096-8628(19970110)68:1<1::AID-AJMG1>3.0.CO;2-V; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PELOSI L, 1991, J NEUROL NEUROSUR PS, V54, P1099, DOI 10.1136/jnnp.54.12.1099; POLO JM, 1993, J NEUROL NEUROSUR PS, V56, P175, DOI 10.1136/jnnp.56.2.175; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; Reid E, 1997, J MED GENET, V34, P499, DOI 10.1136/jmg.34.6.499; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; RHEIN J, 1914, J NERV MENT DIS, V44, P115; ROBERTS L, 1991, SCIENCE, V254, P805, DOI 10.1126/science.1948063; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Sambrook J., 1989, MOL CLONING LAB MANU; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHADY W, 1991, J NEUROL NEUROSUR PS, V54, P1099; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SHOFFNER JM, 1995, METABOLIC MOL BASES, P1535; SUTHERLAND JM, 1975, HDB CLIN NEUROLOGY, V22, P420; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; TEDESCHI G, 1991, J NEUROL SCI, V103, P55, DOI 10.1016/0022-510X(91)90284-E; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Webb S, 1997, EPILEPSIA, V38, P495, DOI 10.1111/j.1528-1157.1997.tb01741.x; Zeviani M, 1997, CURR OPIN NEUROL, V10, P160, DOI 10.1097/00019052-199704000-00015	57	608	627	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 12	1998	93	6					973	983		10.1016/S0092-8674(00)81203-9	http://dx.doi.org/10.1016/S0092-8674(00)81203-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZU514	9635427	Bronze			2022-12-01	WOS:000074205700009
J	Turka, LA				Turka, LA			What's new in transplant immunology: Problems and prospects	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INTRATHYMIC ISLET TRANSPLANTATION; LONG-TERM ACCEPTANCE; ALLOGRAFT-REJECTION; CARDIAC ALLOGRAFTS; CYCLOSPORINE; PREVENTION; CHIMERISM	In the past 40 years, transplantation has moved from an experimental form of therapy used almost exclusively for renal failure to an accepted treatment for end-stage kidney disease, heart disease, liver disease, lung disease, and diabetes mellitus. Tissue transplantation for conditions from thermal injury to Parkinson disease is being investigated. The primary barrier in transplantation medicine is the immunologic reaction of the recipient to donor organs and tissues. Currently available drugs permit excellent short-term graft survival but have not led to reliable longterm survival. Recent advances in the understanding of this immune response have suggested new approaches to induction of immunologic tolerance and reduction of late graft losses. Because of the excellent short-term success of current agents, integration of these new approaches into clinical trials is challenging and raises important questions about the design of such trials.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Turka, LA (corresponding author), Univ Penn, Dept Med, 901 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.							BIERER BE, 1993, CURR OPIN HEMATOL, P149; Elwood ET, 1997, LANCET, V349, P1358, DOI 10.1016/S0140-6736(96)09105-2; GarciaMorales R, 1997, J CLIN INVEST, V99, P1118, DOI 10.1172/JCI119240; Gjertson DW, 1995, TRANSPLANTATION, V60, P1384, DOI 10.1097/00007890-199560120-00002; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; LIN H, 1993, J EXP MED, V178, P1801, DOI 10.1084/jem.178.5.1801; Lui S L, 1996, Curr Opin Nephrol Hypertens, V5, P508, DOI 10.1097/00041552-199611000-00009; MORRIS PJ, 1994, KIDNEY TRANSPLANTATI, P524; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; Paul Leendert C., 1996, P567; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; Sykes M, 1990, Semin Immunol, V2, P401; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001	22	6	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1998	128	11					946	948		10.7326/0003-4819-128-11-199806010-00015	http://dx.doi.org/10.7326/0003-4819-128-11-199806010-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP980	9634435				2022-12-01	WOS:000073808600011
J	Fontana, W; Schuster, P				Fontana, W; Schuster, P			Continuity in evolution: On the nature of transitions	SCIENCE			English	Article							RNA SECONDARY STRUCTURES; SEQUENCES; SELECTION	To distinguish continuous from discontinuous evolutionary change, a relation of nearness between phenotypes is needed. Such a relation is based on the probability of one phenotype being accessible from another through changes in the genotype. This nearness relation is exemplified by calculating the shape neighborhood of a transfer RNA secondary structure and provides a characterization of discontinuous shape transformations in RNA. The simulation of replicating and mutating RNA populations under selection shows that sudden adaptive progress coincides mostly, but not always, with discontinuous shape transformations. The nature of these transformations illuminates the key role of neutral genetic drift in their realization.	Univ Vienna, Inst Theoret Chem, A-1090 Vienna, Austria; Santa Fe Inst, Santa Fe, NM 87501 USA	University of Vienna; The Santa Fe Institute	Fontana, W (corresponding author), Univ Vienna, Inst Theoret Chem, Wahringerstr 17, A-1090 Vienna, Austria.							BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; CRUTCHFIELD JP, 1995, P NATL ACAD SCI USA, V92, P10742, DOI 10.1073/pnas.92.23.10742; Eldredge N., 1972, P82; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; ELINGTON AD, 1990, NATURE, V346, P818; FONTANA W, 1987, BIOPHYS CHEM, V26, P123, DOI 10.1016/0301-4622(87)80017-0; FONTANA W, 1997, 9711081 SANT FE I; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Gruner W, 1996, MONATSH CHEM, V127, P355, DOI 10.1007/BF00810881; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Huynen MA, 1996, J MOL EVOL, V43, P165; Huynen MA, 1996, P NATL ACAD SCI USA, V93, P397, DOI 10.1073/pnas.93.1.397; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; NUSSINOV R, 1978, SIAM J APPL MATH, V35, P68, DOI 10.1137/0135006; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHUSTER P, 1994, P ROY SOC B-BIOL SCI, V255, P279, DOI 10.1098/rspb.1994.0040; Schuster P, 1997, BIOPHYS CHEM, V66, P75, DOI 10.1016/S0301-4622(97)00058-6; SPIEGELMAN S, 1971, Quarterly Reviews of Biophysics, V4, P213; TUREK C, 1990, SCIENCE, V249, P505; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Waterman M. S., 1978, ADV MATH SUPPLEMENTA, V1, P167; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	26	321	333	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 29	1998	280	5368					1451	1455		10.1126/science.280.5368.1451	http://dx.doi.org/10.1126/science.280.5368.1451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ591	9603737	Green Submitted			2022-12-01	WOS:000073883400060
J	Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD				Kogan, MD; Martin, JA; Alexander, GR; Kotelchuck, M; Ventura, SJ; Frigoletto, FD			The changing pattern of prenatal care utilization in the United States, 1981-1995, using different prenatal care indices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; GESTATIONAL-AGE; PREGNANCY; MEDICAID; HEALTH; ADEQUACY; INDEXES; ULTRASOUND; LITIGATION; EXPANSION	Context.-Two measures traditionally used to examine adequacy of prenatal care indicate that prenatal care utilization remained unchanged through the 1980s and only began to rise slightly in the 1990s. In recent years, new measures have been developed that include a category for women who receive more than the recommended amount of care (intensive utilization). Objective.-To compare the older and newer indices in the monitoring of prenatal care trends in the United States from 1981 to 1995, for the overall population and for selected subpopulations. Second, to examine factors associated with receiving intensive utilization. Design.-Cross-sectional and trend analysis of national birth records. Setting.-The United States. Subjects.-All live births between 1981 and 1995 (N=54 million). Main Outcome Measures.-Trends in prenatal care utilization, according to 4 indices (the older indices: the Institute of Medicine Index and the trimester that care began, and the newer indices: the R-GINDEX and the Adequacy of Prenatal Care Utilization Index). Multiple logistic regression was used to assess the risk of intensive prenatal care use in 1981 and 1995. Results.-The newer indices showed a steadily increasing trend toward more prenatal care use throughout the study period (R-GINDEX, intensive or adequate use, 32.7% in 1981 to 47.1% in 1995; the Adequacy of Prenatal Care Utilization Index, intensive use, 18.4% in 1981 to 28.8% in 1995), especially for intensive utilization. Women having a multiple birth were much more likely to have had intensive utilization in 1995 compared with 1981 (R-GINDEX, 22.8% vs 8.5%). Teenagers were more likely to begin care later than adults, but similar proportions of teens and adults had intensive utilization. Intensive use among low-risk women also increased steadily each year. Factors associated with a greater likelihood of receiving intensive use in 1981 and 1995 were having a multiple birth, primiparity, being married, and maternal age of 35 years or older. Conclusions.-The proportion of women who began care early and received at least the recommended number of visits increased between 1981 and 1995. This change was undetected by more traditional prenatal care indices. These increases have cost and practice implications and suggest a paradox since previous studies have shown that rates of preterm delivery and low birth weight did not improve during this time.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Univ Alabama, Dept Maternal & Child Hlth, Birmingham, AL USA; Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Obstet, Boston, MA USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kogan, MD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd,Room 820, Hyattsville, MD 20782 USA.							Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1987, AM J PREV MED, V3, P243; ALEXANDER GR, 1995, PUBLIC HEALTH REP, V110, P395; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 1997, AM J PREV MED, V13, P290, DOI 10.1016/S0749-3797(18)30177-6; ALEXANDER GR, 1991, AM J PUBLIC HEALTH, V81, P1013, DOI 10.2105/AJPH.81.8.1013; *AM COLL OBST GYN, 1985, PROF LIAB INS ITS EF; *AM COLL OBST GYN, 1974, STAND OBST GYN SERV; [Anonymous], CAR OUR FUT CONT PRE; BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; BUESCHER PA, 1993, AM J PUBLIC HEALTH, V83, P1163, DOI 10.2105/AJPH.83.8.1163; DelgadoRodriguez M, 1996, EPIDEMIOLOGY, V7, P648, DOI 10.1097/00001648-199611000-00016; ENNIS M, 1991, LANCET, V338, P616, DOI 10.1016/0140-6736(91)90616-W; EWIGMAN B, 1993, BIRTH-ISS PERINAT C, V20, P212, DOI 10.1111/j.1523-536X.1993.tb00229.x; Farrow DC, 1997, MED CARE, V35, P297, DOI 10.1097/00005650-199703000-00010; FISCELLA K, 1995, OBSTET GYNECOL, V85, P468, DOI 10.1016/0029-7844(94)00408-6; Floyd L, 1981, J Med Assoc Ga, V70, P871; GORSKY RD, 1989, HLTH SERV RES, V24, P580; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; *I MED, 1993, ACC HLTH CAR AM; *I MED, 1985, PREV LOW BIRTH WEIGH; JEWELL SE, 1995, OBSTET GYNECOL, V85, P229, DOI 10.1016/0029-7844(94)00354-G; JOYCE T, 1988, MED CARE, V26, P348, DOI 10.1097/00005650-198804000-00004; KESSNER DM, 1973, CONTRASTS HLTH STATU, V1, P50; Kirby RS, 1997, PAEDIATR PERINAT EP, V11, P122, DOI 10.1046/j.1365-3016.1997.d01-6.x; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1486, DOI 10.2105/AJPH.84.9.1486; Kotelchuck M, 1994, AM J PUBLIC HEALTH, V84, P1314; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; LEWIS CT, 1996, VITAL HLTH STAT, V21; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; MOR JM, 1995, AM J PREV MED, V11, P79, DOI 10.1016/S0749-3797(18)30481-1; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; *NAT CTR HLTH STAT, 1995, 1992 VIT STAT US, V1; *NAT CTR HLTH STAT, 1982, VIT HLTH STAT, V2; National Center for Health Statistics, 1987, HOSP PHYS HDB BIRTH; OREILLY MP, 1991, P 1991 PUBL HLTH C R, P57; Petersen D J, 1994, Minn Med, V77, P41; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; RICCIOTTI HA, 1995, FUTURE CHILD, V5, P71, DOI 10.2307/1602508; SAARIKEMPPAINEN A, 1995, ACTA OBSTET GYN SCAN, V74, P12, DOI 10.3109/00016349509009935; Schappert SM, 1997, VITAL HLTH STAT, V13; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; *US DEP HHS, 1996, TRENDS WELL BEING AM; *US GEN ACC OFF, 1993, PUBL GAO; VENTURA SJ, 1997, MON VITAL STAT RE S2, V11; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; Wells S, 1991, J Fla Med Assoc, V78, P31; Wilcox LS, 1996, FERTIL STERIL, V65, P361, DOI 10.1016/S0015-0282(16)58100-X	56	154	157	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1998	279	20					1623	1628		10.1001/jama.279.20.1623	http://dx.doi.org/10.1001/jama.279.20.1623			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP489	9613911	Bronze			2022-12-01	WOS:000073758600031
J	Tan, PB; Lackner, MR; Kim, SK				Tan, PB; Lackner, MR; Kim, SK			MAP kinase signaling specificity mediated by the LIN-1 Ets/LIN31 WH transcription factor complex during C-elegans vulval induction	CELL			English	Article							CAENORHABDITIS-ELEGANS; REGULATED KINASE; CELL LINEAGE; LET-60 RAS; PROTEIN; PATHWAY; GENES; ACTIVATION; DEFINES; FATES	The let-23 receptor/mpk-1 MAP kinase signaling pathway induces the vulva in C. elegans. We show that MPK-1 directly regulates both the LIN-31 winged-helix and the LIN-1 Ets transcription factors to specify the vulval cell fate, lin-31 and lin-1 act genetically downstream of mpk-1, and both proteins can be directly phosphorylated by MAP kinase. LIN-31 binds to LIN-1, and the LIN-1/LIN-31 complex inhibits vulval induction. Phosphorylation of LIN-31 by MPK-1 disrupts the LIN-1/LIN-31 complex, relieving vulval inhibition. Phosphorylated LIN-31 may also act as a transcriptional activator, promoting vulval cell fates. LIN-31 is a vulval-specific effector of MPK-1, while LIN-1 acts as a general effector. The partnership of tissue-specific and general effecters may confer specificity onto commonly used signaling pathways, creating distinct tissue-specific outcomes.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.		Lackner, Mark/G-4597-2012	Lackner, Mark/0000-0002-6375-2037				AROIAN RV, 1991, GENETICS, V128, P251; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; FERGUSON EL, 1985, GENETICS, V110, P17; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KOGA M, 1995, DEVELOPMENT, V121, P2655; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Maloof JN, 1998, DEVELOPMENT, V125, P181; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Sundaram M, 1996, DEVELOPMENT, V122, P2823; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wood WB, 1988, NEMATODE CAENORHABDI; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yochem J, 1997, MOL CELL BIOL, V17, P2716, DOI 10.1128/MCB.17.5.2716	33	159	171	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					569	580		10.1016/S0092-8674(00)81186-1	http://dx.doi.org/10.1016/S0092-8674(00)81186-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604932	Bronze			2022-12-01	WOS:000073722200010
J	Oberhauser, AF; Marszalek, PE; Erickson, HP; Fernandez, JM				Oberhauser, AF; Marszalek, PE; Erickson, HP; Fernandez, JM			The molecular elasticity of the extracellular matrix protein tenascin	NATURE			English	Article							ATOMIC-FORCE MICROSCOPE; ADHESION; MODULES; DOMAIN; FLOW	Extracellular matrix proteins are thought to provide a rigid mechanical anchor that supports and guides migrating and rolling cells(1-4). Here we examine the mechanical properties of the extracellular matrix protein tenascin by using atomic-force-microscopy techniques. Our results indicate that tenascin is an elastic protein. Single molecules of tenascin could be stretched to several times their resting length. Force-extension curves showed a saw-tooth pattern, with peaks of force at 137 pN. These peaks were similar to 25 nm apart. Similar results have been obtained by study of titin(5). We also found similar results by studying recombinant tenascin fragments encompassing the 15 fibronectin type III domains of tenascin. This indicates that the extensibility of tenascin map be due to the stretch-induced unfolding of its fibronectin type III domains. Refolding of tenascin after stretching, observed when the force was reduced to near zero, showed a double-exponential recovery with time constants of 42 domains refolded per second and 0.5 domains per second. The former speed of refolding is more than twice as fast as any previously reported speed of refolding of a fibronectin type III domain(6,7). We suggest that the extensibility of the modular fibronectin type III region may be important in allowing tenascin-ligand bonds to persist over long extensions. These properties of fibronectin type III modules may be of widespread use in extracellular proteins containing such domain(8,9).	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Mayo Clinic; Duke University	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.							Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; CAMPBELL ID, 1994, STRUCTURE, V2, P333, DOI 10.1016/S0969-2126(00)00034-4; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; Clark RA, 1997, J CELL BIOL, V137, P755, DOI 10.1083/jcb.137.3.755; Clarke J, 1997, J MOL BIOL, V270, P771, DOI 10.1006/jmbi.1997.1147; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; Keller TCS, 1997, NATURE, V387, P233, DOI 10.1038/387233a0; KELLERMAYER SB, 1997, SCIENCE, V276, P1112; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Plaxco KW, 1997, J MOL BIOL, V270, P763, DOI 10.1006/jmbi.1997.1148; Plaxco KW, 1996, P NATL ACAD SCI USA, V93, P10703, DOI 10.1073/pnas.93.20.10703; Potts JR, 1996, MATRIX BIOL, V15, P313, DOI 10.1016/S0945-053X(96)90133-X; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; REIF M, 1997, SCIENCE, V276, P1109; Rief M, 1997, SCIENCE, V275, P1295, DOI 10.1126/science.275.5304.1295; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0	27	705	719	1	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					181	185		10.1038/30270	http://dx.doi.org/10.1038/30270			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603523				2022-12-01	WOS:000073619900052
J	Fraser, CM; Norris, SJ; Weinstock, CM; White, O; Sutton, GG; Dodson, R; Gwinn, M; Hickey, EK; Clayton, R; Ketchum, KA; Sodergren, E; Hardham, JM; McLeod, MP; Salzberg, S; Peterson, J; Khalak, H; Richardson, D; Howell, JK; Chidambaram, M; Utterback, T; McDonald, L; Artiach, P; Bowman, C; Cotton, MD; Fujii, C; Garland, S; Hatch, B; Horst, K; Roberts, K; Sandusky, M; Weidman, J; Smith, HO; Venter, JC				Fraser, CM; Norris, SJ; Weinstock, CM; White, O; Sutton, GG; Dodson, R; Gwinn, M; Hickey, EK; Clayton, R; Ketchum, KA; Sodergren, E; Hardham, JM; McLeod, MP; Salzberg, S; Peterson, J; Khalak, H; Richardson, D; Howell, JK; Chidambaram, M; Utterback, T; McDonald, L; Artiach, P; Bowman, C; Cotton, MD; Fujii, C; Garland, S; Hatch, B; Horst, K; Roberts, K; Sandusky, M; Weidman, J; Smith, HO; Venter, JC			Complete genome sequence of Treponema pallidum, the syphilis spirochete	SCIENCE			English	Article							PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE; OUTER-MEMBRANE ULTRASTRUCTURE; ENDOFLAGELLAR SHEATH PROTEIN; ESCHERICHIA-COLI; SUBSP PALLIDUM; PHOSPHOTRANSFERASE SYSTEM; ENTAMOEBA-HISTOLYTICA; ENTEROCOCCUS-HIRAE; MOLECULAR-CLONING; PORIN ACTIVITY	The complete genome sequence of Treponema pallidum was determined and shown to be 1,138,006 base pairs containing 1041 predicted coding sequences (open reading frames). Systems for DNA replication, transcription, translation, and repair are intact, but catabolic and biosynthetic activities are minimized. The number of identifiable transporters is small, and no phoiphoenolpyruvate: phosphotransferase carbohydrate transporters were found. Potential virulence factors include a family of 12 potential membrane proteins and several putative hemolysins. Comparison of the T. pallidum genome sequence with that of another pathogenic spirochete, Borrelia burgdorferi, the agent of Lyme disease, identified unique and common genes and substantiates the considerable diversity observed among pathogenic spirochetes.	Inst Genom Res, Rockville, MD 20850 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Ctr Study Emerging & Reemerging Pathogens, Houston, TX 77225 USA	J. Craig Venter Institute; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Fraser, CM (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	tpdb@tigr.org	Norris, Steven James/K-6586-2019; Salzberg, Steven/Q-6514-2019; Salzberg, Steven L/F-6162-2011; Weinstock, George/C-6314-2013	Norris, Steven James/0000-0002-2501-8034; Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Weinstock, George/0000-0002-2997-4592; Fraser, Claire/0000-0003-1462-2428	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031068] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akins DR, 1997, J BACTERIOL, V179, P5076, DOI 10.1128/jb.179.16.5076-5086.1997; BARBIERI JT, 1981, INFECT IMMUN, V31, P1071, DOI 10.1128/IAI.31.3.1071-1077.1981; BARONDES SH, 1993, MOL MENTAL ILLNESS; Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102; Blanco DR, 1996, J BACTERIOL, V178, P6685, DOI 10.1128/jb.178.23.6685-6692.1996; BLANCO DR, 1995, J BACTERIOL, V177, P3556, DOI 10.1128/jb.177.12.3556-3562.1995; Bruchhaus I, 1996, BIOCHEM J, V316, P57, DOI 10.1042/bj3160057; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cartwright Frederick Fox, 1972, DIS HIST; Champion CI, 1997, J BACTERIOL, V179, P1230, DOI 10.1128/jb.179.4.1230-1238.1997; CHAMPION CI, 1990, INFECT IMMUN, V58, P1697, DOI 10.1128/IAI.58.6.1697-1704.1990; CHARON NW, 1992, RES MICROBIOL, V143, P597, DOI 10.1016/0923-2508(92)90117-7; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COMMANS S, 1995, J MOL BIOL, V253, P100, DOI 10.1006/jmbi.1995.0539; COX CD, 1983, PATHOGENESIS IMMUNOL, P57; COX DL, 1990, APPL ENVIRON MICROB, V56, P3063, DOI 10.1128/AEM.56.10.3063-3072.1990; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; DEATH A, 1993, RES MICROBIOL, V144, P529, DOI 10.1016/0923-2508(93)90002-J; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; Fenno JC, 1996, J BACTERIOL, V178, P2489, DOI 10.1128/jb.178.9.2489-2497.1996; Fenno JC, 1997, J BACTERIOL, V179, P1082, DOI 10.1128/jb.179.4.1082-1089.1997; FIELDSTEEL AH, 1981, INFECT IMMUN, V32, P908, DOI 10.1128/IAI.32.2.908-915.1981; FITZGERALD TJ, 1982, BRIT J VENER DIS, V58, P1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Freist W, 1997, BIOL CHEM, V378, P1103; Greene SR, 1997, DNA SEQUENCE, V7, P267, DOI 10.3109/10425179709034046; Guina T, 1997, MOL MICROBIOL, V24, P1201, DOI 10.1046/j.1365-2958.1997.4291786.x; Hagman KE, 1997, INFECT IMMUN, V65, P1701, DOI 10.1128/IAI.65.5.1701-1709.1997; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; Ibba M, 1997, P NATL ACAD SCI USA, V94, P14383, DOI 10.1073/pnas.94.26.14383; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; ISAACS RD, 1990, INFECT IMMUN, V58, P2025, DOI 10.1128/IAI.58.7.2025-2034.1990; ISAACS RD, 1989, INFECT IMMUN, V57, P3403, DOI 10.1128/IAI.57.11.3403-3411.1989; JOHNSON RC, 1981, PROCARYOTES, P582; Jones BE, 1997, J BIOL CHEM, V272, P26530, DOI 10.1074/jbc.272.42.26530; KAISER GE, 1975, NATURE, V255, P656, DOI 10.1038/255656a0; KEMP RG, 1993, J BACTERIOL, V175, P5723, DOI 10.1128/JB.175.17.5723-5724.1993; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; Limberger RJ, 1996, J BACTERIOL, V178, P4628, DOI 10.1128/jb.178.15.4628-4634.1996; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; LYSKO PG, 1977, INFECT IMMUN, V16, P885, DOI 10.1128/IAI.16.3.885-890.1977; LYSKO PG, 1978, INFECT IMMUN, V21, P462, DOI 10.1128/IAI.21.2.462-473.1978; Mathers DA, 1996, INFECT IMMUN, V64, P2904, DOI 10.1128/IAI.64.8.2904-2910.1996; MATSUURA A, 1972, J VITAMINOL, V18, P29, DOI 10.5925/jnsv1954.18.29; NEILSEN H, 1997, PROTEIN ENG, V10, P1; Nichols HJ, 1913, J AMER MED ASSOC, V60, P108, DOI 10.1001/jama.1913.04340020016005; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; NORRIS SJ, 1988, J BACTERIOL, V170, P4072, DOI 10.1128/jb.170.9.4072-4082.1988; NORRIS SJ, UNPUB; OAKES SG, 1982, BRIT J VENER DIS, V58, P220; OBRIEN WE, 1975, J BIOL CHEM, V250, P8690; OJAIMI C, 1994, MICROBIOL-SGM, V140, P2931, DOI 10.1099/13500872-140-11-2931; PALLESEN L, 1989, INFECT IMMUN, V57, P2166, DOI 10.1128/IAI.57.7.2166-2172.1989; PASTER BJ, 1991, J BACTERIOL, V173, P6101, DOI 10.1128/JB.173.19.6101-6109.1991; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Porcella SF, 1996, GENE, V177, P115, DOI 10.1016/0378-1119(96)00286-7; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; REEVES RE, 1976, J BIOL CHEM, V251, P2958; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROBINSON EN, 1993, SYPHILIS DIS HIST ME, P334; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; SCHILLER NL, 1977, INFECT IMMUN, V16, P60, DOI 10.1128/IAI.16.1.60-68.1977; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SELL S, 1983, INT REV EXP PATHOL, V24, P204; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; SONHAMMER EL, 1997, PROTEINS, V28, P405; Stamm LV, 1997, FEMS MICROBIOL LETT, V155, P115, DOI 10.1016/S0378-1097(97)00375-3; STAMM LV, 1991, INFECT IMMUN, V59, P1572, DOI 10.1128/IAI.59.4.1572-1575.1991; Stamm LV, 1996, DNA SEQUENCE, V6, P293, DOI 10.3109/10425179609020876; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VANHORN KG, 1983, CAN J MICROBIOL, V29, P1141, DOI 10.1139/m83-175; WALKER EM, 1991, J BACTERIOL, V173, P5585, DOI 10.1128/jb.173.17.5585-5588.1991; WALKER EM, 1995, J BACTERIOL, V177, P1797, DOI 10.1128/jb.177.7.1797-1804.1995; WONG GHW, 1983, INFECT IMMUN, V41, P636, DOI 10.1128/IAI.41.2.636-643.1983	86	785	1482	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1998	281	5375					375	388		10.1126/science.281.5375.375	http://dx.doi.org/10.1126/science.281.5375.375			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9665876				2022-12-01	WOS:000074918800039
J	ter Borg, F; ten Kate, FJW; Cuypers, HTM; Leentvaar-Kuijpers, A; Oosting, J; Wertheim-van Dillen, PME; Honkoop, P; Rasch, MC; de Man, RA; van Hattum, J; Chamuleau, RAFM; Reesink, HW; Jones, EA				ter Borg, F; ten Kate, FJW; Cuypers, HTM; Leentvaar-Kuijpers, A; Oosting, J; Wertheim-van Dillen, PME; Honkoop, P; Rasch, MC; de Man, RA; van Hattum, J; Chamuleau, RAFM; Reesink, HW; Jones, EA			Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen	LANCET			English	Article							ALANINE AMINOTRANSFERASE; HBV-DNA; CIRRHOSIS; CARRIERS	Background Hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B e antigen (anti-HBe) commonly coexist, and laboratory tests are often requested to assess histological hepatitis activity. An optimum panel of tests has not been found and the usefulness of hepatitis B virus (HBV) DNA assays in this context has not been established. We assessed various blood tests to find which best predicted hepatitis activity. Methods Routine plasma biochemical liver tests and serum HBV DNA (hybridisation and PCR assays) were assessed prospectively in 123 patients positive for HBsAg and anti-HBe. We scored histological hepatitis activity (hepatitis activity index) and determined whether chronic active hepatitis (chronic hepatitis with portal and periportal lesions) was present. We analysed the relation between laboratory data and the hepatitis activity index or risk of chronic active hepatitis by multiple regression and multiple logistic regression, respectively. Findings The analyses provided models for predicting either the hepatitis activity index or the risk of chronic active hepatitis. Aspartate aminotransferase was the most important test in the two models. The contribution of HBV DNA and other assays, especially alanine-aminotransferase activity, were of no practical importance. Interpretation Because screening by aspartate-aminotransferase activity could not be improved by the addition of other assays or HBV DNA, patients positive for HBsAg and anti-HBe could be screened for chronic active hepatitis with a single assay and counselling of patients can be improved if proper reference values are used.	Univ Amsterdam, Acad Med Ctr, Dept Gastrointestinal & Liver Dis C2 117, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Virol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Expt Internal Med, NL-1100 DE Amsterdam, Netherlands; Municipal Publ Hlth Serv, Dept Infect Dis Control, Amsterdam, Netherlands; Dutch Red Cross Blood Transfus Serv, Cent Lab, Dept Viral Serol, Amsterdam, Netherlands; Erasmus Univ Hosp Rotterdam, Dept Hepatogastroenterol, Rotterdam, Netherlands; Univ Hosp, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Public Health Service Amsterdam; Erasmus University Rotterdam; Erasmus MC	ter Borg, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastrointestinal & Liver Dis C2 117, POB 22700, NL-1100 DE Amsterdam, Netherlands.							ALBERTI A, 1994, ANTIVIR RES, V24, P145, DOI 10.1016/0166-3542(94)90063-9; BERGMEYER HU, 1986, J CLIN CHEM CLIN BIO, V24, P481; CARLONI G, 1987, J MED VIROL, V21, P15, DOI 10.1002/jmv.1890210104; Colloredo G, 1996, J HEPATOL, V25, P644, DOI 10.1016/S0168-8278(96)80233-9; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Mangia A, 1996, DIGEST DIS SCI, V41, P2447, DOI 10.1007/BF02100141; MCCULLOUGH AJ, 1987, HEPATOLOGY, V7, P49, DOI 10.1002/hep.1840070112; NIITSUMA H, 1997, GASTROENTEROLOGY, V92, P119; PAZ MOA, 1986, J HEPATOL, V3, P371, DOI 10.1016/S0168-8278(86)80491-3; RAPICETTA M, 1990, EPIDEMIOL INFECT, V104, P511, DOI 10.1017/S0950268800047518; SCHEUER PJ, 1994, LIVER BIOPSY INTERPR, P117; VILLENEUVE JP, 1994, GASTROENTEROLOGY, V106, P1000, DOI 10.1016/0016-5085(94)90760-9; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; *WHO, 1993, GLOB HLTH SIT PROJ E; WILLIAMS ALB, 1988, GASTROENTEROLOGY, V95, P734, DOI 10.1016/S0016-5085(88)80022-2; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; YANG PM, 1987, HEPATO-GASTROENTEROL, V34, P251; ZAAIJER HL, 1994, J CLIN MICROBIOL, V32, P2088, DOI 10.1128/JCM.32.9.2088-2091.1994; Zavaglia C, 1997, LIVER, V17, P83	24	51	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 27	1998	351	9120					1914	1918		10.1016/S0140-6736(97)09391-4	http://dx.doi.org/10.1016/S0140-6736(97)09391-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZW951	9654258				2022-12-01	WOS:000074464700008
J	Kentros, C; Hargreaves, E; Hawkins, RD; Kandel, ER; Shapiro, M; Muller, RV				Kentros, C; Hargreaves, E; Hawkins, RD; Kandel, ER; Shapiro, M; Muller, RV			Abolition of long-term stability of new hippocampal place cell maps by NMDA receptor blockade	SCIENCE			English	Article							COMPLEX-SPIKE CELLS; SPATIAL MEMORY; ANTAGONIST MK-801; UNIT-ACTIVITY; POTENTIATION; ENVIRONMENT; RAT; CPP; ASPARTATE; PERFORMANCE	Hippocampal pyramidal cells are called place cells because Each cell tends to fire only when the animal is in a particular part of the environment-the cell's firing field. Acute pharmacological blockade, of N-methyl-D-aspartate (NMDA) glutamate receptors was used to investigate how NMDA-based synaptic plasticity participates in the formation and maintenance of the firing fields. The results suggest that the formation and short-term stability of firing fields in a new environment involve plasticity that is independent of NMDA receptor activation. By contrast, the long-term stabilization of newly established firing fields required normal NMDA receptor function and, therefore, may be related to other NMDA-dependent processes such as long-term potentiation and spatial teaming.	McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada; New York State Psychiat Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA; SUNY Hlth Sci Ctr, Dept Physiol, Brooklyn, NY 11203 USA	McGill University; New York State Psychiatry Institute; Columbia University; Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Muller, RV (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Hargreaves, Eric/H-4891-2011	Kentros, Clifford/0000-0003-3850-3829; Hargreaves, Eric/0000-0001-5311-9804	NIA NIH HHS [T32 AGO 00189] Funding Source: Medline; PHS HHS [R01 45923, R01 20686] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000189] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; AUSTIN K B, 1990, Society for Neuroscience Abstracts, V16, P263; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; Bures J, 1997, P NATL ACAD SCI USA, V94, P343, DOI 10.1073/pnas.94.1.343; Cain DP, 1997, CURR OPIN NEUROBIOL, V7, P235, DOI 10.1016/S0959-4388(97)80012-8; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; Cho YH, 1998, SCIENCE, V279, P867, DOI 10.1126/science.279.5352.867; COLE BJ, 1993, PSYCHOPHARMACOLOGY, V111, P465, DOI 10.1007/BF02253537; CURRAN HV, 1986, BIOL PSYCHOL, V23, P179, DOI 10.1016/0301-0511(86)90081-5; Davis S, 1997, J NEUROSCI METH, V75, P75, DOI 10.1016/S0165-0270(97)00053-8; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; HERNANDEZ RV, 1994, BRAIN RES, V656, P215, DOI 10.1016/0006-8993(94)91388-9; HETHERINGTON PA, 1993, BEHAV NEUROSCI, V107, P434, DOI 10.1037/0735-7044.107.3.434; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; Isaac JTR, 1996, J PHYSIOLOGY-PARIS, V90, P299, DOI 10.1016/S0928-4257(97)87901-6; JARBE TU, 1986, ACTA NEUROL SCAND  S, V109, P37; KENTROS C, UNPUB; Kubie J. L., 1983, NEUROBIOLOGY HIPPOCA, P433; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MORRIS RG, 1997, T R SOC LONDON B, V352, P1489; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Muller R U, 1991, Hippocampus, V1, P243, DOI 10.1002/hipo.450010306; Muller RU, 1996, J GEN PHYSIOL, V107, P663, DOI 10.1085/jgp.107.6.663; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1987, J NEUROSCI, V7, P1935; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; PELLICANO MP, 1993, PHYSIOL BEHAV, V54, P563, DOI 10.1016/0031-9384(93)90250-J; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; Rotenberg A., 1997, Society for Neuroscience Abstracts, V23, P501; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; SHAPIRO ML, 1992, BEHAV NEUROSCI, V106, P604, DOI 10.1037/0735-7044.106.4.604; THOMPSON LT, 1990, BRAIN RES, V509, P189; UNGERER A, 1991, BRAIN RES, V549, P59, DOI 10.1016/0006-8993(91)90599-Q; WARD L, 1990, PHARMACOL BIOCHEM BE, V35, P785, DOI 10.1016/0091-3057(90)90359-P; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	42	371	376	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 26	1998	280	5372					2121	2126		10.1126/science.280.5372.2121	http://dx.doi.org/10.1126/science.280.5372.2121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZW680	9641919				2022-12-01	WOS:000074435900047
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Homing viruses	SCIENCE			English	Editorial Material									Medsite Commun, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA USA.							Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; ITZHAKI JE, 1991, NUCLEIC ACIDS RES, V19, P3835, DOI 10.1093/nar/19.14.3835; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 19	1998	280	5371					1956	1957						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZV618	9669951				2022-12-01	WOS:000074323800071
J	Egger, M; Low, N; Smith, GD; Lindblom, B; Herrmann, B				Egger, M; Low, N; Smith, GD; Lindblom, B; Herrmann, B			Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: ecological analysis	BRITISH MEDICAL JOURNAL			English	Article							PELVIC INFLAMMATORY DISEASE; SEXUALLY-TRANSMITTED DISEASES; TRACHOMATIS INFECTION; PREVENTION; EPIDEMIOLOGY; PREVALENCE; WISCONSIN; PROGRAM	Objectives: To analyse trends in rates of genital chlamydial infection and ectopic pregnancy between 1985 and 1995 in a county in Sweden. Setting: Uppsala county where screening for chlamydial infection, treatment, and contact tracing has been widespread and where ectopic pregnancies are recorded. Methods: Rates of chlamydial infections and ectopic pregnancy between 1985 and 1995 were calculated for women aged 20-39 years. Poisson and linear regression were used to examine the association between the risk of ectopic pregnancy and the current rates of chlamydial infection and rates of chlamydial infection from up to 5 years earlier. Main outcome measures: Rates of chlamydial infection per 100 examinations, rates of ectopic pregnancy per 1000 pregnancies, rate ratios and 95% confidence intervals for an increase in chlamydial infections of 5 new cases per 100 examinations. Results: 103 870 cervical samples from women aged 15-39 years were analysed; 5648 (5.4%) were positive for chlamydia. 51 630 pregnancies were analysed; 930 (1.8%) were ectopic. Both rates declined over time. For women aged 20-24 years there was a strong correlation between the rate of ectopic pregnancy and the rate of chlamydial infection in the same year (r=0.93, P < 0.001); among older women correlations were stronger with rates of chlamydial infection occurring 1 or 2 years earlier. In Poisson regression ectopic pregnancy was most strongly associated with the current rate of chlamydial infection among women aged 20-24 (rate ratio 1.85, 95% confidence interval 1.44 to 2.38), with the rate of infection 1 year earlier among 25-29 year olds (rate ratio 1.72, 1.33 to 2.22) and 30-34 year olds (rate ratio 2.27, 1.53 to 3.37); and with the rate 2 years earlier among 35 to 39 year olds (rate ratio 2.58, 1.45 to 4.60). Conclusions: Declining rates of genital chlamydial infections have probably led to a fall in the rate of ectopic pregnancies. The timing of the decline in the rate of ectopic pregnancies varies with age. Among young women falling rates of chlamydial infection have been accompanied by an immediate reduction in the rate of ectopic pregnancy.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ London Kings Coll, Sch Med & Dent, Dept Genitourinary Med, London SE5 9RS, England; Univ Uppsala Hosp, Dept Obstet & Gynaecol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Infect Dis & Clin Microbiol, S-75185 Uppsala, Sweden	University of Bristol; University of London; King's College London; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Egger, M (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	m.egger@bristol.ac.uk	Davey Smith, George/A-7407-2013; Low, Nicola/H-4718-2019	Davey Smith, George/0000-0002-1407-8314; Low, Nicola/0000-0003-4817-8986; Egger, Matthias/0000-0001-7462-5132				ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; CHOW JM, 1990, JAMA-J AM MED ASSOC, V263, P3164, DOI 10.1001/jama.263.23.3164; CHOW WH, 1987, EPIDEMIOL REV, V9, P70, DOI 10.1093/oxfordjournals.epirev.a036309; COSTE J, 1994, FERTIL STERIL, V62, P289; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; HERRMANN B, 1995, SEX TRANSM DIS, V22, P253, DOI 10.1097/00007435-199507000-00009; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Kamwendo F, 1996, SEX TRANSM DIS, V23, P384, DOI 10.1097/00007435-199609000-00007; MARDH PA, 1977, NEW ENGL J MED, V296, P1377, DOI 10.1056/NEJM197706162962403; *NAT BOARD HLTH WE, 1990, AN CHLAM INF PREV ME; Padian Nancy S., 1994, Annals of Epidemiology, V4, P128, DOI 10.1016/1047-2797(94)90058-2; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; Robinson AJ, 1996, BRIT J OBSTET GYNAEC, V103, P859, DOI 10.1111/j.1471-0528.1996.tb09901.x; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; Skjeldestad FE, 1997, ACTA OBSTET GYN SCAN, V76, P159, DOI 10.3109/00016349709050073; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; TAYLORROBINSON D, 1994, BMJ-BRIT MED J, V308, P150, DOI 10.1136/bmj.308.6922.150; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y	23	147	157	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1998	316	7147					1776	1780		10.1136/bmj.316.7147.1776	http://dx.doi.org/10.1136/bmj.316.7147.1776			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZV258	9624063	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000074286300023
J	Ludwig, A; Zong, XG; Jeglitsch, M; Hofmann, F; Biel, M				Ludwig, A; Zong, XG; Jeglitsch, M; Hofmann, F; Biel, M			A family of hyperpolarization-activated mammalian cation channels	NATURE			English	Article							THALAMIC RELAY NEURONS; VOLTAGE-CLAMP ANALYSIS; CYCLIC-AMP; SINOATRIAL NODE; PROTEIN-KINASE; MODULATION; I(F); SEQUENCE; SUBUNIT; HEART	Pacemaker activity of spontaneously active neurons(1-3) and heart cells(4-6) is controlled by a depolarizing, mixed Na+/K+ current, named I-h (or I-f in the sinoatrial node of the heart)(1,4). This current is activated on hyperpolarization of the plasma membrane. In addition to depolarizing pacemaker cells, I-h is involved in determining the resting membrane potential of neurons(1,2) and provides a mechanism to limit hyperpolarizing currents in these cells(7-9). Hormones and neurotransmitters that induce a rise in cyclic AMP levels increase I-h by a mechanism that is independent of protein phosphorylation, and which involves direct binding of the cyclic nucleotide to the channel that mediates I-h(10-13). Here we report the molecular cloning and functional expression of the gene encoding a hyperpolarization-activated cation channel (HAC1) that is present in brain and heart. This channel exhibits the general properties of I-h channels. We have also identified full-length sequences of two related channels, HAC2 and HAC3, that are specifically expressed in the brain, indicating the existence of a family of hyperpolarization-activated cation channels.	Tech Univ Munchen, Inst Pharmakol & Toxikol, D-80802 Munchen, Germany	Technical University of Munich	Biel, M (corresponding author), Tech Univ Munchen, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munchen, Germany.		Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; BAYLISS DA, 1994, J NEUROPHYSIOL, V71, P119, DOI 10.1152/jn.1994.71.1.119; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.ph.55.030193.002323; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; HO WK, 1994, PFLUG ARCH EUR J PHY, V426, P68, DOI 10.1007/BF00374672; Ludwig A, 1997, J NEUROSCI, V17, P1339; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P319, DOI 10.1113/jphysiol.1990.sp018332; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.physiol.58.1.299; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PEDARZANI P, 1995, P NATL ACAD SCI USA, V92, P11716, DOI 10.1073/pnas.92.25.11716; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; SOLOMON JS, 1993, J PHYSIOL-LONDON, V462, P393, DOI 10.1113/jphysiol.1993.sp019561; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; YU HG, 1995, J PHYSIOL-LONDON, V485, P469, DOI 10.1113/jphysiol.1995.sp020743; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	28	750	792	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1998	393	6685					587	591		10.1038/31255	http://dx.doi.org/10.1038/31255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT988	9634236				2022-12-01	WOS:000074150100055
J	Darlington, TK; Wager-Smith, K; Ceriani, MF; Staknis, D; Gekakis, N; Steeves, TDL; Weitz, CJ; Takahashi, JS; Kay, SA				Darlington, TK; Wager-Smith, K; Ceriani, MF; Staknis, D; Gekakis, N; Steeves, TDL; Weitz, CJ; Takahashi, JS; Kay, SA			Closing the circadian loop: CLOCK-induced transcription of its own inhibitors per and tim	SCIENCE			English	Article							DROSOPHILA PERIOD PROTEIN; NUCLEAR ENTRY; IDENTIFICATION; COMPONENT; RECEPTOR; TIMELESS; SYSTEM; ARNT; DNA	The circadian oscillator generates a rhythmic output with a period of about 24 hours. Despite extensive studies in several model systems, the biochemical mode of action has not yet been demonstrated for any of its components. Here, the Drosophila CLOCK protein was shown to induce transcription of the circadian rhythm genes period and timeless. dCLOCK functioned as a heterodimer with a Drosophila homolog of BMAL1. These proteins acted through an E-box sequence in the period promoter. The timeless promoter contains an 18-base pair element encompassing an E-box, which was sufficient to confer dCLOCK responsiveness to a reporter gene. PERIOD and TIMELESS proteins blocked dCLOCK's ability to transactivate their promoters via the E-box. Thus, dCLOCK drives expression of period and timeless, which in turn inhibit dCLOCK's activity and close the circadian loop.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92093 USA; Scripps Res Inst, NSF, Ctr Biol Timing, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northwestern Univ, NSF,Ctr Biol Timing, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92093 USA.		Kay, Steve A/F-6025-2011; Jansen, Heiko T./A-5770-2008; Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Kay, Steve A/0000-0002-0402-2878; Jansen, Heiko T./0000-0003-0178-396X; Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878; Ceriani, Maria/0000-0001-8945-3070	NIMH NIH HHS [MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASHBURNER M, 1989, DROSOPHILA LAB HDB, P33; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DARLINGTON T, UNPUB; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 1997, GENETICS, V146, P1049; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Park J.C., UNPUB; PELLEQUER JL, IN PRESS P NATL ACAD; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SIKORSKI RS, 1989, GENETICS, V122, P19; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	32	667	687	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 5	1998	280	5369					1599	1603		10.1126/science.280.5369.1599	http://dx.doi.org/10.1126/science.280.5369.1599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZT213	9616122				2022-12-01	WOS:000074061200040
J	Nan, XS; Ng, HH; Johnson, CA; Laherty, CD; Turner, BM; Eisenman, RN; Bird, A				Nan, XS; Ng, HH; Johnson, CA; Laherty, CD; Turner, BM; Eisenman, RN; Bird, A			Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex	NATURE			English	Article							CHROMATIN STRUCTURE; DNA METHYLATION; CHROMOSOMAL PROTEIN; ACETYLATION; CELLS; MOUSE	Cytosine residues in the sequence 5'CpG (cytosine-guanine) are often postsynthetically methylated in animal genomes. CpG methylation is involved in long-term silencing of certain genes during mammalian development(1,2) and in repression of viral genomes(3,4). The methyl-CpG-binding proteins MeCP1 (ref. 5) and MeCP2 (ref. 6) interact specifically with methylated DNA and mediate transcriptional repression(7-9). Here we study the mechanism of repression by MeCP2, an abundant nuclear protein that is essential for mouse embryogenesis(10). MeCP2 binds tightly to chromosomes in a methylation-dependent manner(11,12). It contains a transcriptional-repression domain (TRD) that can GRAPHICS function at a distance in vitro and in vivo(9). We show that a region of MeCP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases(13-19). Transcriptional repression in vivo is relieved by the deacetylase inhibitor trichostatin A(20), indicating that deacetylation of histones (and/or of other proteins) is an essential component of this repression mechanism. The data suggest that two global mechanisms of gene regulation, DNA methylation and histone deacetylation, can be linked by MeCP2.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	University of Edinburgh; University of Birmingham; Fred Hutchinson Cancer Center	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk	Ng, Huck Hui/A-1135-2009	Bird, Adrian/0000-0002-8600-0372; Johnson, Colin/0000-0002-2979-8234; Nan, Xinsheng/0000-0002-0865-7934	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; LAHERTY CD, 1997, CELL, V89, P849; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li W, 1996, BIOCHEM J, V314, P631, DOI 10.1042/bj3140631; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	30	2599	2707	2	181	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1998	393	6683					386	389		10.1038/30764	http://dx.doi.org/10.1038/30764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ593	9620804				2022-12-01	WOS:000073883600059
J	Conradt, B; Horvitz, HR				Conradt, B; Horvitz, HR			The C-elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; APOPTOSIS; SEQUENCE; BAX; SURVIVAL; GENETICS; ENCODES; DOMAIN; ACTIVATION; INHIBITION	Gain-of-function mutations in the Caenorhabditis elegans gene egl-1 cause the HSN neurons to undergo programmed cell death. By contrast, a loss-of-function egl-1 mutation prevents most if not all somatic programmed cell deaths. The egl-1 gene negatively regulates the ced-9 gene, which protects against cell death and is a member of the bcl-2 family. The EGL-1 protein contains a nine amino acid region similar to the Bcl-2 homology region 3 (BH3) domain but does not contain a BH1, BH2, or BH4 domain, suggesting that EGL-1 may be a member of a family of cell death activators that includes the mammalian proteins Bik, Bid, Harakiri, and Bad. The EGL-1 and CED-9 proteins interact physically. We propose that EGL-1 activates programmed cell death by binding to and directly inhibiting the activity of CED-9, perhaps by releasing the cell death activator CED-4 from a CED-9/CED-4-containing protein complex.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.		Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308				Anderson P, 1995, METHOD CELL BIOL, V48, P31; Bai C, 1996, METHOD ENZYMOL, V273, P331; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOYD JM, 1995, ONCOGENE, V11, P1921; BRENNER S, 1974, GENETICS, V77, P71; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DELONG L, 1993, GENETICS, V133, P875; DESAI C, 1989, GENETICS, V121, P703; Diaz JL, 1997, J BIOL CHEM, V272, P11350; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jacobson MD, 1997, TRENDS CELL BIOL, V7, P467, DOI 10.1016/S0962-8924(97)01182-3; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Riddle DL, 1997, C ELEGANS; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; ROSE MD, 1990, METHODS YEAST GENETI; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 1989, MOL CLONING LAB MANU; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRENT C, 1983, GENETICS, V104, P619; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS BD, 1992, GENETICS, V131, P609; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHOU H, 1997, CELL, V90, P405; Zhu JW, 1997, GENE DEV, V11, P2883, DOI 10.1101/gad.11.21.2883	63	481	500	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 15	1998	93	4					519	529		10.1016/S0092-8674(00)81182-4	http://dx.doi.org/10.1016/S0092-8674(00)81182-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZP152	9604928	Bronze			2022-12-01	WOS:000073722200006
J	Everett, SM; Axon, ATR				Everett, SM; Axon, ATR			Early gastric cancer: disease or pseudo-disease?	LANCET			English	Editorial Material									Gen Infirm, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Everett, SM (corresponding author), Gen Infirm, Ctr Digest Dis, Great George St, Leeds LS1 3EX, W Yorkshire, England.							ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; COLEMAN MP, 1993, IARC SCI PUBL, V121, P193; CORREA P, 1994, CANCER SURV, V20, P55; *DEP HLTH SOC SEC, 1986, BREAST CANC SCREEN R; ECKARDT VF, 1990, GASTROENTEROLOGY, V98, P708, DOI 10.1016/0016-5085(90)90292-9; FONSECA L, 1994, ONCOLOGY, V51, P485; FUJII T, 1994, JPN J CLIN ONCOL, V24, P128; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HAMPSON LG, 1990, CAN J SURG, V33, P349; HISAMICHI S, 1989, WORLD J SURG, V13, P31, DOI 10.1007/BF01671151; IKEDA Y, 1994, SEMIN SURG ONCOL, V10, P150, DOI 10.1002/ssu.2980100218; KOHLI Y, 1981, J CLIN GASTROENTEROL, V3, P129, DOI 10.1097/00004836-198106000-00005; KURIHARA M, CANC MORTALITY STAT, P63; ROKKAS T, 1991, GUT, V32, P1110, DOI 10.1136/gut.32.10.1110; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; VONHOLSTEIN CS, 1991, SCAND J GASTROENTERO, V26, P1020, DOI 10.3109/00365529109003951; YAMAZAKI H, 1989, CANCER-AM CANCER SOC, V63, P613, DOI 10.1002/1097-0142(19890215)63:4<613::AID-CNCR2820630402>3.0.CO;2-0; YOSHIDA S, 1993, GASTRIC CANCER, P246	20	44	46	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	1998	351	9112					1350	1352		10.1016/S0140-6736(98)04365-7	http://dx.doi.org/10.1016/S0140-6736(98)04365-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL499	9643813				2022-12-01	WOS:000073439400042
J	Clark, S				Clark, S			Training in orthopaedic spinal surgery	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Clark, S (corresponding author), Lancet, London WC1B 3SL, England.								0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1224	1224		10.1016/S0140-6736(05)79314-4	http://dx.doi.org/10.1016/S0140-6736(05)79314-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643740				2022-12-01	WOS:000073283600006
J	Nutt, JG				Nutt, JG			Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease	LANCET			English	Editorial Material							LEVODOPA		Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Med, Dept Physiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Sch Med, Dept Pharmacol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Nutt, JG (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA.							Agid Y, 1997, LANCET, V350, P712, DOI 10.1016/S0140-6736(05)63511-8; Baas H, 1997, J NEUROL NEUROSUR PS, V63, P421, DOI 10.1136/jnnp.63.4.421; HAUSER RA, IN PRESS MOV DISORD; Jorga KM, 1997, CLIN PHARMACOL THER, V62, P300, DOI 10.1016/S0009-9236(97)90033-3; Kieburtz K, 1997, ANN NEUROL, V42, P747; Kurth MC, 1997, NEUROLOGY, V48, P81, DOI 10.1212/WNL.48.1.81; Mannisto P T, 1992, Prog Drug Res, V39, P291; NUTT JG, 1987, ANN NEUROL, V21, P584, DOI 10.1002/ana.410210610; NUTT JG, 1994, NEUROLOGY, V44, P913, DOI 10.1212/WNL.44.5.913; Rajput AH, 1997, NEUROLOGY, V49, P1066, DOI 10.1212/WNL.49.4.1066; ROBERTS JW, 1993, NEUROLOGY, V43, P2685, DOI 10.1212/WNL.43.12.2685; Ruottinen HM, 1996, J NEUROL NEUROSUR PS, V60, P36, DOI 10.1136/jnnp.60.1.36; Waters CH, 1997, NEUROLOGY, V49, P665, DOI 10.1212/WNL.49.3.665	13	32	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 25	1998	351	9111					1221	1222		10.1016/S0140-6736(05)79311-9	http://dx.doi.org/10.1016/S0140-6736(05)79311-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK087	9643737				2022-12-01	WOS:000073283600003
